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Robust methods in Mendelian
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Mendelian randomization uses genetic variants as instrumental variables to estimate the
causal effect of a risk factor on an outcome using observational data. If a genetic variant
is included in a Mendelian randomization study that does not satisfy the instrumental
variable assumptions then the causal estimate from traditional instrumental variable
methods will be biased. Since Mendelian randomization studies using publicly available
summary level data (estimates and standard errors of the genetic associations with the
risk factor and the outcome) from large consortia can be performed with relative ease
and little expense, the popularity of Mendelian randomization in epidemiological studies
has increased dramatically. As such, various methods have been developed in Mendelian
randomization that use summary level data and account for possible violations of
the instrumental variable assumptions. However, additional Mendelian randomization
methods that account for violations in the instrumental variable assumptions are still
required.
In this dissertation, we introduce robust methods for Mendelian randomization
that downweight the contribution of genetic variants with heterogeneous causal ratio
estimates. We extend the univariable MR-Egger method to the multivariable setting
to account for both measured and unmeasured pleiotropic effects. We also explore
the possibility of extending multivariable Mendelian randomization to the factorial
setting to estimate statistical interaction effects. Finally, we apply some of the methods
we have developed to perform a Mendelian randomization study to investigate the
effect of adiposity and body composition measurements on asthma using data from
UK Biobank and the GABRIEL consortium.
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Chapter 1
Introduction
Epidemiology investigates the determinants of health outcomes and the distribution of
diseases at the population level. Epidemiological research can inform disease aetiology,
the effectiveness of treatments on disease outcomes, public health policies, and the
prioritization of healthcare resources. To strengthen the credibility of these findings
and recommendations, epidemiology must consider questions of cause and effect.
In this Chapter, we discuss what is meant by the causal effect of a risk factor on
an outcome (Section 1.1), and consider the detection and estimation of these effects
in randomized clinical trials (Section 1.2), epidemiological studies with observational
data (Section 1.3), instrumental variable analyses (Section 1.4), and finally, Mendelian
randomization (Section 1.5). We then provide motivation for the work presented
(Section 1.6), and outline the structure of the dissertation (Section 1.7).
1.1 Causal effect
In this dissertation, we consider a causal effect to be a measure of the impact an
intervention on the risk factor X has on the distribution of an outcome Y . We use the
notation do(X = x) introduced by Pearl [1] to illustrate that X has been intervened
on and set to the value x. If the risk factor has a causal effect on the outcome, then an
intervention on X will change the distribution of Y , and the conditional distribution
p(Y = y|do(X = x)) will be dependent on the value x.
An observational association considers differences in the outcome when the risk
factor is observed at different values. If the risk factor is associated with other variables,
such as variables that confound the association betweenX and Y , then the observational
association of the risk factor on the outcome may highlight differences in the risk factor
and the confounders. Hence, the conditional distribution p(Y = y|X = x) may not
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be equivalent to p(Y = y|do(X = x)) [2]. This distinction between an observational
association and a causal effect has contributed to the phrase ‘correlation does not imply
causation’.
1.2 Randomized clinical trials
Randomized clinical trials (RCT) are considered the ‘gold standard’ of assessing the
effectiveness of a treatment on a disease outcome [3]. In its simplest form, a RCT
randomly allocates participants to receive the treatment or control (no treatment). By
randomizing participants to treatment, all known and unknown confounders should be
balanced between the two treatment groups [4]. It can be inferred that the treatment
has a causal effect on the outcome if the frequency of the disease outcome differs
between the randomized groups. RCTs usually perform an intention to treat (ITT)
analysis where the effect of randomization on the outcome is estimated [5]. The
estimate from a ITT analysis will be equivalent to the causal parameter of the average
treatment effect (ATE) if all of the participants take the treatment they have been
randomly allocated to (‘full compliance to randomization’) [6].
1.3 Epidemiological studies
Due to cost, time, and ethical reasons, it may not be feasible to conduct a RCT
to investigate the causal effect of a treatment or modifiable risk factor on a disease
outcome [7]. Observational data is often used to investigate the effect of a risk factor on
a disease outcome when a RCT cannot be performed. Whilst it is theoretically possible
to adjust for the confounders of the risk factor–outcome association in the statistical
analysis of the observational data, we cannot guarantee that all of the confounders will
have been accounted for (known as ‘residual confounding’) [8]. Observational studies
may also be affected by ‘reverse causation’ in which the observed association between
the risk factor and outcome is due to a causal effect of the outcome on the risk factor
[8].
Due to residual confounding and reverse causation, analyses using observational
data that adjust for potential confounders in the statistical model cannot distinguish
between correlation and causation. This limitation has led to numerous examples where
an apparent association has been identified using observational data, but the result has
not been replicated in a RCT. For example, epidemiological studies using observational
data suggested that vitamin C has a protective effect against cardiovascular disease
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[9, 10], but this result was not supported in a RCT where a null effect was reported
[11].
1.4 Instrumental variable analyses
Using observational data, an instrumental variable (IV) can be used to infer a causal
effect between a risk factor X and an outcome Y . IVs have been applied to a wide
range of research areas, including economics and medical research. For a variable G to
be a valid IV, the following conditions must be satisfied:
• IV1: G is associated with the risk factor (G⊥̸⊥ X);
• IV2: G is (marginally) independent of all unmeasured confounders U of the risk
factor–outcome association (G ⊥ U); and
• IV3: G is independent of the outcome conditional on the risk factor and con-
founders (G ⊥ Y |(X,U)) [2, 12].
Under the IV1 assumption, there will be a systematic difference in the average levels
of the risk factor between the subgroups of G, and the IV2 assumption ensures that
the unmeasured confounders U will be equally distributed between these subgroups.
The IV3 assumption guarantees that G only has an effect on Y via X, i.e. G does not
have a direct effect on Y .
Figure 1.1 is a directed acyclic graph (DAG) of the variables G, X, Y and U ,
where G satisfies the IV assumptions. A DAG is a graphical model that provides a
non-parametric representation of the relationships between a set of variables. In a DAG,
nodes are used to represent variables, and these nodes are connected by directed edges,
usually represented as single headed arrows. For example, A → B implies that the
variable A has a direct effect on variable B. Conversely, if two nodes are not connected
by an arrow, this infers that there is no direct effect between the two variables. A DAG
must not contain a variable C which has a sequence of directed edges that lead back
to C. Hence, a DAG cannot have any complete cycles. DAGs do not have to contain
all intermediate variables, such as C in A → C → B, and a node may represent a
collection of variables.
In Figure 1.1, the IV1 assumption is satisfied by the arrow connecting G to the
risk factor X. IV2 is satisfied as there is no arrow that directly links G and the set of
unmeasured confounders U , and there is no pathway between G and U . Finally, IV3 is
satisfied as the only pathway between G and the outcome Y is via the risk factor X.
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Fig. 1.1 Directed acyclic graph illustrating the instrumental variable assumptions for the
variable G to investigate the causal effect of a risk factor X on a outcome Y , where U are
the set of unmeasured confounding variables of the X − Y association.
DAGs imply that there is a direction of effect between variables, but these effects
are not necessarily causal. From Figure 1.1, the joint distribution of Y , X, U and G
can be factorized as:
p(y, x, u, g) = p(y|u, x)p(x|u, g)p(u)p(g) , (1.1)
and the DAG will have a causal interpretation with respect to X if we can intervene
on X without changing the distributions p(y|u, x), p(u) and p(g) in Equation 1.1 [13].
These three distributions should be the same regardless of whether X is set to x′ (i.e.
do(X = x′)) or x′ is observed. Sheehan and Didelez [13] refer to this condition as the
‘structural assumption’, and this assumption, along with the three IV conditions, must
be satisfied for the DAG in Figure 1.1 to have a causal interpretation with respect to
X. Under this structural assumption, we can express the joint distribution of Y , X, U
and G as:
p(y, u, g|do(X = x′)) = p(y|u, x′)p(u)p(g) . (1.2)
In Section 2.1, we consider how an IV can be used to statistically test for a causal
effect between X and Y within the context of Mendelian randomization. We define
the additional assumptions required to produce a point estimate of the causal effect
(Section 2.2), and outline the methods commonly used in the IV literature to estimate
the causal effect (Section 2.3).
1.5 Mendelian randomization
Mendelian randomization uses genetic variants as IVs to detect and/or estimate the
causal effect of a risk factor on an outcome using observational data. Katan [14] first
introduced the idea of using genetic variants as IVs to detect causal effects, and their
use in epidemiological research has been popularized by Davey Smith and Ebrahim [15].
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In this Section, we discuss the merits of using genetic variants as IVs and introduce
different types of Mendelian randomization studies.
1.5.1 Using genetic variants as instrumental variables
A genetic variant must be associated with the risk factor for the IV1 assumption to be
satisfied. Since there has been a substantial increase in the number of genome wide
association studies (GWAS), and the results from these studies are usually publicly
available, this assumption should be relatively straight forward to verify. Typically,
uncorrelated genetic variants (not in linkage disequilibrium) that are associated with
the risk factor at the genome wide significance level (p-value < 5×10−8) are considered
in a Mendelian randomization study.
Since increases in sample sizes have led to more genetic variants being identified
in GWASs, and common genetic variants typically explain little variation in the risk
factor, many Mendelian randomization analyses now include multiple genetic variants
as IVs [16]. The genetic variants do not have to be causally associated with the risk
factor to be valid IVs. Any genetic variant that is in linkage disequilibrium with the
causal variant and satisfies the IV assumptions can be used as a IV [17]. Including
multiple genetic variants in the analysis will only increase the power to detect the
causal effect if the variants explain additional variability in the risk factor [18, 19].
Note that since genetic variants are determined at conception, the association between
the variant and the risk factor should not be subject to reverse causation [20, 21].
The IV2 assumption that the genetic variant is not associated with any of the un-
measured confounders of the risk factor–outcome association is an untestable condition.
The assumption that genetic variants are ‘randomly’ distributed in the population,
combined with Mendel’s laws of inheritance, are often used to justify the validity of
the IV2 assumption as it implies that the genetic variants are randomly distributed in
the population with respect to potentially confounding variables, such as social and
environmental factors [15]. The credibility of the IV2 condition could be considered
by testing the genetic variants with known measured confounders of the risk factor–
outcome association in the dataset used in the main analysis, and by looking up the
genetic associations with known unmeasured confounders in external datasets and
consortia. Although this is a sensible suggestion, it is by no means exhaustive.
If a genetic variant is associated with more than one trait then it is said to be
a ‘pleiotropic’ variant. The inclusion of a pleiotropic genetic variant in a Mendelian
randomization analysis may lead to the violation of the IV2 or IV3 assumptions. Since
GWASs have identified many genetic variants that are associated with multiple traits,
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including pleiotropic variants in a Mendelian randomization study is a major concern
[22]. This limitation has led to various methods being introduced into the Mendelian
randomization literature that either detect and remove pleiotropic variants, or estimate
consistent causal effects in the presence of pleiotropic variants.
1.5.2 Classification of studies
Figure 1.2 provides an illustration of the two main types of Mendelian randomization
studies considered in the literature and this dissertation, and the type of data that can be
used in the analysis of these two studies. When Mendelian randomization was initially
considered in the literature, data on the same set of individuals was generally used,
known as a ‘one–sample’ Mendelian randomization study [23]. Typically, individual
level data on the risk factor, outcome, and genetic variants are used in the analysis
model for one–sample Mendelian randomization. However, it is possible for estimates
and standard errors of the genetic associations with the risk factor and with the
outcome, referred to as ‘summary level data’, to be used in the analysis of a one–sample
Mendelian randomization study.
It has now become increasingly popular for Mendelian randomization analyses to use
data from two independent samples, known as a ‘two–sample’ Mendelian randomization
study [24]. Two–sample Mendelian randomization studies generally use summary level
data where the estimates and standard errors of the genetic associations with the
risk factor are obtained from one sample, and the estimates and standard errors of
the genetic associations with the outcome are obtained from the other sample. It is
assumed that the two independent samples come from the same underlying population.
Typically, ‘summary level data’ refers to the case where the genetic associations with
the risk factor and the genetic associations with the outcome have been estimated in two
independent samples (i.e. a two–sample Mendelian randomization study). However,
as noted above, it is possible for summary level data to be used in a one–sample
study. Throughout this dissertation, we assume that ‘summary level data’ refers to
the two–sample setting unless explicitly stated otherwise.
Since access to individual level data can be restrictive, and summary level data
is often publicly available from GWASs and large consortia, two–sample Mendelian
randomization studies continue to grow in popularity [25]. This has led to numerous
methodological developments in using summary level data in Mendelian randomization.
Databases, such as Phenoscanner [26], and software, such as MR-Base [27], have been
developed to allow users to extract summary level data from published GWASs and
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Type	of	Mendelian	
randomization	study: One-sample:
data obtained	on	the	same	set	
of	individuals
or Two-sample:
data obtained	on	two	
independent	sets	of	individuals
Type	of	data	used	in	the	
analysis: Individual level:	
data	on	the	risk	factor,	outcome	
and	genetic	variants.	
and/or Summary	level:	
estimates	and	standard	errors	of	
the	genetic	associations	with	the	
risk	factor	and	with	the	outcome
Fig. 1.2 Diagram illustrating some of the types of Mendelian randomization studies and the
data used in the analysis.
consortia databases. MR-Base will even perform a two-sample Mendelian randomization
analysis if the user specifies a risk factor and outcome.
1.6 Motivation for the dissertation
The overarching aim for this dissertation was to develop methods for applied Mendelian
randomization studies. Some of the method development in this dissertation has been
motivated by our main applied example of investigating the effect of adiposity and
body composition on asthma using data from UK Biobank in a one–sample Mendelian
randomization study. UK Biobank is a prospective, population based cohort consisting
of approximately 500,000 participants aged between 40-69 years living in the UK.
Extensive baseline characteristics were collected at recruitment, including adiposity,
body composition measurements and genetic information.
The primary research question for this applied example was to use body mass
index (BMI) as a measure of adiposity to perform a Mendelian randomization study
to investigate the effect of BMI on asthma. Since the results from a Mendelian
randomization study may be invalid if the IV2 or IV3 assumptions are violated, we
consulted the literature on Mendelian randomization to identify methods that detect or
account for the inclusion of pleiotropic variants (discussed in Chapter 2). Identifying
gaps in the literature, we developed and extended ‘robust methods’ that downweight or
remove pleiotropic genetic variants (Chapter 3). It was anticipated that these methods
would be used in the sensitivity analysis for the Mendelian randomization study on
BMI and asthma (Chapter 6).
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UK Biobank has measurements on body composition, including fat mass (FM)
and fat-free mass (FFM). To have a more comprehensive appreciation for the effect of
adiposity and body composition on asthma, we considered the possibility of investigating
the simultaneous effect of FM and FFM on asthma in a one–sample Mendelian
randomization study. Since there is a substantial overlap in the genetic variants that
are associated with FM and FFM, the IV assumptions would have been violated if
the effect of FM and FFM on asthma had been considered in separate Mendelian
randomization analyses. However, multivariable Mendelian randomization has been
developed to allow for causal effects of multiple risk factors that share common genetic
predictors to be estimated in the same analysis [28].
The estimates from multivariable Mendelian randomization may be invalid if
pleiotropic variants that are associated with traits that do not lie on the causal
pathways between the risk factors and outcome (violation of the IV3 assumption
for multivariable Mendelian randomization) are included in the analysis. However,
there are no methods that estimate consistent causal effects of multiple risk factors
when pleiotropic variants that violate the IV3 assumption for multivariable Mendelian
randomization are included in the analysis. Since the MR-Egger method has been
developed to estimate consistent causal effects in the presence of pleiotropic variants
when one risk factor is included in the analysis [29], we considered the extension of
this method to the multivariable setting (Chapter 4) with the anticipation of using
the method in the sensitivity analysis for investigating the effect of FM and FFM on
asthma (Chapter 6).
Whilst expanding MR-Egger to the multivariable setting, it became evident that
there may be circumstances where detecting interaction effects between risk factors
would be of interest. This observation initiated work on estimating statistical interac-
tion effects in ‘factorial’ Mendelian randomization (Chapter 5). The methodological
framework required to estimate interaction effects between risk factors in Mendelian
randomization has not been considered in the literature. However, there has been ap-
plied examples on estimating interaction effects between pharmacological interventions,
but there remain various unresolved methodological issues relating to this application.
Note that this work was not directly relevant to our investigation of the effect of
adiposity and body composition on asthma as we did not suspect that there would be
statistical interactions in this applied project.
In the next Section, we provide an overview of the dissertation and outline the
material presented in each Chapter.
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1.7 Structure of the dissertation
The additional assumptions required to estimate causal effects and the most frequently
used IV methodology in Mendelian randomization are outlined in Chapter 2. The
difficulties of considering binary outcomes in Mendelian randomization are highlighted
and discussed in this Chapter. Chapter 2 also contains a literature review on sensitivity
analyses in Mendelian randomization that try to identify or account for pleiotropic
genetic variants to produce unbiased causal estimates. The review focuses on methods
that use summary level data of the genetic associations with the risk factor and with
the outcome in Mendelian randomization.
Chapter 3 introduces four robust methods for Mendelian randomization using
summary level data. In this Chapter, we assume that heterogeneity among the causal
ratio estimates is due to pleiotropic variants. As such, the proposed methods in Chapter
3 remove or downweight the contribution of genetic variants with heterogeneous causal
ratio estimates. These methods are compared to other methods in the literature
(outlined in Chapter 2) in two applied examples and an extensive simulation study. As
highlighted in the acknowledgements, this work is adapted and extended on material
uploaded to arXiv by Burgess et al. [30] (see Appendix A for a copy of this work). A
paper has now been published on this material [31] (see Appendices B and C for a
copy of the manuscript and its appendix).
In Chapter 4, we extend the MR-Egger method [29] to the multivariable setting to
account for both measured and unmeasured pleiotropy (the ‘multivariable MR-Egger
method’). Through theoretical arguments, we outline the assumptions required to
obtain a consistent causal estimate from the multivariable MR-Egger method. We
apply the method to published genetic data, and consider the performance of the
method in a simulation study. A paper has already been published on this material
[32] (see Appendices D and E for a copy of the manuscript and its appendix).
Chapter 5 presents work on estimating causal interaction effects of risk factors on
an outcome in Mendelian randomization analyses. This extension to the Mendelian
randomization framework is considered in a simulation study and an applied example.
Interaction effects between pharmacological interventions in Mendelian randomization
has already been considered in the literature [33–35], and Chapter 5 also addresses some
of the unresolved methodological issues relating to this work. A paper has now been
published on this material [36] (see Appendices F and G for a copy of the manuscript
and its appendix).
Chapter 6 investigates the causal effect of adiposity and body composition on asthma
using data from UK Biobank in an extensive one–sample Mendelian randomization
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study. A two–sample Mendelian randomization study is also considered by using data
from UK Biobank and the GABRIEL (A Multidisciplinary Study to Identify the Genetic
and Environmental Causes of Asthma in the European Community) Consortium [37].
Various Mendelian randomization methodology, including the multivariable MR-Egger
method developed in Chapter 4, were considered in the studies.
Finally, Chapter 7 discusses the dissertation as a whole, outlines the limitations of
the work, and suggests avenues of further research.
Chapter 2
Statistical methods for Mendelian
randomization
In this Chapter, we outline the sufficient assumptions required to statistically test for
and estimate a causal effect (Sections 2.1 and 2.2), introduce the most commonly used
IV methods in Mendelian randomization, and highlight some of the issues of estimating
the causal effect with a binary outcome (Section 2.3). We define pleiotropic genetic
variants within the context of Mendelian randomization and discuss the impact they
may have on the causal estimate (Section 2.4). We also discuss heterogeneous ratio
estimates and the exploratory analyses typically performed in Mendelian randomization
to detect pleiotropic genetic variants (Section 2.5). Finally, we provide an overview
of methods that detect or account for pleiotropic variants using summary level data
(Section 2.6).
2.1 Testing for a causal effect
We assume that the genetic variant G satisfies the IV assumptions for a risk factor X
and outcome Y . Under the structural assumption (Equation 1.2) in Section 1.4, we can
test for a causal effect of X on Y by testing for an association between G and Y . If G
is associated with Y , we can infer that the risk factor is causally associated with the
outcome [2]. If Y ⊥ X|U (i.e. there is no arrow between X and Y in Figure 1.1), then
the causal effect between X and Y is zero, and G ⊥ Y . However, the converse does
not always hold, i.e. if G ⊥ Y it does not necessarily imply that Y ⊥ X|U ; known as
the ‘non faithfulness’ of a DAG [2].
If Y is a continuous variable, we could regress Y against G in a linear regression
model to determine whether X has a causal effect on Y . Note that the regression
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coefficient will not have a meaningful interpretation and should only be used as a
test for a causal effect. We must make additional assumptions to estimate a causal
parameter for the effect of X on Y (considered in Section 2.2 below).
2.2 Additional assumptions for a point estimate
Additional modelling assumptions must be made to estimate the causal effect of the
risk factor on the outcome. We consider the scenario where we have a continuous risk
factor X, continuous outcome Y , unmeasured confounding variables U of the X − Y
association, and J independent (not in linkage disequilibrium) genetic variants Gj
(j = 1, . . . , J) that satisfy the IV assumptions.
We assume that for each individual i (i = 1, . . . , N1) the risk factor Xi is a linear
function of the J genetic variants Gij (j = 1, . . . , J), the unmeasured confounders Ui
of the X − Y association, and the error term ϵXi:
Xi = β0 +
J∑
j=1
βXjGij + ζXUi + ϵXi ,
where βXj is the effect of the jth genetic variant on X, and ζX is the effect of the
unmeasured confounders U on X. Gij is the number of minor alleles at the jth genetic
variant for the ith individual, and can take the value 0, 1 or 2. The J genetic associations
with the risk factor βXj (j = 1, . . . , J) can be estimated by regressing the risk factor
against each of the genetic variants in linear regression models, where it is assumed that
the minor allele has an additive effect on X. We also assume that for each individual i
(i = 1, . . . , N2) the outcome is a linear function of the risk factor Xi, the unmeasured
confounders Ui of the X − Y association, and the error term ϵY i:
Yi = θ0 + θXi + ζYUi + ϵY i , (2.1)
where ζY is the effect of the unmeasured confounders U on Y , and θ represents the
causal parameter of interest. Under the structural assumption (Equation 1.2), we
assume that Equation 2.1 is valid when X is intervened on or observed. Under these
model assumptions, the causal parameter is given by:
θ = cov(Y,Gj)cov(X,Gj)
(2.2)
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and this can be estimated by the Wald (ratio) estimator defined in Section 2.3.1. Note
that the J genetic associations with the outcome βYj (j = 1, . . . , J) can be estimated
by regressing the outcome against each of the genetic variants in linear regression
models.
Figure 2.1 contains a DAG of Gj, X, U and Y , where Gj satisfies the IV assump-
tions. As highlighted in Section 1.5.1, the arrow between Gj and X does not have to
be causal, but Gj should be in linkage disequilibrium with the genetic variant that
has a causal effect on X. In Figure 2.1, we have included the parameters defined in
the model assumptions, i.e. θ represents the causal parameter of interest as defined in
Equation 2.2. Strictly speaking, DAGs should provide a non-parametric representation
of the relationships between a set of variables, but throughout this dissertation we
include the parameters considered in the model assumptions for ease of interpretation.
𝐺" 𝑋 𝑌𝛽&' 𝜃
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Fig. 2.1 Directed acyclic graph illustrating the Mendelian randomization assumptions for the
J genetic variants Gj (j = 1, . . . , J) to investigate the causal effect of a continuous risk factor
X on a continuous outcome Y . The genetic effect of Gj on X is βXj , and the causal effect of
the risk factor X on the outcome Y is θ. U represents the set of unmeasured variables that
confound the association between X and Y with effects ζX and ζY .
2.3 Estimating the causal effect
Under the model assumptions defined in Section 2.2, we consider the IV methods
that are most frequently used in Mendelian randomization to estimate the causal
parameter θ in Equation 2.2: the Wald (ratio) estimator that typically uses summary
level data (Section 2.3.1) [2]; and two stage-least squares (TSLS) regression that uses
individual level data (Section 2.3.1) [38]. Since this dissertation is primarily interested
in Mendelian randomization methods that use summary level data, the Wald (ratio)
estimator is discussed in detail. Although not considered here, methods based on
limited information maximum likelihood [39], generalised methods of moments [40, 41],
and Bayesian approaches [42, 43] may also be used to estimate the causal effect. Since
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we assume that Y is a continuous variable throughout this Chapter, we highlight some
of the issues of estimating the causal effect when the outcome is binary (Section 2.3.3).
2.3.1 Wald (ratio) estimator
We assume that we have summary level data on the risk factor and outcome from
two independent samples: the genetic association estimates (βˆXj and βˆYj) and their
standard errors (se(βˆXj ) and se(βˆYj )) for the J genetic variants Gj (j = 1, . . . , J). The
causal effect θ of the risk factor X on the outcome Y can be estimated with one genetic
variant Gj using the Wald (ratio) method by dividing the genetic association estimate
with the outcome by the genetic association estimate with the risk factor:
θˆj =
βˆYj
βˆXj
. (2.3)
The ratio method can also be applied directly to individual level data. For example, if
Gj consisted of two subgroups, then the ratio estimator is the average difference in the
risk factor between the two subgroups of Gj divided by the average difference in the
outcome between the two subgroups of Gj.
An estimate of the causal effect based on all the genetic variants can also be obtained
from the weighted average of the J causal ratio estimates:
θˆIV W =
∑J
j=1wj θˆj∑J
j=1wj
, (2.4)
where wj is the inverse-variance of the causal ratio estimate θˆj [44]. The pooled estimate
in Equation 2.4 is known as the ‘inverse-variance weighted’ (IVW) method [45]. Under
a fixed effect model, where we assume that there is no heterogeneity among the causal
ratio estimates [46], the variance of the IVW estimate is given by:
var(θˆIV W ) =
1∑J
j=1wj
. (2.5)
The inverse-variance weights wj in Equations 2.4 and 2.5 can be approximated from
a delta method expansion of the ratio estimate [47]. The first order approximation of
wj from the delta expansion is most commonly used in the IVW estimator [48]:
1st order approximation of wj =
βˆ2Xj
se(βˆYj)2
. (2.6)
2.3 Estimating the causal effect 15
Equation 2.6 assumes that there is no uncertainty in the genetic associations with
the risk factor, known as the NO Measurement Error (NOME) assumption [49]. The
NOME assumption will only be satisfied if N1 is infinite. Since summary level data
is obtained from GWASs and consortia with very large sample sizes, the NOME
assumption may be considered reasonable.
The causal effect of the risk factor on the outcome can also be estimated using
a weighted linear regression of the genetic association estimates with the risk factor
(βˆXj) and the genetic association estimates with the outcome (βˆYj) [45], with the
inverse-variance as weights (se(βˆYj)−2):
βˆYj = θIV W βˆXj + ϵj, ϵj ∼ N (0, φ2 se(βˆYj)2) , (2.7)
where ϵj represents the error term, φ represents the residual standard error, and the
intercept term is set to zero under the IV2 and IV3 assumptions. To obtain the same
variance as the IVW estimate in Equation 2.5, the residual standard error in the
weighted linear regression model in Equation 2.7 must be set to one. By fixing φ to one,
Equation 2.7 is equivalent to performing a fixed-effect meta-analysis of the J causal
ratio estimates θˆj (j = 1, . . . , J) [50].
If heterogeneity among the ratio estimates is suspected, then a multiplicative
random-effects model may be preferred to a fixed-effect model. Although the point
estimates from the fixed- and random-effect models will be the same, the standard
error of the causal estimate from the multiplicative random-effects model will be larger
if there is heterogeneity among the ratio estimates. The variance of the IVW estimator
under a multiplicative random-effect model with first order weights (Equation 2.6) is
given by:
var(θˆIV W ) =
φˆ2∑J
j=1 βˆ
2
Xj
se(βˆYj)−2
,
where φˆ is the estimate of the residual standard error. If φˆ > 1, then this suggests
that there is over-dispersion in the ratio estimates [50]. Note that it is not biologically
plausible for the causal ratio estimates to be under-dispersed (φˆ < 1) if the genetic
variants are independent (not in linkage disequilibrium) [46]. φˆ is not allowed to be
lower than one to ensure that the causal estimate from the multiplicative random-effect
model is never more precise than the estimate from the fixed-effect model.
Instead of using multiplicative random-effects, an additive random-effects model
could be used (not considered throughout this dissertation). This would be equivalent
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to performing an additive random-effects meta-analysis of the J causal ratio estimates
θˆj (j = 1, . . . , J) [50]. The estimates and standard errors from the fixed-effects and
additive random-effects models will differ if there is heterogeneity among the J causal
ratio estimates θˆj (j = 1, . . . , J). However, additive random-effects are rarely used
in Mendelian randomization, with multiplicative random-effects generally being used
when heterogeneity among the ratio estimates is suspected. This preference may be
due to the fixed-effects and multiplicative random-effects models estimating the same
point estimate. Additionally, Bowden et al. [51] have cautioned against the use of
additive random-effects as weak instruments may be given too much weight under
certain scenarios, resulting in more biased estimates of the causal effect under the
additive random-effects model than the fixed-effect model.
2.3.2 Two-stage least squares regression
If there is individual level data on the risk factor, outcome, and genetic variants, then
the casual effect θ can be estimated using two-stage least squares (TSLS) regression
[38] in a one–sample Mendelian randomization study. Under TSLS regression, θ is
estimated from the two linear regression models: 1) the regression of the risk factor
X against the genetic variants G; and 2) the regression of the outcome Y against the
predicted values of the risk factor Xˆ from 1). The coefficient of Xˆ in the second stage
regression model is the TSLS estimate of the causal effect θ. If TSLS is performed
manually, the uncertainty in the first stage regression will not have been accounted for,
and the causal estimate will be too precise. As such, TSLS regression software should
be used to obtain accurate standard errors of the causal estimate. The estimate from
the IVW method will be asymptotically equivalent to the estimate from the TSLS
method if the genetic variants are uncorrelated [52].
2.3.3 Binary outcomes
Throughout this Section, we only consider linear additive models where the risk
factor X and outcome Y are continuous variables. It is likely that the outcome of
interest will be binary in an epidemiological study, and the causal odds ratio will be
the preferred measure of association. Odds ratios are a non-collapsible measure of
association, meaning that if the odds ratio takes a constant value across the strata of
a covariate, the value obtained from the marginal analysis may not be equal to this
constant value [53]. Whilst the numerator in Equation 2.3 could be replaced with the
estimate of the log odds ratio of the jth genetic variant with the outcome, and the
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second stage regression model in TSLS be replaced with logistic regression, due to
the non-collapsibility of the odds ratio, these estimators will generally not produce
consistent estimates of the causal odds ratio [54]. If the outcome is rare, then these
versions of the ratio estimator and TSLS regression will approximate the causal risk
ratio [55]. Hence, the IVW method and TSLS regression will only provide approximate
measures of the causal odds ratio for the effect of a continuous risk factor X on a
binary outcome Y . TSLS with a logistic regression in the second stage will, however,
provide a valid test for the null hypothesis of no causal association [56].
The Mendelian randomization study on the effect of adiposity and body composition
on asthma, considered in Chapter 6, has a binary outcome measurement. We note that
the methods in Chapters 3 to 5 have been primarily developed under the assumption
that the outcome is a continuous variable. We do investigate in a simulation study
whether the methods proposed in Chapter 3 provide a good approximation of the
causal effect when the outcome is binary rather than continuous. The limitations
of considering a continuous outcome variable in Chapters 3 to 5 are highlighted and
discussed in each Chapter.
2.4 Pleiotropic genetic variants
In this Section, we define a pleiotropic genetic variant within the context of Mendelian
randomization. We consider pleiotropic effects and the impact they may have on the
causal estimate from the IVW method.
In a Mendelian randomization study, a pleiotropic variant is defined as a genetic
variant Gj that is associated with multiple traits, including the risk factor X of interest
(Figure 2.2). If a pleiotropic genetic variant is associated with traits that mediate the
relationship between the risk factor and the outcome, and the genetic variant has no
direct effect on these mediators, i.e. the mediators lie on the same causal pathway
as the genetic variant and risk factor, then the IV3 assumption will not be violated
(referred to as ‘vertical pleiotropy’). For example, we may suspect that age at menarche
has an effect on body mass index (BMI), and BMI has an effect on breast cancer. If
the pleiotropic genetic variant used as an IV for age at menarche has no direct effect
on BMI, then the IV3 assumption will not be violated. However, if the variant is
associated with multiple traits on causal pathways that are independent of the risk
factor, then the IV2 or IV3 assumptions will be violated (referred to as ‘horizontal
pleiotropy’).
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Figure 2.2 contains examples of horizontal pleiotropy, where δj represents the effect
of the genetic variant on the unmeasured confounders, and αj represents the direct
effect of Gj on the outcome. The IV2 assumption would be violated if δj ̸= 0, and the
IV3 assumption would be violated if αj ̸= 0. Since it is not possible to distinguish
between vertical and horizontal pleiotropy, and the biological mechanisms between the
genetic variants and the risk factor are rarely understood in a Mendelian randomization
study [57], the inclusion of pleiotropic genetic variants is a real concern.
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Fig. 2.2 Directed acyclic graph illustrating Mendelian randomization assumptions with
potential violation of IV2 or IV3 by a pleiotropic effect indicated by two dotted lines. The
genetic effect of Gj on X is βXj , the genetic effect of Gj on U is represented by δj (representing
the potential violation of the IV2 assumption), the direct effect of Gj on Y is αj (representing
the potential violation of the IV3 assumption), and the causal effect of the risk factor X
on the outcome Y is θ. U represents the set of unmeasured variables that confound the
association between X and Y with effects ζX and ζY .
Throughout this dissertation we only consider pleiotropy with respect to the
violation of the IV3 assumption: a pleiotropic variant is associated with the outcome Y
via a causal pathway that is independent of the risk factor X and the set of unmeasured
confounding variables U (αj ≠ 0 in Figure 2.2). Under this definition of pleiotropy,
and assuming that all of the associations are linear with no effect modification, we can
express the genetic association with the outcome as a linear combination of the direct
effect and the indirect effect via the risk factor:
βY j = αj + θβXj .
The genetic variant Gj is pleiotropic and violates the IV3 assumption if αj ̸= 0. If the
genetic variant Gj is pleiotropic, then the ratio estimand for the causal effect of X on
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Y for the jth genetic variant would be:
θj = θ +
αj
βXj
,
where αj/βXj is the non-zero bias term. If G contains multiple pleiotropic variants
whose average direct effect is zero (referred to as ‘balanced pleiotropy’), and the direct
effects are independent of the genetic associations with the risk factor, then the IVW
method will produce consistent causal estimates [51]. If the average direct effect differs
from zero (referred to as ‘directional pleiotropy’), then the IVW estimate will be biased.
2.5 Heterogeneity and pleiotropic variants
There should be little heterogeneity in the ratio estimates θ if all of the genetic variants
G are valid IVs. Heterogeneity among the causal ratio estimates may provide evidence
that some of the genetic variants are pleiotropic. As such, the validity of the IV
assumptions for genetic variants with outlying or heterogeneous ratio estimates should
be considered in more detail.
In this Section, we outline the exploratory analyses typically used in Mendelian
randomization to assess heterogeneity among the ratio estimates: plots of the genetic
associations; and a formal test for heterogeneity. Finally, we discuss the limitation of
assuming that genetic variants with heterogeneous ratio estimates are pleiotropic.
2.5.1 Plots of the genetic associations
Scatter plots of the genetic association estimates with the outcome βˆY against the
genetic association estimates with the risk factor βˆX are frequently used in Mendelian
randomization to inspect summary level data (used throughout this dissertation) [48].
Figure 2.3 contains an example scatter plot (considered in the applied example in
Chapter 3) of the genetic associations and 95% confidence intervals with Alzheimer's
disease (outcome of interest) against the genetic associations and 95% confidence
intervals with low-density lipoprotein (risk factor of interest) for 75 genetic variants.
Each data point represents a single genetic variant, and the gradient of the line
connecting the data point to the origin represents the ratio estimate θˆj (dotted line in
Figure 2.3 is provided as an example). The weighted average of the ratio estimates from
the IVW method is usually displayed in these scatter plots to allow for comparisons
between the J ratio estimates and the IVW estimate (solid line in Figure 2.3).
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Fig. 2.3 Scatter plot of the estimated genetic associations and 95% confidence intervals
with Alzheimer's disease (log odds ratios) against the estimated genetic associations and
95% confidence intervals with low-density lipoprotein (LDL-C, standard deviation units)
for 75 genetic variants. The dotted line represents the ratio estimate for the rs6859 genetic
variant, and the solid line is the inverse-variance weighted estimate of the effect of LDL-C on
Alzheimer's disease. See Section 3.4 for more detail on the dataset used, and the analyses
performed.
The scatter plots of βˆY against βˆX may highlight heterogeneity among the ratio
estimates. We should observe a dose-response relationship in the scatter plot if all of
the genetic variants are valid IVs. A pleiotropic variant may appear as an outlier if the
majority of the genetic variants are valid IVs. In Figure 2.3, we may suspect that the
genetic variants rs6859 and rs7254892 are pleiotropic as they are outliers to the main
group of genetic variants.
Funnel plots used in the meta-analysis literature can be used in Mendelian random-
ization to detect directional pleiotropy by plotting the precision of the ratio estimates
(
√
w) against θˆ [58, 29]. If the genetic variants are valid IVs, the plot should be a sym-
metric funnel with the precise ratio estimates having less variability [59]. Asymmetry in
the funnel plot suggests that there is heterogeneity among the ratio estimates, and the
average direct effect of the genetic variants may be non-zero (directional pleiotropy).
Bowden et al. [48] have adapted the Galbraith Radial plot used in the meta-analysis
literature [60] as a replacement to the scatter plot in Figure 2.3. The Radial plot
2.5 Heterogeneity and pleiotropic variants 21
provides a more transparent indication of the contribution each genetic variant makes
to the IVW estimate. The authors have also proposed a Radial funnel plot [48].
2.5.2 Test for heterogeneity
Cochran’s Q statistic is used in meta-analysis to test for heterogeneity [61]. Del Greco
et al. [62] first introduced the idea of using the Q statistic to test for heterogeneity
among the ratio estimates in Mendelian randomization:
Q =
∑
j
wj(θˆj − θˆIV W )2 , (2.8)
where Q has an approximate χ2J−1 distribution under the null hypothesis that all J
genetic variants satisfy the IV assumptions [62]. If the Q statistic provides evidence of
heterogeneity among the ratio estimates then a multiplicative random-effects model
should be used in the main analysis (as discussed in Section 2.3.1). A statistically
significant Q statistic may suggest that some of the genetic variants inG are pleiotropic.
The Type I error rate of detecting heterogeneity among the ratio estimates may be
inflated if the first order approximations of wj (Equation 2.6) are used in Equation 2.8
[63]. This limitation has been addressed by Bowden et al. [63] who have proposed a
modified weight for wj.
2.5.3 Limitations
Although the exploratory analyses described above are useful tools in detecting hetero-
geneity among the ratio estimates, their utility may be limited. We have assumed that
heterogeneity among the causal ratio estimates is due to pleiotropic genetic variants.
Whilst this assumption may be correct, there are other reasons why the ratio estimates
may be heterogeneous, including population stratification, systematic measurement
errors in the risk factor and outcome, and non-linearity.
Scatter plots of the genetic associations are easy to interpret and provide a good
overview of the data in a Mendelian randomization study. However, the plots should not
be used uncritically as a tool to exclude genetic variants. Genetic variants that appear
as ‘obvious’ outliers in the scatter plot of the genetic associations may be perfectly
valid IVs. Instead, the plots should be used as a tool to identify genetic variants that
require additional investigation into the plausibility of the IV assumptions. Unlike the
scatter plots, the Q statistic quantifies whether there is heterogeneity among the ratio
estimates. Whilst this can be helpful in determining whether fixed- or random-effects
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should be used in the IVW model, it does not provide any information on the source
of the heterogeneity, and in particular, whether it is a result of balanced or directional
pleiotropy.
In the next Section, we discuss methods that systematically account for pleiotropic
variants in Mendelian randomization analyses.
2.6 Sensitivity analyses
In this Section, we review the methods in the IV literature that detect or account
for pleiotropic genetic variants using summary level data. These methods can be
divided into two broad categories: methods that downweight or remove genetic variants
(Section 2.6.1); and methods that estimate consistent causal effects in the presence of
pleiotropic genetic variants without downweighting their contribution to the causal
estimate. For the second category, we discuss two methods: one method that relaxes
the IV3 assumption and introduces a weaker assumption (MR-Egger method in Sec-
tion 2.6.2); and another method that extends the IV assumptions to the multivariable
setting (‘multivariable Mendelian randomization’ in Section 2.6.3). We discuss these
two methods in detail as they are instrumental to Chapters 4 and 5.
Although this review focuses on methods that use summary level data, we acknowl-
edge that there are many methods in the IV literature that detect or account for
pleiotropic variants using individual level data [64–69].
2.6.1 Downweighting or removing genetic variants
In this Section, we consider methods that try to identify pleiotropic genetic variants
to downweight their contribution to the causal estimate, or exclude them from the
analysis. These methods assume that there is a subgroup of genetic variants that
satisfy the IV assumptions. Note that genetic variants may be assigned a weight of
zero but are not explicitly removed from the dataset.
Downweighting genetic variants
The simple median estimator is the median of the J ratio estimates θˆj (j = 1, . . . , J)
[52]. It will produce consistent causal estimates if at least 50% of the genetic variants
are valid IVs, known as the ‘50% rule’ or ‘majority rule’ [70]. The standard error of
the simple median estimate is obtained through bootstrapping methods. If there is
variability in the precision of the ratio estimates then the efficiency of the median
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estimator can be improved by using the inverse-variance weights, known as the ‘weighted
median estimator’ [52]. The weighted median estimate is the 50th percentile of the
inverse-variance weighted empirical distribution of θˆ. The estimates will be consistent if
50% or more of the weights from valid IVs contribute to the weighted median estimate.
If more than 50% of the genetic variants are invalid IVs, then the simple median
estimator will be biased. To overcome this limitation, Hartwig et al. [71] have
introduced a mode-based estimator (MBE) that produces asymptotically consistent
causal estimates when more than 50% of the variants are invalid IVs. The estimates from
the MBE will be consistent if the valid IVs make up the largest subset of homogeneous
ratio estimates, known as the ‘zero modal pleiotropy assumption’ (ZEMPA). The
estimate from the MBE is the mode of the smoothed empirical density function of the
J ratio estimates:
f(x) = 1
h
√
2π
J∑
j=1
wMBEjexp
[
− 12
(
x− θˆj
h
)2]
,
where the causal estimate x is the value that maximizes f(x), h is the smoothing
bandwidth, and wMBE are the weights [71]. The ratio estimates can either have an
equal contribution to x under the ‘simple MBE’, or standardized inverse-variance
weights can be used under the ‘weighted MBE’. The value of h must be specified by
the user, with larger values producing more precise estimates. Results from the MBE
can be highly sensitive to the values of h [72]. Simulation studies have shown that the
MBE may be less efficient than the weighted median estimator [71].
Burgess et al. [72] have developed a heterogeneity-penalized model-averaging
method that is based on the ZEMPA assumption. The overall causal estimate from
this method is the mode of the mixture distribution of the estimates obtained from
each possible subset of genetic variants (excluding subsets with 0 or 1 genetic variants).
Larger subsets of genetic variants are given a greater weight in the mixture distribution
unless their ratio estimates are heterogeneous, in which case, the contribution of the
subset to the mixture model is dramatically reduced. Unlike the method proposed by
Hartwig et al. [71], a bandwidth does not need to be specified by the user, and the
standard errors are obtained without using bootstrapping methods [72].
Although the median- or mode-based estimators do not explicitly remove any of
the genetic variants from the analysis, some of the genetic variants will have no direct
contribution to the overall causal estimate. As such, these methods may be less efficient
than methods that explicitly exclude genetic variants from the analysis (considered
below).
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Removing genetic variants
The Mendelian randomization pleiotropy residual sum and outlier (MR-PRESSO)
method has three main functions using summary level data: 1) to test for directional
pleiotropy (MR-PRESSO global test); 2) to identify outlying variants that may be
pleiotropic (MR-PRESSO outlier test); and 3) to empirically test the difference between
the IVW estimates using the full and reduced sets of genetic variants [73]. The MR-
PRESSO global test is performed by calculating the global observed residual sum of
squares (RSSobs):
RSSobs =
J∑
j=1
RSSobsj =
J∑
j=1
(βˆYj − θˆIV W−j βˆXj)2 se(βˆY j)−2 ,
where θˆIV W−j is the estimate from the IVW model when the jth genetic variant has
been removed. RSSobs is compared against a simulated expected distribution of the
residual sum of squares under the null hypothesis of no pleiotropy. The expected RSS
is given by:
RSSexp =
J∑
j=1
RSSexpj =
J∑
j=1
(βˆ′Yj − θˆIV W−j βˆ′Xj)2 se(βˆY j)−2 ,
where the genetic associations βˆ′Xj and βˆ
′
Yj
are simulated from the normal distributions:
βˆ′Xj ∼ N (βˆXj , se(βˆXj)2) and βˆ′Yj ∼ N (θˆIV W−j βˆXj , se(βˆYj)2) .
RSSexp is generated N times to obtain a distribution of N expected residual sum of
squares. An empirical p-value for the global test of directional pleiotropy is calculated
as the proportion of times the N expected residual sum of squares is greater than
RSSobs. Verbanck et al. [73] recommend that N ≥ 1, 000 to ensure there is adequate
precision of the p-value. Note that the individual residual sum of squares RSSobsj
can be used to identify pleiotropic genetic variants, allowing for the ‘corrected’ causal
estimate to be obtained from the IVW method based on the reduced set of genetic
variants.
The global and individual tests for direct effects (GLIDE) method has also been
proposed to detect pleiotropy in summary level data [74]. Like the MR-PRESSO
method, GLIDE tests for global pleiotropy among the genetic variants and tries to
identify and exclude genetic variants that may be pleiotropic. This method uses Q-Q
plots and permutation procedures to identify pleiotropic genetic variants. Rather than
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considering a continuous outcome, the GLIDE method expresses the causal effect in
terms of the relative risk.
Other methods have been proposed that identify and remove pleiotropic variants,
including the heterogeneity in dependent instruments (HEIDI) method that was
introduced under the summary data-based Mendelian randomization (SMR) method
[75], and was developed further under the generalized SMR framework (GSMR).
2.6.2 MR-Egger
The MR-Egger (Mendelian randomization-Egger) method [29] was adapted from Egger
regression, a tool used in meta-analysis to detect small study bias [76]. MR-Egger
can be used to estimate consistent causal effects in the presence of pleiotropic genetic
variants, and to test the validity of the IV assumptions. The MR-Egger method
replaces the IV3 condition with the untestable assumption that the genetic associations
with the risk factor are independent of the direct effects of the genetic variants on the
outcome (βX ⊥ α), known as the InSIDE (instrument strength independent of direct
effect) assumption. Like the IVW method, MR-Egger also assumes that the NOME
assumption is satisfied.
The MR-Egger method fits the weighted linear regression of the genetic association
estimates with the risk factor (βˆXj) and the genetic association estimates with the
outcome (βˆYj) [45], with the inverse-variance as weights (se(βˆYj)−2) and the intercept
unrestrained:
βˆYj = θ0E + θEβˆXj + ϵEj ϵEj ∼ N (0, φ2E se(βˆYj)2) , (2.9)
where θ0E is the intercept term, θE is the MR-Egger causal effect, ϵEj is the error
term, and φE represents the residual standard error under the MR-Egger model. The
interpretation of the estimates θˆ0E and θˆE from the MR-Egger method are discussed
alongside the InSIDE and NOME assumptions in the subsections below.
θˆE and the InSIDE assumption
We initially assume that there is no estimation (or measurement) error in the genetic
associations with the risk factor, i.e. the NOME assumption is satisfied. If there are
no pleiotropic effects (α = 0), the MR-Egger estimate θˆE should be asymptotically
equivalent to the IVW estimate θˆIV W (Equation 2.7). The InSIDE assumption must
be satisfied for θˆE to be a consistent estimate of the causal effect θ in the presence of
balanced or directional pleiotropy [29, 64]. If the InSIDE assumption is satisfied, then
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the weighted covariance of βX and α (covw(α,βX)) will tend to zero as the number
of genetic variants J tends to infinity. The estimate of θ from MR-Egger is:
θˆE =
covw(βˆY , βˆX)
varw(βˆX)
N→∞−−−→ covw(βY ,βX)varw(βX) = θ +
covw(α,βX)
varw(βX)
, (2.10)
which is equal to θ if the InSIDE assumption is satisfied, where covw and varw represent
the weighted covariance and weighted variance using the inverse-variance as weights
se(βˆYj)−2:
covw(α,βX) =
∑
j(αj − α¯w)(βXj − β¯Xw) se(βˆYj)−2∑
j se(βˆYj)−2
,
varw(βX) =
∑
j(βXj − β¯Xw)2 se(βˆYj)−2∑
j se(βˆYj)−2
,
α¯w =
∑
j αj se(βˆYj)−2∑
j se(βˆYj)−2
,
β¯Xw =
∑
j βXj se(βˆYj)−2∑
j se(βˆYj)−2
.
If the InSIDE assumption is violated, and there is balanced or directional pleiotropy,
then the estimate of θ from MR-Egger will be biased due to the non-zero bias term in
Equation 2.10.
It seems more plausible that the InSIDE assumption will hold if the pleiotropic
effects are independent of the unmeasured variables U that confound the X − Y
association (δ = 0 in Figure 2.2). If the pleiotropic variants do lie on the same causal
pathway as the unmeasured confounders U of the X − Y association (δ ̸= 0), then it is
difficult to conceive how the InSIDE assumption would be satisfied as the strength of
the genetic associations with X will depend on the strength of the pleiotropic effects via
U . As noted in Section 2.4, throughout this dissertation we assume that a pleiotropic
variant is associated with the outcome Y via a causal pathway that is independent
of the risk factor X and the set of unmeasured confounding variables U (αj ̸= 0 in
Figure 2.2).
In terms of the standard error of θˆE, estimating the intercept term in Equation 2.9
will result in less precise estimates of the causal effect from the MR-Egger method
compared to the IVW method. Since the MR-Egger method allows for the possibility
of the genetic variants to be pleiotropic, applying a fixed-effects model to Equation 2.9
would not be logical. A multiplicative random-effects model, where the residual standard
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error φE is estimated, is therefore applied to the MR-Egger method throughout this
dissertation.
Orientation of the genetic variants
In this dissertation, we assume that Gj (j = 1, . . . , J) can take the value 0, 1 or 2,
representing the number of risk-increasing or risk-decreasing alleles of a bi-allelic genetic
variant. The interpretation of the genetic associations with the risk factor or outcome
will depend on whether Gj relates to the risk-increasing allele or risk-decreasing allele. If
Gj has been orientated with respect to the risk-increasing allele for X, then the genetic
association with the risk factor represents the average change in X per additional copy
of the risk factor-increasing allele. Since the intercept term in Equation 2.4 is fixed at
zero, the orientation of the genetic variants has no affect on the estimate of the causal
effect θ from the IVW method.
The orientation of the genetic variants will affect the estimates θˆ0E and θˆE from the
MR-Egger method as the orientation will determine the definition of the pleiotropic
effect. Hence, the orientation of the genetic variants will also affect the defintion of the
InSIDE assumption. Bowden et al. [29] therefore suggest that the genetic variants be
orientated to ensure the direction of the genetic associations with the risk factor are
either positive for all variants or negative for all variants.
θˆ0E and the MR-Egger intercept test
If we assume that the genetic variants Gj (j = 1, . . . , J) are orientated with respect
to the risk factor-increasing alleles, and the InSIDE assumption is satisfied, then the
estimate of the intercept term θˆ0E can be interpreted as the average direct effect
of the J genetic variants with respect to the risk factor-increasing alleles [52]. The
InSIDE assumption will be satisfied if βX ⊥ α when the genetic variants are orientated
with respect to the risk factor-increasing alleles. If there is balanced pleiotropy, and
the InSIDE assumption is valid, then the intercept term should tend to zero as the
sample size increases. If the intercept term differs from zero, then either the InSIDE
assumption is violated, or there is directional pleiotropy, or both conditions are violated.
Testing the intercept term in Equation 2.9 is a way of assessing the validity of the IV
assumptions, and is known as the ‘MR-Egger intercept test’ [46].
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Violation of the NOME assumption
We now consider the impact the violation of the NOME assumption has on the MR-
Egger method. First consider the weighted variance of the genetic associations with
the risk factor:
varw(βˆX) = varw(βX) + s2w ,
where s2w is the weighted average of the variability in βˆX explained by estimation (or
measurement) error. If the NOME assumption is satisfied, there is no uncertainty in
the genetic associations with the risk factor, and s2w is equal to zero.
If the InSIDE assumption is satisfied, then the expected value of the MR-Egger
estimate can be expresssed as [49]:
E[θˆE] = E
covw(βˆY , βˆX)
varw(βX)
varw(βX)
varw(βˆX)
 ≈ θ varw(βX)varw(βX) + s2w , (2.11)
and the MR-Egger method will produce a consistent estimate of the casual effect if the
NOME assumption is satisfied. From Equation 2.11, the MR-Egger estimate will be
attenuated towards zero if the NOME assumption is violated (s2w ̸= 0). Violation of the
NOME assumption will also lead to an increased Type I error rate for the MR-Egger
intercept test [49].
The extent to which the MR-Egger estimate θˆE is attenuated is dependent upon
varw(βX) and s2w. If there is a lot of variability in βX , and little estimation error, then
the attenuation of the MR-Egger estimate towards the null will be small. However, if
there is little variability in βX relative to the estimation error, then the attenuation of
the MR-Egger estimate will be more severe.
To account for the violation of the NOME assumption in Equation 2.11, we
require an estimate of varw(βX)/ varw(βˆX). Bowden et al. [49] have shown that
varw(βX)/ varw(βˆX) can be estimated through an adapted version of the I2 statistic
used in the meta-analysis literature to assess heterogeneity:
I2 = (QGX − (J − 1))
QGX
, (2.12)
where QGX is Cochran’s Q statistic for the genetic associations with the risk factor:
QGX =
J∑
j=1
(βˆXj se(βˆYj)−1 − ¯ˆβX)2
se(βˆXj)2 se(βˆYj)−2
,
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and ¯ˆβX is the mean of the genetic associations with the risk factor weighted by se(βˆXj )−2.
The I2 statistic will lie between 0 and 1, with smaller values corresponding to more
biased MR-Egger estimates. If the I2 statistic is close to 1, then there should be little
or no attenuation of the causal estimate from the MR-Egger method.
Since Bowden et al. [49] obtained unstable results when the MR-Egger estimate
θˆE was divided by I2, the authors suggest that a simulation extrapolation (SIMEX)
method be used to adjust for the violation of the NOME assumption when I2 < 0.9.
Under the SIMEX approach, estimates of the genetic associations with the risk factor
βˆλXj (j = 1, . . . , J) are simulated from:
βˆλXj ∼ N (βˆXj , λ se(βˆλXj)2) ,
where βˆXj and se(βˆλXj) are the observed data, and var(βˆ
λ
X) = (1 + λ)se(βˆλX)2. For a
given value of λ > 0, the simulated genetic associations βˆλXj (j = 1, . . . , J) and the
observed genetic associations with the outcome βˆYj (j = 1, . . . , J) are used to obtain
a MR-Egger estimate of the causal effect. This process is repeated multiple times
to obtain an average value of the MR-Egger estimate for a specific value of λ. This
whole process is then applied to a range of λ values that increase in small increments.
As λ increases, the average MR-Egger estimate will decrease as there will be more
attenuation towards zero. The average values for the MR-Egger estimates from the
different values of λ are extrapolated to estimate what the MR-Egger estimate may
have been if the NOME assumption had been satisfied.
Instrument strength
The strength of the association between the genetic variants and the risk factor for the
IVW method is usually assessed through the F-statistic from the regression of the risk
factor on the genetic variant(s). Genetic variants are often classified as ‘weak’ IVs if
they have a F-statistic less than 10. Weak IVs will produce asymptotically unbiased
causal estimates, but under finite samples they will bias the causal estimate (known
as ‘weak instrument bias’) [77, 78]. For one–sample Mendelian randomization, this
bias will be towards the confounded observational association, and for two–sample
Mendelian randomization the bias will be towards the null [79].
For MR-Egger, instrument strength should be assessed through the I2 statistic
(Equation 2.12) rather than the F-statistic. An I2 value close to 1 suggests that the
MR-Egger estimate does not suffer from weak instrument bias. If the I2 statistic is
equal to 0.9, then the attenuation of the MR-Egger estimate towards the null will
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be approximately 10% of the causal effect θ. To correspond with the classification of
‘weak’ IVs under the F-statistic for the IVW method, Bowden et al. [49] suggest that
the SIMEX method be applied when the I2 is less than 0.9.
2.6.3 Multivariable Mendelian randomization
Multivariable Mendelian randomization assumes that the direct effect α of the genetic
variants on the outcome is fully mediated through additional measured risk factors.
Rather than replacing the IV3 assumption with a weaker assumption (as done by the
MR-Egger method in Section 2.6.2), multivariable Mendelian randomization expands
the IV assumptions to allow for the causal effects of multiple risk factors on the outcome
to be estimated in the same model. Whilst the MR-Egger method should only be
included in the sensitivity analysis of a Mendelian randomization study, multivariable
Mendelian randomization can be used as a sensitivity analysis, or as the primary
analysis model.
Instrumental variable assumptions
Suppose we have K continuous risk factors Xk (k = 1, . . . , K), a continuous outcome
Y , and K sets of unmeasured confounding variables Uk (k = 1, . . . , K) of the X − Y
associations. The following assumptions must be satisfied in a multivariable Mendelian
randomization analysis:
• IV1(M): each genetic variant Gj (j = 1, . . . , J) is associated with at least one of
the K risk factors Xk (k = 1, . . . , K),
• IV2(M): each risk factor Xk (k = 1, . . . , K) is associated with at least one of the
J genetic variants Gj (j = 1, . . . , J),
• IV3(M): the variants Gj (j = 1, . . . , J) are independent of all unmeasured
confounders U of each of the risk factor–outcome associations, and
• IV4(M): the variants Gj (j = 1, . . . , J) are independent of the outcome Y condi-
tional on the risk factors X and confounders U [28].
From the above conditions, each genetic variant Gj (j = 1, . . . , J) must be associated
with at least one of the risk factors Xk (k = 1, . . . , K), and each risk factor Xk
(k = 1, . . . , K) must be associated with at least one of the genetic variants Gj (j =
1, . . . , J). Genetic variants that are associated with multiple risk factors can be used
in multivariable Mendelian randomization provided that these risk factors are included
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in the analysis. There must be as many genetic variants as there are risk factors for
the causal effects to be estimated, i.e. J ≥ K.
Figure 2.4 contains a DAG where the IV assumptions for multivariable Mendelian
randomization are satisfied for K = 3 risk factors. We assume that for each individual
i (i = 1, . . . , N1) each risk factor Xki is a linear function of the J genetic variants Gj
(j = 1, . . . , J), the unmeasured confounders Uki of the Xk − Y association, and the
error term ϵXki :
Xki = βk0 +
J∑
j=1
βXkjGij + Uki + ϵXki ,
where βXkj is the effect of the j
th genetic variant on Xk. Gij is the number of minor
alleles at the jth genetic variant for the ith individual, and can take the value 0, 1 or 2.
The J genetic associations with the risk factor Xk can be estimated by regressing Xk
against each of the genetic variants in linear regression models, where it is assumed that
the minor allele has an additive effect on Xk. We also assume that for each individual
i (i = 1, . . . , N2) the outcome is a linear function of the risk factors Xk (k = 1, . . . , K),
the unmeasured confounders Uki (k = 1, . . . , K) of the X − Y associations, and the
error term ϵYi . For K = 3, we can express Yi as:
Yi = θ0 + θ1X1i + θ2X2i + θ3X3i + U1i + U2i + U3i + ϵYi .
where θ are the direct effects of the risk factors on the outcome. The J genetic
associations with the outcome βYj (j = 1, . . . , J) can be estimated by regressing the
outcome against each of the genetic variants in linear regression models.
The aim of a multivariable Mendelian randomization analysis is to estimate the
direct effects of the risk factors on the outcome, when conditioned on each other.
These estimates can be obtained by using individual level data in one–sample multi-
variable Mendelian randomization or summary level data in two–sample multivariable
Mendelian randomization data as outlined in the subsections below (considered when
K = 3).
Individual level data
We assume that we have individual level data for the J genetic variantsGj (j = 1, . . . , J),
the three risk factors, and outcome on the same set of participants. Consistent estimates
of θ can be obtained from TSLS regression in a one–sample multivariable Mendelian
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Fig. 2.4 Directed acyclic graph illustrating the multivariable Mendelian randomization
assumptions for the J genetic variants Gj (j = 1, . . . , J) to investigate the causal effect of
K = 3 continuous risk factors Xk (j = k, . . . ,K) on a continuous outcome Y . The genetic
effect of Gj on Xk is βXkj , and the direct causal effect of the risk factor Xk on the outcome Y
is θk. Uk represents the set of unmeasured variables that confound the associations between
Xk and Y .
randomization study by: regressing each of the K risk factors against the J genetic
variants Gj (j = 1, . . . , J) to obtain the predicted values of the risk factors (Xˆ1, Xˆ2
and Xˆ3); and then regressing the outcome Y against Xˆ1, Xˆ2 and Xˆ3. The estimates for
Xˆ1, Xˆ2 and Xˆ3 from the second stage regression model should be consistent estimates
of θ if the IV assumptions for multivariable Mendelian randomization are satisfied.
Summary level data
We assume that we have summary level data for the three risk factors and outcome,
i.e. the genetic associations with the three risk factors are estimated in one sample,
and the genetic associations with the outcome are estimated in an independent sample.
Consistent estimates of θ can be obtained from the multivariable weighted linear
regression of the genetic association estimates with the K risk factors and the genetic
association estimates with the outcome, with se(βˆYj)−2 as weights and the intercept
set to zero (known as the ‘multivariable IVW method’) [80]. Assuming there are three
risk factors, under the multivariable IVW method we consider:
βˆYj = θ1MV βˆX1j + θ2MV βˆX2j + θ3MV βˆX3j + ϵMVj , ϵMVj ∼ N (0, φ2MV se(βˆYj)2) , (2.13)
where θMV are the causal effects of the risk factors Xk (k = 1, . . . , 3) on the outcome
Y , when conditioned on each other and φMV represents the residual standard error
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under the multivariable IVW model. If K = 1, then the multivariable IVW model is
equivalent to the ‘univariable’ IVW method in Equation 2.7.
There may be circumstances where the risk factors X are linearly related. For
example, suppose the risk factors under investigation in Figure 2.4 are low-density
lipoprotein cholesterol (LDL-C), triglycerides and high-density lipoprotein cholesterol
(HDL-C). LDL-C is rarely measured directly, but is estimated from measurements
of total cholesterol, triglycerides and HDL-C via the Friedewald equation as total
cholesterol minus HDL-C minus 0.2 times triglycerides (assuming all measurements
are in mg/dL) [81]. We would therefore expect LDL-C, triglycerides and HDL-C
measurements to be correlated, and since lipid fractions are associated with common
genetic variants, we may find that the estimates of the genetic associations (βˆX)
are also correlated. If the estimates βˆX are correlated, then the multivariable IVW
method (Equation 2.13) may be effected by collinearity, leading to imprecise estimates.
Collinearity in multivariable Mendelian randomization is considered briefly in the main
applied example of the dissertation (Chapter 6) by estimating the correlation structure
between the risk factors and the correlation structure between the genetic associations
of the risk factors.
Instrument strength
For multivariable Mendelian randomization, the set of genetic variantsG are considered
to be strong IVs if: a) the variants are associated with all of the K risk factors; and b)
the variants are jointly associated with the K risk factors [82]. The first condition can
be assessed through the F-statistics from the regression of G against each of the K
risk factors Xk (k = 1, . . . , K). In order for the second condition to hold, the genetic
variants must be able to predict the values of each risk factor Xk after predicting the
values of the remaining K − 1 risk factors. In Figure 2.5, all of the risk factors are
individually strongly predicted by the J genetic variants Gj (j = 1, . . . , J) for DAG A).
X2 and X3 are jointly predicted by G in DAG A), but X1 is not jointly predicted by
G. In DAG B), all of the risk factors are individually predicted and jointly predicted
by G.
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Fig. 2.5 Directed acyclic graph illustrating the potential set up for multivariable Mendelian
randomization for the set of genetic variants G and the risk factors X1, X2 and X3. In DAG
A), X1 is individually, but not jointly, strongly predicted by G. All of the risk factors in
DAG B) are both individually and jointly strongly predicted by G.
To assess whether the J genetic variants Gj (j = 1, . . . , J) are jointly associated
with the K risk factors, the Sanderson-Windmeijer conditional F-statistic should be
estimated for each risk factor [82]. The conditional F-statistic for X1 when there are
K = 3 risk factors can be calculated by:
1. X2 is regressed against the J genetic variants Gj (j = 1, . . . , J) and the predicted
values of X2 (Xˆ2) calculated;
2. the above regression model is refitted with X2 replaced with X3, and Xˆ3 calcu-
lated;
3. X1 is then regressed against Xˆ2 and Xˆ3, and the residual errors from the regression
model (X1 − Xˆ1) saved;
4. the saved residual errors are regressed against the J genetic variants Gj (j =
1, . . . , J), and the F-statistic obtained from this regression model, multiplied
by a degrees of freedom correction factor of J/(J − 2) [83], is the ‘conditional’
F-statistic for X1.
The degrees of freedom correction factor in step 4 takes into consideration that the
same set of genetic variants G were used to predict that values of Xˆ2 and Xˆ3 in steps
1 and 2. Note that fitting the three regression models in steps 1-3 is equivalent to
performing TSLS regression when X1 is treated as the ‘outcome’, and X2 and X3 are
the risk factors. The conditional F-statistics for X2 and X3 should also be calculated,
and the J genetic variants Gj (j = 1, . . . , J) would be considered as strong IVs for
multivariable Mendelian randomization if the F-statistics and conditional F-statistics
for all of the K risk factors Xk (k = 1, . . . , K) were sufficiently large, e.g. we may
apply the traditional cut-off value of 10.
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To calculate the Sanderson-Windmeijer conditional F-statistics we require individual
level data on the J genetic variants Gj (j = 1, . . . , J) and K risk factors Xk (k =
1, . . . , K). In order to assess the strength of the IVs when only summary level data on
the risk factors are available (i.e. in a two–sample Mendelian randomization study),
Sanderson et al. [82] have proposed an adapted version of the Cochran’s Q statistic
to test for instrument strength. Although this modified version of the Cochran’s Q
statistic performed well in the authors’ simulation study, the test statistic requires
information on the covariance structure between the genetic associations of the K risk
factors.
Benefits of multivariable Mendelian randomization
The main benefit of multivariable Mendelian randomization is that it offers an alter-
native to ‘univariable Mendelian randomization’ (as considered in Section 2.2), and
can be used in the primary or sensitivity analysis. Using multivariable Mendelian
randomization may be a good alternative to univariable Mendelian randomization if:
a) the IV2 or IV3 assumptions for univariable Mendelian randomization are suspected
to be violated; and/or b) the risk factor under consideration is known to be correlated
with other risk factors, and the causal effect that all of these risk factors have on the
outcome want to be investigated. For either case, assumptions about the relationships
between the genetic variants, risk factors and outcome must be made, and this should
be informed by biological evidence.
2.7 Conclusion
Ideally, a genetic variant should only be included in a Mendelian randomization
analysis if its biological function is well understood. Although this should reduce the
risk of including pleiotropic genetic variants, only considering variants with known
biological mechanisms would severely limit the scope of Mendelian randomization. To
provide robustness to the results from the main analysis, methods that account for
pleiotropic genetic variants must be considered in the sensitivity analysis of a Mendelian
randomization study.
Section 2.6 highlighted the range of sensitivity analyses that may be used in
Mendelian randomization to account for pleiotropic genetic variants using summary
level data. The majority of these methods focus on identifying and removing pleiotropic
genetic variants from the analysis. Although the multivariable IVW method was
developed to account for measured pleiotropy, there are no methods that can be used
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as a sensitivity analysis under a multivariable framework. The application of the
MR-Egger method to the multivariable setting in Chapter 4 should help to rectify this
gap in the literature.
Since the IVW method is equivalent to performing a meta-analysis of the causal
ratio estimates, a lot of the sensitivity analyses and tests for heterogeneity among the
causal ratio estimates discussed in Sections 2.5 and 2.6 have been adapted from the
meta-analysis literature [48, 63, 29]. Since pleiotropic genetic variants may appear as
outlying data points in a Mendelian randomization analysis, we suspected that some
of the methods in the robust statistics [84] literature that try to reduce the influence
outlying data points have on the analysis may be a useful addition to Mendelian
randomization (considered in Chapter 3). Some of these robust methods, such as Lasso
penalization [65, 67, 85], have already been adapted to Mendelian randomization with
individual level data. Since the use of summary level data in Mendelian randomization
continues to grow in popularity, the application of methods like Lasso penalization to
summary level data should be considered.
Chapter 3
Downweighting or removing
heterogeneous causal estimates:
robust methods for Mendelian
randomization with multiple
genetic variants
3.1 Introduction
If the genetic variants in a Mendelian randomization study are all valid IVs, then
the individual causal ratio estimates should be similar. Pleiotropic genetic variants
are likely to have heterogeneous causal ratio estimates. In the two applied examples
considered in this Chapter, we found that heterogeneity of the causal estimates may
be considered under two scenarios: 1) when there is over–dispersion in the estimates
as there is more variance between the variant specific causal estimates than expected
by chance (as seen in the effect of body mass index on schizophrenia); and 2) when
specific variants have outlying causal estimates, and they alone are responsible for
driving the observed heterogeneity (as seen in the effect of low–density lipoprotein on
Alzheimer’s disease).
There are numerous methods in the Mendelian randomization literature that detect
or account for pleiotropic variants using summary level data. As highlighted in
Section 2.6, these methods can be divided into two broad categories: methods that
detect pleiotropic genetic variants and either downweight or remove them; and methods
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that estimate consistent causal effects in the presence of pleiotropic genetic variants
without downweighting their contribution to the causal estimate. In this Chapter, we
focus on identifying ‘robust methods’ for summary level data that either downweight
or remove genetic variants with heterogeneous causal ratio estimates. We consult the
literature on robust statistics and recent developments in Mendelian randomization
to identify such methods. The methods identified in this Chapter will be applied to
the two examples highlighted above (the effect of body mass index on schizophrenia,
and the effect of low-density lipoprotein on Alzheimer’s disease), and we anticipate
that these methods will be used in our investigation of the effect of adiposity and body
composition on asthma in Chapter 6.
In Section 3.2, we provide a brief overview of the fundamental aims of robust
statistics, and discuss why some of the methods in the robust statistics literature may
be relevant to Mendelian randomization when there is heterogeneity among the causal
ratio estimates. In Section 3.3, we introduce two additional robust methods from
the robust statistics literature (robust regression (MM-estimation) and least trimmed
squares selection), and outline a selection procedure based on Lasso regression and
recent developments in Mendelian randomization [67]. We also outline a robust method
that uses the Q-statistic to penalize genetic variants with heterogeneous causal ratio
estimates. We apply the methods introduced in Section 3.3 to published data on body
mass index and schizophrenia risk, and on low-density lipoprotein and Alzheimer’s
disease risk (Section 3.4). In Section 3.5, we perform a simulation study to compare
bias and coverage properties of the robust methods when some of the genetic variants
are invalid IVs. Finally, we discuss the results of the Chapter and its implications to
applied Mendelian randomization research (Section 3.6).
All of the computational work for the applied examples (Section 3.4) and the
simulation study (Section 3.5) was written and performed by Jessica Rees in RStudio
version 3.5.3 [86] unless explicitly stated otherwise. Details on the packages and
libraries used in RStudio are provided throughout the Chapter.
3.2 Robust statistics and Mendelian randomization
In this Section, we provide a brief overview of the fundamental aims of robust statistics
(Section 3.2.1), discuss the relevance and possible merits of using methods from the
robust statistics literature in Mendelian randomization (Section 3.2.2), and outline the
robust statistics methods considered in Section 3.3 (Section 3.2.3).
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3.2.1 Overview of robust statistics
The primary aim of robust statistics is to develop estimators that are not severely
affected by outliers (data points that differ from the majority) or deviations from
the model assumptions. Robust statistics may estimate location parameters, scale
parameters, and regression coefficients. In this Chapter, we focus on robust statistics
methods for estimating regression coefficients where outlying data points may differ
from the majority.
Robust statistics may act as replacements to popular statistical estimators that
are sensitive to outliers or deviations from the model assumptions. Robust statistics
should be efficient, with small deviations in the model assumptions having a minor
impact on the performance of the estimator [84]. A balance between the efficiency and
stability of a robust statistic must be met. For example, we may prefer a less efficient
estimator if it is more likely to be unbiased in the presence of outliers.
A popular measure of robustness of an estimator is the ‘breakdown point’ [87]. This
represents the proportion of ‘bad observations’, such as outliers, that an estimator can
cope with before it produces an arbitrarily large or small result [84]. For example, the
ordinary least squares (OLS) estimator has a breakdown point of 0% as one outlying
observation can result in a biased OLS estimate, whereas the median has a breakdown
point of 50%. Many robust statistics focus on increasing the breakdown point of
the estimator by reducing the weight of outliers, including the least trimmed squares
estimator and M-estimators considered in Section 3.3.
3.2.2 Relevance of robust statistics to Mendelian randomiza-
tion
The motivation for considering the robust statistics literature to identify methods
for Mendelian randomization was driven by the observation that pleiotropic genetic
variants may have outlying (as seen in Figure 2.3 for the effect of low–density lipoprotein
on Alzheimer’s disease) or over-dispersed (observed for the effect of body mass index
on Schizophrenia) summary level data.
As defined in Section 2.4, we assume that the genetic association with the outcome
can be expressed as the linear combination of the direct effect (αj) and the indirect
effect via the risk factor (θβXj):
βY j = αj + θβXj . (3.1)
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From Equation 3.1, a pleiotropic genetic variant (αj ≠ 0) would be an outlier with
respect to the y-axis in the scatter plot of the genetic association estimates with the
outcome against the genetic association estimates with the risk factor if the majority of
the variants were valid IVs. Since one of the primary objectives of robust statistics is to
reduce the impact outliers have on the performance of the estimator, we hypothesised
that there may be regression estimators in the robust statistics literature that would
produce consistent estimates of the causal effect when pleiotropic genetic variants were
included in a Mendelian randomization study.
If there is over–dispersion in the causal ratio estimates, and all of the genetic
variants are valid IVs, then the IVW estimate will be consistent, and multiplicative
random effects should be used. However, the IVW estimate will be biased if there
is over–dispersion and some of the genetic variants are pleiotropic. We anticipated
that methods in the robust statistics literature that are less sensitive to data from
heavy tailed distributions may be beneficial to Mendelian randomization analyses when
there is general over–dispersion in the ratio estimates and there are pleiotropic genetic
variants.
3.2.3 Methods considered
There are various estimators in the robust statistics literature that are less sensitive to
outliers. Some of these methods perform well in terms of consistency, whilst others
focus on enhancing efficiency. We decided to assess the performance of the two robust
estimators: MM–estimation and the least trimmed squares estimator (described in
detail in Section 3.3). MM–estimation was chosen as it strikes a good balance between
efficiency and consistency [88], whereas least trimmed squares is particularly robust to
outlying data points, but may lack efficiency [89]. Although our decision to consider
these methods may be considered arbitrary, we anticipate that these estimators may
provide a good indication as to whether the robust statistics literature is relevant to
Mendelian randomization.
3.3 Methods
In this Section, we introduce four robust methods for Mendelian randomization using
summary level data: 1) robust regression (MM–estimation); 2) penalized weights; 3)
least trimmed squares selection; and 4) Lasso selection. Robust regression (Section 3.3.1)
and least trimmed squares selection (Section 3.3.4) are based on the MM-estimator
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and least trimmed squares estimator from the robust statistics literature respectively.
The penalized weights method uses the Q-statistic to downweight genetic variants
with heterogeneous ratio estimates (Section 3.3.2). Finally, the Lasso selection method
(Section 3.3.3) is based on Lasso regression and recent developments in Mendelian
randomization [67]. These four methods use summary level data of the genetic
associations with the risk factor (βˆXj , se(βˆXj)) and the outcome (βˆY j , se(βˆY j)) for the
J genetic variants Gj (j = 1, . . . , J).
Throughout the Chapter, we assume linearity and no effect modification of the
causal effect of the risk factor on the outcome, and the associations of the genetic
variants G (bold variables represent vectors) with the risk factor and with the outcome
(as considered in Section 2.2). We also assume that the outcome is a continuous variable,
and all of the genetic variants are independent (not in linkage disequilibrium). The
application of the methods introduced in this Chapter to binary outcomes is discussed
in Section 3.3.5.
3.3.1 Robust regression (MM–estimation)
Before we introduce the robust regression method used in this Chapter, we first consider
M– and S–estimators in relation to estimating the regression coefficients β in the linear
regression model:
yi = β0 + β1xi1 + · · ·+ βmxim + ϵi
= xTi β + ϵi ,
where i = 1, . . . , N , and the error term ϵi has an expected value of zero and scale σ2.
An M–estimator minimises:
N∑
i=1
ρ
(
yi − xTi β
σˆ
)
, (3.2)
where ρ is an objective function and σˆ is a scale estimate for the error term. M-
estimates for β are obtained by taking the partial derivatives of the objective function
in Equation 3.2, and solving the system of equations:
N∑
i=1
ψ
(
ri
σˆ
)
xi =
N∑
i=1
ψ(ui)xi = 0 , (3.3)
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where ψ is proportional to the derivative of ρ, and ri = yi − xTi βˆ. By substituting the
weighting function:
w(u) = ψ(u)
u
, (3.4)
into Equation 3.3, and applying an iteratively reweighted least squares (IRLS) algorithm,
M-estimates βˆM can be obtained. To reduce the impact outliers have on the scale
estimate, the median absolute deviation of the residuals can be considered:
σˆ = median(|ri|)0.6745 , (3.5)
where median(|ri|) is multiplied by 1/0.6745 as the expected value of median(|ri|) is
0.6745 if the residuals are normally distributed [90]. Note that σ is re-estimated at
each iteration until the estimates βˆM converge.
If we assume that the error term is independently and normally distributed ϵi ∼
N (0, 1), and Equation 3.2 is set to ∑Ni=1 r2i , then the M-estimator is equivalent to
the OLS estimator. However, we may want to use an objective function that is less
sensitive to outliers, such as Tukey’s bisquare objective function:
ρ(ui) =

c2
6
(
1−
[
1−
(
ui
c
)2]3 )
if |ui| < c
c2
6 if |ui| ≥ c
, (3.6)
with its weighting function:
w(ui) =

[
1−
(
ui
c
)2]2
if |ui| < c
0 if |ui| ≥ c
. (3.7)
From Equation 3.7, the weight of an observation decreases as ui tends away from
zero, and when |ui| ≥ c the observation will have zero weight. The value of the
tuning parameter c determines the relative efficiency of the M–estimator. For Tukey’s
bisquare weighting function, a standard value of c = 4.685 is used to ensure the
M-estimator has 95% asymptotic efficiency relative to the OLS estimate if the error
term is normally distributed with an expected value of zero and constant variance [89].
Whilst this estimator may be less sensitive to outlying data points with respect to the
y observations, it can be sensitive to leverage points (data points that are outlying
with respect to x). As such, M-estimators may be highly efficient, but lack robustness.
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An M–estimate of the scale of the error term is the value σˆ that solves:
1
N
N∑
i=1
ρ
(
yi − xTi β
σ
)
= K ,
where K is a tuning parameter, and ρ is an objective function. S–estimates βˆS are
the values that minimise the M–estimate of scale σˆS. Estimates of βˆS and σˆS can be
obtained by using the weighting function in Equation 3.4 and an IRLS algorithm. If
Tukey’s bisquare objective function is used, the S-estimator will have an asymptotic
breakdown point of 50% if c = 1.548 and K = 0.5 [91]. Whilst the S-estimator may be
highly robust to outliers and leverage points, it can lack efficiency.
To overcome some of the disadvantages of using the M– and S–estimators, MM–
estimation was proposed by Yohai [92], and consists of the following three stages:
1. The initial estimates βˆS are obtained from a S-estimator with a high breakdown
point and objective function ρ1.
2. Using the residuals ri = yi − xTi βˆS from the stage above, an M-estimate of scale
σˆS is calculated.
3. M–estimates βˆ are obtained using the M-estimate of scale σˆS from the second
stage and the objective function ρ2. Note that the M-estimate of scale σˆS is fixed
for each iteration, i.e. it is not re-estimated using Equation 3.5. The estimates βˆ
from this stage represent the MM-estimates.
By using a S-estimator in the first stage, and M-estimator in the third stage, the
MM-estimator should be efficient and have a high breakdown point.
In this Chapter, we consider the MM–estimation approach (referred to as ‘robust
regression’ in this dissertation) described by Yohai [92] and Koller and Stahel [88] that
is used by the lmrob command in the R package robustbase [93]. lmrob uses Tukey’s
bisquare objective function (Equation 3.6) for ρ1 and ρ2, with c = 1.548 in Equation 3.7
at the S–estimation step to maintain a high breakdown point, and c = 4.685 at the
M–estimation step to provide efficiency.
Instead of using weighted least squares to obtain the estimates for the IVW and MR-
Egger methods (as done in Equations 2.7 and 2.9), we propose using robust regression
(MM–estimation approach used by lmrob). Since the lmrob command allows the user
to specify a vector of weights to be used in conjunction with Tukey’s weighting function,
we also account for se(βˆYj)−2 in the weights of the observations. The estimates from
the MM-estimator using Tukey’s weighting function w(uj) and se(βˆYj )−2 as weights, is
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equivalent to the estimates obtained from weighted least squares where the weights are
the product of w(uj) from the final iteration of the MM-estimator and se(βˆYj)−2.
3.3.2 Penalized weights
As highlighted in Section 2.5.2, Cochran’s Q-statistic has been adapted from the
meta-analysis literature to test for heterogeneity among the ratio estimates for the
IVW method:
Q =
∑
j
Qj =
∑
j
wj(θˆj − θˆ)2 , (3.8)
where Q has an approximate χ2J−1 distribution under the null hypothesis that all J
genetic variants satisfy the IV assumptions, with the J components Qj (j = 1, . . . , J)
having approximate χ2 distributions with one degree of freedom [62]. The Q-statistic
has also been used in Mendelian randomization to downweight [52] or exclude genetic
variants with heterogeneous ratio estimates [63]. The Q-statistic is based on the
first order weights (Equation 2.6) of the IVW method which assumes that there is
no measurement error (NOME) in the genetic associations with the risk factor [63].
When the Q-statistic is used as a test for heterogeneity, the ratio estimates are usually
compared against the IVW estimate (θˆ = θˆIV W in Equation 3.8). If some of the J
genetic variants Gj (j = 1, . . . , J) are pleiotropic, then the IVW estimate will be biased.
By substituting θˆj = βˆY j/βˆXj into Equation 3.8, and using the first order approxi-
mation of wj, we obtain:
Q =
∑
j
Qj =
∑
j
se(βˆY j)−2(βˆY j − θˆβˆXj)2 . (3.9)
We will use the J components Qj (j = 1, . . . , J) of the Q-statistic in Equation 3.9 to
downweight genetic variants with heterogeneous ratio estimates. To provide additional
robustness, the simple (unweighted) median estimator for θˆ will be used in Equation 3.9
as it produces consistent causal estimates if at least 50% of the genetic variants are valid
IVs [52]. We propose fitting the weighted linear regression of the genetic association
estimates with the risk factor (βˆXj) and the genetic association estimates with the
outcome (βˆYj), with the intercept fixed at zero and weights:
se(βˆY j)−2 ×min(1, 100qj) (3.10)
where qj is the probability of observing a value greater than or equal toQj (Equation 3.9)
from the χ2 distribution with one degree of freedom. If min(1, 100qj) = 1 for all of
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the J genetic variants, then all of the weights will remain the same, and the weighted
linear regression model will be equivalent to the IVW method (Equation 2.7).
We initially considered a downweighting factor of min(1, 20qj) in Equation 3.10 as
this was used in the paper by Bowden et al. [52] for the penalized–median estimator.
We found that too many variants were being penalized, resulting in over-precise
estimates that had poor coverage of the true causal effect. By multiplying the first
order approximation of the weights by min(1, 100qj), the outlying variants that are
suspected to be pleiotropic should be severely penalized, without downweighting too
many genetic variants.
We will also consider penalizing the weights for the MR-Egger method by using
the modified Q’ statistic outlined by Bowden et al. [94]:
Q′ =
∑
j
Q′j =
∑
j
se(βˆY j)−2(βˆY j − θˆ0 − θˆ1βˆXj)2 , (3.11)
where θˆ0 and θˆ1 are the MR-Egger estimates from the weighted linear regression of
the genetic association estimates with the risk factor (βˆXj ) and the genetic association
estimates with the outcome (βˆYj) [45], with the inverse-variance as weights (se(βˆYj)−2)
and the intercept unrestrained. If the MR-Egger model is correct, the Q’ statistic in
Equation 3.11 should follow an approximate χ2J−2 distribution, with the J components
Q′j (j = 1, . . . , J) having approximate χ2 distributions with one degree of freedom [95].
We propose re-fitting the MR-Egger regression model with the penalized weights:
se(βˆY j)−2 ×min(1, 100q′j) (3.12)
where q′j is the probability of observing a value greater than or equal to Q′j (Equa-
tion 3.11) from the χ2 distribution with one degree of freedom. If min(1, 100q′j) = 1
for all of the J genetic variants, then all of the weights will be unchanged, and the
MR-Egger estimates will be the same as θˆ0 and θˆ1 in Equation 3.11.
The penalized weights in Equations 3.10 and 3.12 will be applied to the IVW
and MR-Egger methods with weighted least squares regression. These penalized
weights can also be applied to the IVW and MR-Egger method using robust regression
(Section 3.3.1). There may be additional robustness against pleiotropic genetic variants
by combining robust regression with the penalized weights described above.
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3.3.3 Lasso selection
Lasso regression is a regularization method that performs variable selection by estimat-
ing regression coefficients subject to a penalty term [96]. This regularization should
help to reduce over-fitting, creating a more parsimonious model. Using the notation
from Section 3.3.1, the Lasso estimates βˆL are the values that minimise:
N∑
i=1
ρ(xi, yi, β0,β) + λ
P∑
p=1
|βp| ,
where ρ is the objective function, and λ∑ |βp| is the Lasso penalty term (also referred
to as the L1 penalty term). The value of the tuning parameter λ will determine the
amount of shrinkage applied to the Lasso estimates.
The Lasso estimator has been considered in the IV literature using indiviudal level
data [65, 67, 85]. Windmeijer et al. [67] provide an overview of some of the methods
that use Lasso in IV analyses. In particular, they describe the ‘post-lasso’ estimator
that uses Lasso to select the genetic variants that will be used as IVs in the main
analysis. The post-lasso estimator has been considered in the IV literature prior to the
paper by Windmeijer et al. [67], for example, by Belloni et al. [97]. For individual level
data, the post-lasso estimator consists of two stages: 1) the Lasso estimator selects the
genetic variants that will be used as IVs; and 2) the genetic variants selected in the first
stage are used in the TSLS regression model to obtain an estimate of the causal effect.
Since the majority of Mendelian randomization studies use summary level data,
we consider the possibility of applying Lasso regression to summary level data to
select genetic variants that are used as IVs in the IVW method. We first consider the
objective function for the MR-Egger model:
∑
j
se(βˆY j)−2(βˆY j − θ0 − θ1βˆXj)2 .
We propose replacing θ0 with a separate intercept coefficient for each genetic variant
θ0j, and adding a Lasso penalty term for θ0j:
∑
j
se(βˆY j)−2(βˆY j − θ0j − θ1βˆXj)2 + λ
∑
j
|θ0j| . (3.13)
A genetic variant is selected as a valid IV if the estimate for θ0j shrinks to zero in
Equation 3.13. The genetic variants that are selected as valid IVs (i.e. they have a
zero intercept θˆ0j) are included in the IVW model to estimate the causal effect. The
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number of genetic variants that are selected for the IVW model is determined by the
value of the tuning parameter λ in Equation 3.13. If λ =∞, the intercept terms are
forced to be zero for all J variants, and the IVW model is fitted to the full set of
genetic variants. If λ = 0, then all of the variants can be pleiotropic, and the IVW
model cannot be fitted as none of the genetic variants are selected as valid IVs.
To determine the value of λ, two rules were considered: a heterogeneity stopping
rule, and a cross-validation rule. The heterogeneity stopping rule is based on the
estimate of the residual standard error φˆ from the IVW model (Equation 2.7). For the
heterogeneity stopping rule, we fit the Lasso regression model (Equation 3.13) over
a range of values for λ, starting with a value close to zero, and then increasing λ in
small increments. We stop at λ = λn when:
• φˆλn+1 > 1 from the IVW model that used the selected genetic variants from
Equation 3.13 when λ = λn+1; and
• The following condition is satisfied:
(φˆλn+1 − φˆλn) >
χ2(0.95)
Jinc
,
where χ2(0.95) is the upper 95th percentile of a χ2 distribution with one degree of
freedom, and Jinc is the number of genetic variants selected for the IVW model
from Equation 3.13 when λ = λn+1.
The estimate from the IVW model that included the genetic variants selected from
Equation 3.13 when λ = λn is treated as the causal estimate. An algorithm for
the stopping rule was written by Stephen Burgess in R to determine the value of λ
under the heterogeneity stopping rule using the penalized command in the R package
penalized. This R code was used by Jessica Rees in the applied examples (Section 3.4)
and simulation study (Section 3.5).
As an alternative to the heterogeneity stopping rule, we use the optL1 command
in the R package penalized [98]. optL1 compares the predictive ability of the Lasso
regression model for different values of λ through leave-one-out cross-validation. The
optimal value of λ is then determined by maximizing the cross-validated likelihood
function. We may find that the values of λ are substantially different for the hetero-
geneity stopping rule and cross-validation as the stopping rule treats λ as a discrete
variable, whereas the cross-validation method takes a more informative approach by
treating λ as a continuous variable.
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3.3.4 Least trimmed squares selection
OLS regression minimises the sum of the squared residuals over N data points; whereas
least trimmed squares (LTS) minimises the sum of the squared residuals over a subset
h of the N observations [99]. The LTS estimator minimises the following objective
function:
h∑
i=1
(r2)i:N ,
where (r2)1:N , (r2)2:N , . . . , (r2)N :N are the ordered squared residuals. The value of h
will determine the breakdown point of the LTS estimator and must satisfy N/2 <
h ≤ N . The LTS estimator will achieve an asymptotic breakdown point of 50% when
h = ([N/2] + [(p+ 1)]/2), where p is the number of covariates included in the model
[99]. As the value of h increases, the breakdown point will decrease until it reaches
zero at h = N , where the LTS regression estimate θˆLTS,h will be equivalent to the OLS
estimate.
The application of LTS regression has been limited due to its low efficiency and
computational time. Methods have been proposed to overcome these issues, in particu-
lar, the re-weighted version of the LTS estimator was developed to improve efficiency
[100]. Under this method, the LTS scale estimate σˆ (the objective function multiplied
by a consistency factor) is used to compute robust standardized residuals ri/σˆ for all
N observations [101], where the residuals ri are taken from the LTS regression model
based on the h data points. A weighting function is then applied to the standardized
residuals where observations are given a weight of zero if |ri/σˆ| > 2.5, and 1 otherwise.
These weights (wLTS,1) are then used to update the scale estimate and obtain a new
set of robust standardized residuals. The updated standardized residuals are then
applied to the same weighting function to obtain a new set of weights (wLTS,2) for the
N observations. The second set of weights wLTS,2 can then be used in a weighted least
squares regression model.
The ltsReg command in the R package robustbase [93] performs the re-weighted
version of LTS regression, with a default value of ([N/2] + [(p + 1)]/2) for h. The
function reports an estimate of the scale parameter and the coefficients from the
weighted least squares regression model with wLTS,1 as weights. The ltsReg function
also returns the second set of weights wLTS,2 and the h observations used to obtain the
initial LTS estimate θˆLTS,h.
We propose using the LTS estimator to select the genetic variants used in the IVW
model. The estimate from the IVW model will be consistent if at least 50% of the
genetic variants are valid IVs, and the LTS estimator correctly identifies the valid
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IVs. The following three sets of variants will be selected using the LTS estimator
and will used as IVs in the IVW model: 1) the h variants (approximately 50% of the
data) used to estimate the initial LTS estimate θˆLTS,h; 2) the variants with a weight
of 1 in wLTS,2; and 3) the variants selected from an automated approach. Under the
automated method, the value of h is increased to include more variants in the LTS
regression model. h is first set to h1 = (J/2+ 1) and increased in increments of 1 up to
J . For each value of h, the IVW model is fitted to the h variants selected by the LTS
objective function, and the residual standard error from the IVW model is recorded.
We apply the heterogeneity stopping rule outlined for Lasso selection in Section 3.3.3
to the residual standard errors to determine the optimal value of h.
3.3.5 Binary outcomes
The robust methods in this Section have been introduced under the assumption of
linearity and no effect modification in the causal effect of the continuous risk factor X
on the continuous outcome Y , and the associations of the genetic variants G with X
and Y . Hence, the genetic associations with the risk factor βXj (j = 1, . . . , J) or the
outcome βYj (j = 1, . . . , J) can be estimated by regressing the risk factor or outcome
against each of the genetic variants in linear regression models, where it is assumed
that the minor allele has an additive effect on the risk factor or outcome.
We note that the applied examples in Section 3.4, and the main applied example
of the dissertation (Chapter 6), all consider binary outcomes. When Y is binary, the
genetic association estimates βˆYj (j = 1, . . . , J) represent the log odds ratios from a
logistic regression model. As discussed in Section 2.3.3, the IVW method will provide
an approximate measure of the causal odds ratio for the effect of a continuous risk
factor X on a binary outcome Y . The performance of the robust methods introduced
in this Section when the outcome is binary will be considered in the simulation study
(Section 3.5). Note that the estimates presented in the applied examples in Section 3.4
represent estimates of the approximate log causal odds ratios.
3.3.6 Summary and overview of methods
In this Section, we have introduced robust methods that can be used in a Mendelian
randomization study as part of the sensitivity analysis. Table 3.1 provides an overview
of the methods, and indicates whether these methods can be applied to the IVW
method and/or the MR-Egger method. The methods have been categorised according
to whether they downweight genetic variants with heterogeneous ratio estimates whilst
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Table 3.1 Overview of the robust methods introduced in Chapter 3. The methods are
categorised by whether they downweight genetic variants with heterogeneous ratio estimates
(can be applied to the IVW or MR-Egger methods) or select genetic variants for the IVW
method.
IVW method MR-Egger method
Downweighting heterogeneous ratio estimates
Robust regression (Rr) X X
Penalized weights (PW) X X
Robust regression and penalized weights (Rr and PW) X X
Selecting instrumental variables
Lasso selection (LS)
Heterogeneity stopping rule X -
Cross validation X -
Least trimmed squares (LTS) selection
h variants X -
wLTS,2 variants X -
Automated approach (Auto) X -
keeping them in the analysis model (robust regression and penalized weights), or
the method selects the genetic variants used as IVs in the IVW method (Lasso and
LTS selection). Table 3.1 contains the abbreviations used in the result tables for the
simulation study.
Robust regression and penalized weights can be used separately or in combination
with each other, and may be applied to the IVW and MR-Egger methods (Table 3.1).
The Lasso selection method uses the heterogeneity stopping rule or cross validation to
select genetic variants for the IVW method, and LTS selection identifies three sets of
variants for the IVW method.
In the next Section, we apply the robust methods in Table 3.1 with respect to the
IVW method only using published summary level data to investigate the two applied
examples outlined in Section 3.1: the effect of body mass index on schizophrenia risk,
and the effect of low-density lipoprotein on Alzheimer’s disease risk.
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3.4 Applied examples
To illustrate the performance of the methods proposed in Section 3.3 (summarised in
Table 3.1), we considered two applied examples: one where there was evidence of over-
dispersion in the ratio estimates (the effect of body mass index (BMI) on schizophrenia
risk); and another that contained outliers (the effect of low-density lipoprotein (LDL-C)
on Alzheimer’s disease (AD) risk). Using summary data (beta–coefficients and standard
errors) from PhenoScanner [26], we considered the IVW method with: 1) the full set
of genetic variants; 2) robust regression; 3) penalized weights; 4) robust regression and
penalized weights; 5) the two sets of genetic variants from Lasso selection using the
heterogeneity stopping rule and cross-validation; and 6) the three sets of genetic variants
from LTS selection as outlined in Section 3.3.4. Under the heterogeneity stopping rule,
the Lasso selection model was applied to λ = 0.1, 0.2, . . . , 4.9, 5.0, 5.2, 5.4, . . . , 9.8, 10.0.
Hence, the robust methods in Table 3.1 with respect to the IVW method were applied
to the two examples. For comparison with the methods introduced in this Chapter,
estimates from the simple median, weighted median, and MR-Egger methods were
obtained. Multiplicative random-effects models were used in all analyses.
The genetic association estimates from PhenoScanner for the two binary outcomes
(schizophrenia and AD) are the log odds ratios, whereas the genetic association estimates
for the risk factors (BMI and LDL-C) are from linear regression models. As highlighted
in Section 3.3.5, the results in this Section are estimates of the approximate log causal
odds ratios. The simulation study (Section 3.5) will consider how well the robust
methods approximate the causal odds ratio.
3.4.1 Causal effect of body mass index on schizophrenia risk
Although individuals with schizophrenia tend to be over-weight [102], it is generally
believed that this is due to the effect of anti-psychotic medication on body composition
(reverse causation) rather than any causal effect of BMI on schizophrenia risk [103].
For the Mendelian randomization analysis, we used the 97 genetic variants reported by
the Genetic Investigation of Anthropometric Traits (GIANT) consortium that were
associated with BMI in 339,224 European-descent individuals at a genome-wide level
of significance (p-value < 5× 10−8) [104]. The genetic associations with schizophrenia
were obtained from the Psychiatric Genomics Consortium (PGC) based on 35,476 cases
and 46,839 controls mostly of European descent [105]. The summarized data used in
this Chapter was recently applied to a Mendelian randomization study investigating
the causal effect of BMI on psychiatric disorders, including schizophrenia risk [106].
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3.4.2 Causal effect of low-density lipoprotein on Alzheimer’s
disease risk
Epidemiological studies have provided evidence of an association between LDL-C and
increased risk of AD [107, 108]. However, there is also evidence to suggest that patients
with AD have altered lipid metabolism (reverse causation) [109]. In the Mendelian
randomization analysis, we used the 75 genetic variants previously demonstrated to
be associated with LDL-C at a genome-wide level of significance by the Global Lipids
Genetics Consortium (GLGC) [110]. The point estimates for the genetic associations
with LDL-C were taken from the linear regression in up to 188,578 participants from
GLGC [111]. A recent Mendelian randomization study used summarized data from
GLGC to investigate the causal association between low LDL-C levels and AD risk
using data on 380 variants. Our analysis is based on a smaller set of genetic variants
compared to Benn et al. [112] as we excluded variants that were associated with LDL-C
and high density lipoprotein and/or triglycerides. The genetic associations with AD
were obtained from the International Genomics of Alzheimer’s Project (IGAP) based
on 17,008 cases and 37,154 controls of European-descent [113].
3.4.3 Results
The estimated genetic associations with 95% confidence intervals for the two examples
are displayed in Figure 3.1. The plots highlight the over-dispersion in the ratio estimates
for BMI and schizophrenia; and two outliers in the LDL-C and AD example. The
outlying variants (rs6859 and rs7254892) for LDL-C and AD are located near to the
APOE locus and are associated with AD risk with odds ratios of 1.40 (95% CI: 1.35,
1.44) and 1.28 (95% CI: 1.15, 1.44) respectively [113].
Estimates and 95% confidence intervals from the Mendelian randomization analyses
are provided in Table 3.2. All of the estimates for BMI and schizophrenia suggest a
null causal effect (as also observed in the Mendelian randomization study by Hartwig
et al. [106]), although there is wide variation in the standard errors. The use of
penalized weights and robust regression in the IVW method improved the precision
of the estimates. There was little difference in the point estimates or standard errors
obtained from the IVW method with penalized weights, and from the IVW method with
robust regression and penalized weights. With exception of the IVW and MR-Egger
methods, the unweighted median estimate was the least precise, and including weights
in the median estimator had little impact on the standard error of the estimate.
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Fig. 3.1 Graph A) contains the estimated genetic associations and 95% confidence intervals
with body mass index (BMI, standard deviation units) and with schizophrenia (log odds
ratios) for 97 genetic variants. Graph B) contains the estimated genetic associations and 95%
confidence intervals with low-density lipoprotein (LDL-C, standard deviation units) and with
Alzheimer's disease (log odds ratios) for 75 genetic variants: the two outlying variants are
labelled with their rsID codes.
The Lasso selection estimates are displayed in Figure 3.2 (R code for the diagram
written by Stephen Burgess) where the approximate causal estimates are relatively
similar across the different values of the tuning parameter. The value of the tuning
parameter λ was 1.9 under the heterogeneity stopping rule, with 64 genetic variants
included in the IVW model. The cross-validation method returned a much larger value
of λ = 6.63, with 95 of the 97 variants included in the IVW model.
Despite using different sets of genetic variants, all of the estimates from LTS
selection suggested a null causal effect between BMI and schizophrenia risk. 49 variants
were included in the IVW model when LTS selection was based on the h variants used
to obtain the initial LTS estimate. 92 variants were included in the IVW model when
wLTS,2 was used to select the genetic variants, and under the automated approach, 90
variants were included. The point estimate obtained from the h variants was noticeably
more precise than the estimates obtained from the other two sets of variants.
The estimates from the IVW, LTS selection with h variants (38 genetic variants
included in the IVW model), and MR-Egger methods suggested a positive causal effect
of LDL-C on AD risk. This effect was attenuated to the null for the other robust
methods. Compared to the robust methods that reported a null causal effect of LDL-C
on AD risk, the simple and weighted median estimates had larger standard errors. The
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estimates from the IVW and MR-Egger methods from Benn et al. [112] indicated that
lower LDL-C levels may be beneficial in reducing AD risk, whereas their estimate from
the weighted median method suggested a null effect. Since the genetic variants in the
APOE gene region tend to be highly pleiotropic [73], it is likely that the positive effects
obtained from the IVW models in our analysis and in the paper by Benn et al. [112]
are driven by these pleiotropic variants, rather than there being a true causal effect of
LDL-C on AD risk.
None of the estimates in Figure 3.3 (R code for the diagram written by Stephen
Burgess) include information on the rs6859 variant, and this outlying variant was only
included in the IVW model for Lasso selection when λ = 19.8, whereas the other
outlying variant (rs57254892) was included when λ = 3.5. Even though the rs57254892
variant seems to be an obvious outlier in Figure 3.1, the genetic variant was included
in the IVW model under Lasso selection before many of the other genetic variants.
This observation highlights the importance of considering robust methods to identify
outlying variants rather than solely relying on plots such as Figure 3.1 to detect outliers
‘by eye’.
The λ values for the heterogeneity stopping rule (λ = 3.4 based on 72 genetic
variants) and cross-validation (λ = 4.00 based on 73 genetic variants) for Lasso selection
were similar (Figure 3.3). However, the estimate based on 72 genetic variants was much
closer to the null, demonstrating the sensitivity of the IVW method to a single variant.
70 variants were included in the IVW model when wLTS,2 was used to select the genetic
variants under LTS selection, and 72 variants were used under the automated approach.
These sets of variants produced very similar estimates to Lasso selection with the
heterogeneity stopping rule.
3.4.4 Summary
In this Section, we applied the methods outlined in Section 3.3 to published summary
level data to assess the causal effect of BMI on schizophrenia risk, and the causal effect
of LDL-C on AD risk. The consistency of the results from the robust methods for
the BMI and schizophrenia example strengthened the evidence from the primary IVW
analysis. The LDL-C and AD example highlighted the possibility that only using the
IVW method may provide conclusions that are not representative of the majority of
the data. Whilst in practice the outlying rs6859 variant could have been identified
and removed from the dataset prior to the analysis, the robust methods identified this
outlying variant in an automated manner. In the next Section, we perform a simulation
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study to assess the performance of the robust methods, and compare the results to the
IVW, median, and MR-Egger methods.
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Table 3.2 Estimates (standard errors) and 95% confidence intervals of the approximate
causal effect of body mass index on schizophrenia risk (log odds ratio for schizophrenia per 1
standard deviation increase in body mass index) and low-density lipoprotein on Alzheimer's
disease risk (log odds ratio for Alzheimer's per 1 standard deviation increase in low-density
lipoprotein) from the IVW method with: 1) the full set of genetic variants (IVW); 2) robust
regression; 3) penalized weights; 4) robust regression and penalized weights; 5) the two sets
of genetic variants from Lasso selection using the heterogeneity stopping rule and cross-
validation; and 6) the three sets of variants selected under the LTS selection method. Results
from the simple median, weighted median and MR-Egger methods are also presented.
Estimate (SE) 95% CI
Applied example 1: Causal effect of BMI on schizophrenia risk
IVW -0.031 (0.100) -0.227, 0.165
Robust regression -0.024 (0.079) -0.180, 0.132
Penalized weights -0.056 (0.065) -0.184, 0.073
Robust regression with penalized weights -0.052 (0.066) -0.182, 0.078
Lasso selection
Heterogeneity stopping rule -0.022 (0.055) -0.131, 0.086
Cross validation -0.036 (0.087) -0.207, 0.136
LTS selection
h variants 0.077 (0.060) -0.042, 0.195
wLTS,2 variants -0.042 (0.083) -0.205, 0.121
Automated approach -0.056 (0.079) -0.211, 0.099
Median
Simple -0.073 (0.083) -0.237, 0.090
Weighted -0.075 (0.090) -0.252, 0.102
MR-Egger 0.336 (0.241) -0.136, 0.808
Applied example 2: Causal effect of LDL-C on AD risk
IVW 0.239 (0.102) 0.039, 0.439
Robust regression 0.048 (0.038) -0.027, 0.123
Penalized weights 0.040 (0.042) -0.043, 0.123
Robust regression with penalized weights 0.046 (0.032) -0.016, 0.108
Lasso selection
Heterogeneity stopping rule 0.032 (0.044) -0.054, 0.118
Cross validation 0.088 (0.045) 0.000, 0.175
LTS selection
h variants 0.172 (0.072) 0.032, 0.313
wLTS,2 variants 0.029 (0.043) -0.054, 0.113
Automated approach 0.032 (0.044) -0.054, 0.118
Median
Simple 0.108 (0.071) -0.031, 0.247
Weighted 0.046 (0.061) -0.073, 0.165
MR-Egger 0.391 (0.168) 0.061, 0.722
Abbreviations: SE, standard error; CI, confidence interval; BMI, body mass index; IVW, inverse-variance weighted;
LTS, least trimmed squares; LDL-C, low-density lipoprotein cholesterol; AD, Alzheimer's disease.
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Fig. 3.2 Estimates of the approximate log odds ratio and 95% confidence intervals for
schizophrenia per 1 standard deviation increase in body mass index for different values of
the tuning parameter (λ = 0.1, 0.2, . . . , 4.9, 5.0, 5.2, 5.4, . . . , 9.8, 10.0) included in the Lasso
regression model. The number of genetic variants included in the IVW models are also
displayed. The dotted line at λ = 1.9 is the value of the tuning parameter chosen by the
heterogeneity stopping rule. The dashed line at λ = 6.63 is the value chosen by cross-
validation.
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Fig. 3.3 Estimates of the approximate log odds ratio and 95% confidence intervals for
Alzheimer's per 1 standard deviation increase in low-density lipoprotein for different values
of the tuning parameter (λ = 0.1, 0.2, . . . , 4.9, 5.0, 5.2, 5.4, . . . , 9.8, 10.0) included in the Lasso
regression model. The number of genetic variants included in the IVW models are also
displayed. The dotted line at λ = 3.4 is the value of the tuning parameter chosen by the
heterogeneity stopping rule. The dashed line at λ = 4.00 is the value chosen by cross-
validation.
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3.5 Simulation study
In this Section, we perform a simulation study to compare the performances of the
methods outlined in Section 3.3 with the IVW, simple (unweighted) median, weighted
median, and MR-Egger methods. To allow for direct comparisons with the MR-Egger
method, and to assess the performance of the methods when the IV assumptions are
violated, the simulations follow a similar structure to the simulation study performed
in the paper by Bowden et al. [52]. The data generating model and the methods
applied to the simulated data are outlined below.
3.5.1 Data generating model
The simulation study generated data in accordance to Figure 3.4 for participants
indexed by i = 1, . . . , N , and genetic variants indexed by j = 1, . . . , J :
Ui =
J∑
j=1
δjGij + ϵUi ,
Xi =
J∑
j=1
βXjGij + Ui + ϵXi ,
Yi =
J∑
j=1
αjGij + θXi + Ui + ϵY i ,
Gij ∼ Binomial(2, 0.3) independently for all j = 1, . . . , J ,
ϵUi, ϵXi, ϵY i ∼ N (0, 1) independently ,
where αj represents the direct effect of the genetic variant Gj on the outcome, δj
represents the effect of the genetic variant on the unmeasured confounder U of the
risk factor X and outcome Y association, βXj represents the genetic effect of Gj on
X, and θ is the causal effect of X on Y . The error terms ϵUi, ϵXi, and ϵY i were drawn
independently from standard normal distributions.
The performance of the robust methods were investigated under a two-sample
Mendelian randomization setting with N = 10, 000 individuals and J = 15 genetic
variants. Data was generated for 2N participants, and the associations of the variants
with the risk factor were estimated in the first N participants, and associations with the
outcome in the second N participants. Only the summary level data (beta-coefficients
and standard errors) was used in the analyses. A one-sample setting was also considered
where an additional N participants were simulated and all of the genetic associations
were estimated from same the N participants.
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Fig. 3.4 Directed acyclic graph used in the data generating model for the simulation study.
U represents the set of unmeasured variables that confound the association between the risk
factor X and outcome Y . The genetic effect of Gj on X is βXj , the direct (pleiotropic) effect
of Gj on Y is αj , the effect of Gj on U is δj , and the causal effect of X on Y is θ.
If a genetic variant is associated with a confounder of X − Y association, then this
will affect the variant’s association with both the risk factor and the outcome, leading
to the violation of the InSIDE assumption. Using this observation, data was simulated
to consider the following four scenarios:
• Scenario 1 - No pleiotropy, InSIDE automatically satisfied: αj and δj were set to
zero for all j.
• Scenario 2 - Balanced pleiotropy, InSIDE satisfied: αj ∼ U [0.05, 0.15] for invalid
variants, with each αj having a 0.5 probability of being multiplied by -1. δj was
set to zero for all j.
• Scenario 3 - Directional pleiotropy, InSIDE satisfied: αj ∼ U [0.05, 0.15] for invalid
variants, and δj was set to zero for all j.
• Scenario 4 - Directional pleiotropy, InSIDE violated: δj ∼ U [0.05, 0.10] for invalid
variants, and αj was set to zero for all j.
The bounds of the uniform distribution for αj and δj were chosen to ensure the
pleiotropic effects were sufficiently large with a good range. To mimic common genetic
variants, Gj were coded as 0, 1 or 2, and were generated independently from a Binomial
distribution with minor allele frequency 0.3. If a genetic variant was a valid IV then
αj and δj were set to zero in all four scenarios. In Scenarios 2 to 4, the number of
invalid IVs was set to 1, 3 and 6. The causal effect of the risk factor on the outcome
was either θ = 0 (null causal effect) or θ = 0.3 (positive causal effect). To ensure
that the pleiotropic effects (αj and δj) and the effects of the genetic variants on the
risk factor (βXj) were comparable, and the amount of variance explained in X by the
3.5 Simulation study 61
genetic variants was approximately 3% across the four scenarios, βXj was drawn from a
uniform distribution between 0.06 and 0.13. 10 000 simulated datasets were generated
for each combination of parameters (24 different combinations in total).
3.5.2 Methods applied to the simulated data
We applied the methods discussed in Section 3.3 (summarised in Table 3.1) to the
simulated datasets, including the IVW method with: 1) robust regression; 2) penalized
weights; 3) robust regression and penalized weights; 4) the three sets of genetic variants
from the LTS selection method as outlined in Section 3.3.4; and 5) the genetic variants
from the Lasso selection method with the heterogeneity stopping rule. We also applied
robust regression, penalized weights, and robust regression and penalized weights to
the MR-Egger method. Hence, all of the methods in Table 3.1 were considered in the
simulation study apart from Lasso selection with cross validation. The abbreviations
in Table 3.1 are used in the result tables for the simulation study.
The bias and coverage properties of the estimates from the robust methods were
compared to those from the IVW (with all J genetic variants), simple (unweighted)
median, weighted median, and MR-Egger methods. Standard errors for the simple and
weighted median estimates were obtained through bootstrapping [52].
The Lasso selection method was applied to λ = 0.1, 0.2, . . . , 4.9, 5.0, 5.2, 5.4, . . . , 9.8,
10.0 under the heterogeneity stopping rule. The first set of variants used in the IVW
model under LTS selection was based on the h (approximately 50% of the data) variants
used to estimate the initial value of the LTS regression estimate θˆLTS,h. Since the
simulation study generated data for 15 genetic variants, h = 8 variants were selected by
the LTS objective function for each of the simulated datasets, and these variants were
then included in the IVW model. Under the automated approach for LTS selection, h
took an initial value of 8 and increased in increments of one up to 15. The number
of genetic variants whose weights were either penalized (penalized weights method)
or were not selected for the IVW method(Lasso selection and LTS selection methods)
were recorded for each simulated dataset.
The maximum number of invalid instruments was set to 6 in the data generating
model (Section 3.5.1) to ensure 60% or more of the genetic variants were valid IVs.
We anticipated that robust regression and LTS selection would produce consistent
estimates of the causal effect for scenarios 1 to 3 as these methods have a breakdown
point of 50% in the robust statistics literature. Although we anticipated that the
estimates from penalized weights and Lasso selection would be less biased when there
was a smaller proportion of invalid IVs, we were unsure whether these methods were
62 Robust methods for Mendelian randomization
guaranteed to produce consistent estimates if more than 50% of the variants were valid
IVs. Since there was only a maximum of 40% invalid IVs, the simple and weighted
median methods should produce consistent estimates for scenarios 1 to 3.
3.5.3 Results
The mean proportion of variance in the risk factor explained by the genetic variants (R2
statistic), mean F statistic, and mean I2 statistic are contained in Table 3.3 for scenarios
1-4 for the null and positive causal effects by the number of invalid instruments. The
mean R2 values were greater than 3% for all of the scenarios, and the minimum mean
F-statistic was 20.8. The I2 statistic ranged from 39.1% to 77.5%. Since violations
in the NOME assumption can lead to attenuation towards the null for the MR-Egger
estimates, and this attenuation is approximately equal to the I2 statistic, we expected
the MR-Egger estimates for the positive causal effect to be severely attenuated towards
the null [49].
Table 3.3 Mean values of the R2 (%), F-statistic and I2 (%) for Scenarios 1-4 with a null
(θ = 0) or positive (θ = 0.3) causal effect by the number of invalid instrumental variables
(IV).
No invalid IVs 1 invalid IV 3 invalid IVs 6 invalid IVs
R2 F I2 R2 F I2 R2 F I2 R2 F I2
Null causal effect: θ = 0
Scenario 1 3.0 20.8 39.6 - - - - - - - -
Scenario 2 - - - 3.0 20.8 39.6 3.0 20.8 39.3 3.0 20.8 39.5
Scenario 3 - - - 3.0 20.8 39.7 3.0 20.8 39.5 3.0 20.8 39.2
Scenario 4 - - - 3.4 23.6 56.5 4.2 29.3 70.7 5.4 37.7 77.5
Positive causal effect: θ = 0.3
Scenario 1 3.0 20.8 39.3 - - - - - - - -
Scenario 2 - - - 3.0 20.8 39.1 3.0 20.8 39.4 3.0 20.8 39.6
Scenario 3 - - - 3.0 20.8 39.9 3.0 20.8 39.7 3.0 20.8 39.6
Scenario 4 - - - 3.4 23.6 56.4 4.2 29.3 70.8 5.4 37.7 77.4
Results from the simulation study for the IVW model with: 1) the J genetic variants
(IVW); 2) robust regression (Rr); 3) penalized weights (PW); 4) robust regression
and penalized weights; and 5) the three sets of variants selected by LTS selection
are provided in Table 3.4 (Scenario 1 only), Table 3.5 (null causal effect θ = 0),
and Table 3.6 (positive causal effect θ = 0.3). Tables 3.4 to 3.6 also contain the
results from Lasso selection with the heterogeneity stopping rule, simple (unweighted)
3.5 Simulation study 63
median, weighted median and MR-Egger methods, and for each method, information
on the: mean estimate; mean standard error of the estimates; standard deviation of the
estimates; coverage of the true causal effect of the 95% confidence interval; and power
to detect the causal effect at the 5% significance level are provided. The power (at
the 5% significance level) of the intercept test in the MR-Egger method for detecting
directional pleiotropy and/or violation of the InSIDE assumption in all scenarios is
provided in Table 3.7. The number of robust regression models that did not report
a standard error (maximum of 2.6% across all of the scenarios considered) are given
in the Table H.1. Apart from the calculation of the mean standard error, the robust
regression models that did not report a standard error were included in the results,
and the power calculations treated the standard error as infinite.
When all of the genetic variants were valid IVs (Table 3.4), all of the methods
produced unbiased estimates of the null causal effect. With the exception of the IVW
model with the h variants selected from LTS selection, the Type 1 error rates for the
null causal effect were close to the nominal level of 5%. Apart from the simple median
method, there was attenuation towards the null with a positive causal effect for all
methods, and as expected, this was particularly evident for the MR-Egger method
(also observed for Scenarios 2 and 3). Violation of the NOME assumption can lead
to inflation of the intercept term in the MR-Egger method [49], and this was true for
the simulation study where the power to detect the intercept term for Scenarios 1 and
2 was greater than 5% (Table 3.7). Only 7.5% of the MR-Egger models detected a
positive causal effect, and apart from the median estimators and the IVW model with
the h variants from LTS, all of the robust methods had approximately 95% power to
detect the positive causal effect.
Although the mean estimates in Scenario 2 (Tables 3.5 and 3.6) were similar to
those in Scenario 1, there were clear differences in the precision of the estimates for
the null and positive causal effects, with most of the methods reporting larger mean
standard errors under Scenario 2. With the exception of the IVW model with the h
variants from LTS selection, where the mean standard error remained constant, the
mean standard error increased as the number of invalid instruments increased for all
methods. As seen in Scenario 1, the IVW model with the h variants from LTS selection
had inflated Type I error rates and poor coverage. The IVW model with penalized
weights had the most precise estimates, but suffered from inflated Type I error rates
and poor coverage. The estimates from Lasso selection and the automated approach
to LTS selection were almost identical for Scenarios 1 and 2. The simple and weighted
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Table 3.4 Mean (standard error), standard deviation, coverage (%), and power (%) of the
estimates from the IVW model with: 1) the J genetic variants (IVW); 2) robust regression;
3) penalized weights; 4) robust regression and penalized weights; 5) the three sets of variants
selected by the least trimmed squared (LTS) estimator; and 6) the genetic variants from
the Lasso selection method with the heterogeneity stopping rule for Scenario 1 with a null
(θ = 0) or positive (θ = 0.3) causal effect. Results from the simple (unweighted) median,
weighted median and MR-Egger methods are also provided.
Null causal effect (θ = 0) Positive causal effect (θ = 0.3)
Estimate (SE) SD Cov. Pow. Estimate (SE) SD Cov. Pow.
Scenario 1. No pleiotropy, InSIDE automatically satisfied
IVW -0.001 (0.061) 0.058 95.7 4.3 0.287 (0.073) 0.069 95.5 98.2
Robust regression -0.001 (0.066) 0.060 95.1 4.9 0.287 (0.079) 0.072 94.7 94.8
Penalized weights -0.001 (0.060) 0.059 95.0 5.0 0.289 (0.072) 0.071 94.7 98.2
Robust regression with -0.001 (0.064) 0.061 94.5 5.5 0.288 (0.077) 0.073 94.1 95.7
penalized weights
LTSa
Variants from h -0.001 (0.078) 0.116 81.9 18.1 0.291 (0.092) 0.140 80.4 78.5
Variants from wLTS,2 -0.001 (0.061) 0.064 93.3 6.7 0.289 (0.073) 0.077 93.1 97.4
Automated approach -0.001 (0.060) 0.059 95.1 4.9 0.287 (0.072) 0.071 94.9 98.1
Lasso selection -0.001 (0.060) 0.059 94.8 5.2 0.287 (0.072) 0.071 94.6 98.0
Median
Simple -0.002 (0.086) 0.074 97.9 2.1 0.301 (0.105) 0.090 98.0 86.9
Weighted -0.002 (0.080) 0.071 97.4 2.6 0.277 (0.097) 0.085 96.7 85.7
MR-Egger -0.001 (0.219) 0.207 96.1 3.9 0.143 (0.261) 0.251 91.0 7.5
Abbreviations: SE, standard error; SD, standard deviation; Cov., coverage; Pow., power; InSIDE, instrument strength
independent of direct effect; IVW, inverse-variance weighted; LTS, least trimmed squares.
aThe following three sets of genetic variants were selected from the LTS estimator and included in the IVW model: 1)
the h=8 variants used to estimate the initial LTS estimate θˆLTS,h; 2) the variants with a weight of 1 in wLTS,2; and
3) the variants selected from the automated approach based on the heterogeneity stopping rule.
median estimators performed just as well, if not better, than the other robust methods
for Scenario 2.
In Scenario 3 (directional pleiotropy, InSIDE satisfied), the IVW method produced
biased causal estimates with inflated Type 1 error rates, and the degree of bias increased
with the number of invalid IVs. With one invalid instrument, estimates from the robust
methods were slightly biased and Type 1 error rates were fairly well controlled (with
the exception of the IVW model with the h variants from LTS selection). As the
number of instruments increased, bias in the estimates for the robust methods also
increased, although the magnitude of bias was smaller than the IVW method, and
Type 1 error inflation was less severe. The performance of the LTS selection method
varied, and the estimates based on the h variants were the least biased across all of the
robust methods, however, as with Scenarios 1 and 2, the estimates were too precise and
had poor coverage. The estimates from the LTS selection method using the automated
approach and Lasso selection produced almost identical results with the exception of 6
3.5 Simulation study 65
invalid instruments, where the LTS selection method produced less biased estimates.
Robust regression with penalized weights performed reasonably well when there was 1
or 3 invalid instruments.
In Scenario 4 (directional pleiotropy, InSIDE violated), all of the robust methods
produced biased estimates. When there was only one invalid instrument, the magnitude
of bias from the robust methods was less severe than the IVW method, and this was
particularly true for robust regression with penalized weights and LTS selection. Unlike
robust regression with penalized weights, LTS selection suffered from poor coverage of
the causal effect when there was one invalid IV. As the number of invalid IVs increased,
the performance of the robust methods worsened, and there was little advantage in
applying the robust methods compared to the median estimator in Scenario 4 when 6
of the 15 genetic variants were invalid IVs.
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Table 3.5 Mean (standard error), standard deviation, coverage (%), and power (%) of the estimates from
the IVW model with: 1) the J genetic variants (IVW); 2) robust regression (Rr); 3) penalized weights
(PW); 4) robust regression and penalized weights (Rr and PW); 5) the three sets of variants selected by
the least trimmed squared (LTS) estimator; and 6) the genetic variants from the Lasso selection (LS)
method with the heterogeneity stopping rule for Scenarios 2-4 with a null causal effect (θ = 0) by the
number of invalid IVs. Results from the simple median, weighted median and MR-Egger methods are also
provided.
1 invalid IV 3 invalid IVs 6 invalid IVs
Est. (SE) SD Cov. Pow. Est. (SE) SD Cov. Pow. Est. (SE) SD Cov. Pow.
Scenario 2. Balanced pleiotropy, InSIDE satisfied
IVW -0.002 (0.089) 0.092 94.7 5.3 0.000 (0.133) 0.136 93.4 6.6 0.000 (0.180) 0.183 93.0 7.0
Rr -0.002 (0.069) 0.065 94.3 5.7 0.000 (0.096) 0.087 94.5 5.5 0.001 (0.196) 0.173 94.3 5.6
PW -0.002 (0.062) 0.064 94.2 5.8 0.000 (0.066) 0.077 91.1 8.9 0.001 (0.075) 0.116 81.5 18.5
Rr and PW -0.002 (0.071) 0.065 94.6 5.4 0.001 (0.094) 0.078 94.7 5.2 0.001 (0.160) 0.119 91.5 7.3
LTSa
h -0.002 (0.078) 0.115 82.2 17.8 0.001 (0.079) 0.113 83.7 16.3 0.001 (0.080) 0.118 86.2 13.8
wLTS,2 -0.001 (0.064) 0.066 94.2 5.8 0.001 (0.075) 0.086 92.0 8.0 0.002 (0.142) 0.180 85.2 14.8
Auto -0.002 (0.064) 0.064 94.6 5.4 0.000 (0.071) 0.081 91.8 8.3 0.001 (0.091) 0.136 83.5 16.5
LS -0.002 (0.063) 0.065 94.4 5.6 0.000 (0.071) 0.080 91.7 8.3 0.001 (0.088) 0.129 84.5 15.5
Median
Simple -0.002 (0.090) 0.080 97.4 2.6 0.001 (0.097) 0.094 96.5 3.5 0.002 (0.115) 0.132 92.7 7.3
Weighted -0.001 (0.082) 0.076 96.9 3.2 0.000 (0.089) 0.090 95.2 4.8 0.000 (0.101) 0.133 88.9 11.1
MR-Egger -0.004 (0.317) 0.335 92.7 7.3 -0.009 (0.477) 0.496 92.7 7.3 -0.006 (0.646) 0.661 93.0 7.0
Scenario 3. Directional pleiotropy, InSIDE satisfied
IVW 0.064 (0.089) 0.064 94.8 5.2 0.194 (0.126) 0.076 76.0 24.0 0.388 (0.154) 0.089 16.1 83.9
Rr 0.010 (0.069) 0.064 94.3 5.7 0.069 (0.113) 0.083 93.9 6.1 0.335 (0.227) 0.105 63.6 36.4
PW 0.007 (0.062) 0.063 94.2 5.8 0.033 (0.067) 0.078 89.2 10.8 0.148 (0.082) 0.137 57.3 42.7
Rr and PW 0.005 (0.072) 0.065 94.8 5.2 0.025 (0.092) 0.079 93.2 6.7 0.115 (0.138) 0.147 78.6 20.9
LTSa
h 0.000 (0.078) 0.115 82.6 17.4 0.007 (0.079) 0.116 83.0 17.0 0.030 (0.080) 0.143 84.1 15.9
wLTS,2 0.004 (0.064) 0.066 94.2 5.8 0.041 (0.076) 0.085 90.5 9.5 0.283 (0.130) 0.155 37.6 62.4
Auto 0.006 (0.063) 0.064 94.5 5.5 0.030 (0.071) 0.081 90.5 9.5 0.119 (0.093) 0.160 68.7 31.3
LS 0.006 (0.063) 0.065 94.2 5.8 0.031 (0.071) 0.080 90.3 9.7 0.164 (0.096) 0.146 60.5 39.5
Median
Simple 0.021 (0.089) 0.077 97.3 2.7 0.074 (0.100) 0.086 92.9 7.2 0.224 (0.134) 0.124 64.3 35.7
Weighted 0.017 (0.082) 0.074 96.9 3.1 0.065 (0.090) 0.085 91.7 8.3 0.210 (0.110) 0.149 56.9 43.1
MR-Egger -0.003 (0.318) 0.334 92.9 7.2 -0.001 (0.450) 0.465 93.2 6.8 -0.004 (0.544) 0.562 92.4 7.6
Scenario 4. Directional pleiotropy, InSIDE violated
IVW 0.077 (0.070) 0.058 83.4 16.7 0.186 (0.075) 0.056 25.6 74.4 0.290 (0.071) 0.050 0.3 99.7
Rr 0.031 (0.085) 0.069 93.9 6.0 0.142 (0.127) 0.082 73.1 26.0 0.289 (0.079) 0.053 3.3 96.6
PW 0.021 (0.061) 0.070 89.2 10.8 0.083 (0.063) 0.091 64.1 35.9 0.231 (0.061) 0.092 12.2 87.8
Rr and PW 0.018 (0.071) 0.070 92.7 7.3 0.075 (0.084) 0.095 76.2 23.7 0.230 (0.074) 0.101 19.0 80.8
LTSa
h 0.005 (0.078) 0.121 79.6 20.4 0.030 (0.076) 0.139 75.0 25.0 0.162 (0.066) 0.197 45.7 54.3
wLTS,2 0.017 (0.063) 0.074 89.7 10.3 0.090 (0.067) 0.103 61.5 38.5 0.266 (0.069) 0.088 5.8 94.3
Auto 0.025 (0.062) 0.073 88.1 11.9 0.105 (0.066) 0.108 51.9 48.1 0.265 (0.067) 0.103 6.7 93.3
LS 0.024 (0.062) 0.073 88.2 11.8 0.116 (0.066) 0.099 51.1 48.9 0.286 (0.066) 0.070 2.2 97.8
Median
Simple 0.020 (0.089) 0.077 97.3 2.7 0.071 (0.092) 0.083 89.9 10.1 0.192 (0.088) 0.091 40.0 60.0
Weighted 0.055 (0.082) 0.077 91.0 9.0 0.198 (0.081) 0.097 34.8 65.2 0.343 (0.069) 0.074 0.5 99.5
MR-Egger 0.305 (0.214) 0.219 66.8 33.2 0.539 (0.197) 0.183 21.3 78.7 0.644 (0.182) 0.165 5.1 94.9
Abbreviations: IV, instrumental variable; Est. estimate; SE, standard error; SD, standard deviation; Cov., coverage; Pow., power;
InSIDE, instrument strength independent of direct effect; IVW, inverse variance weighted; Rr, robust regression; PW, penalized
weights; LTS, least trimmed squares; LS, Lasso selection; Auto, automated.
aThe following three sets of genetic variants were selected from the LTS estimator and included in the IVW model: 1) the h=8 variants
used to estimate the initial LTS estimate θˆLTS,h; 2) the variants with a weight of 1 in wLTS,2; and 3) the variants selected from the
automated approach based on the heterogeneity stopping rule.
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Table 3.6 Mean (standard error), standard deviation, coverage (%), and power (%) of the estimates from
the IVW model with: 1) the J genetic variants (IVW); 2) robust regression (Rr); 3) penalized weights
(PW); 4) robust regression and penalized weights (Rr and PW); 5) the three sets of variants selected by
the least trimmed squared (LTS) estimator; and 6) the genetic variants from the Lasso selection (LS)
method with the heterogeneity stopping rule for Scenarios 2-4 with a positive causal effect (θ = 0.3) by
the number of invalid IVs. Results from the simple median, weighted median and MR-Egger methods are
also provided.
1 invalid IV 3 invalid IVs 6 invalid IVs
Est. (SE) SD Cov. Pow. Est. (SE) SD Cov. Pow. Est. (SE) SD Cov. Pow.
Scenario 2. Balanced pleiotropy, InSIDE satisfied
IVW 0.286 (0.097) 0.100 94.0 80.9 0.288 (0.139) 0.140 93.5 54.5 0.285 (0.184) 0.184 93.3 34.3
Rr 0.287 (0.084) 0.079 93.9 91.0 0.288 (0.116) 0.107 93.6 71.1 0.286 (0.193) 0.178 93.8 34.5
PW 0.289 (0.074) 0.079 93.2 96.5 0.291 (0.080) 0.098 88.6 91.8 0.295 (0.090) 0.147 78.4 80.5
Rr and PW 0.289 (0.083) 0.080 93.5 92.5 0.290 (0.100) 0.097 92.2 81.6 0.295 (0.145) 0.147 88.1 59.4
LTSa
h 0.292 (0.092) 0.141 80.2 78.8 0.292 (0.093) 0.143 80.5 78.9 0.292 (0.094) 0.164 79.2 78.5
wLTS,2 0.288 (0.076) 0.081 93.2 95.1 0.289 (0.092) 0.108 90.2 83.6 0.287 (0.156) 0.192 85.4 46.5
Auto 0.287 (0.076) 0.079 93.5 95.3 0.289 (0.086) 0.103 89.6 87.2 0.289 (0.112) 0.178 79.0 67.1
LS 0.287 (0.076) 0.080 93.2 95.4 0.288 (0.085) 0.102 89.4 88.0 0.288 (0.108) 0.167 80.5 69.9
Median
Simple 0.302 (0.109) 0.097 97.5 83.1 0.302 (0.118) 0.113 96.1 75.3 0.303 (0.136) 0.155 92.5 61.4
Weighted 0.276 (0.100) 0.091 96.1 81.9 0.277 (0.106) 0.108 94.0 75.6 0.277 (0.119) 0.152 88.2 63.2
MR-Egger 0.143 (0.349) 0.363 90.2 9.0 0.138 (0.495) 0.518 91.2 8.4 0.126 (0.657) 0.681 92.1 7.5
Scenario 3. Directional pleiotropy, InSIDE satisfied
IVW 0.353 (0.098) 0.075 96.1 97.8 0.482 (0.133) 0.087 81.5 99.3 0.673 (0.160) 0.101 28.3 100
Rr 0.306 (0.084) 0.077 95.1 94.8 0.383 (0.134) 0.099 93.9 86.2 0.631 (0.205) 0.112 60.8 90.8
PW 0.303 (0.074) 0.078 93.8 98.0 0.346 (0.081) 0.100 86.4 97.8 0.511 (0.098) 0.164 47.6 99.1
Rr and PW 0.300 (0.083) 0.080 94.1 93.5 0.335 (0.102) 0.102 91.3 88.8 0.485 (0.142) 0.179 66.2 86.9
LTSa
h 0.297 (0.092) 0.144 79.3 79.2 0.308 (0.093) 0.148 80.2 81.4 0.366 (0.094) 0.214 75.1 86.4
wLTS,2 0.299 (0.076) 0.081 93.4 97.0 0.355 (0.092) 0.107 88.8 96.8 0.605 (0.142) 0.147 39.6 99.2
Auto 0.301 (0.076) 0.078 94.3 97.5 0.340 (0.087) 0.105 88.4 96.3 0.490 (0.114) 0.188 56.2 95.9
LS 0.301 (0.076) 0.079 94.0 97.4 0.340 (0.086) 0.104 88.2 96.5 0.513 (0.113) 0.168 53.8 98.5
Median
Simple 0.329 (0.110) 0.095 97.5 89.5 0.393 (0.125) 0.108 93.5 93.2 0.572 (0.158) 0.150 61.8 97.2
Weighted 0.300 (0.100) 0.090 97.2 88.1 0.356 (0.111) 0.104 94.5 93.0 0.516 (0.131) 0.161 63.6 97.4
MR-Egger 0.142 (0.345) 0.353 90.9 8.7 0.138 (0.468) 0.485 91.3 8.1 0.137 (0.555) 0.576 91.9 8.0
Scenario 4. Directional pleiotropy, InSIDE violated
IVW 0.367 (0.080) 0.071 88.8 99.8 0.478 (0.084) 0.067 42.2 100 0.582 (0.078) 0.062 2.3 100
Rr 0.329 (0.100) 0.082 94.3 90.2 0.447 (0.128) 0.085 73.7 90.2 0.581 (0.087) 0.066 8.2 99.7
PW 0.323 (0.072) 0.086 88.6 98.2 0.403 (0.072) 0.102 61.2 98.9 0.546 (0.068) 0.092 11.2 99.9
Rr and PW 0.318 (0.085) 0.087 92.4 94.1 0.397 (0.095) 0.107 72.7 93.6 0.547 (0.077) 0.098 16.0 98.4
LTSa
h 0.306 (0.091) 0.148 77.1 80.9 0.345 (0.087) 0.175 67.5 83.2 0.492 (0.075) 0.205 37.8 93.0
wLTS,2 0.316 (0.074) 0.091 88.2 97.1 0.406 (0.077) 0.112 60.9 98.3 0.567 (0.075) 0.089 6.8 99.6
Auto 0.324 (0.074) 0.088 88.1 97.8 0.424 (0.076) 0.112 52.5 98.4 0.570 (0.074) 0.094 5.4 99.2
LS 0.323 (0.073) 0.089 87.9 97.6 0.430 (0.076) 0.105 52.7 99.3 0.579 (0.073) 0.079 4.4 100
Median
Simple 0.328 (0.108) 0.095 97.0 89.9 0.387 (0.111) 0.101 90.0 95.1 0.509 (0.101) 0.101 43.4 99.5
Weighted 0.344 (0.099) 0.095 94.0 94.4 0.496 (0.097) 0.108 47.2 99.7 0.625 (0.085) 0.087 3.4 100
MR-Egger 0.488 (0.254) 0.259 86.1 51.8 0.767 (0.233) 0.220 45.4 90.0 0.887 (0.214) 0.197 20.2 98.1
Abbreviations: IV, instrumental variable; Est. estimate; SE, standard error; SD, standard deviation; Cov., coverage; Pow., power;
InSIDE, instrument strength independent of direct effect; IVW, inverse variance weighted; Rr, robust regression; PW, penalized
weights; LTS, least trimmed squares; LS, Lasso selection; Auto, automated.
aThe following three sets of genetic variants were selected from the LTS estimator and included in the IVW model: 1) the h=8 variants
used to estimate the initial LTS estimate θˆLTS,h; 2) the variants with a weight of 1 in wLTS,2; and 3) the variants selected from the
automated approach based on the heterogeneity stopping rule.
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Table 3.7 Power (%) of the intercept test in the MR-Egger method for detecting directional
pleiotropy and/or violation of the InSIDE assumption for Scenarios 1-4 with a null (θ = 0)
or positive (θ = 0.3) causal effect by the number of invalid instrumental variables (IV).
Null causal effect Positive causal effect
No. invalid: 0 1 3 6 0 1 3 6
Scenario 1 3.7 - - - 8.7 - -
Scenario 2 - 7.2 7.5 7.0 - 9.4 8.5 7.8
Scenario 3 - 7.2 8.7 13.1 - 11.2 13.8 19.1
Scenario 4 - 8.6 26.2 32.0 - 22.8 49.9 55.9
The performance of the penalized weights, Lasso selection and LTS selection
methods can also be evaluated by considering the mean number of genetic variants
whose weights were penalized or were not selected for the IVW model (Table 3.8). With
the exception of the scenario when there was only one invalid instrument, the mean
numbers of penalized or not selected variants were noticeably smaller than the actual
number of invalid instruments for all of the robust methods. There was little difference
between the mean number of variants penalized or not selected for Scenarios 2 and 3
for the different methods. However, there were large reductions in the mean number
of variants penalized or not selected for the IVW method for Scenario 4 compared to
Scenarios 2 and 3. As the number of invalid IVs increased from 1 to 6, the percentage
of simulated datasets that correctly penalized or did not include all of the invalid
instruments decreased considerably. In terms of the mean number of variants penalized
or not selected for the IVW method, and the frequency that all invalid instruments
were correctly downweighted or not selected, the IVW method with penalized weights
was generally the most effective method across the different scenarios for both the null
and positive causal effects.
Results from applying robust regression and penalized weights to the MR-Egger
method are provided in Table H.2. We had hoped that combining these robust methods
with the MR-Egger method would provide additional robustness. In particular, we
anticipated that there would be less bias in the estimates of the causal effect when the
robust methods and MR-Egger were combined. However, the results were disappointing
as there was no improvement in the performance of the methods when they were
combined, and all of the models were affected by the violation of the NOME assumption.
Finally, results from the one-sample setting are provided in the Table H.3 and
Table H.4. Bias in the direction of the observational association was observed in all
methods. As with the two–sample setting, the IVW model with the h variants from
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LTS selection produced the least biased estimates for all scenarios, and the IVW with
penalized weights was the most precise.
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Table 3.8 Mean estimate, mean number (minimum, maximum) and standard deviation of
variants penalized or not selected for the IVW method, and the frequency (%) all invalid
instruments had their weights penalized by the penalized weights method or were not selected
for the IVW method under Lasso selection with the heterogeneity stopping rule or LTS
selection for wLTS,2 and the automated approach for Scenarios 2-4 with a null (θ = 0) or
positive (θ = 0.3) causal effect by the number of invalid instruments.
Null causal effect (θ = 0) Positive causal effect (θ = 0.3)
Mean Mean no. SD Freq. Mean Mean no. SD Freq.
estimate (min, max) (%) estimate (min, max) (%)
1 invalid IV
Scenario 2. Balanced pleiotropy, InSIDE satisfied
Penalized weights -0.002 1.04 (0, 5) 0.542 86.2 0.289 1.01 (0, 5) 0.632 78.0
Lasso selection -0.002 0.91 (0, 8) 0.621 80.3 0.287 0.83 (0, 8) 0.730 69.8
LTS wLTS,2 variants -0.001 1.10 (0, 7) 0.739 85.3 0.288 1.01 (0, 7) 0.804 75.2
LTS automated -0.002 0.84 (0, 5) 0.475 79.3 0.287 0.74 (0, 5) 0.544 68.0
Scenario 3. Directional pleiotropy, InSIDE satisfied
Penalized weights 0.007 1.04 (0, 5) 0.540 86.5 0.303 1.00 (0, 5) 0.629 76.8
Lasso selection 0.006 0.91 (0, 10) 0.623 80.7 0.301 0.81 (0, 9) 0.681 69.7
LTS wLTS,2 variants 0.004 1.12 (0, 7) 0.737 85.7 0.299 1.02 (0, 7) 0.786 75.4
LTS automated 0.006 0.85 (0, 4) 0.467 79.9 0.301 0.74 (0, 5) 0.536 68.4
Scenario 4. Directional pleiotropy, InSIDE violated
Penalized weights 0.021 0.88 (0, 5) 0.614 70.1 0.301 0.77 (0, 4) 0.673 54.7
Lasso selection 0.024 0.69 (0, 9) 0.725 56.2 0.301 0.57 (0, 10) 0.764 42.3
LTS wLTS,2 variants 0.017 0.95 (0, 7) 0.835 67.7 0.316 0.85 (0, 7) 0.878 54.2
LTS automated 0.025 0.59 (0, 3) 0.558 54 0.324 0.46 (0, 3) 0.559 40.0
3 invalid IV
Scenario 2. Balanced pleiotropy, InSIDE satisfied
Penalized weights 0.000 2.73 (0, 6) 0.723 62.4 0.291 2.51 (0, 7) 0.853 45.0
Lasso selection 0.000 2.48 (0, 10) 0.928 52.5 0.288 2.16 (0, 9) 1.10 35.8
LTS wLTS,2 variants 0.001 2.21 (0, 7) 1.000 41.7 0.289 1.78 (0, 7) 1.07 24.6
LTS automated 0.000 2.35 (0, 6) 0.837 49.5 0.289 1.98 (0, 6) 0.96 31.8
Scenario 3. Directional pleiotropy, InSIDE satisfied
Penalized weights 0.033 2.67 (0, 6) 0.790 56.1 0.346 2.46 (0, 7) 0.942 38.6
Lasso selection 0.031 2.48 (0, 9) 1.06 52.4 0.340 2.14 (0, 10) 1.21 36.1
LTS wLTS,2 variants 0.041 2.15 (0, 7) 1.02 41.2 0.355 1.75 (0, 7) 1.13 26.1
LTS automated 0.030 2.29 (0, 5) 0.912 49.5 0.340 1.92 (0, 7) 1.04 32.9
Scenario 4. Directional pleiotropy, InSIDE violated
Penalized weights 0.083 1.97 (0, 6) 1.01 26.2 0.336 1.58 (0, 5) 1.04 12.8
Lasso selection 0.116 1.45 (0, 11) 1.68 16.4 0.348 1.08 (0, 11) 1.50 8.2
LTS wLTS,2 variants 0.090 1.41 (0, 7) 1.27 22.1 0.406 1.10 (0, 7) 1.19 12.4
LTS automated 0.105 1.10 (0, 5) 1.19 18.9 0.424 0.74 (0, 6) 1.03 9.1
6 invalid IV
Scenario 2. Balanced pleiotropy, InSIDE satisfied
Penalized weights 0.001 5.26 (1, 9) 0.979 37.4 0.295 4.73 (0, 9) 1.14 18.5
Lasso selection 0.001 4.72 (0, 12) 1.64 31.8 0.288 3.87 (0, 13) 1.86 15.5
LTS wLTS,2 variants 0.002 1.64 (0, 7) 1.8 5.3 0.287 1.12 (0, 7) 1.48 1.8
LTS automated 0.001 4.28 (0, 7) 1.53 24.6 0.289 3.30 (0, 7) 1.67 9.5
Scenario 3. Directional pleiotropy, InSIDE satisfied
Penalized weights 0.148 4.94 (0, 11) 1.36 15.6 0.511 4.23 (0, 10) 1.45 5.1
Lasso selection 0.164 4.63 (0, 13) 2.75 23.3 0.513 3.37 (0, 13) 2.65 10.5
LTS wLTS,2 variants 0.283 1.40 (0, 7) 1.82 5.7 0.605 0.93 (0, 7) 1.50 2.5
LTS automated 0.119 3.78 (0, 7) 2.02 26.2 0.490 2.60 (0, 7) 2.09 12.2
Scenario 4. Directional pleiotropy, InSIDE violated
Penalized weights 0.231 2.36 (0, 7) 1.48 1.6 0.399 1.81 (0, 7) 1.30 0.4
Lasso selection 0.286 0.97 (0, 13) 1.87 0.1 0.446 0.83 (0, 13) 1.58 0.0
LTS wLTS,2 variants 0.266 0.59 (0, 7) 1.29 2.2 0.448 0.52 (0, 7) 1.08 0.9
LTS automated 0.265 0.63 (0, 7) 1.44 3.8 0.570 0.44 (0, 7) 1.03 1.2
Abbreviations: no., number; min, minimum; max, maximum; SD, standard deviation; Freq., frequency; IV, instrumental
variable; InSIDE, instrument strength independent of direct effect; LTS, least trimmed squares.
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3.5.4 Increased number of genetic variants
Since many of the methods outlined in Section 3.3 are based on asymptotic theory,
it was anticipated that there would be an improvement in the performance of the
methods when the data was generated with a larger number of genetic variants. We
therefore repeated the simulation study outlined in Section 3.5.1 for Scenarios 2–4
for 1 000 simulated datasets with the number of genetic variants increased from 15 to
100, and the number of invalid IVs was multiplied by 5, increasing from 1, 3 and 6 to
5, 15 and 30. The bounds of the uniform distribution used to generate the genetic
associations with the risk factor (βXj) were divided by
√
100√
15 to ensure the average R
2
values were comparable with the original simulation study. The IVW model with: 1)
the full set of genetic variants; 2) robust regression; 3) penalized weights; 4) robust
regression and penalized weights; 5) the h genetic variants obtained from the LTS
selection method (Section 3.3.4); and 6) the genetic variants from the Lasso selection
method with the heterogeneity stopping rule were all applied to the dataset.
Results
The mean R2 statistic, F-statistic, and I2 statistic are contained in Table 3.9 for
Scenarios 2–4 for the null and positive causal effect by the number of invalid IVs. The
mean R2 values for the 100 genetic variants were slightly higher than the values reported
in the original simulation study (Table 3.3). For all of the scenarios considered, there
was a significant reduction in the mean F-statistic and I2 statistic, and we therefore
expected the estimates to be affected by weak instrument bias.
Table 3.9 Mean values of the R2 (%), F-statistic and I2 (%) for Scenarios 2-4 with a null
(θ = 0) or positive (θ = 0.3) causal effect by the number of invalid instrumental variables
(IV) when the simulation study was re-performed for 100 genetic variants.
5 invalid IV 15 invalid IVs 30 invalid IVs
R2 F I2 R2 F I2 R2 F I2
Null causal effect: θ = 0
Scenario 2 4.0 4.2 3.0 4.0 4.2 3.3 4.0 4.2 2.9
Scenario 3 4.0 4.2 3.1 4.0 4.2 3.0 4.0 4.2 3.0
Scenario 4 5.2 5.4 32.9 7.3 7.8 58.3 10.3 11.4 69.5
Positive causal effect: θ = 0.3
Scenario 2 4.0 4.2 3.2 4.0 4.2 3.1 4.1 4.2 3.1
Scenario 3 4.0 4.2 3.3 4.1 4.2 3.1 4.0 4.2 2.9
Scenario 4 5.2 5.4 33.3 7.3 7.8 58.2 10.3 11.4 69.4
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Results from the simulation study for the IVW model with: 1) the J genetic
variants (IVW); 2) robust regression; 3) penalized weights; 4) robust regression and
penalized weights; 5) the h genetic variants selected by the least trimmed squared
(LTS) estimator; and 6) the genetic variants from the Lasso selection method with the
heterogeneity stopping rule are provided in Table 3.10 (null causal effect θ = 0), and
Table 3.11 (positive causal effect θ = 0.3).
The reduction in the strength of the IVs led to weak instrument bias, and there
was severe attenuation towards the null for the positive causal effect (Table 3.11).
For the null causal effect, there was little difference in the performance of the robust
methods with the increased number of genetic variants. In fact, the methods performed
worst under Scenario 4 when 100 variants were included in the data generating model
rather than 15 (Table 3.10). Due to the attenuation of the positive causal effect when
the number of variants was increased to 100, it was difficult to compare the results
to the original simulations. Nevertheless, there was no evidence to suggest that the
performances of the robust methods improved when the number of genetic variants
was increased.
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Table 3.10 Results from the simulation study when 100 genetic variants were simulated for 1 000 datasets.
Mean (standard error), standard deviation, coverage (%), and power (%) of the estimates from the IVW
model with: 1) the J genetic variants (IVW); 2) robust regression (Rr); 3) penalized weights (PW); 4)
robust regression and penalized weights (Rr and PW); 5) the h genetic variants selected by the least
trimmed squared (LTS) estimator; and 6) the genetic variants from the Lasso selection (LS) method with
the heterogeneity stopping rule for Scenarios 2-4 with a null causal effect (θ = 0) by the number of invalid
instrumental variables.
5 invalid IV 15 invalid IVs 30 invalid IVs
Est. (SE) SD Cov. Pow. Est. (SE) SD Cov. Pow. Est. (SE) SD Cov. Pow.
Scenario 2. Balanced pleiotropy, InSIDE satisfied
IVW -0.003 (0.072) 0.071 95.0 5.0 -0.003 (0.103) 0.105 94.9 5.1 0.000 (0.138) 0.144 94.0 6.0
Rr -0.001 (0.054) 0.051 95.8 4.2 -0.001 (0.065) 0.066 93.7 6.3 0.005 (0.115) 0.114 95.7 4.3
PW -0.001 (0.051) 0.051 94.8 5.2 -0.001 (0.054) 0.063 91.3 8.7 0.001 (0.060) 0.081 86.3 13.7
Rr and PW -0.001 (0.055) 0.052 95.8 4.2 -0.001 (0.064) 0.062 95.6 4.4 0.000 (0.087) 0.078 96.5 3.5
LTSa
h 0.001 (0.069) 0.134 69.1 30.9 0.001 (0.070) 0.127 71.8 28.2 -0.003 (0.072) 0.122 75.9 24.1
Auto -0.001 (0.052) 0.052 94.8 5.2 0.000 (0.057) 0.066 91.6 8.4 0.002 (0.070) 0.095 86.9 13.1
LS -0.001 (0.051) 0.052 94.2 5.8 -0.002 (0.055) 0.063 91.5 8.5 0.002 (0.062) 0.081 87.6 12.4
Scenario 3. Directional pleiotropy, InSIDE satisfied
IVW 0.096 (0.071) 0.058 77.3 22.7 0.287 (0.099) 0.070 9.0 91.0 0.572 (0.126) 0.088 0.0 100
Rr 0.014 (0.055) 0.053 94.8 5.2 0.070 (0.072) 0.064 87.0 13.0 0.355 (0.169) 0.103 41.3 58.7
PW 0.012 (0.051) 0.053 93.9 6.1 0.043 (0.054) 0.061 83.9 16.1 0.156 (0.062) 0.094 34.3 65.7
Rr and PW 0.009 (0.055) 0.054 95.2 4.7 0.031 (0.064) 0.061 91.7 8.3 0.108 (0.087) 0.093 74.6 25.4
LTSa
h 0.003 (0.069) 0.138 66.1 33.9 0.000 (0.070) 0.126 73.4 26.6 0.008 (0.071) 0.116 78.6 21.4
Auto 0.012 (0.052) 0.053 94.2 5.8 0.039 (0.057) 0.065 85.6 14.4 0.146 (0.072) 0.118 51.2 48.8
LS 0.013 (0.051) 0.054 93.2 6.8 0.044 (0.055) 0.062 83.4 16.6 0.165 (0.063) 0.095 32.6 67.4
Scenario 4. Directional pleiotropy, InSIDE violated
IVW 0.170 (0.052) 0.046 7.2 92.8 0.349 (0.049) 0.043 0.0 100 0.476 (0.043) 0.036 0.0 100
Rr 0.076 (0.079) 0.065 87.2 12.8 0.310 (0.089) 0.057 7.7 92.1 0.475 (0.048) 0.038 0.0 100
PW 0.053 (0.049) 0.064 72.9 27.1 0.187 (0.046) 0.082 13.5 86.5 0.401 (0.040) 0.062 0.0 100
Rr and PW 0.047 (0.058) 0.064 84.5 15.5 0.184 (0.065) 0.087 26.7 73.3 0.409 (0.044) 0.062 0.0 100
LTSa
h 0.014 (0.068) 0.136 68.8 31.2 0.042 (0.066) 0.173 59.1 40.9 0.262 (0.053) 0.262 32.2 67.8
Auto 0.070 (0.049) 0.074 62.7 37.3 0.295 (0.047) 0.096 6.1 93.9 0.473 (0.042) 0.040 0.0 100
LS 0.072 (0.048) 0.068 62.9 37.1 0.276 (0.043) 0.072 0.7 99.3 0.474 (0.035) 0.051 0.0 100
Abbreviations: IV, instrumental variable; Est. estimate; SE, standard error; SD, standard deviation; Cov., coverage; Pow., power;
InSIDE, instrument strength independent of direct effect; IVW, inverse variance weighted; Rr, robust regression; PW, penalized
weights; LTS, least trimmed squares; LS, Lasso selection; Auto, automated.
aThe following two sets of genetic variants were selected from the LTS estimator and included in the IVW model: 1) the h=50 variants
used to estimate the initial LTS estimate θˆLTS,h; and 2) the variants selected from the automated approach based on the heterogeneity
stopping rule.
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Table 3.11 Results from the simulation study when 100 genetic variants were simulated for 1,000 datasets.
Mean (standard error), standard deviation, coverage (%), and power (%) of the estimates from the IVW
model with: 1) the J genetic variants (IVW); 2) robust regression (Rr); 3) penalized weights (PW); 4)
robust regression and penalized weights (Rr and PW); 5) the h genetic variants selected by the least
trimmed squared (LTS) estimator; and 6) the genetic variants from the Lasso selection (LS) method with
the heterogeneity stopping rule for Scenarios 2–4 with a positive causal effect (θ = 0.3) by the number of
invalid instrumental variables.
5 invalid IV 15 invalid IVs 30 invalid IVs
Est. (SE) SD Cov. Pow. Est. (SE) SD Cov. Pow. Est. (SE) SD Cov. Pow.
Scenario 2. Balanced pleiotropy, InSIDE satisfied
IVW 0.227 (0.079) 0.076 17.8 82.2 0.229 (0.108) 0.113 45.5 54.5 0.228 (0.141) 0.136 64.2 35.8
Rr 0.227 (0.065) 0.062 6.1 93.9 0.233 (0.080) 0.082 18.6 81.4 0.230 (0.126) 0.119 54.3 45.7
PW 0.230 (0.061) 0.062 3.9 96.1 0.241 (0.064) 0.079 8.2 91.8 0.241 (0.071) 0.100 15.7 84.3
Rr and PW 0.229 (0.064) 0.063 4.8 95.2 0.237 (0.072) 0.077 11.1 88.9 0.236 (0.088) 0.097 25.5 74.5
LTSa
h 0.235 (0.081) 0.157 30.5 69.5 0.234 (0.082) 0.158 30.9 69.1 0.238 (0.082) 0.145 27.9 72.1
Auto 0.227 (0.062) 0.062 4.9 95.1 0.234 (0.069) 0.084 12.8 87.2 0.232 (0.088) 0.125 31.1 68.9
LS 0.227 (0.061) 0.064 4.8 95.2 0.232 (0.065) 0.079 9.2 90.8 0.230 (0.072) 0.095 17.8 82.2
Scenario 3. Directional pleiotropy, InSIDE satisfied
IVW 0.323 (0.079) 0.068 1.1 98.9 0.514 (0.107) 0.081 0 100 0.804 (0.133) 0.098 0.0 100
Rr 0.251 (0.066) 0.066 2.9 97.1 0.342 (0.093) 0.081 1.3 98.7 0.654 (0.162) 0.107 0.2 99.8
PW 0.251 (0.061) 0.066 2.1 97.9 0.308 (0.065) 0.080 0.8 99.2 0.490 (0.076) 0.121 0.0 100
Rr and PW 0.246 (0.065) 0.067 4.1 95.9 0.291 (0.074) 0.080 3.2 96.8 0.442 (0.102) 0.123 1.6 98.3
LTSa
h 0.236 (0.081) 0.156 31.2 68.8 0.244 (0.082) 0.156 30.4 69.6 0.253 (0.083) 0.157 27.1 72.9
Auto 0.248 (0.062) 0.065 2.4 97.6 0.299 (0.070) 0.082 1.6 98.4 0.509 (0.091) 0.15 0.3 99.7
LS 0.247 (0.061) 0.066 2.5 97.5 0.297 (0.065) 0.081 1.3 98.7 0.463 (0.074) 0.115 0.0 100
Scenario 4. Directional pleiotropy, InSIDE violated
IVW 0.411 (0.061) 0.060 0.0 100 0.609 (0.058) 0.054 0.0 100 0.747 (0.051) 0.045 0.0 100
Rr 0.327 (0.095) 0.076 4.5 95.5 0.575 (0.093) 0.065 0.6 99.4 0.746 (0.057) 0.047 0.0 100
PW 0.307 (0.058) 0.080 0.9 99.1 0.479 (0.053) 0.093 0.1 99.9 0.689 (0.046) 0.066 0.0 100
Rr and PW 0.298 (0.072) 0.080 1.7 98.3 0.478 (0.073) 0.098 0.2 99.6 0.697 (0.051) 0.066 0.0 100
LTSa
h 0.239 (0.080) 0.176 31.9 68.1 0.313 (0.076) 0.220 24.7 75.3 0.583 (0.059) 0.274 8.6 91.4
Auto 0.319 (0.058) 0.087 1.1 98.9 0.569 (0.055) 0.088 0.0 100 0.745 (0.049) 0.049 0.0 100
LS 0.314 (0.057) 0.08 0.3 99.7 0.544 (0.050) 0.081 0.0 100 0.742 (0.041) 0.061 0.0 100
Abbreviations: IV, instrumental variable; Est. estimate; SE, standard error; SD, standard deviation; Cov., coverage; Pow., power;
InSIDE, instrument strength independent of direct effect; IVW, inverse variance weighted; Rr, robust regression; PW, penalized
weights; LTS, least trimmed squares; LS, Lasso selection; Auto, automated.
aThe following three sets of genetic variants were selected from the LTS estimator and included in the IVW model: 1) the h=50
variants used to estimate the initial LTS estimate θˆLTS,h; and 2) the variants selected from the automated approach based on the
heterogeneity stopping rule.
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3.5.5 Binary outcome
The data generating model in Section 3.5.1 considered a continuous risk factor X
and continuous outcome Y . As noted in Section 2.3.3, the IVW method provides an
approximate measure of the causal odds ratio for the effect of a continuous risk factor on
a binary outcome. To investigate how well the methods proposed in Section 3.3 estimate
the causal odds ratio, we repeated the simulation study outlined in Section 3.5.1 for
Scenarios 1–4 for 1 000 simulated datasets with a binary outcome Y .
With the exception of the outcome Y , the same data generating model outlined in
Section 3.5.1 was used for the additional simulation. The outcome was generated from
the Binomial distribution:
Yi ∼ Binomial(1, expit(θ0 +
J∑
j=1
αjGij + θXi + Ui)) , (3.14)
where θ represents the log odds ratio per unit increase in the risk factor X, and expit
is the inverse of the logit function:
expit(x) = exp(x)1 + exp(x) .
The constant term θ0 in Equation 3.14 was set to -3.75 to ensure the prevalence of the
outcome Y ranged between 3% and 8% across the different scenarios. The summary
level data for the outcome was obtained by fitting logistic regression models for each
genetic variant Gj (j = 1, . . . , J).
We applied the methods discussed in Section 3.3 (summarised in Table 3.1) to the
simulated datasets, including the IVW method with: 1) robust regression; 2) penalized
weights; 3) robust regression and penalized weights; 4) the three sets of genetic variants
from the LTS selection method as outlined in Section 3.3.4; and 5) the genetic variants
from the Lasso selection method with the heterogeneity stopping rule. The IVW (with
all J genetic variants), simple (unweighted) median, weighted median, and MR-Egger
methods were also considered.
Results
The mean R2 statistic, F-statistic, I2 statistic and prevalence of the outcome are
contained in Table 3.12 for Scenarios 1–4 for the null and positive causal effect by
the number of invalid IVs. As expected, the mean values for the R2 and F-statistics
were very similar to those reported in the original simulation (Table 3.3). There was
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little difference in the mean I2 statistic in Tables 3.3 and 3.12. The prevalence of the
outcome ranged between 3.5% and 5% for the null causal effect, and 5.8% and 7.9%
for the positive causal effect. The prevalence of the outcome generally increased as the
number of invalid IVs increased.
Table 3.12 Mean values of the R2 (%), F-statistic, I2 (%) and prevalence of the outcome
(%) for Scenarios 1-4 with a null (θ = 0) or positive (θ = 0.3) causal effect by the number
of invalid instrumental variables (IV) when the simulation study was re-performed with a
binary outcome for a 1,000 simulated datasets.
No invalid IVs 1 invalid IV 3 invalid IVs 6 invalid IVs
R2 F I2 P R2 F I2 P R2 F I2 P R2 F I2 P
Null causal effect: θ = 0
Scen 1 3.0 20.9 39.8 3.5 - - - - - - - - - - - -
Scen 2 - - - - 3.0 20.7 38.8 3.5 3.1 21.0 40.1 3.6 3.0 21.0 39.0 3.6
Scen 3 - - - - 3.0 20.8 38.9 3.8 3.0 20.6 39.2 4.2 3.0 20.6 40.1 5.0
Scen 4 - - - - 3.4 23.7 55.7 3.7 4.2 29.2 70.9 4.0 5.4 37.8 77.9 4.6
Positive causal effect: θ = 0.3
Scen 1 3.0 20.7 40.5 5.8 - - - - - - - - - - - -
Scen 2 - - - - 3.0 20.8 39.3 5.8 3.0 20.7 40.3 5.9 3.0 20.8 40.7 5.9
Scen 3 - - - - 3.0 20.8 39.9 6.1 3.0 20.8 39.1 6.8 3.1 21.0 40.0 7.9
Scen 4 - - - - 3.4 23.6 56.7 6.1 4.2 29.1 71.4 6.8 5.3 37.5 77.8 7.8
Abbreviations: IV, instrumental variable; Scen, scenario; F, F-statistic; P, prevalence.
Results from the simulation study with a binary outcome for the IVW model with:
1) the J genetic variants (IVW); 2) robust regression (Rr); 3) penalized weights (PW);
4) robust regression and penalized weights; and 5) the three sets of variants selected
by LTS selection are provided in Table 3.13 (Scenario 1 only), Table 3.14 (null causal
effect θ = 0), and Table 3.15 (positive causal effect θ = 0.3). Tables 3.13 to 3.15 also
contain the results from Lasso selection with the heterogeneity stopping rule, simple
(unweighted) median, weighted median and MR-Egger methods, and for each method,
information on the: mean estimate; mean standard error of the estimates; standard
deviation of the estimates; coverage of the true causal effect of the 95% confidence
interval; and power to detect the causal effect at the 5% significance level are provided.
The mean estimates of the null causal effect were slightly biased for all of the
methods when there were no invalid IVs (Table 3.13). As seen in the original simu-
lation (Table 3.4), the Type 1 error rates for the null causal effect were close to the
nominal level of 5% except for the IVW model with the h variants selected from LTS
penalization. The attenuation towards the null with a positive causal effect was more
severe for a binary outcome (Table 3.13) compared to the original simulation with a
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continuous outcome (Table 3.4). Although the coverage of the positive causal effect
was close to 95% for the methods considered, there was a significant drop in power
when the outcome was binary rather than continuous. The IVW method only had
25.4% power to detect the causal effect, and the simple median had 13.1% power. This
reduction in power is reflected in the increase in the mean standard errors for all of
the methods for the null and positive causal effect.
Table 3.13 Results from the simulation study when the outcome was binary and 1,000
datasets were simulated. Mean (standard error), standard deviation, coverage (%), and power
(%) of the estimates from the IVW model with: 1) the J genetic variants (IVW); 2) robust
regression; 3) penalized weights; 4) robust regression and penalized weights; 5) the three
sets of variants selected by the least trimmed squared (LTS) estimator; and 6) the genetic
variants from the Lasso selection method with the heterogeneity stopping rule for Scenario 1
with a null (θ = 0) or positive (θ = 0.3) causal effect. Results from the simple (unweighted)
median, weighted median and MR-Egger methods are also provided.
Null causal effect (θ = 0) Positive causal effect (θ = 0.3)
Estimate (SE) SD Cov. Pow. Estimate (SE) SD Cov. Pow.
Scenario 1. No pleiotropy, InSIDE automatically satisfied
IVW 0.018 (0.233) 0.214 96.2 3.8 0.249 (0.184) 0.173 94.8 25.4
Robust regression 0.017 (0.252) 0.223 96.0 4.0 0.245 (0.197) 0.177 94.3 25.3
Penalized weights 0.020 (0.230) 0.221 95.6 4.4 0.248 (0.181) 0.176 94.5 26.5
Robust regression with 0.018 (0.245) 0.228 95.5 4.5 0.245 (0.192) 0.179 93.7 26.6
penalized weights
LTSa
Variants from h 0.008 (0.299) 0.439 81.7 18.3 0.242 (0.236) 0.350 81.2 28.8
Variants from wLTS,2 0.019 (0.232) 0.243 93.9 6.1 0.248 (0.183) 0.187 93.7 26.8
Automated approach 0.021 (0.231) 0.218 95.8 4.2 0.248 (0.182) 0.176 94.4 25.9
Lasso selection 0.023 (0.231) 0.223 95.3 4.7 0.248 (0.182) 0.177 94.3 26.1
Median
Simple 0.004 (0.330) 0.279 98.4 1.6 0.246 (0.261) 0.228 97.4 12.4
Weighted 0.025 (0.304) 0.267 97.2 2.8 0.236 (0.241) 0.212 97.5 13.1
MR-Egger -0.012 (0.837) 0.768 97.2 2.8 0.119 (0.652) 0.649 94.9 4.8
Abbreviations: SE, standard error; SD, standard deviation; Cov., coverage; Pow., power; InSIDE, instrument strength
independent of direct effect; IVW, inverse-variance weighted; LTS, least trimmed squares.
aThe following three sets of genetic variants were selected from the LTS estimator and included in the IVW model: 1)
the h=8 variants used to estimate the initial LTS estimate θˆLTS,h; 2) the variants with a weight of 1 in wLTS,2; and
3) the variants selected from the automated approach based on the heterogeneity stopping rule.
Although the mean estimates for the null and positive causal effects in Scenario
2 (Tables 3.14 and 3.15) were similar to those in Scenario 1, most of the methods
reported a larger mean standard error under Scenario 2. As with Scenarios 1 and 2,
the mean estimates for the null causal effect under Scenarios 3 and 4 were more biased
when the outcome was binary rather continuous, and the mean estimates for a positive
causal effect had greater attenuation towards the null.
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In terms of the performance of the methods, the overall conclusions drawn from
the original simulation study are applicable to the results with a binary outcome. In
particular, the IVW method with penalized weights had the most precise estimates,
but suffered from inflated Type 1 error rates and poor coverage, and robust regression
with penalized weights performed reasonably well when there was 1 or 3 invalid IVs.
However, as observed in the original simulation, there was little advantage in applying
the robust methods compared to the median estimator.
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Table 3.14 Results from the simulation study when the outcome was binary and 1,000 datasets were
simulated. Mean (standard error), standard deviation, coverage (%), and power (%) of the estimates from
the IVW model with: 1) the J genetic variants (IVW); 2) robust regression (Rr); 3) penalized weights
(PW); 4) robust regression and penalized weights (Rr and PW); 5) the three sets of variants selected by
the least trimmed squared (LTS) estimator; and 6) the genetic variants from the Lasso selection (LS)
method with the heterogeneity stopping rule for Scenarios 2-4 with a null causal effect (θ = 0) by the
number of invalid IVs. Results from the simple median, weighted median and MR-Egger methods are also
provided.
1 invalid IV 3 invalid IVs 6 invalid IVs
Est. (SE) SD Cov. Pow. Est. (SE) SD Cov. Pow. Est. (SE) SD Cov. Pow.
Scenario 2. Balanced pleiotropy, InSIDE satisfied
IVW 0.016 (0.241) 0.218 95.9 4.1 0.014 (0.249) 0.248 94.8 5.2 0.016 (0.273) 0.270 93.6 6.4
Rr 0.013 (0.260) 0.226 95.9 4.1 0.012 (0.265) 0.255 93.9 6.1 0.007 (0.293) 0.278 92.6 7.3
PW 0.013 (0.235) 0.224 95.0 5.0 0.010 (0.239) 0.258 92.8 7.2 -0.003 (0.254) 0.296 89.7 10.3
Rr and PW 0.011 (0.251) 0.230 95.0 5.0 0.010 (0.253) 0.262 92.5 7.5 -0.004 (0.267) 0.299 89.6 10.3
LTSa
h 0.007 (0.302) 0.468 80.2 19.8 0.025 (0.297) 0.462 78.5 21.5 -0.006 (0.298) 0.544 71.1 28.9
wLTS,2 0.016 (0.238) 0.248 93.0 7.0 0.017 (0.243) 0.268 91.6 8.4 0.014 (0.262) 0.304 88.8 11.2
Auto 0.015 (0.238) 0.223 95.3 4.7 0.009 (0.244) 0.256 93.6 6.4 0.006 (0.264) 0.290 90.8 9.2
LS 0.015 (0.238) 0.229 94.8 5.2 0.010 (0.242) 0.257 93.2 6.8 0.007 (0.262) 0.294 89.9 10.1
Median
Simple -0.002 (0.335) 0.290 97.7 2.3 0.000 (0.337) 0.316 96.0 4.0 -0.023 (0.348) 0.355 94.1 5.9
Weighted 0.023 (0.310) 0.274 96.6 3.4 0.032 (0.310) 0.300 95.9 4.1 0.019 (0.318) 0.339 92.7 7.3
MR-Egger -0.003 (0.872) 0.826 96.4 3.6 0.020 (0.896) 0.850 95.6 4.4 -0.007 (0.986) 1.006 93.8 6.2
Scenario 3. Directional pleiotropy, InSIDE satisfied
IVW 0.073 (0.232) 0.217 96.0 4.0 0.204 (0.231) 0.209 87.3 12.7 0.379 (0.231) 0.202 64.1 35.9
Rr 0.061 (0.248) 0.225 94.9 5.0 0.178 (0.250) 0.222 88.8 11.2 0.366 (0.248) 0.210 69.6 30.3
PW 0.060 (0.226) 0.223 95.4 4.6 0.182 (0.222) 0.221 86.4 13.6 0.364 (0.217) 0.218 61.5 38.5
Rr and PW 0.057 (0.241) 0.228 94.6 5.3 0.171 (0.239) 0.228 87.6 12.4 0.358 (0.230) 0.223 66.0 34.0
LTSa
h 0.060 (0.291) 0.441 79.5 20.5 0.108 (0.277) 0.443 77.7 22.3 0.306 (0.254) 0.444 64.4 35.6
wLTS,2 0.061 (0.229) 0.242 93.4 6.6 0.177 (0.225) 0.240 85.5 14.5 0.372 (0.224) 0.227 61.9 38.1
Auto 0.063 (0.229) 0.223 95.4 4.6 0.189 (0.226) 0.221 87.0 13.0 0.370 (0.225) 0.211 63.3 36.7
LS 0.060 (0.228) 0.225 95.4 4.6 0.188 (0.225) 0.225 86.5 13.5 0.366 (0.222) 0.218 63.1 36.9
Median
Simple 0.055 (0.323) 0.283 97.9 2.1 0.161 (0.313) 0.280 93.3 6.7 0.362 (0.298) 0.272 80.2 19.8
Weighted 0.063 (0.299) 0.270 97.8 2.2 0.157 (0.288) 0.266 93.0 7.0 0.333 (0.273) 0.262 77.9 22.1
MR-Egger -0.023 (0.835) 0.859 94.0 6.0 0.001 (0.828) 0.826 94.6 5.4 0.005 (0.817) 0.861 93.5 6.5
Scenario 4. Directional pleiotropy, InSIDE violated
IVW 0.079 (0.215) 0.205 94.8 5.2 0.182 (0.188) 0.170 85.2 14.8 0.279 (0.158) 0.143 56.7 43.3
Rr 0.073 (0.243) 0.220 93.4 6.5 0.176 (0.213) 0.178 84.1 15.8 0.279 (0.171) 0.151 60.5 39.5
PW 0.068 (0.212) 0.217 93.6 6.4 0.168 (0.185) 0.183 84.9 15.1 0.270 (0.154) 0.150 57.5 42.5
Rr and PW 0.068 (0.233) 0.226 92.4 7.5 0.168 (0.206) 0.187 83.6 16.3 0.273 (0.163) 0.155 59.5 40.5
LTSa
h 0.062 (0.277) 0.426 78.6 21.4 0.122 (0.242) 0.373 75.5 24.5 0.257 (0.197) 0.304 59.7 40.3
wLTS,2 0.070 (0.215) 0.238 91.5 8.5 0.168 (0.188) 0.197 84.1 15.9 0.276 (0.156) 0.164 56.7 43.3
Auto 0.072 (0.214) 0.215 94.2 5.8 0.175 (0.186) 0.179 84.7 15.3 0.278 (0.156) 0.149 56.1 43.9
LS 0.069 (0.214) 0.218 93.8 6.2 0.175 (0.186) 0.180 84.1 15.9 0.277 (0.156) 0.151 55.9 44.1
Median
Simple 0.036 (0.309) 0.282 97.0 3.0 0.115 (0.274) 0.239 94.5 5.5 0.219 (0.226) 0.200 85.5 14.5
Weighted 0.121 (0.282) 0.266 94.8 5.2 0.234 (0.243) 0.217 86.2 13.8 0.328 (0.200) 0.181 64.0 36.0
MR-Egger 0.292 (0.697) 0.680 93.2 6.8 0.504 (0.548) 0.524 85.8 14.2 0.619 (0.455) 0.435 71.5 28.5
Abbreviations: IV, instrumental variable; Est. estimate; SE, standard error; SD, standard deviation; Cov., coverage; Pow., power;
InSIDE, instrument strength independent of direct effect; IVW, inverse variance weighted; Rr, robust regression; PW, penalized
weights; LTS, least trimmed squares; LS, Lasso selection; Auto, automated.
aThe following three sets of genetic variants were selected from the LTS estimator and included in the IVW model: 1) the h=8 variants
used to estimate the initial LTS estimate θˆLTS,h; 2) the variants with a weight of 1 in wLTS,2; and 3) the variants selected from the
automated approach based on the heterogeneity stopping rule.
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Table 3.15 Results from the simulation study when the outcome was binary and 1,000 datasets were
simulated. Mean (standard error), standard deviation, coverage (%), and power (%) of the estimates from
the IVW model with: 1) the J genetic variants (IVW); 2) robust regression (Rr); 3) penalized weights
(PW); 4) robust regression and penalized weights (Rr and PW); 5) the three sets of variants selected by
the least trimmed squared (LTS) estimator; and 6) the genetic variants from the Lasso selection (LS)
method with the heterogeneity stopping rule for Scenarios 2-4 with a positive causal effect (θ = 0.3) by
the number of invalid IVs. Results from the simple median, weighted median and MR-Egger methods are
also provided.
1 invalid IV 3 invalid IVs 6 invalid IVs
Est. (SE) SD Cov. Pow. Est. (SE) SD Cov. Pow. Est. (SE) SD Cov. Pow.
Scenario 2. Balanced pleiotropy, InSIDE satisfied
IVW 0.263 (0.190) 0.190 93.8 27.8 0.268 (0.207) 0.207 93.6 28.2 0.274 (0.226) 0.220 94.5 25.7
Rr 0.260 (0.204) 0.196 92.3 27.4 0.266 (0.220) 0.207 93.5 26.9 0.268 (0.237) 0.224 93.9 24.3
PW 0.260 (0.185) 0.199 92.4 29.3 0.262 (0.195) 0.212 92.4 30.9 0.267 (0.205) 0.237 89.6 31.4
Rr and PW 0.259 (0.196) 0.202 91.8 29.3 0.263 (0.206) 0.213 92.4 30.1 0.265 (0.215) 0.238 90.5 29.3
LTSa
h 0.264 (0.235) 0.351 81.4 32.3 0.254 (0.235) 0.376 78.0 34.7 0.271 (0.234) 0.418 72.9 35.5
wLTS,2 0.263 (0.187) 0.211 90.6 31.4 0.272 (0.199) 0.216 92.2 30.8 0.275 (0.214) 0.238 90.6 30.7
Auto 0.261 (0.187) 0.198 92.9 28.7 0.264 (0.200) 0.211 92.0 29.2 0.270 (0.215) 0.235 91.3 29.3
LS 0.259 (0.187) 0.197 92.7 28.5 0.263 (0.198) 0.215 91.0 29.7 0.270 (0.212) 0.242 90.3 30.8
Median
Simple 0.264 (0.264) 0.236 97.6 15.5 0.261 (0.270) 0.244 96.4 13.1 0.270 (0.278) 0.280 95.5 17.5
Weighted 0.255 (0.243) 0.230 96.3 17.9 0.264 (0.249) 0.239 95.6 18.3 0.264 (0.254) 0.263 95.0 19.3
MR-Egger 0.104 (0.686) 0.661 93.8 4.5 0.133 (0.736) 0.733 93.6 5.2 0.100 (0.809) 0.771 94.5 5.0
Scenario 3. Directional pleiotropy, InSIDE satisfied
IVW 0.315 (0.186) 0.164 96.7 38.4 0.421 (0.190) 0.170 93.0 61.7 0.590 (0.191) 0.163 69.4 89.6
Rr 0.300 (0.198) 0.172 96.4 35.3 0.403 (0.202) 0.178 93.2 53.6 0.578 (0.206) 0.171 72.8 83.5
PW 0.306 (0.179) 0.172 95.7 40.1 0.401 (0.179) 0.180 91.6 62.0 0.577 (0.177) 0.180 65.7 90.0
Rr and PW 0.299 (0.191) 0.176 95.3 37.0 0.395 (0.189) 0.184 91.7 56.6 0.571 (0.188) 0.184 67.6 85.8
LTSa
h 0.293 (0.229) 0.347 79.2 34.3 0.364 (0.218) 0.360 77.0 42.3 0.526 (0.203) 0.385 64.0 60.4
wLTS,2 0.298 (0.182) 0.183 94.2 38.0 0.400 (0.183) 0.193 90.7 58.6 0.582 (0.185) 0.184 67.1 88.8
Auto 0.304 (0.182) 0.173 95.7 38.7 0.406 (0.184) 0.180 92.0 60.4 0.582 (0.185) 0.176 68.2 89.1
LS 0.303 (0.181) 0.174 95.4 38.5 0.403 (0.182) 0.183 91.8 60.1 0.579 (0.183) 0.185 67.1 88.7
Median
Simple 0.312 (0.257) 0.222 98.4 19.6 0.406 (0.252) 0.223 95.5 33.2 0.593 (0.245) 0.228 79.3 69.6
Weighted 0.288 (0.237) 0.213 97.4 20.2 0.381 (0.231) 0.217 96.1 37.8 0.547 (0.222) 0.222 80.3 68.6
MR-Egger 0.082 (0.664) 0.616 93.6 3.4 0.107 (0.684) 0.705 93.4 6.9 0.141 (0.680) 0.686 92.6 7.1
Scenario 4. Directional pleiotropy, InSIDE violated
IVW 0.320 (0.171) 0.160 95.6 47.0 0.421 (0.150) 0.144 88.9 79.4 0.509 (0.125) 0.116 61.9 98.6
Rr 0.312 (0.195) 0.171 94.6 40.6 0.415 (0.173) 0.154 88.2 70.7 0.507 (0.134) 0.123 63.6 94.4
PW 0.309 (0.168) 0.172 94.2 46.6 0.407 (0.146) 0.159 87.0 78.0 0.500 (0.121) 0.123 61.8 97.3
Rr and PW 0.307 (0.185) 0.176 93.9 42.0 0.406 (0.163) 0.164 86.5 72.6 0.501 (0.127) 0.127 61.8 95.3
LTSa
h 0.289 (0.218) 0.337 79.3 37.4 0.376 (0.189) 0.314 73.4 52.9 0.479 (0.152) 0.251 61.7 76.6
wLTS,2 0.307 (0.171) 0.187 92.4 45.2 0.405 (0.148) 0.174 84.8 75.3 0.504 (0.123) 0.135 59.9 96.3
Auto 0.312 (0.169) 0.170 94.4 46.6 0.415 (0.148) 0.157 86.8 78.8 0.508 (0.123) 0.122 60.6 98.0
LS 0.311 (0.169) 0.173 93.9 46.7 0.415 (0.148) 0.157 86.9 78.8 0.508 (0.122) 0.124 59.7 98.1
Median
Simple 0.294 (0.246) 0.214 97.1 19.3 0.368 (0.217) 0.201 95.5 39.0 0.459 (0.179) 0.162 87.5 75.3
Weighted 0.343 (0.224) 0.201 96.8 31.0 0.458 (0.194) 0.187 87.6 66.8 0.537 (0.159) 0.148 69.9 93.0
MR-Egger 0.406 (0.550) 0.526 94.9 13.1 0.680 (0.432) 0.420 84.8 36.4 0.769 (0.360) 0.346 75.6 57.6
Abbreviations: IV, instrumental variable; Est. estimate; SE, standard error; SD, standard deviation; Cov., coverage; Pow., power;
InSIDE, instrument strength independent of direct effect; IVW, inverse variance weighted; Rr, robust regression; PW, penalized
weights; LTS, least trimmed squares; LS, Lasso selection; Auto, automated.
aThe following three sets of genetic variants were selected from the LTS estimator and included in the IVW model: 1) the h=8 variants
used to estimate the initial LTS estimate θˆLTS,h; 2) the variants with a weight of 1 in wLTS,2; and 3) the variants selected from the
automated approach based on the heterogeneity stopping rule.
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3.5.6 Summary
In this Section, we have performed an extensive simulation study to compare the
performance of the robust methods outlined in Section 3.3 to the IVW, simple median,
unweighted median and MR-Egger methods. The study highlighted the sensitivity of
the IVW model to violations in the IV assumptions. Due to violations in the NOME
assumption, it was not possible to compare the performance of the robust methods to
the MR-Egger model. Although the robust methods introduced in this Chapter did
not perform significantly better than the median estimator, there appears to be some
merit in applying the methods in certain scenarios. For instance, the estimates from
robust regression with penalized weights were more precise than the median estimator
when there were few invalid instruments. There were no noticeable improvements in
the robust methods when the number of genetic variants was increased.
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3.6 Discussion
In this Chapter, we have introduced four robust methods for Mendelian randomization
with summarized level data that downweight the influence of heterogeneous causal
estimates (Section 3.3). The applied examples in Section 3.4 illustrate the importance
of using a variety of methods in a Mendelian randomization analysis. The results from
the robust methods support a null causal effect of BMI on schizophrenia risk. With
the exception of LTS selection with the h variants and Lasso selection with the cross
validation stopping rule, the robust methods did not support the positive causal effects
estimated from the IVW and MR-Egger methods for LDL-C and AD risk.
In Section 3.5 we performed a simulation study to compare the robust methods to
the IVW, simple median, weighted median, and MR-Egger method. The simulation
study highlighted the sensitivity of the IVW method to violations in the IV assumptions,
and the requirement for robust methods to be considered in the sensitivity analysis of
a Mendelian randomization study. The simulations also demonstrated the impact of
violating the NOME assumption on the estimates from the MR-Egger method. The
SIMEX method [49] described in Section 2.6.2 could have been used to adjust for
the effect of violating the NOME assumption on the MR-Egger method. As outlined
in Section 2.6.2, the SIMEX method requires the genetic assoications with the risk
factor to be simulated multiple times, with the MR-Egger method re-fitted to each
simulated dataset. It was decided that this would be too computationally expensive
for the simulation study in Section 3.5, and no adjustment was made for the violation
of the NOME assumption.
The IVW model with the h variants from the LTS selection method, followed
by robust regression with penalized weights, consistently produced the least biased
estimates in the simulation study. Although the power and bias of these two methods
was significantly better than the IVW method when the IV assumptions were violated,
they suffered from poor coverage and increased type I error rates, particularly when
there was a high proportion of invalid instruments. When there was only one invalid
instrument, robust regression with penalized weights produced more precise estimates
than the median estimator. However, when the number of invalid instruments were
increased there was little advantage of using robust regression with penalized weights
compared to the median estimator.
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3.6.1 Comparison with the arXiv paper
As highlighted in the acknowledgments and Section 1.7, this Chapter is based on work
originally carried out by Stephen Burgess and other collaborators (Jack Bowden, Frank
Dudbridge and Simon Thompson). A copy of a draft manuscript uploaded to arXiv by
Stephen Burgess and colleagues on this work has been provided in Appendix A. For
clarity, we now highlight the differences between the work presented in this Chapter
and the work presented in Appendix A.
Stephen Burgess developed the methods in Sections 3.3.1 to 3.3.3. Although these
methods from Appendix A have not been changed, ‘penalization of weights’ and ‘L1
penalization’ have been renamed to ‘penalized weights’ and ‘Lasso selection’ for the
dissertation. The R code for the heterogeneity stopping rule for Lasso selection written
by Stephen Burgess was used for the Chapter. Jessica Rees suggested the idea of using
the least trimmed squares estimators as a means of selecting genetic variants as IVs,
and developed this method independently.
For Section 3.4, the BMI and schizophrenia example is contained in the arXiv paper,
and was reanalysed and rewritten by Jessica Rees for the dissertation. The applied
example of LDL-C and AD was not considered in the arXiv paper. R code written by
Stephen Burgess for producing the Figures 3.2 and 3.3 was used for the Chapter.
Although the simulation study in this Chapter was based on the simulation study in
Appendix A, it was been rewritten and extended for the dissertation. Apart from the
heterogeneity stopping rule, the R code for the simulation study was written by Jessica
Rees. The method used to determine whether the genetic variant was a valid or invalid
IV in the simulation was changed, and the parameters used in the data generating
model were altered. For the dissertation, Jessica Rees proposed and implemented the
idea of presenting the frequency all invalid instruments were either penalized or not
selected for the IVW method (Table 3.8). Sections 3.5.4 and 3.5.5 are new additions
to the simulation study.
3.6.2 Interpretation of heterogeneity among the causal ratio
estimates
Throughout this Chapter, we have assumed that heterogeneity of the causal ratio
estimates is indicative of violations in the IV assumptions, particularly the presence
of pleiotropic effects. As highlighted in Section 2.5.3, heterogeneity among the causal
ratio estimates may arise for a number of reasons [22]. For example, there may be
multiple mechanisms of intervention on a complex risk factor, each of which has an
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associated causal effect. For a two-sample Mendelian randomization analysis, there
may be heterogeneity among the causal ratio estimates due to substantial differences
in the study populations used to estimate the genetic associations with the risk factor
and outcome. The robust methods considered in this Chapter penalize genetic variants
with heterogeneous causal ratio estimates regardless of how this heterogeneity has
materialised. As such, these methods should only be employed if it is suspected that
the IV assumptions have been violated, and other possible reasons for heterogeneity
among the causal ratio estimates explored.
3.6.3 Issues with penalizing genetic variants
The simulation study has highlighted some of the disadvantages of excluding or
downweighting genetic variants from Mendelian randomization analyses. Excluding
genetic variants from the analysis will generally reduce the standard error of the
estimate, resulting in poor coverage of the true causal effect and increased Type 1 error
rates, as seen for the LTS and Lasso selection methods. Outlying or heterogeneous
causal ratio estimates may be valid IVs, and by excluding them from the analysis we
may introduce bias. On balance, it may be more appropriate to consider methods that
reduce the contribution that heterogeneous ratio estimates have on the causal estimate,
such as the median estimator or robust regression, rather than excluding them from
the analysis.
3.6.4 Implication for Mendelian randomization studies
The purpose of this Chapter was not to promote one robust method for Mendelian
randomization over another, but to emphasize the need for multiple sensitivity analyses
that make different sets of assumptions. Although we acknowledge that none of
the proposed methods performed significantly better than the median estimator, the
extensions proposed in this Chapter should provide additional confidence in the findings
from a conventional Mendelian randomization analysis, particularly when the causal
estimates are consistent. Genetic variants that are downweighted or excluded from
the analysis by the robust methods should be examined for pleiotropy to determine
whether they should be removed from the dataset.
The methods introduced in this Chapter, particularly robust regression with penal-
ized weights, may be more suited to certain scenarios than the median estimator. In the
applied example for LDL-C and AD risk, there were two variants that appeared to be
clear outliers. The median estimator and robust regression with penalized weights both
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suggested that there was a null causal effect of LDL-C on AD risk, but the estimates
from the median estimator were less precise. This observation of robust regression
producing more precise estimates was also observed in the simulation study when there
was one invalid IV. Robust regression with penalized weights may be a useful addition
to sensitivity analyses in Mendelian randomization when there are a small proportion
of variants with heterogeneous causal estimates.
Based on the work presented in this Chapter, there appears to be little merit in
using methods from the robust statistics literature in the sensitivity analysis of a
Mendelian randomization study. However, we only considered a limited number of
methods from the robust statistics literature, and there may be other methods that
are more suitable. Since the simulation study with the increased number of IVs was
limited by fixing the R2 value (discussed in the section below), and the high breakdown
points for robust regression and the LTS estimator are based on asymptotic theory, it is
difficult to appreciate how these methods may perform for studies with a large number
of genetic variants. We did not explore the effect of changing the objective function
and/or the value of the tuning parameter for robust regression. The default values used
for the tuning parameters in the robust statistics literature for robust regression (used
throughout this dissertation) may not be optimal for Mendelian randomization. Based
on these observations, and the limitations highlighted in the section below, we decided
not to use the robust methods introduced in this Chapter on the main applied example
of investigating the effect of adiposity and body composition on asthma (Chapter 6).
3.6.5 Limitations
We found that the Lasso selection method may be more appropriate in an applied
setting, where the estimates can be reported over a range of values of the tuning
parameter. The practicality of applying Lasso selection to the simulation study was
more restrictive, and required an automated approach to selecting the tuning parameter.
Whilst we appreciate the limitation of only considering methods with uncorrelated
genetic variants, we argue that robust methods should be used when the IV assumptions
are in doubt, and therefore using one genetic variant from each gene region is a sensible
approach in an applied Mendelian randomization analysis.
The violation of the NOME assumption limited the utility of the simulation study as
the estimates from MR-Egger could not be compared to the robust methods. Given that
MR-Egger is frequently used as part of a sensitivity analysis in Mendelian randomization
studies, this could be viewed as a major weakness of the simulation study.
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The main simulation study was also limited by the number of genetic variants
considered in the data generating model. Since GWASs are now being performed on
large study populations, and estimates of genetic associations are publicly available
from large consortia, only considering 15 variants in the simulation study may have been
conservative. We tried to rectify this limitation by re-performing the simulation study
with 100 genetic variants and found that there was significant attenuation towards the
null due to weak instrument bias. This attenuation was expected as the additional
variants did not explain more variance in the risk factor as the R2 values were kept
constant from the original simulation with 15 variants.
We had thought that the performances of some of the robust methods would have
improved by increasing the number of genetic variants as the methods are based on
asymptotic theory. We did not find any significant improvements in the methods, and
in some cases, the performance of the models worsened with the increased number
of genetic variants. However, since the R2 values were set to the same values for the
simulations with 15 and 100 genetic variants, limited conclusions can be drawn from
the simulation study with the increased number of variants.
This Chapter was also limited by the methods in Section 3.3 only being considered
with respect to a continuous outcome. Since many Mendelian randomization studies
have a binary outcome, this could be viewed as a fundamental limitation to the work
presented. We did try to reduce this limitation by performing additional simulations
when the outcome was binary (Section 3.5.5) to see how well the methods approximated
the causal odds ratios. Along with the IVW method and the median estimator, the
methods introduced in this Chapter produced slightly biased estimates of the null and
positive causal effects under all of the scenarios considered. The approximation of the
causal odds ratio was worse under a positive effect, with all of the methods reporting
mean estimates attenuated towards the null. This attenuation towards the null for the
positive causal effect is a result of the non-collapsibility of the odds ratio. The drop in
power to detect the positive causal effect for a binary outcome was severe, although
the values used to generate the outcome in the data generating model would have
influenced this.
3.6.6 Key points from chapter
• In this Chapter, we introduced four extensions to robust methods for Mendelian
randomization with summarized data: 1) robust regression (MM-estimation);
2) penalized weights; 3) Lasso selection; and 4) least trimmed squares selection.
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These methods can be used to assess the robustness of findings from Mendelian
randomization investigations with multiple genetic variants.
• The methods have been considered in two applied examples: one where there
is evidence of over-dispersion in the causal estimates (the causal effect of body
mass index on schizophrenia risk), and the other containing outliers (the causal
effect of low-density lipoprotein on Alzheimer’s disease risk).
• Although the performances of the proposed methods in the simulation study
were not significantly better than the robust methods that are already in the
literature, the applied example suggested that the methods, particularly robust
regression with penalized weights, may be a worthwhile addition to a Mendelian
randomization study when there is a small proportion of heterogeneous causal
estimates.

Chapter 4
Extending the MR-Egger method
for multivariable Mendelian
randomization to correct for both
measured and unmeasured
pleiotropy
4.1 Introduction
For some sets of risk factors, including lipid fractions, several risk factors have common
genetic predictors. Although such genetic variants are pleiotropic, they can be used to
estimate causal effects in a multivariable Mendelian randomization framework [28]. In
multivariable Mendelian randomization, the IV assumptions are extended to allow a
genetic variant to be associated with multiple risk factors, provided all associated risk
factors are included in the analysis. Alternatively, when genetic variants are suspected
to violate the IV assumptions through unknown pleiotropic pathways, methods have
been developed to estimate consistent causal effects under weaker assumptions. These
include the weighted median [52] and MR-Egger methods [29].
The extension of MR-Egger to a multivariable setting has been implemented by
Helgadottir et al. [114] as part of a sensitivity analysis in their applied work investigating
the effect of lipid fractions on coronary heart disease (CHD) risk. In the supplementary
material, Helgadottir et al. [114] suggest that multiple covariates can be included in the
MR-Egger method proposed by Bowden et al. [29]. The authors then go on to include
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summary level data on high-density lipoprotein cholesterol, low-density lipoprotein
cholesterol and triglycerides in the same MR-Egger model, and refer to this model
as ‘multiple Egger regression’. The supplementary material contains the estimates for
each lipid fraction from the ‘multiple Egger regression’ model.
The model we propose in this Chapter for extending MR-Egger to the multivariable
setting is essentially the same as the ‘multiple Egger regression’ model considered by
Helgadottir et al. [114] in their applied investigation. Since Helgadottir et al. [114] only
considered the extension of MR-Egger within the context of an applied investigation,
there remains several methodological issues relating to the implementation of the
method, and the assumptions required. In particular, Helgadottir et al. [114] did not
address the issues of residual pleiotropic effects, orientation of the genetic variants, or
the assumptions required to obtain consistent causal effects.
In this Chapter, we extend the MR-Egger method to the multivariable setting
through theoretical arguments (Section 4.2). In Section 4.3, we provide an example
analysis using published summary level data on lipid fractions and CHD risk. We also
perform two simulation studies to compare the performance of the methods: one where
the risk factors do not have causal effects on each other (Section 4.4); and another
where this assumption is relaxed (Section 4.5). Finally, in Section 4.6 we discuss
the results from Sections 4.2 to 4.5, and consider the implications of extending the
MR-Egger method to the multivariable setting on future research.
4.2 Methods
In this Section, we use theoretical arguments to expand the MR-Egger method to
the multivariable setting. Initially, we consider the causal effect of a risk factor X
on an outcome Y using J genetic variants Gj (j = 1, . . . , J) that are assumed to be
uncorrelated (not in linkage disequilibrium). Then, we expand to consider multiple risk
factors X1, X2, . . . , XK , and from the MR-Egger and multivariable IVW models we
outline the regression model for multivariable MR-Egger. We provide the assumptions
required for the causal estimates from multivariable MR-Egger to be consistent, and
compare the precision of the causal estimates from univariable MR-Egger and multi-
variable MR-Egger. The advantages of using multivariable MR-Egger over univariable
MR-Egger are discussed in detail. Finally, we provide a recommendation on how the
reference alleles of the genetic variants should be orientated in multivariable MR-Egger.
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We assume that summarized data are available on the associations of each genetic
variant with the risk factor and with the outcome: the beta-coefficients (βˆXj , βˆYj) and
their standard errors (se(βˆXj), se(βˆYj)) from univariable regression on each variant Gj
in turn. For the multivariable setting, we assume that there is summary level data for
the genetic variants on each risk factor, and these genetic variants are associated with at
least one of the risk factors, and the risk factors are associated with at least one of the
genetic variants. Finally, we assume that the associations of genetic variants with the
risk factor and the outcome, and the causal effect of the risk factor on the outcome, are
linear and homogeneous across the population. To distinguish between the parameters
from the different methods considered, we use the following subscript notation: UI
(‘univariable inverse variance weighted (IVW)’); UE (‘univariable MR-Egger’); MI
(multivariable IVW); and ME (‘multivariable MR-Egger’).
4.2.1 Univariable Mendelian randomization
In a univariable Mendelian randomization analysis, each genetic variant must satisfy the
IV assumptions outlined in Section 1.4. Under linearity assumptions, the association
between the genetic variant and the outcome can be decomposed into an indirect effect
via the risk factor and a direct effect:
βY j = αj + θβXj ,
where θ is the causal effect of the risk factor on the outcome. Genetic variant j is
pleiotropic if αj ̸= 0, and αj is the direct effect of the genetic variant on the outcome.
Figure 4.1 contains a direct effect αj via an independent pathway, which violates the
IV3 assumption.
The causal effect of the risk factor on the outcome can be estimated using a weighted
linear regression of the genetic association estimates [45], with the inverse-variance as
weights (se(βˆYj)−2) and the intercept set to zero (the IVW method):
βˆYj = θUI βˆXj + ϵUIj , ϵUIj ∼ N (0, φ2UI se(βˆYj)2) , (4.1)
where θUI is the IVW estimate, ϵUIj represents the error term, and φUI represents the
residual standard error. Under a multiplicative random-effects model (see Section 2.3.1
for more detail), the residual standard error (φUI) can be greater than one, allowing
for heterogeneity among the causal estimates. The point estimate from the fixed- and
92 Multivariable MR-Egger
𝐺" 𝑋 𝑌𝛽&' 𝜃
𝑈
𝛼"
Fig. 4.1 Directed acyclic graph illustrating univariable Mendelian randomization assumptions
with potential violation of IV3 by a pleiotropic effect indicated by a dotted line. The genetic
effect of Gj on X is βXj , the direct (pleiotropic) effect of Gj on Y via an independent pathway
is αj (representing the potential violation of the IV3 assumption), and the causal effect of
the risk factor X on the outcome Y is θ. U represents the set of unmeasured variables that
confound the association between X and Y .
random-effect models will be the same, but the standard error of the causal effect
from the multiplicative random-effects model will be larger if there is heterogeneity
between the causal estimates. Throughout this Chapter, we apply a multiplicative
random-effects model to all the analyses.
The MR-Egger estimate is obtained using the same regression model as Equation 4.1,
but allowing the intercept to be estimated [29]:
βˆYj = θ0UE + θUEβˆXj + ϵUEj , ϵUEj ∼ N (0, φ2UE se(βˆYj)2) ,
where θUE is the MR-Egger estimate, ϵUEj represents the error term, and φUE represents
the residual standard error under the univariable MR-Egger model. If the genetic
variants are not pleiotropic, then the intercept term should tend to zero as the sample
size increases, and the MR-Egger estimate (θˆUE) and the IVW estimate (θˆUI) are both
consistent estimates of the causal effect. If the genetic variants are pleiotropic, and the
InSIDE assumption holds, then the MR-Egger estimate will be a consistent estimate
of θ [29, 64].
Under the InSIDE assumption, the intercept term θˆ0UE can be interpreted as
an estimate of the average direct effect of the genetic variants [52]. If the average
direct effect is zero (balanced pleiotropy), and the InSIDE assumption is satisfied, the
intercept term should tend to zero as the sample size increases, and the MR-Egger
estimate (θˆUE) and the IVW estimate (θˆUI) are both consistent estimates of the causal
effect. If the intercept term differs from zero, then either the InSIDE assumption is
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violated or the average direct effect differs from zero (directional pleiotropy); this is a
test of the validity of the IV assumptions (the MR-Egger intercept test).
4.2.2 Multivariable Mendelian randomization
In a multivariable Mendelian randomization analysis, each genetic variant must satisfy
the IV assumptions outlined in Section 2.6.3. Now, the association of the genetic
variants with the outcome can be decomposed into indirect effects via each of the risk
factors and a residual direct effect α′j. Assuming there are three risk factors and all
relationships are linear:
βYj = α′j + θ1βX1j + θ2βX2j + θ3βX3j , (4.2)
where θk is the causal effect of the risk factor k on the outcome (Figure 4.2). We
assume that the risk factors do not have causal effects on each other; we later relax
this assumption and allow for causal effects between the risk factors.
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Fig. 4.2 Directed acyclic graph illustrating multivariable Mendelian randomization assump-
tions for a set of genetic variants Gj , three risk factors X1, X2 and X3, and outcome Y.
The genetic effect of Gj on Xk is βXkj , the direct (pleiotropic) effect of Gj on Y is α′j , and
the causal effect of the risk factor Xk on the outcome Y is θk. Uk represents the set of
unmeasured variables that confound the associations between Xk and Y .
Causal estimates of the effect of each risk factor on the outcome can be obtained
using multivariable weighted linear regression of the genetic association estimates, with
the intercept set to zero (multivariable IVW method) [115]:
βˆYj = θ1MI βˆX1j + θ2MI βˆX2j + θ3MI βˆX3j + ϵMIj , ϵMIj ∼ N (0, φ2MI se(βˆYj)2) ,
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where θMI are the multivariable IVW estimates, ϵMIj represents the error term, and
φMI represents the residual standard error under the multivariable IVW model.
We propose the natural extension to multivariable MR-Egger using the same
regression model, but allowing the intercept to be estimated:
βˆYj = θ0ME + θ1MEβˆX1j + θ2MEβˆX2j + θ3MEβˆX3j + ϵMEj , ϵMEj ∼ N (0, φ2ME se(βˆYj)2) .
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4.2.3 Assumptions for multivariable MR-Egger
We assume that the causal effect of risk factor one (θ1) is of interest, and provide the
assumptions necessary for the multivariable MR-Egger estimate of θ1 to be consistent.
If all of the causal effects are to be interpreted then these assumptions must apply for
each risk factor.
If the βX1 parameters are independent of the βXk parameters for all k = 2, 3, . . . , K,
then the InSIDE assumption for multivariable MR-Egger is satisfied if the direct effects
of the genetic variants α′ are independent of βX1 . More formally, we require:
βX1 ⊥ α′, if βX1 ⊥ βX2 , . . . ,βXK ,
for the estimate of θ1 from multivariable MR-Egger to be consistent. If the InSIDE
assumption is satisfied, then the weighted covariance of βX1 and α′ (covw(α′,βX1))
will tend to zero as the number of genetic variants J tends to infinity. The estimate of
θ1 from multivariable MR-Egger when the βX1 parameters are independent of βXk for
all k = 2, 3, . . . , K is:
θˆ1ME =
covw(βˆY , βˆX1)
varw(βˆX1)
N→∞−−−→ covw(βY ,βX1)varw(βX1)
= θ1 +
covw(α′,βX1)
varw(βX1)
,
which is equal to θ1 if the InSIDE assumption is satisfied, where covw and varw
represent the weighted covariance and weighted variance using the inverse-variance
weights se(βˆY j)−2:
covw(α′,βX1) =
∑
j(α′j − α¯′w)(βX1j − β¯X1w) se(βˆY j)−2∑
j se(βˆY j)−2
,
varw(βX1) =
∑
j(βX1j − β¯X1w)2 se(βˆY j)−2∑
j se(βˆY j)−2
,
α¯′w =
∑
j α
′
j se(βˆY j)−2∑
j se(βˆY j)−2
,
β¯X1w =
∑
j βX1j se(βˆY j)−2∑
j se(βˆY j)−2
.
If the βX1 parameters are correlated with at least one of the sets of βXk parameters
(k = 2, 3, . . . , K), then the InSIDE assumption is required to hold for βX1 and for all
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of the βXk parameters that are correlated with βX1 . More formally, we require:
βXk ⊥ α′, for all βXk correlated with βX1 (including βX1 itself) .
For example, if k = 2, and βX1 is correlated with βX2 , we require both of the weighted
covariances of α′ with βX1 and βX2 to be zero to produce a consistent estimate of θ1.
The estimate of θ1 from multivariable MR-Egger with two risk factors where βX1 and
βX2 are correlated is:
θˆ1ME =
covw(βˆY , βˆX1) varw(βˆX2)− covw(βˆY , βˆX2) covw(βˆX1 , βˆX2)
varw(βˆX1) varw(βˆX2)− covw(βˆX1 , βˆX2)2
N→∞−−−→ covw(βY ,βX1) varw(βX2)− covw(βY ,βX2) covw(βX1 ,βX2)varw(βX1) varw(βX2)− covw(βX1 ,βX2)2
= θ1 +
covw(α′,βX1) varw(βX2)− covw(α′,βX2) covw(βX1 ,βX2)
varw(βX1) varw(βX2)− covw(βX1 ,βX2)2
, (4.3)
which is equal to θ1 if the InSIDE assumption holds with respect to βX1 and βX2 . As
more risk factors with correlated sets of association parameters with βX1 are included
in the multivariable MR-Egger model, additional terms will be added to the bias term
in Equation 4.3, and the InSIDE assumption must hold for these additional risk factors
to obtain a consistent estimate of θ1.
4.2.4 Precision of the multivariable MR-Egger estimate
The variance of the multivariable MR-Egger estimate θˆ1ME will be heavily influenced
by the denominator in the bias term of Equation 4.3. The variance of the multivariable
MR-Egger estimate θˆ1ME is given by:
var(θˆ1ME) =
φ2ME var(βX2)
N(var(βX1) var(βX2)− cov(βX1 ,βX2)2)
∝ [var(βX1)(1− cor(βX1 ,βX2)2)]−1 ,
where φME is the residual standard error under the multivariable MR-Egger model.
Under a fixed-effect model, the variance of the univariable MR-Egger estimate
is proportional to the inverse of var(βX1) [49]. The estimate from the multivariable
MR-Egger model θˆ1ME will be more precise than its univariable counterpart θˆ1UE if:
1
var(βX1)
>
1
var(βX1)(1− cor(βX1 ,βX2)2)
.
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From the above inequality, θˆ1UE will always be more precise than θˆ1ME when βX1 and
βX2 are correlated. Under a multiplicative random-effects model (used throughout this
Chapter), the residual standard error is estimated under the univariable MR-Egger
model (φUE) and the multivariable MR-Egger model (φME). For θˆ1ME to be more
precise than θˆ1UE, we require:
φ2UE
var(βX1)
>
φ2ME
var(βX1)(1− cor(βX1 ,βX2)2)
.
If βX2 explains additional independent variability in the genetic associations with the
outcome βY , and βX1 and βX2 are independent, then the estimate from multivariable
MR-Egger will be more precise than the estimate from univariable MR-Egger. If βX1
and βX2 are correlated, then the precision of θˆ1ME will depend upon the strength
of the correlation between βX1 and βX2 , and the amount of additional independent
variability βX2 explains in βY . As the correlation between βX1 and βX2 increases,
and βX2 explains no additional independent variability in βY , the precision of the
multivariable MR-Egger estimate θˆ1ME will reduce.
4.2.5 Advantages of multivariable MR-Egger and comparison
with univariable MR-Egger
The bias for the causal estimate from univariable MR-Egger θˆUE depends on the
weighted covariance between α and βX1 , where:
αj = α′j +
K∑
i=2
θiβXij . (4.4)
The expression in Equation 4.4 follows from the multivariable framework outlined in
Equation 4.2, where the direct effect for univariable MR-Egger has been decomposed
into the residual direct effect α′j of multivariable MR-Egger and the indirect effects
via each risk factor. The residual direct effect α′j will be altered with each additional
risk factor included in the multivariable MR-Egger model. If these additional risk
factors are causally associated with the outcome (θk ̸= 0), then α′j will consist of fewer
components.
It seems likely that the InSIDE assumption would be easier to satisfy for multi-
variable MR-Egger than its univariable counterpart as the direct effect for univariable
MR-Egger consists of unmeasured and measured pleiotropy. This observation is based
on the idea that the magnitude of the direct effect may be smaller for multivariable
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MR-Egger compared to its univariable counterpart. However, the remaining direct
effect for multivariable MR-Egger may still contain the component that invalidates
the InSIDE assumption for univariable MR-Egger, and this would also invalidate the
InSIDE assumption for multivariable MR-Egger. Hence, there is no guarantee that the
InSIDE assumption will be more easily satisfied under the multivariable setting.
If the βX1 parameters are independent of the βXk parameters for all k = 2, 3, . . . , K,
then the second term in Equation 4.4 (the measured direct effect) does not contribute
to the value of covw(α,βX1). Under this scenario, bias for the univariable and mul-
tivariable MR-Egger estimates depends on the same covariance term covw(α′,βX1).
As a consequence, the estimates of the causal effects from univariable MR-Egger θˆUE
and multivariable MR-Egger θˆ1ME will be asymptotically the same. In this case,
multivariable MR-Egger may improve precision of the causal estimate, but will not
affect the asymptotic bias.
When the βX1 parameters are correlated with at least one of the sets of βXk
parameters for k = 2, 3, . . . , K, the second term in Equation 4.4 now contributes to the
value of covw(α,βX1). The InSIDE assumption for univariable MR-Egger will therefore
be automatically violated as the weighted covariance between α and βX1 will not equal
zero, resulting in biased causal estimates of θ1. If the InSIDE assumption holds for
multivariable MR-Egger, and βXk are included in the analysis model, then θˆ1ME will
still be a consistent estimate of θ1. Hence, in this case, multivariable MR-Egger should
result in reduced bias compared with univariable MR-Egger.
4.2.6 Orientation of the genetic variants
Genetic associations represent the average change in the risk factor or the outcome
per additional copy of the reference allele (e.g. the major or minor allele). There is no
biological rationale why associations should be expressed with respect to either the
major (wildtype) or the minor (variant) allele. In the univariable and multivariable
IVW methods, the estimate is not affected by the choice of orientation, as the intercept
is fixed at zero. However, in the univariable and multivariable MR-Egger methods,
changing the orientation of the variant affects the intercept term and the causal estimate
as the orientation affects the definition of the pleiotropy terms αj and α′j . For example,
if the genetic variants are orientated with respect to the major alleles, then αj and α′j
represent the average pleiotropic effect for the univariable and multivariable models
with respect to the major alleles. If we were to change the orientation of the genetic
variants to the minor alleles, then αj and α′j represent the average pleiotropic effects
with respect to the minor alleles. Since the orientation of the genetic variants changes
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the definition of the pleiotropic effects, the InSIDE assumption will differ with each
orientation, and this may also affect the causal estimate.
To ensure that the MR-Egger analysis does not depend on the reported reference
alleles, Bowden et al. [29] suggested the genetic variants in univariable MR-Egger
be orientated so the direction of association with the risk factor is either positive
for all variants or negative for all variants. However, this may not be possible for
multivariable MR-Egger as the same reference allele must be used for associations
with each risk factor and with the outcome. We suggest that the variants should be
orientated with respect to their associations with the risk factor of primary interest,
although we would recommend a sensitivity analysis considering different orientations
if multiple risk factors are of interest. If the genetic variants are all valid instruments,
then directional pleiotropy should not be detected with respect to any orientation.
4.2.7 Summary
In this Section, we have expanded MR-Egger to the multivariable setting. We have out-
lined the assumptions required to obtain consistent causal estimates from multivariable
MR-Egger and provided a recommendation on the orientation of the genetic variants.
We have also discussed the potential benefits of using multivariable MR-Egger over its
univariable counterpart. In the next Section, we will apply the methods discussed to
published summary level data to investigate the causal effect of cholesterol on CHD
risk.
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4.3 Mendelian randomization analysis on the causal
effect of high-density lipoprotein cholesterol on
coronary heart disease risk
The effects of high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein
cholesterol (LDL-C), and triglycerides on the risk of CHD have been investigated by
numerous Mendelian randomization studies [116]. For HDL-C, univariable Mendelian
randomization suggested a causally protective role against CHD risk, whereas univari-
able MR-Egger provided no evidence of a causal effect and the test for directional
pleiotropy was statistically significant at the 5% level [52]. A null causal effect for
HDL-C was also reported from a multivariable Mendelian randomization analysis that
included LDL-C and triglycerides using the multivariable IVW method [28], although
a small but protective causal effect was estimated in a further multivariable Mendelian
randomization analysis using a wider range of 185 genetic variants [117]. In this Section,
we investigate the causal effect of HDL-C on CHD risk further using the multivariable
MR-Egger method described in Section 4.2.
4.3.1 Methods
We consider the 185 genetic variants having known association with at least one
of HDL-C, LDL-C and triglycerides at GWAS significance in 188,578 participants
reported by the Global Lipids Genetics Consortium [111]. The point estimates for the
associations between these genetic variants and lipids were taken from Do et al. [110].
The CARDIoGRAMplusC4D consortium consisting of 60,801 cases and 123,504 controls
was used to obtain the estimates of the association between the variants and CHD risk
[118]. The IVW and MR-Egger methods were applied to the data under univariable
and multivariable frameworks as described in Section 4.2. For the univariable IVW
and MR-Egger methods, the models were fitted using two sets of variants: firstly using
all 185 variants; and secondly using all variants associated with HDL-C at GWAS
significance (p-value < 5× 10−8). The genetic variants were orientated with respect
to the risk increasing allele for HDL-C. These analyses differ from those provided in
Burgess et al. [117] and Do et al. [110] as they use summarized data from different
versions of the CARDIoGRAMplusC4D study; here we use associations from the 2015
data release [118].
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As a sensitivity analysis, the multivariable MR-Egger method was re-performed
with the genetic variants orientated with respect to the risk increasing alleles for LDL-C
and triglycerides.
Throughout this Chapter, we have assumed that the associations of the genetic
variants with the risk factor and the outcome, and the causal effect of the risk factor on
the outcome, are linear and homogeneous. Since the outcome for this applied example
is binary, the linearity assumption is violated. The estimates of the causal effects from
the analyses will therefore be approximations of the causal odds ratios (Section 2.3.3).
The code used for the analysis was written and performed by Jessica Rees in
RStudio version 3.5.3 [86].
4.3.2 Results
The univariable IVW method suggested a significant protective effect of HDL-C for
both sets of variants with an approximate causal odds ratio of 0.88 (95% CI: 0.80, 0.97)
for all variants (Table 4.1). This estimate attenuated to the null in the univariable
MR-Egger method (0.98, 95% CI: 0.87, 1.11) with evidence of directional pleiotropy
(p-value=0.004). The approximate causal odds ratios from multivariable IVW (0.96,
95% CI: 0.89, 1.05) and multivariable MR-Egger (1.04, 95% CI: 0.94, 1.14) had opposite
directions of association, with both analyses indicating that HDL-C is not causally
associated with CHD risk. The significant result for directional pleiotropy in the
multivariable MR-Egger method suggests that LDL-C and triglycerides do not fully
explain the direct effects of the genetic variants on the outcome, suggesting that
there is still residual pleiotropy via other unmeasured risk factors and/or the InSIDE
assumption is violated.
The results from the analysis correspond with previous findings that HDL-C has a
causal effect on CHD when considered in isolation and without accounting for pleiotropic
effects. Univariable MR-Egger, multivariable IVW and multivariable MR-Egger are all
consistent with previous findings that HDL-C does not have a causal effect on CHD.
Unlike previous studies, we have been able to consider the possibility of there being
residual pleiotropy in the multivariable model with HDL-C, LDL-c and triglycerides.
Although the significant result for directional pleiotropy in multivariable MR-Egger is
of interest, it is not possible to determine whether this is due to residual pleiotropy
and/or the InSIDE assumption being violated.
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Table 4.1 Approximate log causal odds ratios (95% confidence intervals) for coronary heart
disease per standard deviation increase in HDL-C. Estimates of the intercept are given in
univariable and multivariable MR-Egger.
Approximate causal estimate MR-Egger intercept test
θˆHDL-C (CI) se(θˆHDL-C) p-value θˆ0E se(θˆ0E) p-value
UV IVW
All variants -0.130 (-0.227, -0.033) 0.049 0.009 - - -
Reduced seta -0.114 (-0.211, -0.017) 0.049 0.022 - - -
UV MR-Egger
All variants -0.016 (-0.138, 0.106) 0.062 0.800 -0.007 0.002 0.004
Reduced seta 0.067 (-0.070, 0.204) 0.069 0.332 -0.012 0.004 0.001
MV IVW -0.039 (-0.123, 0.045) 0.042 0.359 - - -
MV MR-Egger 0.036 (-0.063, 0.134) 0.050 0.477 -0.005 0.002 0.008
Abbreviations: MR, Mendelian randomization; UV, univariable; MV, multivariable; HDL-C, high-density lipoprotein
cholesterol; IVW, inverse-variance weighted; CI, confidence interval; SE, standard error.
a95 variants associated with HDL-C at a genome-wide level of significance (p-value< 5× 10−8).
Varying the orientation of the genetic variants
The approximate causal estimates for HDL-C, LDL-C, and triglycerides from multi-
variable MR-Egger when the variants were orientated with respect to HDL-C, LDL-C
or triglycerides are presented in Table 4.2. Estimates of the MR-Egger intercept are
also provided for the three models. To allow for comparisons between the multivariable
methods, the approximate causal estimates from multivariable IVW are included in
Table 4.2. The approximate causal estimates in bold follow the recommendation
outlined in Section 4.2.6 that the genetic variants should be orientated with respect to
the risk factor-increasing allele for the risk factor of interest.
All of the approximate causal odds ratios for HDL-C from the multivariable MR-
Egger models indicated that HDL-C is not causally associated with CHD risk. Sig-
nificant adverse effects of LDL-C on CHD risk were reported from the multivariable
IVW (1.45, 95% CI: 1.34, 1.58) and multivariable MR-Egger (1.52, 95% CI: 1.37, 1.69)
methods. Orientating the variants with respect to the risk increasing alleles for HDL-C
and triglycerides had little impact on the approximate causal estimates for LDL-C
from multivariable MR-Egger. The multivariable IVW method suggested a significant
adverse effect of triglycerides on CHD risk with an approximate causal odds ratio of
1.19 (95% CI: 1.07, 1.33), this estimate was attenuated to the null in the multivariable
MR-Egger method (1.09, 95% CI: 0.96, 1.23). The approximate causal odds ratios for
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triglycerides remained significant, however, when the variants were orientated with
respect to HDL-C and LDL-C in the multivariable MR-Egger models.
Since the orientation of the genetic variants affects the interpretation of the direct
effect, and the definition of the InSIDE assumption, the MR-Egger intercept will vary
between different orientations. In this example, the MR-Egger intercept differed from
zero when the variants were orientated with respect to HDL-C and triglycerides, yet
there was no evidence of directional pleiotropy or the InSIDE assumption being violated
when the variants were orientated with respect to LDL-C.
Table 4.2 Approximate causal log odds ratios (95% confidence intervals) for coronary
heart disease per standard deviation increase in HDL-C, LDL-C, and triglycerides from
multivariable IVW and multivariable MR-Egger. Estimates from multivariable MR-Egger are
presented from three models where the reference allele is the risk increasing allele for HDL-C,
LDL-C or triglycerides. Estimates of the intercept are given for multivariable MR-Egger.
Approximate causal estimates MR-Egger intercept
θˆHDL-C θˆLDL-C θˆTG θˆ0E
MV IVW -0.039 (-0.123, 0.045) 0.375 (0.292, 0.457) 0.173 (0.063, 0.283) -
MV MR-Eggera
HDL-C 0.036 (-0.063, 0.134) 0.378 (0.297, 0.458) 0.136 (0.024, 0.247) -0.005 (-0.009, -0.001)
LDL-C -0.034 (-0.118, 0.049) 0.420 (0.318, 0.522) 0.194 (0.081, 0.308) -0.003 (-0.007, 0.001)
TG -0.018 (-0.102, 0.066) 0.350 (0.267, 0.433) 0.083 (-0.045, 0.211) 0.005 (0.001, 0.009)
Abbreviations: MR, Mendelian randomization; UV, univariable; MV, multivariable; HDL-C, high-density lipoprotein
cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides.
aAlleles orientated for all genetic associations with respect to the risk increasing allele for HDL-C, LDL-C or triglyc-
erides.
4.3.3 Summary
In this Section, we applied the methods discussed in Section 4.2 to published summary
level data on HDL-C, LDL-C, triglycerides, and CHD risk. When the genetic variants
were orientated with respect to the HDL-C risk increasing alleles, the multivariable
MR-Egger model containing HDL-C, LDL-C and triglycerides suggested that HDL-C
was not causally associated with CHD risk, but there was evidence of residual pleiotropy
and/or the InSIDE assumption being violated. The analysis highlighted the sensitivity
of the intercept term in the multivariable MR-Egger model to changes in the orientation
of the genetic variants. In the next Section, we perform a simulation study based on
the applied example considered in this Section to compare the performances of the
multivariable IVW, univariable MR-Egger and multivariable MR-Egger methods.
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4.4 Simulation study
In order to assess the merits of using multivariable MR-Egger over multivariable IVW
and univariable MR-Egger in realistic settings, we perform a simulation study. The
code used for the simulation study was written and performed by Jessica Rees in
RStudio version 3.5.3 [86].
Univariable and multivariable MR-Egger will be compared with respect to the
consistency of the causal estimates and statistical power to detect the causal effect.
The setup of the simulation study corresponds to the applied example in Section 4.3
and will be considered under two broad scenarios: (1) βXk are generated independently
for all k = 1, 2, . . . , K; and (2) βXk are correlated for all k = 1, 2, . . . , K.
We simulated summarized level data for 185 genetic variants (value taken from the
applied example in Section 4.3) indexed by j = 1, 2, . . . , J for three risk factors (X1,
X2, X3) and an outcome Y from the following data-generating model:

βX1j
βX2j
βX3j
 ∼ N3


0.08
0.03
−0.05
 ,

σ1
2 ρ12σ1σ2 ρ13σ1σ3
ρ12σ1σ2 σ2
2 ρ23σ2σ3
ρ13σ1σ3 ρ23σ2σ3 σ3
2

 ,
βY j = α′j + θ1|βX1j |+ θ2βX2j + θ3βX3j + ϵj ,
ϵj ∼ N (0, 1) ,
α′j ∼ N (µ, 0.004) . (4.5)
The primary objective was to estimate θ1, with the causal effects set to: θ1 = 0 (null
causal effect) or θ1 = 0.3 (positive causal effect); θ2 = 0.1; and θ3 = −0.3. These causal
effects were chosen to ensure the direction and magnitude of effects differed across the
three risk factors. The data were simulated to consider the following four scenarios:
1. No pleiotropy (α′j = 0 for all j), InSIDE assumption automatically satisfied;
2. Balanced pleiotropy (µ = 0), InSIDE assumption satisfied;
3. Directional pleiotropy (µ = 0.01, 0.05 or 0.1), InSIDE assumption satisfied;
4. Directional pleiotropy (µ = 0.01, 0.05 or 0.1), InSIDE assumption violated.
The values for µ and the mean values of the genetic associations with the risk factors
in Equation 4.5 were chosen to ensure the magnitude of the effects were comparable.
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When the InSIDE assumption for multivariable MR-Egger was satisfied, α′j and
βX1j were drawn from independent distributions, and when it was violated they were
drawn from a multivariate normal distribution with cor(α′,βX1) = 0.3. The above four
scenarios were applied to the simulated data when βXk were generated independently
for all k, with the parameters in the covariance matrix set to: σ21 = 0.03; σ22 = 0.02;
σ23 = 0.04; and ρ12 = ρ13 = ρ23 = 0. The four scenarios were repeated when βXk were
correlated for all k with ρ12 = 0.2, ρ13 = −0.3 and ρ23 = 0.1. These values were chosen
to provide a range in the strength and direction of the correlation structure, and to
make sure they were comparable with cor(α′,βX1) when the InSIDE assumption for
multivariable MR-Egger was violated. In total, data were simulated for 32 different
choices of parameters.
To ensure the direction of association between Gj and X1 was the same for all j
variants, the absolute value of the genetic associations with X1 (|βX1j |) were used to
generate βYj (4.5). It was assumed that βXkj (for all k) and βYj had the same reference
allele and the variants were uncorrelated. The multivariable IVW, univariable MR-
Egger and multivariable MR-Egger methods were applied to the simulated datasets.
The weights for the multivariable IVW and multivariable MR-Egger are given by
equation 4.6, while equation 4.7 contains the weights for univariable MR-Egger:
se(βYj)−2 = (ϵj2 + σα′2)
−1
, (4.6)
se(βYj)−2 = (ϵj2 + σα′2 + θ22σ22 + θ32σ32)
−1
. (4.7)
Since the data–generating model produces summary level data for each risk factor
directly, it was not possible to estimate the F-statistic or I2 statistic without making
additional assumptions. For a two-sample Mendelian randomization analysis with
summarized data, the F-statistic for each genetic variant j can be approximated by
Fj ≈ βˆ2Xj/ se(βˆXj)2, and the formula for the I2 statistic using summary level data
is given in Section 2.6.2. To provide approximate values for both of these summary
measures, we require estimates of the standard errors of the genetic associations with
the risk factors se(βˆXk). Although the data–generating model made assumptions about
the variances of the genetic associations of the risk factors, the standard errors of the
genetic associations were not considered. Note that se(βˆXk) are not required to fit
the IVW, univariable MR-Egger or multivariable MR-Egger models considered in the
simulation study.
We must make additional assumptions to approximate se(βˆXk). If we assume that
the genetic associations with the risk factors are measured on the standard deviation
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scale, and the associations were estimated from a sample size of 10,000, then this results
in a standard error of 0.01. For βX1 , where the mean value of the genetic associations
was 0.08, a standard error of 0.01 would result in an approximate Z-statistic of 8,
equivalent to a p-value of 1× 10−15. This is relatively close to a Z-statistic of 5.45 that
is required for a genome-wide level of significance (p-value < 5× 10−8).
Assuming that the standard errors of the genetic associations with the three risk
factors are 0.01 across the 185 genetic variants, we can estimate the mean F-statistics
and I2 statistics (Table 4.3 and Table 4.4). The I2 statistics (reported as a %) were
close to 100% across the different scenarios, and the mean F-statistics were greater
than 200. For multivariable Mendelian randomization analyses, the F-statistic and
Sanderson-Windmeijer conditional F-statistic should be provided for each risk factor
as a measure of instrument strength [83]. Since the data-generating model did not
produce individual level data, we were unable to calculate the conditional F-statistic,
although the F-statistics suggested that the genetic variants were strongly associated
with the three risk factors.
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Table 4.3 Estimates of the mean F-statistic and I2 statistic (reported as a %) for each risk
factor for a null (θ1 = 0) and positive (θ1 = 0.3) causal effect where βXk were generated
independently for all k.
βˆX1j βˆX2j βˆX3j
F-statistic I2 statistic F-statistic I2 statistic F-statistic I2 statistic
Null causal effect: θ1 = 0
1. No pleiotropy, InSIDE satisfied
363.3 99.5 208.8 99.2 425.7 99.6
2. Balanced pleiotropy, InSIDE satisfied
α′j ∼ N (0,0.004) 364.3 99.5 209.1 99.2 425.6 99.6
3. Directional pleiotropy, InSIDE satisfied
α′j ∼ N (0.01,0.004) 364.4 99.5 208.9 99.2 425.6 99.6
α′j ∼ N (0.05,0.004) 363.5 99.5 209.6 99.2 424.9 99.6
α′j ∼ N (0.1,0.004) 364.0 99.5 209.2 99.2 425.5 99.6
4. Directional pleiotropy, InSIDE violated
α′j ∼ N (0.01,0.004) 364.1 99.5 208.8 99.2 425.4 99.6
α′j ∼ N (0.05,0.004) 364.4 99.5 208.7 99.2 425.4 99.6
α′j ∼ N (0.1,0.004) 363.8 99.5 209.1 99.2 425.1 99.6
Positive causal effect: θ1 = 0.3
1. No pleiotropy, InSIDE satisfied
363.9 99.5 209.2 99.2 424.7 99.6
2. Balanced pleiotropy, InSIDE satisfied
α′j ∼ N (0,0.004) 363.7 99.5 209.1 99.2 425.0 99.6
3. Directional pleiotropy, InSIDE satisfied
α′j ∼ N (0.01,0.004) 364.1 99.5 209.0 99.2 425.2 99.6
α′j ∼ N (0.05,0.004) 364.3 99.5 208.6 99.2 425.5 99.6
α′j ∼ N (0.1,0.004) 363.8 99.5 209.1 99.2 424.7 99.6
4. Directional pleiotropy, InSIDE violated
α′j ∼ N (0.01,0.004) 363.6 99.5 209.1 99.2 424.8 99.6
α′j ∼ N (0.05,0.004) 364.6 99.5 208.9 99.2 424.8 99.6
α′j ∼ N (0.1,0.004) 364.0 99.5 208.9 99.2 425.9 99.6
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Table 4.4 Estimates of the mean F-statistic and I2 statistic (reported as a %) for each risk
factor for a null (θ1 = 0) and positive (θ1 = 0.3) causal effect where βXk were correlated for
all k.
βˆX1j βˆX2j βˆX3j
F-statistic I2 statistic F-statistic I2 statistic F-statistic I2 statistic
Null causal effect: θ1 = 0
1. No pleiotropy, InSIDE satisfied
364.1 99.5 208.5 99.2 424.5 99.6
2. Balanced pleiotropy, InSIDE satisfied
α′j ∼ N (0,0.004) 363.8 99.5 209.4 99.2 424.4 99.6
3. Directional pleiotropy, InSIDE satisfied
α′j ∼ N (0.01,0.004) 363.5 99.5 208.8 99.2 424.6 99.6
α′j ∼ N (0.05,0.004) 364.3 99.5 209.0 99.2 425.1 99.6
α′j ∼ N (0.1,0.004) 364.3 99.5 208.9 99.2 424.7 99.6
4. Directional pleiotropy, InSIDE violated
α′j ∼ N (0.01,0.004) 364.0 99.5 208.9 99.2 425.0 99.6
α′j ∼ N (0.05,0.004) 364.0 99.5 209.4 99.2 425.2 99.6
α′j ∼ N (0.1,0.004) 364.3 99.5 209.1 99.2 425.2 99.6
Positive causal effect: θ1 = 0.3
1. No pleiotropy, InSIDE satisfied
364.0 99.5 208.9 99.2 425.2 99.6
2. Balanced pleiotropy, InSIDE satisfied
α′j ∼ N (0,0.004) 364.0 99.5 208.8 99.2 425.1 99.6
3. Directional pleiotropy, InSIDE satisfied
α′j ∼ N (0.01,0.004) 363.5 99.5 209.1 99.2 425.5 99.6
α′j ∼ N (0.05,0.004) 363.9 99.5 209.1 99.2 424.6 99.6
α′j ∼ N (0.1,0.004) 364.0 99.5 209.1 99.2 425.8 99.6
4. Directional pleiotropy, InSIDE violated
α′j ∼ N (0.01,0.004) 364.1 99.5 208.8 99.2 425.3 99.6
α′j ∼ N (0.05,0.004) 364.7 99.5 208.8 99.2 425.4 99.6
α′j ∼ N (0.1,0.004) 363.7 99.5 208.9 99.2 424.5 99.6
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4.4.1 Results
The results from the simulation study using 10 000 simulated datasets are presented
in Table 4.5 (βXk generated independently) and Table 4.6 (βXk correlated). For each
scenario, the mean estimate, the mean standard error, and the statistical power to
detect a null or positive causal effect at a nominal 5% significance level are presented in
Tables 4.5 and 4.6 for the multivariable IVW, univariable MR-Egger and multivariable
MR-Egger methods. For univariable and multivariable MR-Egger, the statistical power
of the MR-Egger intercept test is also provided.
βXk generated independently: In scenarios 1 and 2 (no and balanced pleiotropy),
estimates from all methods were unbiased, and those from the multivariable IVW
method were the most precise. In scenarios 3 and 4 (directional pleiotropy), estimates
from the multivariable IVW method were biased, with the magnitude of bias increasing
as the average value of α′ increased from 0.01 to 0.1. In scenario 3 (InSIDE satisfied),
estimates from the univariable and multivariable MR-Egger methods were unbiased,
whereas in scenario 4 (InSIDE violated), they were biased. Although the causal
estimates for both multivariable IVW and multivariable MR-Egger were biased under
scenario 4, the magnitude of bias was less for multivariable MR-Egger, with the
exception of when α′j was generated from N (0.01, 0.004). Precision and power to
detect a causal effect were always better for the multivariable MR-Egger method than
univariable MR-Egger, although the univariable MR-Egger method detected directional
pleiotropy more often. The average value of α′ had no impact on the degree of bias for
univariable or multivariable MR-Egger.
βXk correlated: Bias for the multivariable IVW method was present in scenarios
3 and 4 only, as in the independently generated setting. In this setting, the InSIDE
assumption for univariable MR-Egger was violated for all four scenarios, resulting
in biased point estimates of θ1. However, the multivariable InSIDE assumption was
satisfied for scenarios 1, 2 and 3, and so causal estimates from multivariable MR-Egger
were unbiased. When the multivariable InSIDE assumption was violated (scenario 4)
the estimates from multivariable MR-Egger were biased, yet the magnitude of bias was
less compared with univariable MR-Egger as | cov(α′,βX1)| < | cov(α,βX1)|.
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Table 4.5 Performance of multivariable IVW, univariable MR-Egger and multivariable
MR-Egger with respect to θˆ1 for a null (θ1 = 0) and positive (θ1 = 0.3) causal effect where
βXk are generated independently for all k. All tests were performed at the 5% level of
significance.
MV IVW UV MR-Egger MV MR-Egger
Mean θˆ1 Power, Mean θˆ1 Power, % Mean θˆ1 Power, %
(mean SE) % (mean SE) Int. θˆ1 (mean SE) Int. θˆ1
Null causal effect: θ1 = 0
1. No pleiotropy, InSIDE satisfied
0.000 (0.045) 3.8 -0.002 (0.158) 9.1 4.7 0.000 (0.084) 3.7 4.1
2. Balanced pleiotropy, InSIDE satisfied
α′j ∼ N (0,0.004) -0.001 (0.100) 4.7 -0.001 (0.187) 7.8 4.7 0.000 (0.165) 4.6 4.6
3. Directional pleiotropy, InSIDE satisfied
α′j ∼ N (0.01,0.004) 0.041 (0.100) 6.7 -0.003 (0.187) 12.2 4.3 -0.002 (0.165) 5.9 4.5
α′j ∼ N (0.05,0.004) 0.210 (0.100) 55.3 0.002 (0.187) 49.2 4.6 0.002 (0.166) 36.3 4.6
α′j ∼ N (0.1,0.004) 0.417 (0.102) 97.4 0.000 (0.187) 91.6 4.3 0.001 (0.165) 88.0 4.6
4. Directional pleiotropy, InSIDE violated
α′j ∼ N (0.01,0.004) 0.074 (0.100) 12.3 0.089 (0.187) 6.7 7.6 0.088 (0.165) 4.3 8.4
α′j ∼ N (0.05,0.004) 0.240 (0.100) 67.2 0.089 (0.187) 34.1 7.8 0.088 (0.165) 21.1 8.8
α′j ∼ N (0.1,0.004) 0.450 (0.101) 98.6 0.088 (0.187) 84.1 7.6 0.088 (0.165) 78.7 8.7
Positive causal effect: θ1 = 0.3
1. No pleiotropy, InSIDE satisfied
0.300 (0.044) 98.9 0.300 (0.157) 9.3 50.1 0.300 (0.084) 4.3 87.3
2. Balanced pleiotropy, InSIDE satisfied
α′j ∼ N (0,0.004) 0.301 (0.100) 84.6 0.303 (0.187) 7.5 38.2 0.302 (0.166) 4.9 46.4
3. Directional pleiotropy, InSIDE satisfied
α′j ∼ N (0.01,0.004) 0.343 (0.100) 91.5 0.300 (0.187) 12.8 36.8 0.299 (0.165) 6.0 45.8
α′j ∼ N (0.05,0.004) 0.509 (0.100) 99.7 0.300 (0.188) 50.6 37.3 0.299 (0.166) 37.1 46.1
α′j ∼ N (0.1,0.004) 0.716 (0.102) 100.0 0.300 (0.187) 91.1 37.1 0.299 (0.166) 87.9 46.1
4. Directional pleiotropy, InSIDE violated
α′j ∼ N (0.01,0.004) 0.374 (0.099) 94.3 0.390 (0.187) 6.6 56.4 0.389 (0.165) 4.6 65.8
α′j ∼ N (0.05,0.004) 0.539 (0.100) 99.8 0.388 (0.187) 34.4 55.6 0.387 (0.165) 21.5 65.5
α′j ∼ N (0.1,0.004) 0.747 (0.101) 100.0 0.383 (0.187) 84.7 55.1 0.384 (0.165) 78.3 65.2
Abbreviations: MR, Mendelian randomization; UV, univariable; MV, multivariable; Int., intercept; SE, standard error;
IVW, inverse-variance weighted; InSIDE, Instrument Strength Independent of Direct Effect.
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Table 4.6 Performance of multivariable IVW, univariable MR-Egger and multivariable
MR-Egger with respect to θˆ1 for a null (θ1 = 0) and positive (θ1 = 0.3) causal effect where
βXk were correlated for all k. All tests were performed at the 5% level of significance.
MV IVW UV MR-Egger MV MR-Egger
Mean θˆ1 Power, Mean θˆ1 Power, % Mean θˆ1 Power, %
(mean SE) % (mean SE) Int. θˆ1 (mean SE) Int. θˆ1
Null causal effect: θ1 = 0
1. No pleiotropy, InSIDE satisfied
0.000 (0.047) 4.0 0.099 (0.157) 4.3 10.1 0.000 (0.086) 4.4 4.6
2. Balanced pleiotropy, InSIDE satisfied
α′j ∼ N (0,0.004) -0.001 (0.104) 4.7 0.093 (0.187) 4.5 7.4 -0.003 (0.169) 4.6 4.4
3. Directional pleiotropy, InSIDE satisfied
α′j ∼ N (0.01,0.004) 0.043 (0.104) 7.0 0.099 (0.187) 5.8 8.0 0.001 (0.169) 5.9 4.8
α′j ∼ N (0.05,0.004) 0.213 (0.105) 52.7 0.095 (0.187) 33.3 7.6 0.000 (0.169) 37.2 4.5
α′j ∼ N (0.1,0.004) 0.426 (0.107) 96.3 0.096 (0.187) 84.5 7.6 -0.001 (0.169) 89.2 4.6
4. Directional pleiotropy, InSIDE violated
α′j ∼ N (0.01,0.004) 0.062 (0.104) 9.5 0.184 (0.187) 4.6 17.9 0.078 (0.169) 4.7 7.6
α′j ∼ N (0.05,0.004) 0.235 (0.104) 62.1 0.187 (0.187) 20.5 18.3 0.082 (0.169) 22.3 7.5
α′j ∼ N (0.1,0.004) 0.448 (0.106) 97.9 0.181 (0.187) 73.3 17.8 0.077 (0.169) 80.3 7.2
Positive causal effect: θ1 = 0.3
1. No pleiotropy, InSIDE satisfied
0.300 (0.047) 98.7 0.395 (0.158) 4.4 70.8 0.299 (0.087) 3.9 86.2
2. Balanced pleiotropy, InSIDE satisfied
α′j ∼ N (0,0.004) 0.300 (0.104) 81.5 0.399 (0.187) 4.4 58.0 0.301 (0.169) 4.6 44.4
3. Directional pleiotropy, InSIDE satisfied
α′j ∼ N (0.01,0.004) 0.342 (0.104) 89.4 0.395 (0.187) 6.4 57.4 0.301 (0.169) 5.9 44.4
α′j ∼ N (0.05,0.004) 0.513 (0.105) 99.4 0.394 (0.187) 33.0 57.4 0.296 (0.169) 38.0 43.4
α′j ∼ N (0.1,0.004) 0.729 (0.107) 100.0 0.400 (0.187) 83.5 58.2 0.304 (0.169) 88.6 45.5
4. Directional pleiotropy, InSIDE violated
α′j ∼ N (0.01,0.004) 0.365 (0.104) 92.1 0.489 (0.187) 4.2 74.0 0.382 (0.169) 4.6 63.2
α′j ∼ N (0.05,0.004) 0.535 (0.104) 99.7 0.486 (0.187) 20.3 72.9 0.382 (0.169) 21.1 63.2
α′j ∼ N (0.1,0.004) 0.749 (0.106) 100.0 0.488 (0.187) 72.5 73.4 0.381 (0.169) 79.6 62.8
Abbreviations: MR, Mendelian randomization; UV, univariable; MV, multivariable; Int., intercept; SE, standard error;
IVW, inverse-variance weighted; InSIDE, Instrument Strength Independent of Direct Effect.
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4.4.2 Summary
In this Section, we have performed a simulation study to investigate the benefits of
using multivariable MR-Egger over multivariable IVW and univariable MR-Egger when
the risk factors do not have causal effects on each other. The simulation study has
highlighted the sensitivity of univariable MR-Egger to the correlation structure of βXk ,
and has demonstrated the merits of using multivariable MR-Egger in terms of the
consistency and precision of the causal effect. In the next Section we allow the risk
factors to have a causal effect on each other and re-perform the simulation study.
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4.5 Causal relationships between risk factors
The simulations performed in Section 4.4 assumed that the effect of each risk factor on
the outcome is not mediated through another risk factor. There may be circumstances
where causal relationships between risk factors are biologically plausible. Burgess et al.
[28] illustrated that the multivariable IVW method estimates the direct causal effects
(θk) of each risk factor on the outcome, irrespective of whether causal relationships
between the risk factors exist.
In the applied example (Section 4.3), there may also be deterministic dependencies
between the risk factors. LDL-C is rarely measured directly, but is estimated from
measurements of total cholesterol, triglycerides and HDL-C via the Friedewald equation
as total cholesterol minus HDL-C minus 0.2 times triglycerides (assuming all measure-
ments are in mg/dL) [81]. It has previously been shown that the coefficient for LDL-C
is the same as the coefficient for non-HDL-C (calculated as total cholesterol minus
HDL-C) in a regression model including HDL-C and triglycerides (see Appendix 2 in
the paper by Di Angelantonio et al. [119]). However, the coefficient for triglycerides
will change, as the non-HDL-C measure contains more triglycerides than the LDL-C
measure. Hence, in the case that there are deterministic relationships between the risk
factors, effect estimates may change as the choice of risk factors varies due to their
interpretation as direct effects conditional on other risk factors in the regression model.
To investigate the behaviour of the multivariable MR-Egger method when associa-
tions between risk factors exist, the following simulation study was performed when
X2 was dependent on X1.
4.5.1 Simulation study
We assume that X2 is causally dependent on X1, and the causal effect of X1 on X2 is
γ (Figure 4.3). The total causal effect of X1 on Y is θ1 + γθ2; consisting of the direct
effect (θ1) and the indirect effect via X2 (γθ2).
The simulations outlined in Section 4.4 were repeated with the second line in the
data-generating model (Equation 4.5) replaced with:
βYj = α′j + θ1|βX1j |+ θ2(βX2j + γ|βX1j |) + θ3βX3j + ϵj .
The causal effect of X1 on X2 (γ) was set to 0.5. All other parameters were the same
as the original simulation study. |βX1j |, (βX2j + γ|βX1j |), and βX3j were the covariates
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Fig. 4.3 Directed acyclic graph illustrating the causal relationships between the two risk
factors X1 and X2, and outcome Y . The causal effect of X1 on X2 is γ, and the direct causal
effect of the risk factor Xk on the outcome Y is θk. The total causal effect of X1 on Y is
θ1 + γθ2; consisting of the direct effect (θ1) and the indirect effect via X2 (γθ2).
included in the multivariable IVW and multivariable MR-Egger models. Note that the
functional relationship between X1 and X2 induces a correlation structure between the
covariates |βX1j | and (βX2j + γ|βX1j |) included in the multivariable models, even when
βX1 and βX2 are generated independently. To account for the additional uncertainty in
βYj , the weights for univariable MR-Egger are given by equation 4.8, while the weights
for multivariable IVW and multivariable MR-Egger were the same as the original
simulation study (equation 4.6).
se(βYj)−2 = (ϵj2 + σα′2 + θ22σ22 + (θ2γ)
2σ1
2 + 2θ2γρ12σ1σ2 + θ32σ32)
−1
. (4.8)
Results
The results from the simulations that included a causal relationship between X1 and
X2, using 10 000 simulated datasets, are presented in Table 4.7 (βXk generated inde-
pendently, with the functional relationship between X1 and X2 inducing a correlation
structure between |βX1j | and (βX2j + γ|βX1j |)) and Table 4.8 (βXk correlated).
βXk generated independently, with a correlation structure between the
covariates |βX1j | and (βX2j + γ|βX1j |): In scenarios where there was no bias in
the original set of simulations, the multivariable IVW and multivariable MR-Egger
methods consistently estimated the direct effect of X1 on Y (θ1), whilst the univariable
MR-Egger method consistently estimated the total causal effect of X1 on Y (θ1 + γθ2).
Bias for the multivariable IVW method was present in scenarios 3 and 4 only, as in
the original simulation study (Tables 4.5 and 4.6). Compared to the results in Table
4.5, precision and power to detect a causal effect were reduced for the multivariable
IVW and multivariable MR-Egger methods. This reduction in power may be due to
the correlation structure between |βX1j | and (βX2j + γ|βX1j |), and the multivariable
models conditioning on a mediator. Univariable and multivariable MR-Egger methods
produced biased estimates of the total and direct causal effects in scenario 4 (InSIDE
4.5 Causal relationships between risk factors 115
violated) only. Unlike the original simulation study, precision and power to detect a
causal effect were always better for the univariable MR-Egger method.
βXk correlated: The multivariable IVW and multivariable MR-Egger methods
estimated the direct effect of X1 on Y , as in the independently generated setting. As
with the original simulations (Tables 4.5 and 4.6), the InSIDE assumption for univariable
MR-Egger was violated for all four scenarios, resulting in biased point estimates.
However, as with the original simulation study, the multivariable InSIDE assumption
was satisfied for scenarios 1,2 and 3, and so causal estimates from multivariable MR-
Egger were unbiased. There was a more noticeable reduction in the precision and
power to detect a causal effect for the multivariable IVW and multivariable MR-Egger
methods under the correlated setting.
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Table 4.7 Performance of multivariable IVW, univariable MR-Egger and multivariable
MR-Egger with respect to θˆ1 for a null (θ1 = 0) and positive (θ1 = 0.3) causal effect where
βXk are generated independently for all k (with a correlation structure between the covariates
|βX1j | and (βX2j + γ|βX1j |)), with a causal effect of X1 on X2 (γ = 0.5). All tests were
performed at the 5% level of significance.
MV IVW UV MR-Egger MV MR-Egger
Mean θˆ1 Power, Mean θˆ1 Power, % Mean θˆ1 Power, %
(mean SE) % (mean SE) Int. θˆ1 (mean SE) Int. θˆ1
Null causal effect: θ1 = 0
1. No pleiotropy, InSIDE satisfied
0.000 (0.057) 3.5 0.051 (0.158) 8.9 5.8 0.001 (0.090) 4.5 4.2
2. Balanced pleiotropy, InSIDE satisfied
α′j ∼ N (0,0.004) 0.001 (0.127) 4.4 0.049 (0.187) 7.6 5.6 0.001 (0.178) 4.6 4.2
3. Directional pleiotropy, InSIDE satisfied
α′j ∼ N (0.01,0.004) 0.041 (0.127) 6.0 0.049 (0.187) 12.3 5.4 0.000 (0.178) 5.8 4.8
α′j ∼ N (0.05,0.004) 0.195 (0.128) 34.4 0.048 (0.187) 50.1 5.3 -0.001 (0.178) 36.6 4.6
α′j ∼ N (0.1,0.004) 0.393 (0.130) 82.3 0.052 (0.187) 91.4 5.6 0.002 (0.178) 88.4 4.7
4. Directional pleiotropy, InSIDE violated
α′j ∼ N (0.01,0.004) 0.076 (0.127) 9.8 0.138 (0.187) 6.4 11.6 0.088 (0.178) 4.3 7.6
α′j ∼ N (0.05,0.004) 0.231 (0.127) 45.2 0.137 (0.187) 34.4 11.9 0.088 (0.178) 21.7 8.2
α′j ∼ N (0.1,0.004) 0.426 (0.129) 88.3 0.141 (0.187) 83.7 11.9 0.089 (0.178) 78.2 8.1
Positive causal effect: θ1 = 0.3
1. No pleiotropy, InSIDE satisfied
0.301 (0.057) 96.3 0.353 (0.158) 9.3 62.3 0.301 (0.090) 3.9 84.6
2. Balanced pleiotropy, InSIDE satisfied
α′j ∼ N (0,0.004) 0.298 (0.127) 65.4 0.350 (0.187) 7.4 47.8 0.298 (0.178) 4.4 41.2
3. Directional pleiotropy, InSIDE satisfied
α′j ∼ N (0.01,0.004) 0.338 (0.127) 75.5 0.352 (0.187) 11.8 48.3 0.300 (0.178) 6.1 41.1
α′j ∼ N (0.05,0.004) 0.494 (0.128) 95.2 0.348 (0.188) 49.2 46.9 0.298 (0.179) 36.8 40.3
α′j ∼ N (0.1,0.004) 0.689 (0.130) 99.6 0.347 (0.188) 91.5 47.1 0.296 (0.178) 88.2 39.6
4. Directional pleiotropy, InSIDE violated
α′j ∼ N (0.01,0.004) 0.375 (0.127) 82.6 0.440 (0.187) 6.6 65.7 0.390 (0.178) 4.7 60.1
α′j ∼ N (0.05,0.004) 0.530 (0.128) 97.0 0.438 (0.187) 34.7 65.5 0.386 (0.178) 21.7 59.9
α′j ∼ N (0.1,0.004) 0.728 (0.129) 99.7 0.441 (0.187) 83.6 65.8 0.390 (0.178) 78.5 60.1
Abbreviations: MR, Mendelian randomization; UV, univariable; MV, multivariable; Int., intercept; SE, standard error;
IVW, inverse-variance weighted; InSIDE, Instrument Strength Independent of Direct Effect.
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Table 4.8 Performance of multivariable IVW, univariable MR-Egger and multivariable
MR-Egger with respect to θˆ1 for a null (θ1 = 0) and positive (θ1 = 0.3) causal effect where
βXk are correlated for all k, with a causal effect of X1 on X2 (γ = 0.5). All tests were
performed at the 5% level of significance.
MV IVW UV MR-Egger MV MR-Egger
Mean θˆ1 Power, Mean θˆ1 Power, % Mean θˆ1 Power, %
(mean SE) % (mean SE) Int. θˆ1 (mean SE) Int. θˆ1
Null causal effect: θ1 = 0
1. No pleiotropy, InSIDE satisfied
0.000 (0.062) 4.1 0.146 (0.158) 3.9 15.6 0.000 (0.097) 4.0 4.0
2. Balanced pleiotropy, InSIDE satisfied
α′j ∼ N (0,0.004) 0.000 (0.137) 4.5 0.146 (0.188) 4.1 11.9 0.000 (0.190) 4.6 4.7
3. Directional pleiotropy, InSIDE satisfied
α′j ∼ N (0.01,0.004) 0.041 (0.137) 5.7 0.151 (0.187) 5.4 12.8 0.003 (0.189) 5.7 4.4
α′j ∼ N (0.05,0.004) 0.209 (0.138) 34.2 0.148 (0.187) 32.8 12.6 0.000 (0.190) 36.9 4.7
α′j ∼ N (0.1,0.004) 0.422 (0.140) 82.2 0.151 (0.188) 83.0 12.9 0.004 (0.190) 89.0 4.8
4. Directional pleiotropy, InSIDE violated
α′j ∼ N (0.01,0.004) 0.053 (0.137) 6.2 0.235 (0.188) 4.3 25.7 0.069 (0.189) 4.9 6.4
α′j ∼ N (0.05,0.004) 0.218 (0.137) 37.2 0.235 (0.188) 20.3 26.4 0.067 (0.189) 21.8 6.7
α′j ∼ N (0.1,0.004) 0.429 (0.139) 84.3 0.238 (0.188) 71.3 26.7 0.071 (0.189) 79.2 6.6
Positive causal effect: θ1 = 0.3
1. No pleiotropy, InSIDE satisfied
0.299 (0.062) 94.7 0.446 (0.158) 4.1 79.7 0.300 (0.096) 4.0 81.3
2. Balanced pleiotropy, InSIDE satisfied
α′j ∼ N (0,0.004) 0.301 (0.137) 60.5 0.445 (0.187) 4.5 66.6 0.300 (0.189) 4.6 37.0
3. Directional pleiotropy, InSIDE satisfied
α′j ∼ N (0.01,0.004) 0.339 (0.137) 69.9 0.443 (0.188) 5.7 66.1 0.296 (0.190) 6.0 36.1
α′j ∼ N (0.05,0.004) 0.510 (0.138) 94.2 0.449 (0.188) 32.6 67.7 0.302 (0.190) 37.3 37.2
α′j ∼ N (0.1,0.004) 0.715 (0.140) 99.2 0.445 (0.187) 83.4 66.9 0.298 (0.189) 89.4 36.8
4. Directional pleiotropy, InSIDE violated
α′j ∼ N (0.01,0.004) 0.353 (0.137) 73.1 0.534 (0.188) 4.4 79.4 0.367 (0.189) 4.6 50.6
α′j ∼ N (0.05,0.004) 0.519 (0.138) 95.1 0.534 (0.188) 20.3 79.6 0.366 (0.190) 21.7 50.5
α′j ∼ N (0.1,0.004) 0.728 (0.139) 99.5 0.533 (0.188) 72.5 79.6 0.368 (0.189) 80.1 51.0
Abbreviations: MR, Mendelian randomization; UV, univariable; MV, multivariable; Int., intercept; SE, standard error;
IVW, inverse-variance weighted; InSIDE, Instrument Strength Independent of Direct Effect.
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4.5.2 Summary
In this Section, we have re-performed the simulation study in Section 4.4 to consider
the effect of introducing a causal effect between the risk factors in the data-generating
model. The multivariable methods estimated the direct effect of the risk factor on the
outcome, whilst univariable MR-Egger estimated the total causal effect. In comparison
to Section 4.4, the precision and power to detect the causal effect were reduced for the
multivariable IVW and multivariable MR-Egger methods.
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4.6 Discussion
In this Chapter, we have extended univariable MR-Egger to the multivariable setting
and outlined the assumptions required to obtain consistent causal estimates in the
presence of directional pleiotropy. Multivariable MR-Egger should be viewed as a
sensitivity analysis to provide robustness against both measured and unmeasured
pleiotropy, and to strengthen the evidence from the primary Mendelian randomization
analysis. If the causal estimate from multivariable MR-Egger is substantially different
from the estimate obtained in the primary analysis, then further investigation into the
causal finding and the potential for pleiotropy is required.
The simulation studies (Sections 4.4 and 4.5) have highlighted the benefits of using
multivariable MR-Egger over its univariable counterpart. This is particularly true when
the associations of the genetic variants with the risk factor of interest are associated
with genetic associations with at least one of the risk factors (measured pleiotropy).
Under this scenario, the InSIDE assumption for univariable MR-Egger is likely to be
violated, leading to biased causal estimates. Multivariable MR-Egger will, however,
produce consistent causal estimates if the InSIDE assumption for multivariable MR-
Egger is satisfied. Although the estimates from univariable and multivariable MR-Egger
are asymptotically the same when genetic associations with each risk factor are all
independent, multivariable MR-Egger may have greater power to detect a causal effect
when the InSIDE assumption is satisfied. Given these advantages, and the sensitivity of
the multivariable IVW method to directional pleiotropy, we believe that multivariable
MR-Egger should be considered as an important sensitivity analysis for a Mendelian
randomization study.
4.6.1 Multivariable by design, or multivariable as a sensitivity
analysis?
There are two possible scenarios where multivariable MR-Egger may be used as a
sensitivity analysis: either the primary analysis is considered to be multivariable by
design, or a multivariable framework is only considered as part of the sensitivity analysis.
The first case should be motivated by biological evidence where the set of risk factors
are known to be associated with common genetic variants, such as lipid fractions.
Under this scenario, multivariable IVW should be used as the primary analysis method
with multivariable MR-Egger providing robustness against directional pleiotropy as a
sensitivity analysis.
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In the second scenario, where there is a lack of biological evidence to suggest a
multivariable framework, univariable IVW would generally be considered as the primary
analysis method and univariable MR-Egger as the main sensitivity analysis. However,
if the genetic variants are associated with other risk factors, multivariable MR-Egger
could also be used as a sensitivity analysis as its assumptions are more likely to be
satisfied, and it may have greater power to detect a causal effect than univariable
MR-Egger. An example of the use of multivariable Mendelian randomization as a
sensitivity analysis is a Mendelian randomization study on plasma urate concentrations
and CHD risk [120]. To account for measured and unmeasured pleiotropic associations
of the genetic variants, the authors performed the multivariable IVW and univariable
MR-Egger methods as sensitivity analyses. This investigation may have benefited from
performing the multivariable MR-Egger method to simultaneously account for both
measured and unmeasured pleiotropic effects.
4.6.2 InSIDE assumption and orientation of genetic variants
The validity of multivariable MR-Egger and its ability to estimate consistent causal
effects is dependent upon the InSIDE assumption being satisfied. Whilst it is not
possible to determine whether the InSIDE assumption has been violated, we believe it
is more likely to hold for multivariable MR-Egger then univariable MR-Egger. When
the βX1 parameters are correlated with at least one of the sets of βXk parameters for
k = 2, 3, . . . , K, the InSIDE assumption for univariable MR-Egger is automatically
violated and causal estimates from the method will be inconsistent. Under this setting,
the InSIDE assumption for multivariable MR-Egger will be satisfied if all of the
parameters βXk (k = 1, 2, . . . , K) are included in the model. However, it is possible
that the remaining direct effect for multivariable MR-Egger contains an unmeasured
component that is correlated with one of the βXk (k = 1, 2, . . . , K) parameters, and the
InSIDE assumption for multivariable MR-Egger will be violated. Hence, as highlighted
in Section 4.2.5, there is no guarantee that the InSIDE assumption will be more easily
satisfied for multivariable MR-Egger than univariable MR-Egger.
The recommendation of orientating the genetic variants in multivariable MR-Egger
to the risk factor-increasing or risk factor-decreasing allele for the risk factor of interest
may be considered arbitrary. While we accept this limitation, we would argue it
brings consistency to the results. This recommendation may result in the analysis
being performed up to K times to obtain the causal estimates for all K risk factors.
The orientation of the genetic variants will also affect the interpretation of the direct
effect, thereby altering the InSIDE assumption. This may result in the MR-Egger
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intercept estimate varying between different orientations. This was seen in the applied
example (Section 4.3) where the intercept term was non-significant when the alleles
were orientated with respect to LDL-C, and significant when orientated with respect
to HDL-C and triglycerides.
4.6.3 Linearity and homogeneity assumptions
Throughout this Chapter we have assumed linearity and homogeneity (no effect
modification) of the causal effects of the risk factors on the outcome, and of the
associations between the genetic variants with the risk factors and with the outcome.
Although linearity and homogeneity are strong assumptions, the effect of genetic
variants on the risk factor and outcome tend to be limited to a small range, which may
make the assumptions of linearity and homogeneity more reasonable in a Mendelian
randomization analysis. Note that the assumption of linearity is particularly important
in the multivariable setting if there are mediators, as the mediating effects will only
cancel out if the associations are linear.
The work presented in this Chapter has focused on effect estimation. Whilst the
primary motivation of Mendelian randomization may be the estimation of causal
parameters, the estimates themselves can also be used to test the null hypothesis of
whether the risk factor is causally associated with the outcome. If the assumptions
of linearity and homogeneity are violated then the methods discussed in this Chapter
still provide a valid test for the null hypothesis [121], but the estimates will not have a
literal interpretation [122].
As highlighted in Sections 2.3.3 and 4.3, the linearity assumption will be violated if
the outcome is binary. Under this scenario, the estimates obtained from the Mendelian
randomization analysis will be approximations of the causal effects due to the non-
collapsibility of the odds ratio. Our justification for extending MR-Egger to the
multivariable setting was made under the assumption of linearity, and the simulation
study did not consider the impact of a binary outcome as the summary level data was
generated directly. This could be viewed as a limitation to the work presented in this
Chapter.
The multivariable models have assumed that the risk factors do not have causal
effects on each other. The additional simulation study in Section 4.5 has illustrated
that the multivariable MR-Egger method estimates the direct causal effects of the risk
factors on the outcome, irrespective of whether the risk factors are causally related.
There was, however, a reduction in precision and power to detect the causal effect for
multivariable MR-Egger when a causal relationship between the risk factors was present.
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This reduction in power was anticipated since the multivariable models condition on
the mediator along a causal pathway, which is known to decrease power to detect a
causal effect [123]. When the risk factors were causally related, univariable MR-Egger
will produce consistent causal estimates of the total effect if the InSIDE assumption
for univariable MR-Egger is satisfied.
4.6.4 Implication for future research
The paper by Helgadottir et al. [114] highlights the importance and need to develop
sensitivity analyses for multivariable Mendelian randomization. This is particularly
relevant given the recent advances in high-throughput phenotyping which has led to
the introduction of ‘-omics’ data such as metabolomics, genomics, and proteomics [124].
Genome-wide analyses of high-dimensional ‘-omics’ data are becoming more popular
[125, 126], yet few Mendelian randomization analyses have been performed using these
datasets [116]. As summarized data from large consortia become more accessible, the
opportunities to use Mendelian randomization on high-dimensional datasets will only
increase. Methods such as multivariable MR-Egger will be valuable to investigate the
causal effects of multiple related phenotypes with shared genetic predictors.
Bowden et al. [49] have shown that uncertainty in the associations between the
genetic variants and the risk factor in univariable MR-Egger can lead to attenuation
towards the null when a causal effect exists between the risk factor and the outcome
in two-sample Mendelian randomization. This attenuation is approximately equal to
the I2 statistic from meta-analysis of the weighted associations with the exposure
βˆXj se(βˆY j)−1, with standard errors se(βˆXj) se(βˆY j)−1 [49]. Since the estimated mean
I2 statistics for the simulation study in Section 4.4 were close to 100%, there was no
substantial bias in the causal estimates due to uncertainty in the genetic associations
with the risk factor(s) for either the univariable or multivariable MR-Egger methods.
However, it is unclear whether uncertainty in the genetic associations with the risk
factors would always lead to the attenuation of the causal estimates for the multivariable
MR-Egger method in the two-sample setting.
It was not possible to estimate the Sanderson-Windmeijer conditional F-statistic
in the simulation studies as the data-generating model produced summary level data.
Although the F-statistics did suggest that the genetic variants were strongly associated
with the risk factors, it was unclear whether the variants were jointly associated with
the risk factors. As such, we were unable to investigate the effect the conditional
F-statistic had on the results from the multivariable methods.
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4.6.5 Correlated genetic variants
The methods discussed in this Chapter have assumed that the genetic variants are
uncorrelated (not in linkage disequilibrium). There may, however, be cases where
using multiple correlated variants from the same gene region will be more efficient than
using uncorrelated variants from different gene regions [121]. If the genetic variants
are in partial linkage disequilibrium, and each variant explains independent variation
in the risk factor, then the inclusion of these variants will increase the power of the
Mendelian randomization study. The precision of a Mendelian randomization study
will not increase, however, if the variants are perfectly correlated.
If correlated variants are included in an Mendelian randomization study, using
summarized level data, the analysis should account for the correlation structure of
the variants. If the correlation of the variants is not taken into consideration, the
causal estimate will be too precise and this may lead to inappropriate inferences.
To account for the correlation between the genetic variants for the univariable and
multivariable IVW methods, we can use generalized weighted linear regression of the
genetic associations, where the correlations of the variants are included in the weighting
matrix, with the intercept set to zero [28, 121].
If Ωst = se(βˆYs) se(βˆYt)ρst, where ρst is the correlation between variants s and t,
then the causal estimate from a weighted generalised linear regression for univariable
Mendelian randomization is:
θˆUIC = (βˆTXjΩ
−1βˆXj)−1βˆTXjΩ
−1βˆYj ,
with the standard error of the causal estimate:
θˆUIC =
√
(βˆTXjΩ−1βˆXj)−1 .
Whilst the univariable MR-Egger estimates can be obtained by fitting the same
generalized weighted linear regression model, but allowing the intercept term to be
estimated, the effect of using correlated genetic variants in the univariable MR-Egger
method has not been considered in detail. Further investigation into the impact
correlated variants may have on the interpretation of the direct effect, and the InSIDE
assumption, must be considered at the univariable level first, and then expanded to
multivariable MR-Egger.
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4.6.6 Key points from chapter
• In this Chapter, we have extended the MR-Egger method to the multivariable
setting to correct for both measured and unmeasured pleiotropy.
• Through theoretical arguments and a simulation study, we have shown that the
multivariable MR-Egger method has advantages over its univariable counterpart
in terms of plausibility of the assumption needed for consistent causal estimation,
and power to detect a causal effect when this assumption is satisfied.
• The multivariable MR-Egger method will be useful to analyse high-dimensional
data in situations where the risk factors are highly related and it is difficult
to find genetic variants specifically associated with the risk factor of interest
(multivariable by design), and as a sensitivity analysis when the genetic variants
are known to have pleiotropic effects on measured risk factors.
Chapter 5
Extending Mendelian
randomization to a factorial
framework to detect interaction
effects
5.1 Introduction
An interaction between two risk factors occurs when the effect of one risk factor on
the outcome is dependent upon the value of the other risk factor. Interactions on
disease outcomes can be used to inform public health policies that aim to reduce the
burden of disease in the population. The identification of interaction effects may also
help to prioritize treatment in the general population and avoid adverse events to
treatment. Interaction effects can be considered in randomized clinical trials (RCT)
and epidemiological studies using observational data. RCTs can investigate interaction
effects to identify sub-populations where the effect of treatment may be more beneficial
or even harmful. Interactions in epidemiological studies can highlight whether the
effect of a risk factor on a disease outcome can be considered in isolation, or whether its
effect should be considered with another risk factor. However, estimates of interaction
effects from epidemiological studies and RCTs may not have a causal interpretation
due to residual confounding and non-compliance to randomization.
In this Chapter, we explore the possibility of estimating and detecting interaction
effects in factorial Mendelian randomization. Unlike Chapters 3 and 4, this Chapter is
not centred on developing methodology that accounts for the inclusion of pleiotropic
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genetic variants. As highlighted in Section 1.6, the work presented in this Chapter was
motivated by the observation that estimating interaction effects between risk factors
may be of interest in Mendelian randomization analyses that include two risk factors.
Since we demonstrate that summary level data cannot be used in factorial Mendelian
randomization (Section 5.4.1), this Chapter focuses on using individual level data for
the risk factor, outcome, and genetic variants (‘one–sample’ Mendelian randomization).
In Section 5.2, we introduce interaction effects within the context of RCTs, and
provide an overview of estimating interaction effects. Section 5.3 reviews the literature
on factorial Mendelian randomization and justifies the need for further methodological
development in this area. In Section 5.4.1, we extend multivariable Mendelian ran-
domization to the factorial setting using individual level data, and demonstrate that
standard summary level data cannot be used to estimate the interaction effect of two
risk factors in a factorial Mendelian randomization analysis. A formal framework for
detecting interactions between drug treatments by using variants as proxies for phar-
macological interventions is provided in Section 5.4.2. Finally, we apply the methods
considered in this Chapter to data from UK Biobank to estimate the interaction effect
of body mass index and alcohol consumption on systolic blood pressure (Section 5.5).
5.2 Interaction effects
This Section defines statistical interaction effects within the context of factorial RCTs,
and outlines the types of analyses that may be performed in a factorial RCT. Estimating
interaction effects by using linear regression and IVs is then discussed in detail. Finally,
we consider the interpretation of statistical interactions as causal effects.
5.2.1 Factorial randomized clinical trials
A factorial RCT allows for the simultaneous assessment of two or more treatments in
a single study. In its simplest form, a 2 × 2 factorial RCT investigates the effect of
two binary treatments A and B on a binary outcome Y (Table 5.1). Participants are
randomly allocated to one of four groups: to receive treatment A only (n10); to receive
treatment B only (n01); to receive both treatments A and B (n11); or to receive neither
treatment A nor B (n00). To increase statistical power, participants are normally
randomized to create a ‘balanced’ study where the numbers of participants in each of
the four groups are equal [127].
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Table 5.1 Illustration of a 2 × 2 factorial randomized clinical trial where N participants
are randomized to treatment A (absence/presence), treatment B (absence/presence), both
treatments A and B, or no treatment.
Treatment A
Absence Presence
Treatment B Absence n00 n10 n1+
Presence n01 n11 n2+
n+1 n+2 N
We let the probability of the outcome Y when treatment A = a and treatment
B = b be represented by:
pab = P (Y = 1|A = a,B = b) . (5.1)
Using Equation 5.1, the statistical interaction of treatment A and treatment B on Y
can be measured on the additive scale by:
I+ = p11 − p10 − p01 + p00 .
If I+ > 0, then the effect of both treatments on the outcome is greater than the sum
of the individual effects of the treatments, and the interaction is said to be ‘positive’
or ‘super-additive’. If I+ < 0, then the effect of both treatments on the outcome is less
than the sum of the individual effects of the treatments, and the interaction is said to
be ‘negative’ or ‘sub-additive’.
The effects of the treatments on the outcome can also be considered through the
relative risks (RRs) or odds ratios (ORs). Let RRab = pabp00 represent the risk of the
outcome when A = a and B = b compared to the risk of the outcome in the reference
group (no treatment for both A and B), then the statistical interaction of treatment A
and treatment B on Y can be measured on the multiplicative scale by:
I× =
RR11
RR10RR01
= p11p00
p10p01
.
If I× > 1, then the effect of both risk factors on the outcome is greater than the
product of the individual effects of the risk factors, and if I× < 1, then the effect of
both risk factors on the outcome is less than the product of the individual effects of
the risk factors.
Statistical interactions can be assessed by including a product term between the
treatments in the regression model. For a linear regression model, this product term
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represents an additive statistical interaction, and for a logistic regression model it
represents a statistical multiplicative interaction. Statistical interactions may be present
on the additive scale but not on the multiplicative scale, and vice-versa [128].
Types of analyses
For a 2×2 factorial RCT, the effects of randomization on the outcome can be assessed by
considering the treatments individually, and in combination with each other; allowing
for the interaction between the treatments to be investigated. We assume that there is
full compliance to randomization, so that the effects of randomization on the outcome
from an intention to treat (ITT) analysis are equivalent to the average treatment effects
(ATE).
If no interaction effect between the treatments is assumed in a factorial RCT, then
the analysis is performed ‘at the margins’ [129]. Under this approach, the effectiveness
of treatment A is considered by comparing the outcome among the participants
randomized to treatment A (n+2) with those not randomized to treatment A (n+1),
and the effectiveness of treatment B is considered by comparing the outcome in n2+
with the outcome in n1+. A multivariable regression model of the outcome with the
two treatments and any other necessary covariates, such as baseline characteristics, can
be fitted to estimate the treatment effects [127]. For a continuous outcome measure,
adjusting for the effect of each treatment will help to improve efficiency, particularly if
the study is ‘unbalanced’ [127]. If the true interaction effect between the treatments is
non-zero, then the estimates from this analysis will be biased [129].
When an interaction effect between the treatments is considered, the analysis can
be carried out ‘inside the table’ by treating each group in Table 5.1 as a separate study
arm [130, 129]. Under this approach, the effectiveness of treatment A is considered by
comparing the outcome in those randomized to receive treatment A only (n10) with
those randomized to receive neither treatment A nor B (n00), and the effectiveness
of treatment B is considered by comparing the outcome in n01 with the outcome in
n00. To estimate the statistical interaction effect, the same multivariable regression
model described above would be fitted with the addition of a product term between the
treatments. Although this type of analysis may be less efficient than assuming there
is no interaction effect, the estimates will be unbiased whether the true interaction is
zero or not [130].
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5.2.2 Interaction effects using observational data
We now consider estimating statistical interaction effects using observational data.
First we discuss mean centring continuous variables before generating the product
term to improve efficiency. Issues with residual confounding are then highlighted, and
estimating the interaction effect using IVs discussed.
Mean centring continuous variables
Suppose we have two modifiable continuous risk factors X1 and X2, a continuous out-
come Y , and unmeasured confounders U1 and U2 of the X1−Y and X2−Y associations.
Consider the following linear regression model for i = 1, . . . , N observations:
Yi = θ0 + θ1X1i + θ2X2i + θ12X12i + ϵi , (5.2)
where θ1 and θ2 are the main effects of X1 and X2, X12 is the product of X1 and X2,
θ12 is the statistical interaction effect of X1 and X2 on Y , and U1 and U2 are contained
in the error term ϵ. Since X12 is a function of the main effect variables X1 and X2, it is
likely that X1 and X2 will be highly correlated with X12, resulting in reduced statistical
power to detect the main effects θ1 and θ2. The correlation between these variables can
be reduced by mean centring the main effect variables, and then regressing Y against
(X1 − X¯1), (X2 − X¯2) and (X1 − X¯1) × (X2 − X¯2), where X¯1 and X¯2 are the mean
values of X1 and X2 [131]. Mean centring the variables has no impact on the estimate
or standard error of the interaction term, but should help to improve the precision
of the main effects. By mean centring X1 and X2, the main effects will represent the
marginal effects θ1M and θ2M of X1 and X2 on Y .
Since the linear regression model in Equation 5.2 does not adjust for the unmeasured
confounders U1 and U2, the estimates obtained from the model will be biased. In the
Section below, we consider estimating the interaction effect of X1 and X2 on Y using
IVs.
Instrumental variables
First consider the following set of equations:
E[X1|Z1, U1] = β01 + β11Z1 + U1 ,
E[X2|Z2, U2] = β02 + β12Z2 + U2 ,
E[Y |X1, X2, U1, U2] = θ0 + θ1X1 + θ2X2 + U1 + U2 , (5.3)
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where Z1 and Z2 are IVs (see Section 1.4 for the IV assumptions) for the risk factors
and could be used to estimate θ1 and θ2 in a TSLS regression model [38]. For θ1 and θ2
to be identifiable in a TSLS model, the number of IVs must be equal to or greater than
the number of modifiable risk factors, known as the ‘order condition for identification’
[132]. Equation 5.3 is ‘just identifiable’ under the order condition as the number of
instruments is equal to the number of risk factors.
Now suppose there is a statistical interaction effect of X1 and X2 on Y :
E[Y |X1, X2, X12, U1, U2] = θ0 + θ1X1 + θ2X2 + θ12X12 + U1 + U2 . (5.4)
Although X12 is a function of the original risk factors, X12 should be considered as an
independent risk factor [133]. We now have three risk factors X1, X2 and X12, but only
two IVs. In order for Equation 5.4 to be identifiable, X12 must have its own instrument
[133]. X12 can be expressed in terms of Z1 and Z2:
E[X12|Z1, Z2, v1, v2] = (β11Z1 + v1)× (β12Z2 + v2)
= β11β12Z1Z2 + β11Z1v2 + β12Z2v1 + v1v2 ,
where v1 = β01 + U1, v2 = β02 + U2, and Z1Z2 is the product of the IVs Z1 and Z2.
Since Z1 and Z2 are IVs for X1 and X2, it follows that β11β12 ≠ 0, and Z1Z2 can act
as an IV for X12, making Equation 5.4 just identifiable.
Estimates of θ1, θ2 and θ12 can be obtained through TSLS regression by regressing
the risk factors against the IVs (Z1, Z2 and Z1Z2) to obtain the predicted values Xˆ1,
Xˆ2 and Xˆ12, and the outcome Y is then regressed against these predicted values. It
would be inappropriate to use Xˆ1 and Xˆ2 to obtain the predicted values of X12 as
Xˆ12 ̸= Xˆ1 × Xˆ2. If this approach was taken, then it would be an example of ‘forbidden
regression’ as the non-linear function of the risk factors X1 and X2 is replaced with
the same non-linear function of the predicted values from the first stage regression,
resulting in inconsistent estimates [133].
Suppose that there are two additional IVs Z3 and Z4, such that:
E[X1|Z1, Z3, U1] = β01 + β11Z1 + β21Z3 + U1 ,
E[X2|Z2, Z4, U2] = β02 + β12Z2 + β22Z4 + U2 ,
then Z1Z2, Z1Z4, Z3Z2 and Z3Z4 could act as IVs for X12 in Equation 5.4. In order
for the model to be identifiable, not all of these product terms need to be included
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as IVs. In fact, the model would be identifiable with just Z1, Z2, Z3 and Z4, but the
estimates of θ12 may be imprecise (considered in Section 5.4.1).
As highlighted at the beginning of Section 5.2.2, including a product term between
the main effect variables in a linear regression model can result in reduced statistical
power to detect the main effects, and we would expect the TSLS regression model to
have a similar issue (considered in Section 5.4.1). X1 and X2 should therefore be mean
centred before the product term is calculated, and the main effects from the TSLS
regression model be interpreted as the marginal effects of X1 and X2 on Y .
5.2.3 Causal interpretation
Using the notation in Section 5.2.2, we consider the interpretation of the interaction
effect of X1 and X2 on the outcome.
It is possible for a statistical interaction effect θ12 to have a causal interpretation in
an epidemiological study if both sets of confounders U1 and U2 have been controlled for
[128]. For instance, if the study has taken precise measurements of all the confounders
in U1 and U2, then the interaction could have a causal interpretation if the regression
model adjusted for the effects of U1 and U2. However, if the study has not correctly
identified and measured the variables in U1 and U2, then the interaction will not have
a causal interpretation due to residual confounding. Alternatively, the estimate of θ12
may have a causal interpretation by controlling for the unmeasured confounders either
through the study design, such as a 2 × 2 factorial RCT, or by using instrumental
variable methods, such as TSLS regression.
If there is an interaction between the risk factors, and only U1 has been controlled
for through the study design, then the interaction can only be interpreted as ‘effect
modification’ [134]. For example, let X1 be a randomized drug in a RCT and X2 be a
baseline characteristic. If the effect of the drug on the outcome differs between the
strata of X2 then we can infer that there is effect modification, but we cannot make
any inferences on whether the baseline characteristic is causally relevant in the X1− Y
association.
If both sets of confounders U1 and U2 are controlled for, then the interaction can be
interpreted as a causal effect and we can make inferences on how the outcome would
be effected if we intervened on both X1 and X2 [134]. For example, if X1 and X2 were
randomized treatments in a 2× 2 factorial RCT, then the interaction effect of X1 and
X2 on the outcome Y would have a causal interpretation. Alternatively, if suitable IVs
can be identified then the estimate of the interaction effect from a TSLS regression
model would have a causal interpretation.
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5.2.4 Summary
In this Section, we have introduced the concept of statistical interaction effects within
the context of factorial RCTs, and have discussed the analyses considered in a factorial
RCT. We have highlighted the benefits of mean centring continuous variables before
generating product terms and demonstrated how causal interactions can be estimated in
a TSLS regression model. Finally, we discussed the causal interpretation of interaction
effects. In the next Section, we review the literature on factorial Mendelian randomiza-
tion and IV methodology for estimating interaction effects, providing justification for
the work presented in this Chapter.
5.3 Extending Mendelian randomization to a fac-
torial framework
The application of a factorial RCT framework to a Mendelian randomization study has
been considered under two broad scenarios: a) to estimate interaction effects between
exposures on the risk of disease by using genetic variants as predictors of the risk
factors; and b) to identify interactions between drug treatments on the risk of disease
by using genetic variants as proxies for pharmacological interventions. As motivation
for Section 5.4, the application of these two approaches in the literature, and the need
for further methodological developments is discussed below.
5.3.1 Genetic variants used as predictors for the risk factors
The conceptual idea of applying a factorial framework to a Mendelian randomization
study was first introduced by Davey Smith and Ebrahim [15]. The term ‘factorial
Mendelian randomization’ is credited by the authors to Sheila Bird. The authors
hypothesised that genetic variants could be used as IVs to estimate the simultaneous
effect of two or more exposures on the risk of disease, and the interaction effects of the
exposures on the outcome. Davey Smith and Hemani [135] emphasised the utility of
factorial Mendelian randomization by suggesting that an unconfounded estimate of
the interaction of obesity and alcohol consumption on the risk of liver disease could
be obtained from this type of study design. However, Davey Smith and Ebrahim’s
suggestion of using Mendelian randomization to estimate the interaction effect between
two risk factors has not been considered further in the literature.
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Burgess and Thompson [28] suggested that assessing the causal effects of multiple
risk factors in a single Mendelian randomization study, referred to as ‘multivariable
Mendelian randomization’ [28], is analogous to performing a factorial RCT (Figure 5.1).
Since multivariable Mendelian randomization assumes that there are no interactions
between the risk factors, it would be more accurate to compare this study design to a
factorial RCT when the analysis is performed ‘at the margins’ (Section 5.2.1).
Fig. 5.1 Figure taken from the paper by Burgess and Thompson [28] comparing a factorial
randomized clinical trial to a multivariable Mendelian randomization study.
5.3.2 Genetic variants acting as proxies for pharmacological
interventions
The concept of using genetic variants as proxies for pharmacological interventions to
identify interaction effects between drug treatments was first introduced by Ference
et al. [33], and the method has been used in additional studies to assess interactions
between drug treatments [34, 35]. Ference et al. [33] refer to this type of study design
as a ‘2× 2 factorial Mendelian randomization study’. The authors make no reference
to the concept of ‘factorial Mendelian randomization’ as described by Davey Smith
and Ebrahim [15].
Ference et al. [33] outlined their approach of performing a 2× 2 factorial Mendelian
randomization study by comparing the effect of lowering low density lipoprotein (LDL-
C) levels on the risk of coronary heart disease (CHD) by inhibiting the NPC1L1 gene
with ezetimibe, or inhibiting the HMGCR gene with statins, or through a combination
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of both. Genetic variants associated with LDL-C levels in either gene region were
identified, and two externally weighted gene scores were calculated for each gene region,
where the reference alleles were the LDL-C lowering allele for each variant. To mimic a
2×2 factorial RCT, the two gene scores were dichotomized to create a 2×2 contingency
table (Table 5.2). The gene scores were dichotomized at their median values to ensure
the numbers of participants were balanced across the four groups in Table 5.2, where:
• n00 represents the reference group, which was considered to be equivalent to
receiving no treatment,
• n10 are the group of participants with lower LDL-C mediated by NPC1L1, which
was considered to be equivalent to receiving the ezetimibe treatment only,
• n01 are the group of participants with lower LDL-C mediated by HMGCR, which
was considered to be equivalent to receiving the statin treatment only, and
• n11 are the group of participants with lower LDL-C mediated by NPC1L1 and
HMGCR, which was considered to be equivalent to receiving both ezetimibe and
statin treatments.
The authors performed an ‘inside the table’ analysis (Section 5.2.1) by fitting
separate logistic regression models to each subgroup, with the n00 participants used as
the reference group for each model. By comparing the three OR estimates from the
separate logistic regression models, the authors concluded that there was no evidence of
an interaction effect between ezetimibe and statins, arguing that the effect of lowering
LDL-C on the risk of CHD mediated by variants in NPC1L1, HMGCR or both, was
approximately the same. No formal statistical testing was applied to the three OR
estimates, and the authors did not attempt to estimate the interaction effect of lowering
LDL-C levels by inhibiting the NPC1L1 gene and inhibiting the HMGCR gene on the
risk of CHD.
Table 5.2 Contingency table created by Ference et al. [33] to compare the effect of lowering
low densty lipoprotein levels on the risk of coronary heart disease by inhibiting the NPC1L1
gene with ezetimibe, either alone, or in combination with a statin that inhibits the HMGCR
gene.
Gene score for NPC1L1, GSA
≤ med(GSA) > med(GSA)
Gene score for ≤ med(GSB) n00 n10
HMGCR, GSB > med(GSB) n01 n11
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5.3.3 Effect of obesity and alcohol consumption on the risk
of liver disease
Although the method proposed by Ference et al. [33] (Section 5.3.2) is specifically
designed for considering drug interactions, Carter et al. [136] have applied the method
to investigate the interaction effect of obesity and alcohol consumption on liver disease
using data from the Copenhagen General Population Study. As highlighted in Sec-
tion 5.3.1, the idea of using Mendelian randomization to consider this research question
was initially proposed by Davey Smith and Ebrahim [15]. Since Carter et al. [136]
used the method proposed by Ference et al. [33], they were unable to estimate the
interaction effect of obesity and alcohol consumption on liver disease. Carter et al.
[136] may have followed the approach outlined by Ference et al. [33] as the current
Mendelian randomization literature does not cover the estimation of interaction effects
between risk factors.
In their study, Carter et al. [136] created a weighted gene score for BMI using
five genetic variants, and classified participants as having a ‘low BMI’ or ‘high BMI’
if their gene score was ≤ or > than the median value of the weighted gene score.
The rs1229984 variant in the ADH1B gene region was used as a proxy for alcohol
consumption. Participants were classified as having a ‘low alcohol consumption’ if they
were homozygous or heterozygous for the alcohol decreasing allele, or a ‘high alcohol
consumption’ if they were homozygous for the alcohol increasing allele. Following the
method proposed by Ference et al. [33], these classifications were used to create four
subgroups of participants: 1) low BMI, low alcohol consumption; 2) low BMI, high
alcohol consumption; 3) high BMI, low alcohol consumption; and 4) high BMI, high
alcohol consumption.
Carter et al. [136] used two plasma biomarkers of liver injury and incident cases of
liver disease from hospital records as the outcome measurements. Using the participants
with a high BMI and high alcohol consumption as the reference group, three separate
regression models were fitted to each outcome measurement to estimate the mean
differences (two plasma measurements) or ORs (incident liver disease) for the three
remaining groups of participants. The estimates and 95% confidence intervals from
these three models were compared to consider the direction and overall patterns of
association for each outcome measurement. The authors did not estimate the interaction
effect between BMI and alcohol consumption on liver disease.
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5.3.4 Requirement for further methodological research
We now review the literature on estimating interaction effects in Mendelian randomiza-
tion, and outline the new material considered in this Chapter. Since methodological
developments in Mendelian randomization is heavily linked to the IV literature, a
review of relevant IV methods that estimate interaction effects will be considered first.
Instrumental variable analyses
There has been little method development in the IV literature on estimating inter-
action effects using observational data. However, interactions can be estimated from
observational data using TSLS regression as described in Section 5.2.2.
Whilst there has been a substantial amount of method development in the IV
literature on non-compliance in RCTs with a single treatment, there is little guidance
on how IVs can be used when there is non-compliance in studies where the interaction
between treatments is of primary concern [137]. Since non-compliance to randomization
in a 2× 2 factorial RCT can lead to artificial interaction effects, reduced statistical
power, and biased estimates under an ITT analysis [138], developing methodology
that can be used in a 2 × 2 factorial RCT would be beneficial. Blackwell [137],
recognising this gap in the literature, has used a compliance framework to provide
non-parametric estimators of the local average interaction effect (LAIE) and the local
average conditional effects (LACEs) for a 2× 2 factorial study design. The estimators
of the LAIE and LACEs (local average treatment effect for one treatment with the
other treatment fixed) require estimates of the compliance probabilities for the different
treatment groups.
The application of Blackwell’s method to Mendelian randomization is limited.
To estimate the LAIE under Blackwell’s [137] method, estimates of the compliance
probabilities are required. Whilst it would be possible for these probabilities to be
estimated in a 2× 2 factorial RCT, it is difficult to conceive how these probabilities
could be obtained in a 2×2 factorial Mendelian randomization study. The applicability
of Blackwell’s method to a Mendelian randomization study is further restricted by the
method only considering binary treatments, with each treatment having its own binary
IV. Most Mendelian randomization studies use multiple variants as IVs, and the risk
factors are typically continuous [139].
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Mendelian randomization
As highlighted in Section 5.3.1, the first paper to introduce the idea of estimating
interaction effects between risk factors in Mendelian randomization was written by
Davey Smith and Ebrahim in 2003. There has been no methodological developments
in the Mendelian randomization literature on estimating interaction effects since this
paper was published. We will address this gap in the literature by extending the
multivariable Mendelian randomization method to the factorial setting by estimating
the interaction term between two risk factors. This expansion will be considered for
both individual and summary level data. We will also investigate whether the definition
of a ‘strong instrument’ for multivariable Mendelian randomization (Section 2.6.3) is
applicable to the factorial setting. Finally, the suitability of using the method proposed
by Ference et al. [33] to investigate the interaction effect between two risk factors, as
done by Carter et al. [136], will be investigated.
The application of a factorial framework to a Mendelian randomization study when
the genetic variants are used as proxies for drug treatments has only been considered
in the context of applied projects [33–35]. There are several methodological issues
relating to the implementation of this method that will be addressed in this Chapter.
Rather than performing an ‘inside the table’ analysis and comparing the estimates
from the separate regression models with no statistical testing for an interaction effect,
we will fit a single multivariable regression model with an interaction term between
the gene scores. Although the interpretability of the interaction effect from this model
would be limited, as it represents the effect of the genetic variants on the outcome [33],
rather than the effect of the treatments on the outcome, the estimate could be used to
assess whether there is evidence of an interaction effect. Instead of dichotomizing the
gene scores at their median values, the impact of treating the gene scores as continuous
variables to increase statistical power will also be investigated. Whether the gene scores
are dichotomized or not, the distribution of the gene scores will effect the power of the
study to detect the interaction term, and we will consider this in detail. For example,
if the genetic variants are rare, we would expect the distribution of the gene scores
to be skewed, and the numbers of participants in the 2 × 2 contingency table to be
unbalanced, resulting in reduced statistical power.
Throughout this Chapter, we will continue to make a distinction between a factorial
Mendelian randomization study that uses genetic variants as either: a) predictors
of the risk factors to estimate the interaction effect between two risk factors on an
outcome; or b) proxies for pharmacological interventions to detect interaction effects
between drug treatments. For scenario a), we will use the genetic variants as IVs to
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estimate the interaction effect between two risk factors, and for scenario b), we will
use the genetic variants as proxies for drug treatments to test for an interaction effect
between the variants and the outcome. We class these two study types as ‘factorial
Mendelian randomization’ as they both consider the detection and/or estimation of
an interaction effect. Since the primary aim of the analysis and role of the genetic
variants differ between the two scenarios, the methodological developments for these
study types will be considered separately.
5.3.5 Summary
In this Section, we have reviewed the literature on factorial Mendelian randomization,
and have found that the study design has been considered under two broad scenarios:
a) the genetic variants are used as predictors of the risk factors; and b) the genetic
variants are used as proxies for pharmacological interventions. However, there remain
significant gaps in the literature on this topic. The work presented in this Chapter will
contribute to the factorial Mendelian randomization literature by investigating how
interaction effects can be estimated under scenario a), and providing a more formal
framework for detecting interaction effects under scenario b).
5.4 Performing factorial Mendelian randomization
This Section is divided into two main parts: 1) investigating methodological challenges
of estimating statistical interactions when genetic variants are used as predictors of
the risk factors (Section 5.4.1); and 2) detecting interaction effects between pharma-
cological interventions when genetic variants are used as proxies for drug treatments
(Section 5.4.2).
In Section 5.4.1, we expand multivariable Mendelian randomization with two risk
factors to the factorial setting by outlining an approach to estimating the interaction
effect through TSLS regression using individual level data. The performance of the
TSLS regression model, and the suitability of applying Ference et al’s. [33] method
when the variants are used as predictors of the risk factors is considered in a simulation
study. Since summary level data is commonly used in Mendelian randomization, we
also consider applying a factorial framework to this type of data. Through theoretical
arguments and simulations, we show that standard summary level data cannot be
used in factorial Mendelian randomization to estimate the interaction effect of two risk
factors.
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In Section 5.4.2, we provide a formal framework for using genetic variants as
proxies for pharmacological interventions to detect statistical interactions between drug
treatments, and through simulations, we address the methodological issues outlined in
Section 5.3.4 in relation to the method proposed by Ference et al. [33].
We found that some of the distributions of the parameter estimates and standard
errors in the simulation studies considered in this Section were slightly positively skewed.
As such, we present the median values of the parameter estimates and standard errors
for all of the simulations performed in this Chapter. All of the code for the simulations
were written and performed by Jessica Rees in RStudio version 3.5.3 [86] using the
packages ivpack [140] and ggplot2 [141].
5.4.1 Genetic variants used as predictors of risk factors
Suppose we have two risk factors X1 and X2, an outcome Y , and unmeasured con-
founders U1 and U2 of the X1−Y and X2−Y associations. If there is a set of J genetic
variants Gj (j = 1, . . . , J), where each variant satisfies the following IV assumptions
for multivariable Mendelian randomization:
• IV1(M): the variant is associated with at least one of the risk factors X1 or X2,
• IV2(M): X1 and X2 are associated with at least one of the J genetic variants Gj
(j = 1, . . . , J),
• IV3(M): the variant is independent of all unmeasured confounders U1 and U2 of
the X1 − Y and X2 − Y associations, and
• IV4(M): the variant is independent of the outcome Y conditional on the risk
factors X1 and X2, and confounders U1 and U2 [28].
then the causal relationships between the risk factors and outcome can be assessed
through a multivariable Mendelian randomization analysis (Figure 5.2). From Fig-
ure 5.2, assuming that all of the relationships are linear on the additive scale, and the
genetic variants are uncorrelated (not in linkage disequilibrium), the outcome can be
modelled as:
E[Y |X1, X2, U1, U2] = θ0M + θ1MVX1 + θ2MVX2 + ζ1MVU1 + ζ2MVU2 , (5.5)
where θ1MV and θ2MV are the causal effects of the risk factors X1 and X2 on the
outcome Y , when conditioned on each other and U1 and U2, and ζ1MV and ζ2MV are
the effects of the unmeasured confounders U1 and U2 on the outcome. In Figure 5.2,
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we assume that X1 and X2 do not have causal effects on each other.
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Fig. 5.2 Directed acyclic graph illustrating a multivariable Mendelian randomization frame-
work for a set of genetic variants G, two risk factors X1 and X2, and outcome Y . The genetic
effects of Gj on X1 and X2 are β1j and β2j respectively, and the causal effects of the risk
factors X1 and X2 on the outcome Y is θ1MV and θ2MV . U1 and U2 represent the set of
unmeasured variables that confound the associations between X1−Y and X2−Y , and ζ1MV
and ζ2MV are the effects of the unmeasured confounders U1 and U2 on the outcome.
Estimates of the causal effects in Equation 5.5 can be obtained from individual-level
data using TSLS regression, with each Gj acting as an IV [28]. The same estimates
can also be obtained through the multivariable IVW method [80], where the J genetic
associations with Y are regressed against the genetic associations with X1 and X2 in a
multivariable weighted linear regression model (Section 2.6.3), with the intercept is set
to zero:
βˆYj = θ1MV βˆX1j + θ2MV βˆX2j + ϵMVj , weights = se(βˆYj)−2 , (5.6)
where βˆX1j, βˆX2j and βˆYj are estimates of the j genetic associations with X1, X2 and
Y , and se(βˆYj) are the standard errors of the genetic associations with Y .
A genetic variant is considered to be a strong instrument in a multivariable
Mendelian randomization analysis if: a) the variant is associated with both X1 and X2;
and b) the variant is jointly associated with X1 and X2 [82]. The first condition can
be assessed through the F-statistic of the J genetic variants Gj for X1 and X2. For
the second condition to hold, the variant must be able to predict the values of X1 after
predicting X2, and this can be assessed through the Sanderson-Windmeijer conditional
F-statistic of the J genetic variants Gj for X1 and X2 [83] (Section 2.6.3).
Equation 5.5 implies that there is no interaction of X1 and X2 on Y . However,
we may suspect that a statistical interaction does exist, and the outcome should be
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modelled as:
E[Y |X1, X2, X12, U1, U2] = θ0 + θ1X1 + θ2X2 + θ12X12 + ζ1U1 + ζ2U2 , (5.7)
where X12 is the product of the two risk factors X1 ×X2, and θ1 and θ2 are the main
causal effects of the risk factors X1 and X2 on the outcome Y , when conditioned
on each other and U1 and U2, and θ12 represents the additive statistical interaction
effect of X1 and X2 on Y . A factorial Mendelian randomization analysis is primarily
interested in estimating the interaction effect θ12. Including X12 in Equation 5.7 should
not invalidate the IV assumptions for multivariable Mendelian randomization if the
interaction is accounted for in the analysis using individual level data. The implication
of there being an interaction effect when using the summary level data will be discussed
towards the end of this Section.
The J genetic variants Gj (j = 1, . . . , J) consist of three separate sets of genetic
variants G1j (j = 1, . . . , J1), G2j (j = 1, . . . , J2) and Gcj (j = 1, . . . , Jc), where:
• G1 (bold variables represent vectors) are the variants associated with X1 only,
with genetic associations β1,
• G2 are the variants associated with X2 only, with genetic associations β2, and
• Gc are the set of cross-over variants that are associated with both X1 and X2,
with genetic associations β1c and β2c respectively.
The risk factors X1 and X2 can be written in terms of G1, G2, and Gc as:
E[X1|G1, Gc, U1] = β01 +
J1∑
j=1
β1jG1j +
Jc∑
j=1
β1cjGcj + U1 and
E[X2|G2, Gc, U2] = β02 +
J2∑
j=1
β2jG2j +
Jc∑
j=1
β2cjGcj + U2 ,
where G1 and Gc act as IVs for X1, and G2 and Gc act as IVs for X2. Although X12
is a function of the risk factors X1 and X2, X12 should be treated as a separate risk
factor, where the products of the IVs for X1 (G1 +Gc) and X2 (G2 +Gc) act as IVs
(Section 5.2.2).
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Individual level data
Suppose that we have individual level data on X1, X2, Y , and J genetic variants Gj
(j = 1, . . . , J), and we want to estimate θ1, θ2 and θ12 in Equation 5.7. To estimate
these effects, a TSLS regression model should be applied to the risk factors X1, X2
and X12, with G1, G2, Gc and (G1 +Gc) × (G2 +Gc) acting as IVs. To increase
statistical power to detect the main effects, the risk factors should be replaced with
their mean centred values (X1 − X¯1), (X2 − X¯2), and (X1 − X¯1)× (X2 − X¯2). If the
mean centred variables are used in the analysis, then the main effects θ1 and θ2 should
be interpreted as the marginal effects θ1M and θ2M of X1 and X2 on Y .
The number of product terms used as IVs for X12 is dependent on the number of
cross-over variants Jc. If there are no cross-over variants (Jc = 0), then the G1 ×G2
interaction terms could be used as IVs for X12. If Jc ≥ 1, then (G1 +Gc)× (G2 +Gc)
will consist of interaction and quadratic terms. Since we only need three IVs for
Equation 5.7 to be identifiable under the order condition (Section 5.2.2), a subset of
the product terms in (G1 +Gc)× (G2 +Gc), when Jc ≥ 0, could act as IVs for X12.
Rather than treating each of the genetic variants as individual IVs, the genetic
variants could be combined into two externally weighted gene scores GSX1 and GSX2
for X1 and X2:
GSX1 =
J1∑
j=1
β′1jG1j +
Jc∑
j=1
β′1cjGcj and
GSX2 =
J2∑
j=1
β′2jG2j +
Jc∑
j=1
β′2cjGcj ,
where β′1, β′1c , β′2, and β′2c are the genetic associations estimated from an external
dataset to act as weights in the gene scores. Note that GSX1 contains information on
G1 and Gc, whilst GSX2 contains information on G2 and Gc. The two gene scores
GSX1 and GSX2 and their product GSX1×GSX2 could then be used as IVs in the TSLS
regression model. Alternatively, the idea proposed by Ference et al. [33] to dichotomize
the gene scores at their median value could be applied, and the two binary variables
and their product be used as IVs in the TSLS regression model. By dichotomizing the
gene scores, a contingency table similar to Table 5.2 could be created, where:
• n00 are the individuals with GSX1i ≤ med(GSX1) and GSX2i ≤ med(GSX2), and
represents the group of individuals with genetically low measurements for both
X1 and X2,
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• n10 are the individuals with GSX1i > med(GSX1) and GSX2i ≤ med(GSX2), and
represents the group of individuals with genetically high measurements for X1
and genetically low measurements for X2,
• n01 are the individuals with GSX1i ≤ med(GSX1) and GSX2i > med(GSX2), and
represents the group of individuals with genetically low measurements for X1
and genetically high measurements for X2, and
• n11 are the individuals with GSX1i > med(GSX1) and GSX2i > med(GSX2), and
represents the group of individuals with genetically high measurements for both
X1 and X2.
Simulation study
The two risk factors X1 and X2 were generated for i = 1, 2, . . . , 10 000 participants
from the following data generating model:
X1i = 0.25 +
J1∑
j=1
β1jG1ji +
Jc∑
j=1
β1cjGcji + U1i + ϵ1i and
X2i = 0.3 +
J2∑
j=1
β2jG2ji +
Jc∑
j=1
β2cjGcji + U2i + ϵ2i , (5.8)
where G1 and G2 are the genetic variants associated with X1 and X2 respectively,
and Gc are the set of cross-over variants that are associated with both X1 and X2.
The genotypes (0, 1 or 2) were generated independently from binomial distributions
B(2,MAFj), where MAFj represents the minor allele frequency (MAF) of the jth
genetic variant, and was drawn from a uniform distribution of common genetic variation
U(0.1, 0.5). These bounds for the uniform distribution were chosen to ensure there was
a good range in the MAF as these were used to calculate the genetic associations (see
below). β1 and β1c represent the effects of the genetic variants G1 and Gc on X1, and
β2 and β2c represent the effects of the genetic variants G2 and Gc on X2. The genetic
associations were initially calculated so that G1 and Gc, and G2 and Gc, explained
σ21 = σ22 = 10% of the variance in X1 and X2 respectively. Given that genetic variants
tend to explain a small proportion of variation in risk factors, we acknowledge that σ21
and σ22 may be considered too large. To ensure that each genetic variant explained the
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same amount of variation in the risk factor, we rearranged:
var(G1j) = σ21 = 2β21jMAF1j(1−MAF1j) and
var(G2j) = σ22 = 2β22jMAF2j(1−MAF2j) ,
to calculate the genetic associations:
β1j =
√√√√ σ21/(J1 + Jc)
2×MAF1j(1−MAF1j) ,
βc1j =
√√√√ σ21/(J1 + Jc)
2×MAFcj(1−MAFcj) ,
β2j =
√√√√ σ22/(J2 + Jc)
2×MAF2j(1−MAF2j) ,
βc2j =
√√√√ σ22/(J2 + Jc)
2×MAFcj(1−MAFcj) .
U1 and U2 represent the set of unmeasured confounding variables of the X1 − Y
and X2 − Y associations. To ensure the unmeasured confounders explained 25% of
the variation in the risk factors, U1 and U2 were drawn independently from N (0, 0.25).
To fix the variances of X1 and X2 to one, the error terms ϵ1 and ϵ2 were generated
independently from a normal distribution with mean zero, and variances:
σ2ϵ1 = 1− σ21 − 0.25 and σ2ϵ2 = 1− σ22 − 0.25 .
The outcome Y was generated from:
Yi = θ0 + θ1X1i + θ2X2i + θ12X12i + 0.5U1i + 0.5U2i + ϵY i , (5.9)
where θ1 and θ2 represent the main effects of X1 and X2 on Y , and θ12 represents the
interaction effect of X1 and X2 on Y . X12 was generated by either: a) multiplying
X1 and X2; or b) multiplying the mean centred values of the risk factors (X1 − X¯1)
and (X2 − X¯2), where X¯1 and X¯2 are the mean values of X1 and X2. To ensure the
risk factors and unmeasured confounders explained less than a third of the variance in
the outcome, the error term ϵY was generated from a standard normal distribution
N (0, 1).
TSLS regression models were fitted to either: a) the directly generated values of
the risk factors (X1, X2, X12 = X1 ×X2); or b) the mean centred values of the risk
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factors (X1− X¯1, X2− X¯2, X12 = (X1− X¯1)× (X2− X¯2)). When the risk factors were
mean centred, the model estimated the marginal effects θ1M and θ2M of X1 and X2 on
Y , otherwise θ1 and θ2 were estimated. For example, when there were no cross-over
variants Jc = 0 the marginal effect θM1 is equal to the partial derivative of Equation 5.9
with respect to X1:
θM1 = θ1 + θ12E[X2] ,
and from Equation 5.8:
θM1 = θ1 + θ12E[0.3 +
J2∑
j=1
β2jG2j + U2 + ϵ2] .
Since U2 and ϵ2 were generated from normal distributions with means zero, and the
mean MAF for G2 will be 0.3 as it was generated from U(0.1, 0.5), it follows:
θM1 = θ1 + 0.3θ12 + J2θ12
(√
0.1/J2
2× 0.3× 0.7 × 0.3× 2
)
. (5.10)
Under the same argument, the marginal effect for θM2 is:
θM2 = θ2 + 0.25θ12 + J1θ12
(√
0.1/J1
2× 0.3× 0.7 × 0.3× 2
)
. (5.11)
The genetic variants were either treated as individual IVs or as a single instrument
in externally weighted gene scores GSX1 and GSX2 for X1 and X2. The external
weights for the gene scores were based on an independent set of 10 000 individuals,
and were produced from the same data generating model used for the main set of
participants. Since the same data generating model was used to create the individual
level data and the weights for the gene score, GSX1 and GSX2 represent the optimal
gene scores. The two gene scores GSX1 and GSX2 were dichotomized at their median
values to create two binary variables, and the numbers of participants in the groups
n00, n10, n01, and n11 were recorded. The following four sets of genetic variants were
used as IVs in separate TSLS regression models:
• Model 1 - full set of interactions: the J1, J2 and Jc genetic variants used
to generate X1 and X2, plus the unique interactions and quadratic terms of
(G1 +Gc)× (G2 +Gc).
• Model 2 - reduced set of interactions: the J1, J2 and Jc genetic variants used to
generate X1 and X2, plus the interactions from the product G1 ×G2.
146 Factorial Mendelian randomization
• Model 3 - continuous gene scores: the two weighted gene scores GSX1 and GSX2 ,
and their product GSX1 ×GSX2 .
• Model 4 - dichotomized gene scores: the two dichotomized gene scores, and their
product.
Model 1 represents the ‘gold standard’ (oracle) model as it includes all of the
variables used in the data generating model, whereas Models 2-4 are misspecified
and their performance should be compared to Model 1. However, we do discuss the
robustness of Model 1 to weak instrument bias. In Model 2, we have included a subset
of the product terms between the genetic variants to create a more realistic scenario
where the full set of relevant IVs are not included in the analysis. Model 3 considers
the effect of including all of the genetic variants into two separate weighted gene scores,
and finally, Model 4 considers the impact of dichotomizing the weighted gene scores as
suggested by Ference et al. [33] when the authors were investigating interaction effects
between drug treatments.
The data was generated 10 000 times with θ0 = 0.2, θ1 = 0.3, θ2 = 0.2, and
θ12 = 0.1, 0.3 and 0.5. A range of values for θ12 were chosen to consider the impact
this had on the results, and to ensure they were comparable to θ1 and θ2. Each risk
factor was associated with (J1 + Jc) = (J2 + Jc) = 10 genetic variants, and the number
of cross-over variants Jc was initially set to 0 to consider the scenario where none of
the genetic variants were associated with both risk factors. The correlation between
the predicted values of the risk factors and the predicted values of the product term
from the first stage regression were recorded. The analyses were re-performed on the
mean centred risk factors with θ12 = 0.3, and the number of cross-over variants set to
Jc = 1, 3, 5, 8 and 10. A range of values for Jc were chosen to allow the performance of
the models to be assessed on a sliding scale, starting with no genetic variants being
associated with both risk factors, to all of the genetic variants being associated with
both risk factors.
The following measurements were recorded for the estimates of θ1, θ2 and θ12:
median value; relative median bias; overall bias; standard deviation; median standard
error; power at the 5% significance level; and coverage of the 95% confidence interval.
The data was regenerated for σ21 = σ22 = 5% and 1%, when Jc = 0, 5 and 8, and the
analyses were reperformed on the directly generated values of the risk factors, and
estimates of the F-statistic and conditional F-statistic forX1, X2 andX12 were recorded.
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Results The number of genetic variants used as IVs in Models 1 and 2 are displayed
in Table 5.3. When none of the variants were associated with both risk factors (Jc = 0),
Models 1 and 2 were equivalent and had 10 IVs for X1, 10 IVs for X2 and 10× 10 IVs
for X12 in the model. As the number of cross-over variants increased, the number of
IVs in both models reduced, and this was particularly true for Model 2. When all of
the variants were associated with both X1 and X2, only 10 IVs were included in Model
2, whereas Model 1 had 64 IVs. Although Models 3 and 4 used three IVs, both gene
scores GSX1 and GSX2 contained information on 10 genetic variants irrespective of the
value of Jc.
Table 5.3 Number of instrumental variables for Models 1 and 2 by the number of cross-over
variants Jc.
Jc (J1 = J2)a
0 (10) 1 (9) 3 (7) 5 (5) 8 (2) 10 (0)
Model 1 - full set of interactions
Total number 120 119 114 105 84 65
First order 20 19 17 15 12 10
Interactions and quadratics 100 100 97 90 72 55
Model 2 - reduced set of interactions
Total number 120 100 66 40 16 10
First order 20 19 17 15 12 10
Interactions 100 81 49 25 4 0
aWhere Jc represents the number of genetic variants that were associated with both X1 and X2, and J1 and J2
represent the number of genetic variants associated with X1 and X2 respectively.
The results from the simulation study using 10 000 simulated datasets when Jc = 0
are presented in Table 5.4 (directly generated values of the risk factors) and Table 5.5
(mean centred values of the risk factors). For each model, the median estimate, the
relative median bias of the estimate, the bias of the estimate, the standard deviation
of the estimate, the median standard error, the statistical power to detect the effect at
a nominal 5% significance level, the coverage of the true effect for a 95% confidence
interval, and the median correlation between the predicted values from the first stage
regression were recoded in Tables 5.4 and 5.5. Figure 5.3 contains histograms of the
estimates and standard errors of the interaction term from Models 1, 3 and 4, when
Jc = 0 and θ12 = 0.3.
As expected, mean centring the risk factors substantially reduced the correlation
between the predicted values of the risk factors with the predicted values of the product
term, which helped to improve the precision of the main effect estimates, but had
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no impact on the interaction term. Although the coverage of the main effects in
Table 5.4 were at the nominal 95% level, there was under coverage in the marginal
effects, and this increased in severity as θ12 increased from 0.1 to 0.5 (Table 5.5) due
to the increased variability in the marginal effects (Equations 5.10 and 5.11). The
coverage of the interaction term was close to the nominal level of 95% for all models.
In terms of precision and relative median bias of the interaction term, Model 1/2
(when Jc = 0 Models 1 and 2 are equivalent) out performed Models 3 and 4 (Figure 5.3).
When θ12 = 0.3, Model 1/2 had 98.8% power to detect the interaction term, whereas
Models 3 and 4 had 77.5% and 41.8% respectively. Models 3 and 4 produced consistent
estimates of the marginal and interaction effects despite using the externally weighted
gene scores as IVs. There were noticeable differences in the power to detect the
interaction term when the gene scores were treated as binary variables (Model 4),
rather than continuous variables (Model 3). Since the gene scores were generated under
the ‘best-case’ scenario with the individual level data and weights being generated
from the same model, the discrepancy between the power of the continuous and binary
gene scores to detect the interaction term may increase under more realistic scenarios.
When θ12 = 0.1, Model 4 only had 8% power to detect the interaction effect, compared
to 33.7% and 15.4% for Models 1/2 and 3 respectively. Although the standard errors
of the interaction term for Model 1/2 were symmetric, the standard errors for Models
3 and 4 were skewed (Figure 5.3).
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Fig. 5.3 Estimates of the interaction effect (a) and its standard error (b) from the two stage least squares regression
models when there were no cross-over variants Jc = 0 and θ12 = 0.3, and the mean centred values of the risk factors
(X1 − X¯1, X2 − X¯2, X12 = (X1 − X¯1)× (X2 − X¯2)) were used in the models. The red lines in (a) represent the true
causal effect, and the red lines in (b) represent the median standard error.
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Table 5.4 Performance of the two stage least squares regression models with respect to
θ1, θ2 and θ12 when Jc = 0, and the directly generated values of the risk factors (X1, X2,
X12 = X1 ×X2) were used in the models.
med(θˆ) Rel bias Bias SD SE Power Cov Cora
Models 1 & 2b - full set of interactions
θ1=0.3 0.3013 0.2009 0.0017 0.0917 0.0910 90.2 95.0 0.6694
θ2=0.2 0.2022 0.3167 0.0019 0.0952 0.0945 57.1 94.9 0.6997
θ12=0.1 0.1101 0.4882 0.0096 0.0721 0.0718 33.7 94.6 -
θ1=0.3 0.3043 0.2027 0.0042 0.0918 0.0910 91.0 95.0 0.6695
θ2=0.2 0.2034 0.3172 0.0032 0.0947 0.0945 57.9 95.5 0.6991
θ12=0.3 0.3080 0.1629 0.0077 0.0722 0.0718 98.8 95.2 -
θ1=0.3 0.3048 0.2008 0.0044 0.0911 0.0909 90.7 95.2 0.6701
θ2=0.2 0.2050 0.3109 0.0043 0.0944 0.0945 58.4 95.2 0.6987
θ12=0.5 0.5073 0.0942 0.0076 0.0715 0.0718 100.0 95.2 -
Model 3 - continuous gene scores
θ1=0.3 0.2993 0.2944 -0.0018 0.1362 0.1333 61.4 95.4 0.6802
θ2=0.2 0.1991 0.4692 -0.0011 0.1415 0.1386 30.9 95.5 0.7115
θ12=0.1 0.1010 0.7270 0.0011 0.1113 0.1091 15.4 95.5 -
θ1=0.3 0.2998 0.2964 0.0012 0.1359 0.1332 61.9 95.6 0.6804
θ2=0.2 0.2019 0.4610 0.0008 0.1405 0.1387 31.5 95.8 0.7105
θ12=0.3 0.3000 0.2435 -0.0012 0.1106 0.1091 77.5 95.8 -
θ1=0.3 0.3004 0.2956 0.0001 0.1352 0.1331 61.5 95.4 0.6810
θ2=0.2 0.2008 0.4610 0.0005 0.1409 0.1385 30.7 95.6 0.7102
θ12=0.5 0.4995 0.1461 -0.0002 0.1107 0.1092 98.7 95.6 -
Model 4 - dichotomized gene scores
θ1=0.3 0.2986 0.4609 -0.0021 0.2155 0.2072 31.0 95.7 0.6855
θ2=0.2 0.1989 0.7167 -0.0010 0.2246 0.2168 15.0 96.2 0.7162
θ12=0.1 0.1022 1.1399 0.0010 0.1786 0.1720 8.0 95.9 -
θ1=0.3 0.3039 0.4601 0.0036 0.2145 0.2074 32.1 95.8 0.6840
θ2=0.2 0.2047 0.7220 0.0031 0.2236 0.2164 15.2 96.2 0.7149
θ12=0.3 0.2972 0.3851 -0.0032 0.1777 0.1722 41.8 96.0 -
θ1=0.3 0.3010 0.4618 -0.0008 0.2148 0.2073 31.4 96.2 0.6857
θ2=0.2 0.2002 0.7250 -0.0002 0.2233 0.2163 15.3 96.1 0.7147
θ12=0.5 0.5002 0.2309 0.0003 0.1776 0.1718 80.7 96.1 -
Abbreviations: Rel bias, relative median bias; SD, standard deviation; SE, standard error; Cov, coverage; Cor, corre-
lation.
aMedian correlation between the predicted values of the risk factor X1 or X2 and the predicted values of X12 from
the first stage regression of the TSLS model.
bWhen Jc = 0, Models 1 and 2 are equivalent.
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Table 5.5 Performance of the two stage least squares regression models with respect to θ1M ,
θ2M and θ12 when Jc = 0, and the mean centred values of the risk factors (X1− X¯1, X2− X¯2,
X12 = (X1 − X¯1)× (X2 − X¯2)) were used in the models.
med(θˆ) Rel bias Bias SD SE Power Cov Cora
Models 1 & 2b - full set of interactions
θ1M=0.4176 0.4311 0.0574 0.0136 0.0327 0.0320 100.0 92.3 0.0153
θ2M=0.3226 0.3370 0.0757 0.0143 0.0328 0.0320 100.0 91.9 0.0146
θ12=0.1 0.1101 0.4882 0.0096 0.0721 0.0718 33.7 94.6 -
θ1M=0.6527 0.6679 0.0454 0.0147 0.0408 0.0320 100.0 84.9 0.0142
θ2M=0.5677 0.5823 0.0518 0.0144 0.0413 0.0320 100.0 85.0 0.0155
θ12=0.3 0.3080 0.1629 0.0077 0.0722 0.0718 98.8 95.2 -
θ1M=0.8879 0.9044 0.0418 0.0163 0.0527 0.0320 100.0 74.4 0.0141
θ2M=0.8129 0.8290 0.0467 0.0165 0.0528 0.0320 100.0 73.9 0.0148
θ12=0.5 0.5073 0.0942 0.0076 0.0715 0.0718 100.0 95.2 -
Model 3 - continuous gene scores
θ1M=0.4176 0.4178 0.0555 -0.0000 0.0348 0.0343 100.0 94.7 0.0000
θ2M=0.3226 0.3234 0.0728 0.0008 0.0349 0.0343 100.0 94.4 0.0010
θ12=0.1 0.1010 0.7270 0.0011 0.1113 0.1091 15.4 95.5 -
θ1M=0.6527 0.6539 0.0442 0.0013 0.0424 0.0343 100.0 88.9 -0.0015
θ2M=0.5677 0.5691 0.0506 0.0012 0.0431 0.0343 100.0 87.9 0.0011
θ12=0.3 0.3000 0.2435 -0.0012 0.1106 0.1091 77.5 95.8 -
θ1M=0.8879 0.8906 0.0410 0.0029 0.0539 0.0343 100.0 78.5 -0.0020
θ2M=0.8129 0.8165 0.0459 0.0033 0.0543 0.0343 100.0 79.0 -0.0001
θ12=0.5 0.4995 0.1461 -0.0002 0.1107 0.1092 98.7 95.6 -
Model 4 - dichotomized gene scores
θ1M=0.4176 0.4173 0.0705 -0.0006 0.0438 0.0435 100.0 95.1 0.0002
θ2M=0.3226 0.3236 0.0929 0.0008 0.0438 0.0434 100.0 95.0 0.0027
θ12=0.1 0.1022 1.1399 0.0010 0.1786 0.1720 8.0 95.9 -
θ1M=0.6527 0.6538 0.0511 0.0012 0.0496 0.0435 100.0 91.5 -0.0013
θ2M=0.5677 0.5687 0.0594 0.0010 0.0506 0.0435 100.0 91.0 0.0034
θ12=0.3 0.2972 0.3851 -0.0032 0.1777 0.1722 41.8 96.0 -
θ1M=0.8879 0.8913 0.0458 0.0029 0.0597 0.0435 100.0 84.5
θ2M=0.8129 0.8165 0.0502 0.0033 0.0603 0.0435 100.0 84.5 0.0011
θ12=0.5 0.5002 0.2309 0.0003 0.1776 0.1718 80.7 96.1 -
Abbreviations: Rel bias, relative median bias; SD, standard deviation; SE, standard error; Cov, coverage; Cor, corre-
lation.
aMedian correlation between the predicted values of the centred risk factor X1 − X¯1 or X2 − X¯2 and the predicted
values of X12 from the first stage regression of the TSLS model.
bWhen Jc = 0, Models 1 and 2 are equivalent.
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The number of participants contained in each cell of the 2× 2 contingency table
when the gene scores were dichotomized at their median values for Model 4 are
contained in Table 5.6. The results from the simulated datasets for when θ12 = 0.3
and Jc = 0, 1, 3, 5, 8 and 10 are presented in Table 5.7. For each model, the median
estimate, the relative median bias of the estimate, the bias of the estimate, the standard
deviation of the estimate, the median standard error, the statistical power to detect
the effect at a nominal 5% significance level, and the coverage of the true effect for
a 95% confidence interval for the interaction term are presented in Table 5.7, along
with the total number of IVs included in the model. Figure 5.4 contains the median
standard error of the interaction effect across the four models for the different values
of Jc.
All of the models produced consistent estimates of θ12, and had good coverage
properties for all values of Jc (Table 5.7). Increasing Jc had no impact on the estimates
from Model 1, or the power to detect the interaction term (Figure 5.4), which never
dropped below 98.8%. However, increasing the number of cross-over variants did reduce
the power to detect θ12 in Model 2, where the power decreased from 96.7% (Jc = 1) to
8.7% (Jc = 10).
When the gene scores were treated as continuous variables (Model 3), the power to
detect the interaction term increased from 77.5% (Jc = 1) to 93% (Jc = 8), and then
dropped to 42.7% when Jc = 10. When the gene scores were dichotomized (Model
4), the power to detect θ12 decreased from 42.2% (Jc = 1) to 0.7% (Jc = 10). This
reduction in power is reflected in Table 5.6, where the mean numbers of participants
in groups n00, n10, n01, and n11 were more unbalanced for larger values of Jc. When
Jc = 0, the number of participants were evenly distributed across the four groups, but
when Jc = 10, n10 and n01 only contained 2.2% of the data each.
Table 5.6 Mean numbers (%) of participants in the groups n00, n10, n01, and n11 when the
gene scores were dictohomized at their median values by the number of cross-over variants Jc.
Mean numbers (%) of participants
Jc (J1 = J2)a n00 n10 n01 n11
0 (10) 2,502.3 (25.0) 2,497.7 (25.0) 2,497.7 (25.0) 2,502.3 (25.0)
1 (9) 2,658.0 (26.6) 2,342.0 (23.4) 2,342.0 (23.4) 2,658.0 (26.6)
3 (7) 2,979.9 (29.8) 2,020.1 (20.2) 2,020.1 (20.2) 2,979.9 (29.8)
5 (5) 3,323.0 (33.2) 1,677.0 (16.8) 1,677.0 (16.8) 3,322.9 (33.2)
8 (2) 3,951.9 (39.5) 1,048.5 (10.5) 1,048.5 (10.5) 3,951.2 (39.5)
10 (0) 4,781.6 (47.8) 220.1 (2.2) 220.1 (2.2) 4,778.3 (47.8)
aWhere Jc represents the number of genetic variants that were associated with both X1 and X2, and J1 and J2
represent the number of genetic variants associated with X1 and X2 respectively.
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Table 5.7 Performance of the four two stage least squares regression models with respect to
the interaction when θ12 = 0.3 and Jc = 0, 1, 3, 5, 8 and 10.
med(θˆ12) Rel bias Bias SD SE Power Coverage Jc IV total
Model 1 - full set of interactions
0.3080 0.1629 0.0077 0.0722 0.0718 98.8 95.2 0a 120
0.3080 0.1647 0.0081 0.0723 0.0719 98.8 95.0 1 119
0.3090 0.1654 0.0081 0.0717 0.0716 98.9 95.3 3 114
0.3078 0.1655 0.0077 0.0716 0.0707 98.9 94.9 5 105
0.3073 0.1548 0.0071 0.0682 0.0687 99.3 95.2 8 84
0.3056 0.1497 0.0055 0.0670 0.0673 99.2 95.3 10 65
Model 2 - reduced set of interactions
0.3073 0.1800 0.0074 0.0804 0.0794 96.7 94.9 1 100
0.3088 0.2225 0.0077 0.1003 0.0997 86.1 95.2 3 66
0.3056 0.2958 0.0058 0.1340 0.1334 63.2 95.7 5 40
0.3054 0.5389 0.0068 0.2520 0.2471 23.9 97.1 8 16
0.3057 0.7879 0.0091 0.3883 0.3891 8.7 99.3 10 10
Model 3 - continuous gene scores
0.3000 0.2435 -0.0012 0.1106 0.1091 77.5 95.8 0 3
0.3005 0.2446 -0.0002 0.1111 0.1088 77.8 95.4 1 3
0.2998 0.2305 -0.0010 0.1051 0.1048 81.0 95.6 3 3
0.3015 0.2199 0.0019 0.0997 0.0980 85.6 95.5 5 3
0.3003 0.1889 0.0005 0.0857 0.0858 93.0 95.8 8 3
0.2993 0.2854 -0.3764 32.31 0.1711 42.7 99.2 10 3
Model 4 - dichotomized gene scores
0.2972 0.3851 -0.0032 0.1777 0.1722 41.8 96.0 0 3
0.3028 0.3780 -0.0002 0.1757 0.1724 42.2 96.3 1 3
0.3002 0.3874 0.0005 0.1818 0.1773 39.8 96.4 3 3
0.3005 0.4177 0.0016 0.1948 0.1884 36.6 96.6 5 3
0.3007 0.5236 0.0009 0.2474 0.2340 25.7 97.2 8 3
0.2896 1.855 0.5258 133.5 1.3578 0.7 100.0 10 3
Abbreviations: Rel bias, relative median bias; SD, standard deviation; SE, standard error; Cov, coverage; IV, instru-
mental variable.
aWhen Jc = 0, Models 1 and 2 are equivalent.
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Fig. 5.4 Median standard errors of the interaction term when θ12 = 0.3 for the four two
stage least squares regression models when Jc was 0, 1, 3, 5, 8 and 10.
The results from the simulated datasets for when θ1 = 0.3, and the amount of
variance in X1 and X2 explained by the genetic variants was σ21=σ22=10%, 5% and 1%
are displayed in Table 5.8 (Jc = 0), Table 5.9 (Jc = 5), and Table 5.10 (Jc = 8). For
θ1, θ2 and θ12, the median estimate, the relative median bias of the estimate, the bias
of the estimate, the standard deviation of the estimate, the median standard error,
the statistical power to detect the effect at a nominal 5% significance level, and the
coverage of the true effect for a 95% confidence interval are presented in Tables 5.8 to
5.10. The mean F-statistic and mean Sanderson-Windmeijer conditional F-statistic for
X1, X2 and X12 are also recorded in Tables 5.8 to 5.10. For ease of comparison, the
mean F-statistic, mean conditional F-statistic, and median estimates for θ1, θ2 and θ12
are presented in Table 5.11 for all values of σ21, σ22 and Jc.
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As the number of cross-over variants increased, the mean F-statistic increased
for all models when σ21=σ22=10%, 5% and 1% (Table 5.11). Except for Model 4, the
conditional F-statistic either increased or remained the same with more cross-over
variants. Increasing Jc had a greater influence on the conditional F-statistic for X12
than X1 or X2. For all scenarios considered, Model 1 consistently had the smallest
mean F-statistic and mean conditional F-statistic, whilst Model 3 always had the
largest.
As the amount of variance explained by the genetic variants in X1 and X2 decreased
from 10% to 1%, the mean F-statistic and conditional F-statistic decreased for all
models when Jc = 0, 5 and 8. When the mean F-statistic was less than 10, the main
effect terms θ1 and θ2 suffered from weak instrument bias for Models 1 and 2. The
mean F-statistic never dropped below 10 for Models 3 and 4 for all of the scenarios
considered. The reduction in the mean F-statistic as σ21 and σ22 decreased had no
impact on the estimates for θ12 for Models 1 or 2. There was slight bias in the estimates
for θ12 when σ21 = σ22=1% for Models 3 and 4.
As the number of cross-over variants increased, the power to detect the main effects
θ1 and θ2 decreased for all models except Model 3 (Tables 5.8 to 5.10). The impact
of increasing Jc on the power to detect θ12 across the four TSLS regression models
has already been discussed (Table 5.7), and the same conclusions are observed for
σ21=σ22=5% and 1%. As σ21 and σ22 decreased, the power to detect the interaction
term decreased for all models. Model 1 was least affected by the reduction in variance
explained, whereas the power to detect θ12 in Models 3 and 4 decreased significantly
for all values of Jc as σ21 and σ22 decreased. When Jc = 0, the power to detect the
interaction term for Model 3 when the variants explained 10% of the variance in the
risk factors was 77.5%, and this reduced to 0.7% when 1% of the variance was explained.
The lowest power to detect the interaction for Model 1 was 74.7% when Jc = 10, and
1% of the variances in X1 and X2 were explained.
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Table 5.8 Performance of the two stage least squares regression models by the amount of
variance the genetic variants G1 and G2 explained in X1 and X2 when θ1 = 0.3, θ2 = 0.2,
θ12 = 0.3 and Jc = 0, and the directly generated values of the risk factors (X1, X2,
X12 = X1 ×X2) were used in the models.
F-stata CF-stata med(θˆ) Rel bias Bias SD SE Pow Cov
G1 and G2 explained 10% of the variance in X1 and X2
Models 1 & 2b - full set of interactions
θ1 10.3 (0.6) 2.1 (0.3) 0.3043 0.2027 0.0042 0.0918 0.0910 91.0 95.0
θ2 10.3 (0.6) 2.1 (0.3) 0.2034 0.3172 0.0032 0.0947 0.0945 57.9 95.5
θ12 8.1 (0.6) 1.9 (0.2) 0.3080 0.1629 0.0077 0.0722 0.0718 98.8 95.2
Model 3 - continuous gene scores
θ1 364.2 (23.4) 104.5 (25.6) 0.2998 0.2964 0.0012 0.1359 0.1332 61.9 95.6
θ2 364.5 (23.2) 103.9 (25.3) 0.2019 0.4610 0.0008 0.1405 0.1387 31.5 95.8
θ12 273.7 (22.4) 97.8 (22.8) 0.3000 0.2435 -0.0012 0.1106 0.1091 77.5 95.8
Model 4 - dichotomized gene scores
θ1 224.2 (17.7) 41.9 (13.4) 0.3039 0.4601 0.0036 0.2145 0.2074 32.1 95.8
θ2 224.4 (17.7) 41.7 (13.3) 0.2047 0.7220 0.0031 0.2236 0.2164 15.2 96.2
θ12 168.2 (16.3) 40.0 (12.4) 0.2972 0.3851 -0.0032 0.1777 0.1722 41.8 96.0
G1 and G2 explained 5% of the variance in X1 and X2
Models 1 & 2b - full set of interactions
θ1 5.4 (0.4) 1.5 (0.2) 0.3174 0.2093 0.0169 0.0931 0.0920 92.4 94.5
θ2 5.4 (0.4) 1.4 (0.2) 0.2166 0.3220 0.0169 0.0957 0.0959 62.0 94.8
θ12 3.9 (0.4) 1.2 (0.2) 0.3087 0.1981 0.0074 0.0889 0.0888 92.8 95.0
Model 3 - continuous gene scores
θ1 170.2 (15.5) 25.4 (11.7) 0.2988 0.4733 -0.0026 0.2298 0.2121 29.9 96.9
θ2 170.1 (15.7) 25.2 (11.5) 0.1985 0.7494 -0.0026 0.2421 0.2237 13.8 96.9
θ12 109.4 (13.3) 23.8 (10.4) 0.3020 0.5061 0.0020 0.2458 0.2276 26.7 96.9
Model 4 - dichotomized gene scores
θ1 107.3 (12.2) 10.7 (6.7) 0.2970 0.7506 0.0382 3.928 0.3367 12.6 98.9
θ2 106.9 (12.0) 10.6 (6.6) 0.1948 1.181 0.0357 3.804 0.3551 5.4 98.7
θ12 68.8 (10.2) 10.2 (6.1) 0.3033 0.8104 -0.0404 4.065 0.3654 10.8 98.8
G1 and G2 explained 1% of the variance in X1 and X2
Models 1 & 2b - full set of interactions
θ1 1.8 (0.2) 1.4 (0.2) 0.3681 0.2637 0.0677 0.0910 0.0901 97.7 88.4
θ2 1.8 (0.2) 1.4 (0.2) 0.2670 0.3987 0.0673 0.0930 0.0930 81.4 88.6
θ12 1.4 (0.2) 1.0 (0.1) 0.3029 0.2152 0.0012 0.0971 0.0972 86.4 95.4
Model 3 - continuous gene scores
θ1 29.5 (6.4) 1.9 (2.9) 0.2854 1.446 0.0373 29.26 0.8411 2.8 99.9
θ2 29.4 (6.4) 1.9 (2.8) 0.1883 2.379 0.0320 31.58 0.9203 1.0 99.9
θ12 12.3 (4.1) 1.6 (2.1) 0.3185 2.655 -0.0196 52.32 1.537 0.7 100.0
Model 4 - dichotomized gene scores
θ1 19.1 (5.1) 1.6 (2.8) 0.2992 1.690 -0.0787 123.8 1.063 1.9 99.9
θ2 19.0 (5.0) 1.5 (2.4) 0.1930 2.785 0.7563 217.5 1.163 0.6 100.0
θ12 8.1 (3.3) 1.2 (1.7) 0.3121 3.069 -1.376 347.4 1.933 0.3 100.0
Abbreviations: F-stat, F-statistic; CF-stat, conditional F-statistic; Rel bias, relative median bias; SD, standard devia-
tion; SE, standard error; Pow, power; Cov, coverage.
aThe F-statistic and conditional F-statistic were calculated for X1, X2, and X12.
bWhen Jc = 0, Models 1 and 2 are equivalent.
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Table 5.9 Performance of the two stage least squares regression models by the amount
of variance the genetic variants G1, G2 and Gc explained in X1 and X2 when θ1 = 0.3,
θ2 = 0.2, θ12 = 0.3 and Jc = 5, and the directly generated values of the risk factors (X1, X2,
X12 = X1 ×X2) were used in the models.
F-stata CF-stata med(θˆ) Rel bias Bias SD SE Pow Cov
G1 +Gc and G2 +Gc explained 10% of the variance in X1 and X2
Model 1 - full set of interactions
θ1 11.6 (0.7) 2.5 (0.4) 0.2981 0.2091 -0.0011 0.0933 0.0927 89.1 95.0
θ2 11.6 (0.7) 2.5 (0.4) 0.1988 0.3178 -0.0015 0.0955 0.0960 55.0 95.5
θ12 13.4 (0.9) 2.2 (0.3) 0.3074 0.1588 0.0076 0.0707 0.0706 99.0 95.0
Model 2 - reduced set of interactions
θ1 28.8 (1.8) 2.6 (0.4) 0.2970 0.3677 -0.0045 0.1664 0.1649 44.2 95.8
θ2 28.8 (1.8) 2.6 (0.4) 0.1966 0.5672 -0.0049 0.1719 0.1715 21.0 95.9
θ12 32.6 (2.1) 2.3 (0.3) 0.3056 0.2965 0.0062 0.1337 0.1333 63.4 95.8
Model 3 - continuous gene scores
θ1 366.4 (23.2) 131.8 (30.9) 0.2993 0.2848 -0.0006 0.1272 0.1244 67.0 95.4
θ2 366.3 (23.4) 131.0 (30.7) 0.1992 0.4385 -0.0005 0.1314 0.1293 35.1 95.4
θ12 426.6 (29.1) 120.9 (26.9) 0.3008 0.2240 0.0003 0.1000 0.0978 84.8 95.4
Model 4 - dichotomized gene scores
θ1 233.5 (18.1) 35.8 (12.4) 0.2984 0.5087 -0.0027 0.2399 0.2302 25.9 96.4
θ2 233.5 (18.2) 35.6 (12.3) 0.2005 0.7954 -0.0019 0.2482 0.2396 13.0 96.4
θ12 284.1 (21.6) 33.8 (11.2) 0.3006 0.4126 0.0017 0.1950 0.1877 36.8 96.4
G1 +Gc and G2 +Gc explained 5% of the variance in X1 and X2
Model 1 - full set of interactions
θ1 6.0 (0.5) 1.6 (0.2) 0.3052 0.2184 0.0073 0.0980 0.0983 87.7 95.2
θ2 6.0 (0.5) 1.5 (0.2) 0.2078 0.3347 0.0069 0.1018 0.1022 53.3 95.2
θ12 6.1 (0.5) 1.3 (0.2) 0.3097 0.2065 0.0088 0.0925 0.0919 91.3 95.3
Model 2 - reduced set of interactions
θ1 14.2 (1.2) 1.6 (0.3) 0.2982 0.3577 -0.0005 0.1600 0.1588 48.4 96.3
θ2 14.2 (1.2) 1.6 (0.3) 0.1994 0.5431 -0.0001 0.1665 0.1664 22.7 96.1
θ12 13.9 (1.3) 1.4 (0.2) 0.3087 0.3591 0.0071 0.1621 0.1615 49.0 96.1
Model 3 - continuous gene scores
θ1 171.8 (15.6) 32.9 (14.1) 0.3014 0.4376 0.0012 0.2078 0.1951 35.7 96.4
θ2 172.1 (15.4) 32.6 (13.9) 0.2041 0.6828 0.0026 0.2169 0.2043 16.9 96.5
θ12 171.7 (17.6) 30.0 (12.0) 0.2981 0.4558 -0.0021 0.2147 0.2010 32.6 96.5
Model 4 - dichotomized gene scores
θ1 111.9 (12.5) 9.5 (6.4) 0.2933 0.8209 -0.0136 0.8024 0.3732 10.2 99.1
θ2 112.2 (12.3) 9.4 (6.3) 0.1981 1.2850 -0.0120 0.8127 0.3926 4.6 98.9
θ12 117.6 (13.5) 8.9 (5.7) 0.3066 0.8749 0.0135 0.8619 0.3967 9.6 99.1
G1 +Gc and G2 +Gc explained 1% of the variance in X1 and X2
Model 1 - full set of interactions
θ1 2.0 (0.2) 1.4 (0.2) 0.3504 0.2507 0.0502 0.0975 0.0971 94.4 92.0
θ2 2.0 (0.2) 1.3 (0.2) 0.2478 0.3740 0.0485 0.1003 0.1002 69.6 92.2
θ12 1.6 (0.2) 1.0 (0.1) 0.3037 0.2362 0.0028 0.1051 0.1043 82.0 95.3
Model 2 - reduced set of interactions
θ1 3.5 (0.6) 1.4 (0.2) 0.3225 0.3105 0.0223 0.1398 0.1395 63.8 95.6
θ2 3.5 (0.5) 1.4 (0.2) 0.2243 0.4832 0.0227 0.1459 0.1457 34.3 95.7
θ12 2.6 (0.5) 1.1 (0.1) 0.3036 0.3886 0.0040 0.1771 0.1758 41.8 96.1
Model 3 - continuous gene scores
θ1 31.0 (6.6) 2.5 (3.7) 0.2912 1.353 0.4689 47.33 0.7448 3.6 99.9
θ2 30.9 (6.5) 2.3 (3.4) 0.1939 2.201 0.4324 41.15 0.8014 1.1 99.9
θ12 19.9 (5.4) 1.9 (2.4) 0.3030 2.399 -0.6582 72.69 1.315 0.6 99.9
Model 4 - dichotomized gene scores
θ1 20.9 (5.3) 1.6 (2.9) 0.2967 1.760 0.4713 65.97 1.108 1.5 99.9
θ2 20.8 (5.2) 1.5 (2.5) 0.1959 2.887 0.4772 54.84 1.208 0.4 100.0
θ12 14.1 (4.4) 1.2 (1.6) 0.3096 3.205 -0.8906 105.7 1.991 0.2 100.0
Abbreviations: F-stat, F-statistic; CF-stat, conditional F-statistic; Rel bias, relative median bias; SD, standard devia-
tion; SE, standard error; Pow, power; Cov, coverage.
aThe F-statistic and conditional F-statistic were calculated for X1, X2, and X12.
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Table 5.10 Performance of the two stage least squares regression models by the amount
of variance the genetic variants G1, G2 and Gc explained in X1 and X2 when θ1 = 0.3,
θ2 = 0.2, θ12 = 0.3 and Jc = 8, and the directly generated values of the risk factors (X1, X2,
X12 = X1 ×X2) were used in the models.
F-stata CF-stata med(θˆ) Rel bias Bias SD SE Pow Cov
G1 +Gc and G2 +Gc explained 10% of the variance in X1 and X2
Model 1 - full set of interactions
θ1 14.2 (0.9) 3.2 (0.4) 0.2966 0.2143 -0.0029 0.0965 0.0967 86.1 95.4
θ2 14.2 (0.8) 3.2 (0.4) 0.1971 0.3324 -0.0038 0.0993 0.0997 50.9 95.4
θ12 19.9 (1.2) 3.0 (0.4) 0.3073 0.1548 0.0071 0.0682 0.0687 99.3 95.2
Model 2 - reduced set of interactions
θ1 70.4 (4.4) 3.6 (0.5) 0.2949 0.6673 -0.0071 0.3126 0.3047 16.1 97.0
θ2 70.5 (4.4) 3.6 (0.5) 0.1914 1.0321 -0.0075 0.3233 0.3168 8.3 97.3
θ12 96.2 (5.8) 3.4 (0.5) 0.3054 0.5389 0.0068 0.2520 0.2471 23.9 97.1
Model 3 - continuous gene scores
θ1 367.3 (23.5) 168.0 (33.0) 0.2989 0.2616 -0.0004 0.1190 0.1191 71.4 95.5
θ2 368.0 (23.2) 167.3 (32.8) 0.1996 0.4042 -0.0011 0.1223 0.1227 36.9 95.3
θ12 520.7 (32.8) 156.4 (31.7) 0.3003 0.1889 0.0005 0.0857 0.0858 93.0 95.8
Model 4 - dichotomized gene scores
θ1 243.2 (18.7) 24.2 (10.3) 0.2979 0.6628 -0.0023 0.3134 0.2981 16.4 97.0
θ2 243.8 (18.7) 24.1 (10.1) 0.2007 1.018 -0.0008 0.3253 0.3091 8.5 97.0
θ12 340.8 (24.2) 22.1 (8.9) 0.3007 0.5236 0.0009 0.2474 0.2340 25.7 97.2
G1 +Gc and G2 +Gc explained 5% of the variance in X1 and X2
Models 1 - full set of interactions
θ1 7.3 (0.6) 1.7 (0.3) 0.3047 0.2430 0.0035 0.1098 0.1095 79.2 95.2
θ2 7.3 (0.6) 1.7 (0.3) 0.2039 0.3747 0.0041 0.1122 0.1135 43.7 95.6
θ12 8.7 (0.7) 1.5 (0.2) 0.3072 0.2139 0.0070 0.0962 0.0966 88.6 95.4
Model 2 - reduced set of interactions
θ1 33.9 (3.0) 2.0 (0.3) 0.2977 0.5994 -0.0011 0.2825 0.2759 18.6 97.8
θ2 33.9 (3.0) 1.9 (0.3) 0.1974 0.9480 0.0012 0.2964 0.2896 8.9 97.8
θ12 39.7 (3.5) 1.7 (0.3) 0.3028 0.6108 0.0022 0.2906 0.2849 18.1 98.1
Model 3 - continuous gene scores
θ1 173.1 (15.7) 44.6 (16.9) 0.2998 0.4113 0.0003 0.1926 0.1844 38.0 96.1
θ2 173.1 (15.6) 44.0 (16.7) 0.2035 0.6260 0.0026 0.1973 0.1920 18.2 96.2
θ12 209.5 (19.7) 38.5 (14.1) 0.2977 0.3901 -0.0016 0.1832 0.1759 40.5 96.5
Model 4 - dichotomized gene scores
θ1 117.5 (12.7) 6.7 (5.5) 0.3056 1.074 -0.2320 20.77 0.4940 5.7 99.3
θ2 117.4 (12.8) 6.7 (5.4) 0.2061 1.664 -0.2843 25.93 0.5204 2.5 99.5
θ12 142.4 (14.9) 5.9 (4.5) 0.2983 1.109 0.2829 25.47 0.5114 4.8 99.6
G1 +Gc and G2 +Gc explained 1% of the variance in X1 and X2
Models 1 - full set of interactions
θ1 2.2 (0.3) 1.3 (0.2) 0.3368 0.2633 0.0374 0.1117 0.1105 85.8 94.0
θ2 2.2 (0.3) 1.2 (0.2) 0.2362 0.3949 0.0372 0.1134 0.1140 54.8 94.0
θ12 1.9 (0.3) 1.0 (0.2) 0.3056 0.2546 0.0050 0.1173 0.1169 74.7 95.2
Model 2 - reduced set of interactions
θ1 7.3 (1.3) 1.4 (0.2) 0.3113 0.4897 0.0087 0.2292 0.2261 28.5 97.4
θ2 7.3 (1.3) 1.4 (0.2) 0.2077 0.7600 0.0074 0.2388 0.2373 12.7 97.6
θ12 5.6 (1.2) 1.2 (0.2) 0.3066 0.6499 0.0033 0.3054 0.3042 15.6 98.2
Model 3 - continuous gene scores
θ1 31.9 (6.6) 2.9 (3.9) 0.3048 1.339 -0.7866 95.56 0.7330 2.9 99.8
θ2 32.0 (6.6) 2.8 (3.8) 0.2129 2.117 -1.464 141.5 0.7834 1.0 99.8
θ12 24.5 (5.9) 2.1 (2.5) 0.2868 2.170 2.167 220.6 1.196 0.8 100.0
Model 4 - dichotomized gene scores
θ1 22.5 (5.5) 1.3 (2.1) 0.3099 2.113 -0.4121 26.77 1.486 0.8 99.9
θ2 22.5 (5.5) 1.3 (2.2) 0.2035 3.358 0.0140 27.80 1.619 0.2 100.0
θ12 17.5 (4.8) 1.0 (1.4) 0.2851 3.203 0.4207 45.99 2.334 0.1 100.0
Abbreviations: F-stat, F-statistic; CF-stat, conditional F-statistic; Rel bias, relative median bias; SD, standard devia-
tion; SE, standard error; Pow, power; Cov, coverage.
aThe F-statistic and conditional F-statistic were calculated for X1, X2, and X12.
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Table 5.11 Summary of the performance of the two stage least squares regression models by the amount
of variance the genetic variants G1, G2 and Gc explained in X1 and X2 when θ1 = 0.3, θ2 = 0.2, θ12 = 0.3
and Jc = 0, 5 and 8, and the directly generated values of the risk factors (X1, X2, X12 = X1 ×X2) were
used in the models.
10% variance explained 5% variance explained 1% variance explained
F-stata CF-stata med(θˆ) F-stat CF-stat med(θˆ) F-stat CF-stat med(θˆ)
Jc = 0
Models 1 & 2b - full set of interactions
θ1 10.3 (0.6) 2.1 (0.3) 0.3043 5.4 (0.4) 1.5 (0.2) 0.3174 1.8 (0.2) 1.4 (0.2) 0.3681
θ2 10.3 (0.6) 2.1 (0.3) 0.2034 5.4 (0.4) 1.4 (0.2) 0.2166 1.8 (0.2) 1.4 (0.2) 0.2670
θ12 8.1 (0.6) 1.9 (0.2) 0.3080 3.9 (0.4) 1.2 (0.2) 0.3087 1.4 (0.2) 1.0 (0.1) 0.3029
Model 3 - continuous gene scores
θ1 364.2 (23.4) 104.5 (25.6) 0.2998 170.2 (15.5) 25.4 (11.7) 0.2988 29.5 (6.4) 1.9 (2.9) 0.2854
θ2 364.5 (23.2) 103.9 (25.3) 0.2019 170.1 (15.7) 25.2 (11.5) 0.1985 29.4 (6.4) 1.9 (2.8) 0.1883
θ12 273.7 (22.4) 97.8 (22.8) 0.3000 109.4 (13.3) 23.8 (10.4) 0.3020 12.3 (4.1) 1.6 (2.1) 0.3185
Model 4 - dichotomized gene scores
θ1 224.2 (17.7) 41.9 (13.4) 0.3039 107.3 (12.2) 10.7 (6.7) 0.2970 19.1 (5.1) 1.6 (2.8) 0.2992
θ2 224.4 (17.7) 41.7 (13.3) 0.2047 106.9 (12.0) 10.6 (6.6) 0.1948 19.0 (5.0) 1.5 (2.4) 0.1930
θ12 168.2 (16.3) 40.0 (12.4) 0.2972 68.8 (10.2) 10.2 (6.1) 0.3033 8.1 (3.3) 1.2 (1.7) 0.3121
Jc = 5
Models 1 - full set of interactions
θ1 11.6 (0.7) 2.5 (0.4) 0.2981 6.0 (0.5) 1.6 (0.2) 0.3052 2.0 (0.2) 1.4 (0.2) 0.3504
θ2 11.6 (0.7) 2.5 (0.4) 0.1988 6.0 (0.5) 1.5 (0.2) 0.2078 2.0 (0.2) 1.3 (0.2) 0.2478
θ12 13.4 (0.9) 2.2 (0.3) 0.3074 6.1 (0.5) 1.3 (0.2) 0.3097 1.6 (0.2) 1.0 (0.1) 0.3037
Model 2 - reduced set of interactions
θ1 28.8 (1.8) 2.6 (0.4) 0.2970 14.2 (1.2) 1.6 (0.3) 0.2982 3.5 (0.6) 1.4 (0.2) 0.3225
θ2 28.8 (1.8) 2.6 (0.4) 0.1966 14.2 (1.2) 1.6 (0.3) 0.1994 3.5 (0.5) 1.4 (0.2) 0.2243
θ12 32.6 (2.1) 2.3 (0.3) 0.3056 13.9 (1.3) 1.4 (0.2) 0.3087 2.6 (0.5) 1.1 (0.1) 0.3036
Model 3 - continuous gene scores
θ1 366.4 (23.2) 131.8 (30.9) 0.2993 171.8 (15.6) 32.9 (14.1) 0.3014 31.0 (6.6) 2.5 (3.7) 0.2912
θ2 366.3 (23.4) 131.0 (30.7) 0.1992 172.1 (15.4) 32.6 (13.9) 0.2041 30.9 (6.5) 2.3 (3.4) 0.1939
θ12 426.6 (29.1) 120.9 (26.9) 0.3008 171.7 (17.6) 30.0 (12.0) 0.2981 19.9 (5.4) 1.9 (2.4) 0.3030
Model 4 - dichotomized gene scores
θ1 233.5 (18.1) 35.8 (12.4) 0.2984 111.9 (12.5) 9.5 (6.4) 0.2933 20.9 (5.3) 1.6 (2.9) 0.2967
θ2 233.5 (18.2) 35.6 (12.3) 0.2005 112.2 (12.3) 9.4 (6.3) 0.1981 20.8 (5.2) 1.5 (2.5) 0.1959
θ12 284.1 (21.6) 33.8 (11.2) 0.3006 117.6 (13.5) 8.9 (5.7) 0.3066 14.1 (4.4) 1.2 (1.6) 0.3096
Jc = 8
Models 1 - full set of interactions
θ1 14.2 (0.9) 3.2 (0.4) 0.2966 7.3 (0.6) 1.7 (0.3) 0.3047 2.2 (0.3) 1.3 (0.2) 0.3368
θ2 14.2 (0.8) 3.2 (0.4) 0.1971 7.3 (0.6) 1.7 (0.3) 0.2039 2.2 (0.3) 1.2 (0.2) 0.2362
θ12 19.9 (1.2) 3.0 (0.4) 0.3073 8.7 (0.7) 1.5 (0.2) 0.3072 1.9 (0.3) 1.0 (0.2) 0.3056
Model 2 - reduced set of interactions
θ1 70.4 (4.4) 3.6 (0.5) 0.2949 33.9 (3.0) 2.0 (0.3) 0.2977 7.3 (1.3) 1.4 (0.2) 0.3113
θ2 70.5 (4.4) 3.6 (0.5) 0.1914 33.9 (3.0) 1.9 (0.3) 0.1974 7.3 (1.3) 1.4 (0.2) 0.2077
θ12 96.2 (5.8) 3.4 (0.5) 0.3054 39.7 (3.5) 1.7 (0.3) 0.3028 5.6 (1.2) 1.2 (0.2) 0.3066
Model 3 - continuous gene scores
θ1 367.3 (23.5) 168.0 (33.0) 0.2989 173.1 (15.7) 44.6 (16.9) 0.2998 31.9 (6.6) 2.9 (3.9) 0.3048
θ2 368.0 (23.2) 167.3 (32.8) 0.1996 173.1 (15.6) 44.0 (16.7) 0.2035 32.0 (6.6) 2.8 (3.8) 0.2129
θ12 520.7 (32.8) 156.4 (31.7) 0.3003 209.5 (19.7) 38.5 (14.1) 0.2977 24.5 (5.9) 2.1 (2.5) 0.2868
Model 4 - dichotomized gene scores
θ1 243.2 (18.7) 24.2 (10.3) 0.2979 117.5 (12.7) 6.7 (5.5) 0.3056 22.5 (5.5) 1.3 (2.1) 0.3099
θ2 243.8 (18.7) 24.1 (10.1) 0.2007 117.4 (12.8) 6.7 (5.4) 0.2061 22.5 (5.5) 1.3 (2.2) 0.2035
θ12 340.8 (24.2) 22.1 (8.9) 0.3007 142.4 (14.9) 5.9 (4.5) 0.2983 17.5 (4.8) 1.0 (1.4) 0.2851
Abbreviations: F-stat, F-statistic; CF-stat, conditional F-statistic.
aThe F-statistic and conditional F-statistic were calculated for X1, X2, and X12.
bWhen Jc = 0, Models 1 and 2 are equivalent.
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Summary level data
As data on genetic associations has become more publicly accessible, Mendelian
randomization analyses tend to be implemented using summarized level data [142].
Summarized data on the associations of each genetic variant with the trait(s) may
be obtained from a consortium: the beta-coefficients and their standard errors from
univariable regression on each variant in turn. Typically, consortia do not provide
summarized data on the product of two traits or the interaction effect of genetic variants
with the trait(s). Using the same framework and notation outlined in Section 5.4.1, we
show that it is not possible to extend the multivariable IVW model to estimate the
interaction effect between two risk factors using standard summarized data (genetic
associations of each variant with the risk factors and outcome).
Suppose we have summarized data on the genetic associations for the J genetic
variants Gj with X1, X2, and Y , and we consider estimating θ12 in Equation 5.7 by
including the product of the genetic associations of X1 and X2 in Equation 5.6:
βˆYj = θ′1βˆX1j + θ′2βˆX2j + θ′12βˆX1j × βˆX2j + ϵj , weights = se(βˆYj)−2 , (5.12)
where βˆX1j, βˆX2j and βˆYj are estimates of the j genetic associations with X1, X2
and Y , and se(βˆYj)−2 are the standard errors of the genetic associations with Y . For
simplicity, we assume that the MAF and the genetic associations are the same within
each subgroup of the genetic variants (G1, G2 and Gc). From Section 5.4.1, the risk
factors X1 and X2 can be expressed as:
X1 = β01 + β1
∑
G1 + β1c
∑
Gc + U1 + ϵ1 and
X2 = β02 + β2
∑
G2 + β2c
∑
Gc + U2 + ϵ2 ,
where we assume that the unmeasured confounders U1 and U2 are from a normal
distribution with mean zero. If we let µ1 = β01 + U1 and µ2 = β02 + U2, then the
product term X12 can be written as:
X12 = X1 ×X2 = (µ1 + β1
∑
G1 + β1c
∑
Gc)(µ2 + β2
∑
G2 + β2c
∑
Gc)
= µ1µ2 + µ2β1
∑
G1 + µ1β2
∑
G2 + β1β2
∑
G1
∑
G2+∑
Gc(µ1β2c + µ2β1c + β1β2c
∑
G1 + β1cβ2
∑
G2 + β1cβ2c
∑
Gc) .
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If we were to mean centre the risk factors and the genetic variants, then X12 can be
expressed as:
X12 = (X1 − µ1)× (X2 − µ2)
= β1β2
∑
G1
∑
G2 +
∑
Gc(β1β2c
∑
G1 + β1cβ2
∑
G2 + β1cβ2c
∑
Gc) .
(5.13)
By substituting Equation 5.13 and the mean centred values for X1 and X2 into
Equation 5.5, the outcome Y can be expressed as:
Y = θ0 + θ1(β1
∑
G1 + β1c
∑
Gc) + θ2(β2
∑
G2 + β2c
∑
Gc)+
θ12(β1β2
∑
G1
∑
G2 +
∑
Gc(β1β2c
∑
G1 + β1cβ2
∑
G2 + β1cβ2c
∑
Gc)) .
(5.14)
Consider the expected value of Y in Equation 5.14 conditional on each set of genetic
variants G1, G2 and Gc:
E(Y |∑G1) = (β1θ1 + θ12(β1β22J2MAF2 + β1β2c2JcMAFc))∑G1 , (5.15)
E(Y |∑G2) = (β2θ2 + θ12(β1β22J1MAF1 + β1cβ22JcMAFc))∑G2 , (5.16)
E(Y |∑Gc) = β1cθ1 + β2cθ2 + θ12(β1β2c2J1MAF1 + β2β1c2J2MAF2+
2β1cβ2c2JcMAFc)
∑
Gc , (5.17)
where J1, J2 and Jc are the number of genetic variants in G1, G2 and Gc, and
MAF1, MAF2 and MAFc are the MAFs of the variants. Equations 5.15 to 5.17 are
approximately equivalent to the genetic associations of the outcome Y with respect to
G1, G2 and Gc.
Using summarized data for the genetic associations of G1, G2 and Gc with X1, X2
and Y , from Equations 5.15 to 5.17, we want to solve:

β1 0 A1
0 β2 A2
β1c β2c A3


θ1
θ2
θ12
 =

βˆY 1
βˆY 2
βˆY c
 (5.18)
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where:
A1 = β1(β22J2MAF2 + β2c2JcMAFc) ,
A2 = β2(β12J1MAF1 + β1c2JcMAFc) ,
A3 = β1β2c2J1MAF1 + β2β1c2J2MAF2 + 2β1cβ2c2JcMAFc ,
and βˆY 1, βˆY 2 and βˆY c represent the estimates from regressing Y against G1, G2 and
Gc respectively. We assume that there is at least one cross-over variant Gc that is
associated with both risk factors, otherwise θ1, θ2, and θ12 could not be expressed as a
system of three equations. By using estimates of the genetic associations β1, β2, β1c
and β2c, and information on the MAFs, we want to solve AθT = βˆY . However, we find
that the matrix Aˆ is singular:
det(A) = β1
∣∣∣∣∣∣β2 A2β2c A3
∣∣∣∣∣∣︸ ︷︷ ︸
(1)
−0
∣∣∣∣∣∣ 0 A2β1c A3
∣∣∣∣∣∣+ A1
∣∣∣∣∣∣ 0 β2β1c β2c
∣∣∣∣∣∣︸ ︷︷ ︸
(2)
where:
(1) = β1(β1β2β2c2J1MAF1 + β22β1c2J2MAF2 + 2β2β1cβ2c2JcMAFc−
β1β2β2c2J1MAF1 − β2β1cβ2c2JcMAFc)
= β1(β22β1c2J2MAF2 + β2β1cβ2c2JcMAFc) ,
(2) = β1(−β22β1c2J2MAF2 − β2β1cβ2c2JcMAFc)
⇒ det(A) = (1)− (2) = 0 ,
and it is not possible to estimate θT as Equations 5.15 to 5.17 are linearly dependent.
The above highlights that the multivariable IVW model cannot be extended to
estimate the interaction effect between two risk factors using standard summarized
level data, and this result is confirmed in the simulation study below. For illustrative
purposes, the following simulations consider summarized data that would not normally
be accessible from consortia, including summarized data for the product term X12,
and summarized data for the products of the genetic variants G1 ×G2 with the risk
factors and outcome.
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Simulation study
Summarized data on the genetic associations for J genetic variants Gj (j = 1, . . . , J)
with the mean centred variables X1, X2, X12, and Y were obtained from the data
generated in Section 5.4.1 when θ12 = 0.3 and J1 = J2 = Jc = 5. The products of
G1×G2 were taken to create 25 new variables, and summarized data of these products
with the mean centred variables X1, X2, X12, and Y were estimated. The summarized
data was used to fit the following IVW models to the 10 000 simulated datasets:
• Model 1 - estimates of the J = 15 genetic associations with mean centred X1,
X2, and Y were fitted to the model in Equation 5.12.
• Model 2 - the product term (βˆX1j × βˆX2j) in Equation 5.12 was replaced with
the J = 15 genetic associations with X12:
βˆYj = θ1βˆX1j + θ2βˆX2j + θ12βˆX12j + ϵj , weights = se(βˆYj)−2 , (5.19)
where βˆX12j are the J genetic associations with X12.
• Model 3 - Equation 5.19 was re-fitted with the number of IVs increased from 15
to 40 by including summarized data on the 25 genetic products G1 ×G2.
The following measurements were recorded for the estimate of θ12: median value;
relative median bias; overall bias; standard deviation; median standard error; power at
the 5% significance level; and coverage.
Since this section uses the data generated in Section 5.4.1, ‘summary level data’ in
this simulation study does not refer to the two–sample setting defined in Section 1.5.2.
Instead, we have used one–sample data from Section 5.4.1 to obtain summary level
data. The conclusions drawn from the simulation should not be effected by the sum-
mary level data being obtained from the one–sample rather than the two–sample setting.
Results The results from the 10 000 simulated datasets are presented in Table 5.12.
For each model, the median estimate, the relative median bias of the estimate, the bias
of the estimate, the standard deviation of the estimate, the median standard error,
the statistical power to detect the effect at a nominal 5% significance level, and the
coverage of the true effect for a 95% confidence interval are presented in Table 5.12.
When the IVW model only contained summarized data on the genetic associations
with the mean centred variables X1, X2 and Y , and there was a product term between
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βˆX1j and βˆX2j (Model 1), the estimates of the interaction were biased and highly un-
stable owing to the singular/near singular matrix in Equation 5.18. When βˆX1j × βˆX2j
was replaced with the genetic associations of X12, the estimates of the interaction
term were consistent (Models 2 and 3). By including the genetic associations with the
products G1×G2 in Model 3, the power to detect the interaction increased from 4.7%
(Model 2) to 23.2%.
Table 5.12 Performance of the three IVW models with respect to the interaction term using
the simulated data from Section 5.4.1 when θ12 = 0.3 and J1 = J2 = Jc = 5.
No. of IVs med(θˆ12) Rel bias Bias SD SE Power Cov
Model 1 15 0.1850 1.1369 -0.1231 0.5048 0.6930 1.1 99.1
Model 2 15 0.3048 0.6468 0.0023 0.2992 0.4050 4.7 99.6
Model 3 40 0.3088 0.5232 0.0085 0.2381 0.2474 23.2 96.0
Abbreviations: No., number; IVs, instrumental variables; Rel bias, relative median bias; SD, standard deviation; SE,
standard error; Cov, coverage.
Summary
In the first half of this Section we extended multivariable Mendelian randomization
with two risk factors to the factorial setting. We have demonstrated how the interaction
effect of two risk factors on the outcome can be estimated using individual level data in
a TSLS regression model when the genetic variants are either treated as individual IVs,
or are combined into two weighted gene scores. We have shown that by mean centring
the risk factors and taking the product of these variables the power to detect the main
effects in TSLS regression increases. The effect of including variants that are associated
with both risk factors (referred to as ‘cross-over’ variants) has also been considered in
detail. Unlike multivariable Mendelian randomization [82], there appears to be little
advantage in including genetic variants that are jointly associated with both of the
risk factors to estimate the interaction effect in factorial Mendelian randomization. In
our simulations, there was little evidence of weak instrument bias for the interaction
term as the proportion of variance explained by the genetic variants reduced.
Through theoretical arguments and a simulation study, we have shown that it is
not possible to extend the multivariable IVW model to the factorial setting using
summarized data we would usually expect to obtain from a consortium. Given that
the addition of an interaction term should be treated as a separate risk factor with its
own IV (Section 5.2.2), this result was not surprising. As noted in Section 1.5.2, using
summary level data in Mendelian randomization is becoming increasingly popular as it
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is often publicly available. As such, the restriction of only being able to use individual
level data may limit the scope of factorial Mendelian randomization.
In the second half of this Section we introduce a formal framework for using genetic
variants as proxies for pharmacological interventions to detect statistical interactions
between drug treatments. Through simulations, we consider some of the methodological
challenges of this approach.
5.4.2 Genetic variants used as proxies for drug treatments
Suppose we have a biomarker X, a disease outcome Y , and a set of unmeasured
confounders U of the X − Y association, such that:
E[Y |X,U ] = θ0 + θ1X + ζYU ,
where ζY is the effect of the unmeasured confounders on the outcome, and θ1 is the
causal effect of X on Y , with lower values of X reducing the risk of the disease outcome.
Suppose there is a drug A that targets the gene region A which regulates X, and this
drug reduces the risk of the disease outcome by decreasing the levels of the biomarker.
If there is a genetic variant GA in the gene region A that satisfies the IV assumptions,
and the outcome Y is associated with GA, then it can be inferred that the biomarker
X causes the outcome Y . Since GA is associated with X, and lies in the gene region
that drug A is targeting, then GA could be considered as a proxy for drug A. Hence,
randomization to the genetic variant GA acts as a proxy to being randomized to drug
A. Results from a Mendelian randomization analysis that uses GA as an IV for X
could therefore provide information on the potential effect of drug A on the disease
outcome.
Now suppose we have an additional drug treatment B, and this drug reduces the
risk of the outcome Y by targeting a separate gene region B that also regulates X. We
assume that there is a genetic variant GB in the gene region B that satisfies the IV
assumptions and is uncorrelated with GA (not in linkage disequilibrium). Using the
same logic applied to GA, GB could be considered as a proxy for drug B and be used
in a Mendelian randomization analysis to consider the potential effect of drug B on
the disease outcome. The biomarker X can be expressed in terms of GA and GB:
E[X|GA, GB, U ] = θ0 + β′AGA + β′BGB + ζ ′XU ,
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where β′A is the genetic association of GA with X, β′B is the genetic association of GB
with X, and ζ ′X is the effect of the unmeasured confounder on X.
We may suspect that there is a statistical interaction of GA and GB on X:
E[X|GA, GB, GAB, U ] = θ0 + βAGA + βBGB + βABGAB + ζXU ,
where GAB represents the product term GA × GB, and βAB is the interaction effect
of GAB on X. If Y is regressed against GA, GB and GAB, and there is evidence of an
interaction effect, then this would suggest that the effect of reducing X via GA on the
risk of disease differs depending on whether GB is present or not. If we assume that
GA and GB act as proxies for drug treatments A and B, then we could infer that there
is an interaction effect between drug A and drug B on the risk of disease.
To avoid issues with weak instrument bias, we may wish to identify multiple genetic
variants that explain additional independent variability in the biomarker X and satisfy
the IV assumptions:
E[X|GA, GB, GAB, U ] = θ0 +
JA∑
j=1
βAjGAj +
JB∑
j=1
βBjGBj +
JA×JB∑
jab=1
βABjabGABjab + U ,
(5.20)
where GA are the JA uncorrelated genetic variants in gene region A, GB are the
uncorrelated JB genetic variants in gene region B, and GAB are the JA × JB product
terms of GA ×GB. Since the GA and GB are selected from individual gene regions it
may be difficult to identify uncorrelated genetic variants that are associated with X.
As such, we would expect the number of genetic variants JA and JB to be modest, as
seen in the applied examples considered in the literature [33–35]. Rather than treating
each of the genetic variants as separate IVs, GA and GB could be combined into two
externally weighted gene scores:
GSA =
JA∑
j=1
βAjGAj and GSB =
JB∑
j=1
βBjGBj ,
where GSA is the gene score for the variants in gene region A, and GSB is the gene
score for the variants in gene region B. The outcome Y could then be regressed against
GSA, GSB and the product of the two gene scores GSA ×GSB. If there was evidence
of an interaction effect between GSA and GSB, then under the same argument used
for when GA and GB consisted of one variant each, we could deduce that there is an
interaction effect of the drug treatments A and B on the outcome Y .
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Instead of treating the gene scores as continuous variables, they could be di-
chotomized to create two binary variables, and these binary variables and their product
could be included in a regression model with Y . Ference et al. [33] dichotomize the gene
scores at their median value (Section 5.3.2), but rather than modelling the outcome on
these dichotomized gene scores, they create a 2× 2 contingency table (Table 5.2) and
compare the outcome in the groups n10, n01 and n11 with n00 in separate models.
The distribution of the weighted gene scores will affect the number of participants
in each cell of the 2 × 2 contingency table. For the number of participants to be
balanced in the contingency table the distribution of the weighted gene scores should be
approximately symmetric. The MAF of the genetic variants will affect the distribution
of the scores. If the genetic variants are rare, then the distribution of the gene scores
will be skewed, whereas gene scores based on common genetic variants will be more
symmetric. Since we are dichotomizing the weighted gene scores, the estimates of the
genetic associations used as weights will also have an impact on the dichotomization.
The magnitude of the genetic associations are influenced by the MAF of the variant and
the amount of variance the genetic variant explains in the risk factor. Since the weights
are constant values, they should not have a dramatic impact on how symmetric the
distribution of the gene scores are, but they will influence the spread of the distribution.
Investigating the effect that the MAF and the proportion of variance in the risk
factor explained by the genetic variants has on dichotomizing the gene scores may
provide an insight into which genetic variants should be included in the gene scores.
This is particularly relevant for when the genetic variants are used as proxies for drug
treatments as there may be few uncorrelated genetic variants within the given gene
region. For instance, we may prefer to have more common variants that explain less
variation in the risk factor but the gene score is symmetric, than have rare variants
that explain more variation in the risk factor and the gene score is skewed.
The simulation study below assesses the advantages of modelling the interaction
term of the gene scores on the outcome, and the merit of treating the scores as
continuous variables rather than dichotomizing them. As noted in Section 5.3.4, the
interpretability of the estimate for the interaction term in this setting will be limited
as it represents the effect of the genetic variants on the outcome, and not the effect of
the treatments on the outcome. Although the simulation study will provide summary
measures on the estimates of the interaction term, the main focus of the simulation to
assess whether the models can detect an interaction effect. As such, the estimates of
the interaction term should not be overly interpreted. Whilst the simulations do not
fit the models used by Ference et al. [33], it does consider the impact the distribution
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of the gene scores have on the numbers of participants in the 2× 2 contingency table,
and the effect that this has on the power to detect the interaction term.
Simulation study
Using the same notation defined above, the risk factor X was generated for i =
1, 2, . . . , 10 000 participants from the following data generating model:
Xi = 0.3 +
JA∑
j=1
βAjGAji +
JB∑
j=1
βBjGBji + βAB
JA×JB∑
jab=1
GABjabi + Ui + ϵXi .
We assume that the two gene regions are distinct, and the genetic variants GA and
GB are not in linkage disequilibrium. The genotypes were generated independently
from binomial distributions B(2,MAFj), where MAFj represents the MAF for the
jth genetic variant. MAFj was drawn from a uniform distribution U(MAFL,MAFU),
where the value of MAFL and MAFU differed between the two gene regions and
scenarios considered. Unlike Equation 5.20, we assumed that the interaction effect βAB
was constant across the JA × JB product terms for simplicity.
The approximate proportion of variance explained in X by GA (σ2A) and GB
(σ2B) varied between scenarios. In total, GA and GB explained a minimum of 6%
and a maximum of 10% of the variance in X, with σ2A = σ2B or σ2A < σ2B. As with
the simulation study in Section 5.4.1, we acknowledge that the amount of variation
explained may be too large. As done in Section 5.4.1, the genetic associations βA and
βB were calculated by rearranging the formula for the variance of the genetic variants
and ensuring the amount of variance explained by each variant was the same:
βAj =
√√√√ σ2A/JA
2×MAFAj(1−MAFAj) and
βBj =
√√√√ σ2B/JB
2×MAFBj(1−MAFBj) .
As done in the previous simulation, the unmeasured confounders U were drawn from
N (0, 0.25), and the error term ϵX was generated from N (0, 0.65). The outcome Y was
generated from:
Yi = θ0 + θ1Xi + Ui + ϵY i ,
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where θ1 represents the causal effect of X on Y , and the error term ϵY was generated
from a standard normal distribution N (0, 1). The data was generated 10 000 times
under the following scenarios:
• Scenario 1: MAFA ∼ U(0.4, 0.5), MAFB ∼ U(0.4, 0.5), σ2A = 3% and σ2B = 3%
• Scenario 2: MAFA ∼ U(0.4, 0.5), MAFB ∼ U(0.4, 0.5), σ2A = 5% and σ2B = 5%
• Scenario 3: MAFA ∼ U(0.1, 0.2), MAFB ∼ U(0.1, 0.2), σ2A = 5% and σ2B = 5%
• Scenario 4: MAFA ∼ U(0.1, 0.5), MAFB ∼ U(0.1, 0.5), σ2A = 5% and σ2B = 5%
• Scenario 5: MAFA ∼ U(0.4, 0.5), MAFB ∼ U(0.1, 0.2), σ2A = 5% and σ2B = 5%
• Scenario 6: MAFA ∼ U(0.4, 0.5), MAFB ∼ U(0.4, 0.5), σ2A = 3% and σ2B = 7%
• Scenario 7: MAFA ∼ U(0.4, 0.5), MAFB ∼ U(0.1, 0.2), σ2A = 3% and σ2B = 7%
with JA = JB = 3, θ0 = 0.2, θ1 = 0.1, and βAB = 0.1, 0.3 and 0.5. To be consistent
with the analysis performed by Ference et al. [33], only three genetic variants were
generated for each gene region, and we chose a range of values for βAB to investigate
the impact this had on the results. The seven scenarios were selected to consider
the impact the MAF and the amount of variance in the risk factor explained by the
genetic variants had on the performance of the models. We considered genetic variants
generated with a MAF∼ U(0.4, 0.5) to be ‘common’, and a MAF∼ U(0.1, 0.2) to be
‘rare’. We acknowledge that this could be viewed as a crude classification, and the
bounds for the rare variants may be considered to be too liberal.
For each scenario, optimal weighted gene scores GSA and GSB were generated for
each gene region, where the external weights were produced from an independent set
of 10 000 individuals from the same data generating model used for the main set of
participants. The two gene scores were dichotomized at their median values to create
two binary variables. The outcome was then regressed against: a) the two continuous
gene scores and their product; and b) the dichotomized gene scores and their product.
The following measurements were recorded for the estimate of the interaction effect
between the gene scores on the outcome: median value; standard deviation; median
standard error; and power at the 5% significance level. When the gene scores were
dichotomized, the number of participants in the groups n00, n10, n01 and n11 were
recorded.
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Results
The mean numbers of participants contained in each cell of the 2× 2 contingency table
when the gene scores were dichotomized at the median values for each scenario are
contained in Table 5.13. The results from the simulation study using 10 000 simulated
datasets when the gene scores were treated as continuous and binary variables for the
seven different scenarios are presented in Table 5.14. For each scenario, the median
estimate, the standard deviation, the median standard error, and the statistical power
to detect the effect at a nominal 5% significance level for the interaction term when
the gene scores were treated as continuous and binary are presented in Table 5.14.
Table 5.13 Mean numbers (%) of participants in the groups n00, n10, n01, and n11 when
the gene scores were dictohomized at their median values for each scenario.
Mean numbers (%) of participants
Scenario n00 n10 n01 n11
1 2,822.4 (28.2) 2,492.0 (24.9) 2,487.6 (24.9) 2,197.9 (22.0)
2 2,818.5 (28.2) 2,488.1 (24.9) 2,493.2 (24.9) 2,200.1 (22.0)
3 3,248.5 (32.5) 2,456.3 (24.6) 2,446.6 (24.5) 1,848.7 (18.5)
4 3,007.9 (30.1) 2,480.2 (24.8) 2,472.5 (24.7) 2,039.5 (20.4)
5 3,031.1 (30.3) 2,281.3 (22.8) 2,674.4 (26.7) 2,013.1 (20.1)
6 2,820.1 (28.2) 2,490.3 (24.9) 2,490.9 (24.9) 2,198.7 (22.0)
7 3,030.3 (30.3) 2,281.2 (22.8) 2,675.4 (26.8) 2,013.1 (20.1)
There was heterogeneity between the estimates of the interaction effects for the
seven scenarios for the continuous and binary gene scores (Table 5.14). As we have
already highlighted, the interpretability of the estimate of the interaction effect under
this setting is limited, and this is confirmed by the simulation study. The introduction
of the interaction term should be viewed as a means for detecting rather than estimating
the interaction effect.
For all of the scenarios, the continuous gene scores had more power to detect the
interaction term than the binary gene scores. The continuous and binary gene scores
had the greatest power to detect the interaction effect under Scenarios 1 and 2 when
both of the MAFs were generated from U(0.4, 0.5). Changing the values of σ21 and σ22
had little impact on the performance of the two models, and the power to detect the
interaction effect remained the same when σ21 and σ22 increased from 3% (Scenario 1)
to 5% (Scenario 2).
The lower and upper bounds of the uniform distributions used to generate MAFA
andMAFB affected the power to detect the interaction term for both models. Compared
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to Scenario 2 where MAFA and MAFB were both generated from U(0.4, 0.5), the
power to detect the interaction term decreased as the lower and/or upper bound of the
uniform distribution decreased for either both, or one ofMAFA andMAFB. Compared
to Scenario 2, the greatest reduction in power occurred when both MAFA and MAFB
were generated from U(0.1, 0.2) (Scenario 3), where the power to detect the interaction
term halved for the binary gene scores.
Apart from Scenarios 5 and 7, the mean values for n01 and n10 were approximately
25% (Table 5.13). The mean value for n00 was consistently larger than the mean value
for n11 across all of the scenarios, and this was particularly true for Scenario 3 where
n00 = 32.5% and n11 = 18.5%. Note that Scenario 3 had the lowest power to detect
the interaction effect for both the continuous and binary gene scores.
Recommendation
The distributions of the weighted gene scores had a significant impact on the power to
detect the interaction term when the gene scores were regressed against the outcome.
The results from the simulation study illustrated that the MAF has a greater influence
on the performance of the models compared to the amount of variance explained by
the genetic variants. This observation supports the notion that the symmetry of the
distributions of the gene scores, primarily determined by the MAF, plays an important
role in the performance of the models, particularly when the scores are dichotomized.
If the gene scores are based on rarer variants, then the distributions of the gene scores
will be skewed, whereas if the scores are based on more common variants, or the MAFs
have a good range, then the distributions of the gene scores will be more symmetric.
If both of the gene scores are relatively symmetric, then using the median values
to dichotomize the variables will lead to more equally sized groups within the 2× 2
contingency table. If there is a choice of genetic variants within each gene region, it
may be advantageous to include the more common variants in the gene scores to ensure
the distributions are symmetric.
5.4 Performing factorial Mendelian randomization 171
Table 5.14 Estimates of the interaction between the gene scores when they were treated as
continous and binary variables for the seven scenarios considered.
Continuous gene scores Binary gene scores
med(θˆ12) SD SE Power med(θˆ12) SD SE Power
Scenario 1: MAFA ∼ U(0.4, 0.5), MAFB ∼ U(0.4, 0.5), σ2A = 3% and σ2B = 3%
θ12=0.1 0.0583 0.0420 0.0417 29.3 0.0368 0.0423 0.0421 13.5
θ12=0.3 0.0330 0.0080 0.0078 98.7 0.1102 0.0429 0.0423 73.5
θ12=0.5 0.0224 0.0034 0.0032 100.0 0.1846 0.0428 0.0427 98.9
Scenario 2: MAFA ∼ U(0.4, 0.5), MAFB ∼ U(0.4, 0.5), σ2A = 5% and σ2B = 5%
θ12=0.1 0.0484 0.0343 0.0343 29.1 0.0372 0.0420 0.0422 13.5
θ12=0.3 0.0304 0.0074 0.0072 98.8 0.1108 0.0424 0.0423 74.3
θ12=0.5 0.0212 0.0033 0.0030 100.0 0.1851 0.0439 0.0427 99.0
Scenario 3: MAFA ∼ U(0.1, 0.2), MAFB ∼ U(0.1, 0.2), σ2A = 5% and σ2B = 5%
θ12=0.1 0.0824 0.1152 0.1150 10.9 0.0168 0.0435 0.0430 7.0
θ12=0.3 0.1082 0.0519 0.0500 58.8 0.0526 0.0434 0.0430 23.3
θ12=0.5 0.0996 0.0300 0.0278 94.6 0.0879 0.0436 0.0430 53.0
Scenario 4: MAFA ∼ U(0.1, 0.5), MAFB ∼ U(0.1, 0.5), σ2A = 5% and σ2B = 5%
θ12=0.1 0.0663 0.0638 0.0603 19.9 0.0292 0.0428 0.0424 10.5
θ12=0.3 0.0531 0.0218 0.0163 90.4 0.0876 0.0434 0.0425 53.6
θ12=0.5 0.0410 0.0139 0.0074 100.0 0.1467 0.0463 0.0426 90.7
Scenario 5: MAFA ∼ U(0.4, 0.5), MAFB ∼ U(0.1, 0.2), σ2A = 5% and σ2B = 5%
θ12=0.1 0.0669 0.0699 0.0685 16.7 0.0246 0.0434 0.0425 9.1
θ12=0.3 0.0618 0.0211 0.0204 85.5 0.0763 0.0433 0.0426 42.8
θ12=0.5 0.0489 0.0109 0.0097 99.9 0.1279 0.0434 0.0428 84.1
Scenario 6: MAFA ∼ U(0.4, 0.5), MAFB ∼ U(0.4, 0.5), σ2A = 3% and σ2B = 7%
θ12=0.1 0.0498 0.0350 0.0352 29.2 0.0371 0.0422 0.0422 14.1
θ12=0.3 0.0305 0.0075 0.0072 99.0 0.1106 0.0426 0.0423 74.2
θ12=0.5 0.0213 0.0033 0.0030 100.0 0.1844 0.0430 0.0427 99.1
Scenario 7: MAFA ∼ U(0.4, 0.5), MAFB ∼ U(0.1, 0.2), σ2A = 3% and σ2B = 7%
θ12=0.1 0.0748 0.0756 0.0742 17.8 0.0259 0.0432 0.0426 9.7
θ12=0.3 0.0649 0.0221 0.0215 85.4 0.0758 0.0430 0.0426 42.9
θ12=0.5 0.0510 0.0113 0.0101 99.9 0.1271 0.0435 0.0428 83.9
Abbreviations: SD, standard deviation; SE, standard error.
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5.4.3 Summary
In the second half of this Section we provided a formal framework for using weighted gene
scores as proxies for drug treatments to detect interactions between pharmacological
interventions. Rather than fitting multiple regression models and comparing the point
estimates with no formal statistical testing, as done by Ference et al. [33], we propose
fitting one model with an interaction term between the gene scores to detect interaction
effects. However, the estimates of the interaction effects should not be overly interpreted
as they represent the effect of the genetic variants on the outcome, and not the effect
of the drug treatments on the outcome. In terms of the power to detect the interaction
effect, the simulation study has also highlighted the benefit of treating the gene scores
as continuous variables rather than binary variables.
In the next Section, we use the TSLS regression model described in Section 5.4.1
to estimate the interaction of body mass index and alcohol consumption on systolic
blood pressure using data from UK Biobank. Whilst this applied example is primarily
concerned with factorial Mendelian randomization analyses that use genetic variants
as predictors of the risk factors, we will also apply the approach taken by Ference et al.
[33] of dichotomizing the weighted gene scores and creating a 2× 2 contingency table.
5.5 Interaction effect of body mass index and al-
cohol consumption on systolic blood pressure
using UK Biobank data
Increased systolic blood pressure (SBP) is associated with a range of health conditions,
including cardiovascular disease and diabetes [143, 144]. Identifying modifiable risk
factors that are associated with SBP may help to reduce the burden of these disease
outcomes in the general population. Whilst there have been numerous studies high-
lighting the adverse effects of increased body mass index (BMI) on SBP [145, 146], and
the adverse effects of increased alcohol consumption [147], there has been little research
on the combined effect of BMI and alcohol consumption on SBP. We will contribute to
this gap in the literature by performing a factorial Mendelian randomization analysis
using individual level data from UK Biobank to estimate the interaction effect of BMI
and alcohol consumption on SBP.
All of the code for the applied example was written and performed by Jessica Rees
in RStudio version 3.5.3 [86] using the packages ivpack [140].
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5.5.1 Methods
UK Biobank is a prospective, population based cohort consisting of approximately
500,000 participants aged between 40-69 years living in the UK. Extensive baseline
characteristics were collected at recruitment, including lifestyle factors, sociodemo-
graphic information, and physical attributes. For the analysis, we considered the
367,643 unrelated participants of European descent who passed data quality control
measures and had genetic data.
BMI (kg/m2) and SBP (mmHg) were measured at baseline when the participants
attended the assessment centre. SBP was measured twice with at least a one minute
break between measurements using a digital sphygmomanometer (Omron HEM-705IT).
The average value of the two measurements were used in the analysis. Information on
baseline alcohol consumption was obtained from a touchscreen questionnaire which
included questions on alcohol drinking status, frequency of alcohol consumption, and
beverage type. The responses to the amount of alcohol drank and beverage type were
used to create a continuous variable that represented alcohol consumption in units
per day. To adjust for blood pressure medication, 15 mmHg was added to SBP for
individuals who reported to be on blood pressure lowering medication [148].
We used the 77 genome wide significant (p-value < 5×10−8) variants from the most
recent meta-analysis by the Genetic Investigation of ANthropometric Traits (GIANT)
consortium in participants of European ancestry to act as IVs for BMI [104]. For
alcohol, we identified 10 genetic variants that have been shown to be associated with
alcohol consumption [149], including the rs1229984 variant in the ADH1B gene region.
The genetic variants used as IVs for BMI and alcohol consumption were cross-referenced
to check for any overlap. BMI was regressed separately against each of the 10 alcohol
variants, and alcohol consumption was regressed against each of the 77 BMI variants,
all models were adjusted for gender, age, and the first ten principal components (PC).
Internally weighted gene scores were created for BMI GSBMI based on the 77
genetic variants, and for alcohol consumption GSAC based on the 10 genetic variants,
and these gene scores were dichotomized at their median values to create two binary
variables. A separate binary variable was generated using the rs1229984 variant only,
where participants were either considered to have: a) a low alcohol consumption if
they were homozygous or heterozygous for the alcohol decreasing allele; or b) a high
alcohol consumption if they were homozygous for the alcohol increasing allele (as done
in the paper by Carter et al. [136]). Using these binary variables, the following groups
of participants were created:
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• Low BMI, low alcohol consumption: GSBMI ≤ med(GSBMI) and GSAC ≤
med(GSAC) or was homozygous or heterozygous for the alcohol decreasing allele
for the rs1229984 variant,
• High BMI, low alcohol consumption: GSBMI > med(GSBMI) and GSAC ≤
med(GSAC) or was homozygous or heterozygous for the alcohol decreasing allele
for the rs1229984 variant,
• Low BMI, high alcohol consumption: GSBMI ≤ med(GSBMI) and GSAC >
med(GSAC) or was homozygous for the alcohol increasing allele for the rs1229984
variant, and
• High BMI, high alcohol consumption: GSBMI ≤ med(GSBMI) and GSAC >
med(GSAC) or was homozygous for the alcohol increasing allele for the rs1229984
variant.
The above criteria created four groups of participants based on the dichotomized
gene scores for BMI and alcohol consumption, and another four groups based on
the dichotomized gene score for BMI and the rs1229984 variant. The numbers of
participants, and the mean and standard deviation of BMI, alcohol consumption, and
SBP were recorded for each group.
TSLS regression models of SBP were fitted to BMI, alcohol consumption, and the
product of BMI and alcohol consumption. The following sets of IVs were considered:
• Model 1: the 77 variants for BMI and 10 variants for alcohol consumption, plus
the 770 product terms between the two sets of variants.
• Model 2: the continuous gene scores GSBMI and GSAC , plus their product
GSBMI ×GSAC .
• Model 3: the dichotomized gene scores of GSBMI and GSAC , plus their product.
The models were refitted when all of the variants for alcohol consumption were excluded
apart from the rs1229984 variant. All models were adjusted for gender, age, and the
first ten PCs. For each model, the estimate and standard error of the interaction term
was recorded with its p-value. In total, six TSLS regression models were fitted to the
dataset, and all of the models were adjusted for age, gender and the first 10 PCs. The
F-statistic and the Sanderson-Windmeijer conditional F-statistic were estimated for
each set of IVs with respect to BMI, alcohol consumption, and the product of BMI
and alcohol consumption.
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5.5.2 Results
291,781 (79.4%) of the 367,643 participants had measurements for BMI, alcohol con-
sumption, SBP, gender and age. 57,917 (19.8%) of these 291,781 participants reported
to be on blood pressure lowering medication. There were no cross-over variants between
the groups of genetic variants used as IVs for BMI and alcohol consumption. rs1229984
was the only variant from the set of 10 IVs for alcohol consumption that was associated
with BMI at the genome wide significance level, and 4 of the 77 variants used as IVs for
BMI reached genome wide levels of significance with respect to alcohol consumption.
The numbers of participants, and mean (standard deviation) BMI, alcohol con-
sumption and SBP by gene score classification are presented in Table 5.15. When the
gene score for alcohol consumption consisted of 10 variants, the numbers of participants
in the four groups were balanced. When the rs1229984 variant was used, the groups
were very uneven, with each of the high alcohol consumption groups containing 47.6%
of the data, suggesting that the majority of participants were homozygous for the
alcohol increasing allele. There was little difference between the means and standard
deviations of BMI or SBP when the IVs for alcohol consumption consisted of 1 or 10
variants. There was more discrepancy between mean alcohol consumption when only
the rs1229984 variant was used, rather than the 10 genetic variants.
Table 5.15 Numbers (%) of participants and mean (standard deviation) body mass index,
alcohol consumption and systolic blood pressure by gene score classification when either 10
genetic variants or the rs1229984 variant acted as IVs for alcohol consumption.
Mean (SD)
No. participants (%) BMI (kg/m2) Alcohol (units/day) SBP (mmHg)
Dataset used for analysis 291,781 (100.0) 27.1 (4.51) 2.54 (2.58) 140.0 (19.8)
10 variants for alcohol
Low BMI, low alcohol con. 73,003 (25.0) 26.6 (4.25) 2.50 (2.52) 140.6 (20.6)
High BMI, low alcohol con. 72,889 (25.0) 27.5 (4.65) 2.47 (2.50) 141.2 (20.6)
Low BMI, high alcohol con. 72,888 (25.0) 26.7 (4.30) 2.61 (2.68) 140.8 (20.7)
High BMI, high alcohol con. 73,001 (25.0) 27.6 (4.71) 2.59 (2.59) 141.3 (20.6)
rs1229984 variant for alcohol
Low BMI, low alcohol con. 6,997 (2.4) 26.3 (4.10) 2.00 (2.04) 139.2 (20.2)
High BMI, low alcohol con. 6,863 (2.4) 27.3 (4.50) 1.95 (1.99) 139.7 (20.2)
Low BMI, high alcohol con. 138,894 (47.6) 26.7 (4.28) 2.59 (2.59) 140.8 (20.6)
High BMI, high alcohol con. 139,027 (47.6) 27.6 (4.69) 2.56 (2.56) 141.3 (20.6)
Abbreviations: No., number; SD, standard deviation; BMI, body mass index; SBP, systolic blood pressure; con.,
consumption.
The F-statistic and the Sanderson-Windmeijer conditional F-statistic for BMI,
alcohol consumption, and the product of BMI and alcohol consumption for the different
sets of IVs used in the models are contained in Table 5.16. When ten variants were
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used for alcohol consumption, all of the F-statistics for Model 1 were below 10, and
BMI was the only covariate that had a F-statistic greater than 10 when the rs1229984
variant was used for alcohol consumption in Model 1. The 10 genetic variants had a
R2 value of 0.28% for alcohol consumption, and the single variant had a R2 value of
0.24%. BMI had the largest F-statistics for Models 2 and 3 for both sets of variants
used for alcohol consumption. There was a significant reduction in the F-statistic for
alcohol consumption and the product term between Models 2 and 3 when 10 variants
for alcohol consumption were included in the gene score, whereas the reduction in the
F-statistic between Models 2 and 3 when the gene scores for alcohol only consisted of
one variant was minimal. Apart from Model 1 and Model 3 (10 genetic variants for
alcohol consumption), the conditional F-statistic was greater than 10 for all covariates.
The conditional F-statistics from Model 1 were particularly small for both sets of
genetic variants for alcohol consumption.
Table 5.16 F-statistic and Sanderson-Windmeijer conditional F-statistic for body mass
index, alcohol consumption and the product of body mass index and alcohol consumption
by two stage least squares regression model, and the number of genetic variants used as
instruments for alcohol consumption
Model 1 Model 2 Model 3
F-statistic CF-statistic F-statistic CF-statistic F-statistic CF-statistic
10 variants for alcohol
BMI 6.8 1.3 1662.8 21.1 1054.1 7.0
Alcohol consumption 2.4 1.1 268.0 20.9 55.6 6.9
Product terma 2.4 1.1 298.6 21.0 73.2 6.9
rs1229984 for alcohol
BMI 32.8 1.3 1654.9 17.2 1066.8 13.5
Alcohol consumption 7.7 1.2 245.1 17.1 241.6 13.4
Product terma 7.9 1.2 267.7 17.1 266.5 13.4
aProduct of body mass index and alcohol consumption.
Abbreviations: CF-statistic, conditional F-statistic; BMI, body mass index.
Results from the TSLS regression models are contained in Table 5.17. None of the
models provided evidence of an interaction effect of BMI and alcohol consumption
on SBP levels. The estimates of the interaction were most precise when the variants
were treated as individual IVs (Model 1), and least precise when the binary gene
scores acted as IVs (Model 3). Apart from Model 3, where the standard error reduced
by a third, the precision of the estimates decreased for all of the models when the
number of IVs for alcohol consumption was reduced from 10 to 1. The improvement
in the precision of the estimate from the dichotomized gene score model when the
groups of participants were based on the different genotypes of one genetic variant
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highlights the importance of considering different cut-off values for the weighted gene
scores. By grouping the participants by the rs1229984 genotypes the high proportion
of participants who were homozygous for the alcohol increasing allele was reflected in
the model. This observation would not have been captured when the weighted gene
score based on 10 genetic variants was dichotomized at the median value.
Table 5.17 Number of instrumental variables included the two stage least squares models
and estimates of the interaction term with its standard error and p-value from the factorial
Mendelian randomization analyses when either 10 genetic variants or the rs1229984 variant
acted as IVs for alcohol consumption.
No. of IVs Estimate Standard error P-value
10 variants for alcohol
Model 1: individual variants 857 0.0023 0.0503 0.9636
Model 2: continuous gene scores 3 0.0655 0.3402 0.8472
Model 3: binary gene scores 3 0.1011 0.6411 0.8746
rs1229984 variant for alcohol
Model 1: individual variants 149 -0.0170 0.1136 0.8809
Model 2: continuous gene scoresa 3 0.1917 0.3725 0.6068
Model 3: binary gene scores 3 0.1499 0.4174 0.7195
Abbreviations: No., number; IVs, instrumental variables.
ars1229984 was treated as a continuous variable and could be 0, 1 and 2.
5.5.3 Summary
In this Section, we have used individual level data from UK Biobank to estimate the
statistical interaction effect of BMI and alcohol consumption on SBP in a factorial
Mendelian randomization study where genetic variants are used as predictors of the
risk factors. None of the TSLS regression models provided evidence of an interaction
effect of BMI and alcohol consumption. As seen in the simulations in Section 5.4.1,
the estimate for the interaction effect was most precise when the variants were treated
as individual IVs and all of the product terms were included in the analysis. Since the
F-statistics for BMI and alcohol consumption were below 10 when the variants were
treated as individual IVs, the estimates of the main effects from this analysis, although
not presented, may have suffered from weak instrument bias. Since the simulations
suggested that the interaction term does not suffer from the same weak instrument
bias as the main effect terms, we should have more confidence in interpreting these
estimates.
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5.6 Discussion
In this Chapter, we have considered the methodological issues for factorial Mendelian
randomization when the genetic variants are used as: a) predictors of risk factors to
estimate interaction effects between two risk factors on an outcome; and b) are used
as proxies for drug treatments to detect interaction effects between pharmacological
interventions.
To estimate the interaction effect under scenario a), we expanded multivariable
Mendelian randomization to the factorial setting by including an interaction term
in the model. Through simulations, we have shown that consistent estimates of the
interaction effect from TSLS regression can be obtained when the genetic variants are
either treated as individual IVs, or as single IVs in weighted gene scores. As anticipated,
the power to detect the interaction effect was noticeably higher when the variants
were treated as individual instruments, and was maximized by including all of the
genetic variants and products of the variants in the data generating model as IVs
(referred to as the oracle model). The precision of the interaction term decreased when
subsets of the product terms between the genetic variants were excluded as instruments.
Reducing the amount of variance the genetic variants explained in the risk factors
had little impact on the consistency of the interaction estimates when the full set
of genetic variants and their products were used as instruments, although there was
evidence of weak instrument bias for the main effects. We would therefore suggest that
factorial Mendelian randomization be used with the primary motive of estimating the
interaction effect between two risk factors.
The simulation study for scenario a) illustrated the sensitivity of the TSLS regression
model to reductions in the set of product terms used as IVs compared to the data
generating model. The simulation study and applied example suggested that as many
of the genetic variants and cross products should be included as IVs as possible.
Including large numbers of genetic variants that are not strongly associated with the
risk factor in a Mendelian randomization analysis is not normally encouraged due to
weak instrument bias. Although we did not observe any evidence of weak instrument
bias for the interaction estimates in the simulation study, we acknowledge that many
researchers would be reluctant to include hundreds of IVs in a Mendelian randomization
analysis. We therefore recommend that the continuous weighted gene scores and their
product be used as IVs in a sensitivity analysis. By using the gene scores as IVs,
fewer parameters will be estimated, and this may help to reduce the impact of weak
instrument bias. Furthermore, using the continuous gene scores in a sensitivity analysis
may also provide some robustness against model misspecification.
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For scenario b), we have provided a formal framework for using weighted gene
scores as proxies for drug treatments to detect interactions between pharmacological
interventions. If genetic variants are to be used as proxies for drug treatments to detect
interactions, we suggest that the interaction effect, although not interpretable, should
be estimated using continuous gene scores in a linear regression model. If the gene
scores are dichotomized, then the distributions of the gene scores should be considered
when determining the cut-off values used to create the binary variables.
5.6.1 Interpretation of the interaction effect
The estimate of the interaction effect of two risk factors on the outcome from a factorial
Mendelian randomization analysis should be interpreted with some caution. If the
genetic variants satisfy the IV assumptions for multivariable Mendelian randomization,
and there truly is an interaction, then the interaction effect will have a causal interpre-
tation. However, the interaction term may be an artefact of underlying non-linearity
in the relationship between the risk factors and the outcome.
When the genetic variants are used as proxies for drug treatments, and the outcome
is regressed against two gene scores and their products, the estimate of the interaction
term from this model represents the effect of randomization to the genetic variants
on the outcome, and not the effect of randomization to the drug treatments on the
outcome. By estimating the effect of randomization to the variants on the outcome,
we are essentially performing an ITT analysis.
5.6.2 Strength of the instrumental variables
We applied the recommendation of Sanderson and Windmeijer [83] of presenting the
standard F-statistic and conditional F-statistic for each risk factor in a multivariable
Mendelian randomization analysis to the factorial setting. Although the main effect
estimates suffered from weak instrument bias when the mean F-statistic fell below 10,
there was little bias in the interaction effect. As Mendelian randomization analyses can
include weak IVs, it is our recommendation that under such circumstances only the
interaction estimate is interpreted. Despite many of the risk factors having a mean con-
ditional F-statistic less than 5, the estimates were not affected by weak instrument bias
if the standard F-statistic was greater than 10. The role of the Sanderson-Windmeijer
conditional F-statistic to measure instrument strength in factorial Mendelian random-
ization is not clear, and requires further consideration, particularly in relation to the
conditional F-statistic for the product term X12.
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5.6.3 Number of cross-over variants
There are two main situations where factorial Mendelian randomization may be used: a)
as a sensitivity analysis for when the primary analysis is considered to be multivariable
by design; or b) as the primary analysis with the objective of estimating the interaction
effect of the two risk factors. In the first case, we would expect there to be cross-
over variants as risk factors in multivariable Mendelian randomization tend to be
correlated, and share common genetic variants. Under the second scenario, where
factorial Mendelian randomization is used as the primary analysis, it is likely that
there would be no cross-over variants as the risk factors will probably be distinct. For
instance, consider the example proposed by Davey Smith and Hemani [135] to estimate
the interaction effect of obesity and alcohol consumption on the risk of liver disease,
given that these risk factors are distinct, there will probably be few, or perhaps no
genetic variants that are associated with both risk factors.
The simulations have shown that the number of cross-over variants has little impact
on the estimates from the TSLS model when the full set of genetic variants and their
products are included as individual IVs. The power to detect the interaction term
using continuous gene scores increased, and decreased for the dichotomized gene scores,
as the number of cross-over variants increased. Therefore, it may be unwise to apply
the method proposed by Ference et al. [33] or estimate the interaction effect using the
binary gene scores as IVs if there are a lot of cross-over variants. Note that when the
genetic variants are used as proxies for drug treatments, there are no cross-over variants
as the two groups of genetic variants are from different gene regions and are not in
linkage disequilibrium, providing justification for Ference et al’s. [33] recommendation
for dichotomizing the gene scores.
5.6.4 Dichotomization of the gene scores
Throughout this Chapter, we followed the recommendation by Ference et al. [33] to
dichotomize the gene scores at the median value. Whilst this was effective when the
distribution of the gene scores were symmetric, or there were no cross-over variants,
the power to detect the interaction term decreased as the distributions became more
skewed, and the numbers of participants in each group of the contingency table became
more unbalanced. If rare variants are included in the gene score then a different criteria
for dichotomizing the gene scores should be considered, for example, if there is an
obvious break in the gene scores, then perhaps this should inform the cut-off values
used to create the binary variables.
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5.6.5 Limitations
We have only considered continuous risk factors and continuous outcomes in the
TSLS regression models, and the regression models of the outcome against the genetic
variants. Only considering continuous outcome measurements could be viewed as a
significant limitation. As highlighted in Section 2.3.3, the TSLS regression model will
only produce approximate estimates of the odds ratio when the outcome is binary
due to non-collapsibility. Since we only considered continuous outcome measurements
in this Chapter, we were unable to assess the impact non-collapsibility has on the
approximate measure of the odds ratio when detecting and/or estimating interaction
effects. Furthermore, throughout this Chapter we have only looked at additive interac-
tions, and since statistical interactions are scale dependent, detecting multiplicative
interactions in factorial Mendelian randomization needs to be addressed. The methods
proposed for factorial Mendelian randomization are also limited by only allowing for
the effects of two risk factors or two drug treatments to be considered at one time.
Throughout this Chapter we have assumed that the genetic variants are uncorrelated.
Whilst this may be a reasonable assumption for factorial Mendelian randomization
when the genetic variants are used as predictors of the risk factor, this assumption may
be restrictive for when the genetic variants are used as proxies for drug treatments as
we would expect many of the variants associated with the biomarker to be correlated.
Further consideration on the impact of including correlated genetic variants should
therefore be considered.
We would also like to highlight some of the limitations of the simulation studies
performed in this Chapter. The simulation study in Section 5.4.1 only considered
misspecification of the data generating model in terms of the number of IVs included in
the TSLS regression model and the impact of treating the genetic variants as one IV by
generating weighted gene scores for each risk factor. Additional misspecifications, such
as misspecified genetic associations, must be considered to determine the robustness
of the TSLS model when estimating interaction effects. The weights generated for
the gene scores in Section 5.4.1 were obtained from the same data generating model
with the same number of participants used in the original simulation. Although we
do not expect this assumption to hold in applied practice, and the results from the
TSLS model in the simulation study using weighted gene scores may be overly precise,
we made this assumption to assess the performance of Models 3 and 4 under the best
possible scenario.
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5.6.6 Key points from chapter
• Factorial Mendelian randomization uses genetic variants as IVs to detect in-
teraction effects under broad two scenarios: 1) where the genetic variants act
as predictors of the risk factors and are used to estimate the causal effect of
two risk factors on the outcome; and 2) the genetic variants act as proxies for
pharmacological interventions to identify interactions between drug treatments
on the risk of disease.
• Although Factorial Mendelian randomization has already been considered in
applied work, there has been little methodological developments on how this
type of study design should be performed, and no attempt at estimating the
interaction effect.
• We have shown that additive statistical interactions can be estimated from
TSLS regression models using individual level data under a factorial Mendelian
randomization study when the genetic variants are treated as individual IVs or
as single IVs through weighted gene scores.
• Through simulations and an applied example, we have shown that the power to
detect the interaction term in a factorial Mendelian randomization analysis is
maximised when all of the genetic variants and their interactions are included
as individual IVs. As a sensitivity analysis, continuous gene scores can be used
as IVs to safeguard against potential bias from model misspecification or weak
instruments.
Chapter 6
Effect of adiposity and body
composition on asthma: A
Mendelian randomization study
6.1 Introduction
This Chapter considers the main applied example of the dissertation: a Mendelian
randomization study on the effect of adiposity and body composition on asthma. We
partially address this research question by using body mass index (BMI) as a measure of
adiposity in a univariable Mendelian randomization analysis. BMI is often considered in
epidemiological studies as it only requires height and weight measurements. Although
it can be measured with relative ease and little expense, BMI measurements may not
accurately reflect body composition. For example, an individual may have a BMI
measurement that is classed as obese, but have a perfectly healthy body composition.
To have a more comprehensive appreciation for the effect adiposity and body
composition has on asthma, this Chapter also performs Mendelian randomization
analyses on the effect of whole body fat mass (FM) and whole body fat free mass
(FFM) on asthma. Throughout this Chapter, we will refer to ‘whole body FM’ as FM,
and ‘whole body FFM’ as FFM. Since some of the genetic variants associated witth FM
and FFM are the same [150], the IV3 assumption (Section 1.4) would be violated if FM
and FFM were considered in separate univariable Mendelian randomization analyses.
To investigate the effect of FM and FFM on asthma we therefore perform Mendelian
randomization analyses under a multivariable framework, and we use the multivariable
MR-Egger method developed in Chapter 4 to consider the possible violation of the
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IV4 assumption for multivariable Mendelian randomization (Section 2.6.3). Since the
effect of FM and FFM on asthma has not been considered in the literature using
multivariable Mendelian randomization methods, the work presented in this Chapter
should address this gap in the literature.
In Section 6.1.1, we discuss the importance of identifying modifiable risk factors of
asthma, and highlight the benefits of performing a Mendelian randomization study on
this research question. Section 6.1.2 provides detail on body composition measurements,
and Section 6.1.3 reviews the literature on genome wide association studies on body
composition and asthma. Section 6.1.4 provides a detailed overview of the Mendelian
randomization studies considered in this Chapter. We perform a one-sample Mendelian
randomization study using data from UK Biobank (Section 6.2), and a two-sample
Mendelian randomization study using data from UK Biobank and the GABRIEL (A
Multidisciplinary Study to Identify the Genetic and Environmental Causes of Asthma
in the European Community) Consortium (Section 6.3). In Section 6.4, we compare
the results of the Mendelian randomization studies from Sections 6.2 and 6.3.
6.1.1 Motivation
Asthma is a chronic and complex condition that can be difficult to diagnose [151].
Although the prevalence of asthma has plateaued in the UK since the 1990s [152], the
NHS still spends around £1.1 billion per year on treating asthmatics [153]. Diagnosis
of asthma tends to occur early on in childhood, with the number of incident cases
generally decreasing with age [154]. Although the symptoms of asthma can be effectively
controlled through medication, sufferers in the UK are still dying from the condition
[155], and identifying modifiable risk factors of asthma should remain a priority [154].
Observational and longitudinal studies have provided evidence of a positive asso-
ciation between BMI and asthma in children [156–160] and adults [161–163]. Due
to reverse causation and residual confounding, it is not possible to infer a causal
association between BMI and asthma from these epidemiological studies. It seems
likely that reverse causation may be an issue, particularly in relation to adults, as the
effects of asthma may have contributed to long term physical inactivity, resulting in
weight gain. The biological reasoning behind a positive association between BMI and
asthma is not well understood, and various biological mechanisms have been suggested
[164].
Mendelian randomization studies have considered the causal association between
body composition and asthma [164, 165]. The Mendelian randomization study by
Granell et al. [164] in children used measurements of BMI, FM and lean mass (LM)
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for adiposity and body composition. These three measurements were considered in
seperate univariable Mendelian randomization analyses, and there was evidence to
suggest that all of these body composition measurements have a positive causal effect
on asthma [164]. Since FM and LM are associated with common genetic variants [150],
the IV3 assumption for univariable Mendelian randomization may have been violated
for FM and LM in the paper by Granell et al. [164]. The study by Skaaby et al. [165] in
adults used a reduced dataset from UK Biobank (N=162,124), and reported a positive
causal association between BMI and asthma [165]. The effect of body composition on
asthma has not been considered using multivariable Mendelian randomization methods,
such as the multivariable IVW [28] and multivariable MR-Egger [32] methods. This
Chapter addresses this gap in the literature.
6.1.2 Measurements for adiposity and body composition
BMI is derived from an individual’s weight and height (BMI=weight (kg)/height2
(m2)), and is strongly correlated with body fat in adults [166]. Since variation in BMI
measurements are usually attributed to differences in FM, an individual with a high
proportion of LM or FFM may have a BMI that is classed as overweight or obese, but
have a healthy body composition [167, 168]. Some epidemiological studies measure FM,
FFM and LM to investigate the effect of body composition on disease outcomes. LM
and FFM tend to be highly correlated as both measurements consist of muscle, bone,
organs, and extracellular fluid [169]. Unlike FFM, LM also includes a small proportion
of essential fats [170]. Fat mass index (FMI), fat-free mass index (FFMI), and lean
mass index (LMI) can be calculated by dividing the body composition measurement
(kg) by the square of height (m2).
FM, FFM and LM can be measured through bioelectrical impedance analysis (BIA)
or dual X-ray emission absorptiometry (DXA). DXA is considered to be the ‘gold
standard’ for measuring body composition [171], but it requires specialist equipment
and exposes individuals to small amounts of radiation [172]. BIA is more commonly
used in clinical practice and large scale epidemiological studies as it is uses low cost,
portable devices, that are simple to use [173]. BIA estimates FM and FFM from a
body composition analyser that assumes each individual has a fixed water mass. BIA
tends to underestimate FM in obese patients [172], and is not considered to be a
reliable method for measuring FM and FFM in children [174]. Measurements for FM
are generally larger under DXA than BIA, whereas FFM is usually smaller under DXA
[173]. In addition to measuring FM and FFM, DXA can also be used to calculate LM.
Since LM and FFM are highly correlated, many epidemiological studies only consider
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one measurement. In this Chapter, we will only consider whole body FM and whole
body FFM. As noted in Section 6.1, throughout this Chapter we will refer to ‘whole
body FM’ as FM, and ‘whole body FFM’ as FFM.
6.1.3 Genome wide association studies on adiposity, body
composition and asthma
There have been numerous GWASs on BMI in adults [175], with some of the earlier
studies identifying common genetic variants in the FTO and MC4R gene regions
[176, 177]. The Genetic Investigation of ANthropometric Traits (GIANT) Consortium
identified 32 loci that were associated with BMI at the genome wide significance (GWS)
level (p-value< 5× 10−8) [178], and this figure increased to 97 when additional studies,
including participants of non-European descent, were included in the analysis [104].
The 97 variants discovered by Locke et al. [104] explained 2.7% of the phenotypic
variance of BMI, with the majority of the genetic variants lying in non-coding regions
of the genome [104].
There have been few GWASs on FM or LM. Pei et al. [179] performed a GWAS
on FM and identified 10 genetic variants that were associated with FM at the GWS
level, and some of these variants had not been identified by the GIANT consortium for
BMI. Zillikens et al. [180] performed a GWAS on LM and discovered the first set of
genetic variants associated with LM at the GWS level. One of the genetic variants
identified by Zillikens et al. [180] was not associated with any of the anthropometric
traits considered in the GIANT consortium [180].
GWASs have been performed on asthma, but the variability in diagnosing the
condition has made the interpretation and validation of results difficult [181]. The
GABRIEL consortium was established to investigate the effect of genetic and environ-
mental factors on the risk of asthma in the European Community [37], and one of their
primary aims was to perform the largest GWAS on individuals diagnosed with asthma
by a physician [37]. All of the studies provided data on individuals diagnosed with
asthma before the age of 16 years, and over half of the studies provided data on adults
(diagnosed with asthma 16 years or older). Five loci were associated with asthma at
the GWS level using the complete dataset [37].
6.1.4 Study design
It could be argued that a Mendelian randomization study investigating the effect of
adiposity and body composition on asthma should use data from a child cohort as
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asthma tends to be diagnosed during childhood. However, cohort studies on children
tend to have small sample sizes. To avoid issues with low statistical power, we therefore
investigated the effect of adiposity and body composition on asthma using data on
adults from UK Biobank and the GABRIEL consortium.
The directed acyclic graph (DAG) a) in Figure 6.1 illustrates the assumed relation
between BMI and asthma, and we considered this DAG in univariable Mendelian
randomization analyses. DAG b) in Figure 6.1 illustrates the assumed relation be-
tween FMI, FFMI and asthma, and this DAG was investigated through multivariable
Mendelian randomization analyses. As highlighted by DAG b) in Figure 6.1, we assume
that FM and FFM are not directly associated.
Fig. 6.1 Figure containing two directed acyclic graphs (DAG) used to inform the Mendelian
randomization analyses. DAG a) illustrates the assumed relationship between body mass
index (BMI) and asthma for the univariable Mendelian randomization analyses. DAG b)
illustrates the assumed relationship between fat mass index (FMI), fat-free mass index (FFMI)
and asthma for the multivariable Mendelian randomization analyses.
Confounders
BMI AsthmaGroup	of	genetic	variants
a)
Confounders
FMI
AsthmaGroup	of	genetic	variants
FFMI
b)
Abbreviations: BMI, body mass index; FMI, body fat mass index; and FFMI, body fat-free
mass index.
For DAGs a) and b), we considered the genetic variants that reached GWS in
participants of European descent for BMI in the study by Locke et al. [104] as potential
IVs. We used the 77 genetic variants rather than the full set of 97 variants identified
by Locke et al. [104] (as discussed in Section 6.1.3) as UK Biobank and the GABRIEL
consortium predominately consist of participants of European decent. We did not
consider genetic variants from GWASs on FM or FFM as IVs in any of the Mendelian
randomization analyses. This decision was influenced by two factors: 1) many of the
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genetic variants that effect BMI also appear to influence FM and FFM; and 2) the
GWASs on BMI have significantly larger sample sizes than those on FM and FFM.
Hence, the same group of genetic variants were used as IVs in DAGs a) and b) in
Figure 6.1.
To investigate the effect of adiposity and body composition on asthma using the
77 genetic variants identified by Locke et al. [104] as potential IVs, we performed two
Mendelian randomization studies: a one–sample Mendelian randomization study using
data from UK Biobank (Section 6.2); and a two–sample Mendelian randomization study
using data from UK Biobank and the GABRIEL consortium (Section 6.3). Figure 6.2
provides an overview of the characteristics of these studies. Both of these Mendelian
randomization studies performed univariable and multivariable analyses to investigate
DAGs a) and b) in Figure 6.1.
Fig. 6.2 Figure highlighting the characteristics of the two Mendelian randomization studies
performed in Sections 6.2 and 6.3.
Study 1 (Section 6.3)
Study design: one–sample Mendelian
randomization
Risk factors: 1) BMI (univariable
analyses); and 2) FMI and FFMI
(multivariable analyses)
Data used: Summary levela
Source of data: Summary level data
for BMI, FMI, FFMI and asthma were
estimated by Jessica Rees using data
from UK Biobank
Study 2 (Section 6.4)
Study design: two–sample Mendelian
randomization
Risk factors: 1) BMI (univariable
analyses); and 2) FMI and FFMI
(multivariable analyses)
Data used: Summary levela
Source of data: Summary level data
for BMI, FMI and FFMI were estimated
by Jessica Rees using data from UK
Biobank. Summary level data for
asthma was taken from the GABRIEL
consortium.
aNote that summary level data was used in the analysis for the one–sample (Study 1) and
two–sample (Study 2) Mendelian randomization studies.
Abbreviations: BMI, body mass index; FMI, body fat mass index; and FFMI, body fat-free
mass index.
Summary level data is normally used in a two–sample Mendelian randomization
study when the genetic associations with the risk factor and the genetic associations
with the outcome are obtained from two separate samples (Section 1.5.2). Although
a one–sample Mendelian randomization study typically uses individual level data in
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TSLS regression, it is possible for summary level data to be used in the analysis
(Figure 1.2). As stated in Section 1.5.2, throughout this dissertation we have assumed
that ‘summary level data’ refers to the two–sample setting. However, the one–sample
Mendelian randomization study performed in Section 6.2 uses summary level data in
the univariable (IVW, median and MR-Egger) and multivariable (IVW and MR-Egger)
analyses. The summary level data for BMI, FMI, FFMI and asthma were estimated
by Jessica Rees using data on the same set of participants from UK Biobank (more
detail provided in Section 6.2).
Weak instruments in a one–sample Mendelian randomization study can bias the
estimate towards the confounded observational estimate when individual level data
is used in the TSLS regression model [182]. However, the one–sample Mendelian
randomization study considered in this Chapter applies summary level data to methods
specifically designed for the two–sample setting (IVW, median and MR-Egger). Since
the estimates from the IVW and TSLS methods are asymptotically equivalent, the
degree of weak instrument bias for the IVW method using one–sample summary level
data should be approximately equivalent to the weak instrument bias for the TSLS
method in finite samples [182]. Hartwig et al. [183] highlighted that weak instrument
bias for univariable MR-Egger under the one–sample setting will bias the estimate
towards the confounded observational estimate.
Since the one–sample Mendelian randomization study in Section 6.2 may suffer
from an increased Type I error rate, we also performed a two–sample Mendelian
randomization study as weak instruments under the two–sample setting will bias the
estimate towards the null. For the two–sample Mendelian randomization study in
Section 6.3, summary level data was used under the more conventional setting of
obtaining the genetic associations with the risk factors (BMI, FMI and FFMI) and
the genetic associations with the outcome (asthma) from two separate samples. The
summary level data for BMI, FMI and FFMI estimated in Section 6.2 using data from
UK Biobank was used in the two–sample setting, and summary level data for asthma
was extracted from the GABRIEL consortium.
6.1.5 Summary
In this Section, we have motivated the main applied example of the dissertation:
the investigation into the effect of adiposity and body composition on asthma using
Mendelian randomization. We have highlighted the benefits of performing both
univariable and multivariable Mendelian randomization analyses. We have also provided
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an in depth overview of the two Mendelian randomization studies considered in
Sections 6.2 and 6.3.
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6.2 One–sample Mendelian randomization analysis
on the effects of adiposity and body composi-
tion on asthma
This Section contains the one–sample Mendelian randomization study on the effects of
adiposity and body composition on asthma. BMI was used as a measure for adiposity,
and its effect on asthma was considered in univariable Mendelian randomization analyses.
The effect of body composition on asthma was considered through multivariable
Mendelian randomization with FMI and FFMI used as measures for body composition.
To address these research questions, we considered two criteria for asthma status: 1)
ever diagnosis; and 2) current diagnosis (details provided in Section 6.2.1).
Methods
As highlighted in Section 6.1.4, summary level data was used in all of the analyses
for this one–sample Mendelian randomization study, with individual level data from
UK Biobank used to generate the summary level data. UK Biobank is a prospective
cohort study of approximately 500,000 participants aged between 40-69 years who were
recruited across 22 centres in the UK between 2006 and 2010. The study was established
to promote research into the aetiology of common diseases by environmental, lifestyle,
and genetic components [184]. Interview led questionnaires, physical measurements and
touch screen questionnaires were used to collect extensive baseline characteristics at
recruitment, including lifestyle factors, socio-demographic information, medical history,
biological samples, and physical attributes [185].
In Section 6.2.1 we provide an overview of the exposure and outcome measurements
recorded by UK Biobank that were used to generate the summary level data for the
Mendelian randomization analyses. Section 6.2.2 outlines the quality control steps
applied to the genetic and phenotypic data. The criteria applied to the 77 genetic
variants that reached GWS in the study by Locke et al. [104] to select the IVs for the
Mendelian randomization analyses is discussed in Section 6.2.3. Finally, we outline
the models fitted to obtain the summary level data on the selected IVs (Section 6.2.4),
and the Mendelian randomization analyses performed on the summary level data
(Section 6.2.5).
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6.2.1 Exposure and outcome measurements
Participants were asked a range of questions about their medical history in the touch-
screen questionnaire at recruitment, including the question (data field 6152): ‘Has a
doctor ever told you that you have had any of the following conditions? (You can
select more than one answer) a) blood clot in the leg; b) blood clot in the lung; c)
emphysema/chronic bronchitis; d) asthma; e) hayfever, allergic rhinitis or eczema; f)
none of the above’ [186]. Participants were also asked whether they had experienced
any wheezing or whistling in the chest during the last year. The participants underwent
a verbal interview by a trained nurse to confirm whether they had provided the correct
answers to the medical history questions in the touchscreen questionnaire [187]. If the
participant had selected the wrong response, then their answers were amended by the
interviewer, and recorded in data field 20002.
Since question 6152 included the phrase ‘has a a doctor ever told you’, and many
children outgrow asthma, we were concerned that a large proportion of the UK Biobank
participants who answered d) to question 6152 were not asthmatic at baseline. As
such, we considered two definitions for asthma: 1) ever diagnosis of asthma; and 2)
current asthma. For definition 1), a participant was considered as asthmatic if they
included d) in their response to question 6152 following their interview with the trained
nurse (recorded in 20002). For definition 2), a participant was considered as a current
asthmatic if they had been classed as having an ever diagnosis of asthma, and had
reported wheezing or whistling in the chest during the last year. We anticipated that
participants classed as having ‘current asthma’ were more likely to be asthmatic at
baseline.
If the participant had included d) in their response to question 6152, they were
asked what age they were when the asthma was first diagnosed. The mean (standard
deviation) age of diagnosis was calculated, and the number of participants who were
diagnosed with asthma by age 9 recorded. The dataset was split at the median year of
birth, and the mean (standard deviation) age of diagnosis for asthma was calculated in
the two subgroups. During the physical assessment, forced volume vital capacity (FVC)
and forced expiratory volume in 1 second (FEV1) were measured by the participant
blowing into a spirometer two or three times [188], and the average value of the these
measurements were recorded.
Weight (kg) was measured at recruitment during the physical assessment using the
Tanita BC418MA body composition analyser, and standing height (m) was measured
using the Seca 202 device [188]. Whole body FM (kg) and whole body FFM (kg)
were estimated from bioimpedance analysis (BIA) using the Tanita BC418MA body
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composition analyser [188]. As stated in Section 6.1, we will refer to ‘whole body FM’
as ‘FM’, and ‘whole body FFM’ as ‘FFM’. FM and FFM were also estimated in a
subset of participants (approximately 5,000 people) in a pilot study using Dual-energy
X-ray (DXA) data from a GE-Lunar iDXA [189]. Weight, FM and FFM were converted
into indices by dividing each measurement by the square of the participant’s height.
For those participants who had measurements for both BIA and DXA, the average
difference between the measurements for fat mass index (FMI=fat mass (kg)/height2
(m2)) and fat-free mass index (FFMI=fat-free mass (kg)/height2 (m2)) was recorded.
Summary statistics of demographic characteristics, including body composition mea-
surements and asthma status, were recorded for the participants whose measurements
were used to create the summary level data for the Mendelian randomization analyses.
The distributions of height, weight, BMI, FMI (both BIA and DXA measurements)
and FFMI (both BIA and DXA measurements) were also assessed through histograms.
6.2.2 Data quality control
This Mendelian randomization study uses genetic data released by UK Biobank in
July 2017. Genome-wide genotyping was carried out by UK Biobank in 106 batches of
samples using the Affymetrix UK BiLEVE Axiom array or the Affymetrix UK Biobank
Axiom array for 805,426 genetic variants. Imputation was performed centrally by the
Wellcome Trust Centre for Human Genetics using the Haplotype Reference Cohort.
After excluding participants who had withdrawn from the study or had no imputed
genetic data, genotyped data was available on 487,409 participants of the initial 502,664
participants (Figure 6.3). The quality control (QC) steps applied to the genotyped
data on the autosomal chromosomes by the Cardiovascular Epidemiology Unit at
the University of Cambridge are outlined in Figure 6.4. 782,205 genotyped genetic
variants on 367,643 participants passed the QC steps. Participants with missing
data for BMI, FMI (BIA measurement), FFMI (BIA measurement), ever diagnosis
of asthma or current asthma were excluded from the 367,643 participants, leaving
360,409 participants with phenotypic (BMI, FMI (BIA), FFMI (BIA), and asthma
status) and QC genetic data (Figure 6.3). Only 3,901 of the 360,409 participants had
DXA measurements for FMI and FFMI.
As outlined in Section 6.1.4, the 77 genetic variants that reached GWS for BMI in
the study by Locke et al. [104] were considered as potential IVs. All of the 77 genetic
variants passed the QC steps outlined in Figure 6.4. Regardless of whether genotyped
data was available, imputed genetic data was used to generate the summary level data
for the Mendelian randomization analyses (see Section 6.2.4). Jessica Rees used the
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QCTOOL v2 command–line programme to extract imputed genetic data on the 77
variants for the 360,409 participants. All of the genetic variants had an imputation
quality score > 0.96 (Table I.1).
Fig. 6.3 Flowchart highlighting the number of participants with phenotypic and quality
controlled (QC) genetic data from UK Biobank.
UK Biobank data → N=502,664
Genetic data → N=487,409
Excluded particiapants who withdrew from
the study or had no imputed genetic data
QC genetic data → N=367,643
Excluded participants if they failed the QC steps
applied to the genotyped data (see Figure 6.4)
Phenotypic and QC genetic data → N=360,409
Excluded participants for missing adiposity measure-
ments (BMI, FMI (BIA), FFMI (BIA)) or missing
asthma status. Only 3,901 of the 360,409 partici-
pants had DXA measurements for FMI and FFMI.
Abbreviations: BMI, body mass index; FMI, body fat mass index; and FFMI, body fat-free
mass index; BIA, bioelectrical impedance analysis; DXA, dual X-ray emission absorptiometry.
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Fig. 6.4 Flowchart highlighting the quality control steps applied to the genotyped genetic data
from UK Biobank by the Cardiovascular Epidemiology Unit at the University of Cambridge.
STEP 1: genetic variants used in the principle component analysis (PCA)
Genotyped variants from the 106 batches were included in the PCA if:
• Call rate ≥ 99%;
• Minor allele frequency (MAF) ≥ 0.05;
• Hardy-Weinberg Equilbrium (HWE) test p-value ≥ 10−5; and
• Linkage disequilbrium (LD) pruning determined by the r2 value (included if
r2 < 0.2).
All of the genetic variants in the 1000 Genomes Phase 3 data were also kept for the
PCA. Variants that were in three long range LD regions were excluded.
STEP 2: European ancestry subset
PCA was run on the genotyped variants selected in Step 1. The first 15 PCs were ap-
plied to the method outlined in Astle et al. [190] to identify a subset of participants
with European ancestry.
STEP 3: QC of batch level data
Participants not included in the European ancestry subset were removed, and the follow-
ing QC measures were applied to each batch of genotyped data:
• First stage: genetic variants were kept if they had a call rate ≤ 3 standard
deviations (SD) from the mean, and HWE test p-value ≥ 10−12 for rare variants
(MAF< 0.01) and p-value ≥ 10−6 for common variants (MAF≥ 0.01).
• Second stage: sample QC was then performed on each batch using the variants
that passed the first stage. Participants were excluded if the call rate or
heterozygosity was > 3 SDs from the mean.
STEP 4: Additional QC
Finally, the following QC measures were applied to the data in Step 3:
• Participants whose reported gender was different from their genetically inferred
gender were removed.
• The European subset was refined and verified by performing an additional PCA
on the participants from Step 3 and the variants used in the original PCA in Step
1. Genetic variants were retained using the same criteria outlined in Step 1.
• The list provided by UK Biobank outlining sample pairs related up to the 3rd
degree was used to remove related participants.
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6.2.3 Selection of genetic variants
To identify possible pleiotropic variants, the rs numbers of the 77 genetic variants that
reached GWS for BMI in the study by Locke et al. [104] were searched in Phenoscanner
[26] with the option of searching for genetic variants that could act as proxies for the
77 genetic variants. Phenoscanner identified proxies for the 77 genetic variants by
using a pairwise r2 (based on the 1,000 Genome Project) threshold of 0.6. Hence, a
genetic variant was classed as a proxy variant if its r2 value with one of the specified
77 genetic variants was greater than 0.6. Note that the r2 value takes into account the
linkage disequilibrium between the genetic variants and the minor allele frequency of
the genetic variants.
Data was extracted from the Phenoscanner search on all of the genetic variants
that reached GWS with any trait. A function written by Jessica Rees in RStudio
version 3.5.3 [86] was applied to the extracted data to create a list of traits (excluding
BMI, weight, height, FM and FFM) for each of the 77 genetic variants that were
associated at the GWS level with either the variant itself, or a proxy of the variant.
These lists were recorded for each of the 77 genetic variants by whether the trait was
adiposity related or not (Table 6.1). 29 of the 77 variants were associated with at least
one non-adiposity related trait at GWS, and 13 variants were associated with age at
menarche at GWS.
Since socioeconomic status and smoking may act as confounders of the BMI-asthma
association, the p-values of the genetic associations of the 77 variants with years
of educational attainment from the Social Science Genetic Association Consortium
(SSGAC) [191], and with smoking status from the Tobacco, Alcohol and Genetics
(TAG) consortium [192] were extracted from Phenoscanner (Table 6.1). Two variants
were associated with years of educational attainment at GWS, and 32 were nominally
associated (p-value > 0.5) with years of educational attainment. None of the variants
were associated with smoking at GWS, whereas 13 were associated at the nominal
level.
Physical activity may also act as a confounder of the BMI-asthma association, and
since there was no data for this trait in Phenoscanner, the genetic associations of the
77 variants with duration of walks (minutes per day) and duration of moderate activity
(minutes per day) were estimated in the UK Biobank dataset using the imputed genetic
data. Jessica Rees used the command–line programme SNPTEST v2 with the options
-method expected, -frequentist 1, and -use_raw_phenotypes to estimate these genetic
associations adjusted for the first 10 ancestry informative principle components (PC)
(obtained by the Cardiovascular Epidemiology Unit in Step 4 of Figure 6.4) and gender.
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By specifying ‘-method expected’ as an option, SNPTEST v2 uses the three genotype
probabilities (with respect to the minor allele) to calculate the expected genotype for
each variant. Note that this method does not take into account the uncertainty in the
imputed genotypes. The expected genotype is applied to an additive linear regression
model (-frequentist 1 ) with the option of mean centering and scaling the phenotype
turned off. None of the genetic associations for duration of walking or duration of
moderate exercise estimated from the UK Biobank dataset using SNPTEST v2 reached
GWS.
Using the information in Table 6.1, two sets of genetic variants were created using
the following criteria: 1) under the liberal approach, the variants that were associated
with smoking status at the nominal significance level (p-value < 0.05), or associated
with years of educational attainment or physical activity at the GWS level (p-value
< 5× 10−8), or associated with five or more non-adiposity related independent traits
from Phenoscanner at the GWS level were excluded; and 2) in addition to the variants
excluded under the liberal criteria, the conservative approach excluded variants that
were associated with years of educational attainment at the nominal level.
Note that the conservative set of genetic variants was a subset of the liberal set
of genetic variants, and the two sets only differed by whether the genetic variant was
nominally associated with years of educational attainment or not. A nominal level of
significance for years of educational attainment was only considered for the conservative
set of genetic variants as educational attainment was used as an approximate measure
for socioeconomic status. However, a GWS level for educational attainment was
considered for the liberal set of variants.
In total, 60 variants passed the liberal criteria, and 39 passed the conservative
criteria (see Table I.1). The Mendelian randomization analyses outlined in Section 6.2.5
were applied to both sets of genetic variants. Note that the rs1558902 variant in the
FTO gene region was associated with the following six traits at the GWS level: type
2 diabetes, age at menarche, fasting insulin, dietary macronutrient intake, HDL-C
and metabolic syndrome. Under the liberal criteria this genetic variant should have
been excluded from the analysis. However, many of these six traits are related to
BMI and are not strictly independent (e.g. type 2 diabetes, fasting insulin). Since
the six traits have no obvious biological relationship with asthma, it seems unlikely
that the IV3 assumption for univariable Mendelian randomization (Section 1.4) and
the IV4 assumption for multivariable Mendelian randomization (Section 2.6.3) would
be violated. As such, the rs1558902 variant was not excluded from the liberal or
conservative sets of variants used in the Mendelian randomization analysis.
Table 6.1 Genetic variants from the 77 variants selected from the GIANT consortium [104] that were associated with a phenotype
at the genome wide significance level classified as non-adiposity or adiposity related, and/or associated with years of education and
smoking at the nominal significance level (p-values provided).
rs no. Chr no. Gene GWSa P-value
Non-adiposity Adiposity Years of
educationb
Ever smokerc
rs11165643 1 PTBP2 HC
rs11583200 1 ELAVL4 0.04237 0.02848
rs12401738 1 FUBP1 HC 0.00002
rs12566985 1 FPGT-
TNNI3K
Age at menarche HC
rs17024393 1 GT2 HC
rs2820292 1 V1 WC 0.00180
rs3101336 1 NEGR1 Age at menarche HC 2.09×10−6 0.01734
rs543874 1 SEC16B Age at menarche HC, BFP 0.04843
rs657452 1 AGBL4 WC
rs1016287 2 LINC01122 HC 0.02463
rs10182181 2 ADCY3 HC 0.03967
rs11126666 2 KCNK3 0.02694
rs13021737 2 TMEM18 Age at menarche, stretch marks HC, BFP 0.02040
rs1528435 2 UBE2E3 0.01873
rs2121279 2 LRP1B 0.02124
rs13078960 3 CADM2 HC
rs1516725 3 ETV5 Age at menarche, log(eGFR creatinine in non
diabetics)
HC 0.00004
rs16851483 3 RASA2 0.00466
rs2365389 3 FHIT 0.04086
rs3849570 3 GBE1 WC
rs6804842 3 RARB
rs10938397 4 GNPDA2 Age at menarche HC 0.00526
rs13107325 4 SLC39A8 HDL-C, Chron’s disease, schizophrenia, blood
pressure, DBP, SBP, arterial pressure
0.00683
rs2112347 5 POC5 LDL-C, total cholesterol HC 0.00068
rs13191362 6 PARK2 Methylation levels 0.02458
rs2033529 6 TDRG1 WC
rs205262 6 C6orf106 HDL-C HC 0.01071
rs2207139 6 TFAP2B HC
rs9400239 6 FOXO3 Schizophrenia WC 0.02136 0.04902
rs1167827 7 HIP1 0.02364
rs2245368 7 PMS2L11 0.03428
rs17405819 8 HNF4G 0.00189
rs10968576 9 LINGO2 WC
rs1928295 9 TLR4 WC 0.01243
rs4740619 9 C9orf93 0.04199
rs6477694 9 EPB41L4B
rs11191560 10 NT5C2 CAD, schizophrenia, SBP
rs7903146 10 TCF7L2 Type 2 diabetes, fasting glucose and insulin HC
rs11030104 11 BDNF Age at menarche HC 0.04650 0.00020
rs12286929 11 CADM1 0.03439
rs3817334 11 MTCH2 log(Proinsulin), HDL-C WC
rs4256980 11 TRIM66 Age at menarche WC
rs11057405 12 CLIP1 HDL-C, adiponectin levels HC
rs7138803 12 BCDIN3D Age at menarche HC
rs12429545 13 OLFM4 HC
rs9581854 13 MTIF3 Weight 0.02130
rs10132280 14 STXBP6 HC
rs11847697 14 PRKD1
rs12885454 14 PRKD1 WC
rs7141420 14 NRXN3 HC 0.04606
rs16951275 15 MAP2K5 Age at menarche WC 0.03644
rs12446632 16 GPRC5B Age at menarche HC
rs1558902 16 FTO Type 2 diabetes, age at menarche, fasting
insulin, dietary macro-nutrient intake, HDL-
C, metabolic syndrome
HC, BFP,
WC
rs2650492 16 SBK1 Crohn’s disease, inflammatory bowel disease,
methylation levels
HC 0.02098 0.01912
rs3888190 16 ATP2A1 Crohn’s disease, inflammatory bowel disease,
years of educational attainment, methylation
levels, exon level expression of TUFM
HC, BFP 6.96×10−8
rs758747 16 NLRC3 0.00739
rs9925964 16 KAT8 Triglycerides, warfarin dose, Parkinson’s HC
rs1000940 17 RABEP1 Age at menopause, differential exon level ex-
pression of RPAIN, splicing of RABEP1
rs1808579 18 C18orf8 Years of educational attainment HC 2.15×10−8
rs6567160 18 MC4R Type 2 diabetes, HDL-C, CAD HC, BFP
rs17724992 19 GDF15 WC 0.00031 0.02425
rs2075650 19 TOMM40 HDL-C, LDL-C, total cholesterol, triglyc-
erides, CAD, macular degeneration,
Alzheimer’s disease, cognitive decline,
longevity, C-reactive protein, APOB
apolipoprotein, cerebrospil fluid, neurofibril-
lary tangles, neuritic plaque, verbal memory,
cortical amyloid beta load
WC, BFP 0.01957
rs2287019 19 QPCTL Fasting blood glucose, insulinogenic index,
LDL-C, total cholesterol
HC 0.04889
rs29941 19 KCTD15 0.04850 0.03473
rs3810291 19 ZC3H4 HC
Abbreviations: no., number; Chr, chromosome; GWS, genome wide significance; BFP, Body fat percentage; CAD, Coronary artery disease; DBP, Diastolic blood pressure;
HC, Hip circumference; HDL-C, High-density lipoprotein cholesterol; LDL-C, Low-density lipoprotein cholesterol; SBP, Systolic blood pressure; WC, Waist circumference.
aGenome wide significance, p-value< 5 × 10−8. bTaken the Social Science Genetic Association Consortium from Phenoscanner [191]. cTaken from the Tobacco, Alcohol
and Genetics consortium from Phenoscanner [192].
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6.2.4 Summary level data
Summary level data for the 60 genetic variants selected under the liberal criteria
(Section 6.2.3) was obtained by Jessica Rees using SNPTEST v2. For each genetic
variant, genetic associations were estimated for BMI, FMI (both BIA and DXA
measurements), FFMI (both BIA and DXA measurements), and both definitions
of asthma status (ever diagnosis and current asthma). The genetic associations for
BMI, FMI (BIA), FFMI (BIA) and asthma (ever diagnosis and current asthma)
were estimated using data on 360,409 participants. The genetic association for DXA
measurements of FMI and FFMI were estimated using data on 3,901 of the 360,409
participants (Figure 6.4).
As done in Section 6.2.3 for the physical activity measurements, SNPTEST v2 was
used to estimate the genetic associations with BMI, FMI (BIA and DXA measurements)
and FFMI (BIA and DXA measurements) with the options -method expected, -frequentist
1, and -use_raw_phenotypes. Hence, SNPTEST v2 fitted linear regression models where
the effect of the genetic variant on the body composition measurement was assumed to
be additive for each additional copy of the minor allele. The genetic associations for
BMI, FMI (BIA and DXA measurements) and FFMI (BIA and DXA measurements)
were adjusted for population stratification by including the first 10 ancestry informative
PCs in the linear regression models (obtained by the Cardiovascular Epidemiology
Unit in Step 4 of Figure 6.4). The genetic associations were also adjusted for gender to
improve the precision of the estimates. Despite accounting for height in the formulae for
BMI, FMI and FFMI (Section 6.2.1), the measurements may not be fully independent
of height. In addition to the first 10 PCs and gender, we therefore decided to adjust
the BMI, FMI and FFMI genetic associations by height.
For linear regression models, we assume that the residuals are independent, normally
distributed, and homoscedastic. Since the distribution of the measurements for BMI,
FMI (BIA and DXA measurements) and FFMI (BIA and DXA measurements) were
bimodal with respect to gender, and tended to be positively skewed (Figures I.1-
I.3), the normality and homoscedasticity assumptions may not have been satisfied.
Although this may have been rectified by transforming the BMI, FMI and FFMI data,
the estimates from the Mendelian randomization analyses would not have been as
easily interpreted. As such, the -use_raw_phenotypes option was used to ensure BMI,
FMI and FFMI were not mean centred or scaled. The genetic associations obtained
from SNPTEST v2 therefore represent the average change in BMI, FMI or FFMI per
additional copy of the minor allele.
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The power to detect a genetic association with a continuous trait was estimated by
Jessica Rees using the function GeneticPower.Quantitative.Numeric() in the R package
GeneticsDesign [193]. Assuming an additive effect of the genetic variant on the trait,
and applying a GWS level, there would be 50.7% power to detect a genetic effect if the
variant explained 0.01% of the variance in the trait. This power calculation is based on
a sample size of 360,409 and the assumption that 13 additional parameters (10 PCs,
gender, age and height) are included in the linear regression model.
Since 60 genetic associations will be estimated on each of the BMI, FMI and FFMI
measurements, using a GWS level for power calculations may be conservative. As such,
it may be more appropriate to use a Bonferonni adjusted significance level of 0.05/60.
Under this significance level, and using the same assumptions as above, there would be
99.0% power to detect a genetic effect. This power was reduced to 0.002% when the
sample size was 3,901 rather than 360,409.
As a measure of instrument strength, the R2, adjusted R2 and F-statistic were
recorded when BMI, FMI (BIA and DXA measurements) and FFMI (BIA and DXA
measurements) were regressed against each of the 60 genetic variants in turn, and when
they were regressed against all of the 60 liberal and 39 conservative variants. To consider
the strength of the genetic variants for the multivariable Mendelian randomization
analyses, the Sanderson-Windmeijer conditional F-statistic [83] were estimated for all
of the BIA and DXA measurements for the liberal and conservative sets of genetic
variants.
For asthma status (ever diagnosis and current asthma), all of the genetic associations
were adjusted for the first 10 ancestry informative PCs and gender with the SNPTEST
v2 options -method expected and -frequentist 1. Hence, SNPTEST v2 fitted logistic
regression models where the effect of the genetic variant on asthma status was assumed
to be additive on the log scale. Note that the logistic regression models included the
first 10 ancestry informative PCs to adjust for population stratification. The genetic
associations were also adjusted for gender to improve the precision of the estimates.
Plots of the genetic associations with 95% confidence intervals with BMI and asthma
were assessed for pleiotropic variants. These plots were created by Jessica Rees in
RStudio version 3.5.3 [86] using the package ggplot2 [141]. To consider collinearity in
the multivariable Mendelian randomization models (as discussed in Section 2.6.3), the
correlation between the genetic associations of FMI and FFMI were recorded for the
BIA and DXA measurements. Plots of the genetic associations with 95% confidence
intervals with FMI and FFMI were also considered for the BIA and DXA measurements.
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6.2.5 Mendelian randomization analyses
The summary level data obtained from the UK Biobank dataset (Section 6.2.4) was
used to perform univariable and multivariable Mendelian randomization analyses
(Figure 6.5). These analyses were performed on the genetic associations for an ever
diagnosis of asthma and current asthma (Section 6.2.1). As outlined in Figure 6.5, the
effect of BMI on asthma (ever diagnosis and current) was considered through IVW
models using the following three groups of IVs: 1) 60 liberal genetic variants selected in
Section 6.2.3; 2) 39 conservative genetic variants selected in Section 6.2.3; and 3) two
genetic variants from the FTO and MC4R gene regions (i.e. one genetic variant from
each region). Groups 1) and 2) were considered in the following sensitivity analyses:
simple median [52]; weighted median [52]; and MR-Egger [29].
Fig. 6.5 Figure highlighting the univariable and multivariable Mendelian randomization
analyses performed to investigate the effect of adiposity and body composition on asthma.
Univariable analyses
Risk factor: BMI
Methods: univariable IVW, median
estimator and univariable MR-Egger
using summary level data (Section 6.2.4)
IVs used in the methods: set of
liberal genetic variants (60 IVs), set of
conservative genetic variants (39 IVs),
and 2 genetic variants from gene regions
FTO and MC4R (applied to IVW only)
No. of analyses: 7 for ever diagnosis
of asthma and 7 for current asthma
Multivariable analyses
Risk factors: FMI and FFMI (BIA
and DXA measurements considered
separately)
Methods: multivariable IVW and
multivariable MR-Egger using summary
level data (Section 6.2.4)
IVs used in the methods: set of
liberal genetic variants (60 IVs) and set
of conservative genetic variants (39 IVs)
No. of analyses for BIA and DXA
measurements: 8 for ever diagnosis of
asthma and 8 for current asthma
Abbreviations: BMI, body mass index; FMI, body fat mass index; and FFMI, body fat-free
mass index; BIA, bioelectrical impedance analysis; DXA, dual X-ray emission absorptiometry;
IVW, inverse variance weighted; IV, instrumental variable.
To assess the effect of FMI and FFMI on asthma (ever diagnosis and current),
multivariable IVW and multivariable MR-Egger methods were fitted to the summary
level data for the 60 liberal genetic variants and 39 conservative genetic variants. The
BIA and DXA measurements for FMI and FFMI were considered separately. As
highlighted in Section 6.2.4, the summary level data for the BIA measurements was
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estimated using measurements on 360,409 participants, whereas the summary level
data for the DXA measurements was only based on 3,901 of the 360,409 participants.
We refer back to the simulations performed in Sections 3.5 and 4.4 for an indication
of the statistical power we may expect for the univariable and multivariable IVW
analyses. For univariable IVW, we had 98.2% power (Table 3.4) to detect a positive
causal effect of 0.3 when 15 genetic variants (all valid IVs) explained 3% of the variance
in the risk factor with a sample size of 10,000 (see Section 3.5.1 for the data generating
model). For multivariable IVW with 185 genetic variants (all valid IVs), we had 98.9%
power to detect a positive causal effect of 0.3 for one risk factor when the summary
level data for the three risk factors were generated independently (Table 4.5). The
data generating model for this simulation study did not specify the sample size as it
generated the summary level data directly.
For the multivariable MR-Egger model, the reference alleles were orientated to
ensure all of the genetic associations for FMI were positive, and the estimates for FMI
and the intercept term were recorded. The multivariable MR-Egger model was refitted
when the genetic associations for FFMI were all positive, and the estimates for FFMI
and the intercept term were recorded. These multivariable MR-Egger models were
applied to the BIA and DXA measurements of FMI and FFMI. All of the Mendelian
randomization analyses used random effects (see Section 2.3.1 for details).
All of the Mendelian randomization analyses were performed by Jessica Rees in
RStudio version 3.5.3 [86].
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Results
This Section contains the results from the one–sample Mendelian randomization study
on the effect of adiposity and body composition on asthma using univariable and
multivariable analyses. In Section 6.2.6, we provide a summary of the demographic
characteristics of the 360,409 UK Biobank participants used to create the summary
level data for the Mendelian randomization analyses. Details on the summary level
data, including the R2, adjusted R2, and F-statistics, are contained in Section 6.2.7.
The results from the univariable and multivariable Mendelian randomization analyses
for an ever diagnosis of asthma are presented in Section 6.2.8. Finally, the results
from the univariable and multivariable Mendelian randomization analyses for current
asthma are presented in Section 6.2.9.
6.2.6 Descriptive statistics of the individual level data
A summary of the demographic characteristics of the 360,409 participants with pheno-
typic and QC genetic data (Figure 6.3) are recorded in Table 6.2. The mean age of
the participants was 56.6 (8.0) years, and 54.2% of participants were women. 41,978
(11.6%) had reported to have been diagnosed by a doctor with asthma. Men were more
likely to smoke than women, and women were less likely to do physical exercise.
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Table 6.2 Summary of the demographic characteristics recorded at baseline of the 360,409
participants used to estimate the summary level data for the Mendelian randomization
analyses. Mean (standard deviation) values are presented for continuous, and numbers (%)
are presented for categorical measurements.
All (N=360,409) Women (N=195,479) Men (N=164,930)
Age, yrs 56.6 (8.0) 56.5 (7.9) 56.9 (8.1)
BMI, kg/m2 27.4 (4.73) 27.0 (5.12) 27.8 (4.18)
Ever diagnosis of asthma:
Yes 41,978 (11.6) 24,088 (12.3) 17,890 (10.8)
No 318,431 (88.4) 171,391 (87.7) 147,040 (89.2)
Smoking status:
No 323,087 (89.7) 178,244 (91.2) 144,843 (87.9)
Yes, on most days 27,100 (7.5) 12,906 (6.6) 14,194 (8.6)
Only occasionally 9,802 (2.7) 4,087 (2.0) 5,715 (3.5)
Prefer not to say 220 (0.1) 130 (0.1) 90 (0)
Missing observations 200 112 88
Alcohol consumption:
Never 23,566 (6.5) 15,414 (7.9) 8,152 (4.9)
Special occasions only 38,239 (10.6) 27,379 (14.0) 10,860 (6.6)
1-3 times a month 40,001 (11.1) 25,479 (13.0) 14,522 (8.8)
1-2 times a week 93,973 (26.1) 51,181 (26.2) 42,792 (26.0)
3-4 times a week 86,811 (24.1) 42,254 (21.6) 44,557 (27.0)
Daily or almost daily 77,345 (21.5) 33,519 (17.2) 43,826 (26.6)
Prefer not to say 273 (0.1) 140 (0.1) 133 (0)
Missing observations 201 113 88
Walking, mins/day 54.8 (76.3) 51.5 (71.5) 58.6 (81.5)
Missing observations 13,186 6,781 6,405
Moderate activity, mins/day 59.5 (75.8) 56.0 (68.7) 63.5 (83.2)
Missing observations 60,470 33,856 26,614 (16.1)
Townsend scorea, -1.48 (2.99) -1.51 (2.94) -1.44 (3.05)
Missing observations 425 231 194
Household income before tax:
<£18,000 66,180 (18.4) 38,034 (19.5) 28,146 (17.1)
£18,000 to £30,999 78,315 (21.8) 42,585 (21.9) 35,730 (21.8)
£31,000 to £51,999 82,319 (22.9) 41,881 (21.5) 40,438 (24.7)
£52,000 to £100,000 65,933 (18.5) 31,703 (16.3) 34,230 (20.8)
>£100,000 17,738 (4.90) 8,319 (4.30) 9,419 (5.7)
Do not know 13,838 (3.80) 10,482 (5.40) 3,356 (2.0)
Prefer not to say 34,686 (9.70) 21,787 (11.1) 12,899 (7.9)
Missing observations 1,400 688 712
University or higher educationb
Yes 85,743 (55.3) 35,887 (42.9) 33,316 (46.7)
No 69,203 (44.7) 47,850 (57.1) 37,893 (53.3)
Missing observations 205,463 111,742 93,721
Abbreviations: yrs, years; BMI, body mass index.
aHigher scores represent a greater degree of deprivation.
bBinary variable based on the 6138 data field. Participants who stated they had a college or university degree, or other
professional qualifications (e.g. nursing, teaching) were considered to have a university or higher education.
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Table 6.3 contains summary measures of the adiposity and body composition mea-
surements, and Figures I.1-I.3 contain histograms of these traits. Although there was
little difference in BMI between gender, mean FMI was larger in women than men, and
mean FFMI was smaller in women. The mean difference in the measurements for BIA
and DXA for FMI and FFMI are also recorded in Table 6.5. On average, FMI was
larger when it is measured by DXA compared to BIA, whereas FFMI was generally
smaller when it is measured by BIA. There appears to be more discrepancy between
the BIA and DXA measurements for men than women.
Table 6.3 Mean (standard deviation) adiposity and body composition measurements of the
360,409 participants used to estimate the summary level data for the Mendelian randomization
analyses.
All (N=360,409) Women (N=195,470) Men (N=164,930)
Weight, kg 78.2 (15.8) 71.4 (13.9) 86.2 (14.1)
Height, m 1.69 (0.09) 1.63 (0.06) 1.76 (0.07)
BMI, kg/m2 27.4 (4.73) 27.0 (5.12) 27.8 (4.18)
BIA measurements, kg/m2
FMI 8.80 (3.61) 10.1 (3.77) 7.22 (2.65)
FFMI 18.6 (2.61) 16.8 (1.69) 20.6 (1.94)
DXA measurements, kg/m2
FMI 9.11 (3.41) 10.1 (3.63) 8.01 (2.77)
Missing observations 356,508 193,435 163,064
FFMI 17.2 (2.23) 15.8 (1.54) 18.8 (1.70)
Missing observations 356,508 193,435 163,064
Mean differencea, kg/m2
FMI -0.74 (1.66) -0.4 (1.73) -1.12 (1.5)
Missing observations 356,508 193,435 163,064
FFMI 1.22 (1.01) 0.89 (0.9) 1.58 (1.01)
Missing observations 356,508 193,435 163,064
Abbreviations: BMI, body mass index; FMI, fat mass index; FFMI, fat-free mass index; BIA, bioimpedance analysis;
DXA, Dual-energy X-ray based on 3,901 participants.
aMean (standard deviation) difference between bioelectrical impedance analysis and Dual-energy X-ray for fat mass
index and fat-free mass index.
The mean age of asthma diagnosis was 31.1 years (Table 6.4). The mean age of
diagnosis was 37.6 (20.5) years and 26.0 (15.6) years before and after the median year
of birth (1950). 6,229 (17.2%) of the 41,978 participants with an ever diagnosis of
asthma had been diagnosed by a doctor before the age of 9 years. The proportion of
participants who reported to have a wheeze or whistle on the chest in the last year,
and the mean (standard deviation) FVC and FEV1 values by an ever diagnosis of
asthma are contained in Table 6.5. Using self-reported wheeze or whistling on the
chest, only 27,095 (7.5%) participants were considered as current asthmatics. Of the
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3,901 participants with DXA measurements, 485 (14.2%) had an ever diagnosis of
asthma, and 280 (7.2%) were classed as current asthmatics.
Table 6.4 Mean (standard deviation) age of asthma diagnosis for the 41,978 who reported
to have been diagnosed by a doctor with asthma by median year of birth (1950).
All (N=41,978) Year of birth
<1950 (N=15,620) ≥1950 (N=20,539)
Mean (SD), yrs 31.1 (18.7) 37.6 (20.5) 26.0 (15.6)
Did not know (%) 4,319 (10.7) 1,951 (13.1) 2,368 (12.0)
Preferred not to say (%) 25 (0.10) 10 (0.06) 15 (0.07)
Missing observations 1,475 676 799
Abbreviations: SD, standard deviation; yrs, years.
Table 6.5 Number (%) of participants that reported having a wheeze or whistling on the chest
in the last year, and mean (standard deviation) forced vital capacity and forced expiratory
volume in 1 second by ever diagnosis of asthma.
Ever diagnosis of asthma
Yes (N=41,978) No (N=325,432)
Wheeze or whistling on the chest
Yes 27,095 (64.6)a 45,429 (14.0)
No 14,190 (33.8) 266,766 (82.0)
Preferred not to say 20 (0.05) 127 (0.10)
Did not know 654 (1.65) 5,927 (1.82)
Missing observations 19 182
FVC, litres 3.50 (1.05) 3.67 (1.00)
Missing observations 5,847 25,361
FEV1, litres 2.56 (0.78) 2.79 (0.77)
Missing observations 5,847 25,361
aThese participants were classed as current asthmatics.
Abbreviations: FVC, forced volume vital capacity; FEV1, forced expiratory volume in 1 second.
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6.2.7 Summary level data
Tables I.2 to I.4 and I.7 contain estimates of the genetic associations of the 60 liberal
variants for BMI, FMI (BIA measurements), FFMI (BIA measurements) and asthma
(ever diagnosis and current asthma) based on 360,409 participants from UK Biobank.
Tables I.5 and I.6 contain estimates of the genetic associations of the DXA measurements
for FMI and FFMI on 3,901 of 360,409 the participants. Two variants (rs11126666
and rs11727676) had p-values > 0.05 for both BMI and FMI (BIA), and 13 of the 60
variants did not reach GWS for BMI. None of the indices for the DXA measurements
reached GWS, and a maximum of six variants were nominally associated with FMI or
FFMI.
Table 6.6 contains the R2, adjusted R2, and F-statistics when the adiposity and
body composition measurements were regressed against the liberal and conservative
sets of genetic variants. The liberal variants explained 1.4% of the variance in BMI,
and the conservative variants explained 0.9%. The liberal and conservative sets of
genetic variants explained more variation in FMI (BIA) than FFMI (BIA). Due to the
small sample size, there were noticeable differences between the R2 and adjusted R2
values for the DXA measurements. Both sets of genetic variants acted as weak IVs
for the multivariable methods for the BIA and DXA measurements, with the largest
conditional F-statistic being 5.1 for FMI (BIA).
Table 6.6 Values of the R2, adjusted R2, and F-statistic for the adiposity and body
composition measurements from the model including the full set of liberal or conservative
variants on the 360,409 participants from UK Biobank. The Sanderson-Windmeijer conditional
F-statistic are provided for the BIA and DXA measurements.
60 liberal variants 39 conservative variants
R2 Adjusted R2 F-stat CF-stat R2 Adjusted R2 F-stat CF-stat
BMI 0.0137 0.0136 83.5 - 0.0093 0.0092 86.4 -
BIA measurements
FMI 0.0094 0.0093 57.2 4.0 0.0063 0.0062 58.6 5.1
FFMI 0.0067 0.0065 40.5 3.9 0.0047 0.0046 43.4 5.0
DXA measurementsa
FMI 0.0170 0.0016 1.1 0.99 0.0116 0.0016 1.2 0.94
FFMI 0.0162 0.0009 1.1 0.88 0.0107 0.0007 1.1 0.74
Abbreviations: F-stat, F-statistic; CF-stat, conditional F-statistic; BMI, body mass index; BIA, bioelectrical impedance
analysis; FMI, fat mass index; FFMI, fat-free mass index; DXA, Dual-energy X-ray.
aEstimated from the 3,901 of the 360,409 participants with DXA measurements.
6.2 One–sample Mendelian randomization analysis 211
The correlation between FMI and FFMI was 0.138 and 0.162 for the BIA and
DXA measurements respectively. The correlation between the estimates of the genetic
associations for the BIA measurements for FMI and FFMI was 0.957 and 0.952 for
the liberal and conservative sets of genetic variants. For the DXA measurements,
correlation between the genetic associations for FMI and FFMI was 0.658 and 0.715
for the liberal and conservative variants. Despite the values for FMI and FFMI being
weakly correlated, the estimates of the genetic associations for FMI and FFMI were
highly correlated for both the BIA and DXA measurements. Despite these strong
correlations, we would still advise that the genetic associations for FMI and FFMI be
included in the same multivariable IVW model to safe guard against the IV assumptions
being violated, and to provide insight into the aetiological role of FMI and FFMI on
asthma.
Figure 6.6 contains four scatter plots of the genetic associations for FMI and
FFMI for the BIA and DXA measurements using the liberal and conservative sets of
genetic variants selected for the Mendelian randomization analyses. Plots a. and b.
in Figure 6.6 highlight the strong linear trend in the genetic associations for the BIA
measurements. Only one of the genetic variants in the liberal and conservative sets of
genetic variants had opposite directions of association for FMI and FFMI using the BIA
measurements, and the estimate of the genetic association for FMI for this variant did
not reach the nominal level of significance. Although there was a clear positive trend
to the genetic associations for FMI and FFMI using the DXA measurements (plots c.
and d. in Figure 6.6), only 42 of the 60 liberal genetic variants had the same direction
of association for FMI and FFMI. However, the estimates for the DXA measurements
were far less precise than the estimates from BIA, and few reached nominal significance
for the DXA measurements.
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a. b.
c. d.
Fig. 6.6 Scatter plots of the genetic associations with 95% confidence intervals for fat
mass index (FMI) and fat-free mass index (FFMI) using bioelectrical impedance analysis
(BIA) for the 60 liberal (a.) and 39 conservative (b.) sets of genetic variants. The genetic
associations for the BIA measurements were estimated using data on 360,409 participants
from UK Biobank. The figure also contains scatter plots of the genetic associations with FMI
and FFMI using dual X-ray emission absorptiometry (DXA) for the 60 liberal (c.) and 39
conservative (d.) sets of genetic variants are also displayed. The genetic associations for the
DXA measurements were estimated using data on 3,901 of the 360,409 individuals from UK
Biobank.
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6.2.8 Ever diagnosis of asthma
In this Section, we present the results from the univariable and multivariable Mendelian
randomization analyses investigating the effect of adiposity and body composition on
an ever diagnosis of asthma (see Section 6.2.1 for definition).
Figure 6.7 contains the scatter plot of the genetic associations with BMI and ever
diagnosis of asthma for the 60 liberal genetic variants, and Figure 6.8 contains the
scatter plot of the 39 conservative genetic variants. There appears to be a positive
dose-response relationship in Figures 6.7 and 6.8, although there is some heterogeneity
in the genetic associations.
Results from the Mendelian randomization analyses are contained in Table 6.7. All
of the estimates for BMI were positive for both sets of genetic variants, and apart
from the MR-Egger model, all of the estimates were nominally associated with an ever
diagnosis of asthma. There was little difference in the estimates for the liberal and
conservative sets of genetic variants for the different methods. The estimate from the
IVW model when the variants were treated as separate instruments was 0.047 (95%
CI: 0.025, 0.069) and 0.048 (95% CI: 0.021, 0.074) for the liberal and conservative sets
of genetic variants respectively. The estimate for BMI was 0.036 (95% CI: 0.002, 0.070)
with a p-value of 0.038 when the two variants in the FTO and MC4R gene regions
acted as IVs in the IVW model.
The estimates for FMI and FFMI using the BIA measurements from the multivari-
able IVW and multivariable MR-Egger models were positive and negative respectively
for both sets of genetic variants. None of the estimates were significant at the nominal
level, and the precision of the estimates reduced when the conservative set of variants
were used as IVs in the multivariable IVW model.
The estimates for FMI using the DXA measurements were both positive from the
multivariable IVW and multivariable MR-Egger models for the two sets of variants.
The estimates for FMI using the DXA measurements reached nominal significance
in the multivariable IVW model for the liberal (0.041, 95% CI: 0.001, 0.081) and
conservative (0.050, 95% CI: 0.004, 0.095) sets of genetic variants. Although the
estimates for FMI (DXA) from the multivariable MR-Egger model did reach nominal
significance for the two sets of genetic variants, the p-value of the intercept term was
0.008 and 0.023 for the liberal and conservative variants respectively.
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Fig. 6.7 Scatter plot of the genetic associations with body mass index and ever diagnosis of
asthma (41,978 cases) for the 60 liberal variants included in the Mendelian randomization
analyses. The genetic associations were estimated using data on 360,409 participants from
UK Biobank. The blue line represents the estimate of the approximate causal log odds ratio
for an ever diagnosis of asthma per unit increase in body mass index from the IVW method.
Fig. 6.8 Scatter plot of the genetic associations with body mass index and ever dignosis of
asthma (41,978 cases) for the 39 conservative variants included in the Mendelian randomization
analyses. The genetic associations were estimated using data on 360,409 participants from
UK Biobank. The blue line represents the estimate of the approximate causal log odds ratio
for an ever diagnosis of asthma per unit increase in body mass index from the IVW method.
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Table 6.7 Estimates of the approximate causal log odds ratios (standard errors) for ever
diagnosis of asthma per unit increase in body mass index from IVW, simple median, weighted
median and MR-Egger (with intercept estimate) methods. The table contains estimates
of the approximate causal log odds ratios for ever diagnosis of asthma per unit increase
in the BIA and DXA measurements from multivariable IVW and multivariable MR-Egger
(with intercept estimate). Estimates from multivariable MR-Egger are presented for each
body composition measurement where the reference allele is the trait increasing allele for the
measurement. Estimates are provided for the liberal and conservative sets of genetic variants.
60 liberal variants 39 conservative variants
Estimate (se) 95% CI P-value Estimate (se) 95% CI P-value
BMI
IVW 0.047 (0.011) 0.025, 0.069 2×10−5 0.048 (0.014) 0.021, 0.074 4×10−4
Median 0.046 (0.016) 0.016, 0.077 0.003 0.050 (0.020) 0.010, 0.089 0.014
Weighted median 0.044 (0.016) 0.014, 0.075 0.004 0.045 (0.018) 0.010, 0.080 0.012
MR-Egger 0.045 (0.023) 0.000, 0.090 0.050 0.046 (0.026) -0.004, 0.097 0.074
(Intercept) 0.000 (0.003) -0.005, 0.006 0.904 0.000 (0.003) -0.006, 0.006 0.949
BIA measurements
Multivariable IVW
FMI 0.119 (0.066) -0.010, 0.248 0.070 0.077 (0.079) -0.077, 0.232 0.328
FFMI -0.075 (0.111) -0.292, 0.142 0.497 -0.001 (0.128) -0.253, 0.251 0.994
Multivariable MR-Egger
FMI 0.113 (0.076) -0.039, 0.266 0.141 0.062 (0.094) -0.128, 0.252 0.512
(Intercept) 0.000 (0.003) -0.005, 0.006 0.881 0.001 (0.003) -0.006, 0.008 0.758
FFMI -0.075 (0.112) -0.299, 0.149 0.505 -0.001 (0.130) -0.265, 0.263 0.994
(Intercept) 0.000 (0.003) -0.005, 0.005 0.982 0.000 (0.003) -0.007, 0.007 0.994
DXA measurementsa
Multivariable IVW
FMI 0.041 (0.021) 0.001, 0.081 0.046 0.050 (0.023) 0.004, 0.095 0.033
FFMI 0.009 (0.038) -0.065, 0.083 0.815 0.021 (0.044) -0.065, 0.107 0.631
Multivariable MR-Egger
FMI 0.092 (0.026) 0.039, 0.145 0.001 0.091 (0.028) 0.035, 0.147 0.002
(Intercept) -0.006 (0.002) -0.010, -0.002 0.006 -0.006 (0.002) -0.011, -0.001 0.019
FFMI 0.045 (0.050) -0.055, 0.145 0.371 0.052 (0.055) -0.059, 0.162 0.349
(Intercept) -0.002 (0.002) -0.007, 0.002 0.274 -0.002 (0.002) -0.007, 0.003 0.349
Abbreviations: se, standard error; CI, confidence interval; BMI, body mass index; IVW, inverse-variance weighted;
FMI, fat mass index; FFMI, fat-free mass index; BIA, bioelectrical impedance analysis; DXA, Dual-energy X-ray.
aResults based on the genetic associations for the DXA measurements estimated on 3,901 of the 360,409 participants,
and the genetic associations for ever diagnosis of asthma estimated on 360,409 participants.
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6.2.9 Current asthma
In this Section, we present the results from the univariable and multivariable Mendelian
randomization analyses investigating the effect of adiposity and body composition on
current asthma (see Section 6.2.1 for definition).
Figures 6.9 and 6.10 contain the scatter plots of the genetic associations with BMI
and current asthma status for the liberal and conservative sets of genetic variants.
There is little difference between Figures 6.9 and 6.10, and we still observe positive
dose-response relationships when current asthma is considered rather than an ever
diagnosis of asthma (Figure 6.7 and 6.8).
The results from the Mendelian randomization models for current asthma are
contained in Table 6.8. The estimates for BMI increased for all models compared to the
estimates in Table 6.7. The precision of the estimates decreased when current asthma
(Table 6.8) was considered rather than an ever diagnosis of asthma (Table 6.7). The
estimate from the IVW model with the two variants from the FTO and MC4R gene
region was 0.059 (95% CI: 0.017, 0.100) with p-value of 0.006. The estimates from the
MR-Egger model when the liberal (0.056, 95% CI: 0.003, 0.109) and conservative (0.071,
95% CI: 0.012, 0.129) sets of variants acted as IVs were significant at the nominal level.
The results from the multivariable models were similar to an ever diagnosis of
asthma (Table 6.7). The estimates for FMI (DXA) still reached the nominal level
of significance for the multivariable IVW and multivariable MR-Egger models. The
estimates of the intercept term from the multivariable MR-Egger models had a p-value
< 0.05 for both sets of variants.
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Fig. 6.9 Scatter plot of the genetic associations with body mass index and current asthma
status (27,095 cases) with 95% confidence intervals for the 60 liberal variants included in
the Mendelian randomization analyses. The genetic associations were estimated using data
on 360,409 participants from UK Biobank. The blue line represents the estimate of the
approximate causal log odds ratio for current diagnosis of asthma per unit increase in body
mass index from the IVW method.
Fig. 6.10 Scatter plot of the genetic associations with body mass index and current asthma
status (27,095 cases) with 95% confidence intervals for the 39 conservative variants included
in the Mendelian randomization analyses. The genetic associations were estimated using
data on 360,409 participants from UK Biobank. The blue line represents the estimate of the
approximate causal log odds ratio for current diagnosis of asthma per unit increase in body
mass index from the IVW method.
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Table 6.8 Estimates of the approximate causal log odds ratios (standard errors) for current
asthma per unit increase in body mass index from IVW, simple median, weighted median
and MR-Egger (with intercept estimate) methods. The table contains the estimates of the
approximate causal log odds ratios for current asthma per unit increase in the BIA and
DXA measurements from multivariable IVW and multivariable MR-Egger (with intercept
estimate). Estimates from multivariable MR-Egger are presented for each body composition
measurement where the reference allele is the trait increasing allele for the measurement.
Estimates are provided for the liberal and conservative sets of genetic variants.
60 liberal variants 39 conservative variants
Estimate (se) 95% CI P-value Estimate (se) 95% CI P-value
BMI
IVW 0.059 (0.013) 0.033, 0.085 1×10−5 0.063 (0.016) 0.033, 0.094 5×10−5
Simple median 0.072 (0.019) 0.035, 0.110 2×10−4 0.072 (0.024) 0.025, 0.119 0.003
Weighted median 0.075 (0.018) 0.039, 0.110 5×10−5 0.075 (0.022) 0.033, 0.117 0.001
MR-Egger 0.056 (0.027) 0.003, 0.109 0.039 0.071 (0.030) 0.012, 0.129 0.018
(Intercept) 0.000 (0.003) -0.006, 0.007 0.892 -0.001 (0.004) -0.008, 0.006 0.778
BIA measurements
Multivariable IVW
FMI 0.132 (0.078) -0.020, 0.285 0.090 0.107 (0.091) -0.071, 0.284 0.241
FFMI -0.065 (0.131) -0.323, 0.192 0.619 -0.007 (0.148) -0.297, 0.282 0.960
Multivariable MR-Egger
FMI 0.112 (0.090) -0.068, 0.293 0.217 0.094 (0.108) -0.125, 0.313 0.390
(Intercept) 0.001 (0.003) -0.005, 0.008 0.658 0.001 (0.004) -0.007, 0.009 0.826
FFMI -0.065 (0.133) -0.331, 0.200 0.624 -0.006 (0.150) -0.310, 0.297 0.968
(Intercept) 0.000 (0.003) -0.006, 0.006 0.989 -0.001 (0.004) -0.009, 0.006 0.726
DXA measurementsa
Multivariable IVW
FMI 0.055 (0.024) 0.007, 0.102 0.025 0.063 (0.027) 0.010, 0.116 0.019
FFMI 0.007 (0.045) -0.080, 0.095 0.869 0.034 (0.051) -0.066, 0.134 0.503
Multivariable MR-Egger
FMI 0.110 (0.032) 0.046, 0.173 0.001 0.111 (0.032) 0.046, 0.176 0.001
(Intercept) -0.006 (0.002) -0.011, -0.001 0.013 -0.007 (0.003) -0.012, -0.001 0.021
FFMI 0.045 (0.059) -0.074, 0.163 0.455 0.045 (0.064) -0.085, 0.175 0.485
(Intercept) -0.002 (0.003) -0.008, 0.003 0.343 -0.001 (0.003) -0.006, 0.005 0.773
Abbreviations: se, standard error; CI, confidence interval; BMI, body mass index; IVW, inverse-variance weighted;
FMI, fat mass index; FFMI, fat-free mass index; BIA, bioelectrical impedance analysis; DXA, Dual-energy X-ray.
aResults based on the genetic associations for the DXA measurements estimated on 3,901 of the 360,409 participants,
and the genetic associations for ever diagnosis of asthma estimated on 360,409 participants.
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6.2.10 Summary
In this Section, we have performed a one-sample Mendelian randomization analysis to
investigate the effect of adiposity and body composition on an ever diagnosis of asthma
and current asthma. We have presented evidence of a positive causal association
between BMI and asthma for both an ever diagnosis of asthma and current asthma for
all sets of IVs considered in the IVW models. The effect of body composition (measured
through FMI and FFMI) on asthma was less clear. None of the measurements for FMI
and FFMI under BIA reached the nominal level of significance for the multivariable
analyses, although the direction of the point estimates suggested that FMI may
have an adverse effect on asthma. This was supported from the estimates for the
DXA measurements where FMI was nominally associated with asthma in all of the
multivariable models. However, the intercept term from the multivariable MR-Egger
model for FMI was significant for all models, suggesting that the InSIDE assumption
for multivariable MR-Egger was not satisfied and/or there was unmeasured pleiotropy
[32].
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6.3 Two–sample Mendelian randomization analysis
on the effects of adiposity and body composi-
tion on asthma
In this Section, we perform a two–sample Mendelian randomization analysis using
summary level data. For this Mendelian randomization study, summary level data
is estimated under the conventional setting (Section 1.5.2): the genetic associations
with the risk factor and the genetic associations with the outcome are estimated
in two separate samples. The genetic associations with BMI, FMI (BIA and DXA
measurements) and FFMI (BIA and DXA measurements) are estimated from UK
Biobank (predominantly taken from Section 6.2), and the estimates of the genetic
associations with asthma are taken from the GABRIEL Consortium. The GABRIEL
consortium consists of 10,365 asthma cases (diagnosed by a doctor) and 16,110 controls
from 23 studies. All of the studies provided data on individuals diagnosed with
asthma before the age of 16 years, and over half of the studies provided data on adults
(diagnosed with asthma 16 years or older). A GWAS on asthma was performed on the
entire dataset [37].
This two–sample Mendelian randomization study used the same methods consid-
ered for the one–sample Mendelian randomization study (Section 6.2). To allow for
comparisons between the one–sample and two–sample estimates, the genetic variants
selected under the liberal and conservative criteria in Section 6.2.3 were considered for
this two–sample Mendelian randomization study. Section 6.3.1 provides an overview
of the summary level data and the methods used in the analysis, and the results are
presented in Section 6.3.2.
6.3.1 Methods
Figure 6.11 provides an overview of the summary level data used in the Mendelian
randomization analyses. In the first step, the rs numbers of the 60 genetic variants
selected under the liberal criteria in Section 6.2.3 were searched in Phenoscanner by
Jessica Rees with the option of searching for genetic variants that could act as proxies
for the 60 genetic variants (no cut-off value was used for the p-value of the genetic
associations). Phenoscanner identified proxies of the 60 genetic variants by using a
pairwise r2 (based on the 1,000 Genome Project) threshold of 0.8. Hence, a genetic
variant was classed as a proxy variant if its r2 value with one of the specified 60 genetic
variants was greater than 0.8. As noted in Section 6.2.3, r2 takes into account the
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linkage disequilibrium between the genetic variants and the minor allele frequency of
the genetic variants.
The genetic associations with asthma from the GABRIEL consortium [37] were
then extracted from the Phenoscanner results obtained from the above search. Since
the option for searching for proxy variants had been used, some of the genetic variants
had more than one estimate from the GABRIEL consortium. The following selection
criteria was used to ensure that each of the 60 liberal variants only had one estimate
for the genetic association with asthma: 1) if there was an estimate of the genetic
association on the exact variant then this was retained; and 2) if there was no estimate
for the exact variant but there were estimates for proxy variants, then the genetic
association estimate with the proxy variant with the highest r2 value was retained.
42 of the 60 genetic variants searched in Phenoscanner had genetic associations
(either with the exact variant or a proxy variant) with asthma in the GABRIEL
consortium (Figure 6.11). Of these 42 genetic variants, 23 had estimates based on the
exact variant, and 19 had estimates based on a proxy variant. 29 of the 39 genetic
variants selected under the conservative criteria in Section 6.2.3 had genetic association
estimates for asthma from the GABRIEL consortium. Of the 29 genetic variants in the
conservative set, 16 had estimates based on the exact variant, and 13 had estimates
based on a proxy variant. Table I.8 provides the rs number and r2 value of the proxy
variant when relevant, and contains information on whether the variant was included
in the conservative set of variants.
As highlighted in Figure 6.11, the genetic associations with BMI, FMI (BIA and
DXA measurements) and FFMI (BIA and DXA measurements) were taken from the
one–sample Mendelian randomization study (Section 6.2.4) for the 23 variants that
had genetic association estimates for asthma based on the exact variant. The genetic
associations with BMI, FMI (BIA and DXA measurements) and FFMI (BIA and DXA
measurements) were re-estimated using the UK Biobank dataset for the 19 variants
whose genetic association estimate for asthma was based on a proxy variant. Jessica
Rees used the QCTOOL v2 command–line programme to extract the imputed genetic
data on the 19 proxy variants for the 360,409 participants from UK Biobank. As
outlined in Section 6.2.4, SNPTEST v2 was used to estimate the genetic associations
for BMI, FMI (BIA and DXA measurements) and FFMI (BIA and DXA measurements)
adjusted for the first 10 ancestry informative PCs, gender and height.
The genetic associations with BMI from UK Biobank were plotted against the
genetic associations with asthma from the GABRIEL consortium for the 42 liberal and
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29 conservative sets of genetic variants. These plots were created by Jessica Rees in
RStudio version 3.5.3 [86] using the package ggplot2 [141].
With the exception of the IVW method with the two genetic variants from the
gene regions FTO and MC4R, all of the univariable and multivariable Mendelian
randomization analyses outlined in Section 6.2.5 were performed on the summary level
data for the 42 liberal and 29 conservative sets of genetic variants. All of the analyses
were performed by Jessica Rees in RStudio version 3.5.3 [86].
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Fig. 6.11 Flowchart highlighting the number of variants with genetic association estimates
with asthma in the GABRIEL consortium by whether the estimates are based on the exact
or proxy variant. The source of the summary level data for BMI, FMI and FFMI is also
outlined.
Phenoscanner search
60 genetic variants selected under the liberal criteria in
Section 6.2.3 searched in Phenoscanner with the option
of searching for proxy variants (r2> 0.8)
GABRIEL consortium estimates
42 variants had genetic association estimates with
asthma in the GABRIEL consortium with either the
exact variant or a proxy variant
Exact variants
23 variants had genetic associa-
tion estimates with asthma for
the exact variants
Summary level data for BMI,
FMI and FFMI: taken from the
one–sample Mendelian randomiza-
tion study (Section 6.2.7)
Proxy variants
19 variants had genetic associa-
tion estimates with asthma for a
proxy variant only (variant with
the highest r2 value chosen)
Summary level data for BMI,
FMI and FFMI: estimated us-
ing data from UK Biobank using
the model specified for the one–
sample Mendelian randomization
study (Section 6.2.4)
16 variants also contained in the
conservative set of genetic vari-
ants
13 variants also contained in the
conservative set of genetic vari-
ants
Abbreviations: BMI, body mass index; FMI, body fat mass index; and FFMI, body fat-free
mass index.
224 Applied example: adiposity and asthma
6.3.2 Results
The genetic associations of the 19 proxy variants with BMI, FMI (BIA and DXA
measurements) and FFMI (BIA and DXA measurements) from UK Biobank are
displayed in Table I.9. 3 proxy variants for BMI, 5 for FMI (BIA), and 4 for FFMI
(BIA) did not reach GWS significance. Figures 6.12 and 6.13 contain the scatter plots
of the genetic associations of BMI against the genetic associations of asthma. There
appeared to be no obvious trend in the associations, and there was clear heterogeneity
in the approximate causal estimates.
The results from the Mendelian randomization analyses are contained in Table 6.9.
The IVW estimates for the liberal variants and conservative variants were 0.040 (95%
CI: -0.030, 0.110) and 0.050 (95% CI: -0.034, 0.134) respectively. Although the IVW
estimates for BMI were positive, they did not reach nominal significance as seen in the
one-sample setting (Section 6.2). The median estimators and MR-Egger model did not
provide any evidence of a causal effect of BMI on asthma.
As seen in the one-sample setting (Section 6.2), the multivariable IVW and multi-
variable MR-Egger models for the BIA measurements did not provide any evidence of
a causal effect of FMI or FFMI on asthma for both sets of genetic variants. Apart from
the estimates from the multivariable IVW model with the liberal variants, the point
estimates for FMI (BIA) and FFMI (BIA) were positive and negative respectively for
the multivariable IVW and multivariable MR-Egger models. The intercept term for
the liberal and conservative sets of variants were not significant at the nominal level.
The point estimates for FMI and FFMI using the DXA measurements were positive
and negative respectively for all of the multivariable models. The estimates for FMI
(DXA) from the multivariable IVW method were borderline significant for the liberal
(0.112, 95% CI: -0.002, 0.225) and conservative (0.137, 95% CI: -0.004, 0.278) sets of
genetic variants. There was no evidence of a causal effect of FFMI (DXA) on asthma.
Unlike Section 6.2, the intercept term for the multivariable MR-Egger model did not
reach nominal significance for either the liberal or conservative sets of variants.
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Fig. 6.12 Scatter plot of the genetic associations with body mass index from UK Biobank
and the genetic associations with asthma from the GABRIEL consortium (10,365 physician
diagnosed cases) for the 42 liberal variants (19 were proxy variants) with 95% confidence
intervals. The genetic associations for BMI were estimated using data on 360,409 participants
from UK Biobank. The blue line represents the estimate of the approximate causal log odds
ratio for asthma per unit increase in body mass index from the IVW model.
Fig. 6.13 Scatter plot of the genetic associations with body mass index from UK Biobank
and the genetic associations with asthma from the GABRIEL consortium (10,365 physician
diagnosed cases) for the 29 conservative variants (13 were proxy variants) with 95% confidence
intervals. The genetic associations for BMI were estimated using data on 360,409 participants
from UK Biobank. The blue line represents the estimate of the approximate causal log odds
ratio for asthma per unit increase in body mass index from the IVW model.
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Table 6.9 Estimates of the approximate causal log odds ratios (standard errors) for asthma
per unit increase in body mass index from IVW, simple median, weighted median and
MR-Egger (with intercept estimate) methods for the liberal and conservative sets of genetic
variants. The table also contains the estimate of the approximate causal log odds ratios for
asthma per unit increase in the BIA and DXA measurements from multivariable IVW and
multivariable MR-Egger (with intercept estimate).
42 liberal variantsa 29 conservative variantsb
Estimate (se) 95% CI P-value Estimate (se) 95% CI P-value
IVW 0.040 (0.036) -0.030, 0.110 0.261 0.050 (0.042) -0.034, 0.134 0.242
Simple median 0.030 (0.051) -0.070, 0.129 0.556 0.035 (0.061) -0.085, 0.156 0.566
Weighted median 0.010 (0.050) -0.088, 0.108 0.839 0.005 (0.058) -0.109, 0.119 0.931
MR-Egger 0.031 (0.088) -0.142, 0.204 0.726 -0.043 (0.102) -0.244, 0.158 0.674
(Intercept) 0.001 (0.009) -0.017, 0.019 0.911 0.011(0.011) -0.010, 0.032 0.318
BIA measurements
Multivariable IVW
FMI 0.055 (0.200) -0.338, 0.448 0.783 0.157 (0.238) -0.311, 0.623 0.511
FFMI 0.013 (0.346) -0.665, 0.692 0.969 -0.132 (0.401) -0.919, 0.656 0.743
Multivariable MR-Eggerc
FMI 0.053 (0.197) -0.342, 0.447 0.791 0.136 (0.228) -0.327, 0.599 0.556
FFMI -0.026 (0.341) -0.710, 0.658 0.940 -0.132 (0.384) -0.911, 0.647 0.733
(Intercept) 0.006 (0.004) -0.002, 0.014 0.129 0.008 (0.004) -0.001, 0.017 0.071
DXA measurementsd
Multivariable IVW
FMI 0.112 (0.058) -0.002, 0.225 0.054 0.137 (0.072) -0.004, 0.278 0.057
FFMI -0.087 (0.100) -0.284, 0.109 0.383 -0.114 (0.127) -0.362, 0.134 0.369
Multivariable MR-Egger
FMI 0.166 (0.090) -0.015, 0.346 0.074 0.184 (0.106) -0.031, 0.400 0.095
(Intercept) -0.005 (0.006) -0.017, 0.007 0.441 -0.005 (0.007) -0.020, 0.011 0.548
FFMI -0.229 (0.147) -0.522, 0.064 0.126 -0.305 (0.163) -0.636, 0.026 0.073
(Intercept) 0.007 (0.006) -0.004, 0.019 0.196 0.011 (0.006) -0.002, 0.024 0.090
Abbreviations: se, standard error; CI, confidence interval; BMI, body mass index; IVW, inverse-variance weighted;
FMI, fat mass index; FFMI, fat-free mass index; BIA, bioelectrical impedance analysis; DXA, Dual-energy X-ray.
a19 of the 42 genetic variants were proxy variants. b13 of the 29 genetic variants were proxy variants. cMultivariable
MR-Egger model only fitted once as the direction of association for FMI and FFMI was the same across the 42 genetic
variants.
dResults based on data from 3,901 of the 360,409 participants.
6.3.3 Summary
In this Section, we have performed a two-sample Mendelian randomization analysis using
summary level data from UK Biobank and the GABRIEL consortium. Contrary to the
results obtained in Section 6.2, we have found no evidence of a causal association between
BMI and asthma. The multivariable methods supported the results in Section 6.2
of a null causal effect of FMI and FFMI on asthma for the BIA measurements. The
estimate for FMI using the DXA measurements were borderline significant in the
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multivariable IVW model. In the next Section, we compare the results from the
Mendelian randomization studies that have been performed in the Chapter.
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6.4 Comparison of the results from the Mendelian
randomization analyses
In this Section, we compare the results from the Mendelian randomization analyses
performed in Sections 6.2 and 6.3.
6.4.1 Univariable analyses
Figure 6.14 contains the log odds ratios with 95% confidence intervals for asthma
per unit increase in BMI from the IVW models when the liberal (green bars) and
conservative (blue bars) sets of genetic variants were used as IVs in Sections 6.2 and 6.3.
For the one–sample Mendelian randomization analysis, the IVW estimates are based on
an ever diagnosis of asthma (as contained in Section 6.2.8). There were 60 liberal and
39 conservative genetic variants for the one–sample Mendelian randomization analysis.
The results from the two–sample Mendelian randomization analyses are based on 42
liberal (19 were proxy variants) and 29 conservative (13 were proxy variants) genetic
variants.
Both estimates from the one–sample Mendelian randomization study were nominally
significant, and the magnitude of the estimates were very similar. The point estimates
from the two-sample Mendelian randomization study were similar to the estimates
obtained from the one–sample. Unlike the one–sample estimates, the two-sample
estimates did not reach nominal significance. This discrepancy in the results may be
due to the GABRIEL consortium containing data on children and adults, whereas the
one–sample analysis was only based on UK Biobank data where participants were adults
aged between 40-69 years. There were also differences in the genetic variants used as
IVs for the one–sample and two-sample studies. Although all of the 60 liberal genetic
variants were considered for the two-sample study, we could only obtain estimates of
the genetic associations with asthma on 42 of the 60 variants, and 19 of these variants
were proxies.
The discrepancy between the results from the one–sample and the two-sample
studies may have also arisen by the GABRIEL consortium requiring a physician
diagnosis for the participant to be considered an asthma case, whereas we used self-
reported measurements to define asthma status in UK Biobank. In fact, the summary
level data from the GABRIEL consortium was based on data from 26,475 participants,
with 10,365 (39.2%) being classed as asthma cases. The genetic associations for asthma
from UK Biobank were based on 360,409 participants, with 41,978 (11.6%) classed as
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having an ever diagnosis of asthma. This difference in the proportion of participants
classed as asthmatic highlights the differences in the study designs for UK Biobank
and the GABRIEL consortium.
For the one–sample study, we estimated the summary level data for the risk factors
and the outcome on the same set of individuals. As highlighted in Section 6.1.4, we
apply this summary level data to methods specifically designed for the two–sample
setting (IVW, median and MR-Egger). These methods assume that the genetic as-
sociations for the risk factor and outcome are estimated from two unrelated samples.
For the two–sample case, the genetic associations were estimated from two samples.
This may have contributed to the discrepancy between the estimates obtained from
the one–sample and two–sample setting.
Fig. 6.14 Estimates of the approximate causal log odds ratios with 95% confidence intervals
for asthma per unit increase in body mass index from the IVW models for the one–sample
(estimates from an ever diagnosis of asthma) and two–sample Mendelian randomization
studies. The green bars represent the estimates from the liberal sets of genetic variants, and
the blue bars represent the estimates from the conservative sets of genetic variants.
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6.4.2 Multivariable analyses
Figure 6.15 contains the log odds ratios with 95% confidence intervals for asthma per
unit increase in FMI and FFMI from the multivariable IVW models for the BIA and
DXA measurements from Sections 6.2 and 6.3.
Figure 6.15 highlights the differences in the precision of the estimates for the BIA
and DXA measurements. The estimates for FMI and FFMI from the one–sample
and two–sample analyses were more precise for the DXA measurements than the
BIA measurements. This result seems somewhat surprising considering the genetic
associations for the DXA measurements were only based on 3,901 of the 360,409
participants. The differences in the precision between the BIA and DXA measurements
may be due to: 1) the DXA measurements capturing more variability in the FM and
FFM measurements; 2) the FMI and FFMI genetic associations being less correlated
under the DXA measurements; or 3) a systematic difference in the characteristics of
the participants in the complete dataset (N=360,409) compared to the participants
with BIA and DXA measurements (N=3,901).
The results obtained from the multivariable methods should be interpreted with
some caution, particularly the positive results for the DXA measurement of FMI as
there was evidence of weak instruments. As discussed in Section 2.6.3, a genetic
variant is classed as a strong instrument in the multivariable setting if: a) it is strongly
associated with all of the explanatory variables (measured through the F-statistic);
and b) it is jointly associated with the explanatory variables (measured through the
conditional F-statistic). Although some of the sets of genetic variants were strongly
associated with the BIA measurements, the conditional F-statistics were small for all of
the BIA and DXA measurements (Section 6.2.4). Since UK Biobank will be releasing
additional data on the DXA measurements, it would be advisable for the multivariable
models to be refitted to the larger dataset to increase the strength of the IVs.
The results from the two-sample analysis supported the null causal effect of FMI
on asthma in the analysis using BIA on the UK Biobank dataset. Unlike the estimates
from the one-sample study, the two-sample study provided evidence of a positive
causal effect of FMI on asthma using the DXA measurements. Possible reasons for
the discrepancy between the results obtained from the one–sample and two–sample
analyses have been highlighted for the univariable case (Section 6.4.1), and these may
also be applicable to the multivariable case.
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Fig. 6.15 Estimate of the approximate causal log odds ratios with 95% confidence intervals
for asthma per unit increase in fat mass index and fat-free mass index from the multivariable
IVW models for the one–sample (estimates from an ever diagnosis of asthma) and two-sample
Mendelian randomization studies. The green bars represent the estimates from the liberal
sets of genetic variants, and the blue bars represent the estimates from the conservative sets
of genetic variants.
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6.4.3 Summary
In this Section, we have compared the estimates from the univariable and multivariable
analyses for the one–sample and two–sample Mendelian randomization studies. We
have highlighted the similarities in the point estimates obtained from the one–sample
and two–sample Mendelian randomization studies, and have discussed possible reasons
for the null results in the two-sample study. The estimates from the multivariable
IVW models have also been compared. Potential issues with weak instrument bias in
the multivariable models have been highlighted, particularly in relation to the positive
results for the DXA measurement of FMI. Differences in the precision of the estimates
for the BIA and DXA measurements have also been highlighted.
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6.5 Discussion
In this Chapter, we have performed univariable and multivariable Mendelian random-
ization analyses in the one–sample and two-sample setting to investigate the effect of
adiposity and body composition measurements on asthma. The one-sample Mendelian
randomization analyses in UK Biobank supported the epidemiological evidence of
there being a positive causal association between BMI and asthma in adults, yet the
two-sample study produced a null result. The multivariable models for the DXA
measurements suggested that increased FMI had a positive causal effect on asthma,
but this result was not replicated in the BIA measurements.
6.5.1 Measurements for asthma and body composition
Since asthma status in UK Biobank was based on self-report, the possibility of intro-
ducing bias into the analysis through misclassification of the outcome is a concern.
There has not been any validation studies on asthma status in UK Biobank, and this
should be explored further, especially since there are no questions that directly relate
to current asthma status. In fact, since asthma is usually developed during childhood,
and it is possible to outgrow the condition, some of the participants in UK Biobank
who were classed as asthmatic under the ever diagnosis criteria may not have been
asthmatic at recruitment. We hoped to have a better appreciation for the number of
participants who were current asthmatics by including wheezing or whistling on the
chest in our second measure for asthma status.
It is often assumed that BMI is fully adjusted for height. Since body composition
varies with age and gender, this assumption is not always true, and rather than squaring
height, it may be more appropriate to apply a different power (BMI[x]=weight(kg)/height(mx))
[194]. This logic could also be applied to the other index measurements of body com-
position. To help with interpretation and comparison between the measurements, we
decided that all of the indices should be calculated using the square of height. We
acknowledge that using the square of height may not have been ideal, particularly for
FM and FFM, and we tried to rectify this limitation by adjusting all of the genetic
associations for height.
6.5.2 Instrumental variables for body composition
This Chapter has highlighted the lack of GWASs on body composition measurements,
particularly for FM and FFM (Section 6.1.3). All of the Mendelian randomization
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analyses performed in this Chapter used the genetic variants that were associated with
BMI at the GWS level as instruments for FMI and FFMI. Ideally, we would have used
genetic variants that have been shown to be robustly associated with FM and FFM as
IVs. Although there is evidence to suggest that there is significant overlap between the
variants that are associated with BMI, FM and FFM, the effect that these variants
have on the different body composition measurements will vary.
6.5.3 Application of multivariable methods
This Chapter has highlighted the benefits of applying multivariable methods to
Mendelian randomization analyses. Despite the genetic associations between FMI
and FFMI being highly correlated for both the BIA and DXA measurements, we still
obtained reasonably precise estimates from the multivariable IVW method, particularly
for the DXA measurements. However, the sensitivity of the multivariable methods to
the strength of the correlation between the genetic associations and the correlation of
the risk factors should be considered in more detail.
The discrepancy between the estimates obtained for BIA and DXA from the multi-
variable IVW method was unexpected. DXA is considered to be the ‘gold standard’ for
measuring body composition, and this may have contributed to the estimates from DXA
being more precise than BIA. We recommend that the analysis is re-performed when
UK Biobank releases additional DXA measurements. This is particularly important as
there was evidence of weak instruments under the multivariable setting for the DXA
measurements.
In this Chapter, we were able to apply the multivariable MR-Egger method devel-
oped in Chapter 4 to an extensive Mendelian randomization study. As illustrated by
the applied example in Chapter 4, the intercept term is sensitive to the orientation
of the genetic variants. There were discrepancies in the MR-Egger intercept test for
the univariable and multivariable models. For the one–sample study, the intercept was
non-significant in the model for BMI, but the intercept term was significant for the
DXA measurement of FMI in the multivariable MR-Egger model. This may suggest
that the InSIDE assumption under the multivariable framework was not satisfied for
FMI.
6.5.4 Limitations
Throughout this Chapter, we have assumed that the genetic associations from UK
Biobank have been fully adjusted for ancestry by removing individuals related up to
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the third degree and including the first 10 ancestry informative PCs in the regression
models used to estimate the genetic associations. However, there is no guarantee that
these measures would have fully accounted for population stratification. Failing to
fully account for population stratification may confound the genetic association, and
result in biased genetic association estimates with increased Type I error rates. Since
the genetic variants selected as potential IVs were identified from an independent study
to UK Biobank, the effect of having an increased Type I error rate as a result of
population stratification in UK Biobank should not have biased the selection of the
genetic variants. Nevertheless, if ancestry had not been fully adjusted for, then the
genetic association estimates from UK Biobank may have been biased, effecting the
estimates obtained from the Mendelian randomization analyses.
The genetic association estimates obtained from UK Biobank were based on the
imputed genetic data, regardless of whether the genetic variant had been directly
genotyped or not. Only using the imputed genetic data in the one–sample and two–
sample Mendelian randomization studies could be seen as a limitation as it introduces
additional uncertainty into the genetic association estimates. Furthermore, the genetic
association estimates may have been overly precise as the models used to estimate
the genetic associations did not account for the uncertainty in the imputation of the
genetic data (Section 6.2.4). Since all of the 60 genetic variants in the liberal set had
an imputation quality score > 0.96, we anticipate that the effect of using imputed
genetic variants would have been minimal.
As highlighted in Section 6.2.4, the normality and homoscedasticity assumptions for
the linear regression models used to estimate the genetic associations for BMI, FMI and
FFMI may have been violated. This may have been rectified by transforming the data
for BMI, FMI and FFMI. For ease of interpreting the estimates from the Mendelian
randomization analyses, we decided not to transform BMI, FMI or FFMI. As such, the
estimates and standard errors of the genetic associations with BMI, FMI and FFMI
may be biased as a result of the assumptions being violated. Discrepancies in the
standard errors of the genetic associations with BMI, FMI and FFMI should not affect
the results from the Mendelian randomization study as they are not used in the analysis
model. However, if the violation of the assumptions for linear regression effected the
point estimates for the genetic associations then the Mendelian randomization estimates
may have been effected as well, limiting the interpretation of the results.
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6.5.5 Key points from the chapter
• In this Chapter, we investigated the effect of adiposity and body composition on
asthma using univariable and multivariable Mendelian randomization analyses in
the one–sample and two–sample setting.
• This is the first time that multivariable Mendelian randomization methods has
been applied to this research question.
• The Mendelian randomization analyses suggested that there was a positive causal
association between BMI and asthma in the one–sample setting. This was not
supported by the two–sample Mendelian randomization study.
• There was some evidence from the multivariable IVW model in the one–sample
study that the DXA measurement for FMI was adversely associated with asthma
in adults, whereas the BIA measurement suggested that there was a null effect.
However, the results were inconclusive.
Chapter 7
Conclusions and future work
The main aim of this dissertation was to develop and extend methods for Mendelian
randomization analyses. Four robust methods that downweight or remove pleiotropic
genetic variants were outlined in Chapter 3, MR-Egger was extended to the multivari-
able framework in Chapter 4, and estimating statistical interaction effects in factorial
Mendelian randomization was considered in Chapter 5. These methodological devel-
opments were motivated by the applied examples within each Chapter and existing
Mendelian randomization methods. Note that the methods developed in Chapters 3
and 4 both considered the issue of estimating consistent causal effects in the presence
of pleiotropic genetic variants in either univariable or multivariable Mendelian random-
ization. Chapter 5 did not consider the implications of including pleiotropic genetic
variants, but considered the possibility of estimating statistical interaction effects in
Mendelian randomization.
The motivation for the work presented in Chapters 3 and 4 was also influenced
by the main applied example of the dissertation: the investigation into the effect of
adiposity and body composition on asthma in one–sample and two–sample Mendelian
randomization studies (Chapter 6). For the one–sample and two–sample studies,
the effect of BMI on asthma was considered in univariable Mendelian randomization
analyses, and the effect of FMI and FFMI on asthma was considered in multivariable
Mendelian randomization analyses. There was some evidence of an adverse effect of
BMI on asthma, but the effect of FMI and FFMI on asthma was inconclusive. We
had hoped to use the methods developed in Chapter 3 in the univariable analyses, but
since the performances of the methods were not optimal, they were not included in
Chapter 6. However, multivariable MR-Egger was used in Chapter 6. The factorial
Mendelian randomization work was not considered, as we did not suspect that there
was an interaction effect between FMI and FFMI on asthma.
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We hope that this dissertation has highlighted the benefits of using Mendelian
randomization to consider the causal effect of a risk factor on an outcome using
observational data. Whilst the methods introduced in Chapter 3 were not optimal
under all of the scenarios considered, we hope that the Multivariable MR-Egger
method will be a useful addition to the literature. The work presented in Chapter 5
addresses an important gap in the Mendelian randomization literature of estimating
statistical interaction effects. Finally, we hope that the application of some of the
methods developed and discussed in this dissertation to the main applied example
was a useful addition, despite producing inconclusive results. In the Section below,
we highlight the specific contributions and limitations of the work presented in each
Chapter (Section 7.1), and outline avenues of future work (Section 7.2).
7.1 Summary of the thesis
In this Section, we summarize the main findings, conclusions, and limitations of each
Chapter presented in this dissertation.
7.1.1 Chapter 1
Chapter 1 provides an overview of the study designs that can detect and estimate causal
effects. In particular, the Chapter introduces the concept of Mendelian randomization
studies, and highlights some of the benefits and limitations of using genetic variants as
IVs.
7.1.2 Chapter 2
Chapter 2 reviews the methods used in Mendelian randomization to estimate the
causal effect of a risk factor on an outcome using summary level data in: 1) the
primary analysis when the IV assumptions are considered to be satisfied; and 2) the
sensitivity analysis when some of the genetic variants may violate the IV assumptions
through pleiotropic effects. The review highlights the wide range of methods that
estimate consistent causal effects when pleiotropic genetic variants are included in
a Mendelian randomization analysis. The review also highlights areas that require
further development: 1) identifying methods in the robust statistics literature that
could be used in the sensitivity analysis of a Mendelian randomization study; and 2)
developing multivariable methods that account for both measured and unmeasured
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pleiotropic effects. These two limitations, and the observation of there being a lack of
IV methods that estimate statistical interaction effects are considered in Chapters 3-5.
7.1.3 Chapter 3
Chapter 3 proposes four robust methods for Mendelian randomization that use summary
level data. These methods are based on extensions from the robust statistics literature
and robust methods in Mendelian randomization. Through an extensive simulation
study and applied example, the performance of the proposed methods are compared to
those frequently used in Mendelian randomization. Under certain scenarios, some of
the methods proposed out perform the current methods used in the literature. Most
notably, robust regression with penalized weights appears to be a worthwhile addition
to sensitivity analyses when there is a small proportion of heterogeneous ratio estimates.
However, in general, the weighted median estimator performed just as well, if not
better, than the methods proposed in the Chapter.
The weights used in the Q-statistic were based on the NOME assumption that there
was no measurement error in the genetic associations with the risk factor. However, the
NOME assumption was violated in the simulation study. It is likely that the violation
of the NOME assumption would have affected the performance of applying penalized
weights through the Q statistic in the simulation study. The violation of the NOME
assumption also limited the utility of the simulation study as it was not possible to
compare the performance of the MR-Egger method with the proposed methods. Rather
than using the first order weights, the modified weights proposed by Bowden et al.
[63] that account for the violation of the NOME assumption may have been more
appropriate for the simulation study.
The simulation study highlights the limitations of the four robust methods proposed
in the Chapter. Most notably, there was no improvement in the performance of the
methods when the number of genetic variants is increased. The methods were also
sensitive to the type of heterogeneity contained in the data, with some methods working
better under certain scenarios.
7.1.4 Chapter 4
Chapter 4 addresses the lack of methodology on robust methods for multivariable
Mendelian randomization by extending the MR-Egger method to the multivariable
setting to account for both measured and unmeasured pleiotropic effects. The assump-
tions required to obtain consistent causal estimates from the multivariable MR-Egger
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method are considered in detail. The benefits of using multivariable MR-Egger over
its univariable counterpart are also demonstrated in an extensive simulation study.
Multivariable MR-Egger will be a useful addition to Mendelian randomization analyses
that consider high-dimensional data where the risk factors are highly related.
As seen in the univariable version, it is not possible to determine whether the
InSIDE assumption holds for multivariable MR-Egger. Furthermore, the InSIDE
assumption for multivariable MR-Egger is sensitive to the correlation structure of
the genetic associations and the orientation of the alleles. The recommendation of
orientating the genetic variants with respect to the risk factor increasing allele is a
major limitation of the method as it may result in the model being fitted multiple
times in one analysis. Changing the orientation of the genetic variants will also alter
the definition of the intercept term, and this may make it difficult to interpret the
results if the intercept term is significant for one orientation and not another.
Since summary level data is often used in Mendelian randomization, the simulation
study in Chapter 4 generated the genetic associations directly. Whilst this helped to
reduce the computational burden of the simulation study, it also limited the scope
of the study. By generating the summary level data directly, the impact of weak
instrument bias under the multivariable setting could not be explored fully. Although
the F-statistic was approximated in the simulation study, it was not possible to calculate
the Sanderson-Windmeijer conditional F-statistic to consider the joint strength of the
instruments.
The simulation study and findings of the Chapter were limited by the NOME
assumption not being violated in the simulation study. The sensitivity of the univariable
MR-Egger method to the violation of the NOME assumption has been highlighted
by Bowden et al. [63], and is supported by the results obtained in the simulation
study in Chapter 3. The impact of violating the NOME assumption, and whether
the I2 statistic is an appropriate measure to assess bias from this violation under the
multivariable setting should be considered to inform applied practice.
7.1.5 Chapter 5
Chapter 5 considers the possibility of estimating statistical interaction effects in
Mendelian randomization under two settings: 1) to estimate the interaction effects
between two risk factors; and 2) to detect interactions between drug treatments on the
risk of disease. Under the first setting, the Chapter outlines the TSLS regression model
required to estimate a statistical additive interaction effect when the genetic variants
are either treated as individual instruments or combined into gene scores. An extensive
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simulation study shows that the power to detect the interaction term is maximised
when all of the genetic variants and their interactions are included as individual IVs.
The Chapter also provides useful recommendations on using genetic variants to
detect interactions between drug treatments. Although this scenario has already been
considered in the applied literature, there remained unresolved methodological issues.
Through simulations, the power to detect the interaction effect is considered with
respect to the distribution of the gene scores, and whether the scores are treated
as continuous or binary variables. The simulation study highlights the advantage of
treating the gene scores as continuous variables, and the sensitivity of the method to
non-symmetric distributions of the gene scores.
One of the major limitations of the work presented in the Chapter is that only
two risk factors or two drug treatments can be considered in the analysis model. The
applicability of the method is also limited by the risk factors and outcome only being
considered with respect to continuous variables. Furthermore, the methods have only
been considered with respect to statistical additive interaction effects.
We used the same criteria as multivariable Mendelian randomization to assess
instrument strength. In particular, we used the Sanderson-Windmeijer conditional
F-statistic to assess the joint strength of the instruments. However, it is not clear
whether this is an appropriate measure for instrument strength for a factorial Mendelian
randomization study.
Various factors limited the simulation studies, including: 1) the use of optimal
weights in the gene scores; 2) assuming the genetic variants are uncorrelated; and 3)
the lack of misspecification in the data generating model. The assumption that the
genetic variants are uncorrelated particularly limits the applicability of the results
presented for detecting interaction effects between drug treatments as it is likely that
genetic variants in the same gene region will be in linkage disequilibrium. To consider
the performance of factorial Mendelian randomization under more realistic settings,
the simulations would benefit from considering additional misspecifications in the data
generating model, such as misspecification of the genetic associations.
7.1.6 Chapter 6
Chapter 6 performs an extensive Mendelian randomization study to investigate the
effect of adiposity and body composition on asthma using univariable and multivariable
Mendelian randomization methods, including the multivariable MR-Egger method
developed in Chapter 4. A one–sample Mendelian randomization study was performed
using data from UK Biobank, and a two–sample Mendelian randomization study was
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performed using data from UK Biobank and the GABRIEL consortium. The analyses
provided some evidence of an adverse causal effect of BMI on asthma, but there
was little or no evidence of a causal effect of FMI or FFMI on asthma. The DXA
measurements used in UK Biobank did support an adverse effect of FMI on asthma,
however, these analyses may have suffered from weak instrument bias.
The multivariable analyses may have been undermined by the genetic variants
being associated with BMI, rather than being specifically associated with FMI and/or
FFMI. As such, the analyses should be reperformed if results from GWASs on FMI
and FFMI are released. The discrepancy in the results obtained from the analysis on
adults for FMI from the BIA and DXA measurements should also be reconsidered
when UK Biobank releases additional DXA measurements.
7.2 Future work
As a result of the work presented in this dissertation, we discuss potential avenues for
future methodological developments in Mendelian randomization.
7.2.1 Extension to correlated genetic variants
All of the methods introduced in this dissertation assume that the genetic variants are
uncorrelated. This assumption was made for two reasons: 1) for simplicity; and 2) if
the validity of the IV assumptions are in doubt then it would be unwise to include
correlated genetic variants. However, there will be scenarios where including correlated
genetic variants would be beneficial to a Mendelian randomization study. This is
particularly true for multivariable analyses where there may be few independent genetic
variants that are associated with highly related risk factors. Extending the multivariable
MR-Egger model to correlated genetic variants should therefore be considered. As
discussed in Section 4.6, using correlated genetic variants in univariable MR-Egger
should be considered first, and then extended to the multivariable setting.
The use of correlated genetic variants should also be considered for detecting
interaction effects between drug treatments. As highlighted in Section 5.4.2, it is
unlikely that there will be numerous independent genetic variants in the same gene
region that are associated with a risk factor. It would therefore be beneficial to consider
the impact of including correlated genetic variants in this setting.
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7.2.2 Unresolved issues for multivariable MR-Egger
In addition to considering correlated genetic variants, there are other issues that should
be addressed for multivariable MR-Egger. Perhaps one of the most pressing issues is
the effect of violating the NOME assumption in the multivariable setting. Investigating
the impact this violation may have would help to inform applied practice, and may be
particularly important in the multivariable setting. Measurement error will bias the
estimate towards the null in univariable models (as shown for MR-Egger), however,
measurement error in multivariable models can bias the estimates towards or away
from the null [195]. Since the violation of the NOME assumption for multivariable
MR-Egger may lead to increased Type I error rates, identifying an appropriate statistic
that may be able to quantify the direction and degree of bias should be considered.
One of the major limitations of the multivariable MR-Egger method is the require-
ment to change the orientation of the genetic variants. Bowden et al. [48] have rectified
this issue for the univariable MR-Egger method by suggesting that radial regression be
applied to the method as the estimates are independent of the orientation of the genetic
variants. As such, the extension of the radial regression framework to multivariable
MR-Egger should be considered.
7.2.3 Multivariable methods
The performance of multivariable methods, including the IVW method, in Mendelian
randomization requires further attention. In particular, the impact of the correlation
structure in the raw data and genetic associations should be investigated. The re-
sults from the multivariable models in Chapter 6 provided reasonable results despite
the genetic associations being highly correlated. Perhaps the correlation structure
between the risk factors, rather than the genetic associations, is more influential in the
multivariable methods.
This dissertation has highlighted the lack of robust methods for multivariable
Mendelian randomization. Since the application of Mendelian randomization to ‘-omics’
data is becoming more popular, the development of robust methods that can account
for measured and unmeasured pleiotropy must be considered. Although multivariable
MR-Egger does contribute to this gap in the literature, additional methods are required.
In particular, the literature requires methods that try to identify and remove pleiotropic
genetic variants under the multivariable setting. The possibility of applying the robust
methods introduced in Chapter 3, such as Lasso penalization, to the multivariable
framework should be considered.
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7.2.4 Interaction effects
Mendelian randomization is often compared to a RCT, with some arguing that a
Mendelian randomization analysis is analogous to a ‘naturally’ randomized trial [196].
Although they share some similarities, the work in Chapter 5 highlighted the substantial
differences in the two study designs. In particular, the difficulties in applying the
compliance framework to Mendelian randomization was discussed. Investigating ways
in which Mendelian randomization can be considered under a compliance framework
would be a useful addition to the literature, and this may allow for the method proposed
by Blackwell [137] to be applied to factorial Mendelian randomization.
Whilst Blackwell’s [137] method would be a useful addition to Mendelian random-
ization, the suitability of the compliance framework in Mendelian randomization is
limited [197, 198]. Unlike RCTs, there is no clear definition of what it means to be a
complier in a Mendelian randomization study [197]. For example, if we were to perform
a Mendelian randomization analysis where LDL-C was the risk factor of interest, it is
not clear whether a participant would be considered as a complier to randomization
if they had the LDL-C lowering variant and their LDL-C level was low, or whether
we would require the LDL-C level to fall below a specified value [197]. As such, there
appears to be little scope in considering Mendelian randomization under a compliance
framework.
7.3 Conclusion
To conclude, the methodological developments presented in this dissertation have been
motivated from applied examples. In particular, our investigation into the effect of
adiposity and body composition on asthma partly motivated the work in Chapters 3
and 4. Furthermore, will have illustrated the utility of using the methods outlined
in Chapters 3 to 5 in applied examples within the Chapters themselves. As such, we
hope that these methods will make useful additions to the Mendelian randomization
literature.
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Abstract
Mendelian randomization is the use of genetic variants to make causal inferences from
observational data. The field is currently undergoing a revolution fuelled by increasing
numbers of genetic variants demonstrated to be associated with exposures in genome-
wide association studies, and the public availability of summarized data on genetic
associations with exposures and outcomes from large consortia. A Mendelian ran-
domization analysis with many genetic variants can be performed relatively simply
using summarized data. However, a causal interpretation is only assured if each ge-
netic variant satisfies the assumptions of an instrumental variable. To provide some
protection against failure of these assumptions, robust methods for instrumental vari-
able analysis have been proposed. Here, we develop three extensions to instrumental
variable methods using: i) robust regression, ii) the penalization of weights from
candidate instruments with heterogeneous causal estimates, and iii) L1 penalization.
Results from a wide variety of robust methods, including the recently-proposed MR-
Egger and median-based methods, are compared in an extensive simulation study.
We demonstrate that two methods, robust regression in an inverse-variance weighted
method and a simple median of the causal estimates from the individual variants, have
considerably improved Type 1 error rates compared with conventional methods in a
wide variety of scenarios when up to 30% of the genetic variants are invalid instru-
ments. While the MR-Egger method gives unbiased estimates when its assumptions
are satisfied, these estimates are less efficient than those from other methods and are
highly sensitive to violations of the assumptions. Methods that make different as-
sumptions should be used routinely to assess the robustness of findings from applied
Mendelian randomization investigations with multiple genetic variants.
Keywords: Mendelian randomization, instrumental variables, robust methods,
summarized data, aggregated data, MR-Egger.
2
1 Introduction
An instrumental variable (denoted Z) is a randomized or quasi-randomized variable
that can be used to estimate the causal effect of an exposure (or risk factor, denoted
X) on an outcome (Y ) in the presence of arbitrary unmeasured confounding [1]. An
instrumental variable satisfies three assumptions:
i) association with the exposure: Z 6⊥ X ;
ii) independence from confounders (denoted U) of the exposure–outcome associa-
tion: Z ⊥ U ;
iii) independence from the outcome conditional on the exposure and confounders:
Z ⊥ Y |X,U .
The assumptions imply that an instrumental variable cannot have a direct effect on
the outcome, but instead any effect is mediated via the exposure (this is known as
the exclusion restriction assumption) [2]. A directed acyclic graph illustrating these
assumptions is given as Figure 1.
[Figure 1 should appear about here.]
The instrumental variable assumptions are restrictive and often unrealistic in prac-
tice. One way of assessing whether these assumptions are satisfied is to compare the
causal estimates from several proposed instrumental variables [3]. If the instrumen-
tal variable assumptions are satisfied, and under additional parametric assumptions
(sufficient conditions are linearity of the instrumental variable–exposure, instrumental
variable–outcome and exposure–outcome relationships with no effect heterogeneity),
the same causal parameter is estimated by each of the instrumental variables [4]. In
this paper, we use the term ‘candidate instrument’ to describe a variable that is asso-
ciated with the exposure and hypothesized to satisfy the other instrumental variable
assumptions, without prejudicing whether those assumptions are satisfied or not.
A context in which there are often multiple candidate instruments that may plau-
sibly satisfy the instrumental variable assumptions is Mendelian randomization [5, 6],
the use of genetic variants as instrumental variables [4, 7]. For complex (i.e. polygenic
and multifactorial) exposures, such as body mass index [8] or blood pressure [9], many
associated genetic variants have been discovered in genome-wide association studies.
A recent development in Mendelian randomization is the availability of summarized
data [10]. These data comprise the associations (beta-coefficients and standard errors)
of genetic variants with the exposure and with the outcome estimated from univariable
regression models. Such associations estimated in large sample sizes have been made
publicly available for download by many consortia; examples include associations
with glycaemic traits from the Meta-Analyses of Glucose and Insulin-related traits
Consortium [11] and with coronary artery disease from the CARDIoGRAMplusC4D
consortium [12]. Instrumental variable methods using summarized data have been
recently developed, and include an inverse-variance weighted method [13], and two
robust methods: a median-based method [14] and MR-Egger [15]; a robust method is
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defined here as one that can provide reasonable estimates under weaker assumptions
than a conventional approach that assumes all candidate instruments are valid.
In this paper, we consider robust methods for causal inference using multiple
instrumental variables, focusing on those that can be implemented using summa-
rized data for uncorrelated candidate instruments. This is typical of an applied
Mendelian randomization investigation; when the instrumental variable assumptions
are in doubt, it is common to include one genetic variant from each gene region in the
analysis. These variants will typically be independently distributed as predicted by
Mendel’s laws due to their physical separation. Although these robust methods have
good theoretical properties, there are several issues particularly with the MR-Egger
method, such as low power in realistic scenarios [14], and the influence of outlying
variants [16].
In Section 2, we introduce three extensions to existing instrumental variable meth-
ods: the use of robust regression, penalization of weights, and L1 penalization. In
Section 3, we perform a simulation analysis to compare estimates from various robust
methods with respect to bias and coverage properties when some of the candidate
instruments do not satisfy the instrumental variable assumptions. Parameters in the
simulation analysis are chosen to reflect a typical Mendelian randomization investi-
gation. In Section 4, we show how these methods perform in an applied analysis
of the causal effect of body mass index on the risk of schizophrenia. We conclude
by discussing the results of this paper, and the potential for future developments
(Section 5).
2 Methods
Existing robust methods for causal inference using instrumental variables have taken
two different approaches [17]. The first approach (which includes the median-based
method [14]) is to assume that some, but not all, of the candidate instruments satisfy
the instrumental variable assumptions. The second approach (which includes the MR-
Egger method [15]) allows all of the candidate instruments not to be valid instrumental
variables, but assumes that the set of variants satisfies a weaker assumption. Software
code for implementing all the methods used in this paper is provided in Web Appendix
A.1.
2.1 Parametric assumptions
We assume throughout that the parametric assumptions of linearity with no effect
heterogeneity hold for the causal exposure–outcome relationship, and for the instru-
mental variable–exposure and instrumental variable–outcome associations for all valid
instruments Zj , j = 1, . . . , J :
E(X|Zj = z) = βX0j + βXj z (1)
E(Y |Zj = z) = βY 0j + βY j z for j = 1, . . . , J
E(Y | do(X = x)) = θ0 + θ x
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where do(X = x) is the do-operator of Pearl meaning that the value of the exposure
is set to x by intervention [18], and the causal effect parameter θ =
βY j
βXj
for all valid
instruments [4]. Issues relating to the plausibility of these parametric assumptions
are left to the discussion.
Under these linearity assumptions, the association of a candidate instrument with
the outcome βY j decomposes into a direct effect αj and an indirect effect that cor-
responds to the causal effect of the exposure on the outcome (θ) multiplied by the
association of the candidate instrument with the exposure (βXj) [19]:
βY j = αj + θ βXj . (2)
The term ‘pleiotropy’ refers to a genetic variant having associations with more than
one risk factor on different causal pathways [7]. A pleiotropic genetic variant is typ-
ically not a valid instrumental variable. In this decomposition, genetic variant j is
pleiotropic if αj 6= 0, and αj is referred to as the pleiotropic effect. The decompo-
sition is illustrated in Figure 2 (the genetic variant is denoted Gj rather than Zj to
emphasize that it is not a valid instrument if αj 6= 0).
The outcome is assumed to be continuous. If the outcome is binary, then the
methods can proceed using genetic associations from logistic regression analyses (log
odds ratios), provided that the linear assumptions above hold for the logit-transformed
probability of the outcome. There are some technical issues with the interpretation of
the causal estimate with a binary outcome and a logistic-linear model [20]. However,
instrumental variable estimates are typically unbiased under the null in this setting,
and Type 1 error rates are not generally inflated (with the notable exception of those
from the two-stage residual inclusion method [21]).
[Figure 2 should appear about here.]
2.2 MR-Egger method and the InSIDE assumption
The MR-Egger method is performed by weighted linear regression of the associations
of the candidate instruments with the outcome (βˆY j) on the associations of the can-
didate instruments with the exposure (βˆXj), using the inverse of the variances of the
associations with the outcome (se(βˆY j)
−2) as weights:
βˆY j = θ0 + θ1 βˆXj + ǫj , weights = se(βˆY j)
−2. (3)
If the intercept term in this regression model is estimated, then the slope coeffi-
cient is the MR-Egger estimate. To ensure that the MR-Egger estimate is invariant to
the original arbitrary choice of the coding allele (effect allele) for each genetic variant,
we first orientate all the associations so that the βˆXj estimates are all positive [16].
If the intercept term is set to zero, then the slope coefficient is the inverse-variance
weighted (IVW) estimate. The IVW estimate can also be obtained by inverse-variance
weighted meta-analysis of the ratio estimates θˆj using standard errors
se(βˆY j)
βˆXj
. Simu-
lations have shown that this simple choice of standard error expression gives reasonable
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inferences in realistic settings [13]. Additionally, the IVW estimate using this expres-
sion is the same as the two-stage least squares estimate that can be calculated using
individual-level data [22] (assuming, as throughout, that the candidate instruments
are uncorrelated).
The ratio estimate based on candidate instrument j is
βˆY j
βˆXj
. This is a consistent
estimate of the causal effect if αj = 0. As a weighted mean of the ratio estimates, the
IVW estimate is consistent if αj = 0 for all j; that is, if none of the candidate instru-
ments are pleiotropic. The MR-Egger method gives consistent estimates of the causal
effect under the condition that the pleiotropic effects of the candidate instruments αj
are uncorrelated with the associations of the candidate instruments with the exposure
βXj [15]. This is referred to as the InSIDE assumption (INstrument Strength Indepen-
dent of Direct Effect). Specifically, we require the weighted covariance covw(α,βX)
to be zero:
covw(α,βX) =
∑
j(αj − α¯w)(βXj − β¯Xw) se(βˆY j)−2∑
j se(βˆY j)
−2 = 0 (4)
where β¯Xw is the weighted mean of the βXj , α¯w is the weighted mean of the αj , and
bold symbols represent vectors across the candidate instruments.
If the intercept term in the MR-Egger analysis differs from zero, then either the
InSIDE assumption is violated, or the average pleiotropic effect differs from zero
(referred to as directional pleiotropy). In either case, the instrumental variable as-
sumptions are violated for at least one of the candidate instruments, and the IVW
estimate will not be consistent. However, provided that the InSIDE assumption holds,
the MR-Egger estimate will still be consistent for the causal effect even in the case of
directional pleiotropy. The statistical test of whether the intercept term in MR-Egger
differs from zero is referred to as the MR-Egger intercept test.
2.3 Motivation: robustness to heterogeneity in causal esti-
mates
The MR-Egger regression has a 100% breakdown point in the sense that all of the
candidate instruments can violate the instrumental variable assumptions by having
direct effects on the outcome (αj 6= 0), provided that the InSIDE assumption is sat-
isfied. However, it relies on the InSIDE assumption being satisfied for the complete
set of candidate instruments. In contrast, in the simple median method (calculated
as the median of the ratio estimates from each candidate instrument individually), up
to 50% of candidate instruments can violate the instrumental variable assumptions
arbitrarily [14]. It would be worthwhile to develop a method that gives robust esti-
mates if either of these two assumptions holds. We propose three novel extensions to
existing instrumental variable methods to explore this possibility: 1) robust regres-
sion, 2) penalization of weights, and 3) L1 penalization. All approaches downweight
the contribution to the causal estimate of candidate instruments with heterogeneous
ratio estimates.
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2.4 Robust regression
Several methods have been proposed for performing robust regression (that is, regres-
sion with greater than a 0% breakdown point) [23]. Here, we use an MM-estimation
approach as described by Koller and Stahel [24]. Each of the letter Ms refers to a
“maximum likelihood type” maximization step. Briefly, the method proceeds by find-
ing a robust S-estimate (“scale-type estimate”) that minimizes an M-estimate of the
scale of the residuals (the first M in the method’s name). The estimated scale is then
held constant whilst a close-by M-estimate of the parameters is located (the second
M) [25]. This provides robustness both to outliers and to data points with high lever-
age. Further robustness is provided by using Tukey’s bisquare objective function [26]:
instead of minimizing the sum of squared residuals, we minimize the sum of a function
of the residuals that is capped at a maximum value for each residual. This means
that an outlier in the regression analysis has the same contribution to the objective
function no matter how extreme the outlier is.
If the objective function of the standardized residuals rj in the regression is∑
j ρ(rj), then ordinary least squares regression minimizes the sum of the square
of the residuals, ρ(rj) = r
2
j . In Tukey’s bisquare objective function,
ρ(rj) =
 c
2
6
{
1−
[
1− ( rj
c
)2]3}
if |rj| < c
c2
6
if |rj| ≥ c.
(5)
The value of the tuning parameter c is chosen as 1.548 to provide a high breakdown
point in the S-estimation step, and as 4.685 to provide an efficient estimator in the M-
estimation steps. This method for robust regression is the default choice implemented
by the lmrob command in the R package robustbase [27]. Robust regression can
replace standard regression in both the IVW and MR-Egger methods.
2.5 Penalization of weights
Another way of providing additional robustness is to penalize the weights of candidate
instruments with heterogeneous ratio estimates in the weighted regression model. This
could be achieved in many ways; we propose an approach using Cochran’s Q statistic
as a measure of heterogeneity. For the IVW method:
Q =
∑
j
Qj =
∑
j
σ−2Y j (βˆY j − θˆβˆXj)2 (6)
where θˆ is here taken as the IVW estimate. The Q statistic has an approximate
χ2J−1 distribution under the null hypothesis that all candidate instruments satisfy
the instrumental variable assumptions; the components of the Q statistic for each
candidate instrument (Qj) approximately have χ
2
1 distributions. So as not to distort
the majority of weights, we propose penalization using the one-sided upper p-value
(denoted qj) on a χ
2
1 distribution corresponding to Qj, by multiplying the weight
(se(βˆY j)
−2) by min(1, 20qj). The same downweighting factor has previously been
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used for weights in the median-based method to give a penalized weighted median
estimate [14]. For the median-based methods, we replace the IVW estimate by the
relevant median estimate in the calculation of the Q statistic.
For the MR-Egger method, we consider a Q statistic equivalent to the residual sum
of squares from the weighted regression, which has an approximate χ2J−2 distribution
if the MR-Egger regression model is correct [28]:
Q =
∑
j
Qj =
∑
j
σ−2Y j (βˆY j − θˆ0 − θˆ1βˆXj)2. (7)
If most candidate instruments are valid instrumental variables, then robust regres-
sion in either the IVW or MR-Egger method should give a consistent causal estimate
asymptotically as the sample size increases, as the association estimates from valid
instruments should all align on a straight-line through the origin [19] (the value of
“most” depends on the breakdown point of the robust regression method). Equally,
provided that the causal estimate in the Q statistic is close to the true causal effect,
penalization of weights should downweight the contribution of invalid instruments to
zero asymptotically as the sample size increases. If the pleiotropic effects of candidate
instruments are independently distributed from their associations with the exposure (a
population version of the InSIDE assumption), then the weighted correlation between
the pleiotropic effects and associations with the exposure should tend to zero asymp-
totically as the number of candidate instruments increases for all choices of weights,
and should be zero on average for a random choice of candidate instruments. This
means that penalization of weights should not affect the consistency of the MR-Egger
method under the population InSIDE assumption, nor the use of any robust regres-
sion method that is equivalent to varying the weights. This provides some motivation
that these extensions should provide reasonable estimates in large samples. However,
it is unclear what will happen if some variants satisfy the InSIDE assumption, but
others do not.
2.6 L1 penalization
An alternative estimation method is to fit a separate intercept coefficient for each
candidate instrument, and to use penalization to identify the model. In the standard
MR-Egger method, a single intercept term is estimated, representing the average
pleiotropic effect. Weighted linear regression in the MR-Egger method minimizes the
following expression: ∑
j
se(βˆY j)
−2(βˆY j − θ0 − θ1βˆXj)2 (8)
We propose replacing the θ0 with θ0j , and adding an L1-penalty term:∑
j
se(βˆY j)
−2(βˆY j − θ0j − θ1βˆXj)2 + λ
∑
j
|θ0j | (9)
where λ is a tuning parameter. If λ = 0, then all the candidate instruments are
allowed to be pleiotropic, and the model is not identified. If λ = ∞, then this is
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equivalent to the IVW method using all candidate instruments, as the pleiotropic
effects are forced to take the value zero – in effect, all candidate instruments are
assumed to be valid instruments. As the value of λ decreases, the number of candidate
instruments for which αj 6= 0 increases, and these candidate instruments are allowed
to be pleiotropic. An advantage of L1 penalization over other penalization options
is the sparsity property – some coefficients are shrunk to zero, representing invalid
instruments. Additionally, it can be shown that the estimate of θ1 in L2 penalization
does not depend on the value of the tuning parameter (see Web Appendix A.2).
Once the value of λ is determined, we perform the IVWmethod using all candidate
instruments that are determined to be valid instruments (that is, for all j such that
θˆ0j = 0). This provides a causal estimate and a standard error.
3 Simulation study
We perform a simulation study to compare the bias and coverage properties of esti-
mates from different methods:
• standard linear regression without and with an intercept term using inverse-
variance weights as in equation (3) – this is equivalent to the IVW and MR-Egger
methods respectively;
• robust linear regression (MM-estimation with bisquare objective function) with-
out and with an intercept term using inverse-variance weights;
• standard linear regression without and with an intercept term using penalized
inverse-variance weights;
• robust linear regression without and with an intercept term using penalized
inverse-variance weights;
• L1 penalization using various approaches for selecting the tuning parameter;
• simple, weighted, and penalized weighted median estimates (for comparison).
We investigate whether these methods give reasonable inferences (in particular, main-
tain nominal Type 1 error rates under the causal null hypothesis [θ = 0], but have
reasonable power under the alternative) in realistic scenarios. Robust regression is
implemented using the lmrob command from the robustbase package in R [29] with
the method = "MM" option [27].
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3.1 Data-generating model
The data-generating model for the simulation study is as follows:
Ui =
J∑
j=1
φjGij + ǫUi (10)
Xi =
J∑
j=1
γjGij + Ui + ǫXi
Yi =
J∑
j=1
αjGij + θXi + Ui + ǫY i
Gij ∼ Binomial(2, 0.3) independently for all j = 1, . . . , J
ǫUi, ǫXi, ǫY i ∼ N (0, 1) independently
for participants indexed by i = 1, . . . , N , and candidate instruments indexed by j =
1, . . . , J . The candidate instruments Gj are simulated to be equivalent to genetic
variants that are single nucleotide polymorphisms in Hardy–Weinberg equilibrium
with minor allele frequency 0.3. The variable U is a confounder in the relationship
between the exposure and the outcome, and is assumed to be unmeasured. The
error terms ǫUi, ǫXi, and ǫY i were each drawn independently from standard normal
distributions. The causal effect of the exposure on the outcome was either θ = 0
(null causal effect) or θ = 0.1 (positive causal effect). The effects of the candidate
instruments on the exposure (γj) were drawn from a uniform distribution between
0.03 and 0.1. The direct effects of a candidate instrument (genetic variant) on the
outcome (αj) and the effects of the candidate instruments on the confounder (φj)
were set to zero if the candidate instrument was a valid instrumental variable; for
candidate instruments that were invalid instrumental variables:
• In Scenario 2 (direct effects average to zero – balanced pleiotropy, population
InSIDE satisfied), the αj parameters were drawn from a uniform distribution
between −0.1 and 0.1, and the φj were taken as 0.
• In Scenario 3 (direct effects do not average to zero – directional pleiotropy,
population InSIDE satisfied), the αj parameters were drawn from a uniform
distribution between 0 and 0.1, and the φj were taken as 0.
• In Scenario 4 (direct effects operate via confounder and hence do not average
to zero – directional pleiotropy, InSIDE not satisfied), the φj parameters were
drawn from a uniform distribution between −0.1 and 0.1, and the αj were taken
as 0.
In Scenario 1, all candidate instruments are taken to be valid instruments. In Sce-
narios 2 to 4, each candidate instrument was determined to be a valid or an invalid
instrumental variable based on a Bernoulli trial with the probability of being invalid
set to 0.1, 0.2, and 0.3. Although we only consider scenarios with (on average) up to
30% invalid instruments, the pleiotropic effects of invalid instruments are fairly large.
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The maximal indirect association of a candidate instrument with the outcome via the
exposure with a positive causal effect is 0.1 × 0.1 = 0.01 (if γj = 0.1), whereas the
maximal direct (pleiotropic) effect is 0.1 (if either αj = 0.1 or φj = 0.1),
A total of 10 000 simulated datasets were generated for N = 20 000 participants
and J = 25 candidate instruments. A ‘two-sample’ setting was assumed in which
associations of the candidate instruments with the exposure were estimated in N par-
ticipants, and associations with the outcome in a separate sample of N participants.
Results obtained in a one-sample setting in which the associations with the exposure
and with the outcome are obtained in the same individuals are given in Web Appendix
A.3. Only the summarized data, that is the estimated univariable associations of the
candidate instruments with the exposure and with the outcome, and their standard
errors, were used by the analysis methods. The average proportion of variance in the
exposure explained by the candidate instruments (R2 statistic) was 2.5% (2.8% in
Scenario 4), and the average F statistic was 20.5 (23.3 in Scenario 4).
Six strategies were undertaken for choosing the value of the tuning parameter λ
in the L1 penalization method. We set λ = 1, λ = 2, and λ = 3, to compare the
performance of the method with different choices of the tuning parameter. Fourthly,
we used leave-one-out cross-validation of the likelihood function. Fifthly, we used a
grid search to pick the value of λ that gave the causal estimate closest to zero; estimates
were calculated for λ = 0.1, 0.2, . . . , 4.9, 5.0, 5.2, 5.4, . . . , 9.8, 10.0. Finally, we used a
heterogeneity criterion to determine how many variants to include in the model; we
increased the value of the tuning parameter by the same increments as in the grid
search, stopping when the residual standard error in the regression model was above 1
and the next value of λ increased the residual standard error by an increment of more
than χ21(0.95)/(Jinc− 1), where χ21(0.95) is the upper 95th percentile of a chi-squared
distribution on 1 degree of freedom, and Jinc is the number of candidate instruments
included in the model. This is motivated by Cochran’s Q heterogeneity statistic (equal
to the residual standard error multiplied by the number of candidate instruments less
1) having a χ2J−1 distribution under the null hypothesis that all candidate instruments
are estimating the same causal parameter.
3.2 Results
Results from the simulation study are provided in Table 1 (Scenario 1 only, all meth-
ods), Table 2 (Scenarios 2-4, weights not penalized), Table 3 (Scenarios 2-4, penalized
weights), and Table 4 (Scenarios 2-4, L1 penalization methods). Table 1 displays the
mean estimate across simulations, standard deviation of estimates, mean standard
error of estimates, and the empirical power to detect a causal effect (the proportion
of simulations where the 95% confidence interval [estimate ± 1.96 standard errors]
excluded the null). With a null causal effect, power to detect a causal effect is the
same as the Type 1 error rate, and the expected power is 5%. In Tables 2, 3 and 4,
the mean standard error of estimates is omitted (the pattern of results for the mean
standard error was similar to that in Scenario 1 except as noted below). In some of
the simulations, the robust regression method did not report a standard error (less
than 1% in all cases, except up to 2.5% for the robust method with an intercept in
Scenario 4); the number of simulations that failed to report a standard error is given
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in Table 1 for Scenario 1, and in Web Table A1 for other scenarios. Simulations were
not excluded from the results if a standard error was not reported (except for the
calculation of the mean standard error); power calculations include these simulations
as if the standard error estimate is infinite. The Monte Carlo standard error (the
uncertainty due to the limited number of simulations considered) for the power was
0.2% with a null effect, and between 0.2% and 0.5% with a positive causal effect. A
graph illustrating the coverage rates for a limited selection of methods is provided as
Figure 3.
Scenario 1 (Table 1): When all candidate instruments were valid instruments,
all methods provided unbiased estimates under the null, with Type 1 error rates close
to or below the nominal significance level of 5%. The standard deviation of estimates
was slightly below the mean standard error of estimates for all methods, with dif-
ferences most marked for the median-based methods. This difference suggests that
methods may be slightly conservative in their inferences. In terms of precision of the
causal estimate, regression methods without an intercept (including the IVW method)
and L1 penalization methods were the most precise, followed closely by the median-
based methods, while regression methods with an intercept (including the MR-Egger
method) were the least precise. Differences in precision between the standard, robust
and penalized methods were slight. The exception was the L1 penalization method
taking the minimal estimate, which gave conservative inference and less variable esti-
mates, particularly under the null.
With a positive causal effect, differing precisions of the causal estimate were also
evidenced by the marked differences in power to detect a causal effect. The power
for the regression methods including an intercept term was barely above 5%. While
precision of the causal estimate for the IVWmethod depends on the proportion of vari-
ance in the exposure explained by the candidate instruments, precision of the causal
estimate for MR-Egger depends on the variability between the instrument–exposure
associations [30]. If all candidate instruments have exactly the same magnitude of
association with the exposure, then the MR-Egger estimate is undefined. The MR-
Egger estimate will always be less precise than the IVW estimate, but the difference
in precision will depend on whether the instrument–exposure associations for different
candidate instruments are similar to each other or not.
While there was some attenuation towards the null with a positive causal effect
for all the methods (except for the simple median method) due to uncertainty in the
associations of the candidate instruments with the exposure, this was minimal for the
IVW and other methods with no intercept, but substantial for the MR-Egger and other
methods with an intercept. This attenuation is a known phenomenon called finite-
sample bias (also known as weak instrument bias [31]). Bias in the two-sample setting
acts towards the null [32] and is related to regression dilution bias [33]; it arises due to
measurement error in the independent variable in a regression model. Relative bias of
the IVW estimate is around 1/F , where F is the expected value of the F statistic from
regression of the exposure on the IVs (here, 1/F ≈ 1/20 = 5%, similar to the observed
attenuation in the mean IVW estimates) [34]; whereas attenuation of the MR-Egger
estimate is approximately equal to the I2 statistic from meta-analysis of the weighted
associations with the exposure βˆXj se(βˆY j)
−1 with standard errors se(βˆXj) se(βˆY j)−1
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[30]. The I2 statistic is large when the candidate instruments have a wide spread of
associations with the exposure or their associations are precisely estimated, and small
when their associations with the exposure are imprecisely measured or all similar.
In the simulation, the average value of the I2 statistic was 60.1%. This bias can be
corrected using the Simulation Extrapolation (SIMEX) method [35, 30], although this
was not computationally feasible in the simulation setting. While measurement error
in the exposure can lead to inflation of the intercept term in the MR-Egger method,
in this case the 95% confidence interval for the intercept term excluded zero for MR-
Egger in 4.7% of simulations – close to the expected nominal 5% level, indicating that
over-rejection of the null hypothesis for the MR-Egger intercept test was not evident
in this example.
[Table 1 should appear about here.]
Scenario 2, 3 and 4, non-penalized weights (Table 2): Mean estimates in
Scenario 2 (balanced pleiotropy, InSIDE satisfied) were unbiased with a null causal
effect for all methods. With a positive causal effect, mean estimates were similar
to those in Scenario 1: close to unbiased for most methods, but with severe atten-
uation for regression methods with an intercept term. However, there were marked
differences in the precision of estimates compared with Scenario 1. Out of previously
proposed methods, estimates from the median-based methods were more precise than
those from the IVW method, although this did not translate into greater power with
a positive causal effect when only 10% of candidate instruments were not valid instru-
ments. However, the greatest power was obtained by the robust regression method
with no intercept. Although the power of the MR-Egger method and other regres-
sion methods with an intercept was low, the use of robust regression did reduce the
standard deviation and mean standard error of estimates.
Scenario 3 (directional pleiotropy, InSIDE satisfied) demonstrates the value of the
MR-Egger and related methods estimating an intercept for providing robust inferences
under the InSIDE assumption. While estimates from other methods (particularly the
IVW method) were biased under the null, mean estimates from regression methods
with an intercept term were close to unbiased, and Type 1 error rates were close to
nominal levels. But again, these methods were unable to identify the presence of a
causal effect with reasonable power, and mean estimates were substantially attenu-
ated. More seriously, in Scenario 4 (directional pleiotropy, InSIDE not satisfied), the
MR-Egger method performed much worse than the IVWmethod, with mean estimates
far more biased and larger Type 1 error rates. While there was some improvement
using robust regression with an intercept term when there were few invalid instru-
ments, there was still substantial bias and Type 1 error inflation, as well as even less
precise estimates compared with the MR-Egger method when there were many invalid
instruments. The MR-Egger and related methods are highly sensitive to the validity
of the InSIDE assumption. As the InSIDE assumption is not testable, this is a major
limitation of these methods.
In contrast, while the median-based methods and robust regression method with-
out an intercept had bias in mean estimates and inflated Type 1 error rates, rates
were substantially below those for the IVW method. In particular, Type 1 error
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rates were close to 10% or below for the simple median and robust regression with-
out an intercept methods in Scenarios 3 and 4 with up to 20% invalid instruments,
and for the simple median method in Scenario 4 with 30% invalid instruments. The
weighted median method was particularly poor in Scenario 4; the data-generating
mechanism meant that the invalid instruments received more weight in the analysis
than the valid instruments as they had greater associations with the exposure (via an
additional association with the confounder). The median-based methods and robust
regression without an intercept also had reasonable power to detect a causal effect
when present.
[Table 2 should appear about here.]
Scenarios 2, 3 and 4, penalized weights (Table 3): The use of penalized
weights generally led to more precise causal estimates, and Type 1 error rates were
somewhat improved in Scenarios 3 and 4 for the IVW and weighted median methods.
However, Type 1 error rates for the penalized methods generally exceeded nominal
levels in all scenarios, especially when 20% or more candidate instruments were in-
valid. A particular cause for concern is the inflated Type 1 error rates in Scenario
2, which did not occur with unpenalized weights. The reason seems to be that the
heterogeneity between the estimates from candidate instruments was underestimated,
and hence there was underestimation of the uncertainty in the causal estimate. This
highlights a danger that penalization of weights can lead to overconfidence in making
inferences, as evidence that points in a different direction is downweighted in the anal-
ysis. Penalization of weights did not seem to be a worthwhile strategy for controlling
Type 1 error rates in this simulation study.
[Table 3 should appear about here.]
Scenarios 2, 3 and 4, L1 penalization method (Table 4): Similarly, al-
though Type 1 error rates for the implementations of the L1 penalization method
were improved compared with the IVW method in Scenarios 3 and 4, there was slight
overprecision in Scenario 2, and Type 1 error rates were consistently greater than
nominal levels. Estimates using the tuning parameter (λ) chosen by cross-validation
had the largest Type 1 error rates and the most variable estimates, but did not always
have the greatest power to detect a causal effect. This suggests that cross-validation
tended to include too few candidate instruments in the causal analysis, and in Sce-
narios 3 and 4, often chose the wrong candidate instruments. Estimates using the
heterogeneity criterion to choose the values of λ produced better inferences than by
simply choosing a fixed value of λ in Scenarios 2 and 3, but worse in Scenario 4. When
the value of λ was chosen to give the minimal causal estimate, Type 1 error rates were
conservative in Scenario 2, and in Scenario 3 with up to 20% invalid instruments.
However, power to detect a causal estimate was also considerably lower.
Supplementary analyses (not done yet for L1 penalization): This simu-
lation was repeated in a one-sample setting in which associations of the candidate
instruments with the exposure and with the outcome were obtained in the same sam-
ple of 20 000 individuals for the methods using non-penalized weights. Results are
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displayed in Web Table A2 (Scenario 1) and Web Table A3 (Scenarios 2 to 4). Bias in
the direction of the observational association was observed in all methods except for
the simple median method (which remained unbiased in Scenarios 1 and 2). However,
the bias of the MR-Egger method was greater and more severe than that of the IVW
method: in Scenario 1 with a null causal effect, the mean estimates were 0.024 for the
IVW method and 0.173 for the MR-Egger method, and Type 1 error rates were 6.8%
and 27.2% respectively. The rejection rate of the MR-Egger intercept test was also
inflated (23.5% with a null causal effect, 20.3% with a positive causal effect). The
one-sample setting is another case where the MR-Egger method performs poorly.
The simulation was also repeated in a two-sample setting with only 10 candidate
instruments, to observe whether the robust methods were able to operate well with
fewer instruments to detect violations of the instrumental variables assumptions. Re-
sults for Scenarios 2 to 4 are presented in Web Table A4. Power to detect a causal
effect was generally much lower, but otherwise similar results were observed.
Finally, Table 5 shows the proportion of datasets for the original simulation study
rejecting the causal null using both the simple median and robust regression method
with no intercept (robust IVW), and the empirical power of the MR-Egger intercept
test for detecting directional pleiotropy and/or violations of the InSIDE assumptions.
The combination of the simple median and robust IVW methods generally provided
conservative inferences, with Type 1 error rates close to or below nominal levels ex-
cept in Scenario 3 with 30% invalid instruments. This suggests that multiple robust
methods could be used as sensitivity analyses in practice to better control Type 1
error rates. The MR-Egger intercept test is a test of directional pleiotropy and/or
violation of the InSIDE assumption: as expected, rejection rates were around 5% in
Scenarios 1 and 2, and greater in Scenarios 3 and 4. This suggests that, even if the
MR-Egger estimate is unreliable, the method may be useful for detecting in which
cases the IVW method is likely to be biased.
[Table 5 should appear about here.]
4 Applied example: causal effect of body mass in-
dex on schizophrenia risk
As an applied example to illustrate the methods, we considered the causal effect of
body mass index (BMI) on schizophrenia risk. Individuals with schizophrenia gener-
ally have higher incidence of obesity than the general population [36], although the
relationship is thought to arise from the effect of anti-psychotic medicine on BMI (re-
verse causation) rather than as a causal effect of BMI [37]. We use 97 genetic variants
previously demonstrated to be associated with BMI at a genome-wide level of signif-
icance by the Genetic Investigation of Anthropometric Traits (GIANT) consortium
[38]. Associations with the exposure were taken from univariable linear regression
analyses in up to 339 224 European-descent individuals from the GIANT consortium
[38]; associations with the outcome were taken from univariable logistic regression
analyses in around 9000 European-descent cases and 8000 controls from the Psychi-
atric Genomics Consortium [39]. The 97 genetic variants explain about 2.7% of the
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variance in BMI. Both sets of genetic associations have previously been made publicly
available, and the association estimates can be obtained using the PhenoScanner tool
at http://phenoscanner.medschl.cam.ac.uk/; they are also displayed visually in
Figure 4. The graph indicates that there are several genetic variants that are clear
outliers in their associations with schizophrenia, suggesting potential pleiotropy. The
I2 statistic for the weighted genetic associations with the exposure was 88.8%, suggest-
ing that attenuation of the MR-Egger and other methods that estimate an intercept
should not be severe.
[Figure 4 should appear about here.]
Estimates and 95% confidence intervals are provided in Table 6. Random-effects
models were used in all analyses. Each estimate represents the log odds ratio for
schizophrenia per 1 standard deviation increase in BMI. Although all estimates are
compatible with the null, there is a wide variation in the standard errors of estimates.
Using non-penalized weights, a similar pattern of results was seen as in the simulation
analyses of Scenario 2: the robust method with no intercept giving the most precise
estimate, followed by the median-based methods, with the MR-Egger method far
behind. The use of penalized weights led to large improvements in precision for all
except the median-based methods, indicating that although penalization of weights
did not seem to add robustness to results in the simulation study, it may have a role
in improving the precision of results in cases like this where there are genetic variants
that are clear outliers. In the IVW method, the use of penalized weights reduced
the residual standard error from 2.14 to 1.12, only slightly above the value of 1 that
would be expected in the absence of heterogeneity. In an applied setting, the genetic
variants that are downweighted in the analysis should be examined for pleiotropy to
determine whether their omission from the analysis is reasonable.
L1 penalization estimates for a range of values of the tuning parameter are dis-
played in Figure 5. Using the heterogeneity criterion, the value of the tuning pa-
rameter was λ = 1.9 and 64 genetic variants were included in the analysis. Using
cross-validation, the value of the tuning parameter was much larger at λ = 6.63 and
95 of the 97 genetic variants were included in the analysis. The heterogeneity crite-
rion almost chose the value of λ corresponding to the most precise causal estimate
(λ = 1.8 gave a slightly more precise estimate), and a more precise estimate than
from any other method. However, as can be seen in Figure 5, causal estimates were
fairly similar in magnitude whatever value of λ was chosen, even for λ = 0.1 when
only 5 genetic variants were included in the analysis. While in the simulation study,
a strategy was required to choose the value of λ, in practice causal estimates can be
compared using a range of values of the tuning parameter.
This applied example illustrates that in addition to providing additional confidence
in the robustness of findings from a conventional analysis, the methods introduced in
this paper have the potential to improve the efficiency of Mendelian randomization
estimates.
[Table 6 should appear about here.]
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5 Discussion
In this paper, we have introduced three extensions to instrumental variable methods
to downweight the influence of candidate instruments with heterogeneous causal esti-
mates, with the aim of providing more robust estimates in Mendelian randomization
investigations. A summary of the methods presented in this paper is provided in
Table 7.
[Table 7 should appear about here.]
While the robust and the penalized versions of MR-Egger have desirable theoretical
properties, in our simulation study neither method was able to reliably detect the
presence of a causal effect of moderate size with reasonable power. Additionally,
both these and the original MR-Egger method were highly sensitive to violations of
the InSIDE assumption. The MR-Egger intercept test was able to detect scenarios
in which the IVW method gave biased estimates, although power was moderate at
best. The two methods that had the best performance across the range of scenarios
considered in terms of Type 1 error rate and power were the robust version of the IVW
method and the simple median method. Although Type 1 error rates were inflated
over nominal levels for all methods in at least one scenario, improvement over the
standard inverse-variance weighted method was considerable.
If alternative parameters or scenarios were chosen in the simulation study, then
different results might have been observed. For example, if candidate instruments had
substantially different strengths (and validity of the candidate instruments did not de-
pend on instrument strength, as in Scenario 4), then the weighted median method
may have been preferable to the simple median method, and the loss of power in the
MR-Egger method compared with the IVW method would have been less severe. Al-
ternatively, if simulations were conducted in a scenario where 100% of the candidate
instruments were invalid but they satisfied the InSIDE assumption, then the MR-
Egger method would have fared better; likewise if the magnitude of the causal effect
was greater (hence the MR-Egger method would have had improved power to detect
a causal effect), or if the sample size for the genetic associations with the exposure
increased (hence the MR-Egger estimates would have been less attenuated). Hence,
the conclusion from this work should not be to promote one method for Mendelian
randomization analysis to the exclusion of others, but rather to emphasize the need
for multiple sensitivity analyses that make different sets of assumptions. The robust
version of the IVW method seems to be a worthwhile sensitivity analysis method in
addition to other robust methods previously proposed (such as simple and weighted
median, and MR-Egger [17]). The use of penalized weights may be worthwhile to
improve precision if a small number of candidate instruments have clearly heteroge-
neous causal estimates (as demonstrated in the applied example), but the approach
is unlikely to lead to robust inferences if several candidate instruments are not valid.
Similarly, L1 penalization can improve precision when causal estimtes are heteroge-
neous, and the approach gave improved inferences over the IVW method when the
InSIDE assumption was satisfied. While it is not clear how to best choose the tuning
parameter in an automated way for a simulation analysis, in an applied example esti-
mates can be reported for a range of values of this parameter. Additionally, if we had
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considered weaker pleiotropic effects in the simulation study, Type 1 error inflation
would have been less pronounced.
5.1 Linearity and homogeneity assumptions
In the specification of the analysis models, we have assumed linearity and homogeneity
(no effect modification) of the causal effect of the exposure on the outcome, and of the
associations of the candidate instruments with the exposure and with the outcome.
These assumptions are not necessary to identify a causal effect; weaker assumptions
can be made [40] (such as monotonicity of the causal effect [41] or a weaker version
of the homogeneity assumption for the causal effect [42, 43]). If the linearity and
homogeneity assumptions are violated, then the causal estimate using a single instru-
mental variable is a valid test of the null hypothesis that the exposure does not have
a causal effect on the outcome [4]; this also applies to the causal estimate from the
IVW method using multiple instruments, as this is a linear combination of the causal
estimates from the individual instruments [44]. Hence, even when the linearity and
homogeneity assumptions are violated, the methods proposed in this paper can still be
used for the assessment of the causal null hypothesis (does the exposure have a causal
effect on the outcome?), even if the estimate does not have a literal interpretation
[45].
Additionally, while the linearity and homogeneity assumptions are stringent, ge-
netic variants tend to have small effects on the exposure and outcome. This means
that linearity and homogeneity may not be unreasonable assumptions in an applied
Mendelian randomization investigation. Linearity and homogeneity in the genetic
associations are not required across the whole distribution of the exposure and the
outcome, but simply in the range of values predicted by the genetic variants.
5.2 Alternative robust methods
Several other methods have been developed for robust estimation using instrumental
variables. Kolesa´r et al. proposed a method within the framework of k-class esti-
mators with a 100% breakdown level under the InSIDE assumption [46]. Kang et
al. proposed a method using individual-level data based on penalized regression for
detecting and accounting for invalid instruments that provides a consistent estimate
of causal effect if at least 50% of the candidate instruments are valid using L1 penal-
ization to downweight the contribution to the analysis of candidate instruments that
have heterogeneous causal estimates [19]. Han proposed a similar penalized estimator
within the generalized method of moments framework, again with a 50% breakdown
level [47]. These ideas were developed further by Windmeijer et al. [48]; several of
the choices made here relating to the L1 penalization method (such as the decision
to use the method to identify invalid instruments and to obtain the causal estimate
using only the valid instruments, referred to by Windmeijer et al. as a ‘post-lasso’
estimator, and the decision to explore a heterogeneity criterion for selecting the tun-
ing parameter) were guided by that paper. However, each of these methods requires
individual-level data, limiting their applicability to applied Mendelian randomization
investigations.
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5.3 Conclusion
We have shown that it is difficult to find methods that give robust causal inferences
with invalid instruments. Even in the examples with moderate numbers of invalid
instruments considered in this paper, all methods had inflated Type 1 error rates in at
least one scenario. Nevertheless, although the methods we have proposed are far from
perfect, they have much improved Type 1 error rates compared with the conventional
IVW method and the recently introduced MR-Egger method in scenarios where the
InSIDE assumption fails to hold.
We have demonstrated that using multiple methods for instrumental variable anal-
ysis (particularly methods that provide consistent estimates under different assump-
tions) can provide more reliable inferences for Mendelian randomization investiga-
tions. A causal conclusion is more plausible in cases where multiple methods suggest
a causal effect. We suggest that the IVW method using robust regression is a worth-
while method to apply in addition to previously proposed methods (in particular the
simple median method), and that the use of penalized weights and L1 penalization
may be valuable in some situations.
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Scenario 1
Method Mean SD Mean SE Power NA 1
Null causal effect: θ = 0
Standard, no intercept 2 0.000 0.044 0.047 3.9 -
Standard, intercept 3 0.002 0.125 0.133 3.8 -
Robust, no intercept 0.000 0.046 0.050 4.5 1
Robust, intercept 0.002 0.130 0.141 5.7 4
Penalized standard, no intercept 0.000 0.046 0.046 5.2 -
Penalized standard, intercept 0.002 0.130 0.130 4.8 -
Penalized robust, no intercept 0.000 0.047 0.047 5.9 2
Penalized robust, intercept 0.001 0.132 0.134 7.1 5
Simple median 0.000 0.059 0.070 1.8 -
Weighted median 0.001 0.056 0.064 2.1 -
Penalized weighted median 0.001 0.059 0.064 3.1 -
L1 penalization, λ = 1 0.000 0.055 0.053 5.7 -
L1 penalization, λ = 2 0.001 0.049 0.046 6.4 -
L1 penalization, λ = 3 0.000 0.045 0.047 4.2 -
L1 penalization, cross-validation 0.001 0.047 0.046 5.4 -
L1 penalization, minimal estimate 0.000 0.029 0.062 0.9 -
L1 penalization, heterogeneity 0.000 0.045 0.047 4.0 -
Positive causal effect: θ = +0.1
Standard, no intercept 2 0.096 0.047 0.050 49.3 -
Standard, intercept 3 0.065 0.136 0.141 6.7 -
Robust, no intercept 0.096 0.048 0.052 46.1 2
Robust, intercept 0.064 0.140 0.148 8.7 4
Penalized standard, no intercept 0.096 0.049 0.048 51.8 -
Penalized standard, intercept 0.064 0.140 0.137 8.3 -
Penalized robust, no intercept 0.096 0.050 0.050 50.1 2
Penalized robust, intercept 0.064 0.142 0.140 10.3 5
Simple median 0.101 0.063 0.074 24.7 -
Weighted median 0.093 0.059 0.067 25.7 -
Penalized weighted median 0.093 0.062 0.067 26.5 -
L1 penalization, λ = 1 0.097 0.059 0.056 40.8 -
L1 penalization, λ = 2 0.097 0.052 0.048 51.9 -
L1 penalization, λ = 3 0.096 0.047 0.049 50.0 -
L1 penalization, cross-validation 0.096 0.051 0.049 50.4 -
L1 penalization, minimal estimate 0.064 0.048 0.067 19.2 -
L1 penalization, heterogeneity 0.096 0.048 0.049 48.9 -
Table 1: Mean, standard deviation (SD), mean standard error (mean SE) of estimates,
and empirical power (%) from weighted linear regression models (weights are penalized
where indicated) using standard and robust regression, without and with an intercept
term, and median-based methods for Scenario 1.
1Number of the 10 000 simulations that failed to report a standard error.
2This is the standard inverse-variance weighted (IVW) method, equivalent to the two-stage least
squares (2SLS) method with individual-level data.
3This is the MR-Egger method.
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Scenario 2 Scenario 3 Scenario 4
Method Mean SD Power Mean SD Power Mean SD Power
Null causal effect: θ = 0
Proportion of invalid instrumental variables: 0.1
Standard, no intercept 0.000 0.069 5.4 0.067 0.067 13.0 0.059 0.076 19.0
Standard, intercept 0.001 0.197 5.6 0.002 0.192 5.8 0.148 0.245 30.7
Robust, no intercept 0.000 0.052 5.1 0.022 0.054 6.1 0.017 0.058 5.6
Robust, intercept 0.001 0.153 6.8 0.001 0.154 6.5 0.081 0.205 11.5
Simple median 0.000 0.066 2.8 0.030 0.066 4.5 0.013 0.066 3.2
Weighted median 0.000 0.061 3.1 0.024 0.061 4.3 0.040 0.077 10.6
Proportion of invalid instrumental variables: 0.2
Standard, no intercept -0.001 0.087 6.1 0.135 0.084 34.8 0.112 0.087 34.0
Standard, intercept 0.003 0.251 6.2 0.008 0.234 6.1 0.255 0.260 43.9
Robust, no intercept 0.000 0.064 5.4 0.062 0.074 10.4 0.049 0.080 9.7
Robust, intercept 0.003 0.192 7.1 0.006 0.192 7.0 0.207 0.269 24.9
Simple median -0.001 0.074 3.8 0.067 0.078 11.3 0.027 0.074 4.9
Weighted median 0.000 0.069 4.5 0.054 0.072 11.5 0.088 0.103 26.4
Proportion of invalid instrumental variables: 0.3
Standard, no intercept 0.001 0.103 5.9 0.204 0.093 59.3 0.161 0.092 48.9
Standard, intercept 0.000 0.288 5.9 0.005 0.263 6.0 0.327 0.256 50.6
Robust, no intercept 0.001 0.082 5.7 0.122 0.100 19.7 0.099 0.102 19.3
Robust, intercept 0.003 0.243 6.3 0.005 0.239 7.5 0.332 0.293 42.0
Simple median 0.000 0.082 5.1 0.115 0.094 25.0 0.046 0.084 8.6
Weighted median 0.001 0.079 6.7 0.094 0.090 24.3 0.148 0.125 46.2
Positive causal effect: θ = +0.1
Proportion of invalid instrumental variables: 0.1
Standard, no intercept 0.095 0.070 32.6 0.162 0.069 69.2 0.155 0.078 63.3
Standard, intercept 0.066 0.202 7.1 0.066 0.196 7.0 0.221 0.252 38.0
Robust, no intercept 0.095 0.055 40.6 0.120 0.057 53.8 0.114 0.062 45.2
Robust, intercept 0.066 0.162 9.0 0.066 0.162 8.8 0.149 0.218 15.8
Simple median 0.100 0.070 23.4 0.132 0.070 38.5 0.114 0.070 29.4
Weighted median 0.093 0.064 24.8 0.117 0.064 37.1 0.134 0.081 45.3
Proportion of invalid instrumental variables: 0.2
Standard, no intercept 0.095 0.089 22.6 0.230 0.085 84.0 0.208 0.089 73.2
Standard, intercept 0.068 0.255 7.3 0.073 0.238 7.0 0.335 0.266 52.0
Robust, no intercept 0.096 0.067 32.5 0.162 0.078 58.5 0.148 0.084 45.6
Robust, intercept 0.069 0.201 9.1 0.071 0.201 8.8 0.278 0.281 29.5
Simple median 0.100 0.077 22.9 0.170 0.083 53.3 0.129 0.078 33.9
Weighted median 0.093 0.072 24.6 0.149 0.077 50.8 0.185 0.107 62.5
Proportion of invalid instrumental variables: 0.3
Standard, no intercept 0.097 0.105 18.6 0.299 0.095 93.8 0.257 0.094 81.6
Standard, intercept 0.065 0.291 6.5 0.070 0.267 6.9 0.411 0.261 59.9
Robust, no intercept 0.096 0.085 25.2 0.223 0.102 64.2 0.200 0.104 52.7
Robust, intercept 0.068 0.251 7.7 0.070 0.247 8.8 0.406 0.304 46.7
Simple median 0.101 0.087 22.5 0.221 0.100 69.2 0.148 0.089 38.9
Weighted median 0.094 0.083 24.9 0.191 0.095 65.8 0.245 0.128 76.8
Table 2: Mean, standard deviation (SD) of estimates, and empirical power (%) from
weighted linear regression models (weights are not penalized) using standard and ro-
bust regression, without and with an intercept term, and simple and weighted median
methods for Scenarios 2, 3, and 4. (Note: power with a null causal effect is the Type
1 error rate.)
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Scenario 2 Scenario 3 Scenario 4
Method Mean SD Power Mean SD Power Mean SD Power
Null causal effect: θ = 0
Proportion of invalid instrumental variables: 0.1
Penalized standard, no intercept 0.000 0.051 6.8 0.022 0.053 9.5 0.019 0.056 11.3
Penalized standard, intercept 0.001 0.149 7.5 0.001 0.154 8.2 0.093 0.198 22.7
Penalized robust, no intercept 0.000 0.052 6.3 0.018 0.053 8.4 0.015 0.055 8.2
Penalized robust, intercept 0.001 0.151 7.9 0.001 0.153 7.9 0.077 0.191 15.4
Penalized weighted median 0.001 0.063 3.7 0.011 0.063 4.0 0.016 0.074 6.6
Proportion of invalid instrumental variables: 0.2
Penalized standard, no intercept 0.000 0.059 9.6 0.056 0.068 24.6 0.049 0.074 25.2
Penalized standard, intercept 0.004 0.178 10.9 0.006 0.194 13.5 0.206 0.241 43.4
Penalized robust, no intercept 0.000 0.059 7.0 0.046 0.066 15.8 0.038 0.070 13.2
Penalized robust, intercept 0.003 0.178 9.1 0.005 0.190 11.4 0.177 0.241 28.5
Penalized weighted median 0.000 0.070 5.3 0.026 0.073 7.2 0.050 0.108 16.8
Proportion of invalid instrumental variables: 0.3
Penalized standard, no intercept 0.001 0.069 13.3 0.106 0.088 46.9 0.091 0.092 43.9
Penalized standard, intercept 0.003 0.210 14.6 0.005 0.247 20.7 0.309 0.259 61.4
Penalized robust, no intercept 0.001 0.068 7.4 0.087 0.085 27.8 0.070 0.089 20.7
Penalized robust, intercept 0.004 0.213 9.4 0.005 0.238 14.3 0.281 0.270 43.1
Penalized weighted median 0.001 0.079 6.4 0.051 0.092 12.9 0.104 0.144 31.7
Positive causal effect: θ = +0.1
Proportion of invalid instrumental variables: 0.1
Penalized standard, no intercept 0.095 0.054 49.0 0.119 0.056 65.2 0.116 0.060 61.3
Penalized standard, intercept 0.065 0.158 9.9 0.066 0.162 10.5 0.164 0.209 29.5
Penalized robust, no intercept 0.095 0.055 43.8 0.115 0.056 57.2 0.111 0.059 53.2
Penalized robust, intercept 0.065 0.159 10.5 0.066 0.161 10.8 0.147 0.202 22.0
Penalized weighted median 0.093 0.066 25.8 0.104 0.067 31.1 0.110 0.079 33.6
Proportion of invalid instrumental variables: 0.2
Penalized standard, no intercept 0.095 0.062 46.8 0.154 0.071 78.4 0.147 0.077 72.1
Penalized standard, intercept 0.069 0.186 13.6 0.070 0.202 15.3 0.282 0.252 51.8
Penalized robust, no intercept 0.096 0.062 37.9 0.145 0.070 65.7 0.136 0.074 57.0
Penalized robust, intercept 0.069 0.187 11.4 0.070 0.198 13.8 0.254 0.253 36.1
Penalized weighted median 0.093 0.074 25.3 0.148 0.078 37.4 0.147 0.113 45.0
Proportion of invalid instrumental variables: 0.3
Penalized standard, no intercept 0.097 0.073 46.1 0.205 0.091 89.3 0.190 0.096 82.6
Penalized standard, intercept 0.069 0.219 16.9 0.069 0.254 21.6 0.390 0.270 68.8
Penalized robust, no intercept 0.096 0.072 33.1 0.187 0.089 72.8 0.171 0.094 60.1
Penalized robust, intercept 0.069 0.221 12.0 0.070 0.247 16.6 0.363 0.282 50.6
Penalized weighted median 0.093 0.083 25.1 0.148 0.097 46.4 0.203 0.119 58.4
Table 3: Mean, standard deviation (SD) of estimates, and empirical power (%) from
weighted linear regression models (weights are penalized) using standard and ro-
bust regression, without and with an intercept term, and penalized weighted median
method for Scenarios 2, 3, and 4.
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Scenario 2 Scenario 3 Scenario 4
Method Mean SD Power Mean SD Power Mean SD Power
Null causal effect: θ = 0
Proportion of invalid instrumental variables: 0.1
λ = 1 0.000 0.062 6.9 0.025 0.062 8.7 0.040 0.074 14.0
λ = 2 0.000 0.053 7.4 0.015 0.055 8.8 0.025 0.066 12.5
λ = 3 0.000 0.050 5.2 0.012 0.052 6.4 0.022 0.071 11.5
Cross-validation 0.001 0.090 6.0 0.070 0.103 10.9 0.118 0.155 36.0
Minimal estimate 0.000 0.028 1.0 0.012 0.030 1.7 0.017 0.042 3.5
Heterogeneity criterion 0.000 0.062 5.4 0.028 0.058 6.2 0.051 0.092 20.9
Proportion of invalid instrumental variables: 0.2
λ = 1 0.000 0.069 8.5 0.057 0.076 17.2 0.104 0.119 31.6
λ = 2 0.000 0.059 8.4 0.037 0.067 15.2 0.082 0.122 29.7
λ = 3 0.000 0.058 7.0 0.034 0.066 11.8 0.088 0.136 31.4
Cross-validation 0.001 0.142 8.3 0.192 0.153 33.3 0.273 0.178 70.1
Minimal estimate 0.000 0.030 1.0 0.026 0.041 4.2 0.057 0.092 15.0
Heterogeneity criterion 0.000 0.067 7.0 0.046 0.065 11.0 0.099 0.127 35.8
Proportion of invalid instrumental variables: 0.3
λ = 1 -0.001 0.079 10.1 0.104 0.108 30.4 0.206 0.176 55.6
λ = 2 0.000 0.068 10.3 0.080 0.102 28.5 0.187 0.185 55.5
λ = 3 0.000 0.068 8.0 0.078 0.103 24.5 0.203 0.189 58.9
Cross-validation 0.001 0.189 10.4 0.321 0.190 59.9 0.389 0.161 88.1
Minimal estimate 0.000 0.034 1.4 0.053 0.072 11.1 0.136 0.151 37.2
Heterogeneity criterion 0.000 0.074 7.7 0.076 0.091 19.7 0.184 0.173 56.5
Positive causal effect: θ = +0.1
Proportion of invalid instrumental variables: 0.1
λ = 1 0.095 0.065 37.5 0.121 0.066 53.2 0.138 0.079 59.4
λ = 2 0.095 0.056 46.8 0.111 0.058 57.6 0.123 0.071 61.9
λ = 3 0.095 0.053 45.0 0.109 0.055 54.4 0.121 0.078 57.0
Cross-validation 0.095 0.090 35.5 0.167 0.105 59.3 0.213 0.157 69.6
Minimal estimate 0.053 0.051 12.7 0.082 0.053 28.5 0.091 0.063 34.4
Heterogeneity criterion 0.096 0.066 39.3 0.125 0.062 54.7 0.149 0.096 60.6
Proportion of invalid instrumental variables: 0.2
λ = 1 0.095 0.073 36.2 0.156 0.080 64.5 0.206 0.125 75.9
λ = 2 0.095 0.063 44.2 0.136 0.072 66.2 0.183 0.127 74.5
λ = 3 0.095 0.061 41.3 0.133 0.071 61.8 0.192 0.142 70.5
Cross-validation 0.094 0.142 23.6 0.287 0.156 75.8 0.370 0.179 87.6
Minimal estimate 0.045 0.054 9.9 0.104 0.063 39.8 0.142 0.109 52.3
Heterogeneity criterion 0.095 0.071 35.7 0.144 0.070 60.2 0.201 0.132 71.9
Proportion of invalid instrumental variables: 0.3
λ = 1 0.095 0.083 34.1 0.206 0.113 75.5 0.310 0.179 86.4
λ = 2 0.095 0.072 41.4 0.180 0.108 75.5 0.293 0.188 86.5
λ = 3 0.096 0.071 38.3 0.180 0.109 71.4 0.309 0.192 85.0
Cross-validation 0.095 0.190 19.2 0.419 0.192 88.8 0.486 0.162 95.7
Minimal estimate 0.042 0.057 8.6 0.140 0.089 53.5 0.231 0.163 70.8
Heterogeneity criterion 0.096 0.079 33.8 0.176 0.098 69.2 0.288 0.176 83.2
Table 4: Mean, standard deviation (SD) of estimates, and empirical power (%) from
L1 penalization methods using different strategies for choosing the tuning parameter
λ for Scenarios 2, 3, and 4.
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Proportion Simple median and robust IVW methods MR-Egger intercept test
invalid Scenario 1 2 3 4 Scenario 1 2 3 4
Null causal effect: θ = 0
0% 0.8% - - - 3.8% - - -
10% - 1.2% 2.2% 1.5% - 5.5% 6.4% 24.4%
20% - 1.6% 5.5% 2.5% - 6.0% 9.4% 31.2%
30% - 2.0% 14.1% 6.2% - 5.9% 13.1% 32.8%
Positive causal effect: θ = +0.1
0% 21.2% - - - 4.7% - - -
10% - 19.1% 33.0% 23.6% - 5.8% 8.0% 21.8%
20% - 16.7% 44.1% 26.6% - 6.1% 11.1% 28.2%
30% - 14.6% 55.8% 31.8% - 6.0% 15.3% 30.0%
Table 5: Proportion of simulated datasets for which the simple median and robust
regression with no intercept (robust IVW) methods rejected the causal null (left),
empirical power of the intercept test in MR-Egger method for detecting directional
pleiotropy and/or violation of the InSIDE assumption in all scenarios.
Non-penalized weights Penalized weights
Method Estimate (SE) 95% CI Estimate (SE) 95% CI
Standard, no intercept -0.031 (0.100) -0.227, 0.165 -0.034 (0.057) -0.147, 0.078
Standard, intercept 0.336 (0.241) -0.136, 0.808 0.154 (0.143) -0.127, 0.435
Robust, no intercept -0.024 (0.079) -0.180, 0.132 -0.033 (0.062) -0.154, 0.089
Robust, intercept 0.255 (0.212) -0.162, 0.671 0.142 (0.150) -0.152, 0.436
Simple median -0.073 (0.088) -0.244, 0.098 - -
Weighted median -0.075 (0.087) -0.246, 0.096 -0.076 (0.090) -0.253, 0.100
L1 pen, cross-validation -0.036 (0.087) -0.207, 0.136 - -
L1 pen, heterogeneity -0.022 (0.055) -0.131, 0.086 - -
Table 6: Estimates (standard errors, SE) and 95% confidence intervals (CI, calculated
as estimate ± 1.96 standard errors) of causal effect of body mass index on schizophre-
nia risk (log odds ratio for schizophrenia per 1 standard deviation increase in body
mass index).
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Method Description
Inverse-variance weighted
(IVW) method
Standard weighted regression with inverse-variance weights and
intercept term set to zero.
MR-Egger method Standard weighted regression with inverse-variance weights and
intercept term estimated.
Median-based method Simple median method is the median of the causal estimates
based on the individual candidate instruments. Weighted me-
dian method uses inverse-variance weights so that more precise
estimates receive more weight in the analysis.
Robust regression (MM-
estimation with bisquare
objective function)
Standard regression in either the IVW (no intercept) or the MR-
Egger (intercept) method can be replaced with robust regression.
Penalization of weights Inverse-variance weights in either the IVW, MR-Egger, or
weighted median method can be replaced with weights that de-
pend on the heterogeneity of the causal estimates – candidate
instruments with outlying estimates are downweighted depend-
ing on the degree of heterogeneity.
L1 penalization A separate intercept term, representing the pleiotropic effect of
the candidate instrument on the outcome, is allowed for each
candidate instrument, but the sum of the absolute values of the
pleiotropic effects is not allowed to be too large. The value
of the tuning parameter, which regulates the extent to which
pleiotropic effects are penalized, must be chosen carefully.
Table 7: Summary of methods investigated in this paper.
30
Figures
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Figure 1: Directed acyclic graph of graphical instrumental variable assumptions.
Gj
X
Y
Xj 
j
Figure 2: Decomposition of association with the outcome Y for genetic variant Gj
into indirect (causal) effect via the exposure X and direct (pleiotropic) effect (see
equation 2).
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Figure 3: Power to detect a causal effect (equivalent to Type 1 error rate with null
causal effect) for selected methods in each scenario. The dashed line is at 5%; the
nominal power expected with a null causal effect.
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Figure 4: Estimated genetic associations and 95% confidence intervals with body mass
index (BMI, standard deviation units) and with schizophrenia risk (log odds ratios)
for 97 genetic variants.
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Figure 5: Causal effect estimates (point estimate and 95% confidence interval) for a
range of values of the tuning parameter in applied example (BMI on schizophrenia).
The number of genetic variants included in each analysis is also displayed. The dotted
line at λ = 1.9 is the value of the tuning parameter chosen by the heterogeneity
criterion. The dashed line at λ = 6.63 is the value chosen by cross-validation.
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Web Appendix
A.1 Software code
We provide R code to implement the methods discussed in this paper. The associations
of the candidate instruments with the exposure are denoted betaXG with standard
errors sebetaXG. The associations of the candidate instruments with the outcome
are denoted betaYG with standard errors sebetaYG. We assume that the candidate
instruments are uncorrelated in their distributions, as is common in applied Mendelian
randomization investigations.
Inverse-variance weighted estimate:
The inverse-variance weighted (IVW) estimate can be calculated by weighted linear
regression:
betaIVW = summary(lm(betaYG~betaXG-1, weights=sebetaYG^-2))$coef[1]
sebetaIVW.fixed = summary(lm(betaYG~betaXG-1, weights=sebetaYG^-2))$coef[1,2]/
summary(lm(betaYG~betaXG-1, weights=sebetaYG^-2))$sigma
sebetaIVW.random = summary(lm(betaYG~betaXG-1, weights=sebetaYG^-2))$coef[1,2]/
min(summary(lm(betaYG~betaXG-1, weights=sebetaYG^-2))$sigma,1)
In the fixed-effect model, we divide the reported standard error by the estimated
residual standard error, to fix the residual standard error to take the value 1 [49]. In
the multiplicative random-effects model, we divide by the estimated residual standard
error in the case of underdispersion (the variability in the genetic associations is less
than would be expected by chance alone). But in the case of overdispersion (that is,
heterogeneity of causal effect estimates), no correction is made. The point estimate
is unaffected by the choice of a fixed- or multiplicative random-effects model.
Alternatively, the inverse-variance weighted estimate can be calculated by meta-
analysis, or via a simple formula:
# meta-analysis
library(meta)
betaIVW = metagen(betaYG/betaXG, abs(sebetaYG/betaXG))$TE.fixed
sebetaIVW.fixed = metagen(betaYG/betaXG, abs(sebetaYG/betaXG))$seTE.fixed
# simple formula
betaIVW = sum(betaYG*betaXG*sebetaYG^-2)/sum(betaXG^2*sebetaYG^-2)
sebetaIVW.fixed = 1/sqrt(sum(betaXG^2*sebetaYG^-2))
The meta-analysis method can be used to perform an additive random-effects anal-
ysis, which makes a different parametric assumption about the heterogeneity between
causal estimates compared with the multiplicative random-effect analysis [22]. While
the causal estimates from the fixed-effect and multiplicative random-effects analyses
are the same, the estimate from the additive random-effects analysis differs.
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MR-Egger regression:
The MR-Egger method is equivalent to the IVW method calculated using weighted re-
gression, except that that intercept term is estimated rather than being set to zero. A
test as to whether the intercept term is equal to zero is a test of directional pleiotropy.
A random-effects model should be used for inference as a fixed-effect model is not jus-
tifiable when the candidate instruments are not all valid.
# coding of genetic variants
betaYG = betaYG*sign(betaXG); betaXG = abs(betaXG)
# causal estimate
betaEGGER = summary(lm(betaYG~betaXG, weights=sebetaYG^-2))$coef[2,1]
sebetaEGGER.random = summary(lm(betaYG~betaXG, weights=sebetaYG^-2))$coef[2,2]/
min(summary(lm(betaYG~betaXG, weights=sebetaYG^-2))$sigma, 1)
betaEGGER.lower = betaEGGER-qt(0.975,df=length(betaXG)-2)*sebetaEGGER.random
betaEGGER.upper = betaEGGER+qt(0.975,df=length(betaXG)-2)*sebetaEGGER.random
p.causal.random = 2*(1-pt(abs(betaEGGER/sebetaEGGER.random),df=length(betaXG)-2))
# test for directional pleiotropy
interEGGER = summary(lm(betaYG~betaXG, weights=sebetaYG^-2))$coef[1,1]
seinterEGGER.random = summary(lm(betaYG~betaXG, weights=sebetaYG^-2))$coef[1,2]/
min(summary(lm(betaYG~betaXG, weights=sebetaYG^-2))$sigma, 1)
p.dpleio.random = 2*(1-pt(abs(interEGGER/seinterEGGER.random),df=length(betaXG)-2))
In this code, we use a t-distribution with J − 2 degrees of freedom for inference.
If there is underdispersion, then the t-distribution may be overly conservative, as the
t-distribution assumes that the residual standard error is estimated (in case of under-
dispersion, the residual standard error is set to 1). Hence, if the residual standard
error is less than one, either a confidence interval using a residual standard error of 1
and a z-distribution, or else a confidence interval using the estimated residual standard
error and a t-distribution may be preferred (the wider of these two intervals should
be preferred – both of these will be narrower than the above confidence interval).
sigmaEGGER = summary(lm(betaYG~betaXG, weights=sebetaYG^-2))$sigma
betaEGGER.lower = ifelse(sigmaEGGER<1, min(betaEGGER-qnorm(0.975)*sebetaEGGER.random,
betaEGGER-qt(0.975,df=length(betaXG)-2)*sebetaEGGER.random*sigmaEGGER),
betaEGGER-qt(0.975,df=length(betaXG)-2)*sebetaEGGER.random)
betaEGGER.upper = ifelse(sigmaEGGER<1, max(betaEGGER+qnorm(0.975)*sebetaEGGER.random,
betaEGGER+qt(0.975,df=length(betaXG)-2)*sebetaEGGER.random*sigmaEGGER),
betaEGGER+qt(0.975,df=length(betaXG)-2)*sebetaEGGER.random)
Median-based method:
The median-based method calculates the median (or weighted median) of the causal
estimates from each candidate instrument. This code calculates the simple median,
weighted median, and penalized weighted median, employing bootstrapping to obtain
a standard error that can used to provide a confidence interval.
weighted.median <- function(betaIV.in, weights.in) {
betaIV.order = betaIV.in[order(betaIV.in)]
weights.order = weights.in[order(betaIV.in)]
weights.sum = cumsum(weights.order)-0.5*weights.order
weights.sum = weights.sum/sum(weights.order)
below = max(which(weights.sum<0.5))
weighted.est = betaIV.order[below] + (betaIV.order[below+1]-betaIV.order[below])*
(0.5-weights.sum[below])/(weights.sum[below+1]-weights.sum[below])
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return(weighted.est) }
#
weighted.median.boot = function(betaXG.in, betaYG.in, sebetaXG.in, sebetaYG.in, weights.in){
# the standard error is estimated based on 1000 bootstrap samples
med = NULL
for(i in 1:1000){
betaXG.boot = rnorm(length(betaXG.in), mean=betaXG.in, sd=sebetaXG.in)
betaYG.boot = rnorm(length(betaYG.in), mean=betaYG.in, sd=sebetaYG.in)
betaIV.boot = betaYG.boot/betaXG.boot
med[i] = weighted.median(betaIV.boot, weights.in)
}
return(sd(med)) }
#
betaIV = betaYG/betaXG
weights = rep(1, length(betaXG)) # unweighted median
betaSIMPLEMED = weighted.median(betaIV, weights)
sebetaSIMPLEMED = weighted.median.boot(betaXG, betaYG, sebetaXG, sebetaYG, weights)
lowerSIMPLEMED = betaSIMPLEMED-qnorm(0.975)*sebetaSIMPLEMED
upperSIMPLEMED = betaSIMPLEMED+qnorm(0.975)*sebetaSIMPLEMED
#
betaIV = betaYG/betaXG
weights = (sebetaYG/betaXG)^-2 # weighted median using inverse-variance weights
betaWEIGHTEDMED = weighted.median(betaIV, weights)
sebetaWEIGHTEDMED = weighted.median.boot(betaXG, betaYG, sebetaXG, sebetaYG, weights)
lowerWEIGHTEDMED = betaWEIGHTEDMED-qnorm(0.975)*sebetaWEIGHTEDMED
upperWEIGHTEDMED = betaWEIGHTEDMED+qnorm(0.975)*sebetaWEIGHTEDMED
#
betaIV = betaYG/betaXG # penalized weighted median
penalty = pchisq(weights*(betaIV-betaWEIGHTEDMED)^2, df=1, lower.tail=FALSE)
pen.weights = (sebetaYG/betaXG)^-2*pmin(1, penalty*20) # penalized weights
betaPENALIZEDMED = weighted.median(betaIV, pen.weights)
sebetaPENALIZEDMED = weighted.median.boot(betaXG, betaYG, sebetaXG, sebetaYG, pen.weights)
lowerPENALIZEDMED = betaPENALIZEDMED-qnorm(0.975)*sebetaPENALIZEDMED
upperPENALIZEDMED = betaPENALIZEDMED+qnorm(0.975)*sebetaPENALIZEDMED
Robust regression:
The IVW and MR-Egger methods can be performed using robust regression (in partic-
ular, MM-estimation using Tukey’s bisquare objective function) rather than standard
linear regression:
library(robustbase)
betaIVW.robust = summary(lmrob(betaYG~betaXG-1, weights=sebetaYG^-2, k.max=500))$coef[1]
sebetaIVW.robust.fixed = summary(lmrob(betaYG~betaXG-1, weights=sebetaYG^-2, k.max=500))$coef[1,2]/
summary(lmrob(betaYG~betaXG-1, weights=sebetaYG^-2, k.max=500))$sigma
sebetaIVW.robust.random = summary(lmrob(betaYG~betaXG-1, weights=sebetaYG^-2, k.max=500))$coef[1,2]/
min(summary(lmrob(betaYG~betaXG-1, weights=sebetaYG^-2, k.max=500))$sigma,1)
betaEGGER.robust = summary(lmrob(betaYG~betaXG, weights=sebetaYG^-2, k.max=500))$coef[2]
sebetaEGGER.robust.random = summary(lmrob(betaYG~betaXG, weights=sebetaYG^-2, k.max=500))$coef[2,2]/
min(summary(lmrob(betaYG~betaXG, weights=sebetaYG^-2, k.max=500))$sigma,1)
The k.max option sets the maximum number of steps evaluated to find initial
parameter values in the S-step of the algorithm.
Penalized weights:
The IVW and MR-Egger methods can be performed using penalized weights:
betaIVW = sum(betaYG*betaXG*sebetaYG^-2)/sum(betaXG^2*sebetaYG^-2)
pweights = pchisq(betaXG^2/sebetaYG^2*(betaYG/betaXG-betaIVW)^2, df=1, lower.tail=FALSE)
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pweightsE = pchisq(sebetaYG^-2*(betaYG - interEGGER - betaEGGER*betaXG)^2, df=1, lower.tail=FALSE)
rweights = sebetaYG^-2*pmin(1, pweights*20)
rweightsE = sebetaYG^-2*pmin(1, pweightsE*20)
betaIVW.penal = summary(lm(betaYG~betaXG-1, weights=rweights))$coef[1]
sebetaIVW.penal.fixed = summary(lm(betaYG~betaXG-1, weights=rweights))$coef[1,2]/
summary(lm(betaYG~betaXG-1, weights=rweights))$sigma
sebetaIVW.penal.random = summary(lm(betaYG~betaXG-1, weights=rweights))$coef[1,2]/
min(summary(lm(betaYG~betaXG-1, weights=rweights))$sigma,1)
betaEGGER.penal = summary(lm(betaYG~betaXG, weights=rweightsE))$coef[2]
sebetaEGGER.penal.random = summary(lm(betaYG~betaXG, weights=rweightsE))$coef[2,2]/
min(summary(lm(betaYG~betaXG, weights=rweightsE))$sigma,1)
Penalized weights can also be used in conjunction with robust regression.
L1 penalization:
Several packages are available for running various flavours of L1 penalization methods.
We chose the penalized package as this gave an option for some of the coefficients in
the model to be penalized (the pleiotropy intercept parameters), and others not to be
penalized (the causal effect parameter):
library(penalized)
betaYGw = betaYG/sebetaYG # dividing the association estimates by sebetaYG is equivalent
betaXGw = betaXG/sebetaYG # to weighting by sebetaYG^-2
pleio = diag(rep(1, length(betaXG)))
l1one_which = which(attributes(penalized(betaYGw, pleio, betaXGw, lambda1=1))$penalized==0)
l1one_beta = lm(betaYG[l1one_which]~betaXG[l1one_which]-1, weights=sebetaYG[l1one_which]^-2)$coef[1]
l1one_se = summary(lm(betaYG[l1one_which]~betaXG[l1one_which]-1, weights=sebetaYG[l1one_which]^-2))$coef[1,2]
/min(summary(lm(betaYG[l1one_which]~betaXG[l1one_which]-1, weights=sebetaYG[l1one_which]^-2))$sigma, 1)
l1two_which = which(attributes(penalized(betaYGw, pleio, betaXGw, lambda1=2))$penalized==0)
l1two_beta = lm(betaYG[l1two_which]~betaXG[l1two_which]-1, weights=sebetaYG[l1two_which]^-2)$coef[1]
l1two_se = summary(lm(betaYG[l1two_which]~betaXG[l1two_which]-1, weights=sebetaYG[l1two_which]^-2))$coef[1,2]
/min(summary(lm(betaYG[l1two_which]~betaXG[l1two_which]-1, weights=sebetaYG[l1two_which]^-2))$sigma, 1)
l1three_which = which(attributes(penalized(betaYGw, pleio, betaXGw, lambda1=3))$penalized==0)
l1three_beta = lm(betaYG[l1three_which]~betaXG[l1three_which]-1, weights=sebetaYG[l1three_which]^-2)$coef[1]
l1three_se = summary(lm(betaYG[l1three_which]~betaXG[l1three_which]-1, weights=sebetaYG[l1three_which]^-2))$coef[1,2]
/min(summary(lm(betaYG[l1three_which]~betaXG[l1three_which]-1, weights=sebetaYG[l1three_which]^-2))$sigma, 1)
# fixing lambda to be 1, 2, and 3 in turn
l1grid = c(seq(from=0.1, to=5, by=0.1), seq(from=5.2, to=10, by=0.2))
# values of lambda for grid search
l1grid_rse = NULL; l1grid_length = NULL; l1grid_beta = NULL; l1grid_se = NULL
for (i in 1:length(l1grid)) {
l1grid_which = which(attributes(penalized(betaYGw, pleio, betaXGw, lambda1=l1grid[i], trace=FALSE))$penalized==0)
l1grid_rse[i] = summary(lm(betaYG[l1grid_which]~betaXG[l1grid_which]-1, weights=sebetaYG[l1grid_which]^-2))$sigma
l1grid_length[i] = length(l1grid_which)
l1grid_beta[i] = lm(betaYG[l1grid_which]~betaXG[l1grid_which]-1, weights=sebetaYG[l1grid_which]^-2)$coef[1]
l1grid_se[i] = summary(lm(betaYG[l1grid_which]~betaXG[l1grid_which]-1, weights=sebetaYG[l1grid_which]^-2))$coef[1,2]/
min(summary(lm(betaYG[l1grid_which]~betaXG[l1grid_which]-1, weights=sebetaYG[l1grid_which]^-2))$sigma, 1)
}
l1which_hetero = c(which(l1grid_rse[1:(length(l1grid)-1)]>1&
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diff(l1grid_rse)>qchisq(0.95, df=1)/l1grid_length[2:length(l1grid)]), length(l1grid))[1]
# heterogeneity criterion for choosing lambda
l1hetero_beta = l1grid_beta[l1which_hetero]
l1hetero_se = l1grid_se[l1which_hetero]
l1which_min = which.min(l1grid_beta)
l1min_beta = l1grid_beta[l1which_min]
l1min_se = l1grid_se[l1which_min]
# minimal estimate criterion for choosing lambda
l1xval_lambda = optL1(betaYGw, pleio, betaXGw)$lambda
l1xval_which = which(attributes(penalized(betaYGw, pleio, betaXGw, lambda1=l1xval_lambda))$penalized==0)
l1xval_beta = summary(lm(alpy[l1xval_which]~alpx[l1xval_which]-1, weights=alpysd[l1xval_which]^-2))$coef[1]
l1xval_se = summary(lm(alpy[l1xval_which]~alpx[l1xval_which]-1, weights=alpysd[l1xval_which]^-2))$coef[1,2]/
min(summary(lm(alpy[l1xval_which]~alpx[l1xval_which]-1, weights=alpysd[l1xval_which]^-2))$sigma, 1)
# cross-validation criterion for choosing lambda
We found that the choice of values of λ for the grid search presented here (0.1, 0.2, . . . , 4.9, 5.0,
5.2, 5.4, . . . , 9.8, 10.0) worked well in both the simulations and the applied example.
However, for different sets of association estimates, a different choice of values may
be preferred. Additionally, particularly with large numbers of variants, a more dense
choice of values may be preferred to ensure that at must one variant is added to the
analysis at each incremental step.
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A.2 Choice of penalty function
When there are two candidate instruments, the use of an L1 penalty function is
equivalent to minimizing:
S1 = (Y1 − θ01 − θ1X1)2 + (Y2 − θ01 − θ1X2)2 + 2λ(|θ01|+ |θ02|)
where Yj is βˆY j/ se(βˆY j) and Xj is βˆXj/ se(βˆY j). The factor of two on the penalty
function and the change of notation are for simplicity of presentation, and dividing
the associations by se(βˆY j) is equivalent to inverse-variance weighting.
Differentiating this expression, we get:
∂S1
∂θ01
= −2(Y1 − θ01 − θ1X1) + 2λ sign(θ01)
∂S1
∂θ02
= −2(Y2 − θ02 − θ1X2) + 2λ sign(θ02)
∂S1
∂θ1
= −2X1(Y1 − θ01 − θ1X1)− 2X2(Y2 − θ02 − θX2)
As S1 is not continuous, this function is minimized either at a discontinuity (θ01 =
0, θ02 = 0), or where the derivatives equal zero. If θˆ01 and θˆ02 both differ from zero,
then:
θˆ01 = Y1 − θˆ1X1 − sign(θˆ01)λ
θˆ02 = Y2 − θˆ1X1 − sign(θˆ02)λ
θˆ1 =
−λ(X1 sign(θˆ01) +X2 sign(θˆ02))
2(X21 +X
2
2 )
When λ is close to zero, θˆ01 and θˆ02 will both differ from zero, whereas when λ is
large, θˆ01 and θˆ02 will both equal zero. The upshot is that the value of θˆ1 depends on
the value of λ.
In contrast, if we were to use an L2 penalty function, we would minimize:
S2 = (Y1 − θ01 − θ1X1)2 + (Y2 − θ01 − θ1X2)2 + λ(θ201 + θ202)
This function is continuous, and so its minimum is where the partial derivatives
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equal zero:
∂S2
∂θ01
= −2(Y1 − θ01 − θ1X1) + 2λθ01
∂S2
∂θ02
= −2(Y2 − θ02 − θ1X2) + 2λθ02
∂S2
∂θ1
= −2X1(Y1 − θ01 − θ1X1)− 2X2(Y2 − θ02 − θX2)
θˆ01 =
Y1 − θˆ1X1
1 + λ
θˆ02 =
Y2 − θˆ1X1
1 + λ
θˆ1 =
X1Y1 +X2Y2
X21 +X
2
2
The causal estimate is not a function of λ. Hence, L2 penalization cannot be used
either for robust estimation, or for identifying valid instruments (as it does not have
a sparsity property; θˆ01 and θˆ02 differ from zero for all finite values of λ).
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A.3 Supplementary tables for simulation study
A.3.1 Number of simulations that failed to report a standard
error
The numbers of simulations for the robust methods that failed to report a standard
error in Scenarios 2 to 4 are provided in Web Table A1. The proportion of simulations
was usually less than 1%, and was less than 2.5% in all cases.
Method Null causal effect Positive causal effect
Proportion invalid: 10% 20% 30% 10% 20% 30%
Scenario 2: balanced pleiotropy, InSIDE satisfied
Robust, no intercept 1 2 0 0 1 0
Robust, intercept 5 20 24 12 18 24
Penalized robust, no intercept 4 5 18 0 10 12
Penalized robust, intercept 15 42 97 10 23 80
Scenario 3: directional pleiotropy, InSIDE satisfied
Robust, no intercept 1 0 0 0 1 1
Robust, intercept 2 18 15 5 10 11
Penalized robust, no intercept 4 5 8 1 2 3
Penalized robust, intercept 2 30 44 15 19 31
Scenario 4: directional pleiotropy, InSIDE not satisfied
Robust, no intercept 2 15 34 3 15 26
Robust, intercept 131 245 244 147 233 227
Penalized robust, no intercept 2 12 44 2 9 41
Penalized robust, intercept 24 69 102 31 51 92
Web Table A1: Number of the 10 000 simulations that failed to report a standard
error using the robust regression method in each of the simulation settings.
A.3.2 One-sample setting
The simulation study from the main body of the paper was repeated, except in a one-
sample setting in which associations of the candidate instruments with the exposure
and with the outcome were obtained in the same sample of 20 000 individuals for
the methods using non-penalized weights. Results are displayed in Web Table A2
(Scenario 1) and Web Table A3 (Scenarios 2 to 4).
A.3.3 Fewer candidate instruments
The simulation was also repeated in a two-sample setting with only 10 candidate in-
struments, to observe whether the robust methods were able to operate well with fewer
instruments to detect violations of the instrumental variables assumptions. Results
for Scenarios 2 to 4 are presented in Web Table A4.
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Scenario 1
Method Mean SD Mean SE Power NA 1
Null causal effect: θ = 0
Standard, no intercept 2 0.024 0.044 0.047 6.8 -
Standard, intercept 3 0.173 0.123 0.131 27.2 -
Robust, no intercept 0.023 0.044 0.049 7.8 0
Robust, intercept 0.174 0.126 0.136 29.0 4
Penalized standard, no intercept 0.024 0.045 0.046 8.5 -
Penalized standard, intercept 0.174 0.126 0.129 28.5 -
Penalized robust, no intercept 0.024 0.046 0.047 9.4 0
Penalized robust, intercept 0.174 0.127 0.131 31.0 3
Simple median 0.000 0.060 0.070 2.0 -
Weighted median 0.038 0.054 0.063 5.5 -
Penalized weighted median 0.038 0.057 0.063 6.5 -
Positive causal effect: θ = +0.1
Standard, no intercept 2 0.123 0.044 0.048 73.6 -
Standard, intercept 3 0.271 0.121 0.136 53.1 -
Robust, no intercept 0.122 0.045 0.050 69.3 0
Robust, intercept 0.271 0.125 0.143 52.4 3
Penalized standard, no intercept 0.122 0.045 0.048 74.1 -
Penalized standard, intercept 0.271 0.123 0.135 53.8 -
Penalized robust, no intercept 0.122 0.046 0.049 71.6 1
Penalized robust, intercept 0.271 0.126 0.139 53.9 2
Simple median 0.099 0.059 0.073 25.4 -
Weighted median 0.136 0.054 0.067 54.6 -
Penalized weighted median 0.136 0.057 0.067 54.5 -
Web Table A2: Mean, standard deviation (SD), mean standard error (mean SE) of
estimates, and empirical power (%) from weighted linear regression models (weights
are penalized where indicated) using standard and robust regression, without and with
an intercept term, and median-based methods for Scenario 1 in one-sample setting
(associations with exposure and with outcome are estimated in the same individuals).
1Number of the 10 000 simulations that failed to report a standard error.
2This is the standard inverse-variance weighted (IVW) method.
3This is the MR-Egger method.
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Scenario 2 Scenario 3 Scenario 4
Method Mean SD Power Mean SD Power Mean SD Power
Null causal effect: θ = 0
Proportion of invalid instrumental variables: 0.1
Standard, no intercept 0.023 0.069 7.3 0.090 0.066 24.5 0.081 0.072 27.1
Standard, intercept 0.174 0.197 19.4 0.175 0.190 19.2 0.276 0.228 50.7
Robust, no intercept 0.023 0.052 8.3 0.045 0.053 13.2 0.039 0.057 10.4
Robust, intercept 0.174 0.148 26.9 0.175 0.148 27.1 0.263 0.187 36.9
Simple median -0.001 0.066 2.9 0.028 0.064 4.5 0.012 0.065 3.2
Weighted median 0.037 0.061 6.8 0.061 0.060 12.6 0.074 0.074 20.0
Proportion of invalid instrumental variables: 0.2
Standard, no intercept 0.022 0.087 6.8 0.158 0.082 50.4 0.133 0.084 44.3
Standard, intercept 0.172 0.248 13.9 0.178 0.232 14.9 0.354 0.243 58.8
Robust, no intercept 0.023 0.063 7.7 0.084 0.072 19.4 0.072 0.078 15.5
Robust, intercept 0.172 0.187 23.0 0.175 0.186 22.6 0.382 0.225 51.9
Simple median -0.001 0.073 3.5 0.064 0.073 11.2 0.026 0.071 4.7
Weighted median 0.037 0.067 7.8 0.089 0.069 22.5 0.121 0.096 39.0
Proportion of invalid instrumental variables: 0.3
Standard, no intercept 0.024 0.102 6.8 0.226 0.091 74.7 0.181 0.088 58.8
Standard, intercept 0.171 0.286 11.0 0.178 0.259 12.8 0.404 0.243 61.8
Robust, no intercept 0.022 0.080 6.7 0.143 0.096 30.3 0.120 0.098 26.8
Robust, intercept 0.172 0.234 17.5 0.176 0.232 17.6 0.485 0.239 65.5
Simple median -0.001 0.082 4.7 0.109 0.085 24.7 0.043 0.080 8.0
Weighted median 0.036 0.077 9.2 0.127 0.084 38.4 0.176 0.117 58.7
Positive causal effect: θ = +0.1
Proportion of invalid instrumental variables: 0.1
Standard, no intercept 0.123 0.069 49.4 0.190 0.066 87.2 0.181 0.072 79.3
Standard, intercept 0.274 0.197 35.7 0.275 0.190 36.4 0.376 0.228 65.1
Robust, no intercept 0.123 0.052 62.8 0.145 0.053 74.8 0.139 0.057 67.3
Robust, intercept 0.274 0.148 49.2 0.275 0.148 49.2 0.363 0.187 55.7
Simple median 0.099 0.066 24.6 0.128 0.064 38.9 0.112 0.065 30.2
Weighted median 0.137 0.061 52.0 0.161 0.060 66.0 0.174 0.074 70.1
Proportion of invalid instrumental variables: 0.2
Standard, no intercept 0.123 0.087 34.9 0.258 0.082 95.2 0.233 0.084 84.8
Standard, intercept 0.272 0.248 25.2 0.278 0.232 27.2 0.454 0.243 69.9
Robust, no intercept 0.123 0.063 52.4 0.184 0.072 76.3 0.172 0.078 64.8
Robust, intercept 0.273 0.187 40.7 0.275 0.186 40.5 0.482 0.225 64.3
Simple median 0.099 0.073 23.9 0.164 0.073 54.6 0.126 0.071 35.1
Weighted median 0.137 0.067 49.8 0.189 0.069 76.4 0.221 0.096 81.4
Proportion of invalid instrumental variables: 0.3
Standard, no intercept 0.124 0.102 26.8 0.326 0.091 98.1 0.281 0.088 89.3
Standard, intercept 0.271 0.286 19.0 0.278 0.259 21.4 0.504 0.243 73.3
Robust, no intercept 0.122 0.080 40.2 0.243 0.096 76.8 0.220 0.098 66.7
Robust, intercept 0.272 0.234 30.6 0.276 0.232 31.0 0.585 0.239 74.3
Simple median 0.099 0.082 23.2 0.209 0.085 69.5 0.143 0.080 40.8
Weighted median 0.136 0.077 46.6 0.227 0.084 84.6 0.276 0.117 89.1
Web Table A3: Mean, standard deviation (SD), mean standard error (mean SE) of
estimates, and empirical power (%) from weighted linear regression models (weights
are not penalized) using standard and robust regression, without and with an intercept
term, and simple and weighted median methods for Scenarios 2, 3, and 4 in one-
sample setting (associations with exposure and with outcome are estimated in the
same individuals).
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Scenario 2 Scenario 3 Scenario 4
Method Mean SD Power Mean SD Power Mean SD Power
Null causal effect: θ = 0
Proportion of invalid instrumental variables: 0.1
Standard, no intercept -0.001 0.113 5.5 0.068 0.109 7.2 0.053 0.112 11.4
Standard, intercept -0.003 0.353 6.2 0.001 0.343 6.3 0.123 0.366 20.0
Robust, no intercept 0.000 0.090 7.0 0.030 0.093 7.4 0.024 0.098 8.4
Robust, intercept 0.001 0.321 12.5 0.002 0.315 12.3 0.092 0.348 19.7
Simple median -0.001 0.105 3.2 0.033 0.106 4.0 0.013 0.103 3.0
Weighted median 0.000 0.098 4.2 0.028 0.100 4.9 0.044 0.124 11.0
Proportion of invalid instrumental variables: 0.2
Standard, no intercept 0.001 0.139 5.8 0.136 0.133 13.9 0.101 0.133 18.4
Standard, intercept 0.001 0.432 7.1 0.002 0.412 7.5 0.213 0.418 30.8
Robust, no intercept 0.002 0.111 7.2 0.076 0.126 9.9 0.058 0.125 12.6
Robust, intercept 0.002 0.398 14.3 0.001 0.387 14.2 0.185 0.418 29.5
Simple median 0.000 0.117 4.0 0.075 0.129 8.2 0.028 0.117 5.0
Weighted median 0.001 0.113 5.8 0.063 0.125 9.9 0.092 0.152 21.8
Proportion of invalid instrumental variables: 0.3
Standard, no intercept 0.001 0.166 7.0 0.205 0.151 24.7 0.148 0.145 25.3
Standard, intercept 0.011 0.510 7.8 0.008 0.461 7.8 0.287 0.426 35.7
Robust, no intercept 0.000 0.140 7.8 0.140 0.160 15.9 0.102 0.148 20.4
Robust, intercept 0.002 0.494 13.4 0.003 0.455 14.7 0.271 0.453 36.7
Simple median 0.001 0.140 6.3 0.134 0.164 17.6 0.052 0.136 8.6
Weighted median 0.001 0.136 8.6 0.110 0.156 17.7 0.144 0.173 34.5
Positive causal effect: θ = +0.1
Proportion of invalid instrumental variables: 0.1
Standard, no intercept 0.095 0.116 18.1 0.164 0.112 30.3 0.149 0.116 32.1
Standard, intercept 0.063 0.361 6.8 0.067 0.352 6.7 0.196 0.376 22.8
Robust, no intercept 0.096 0.095 20.8 0.128 0.098 26.1 0.122 0.103 25.2
Robust, intercept 0.066 0.337 13.3 0.068 0.328 13.7 0.160 0.363 21.8
Simple median 0.101 0.111 11.8 0.136 0.113 17.9 0.115 0.109 14.2
Weighted median 0.093 0.104 13.0 0.122 0.106 18.8 0.140 0.130 25.3
Proportion of invalid instrumental variables: 0.2
Standard, no intercept 0.097 0.141 15.4 0.232 0.136 40.9 0.197 0.136 39.7
Standard, intercept 0.067 0.439 7.4 0.068 0.420 8.1 0.292 0.427 34.5
Robust, no intercept 0.097 0.116 18.7 0.175 0.130 30.3 0.157 0.129 30.1
Robust, intercept 0.068 0.411 14.9 0.067 0.401 15.1 0.259 0.432 31.8
Simple median 0.101 0.123 12.1 0.180 0.136 26.7 0.130 0.124 17.3
Weighted median 0.094 0.118 14.0 0.159 0.130 26.7 0.188 0.158 37.7
Proportion of invalid instrumental variables: 0.3
Standard, no intercept 0.097 0.167 14.4 0.301 0.154 53.0 0.244 0.147 46.9
Standard, intercept 0.077 0.516 8.3 0.074 0.467 8.0 0.371 0.434 39.9
Robust, no intercept 0.096 0.144 16.9 0.240 0.162 38.4 0.202 0.151 37.0
Robust, intercept 0.068 0.505 14.4 0.068 0.464 15.5 0.349 0.465 39.4
Simple median 0.102 0.146 14.1 0.240 0.171 39.9 0.155 0.142 23.4
Weighted median 0.094 0.142 16.4 0.207 0.160 38.1 0.242 0.178 51.2
Web Table A4: Mean, standard deviation (SD), mean standard error (mean SE) of
estimates, and empirical power (%) from weighted linear regression models (weights
are not penalized) using standard and robust regression, without and with an intercept
term, and simple and weighted median methods for Scenarios 2, 3, and 4 in two-sample
setting with only 10 candidate instruments (25 candidate instruments are used in all
other simulations).
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Appendix B
Paper 1: Robust methods in Mendelian
randomization via penalization of
heterogeneous causal estimates
Published paper based on the work in Chapter 3.
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Abstract
Methods have been developed for Mendelian randomization that can obtain consistent
causal estimates under weaker assumptions than the standard instrumental variable
assumptions. The median-based estimator and MR-Egger are examples of such methods.
However, these methods can be sensitive to genetic variants with heterogeneous causal
estimates. Such heterogeneity may arise from over-dispersion in the causal estimates, or
specific variants with outlying causal estimates. In this paper, we develop three extensions
to robust methods for Mendelian randomization with summarized data: 1) robust regression
(MM-estimation); 2) penalized weights; and 3) Lasso penalization. Methods using these
approaches are considered in two applied examples: one where there is evidence of over-
dispersion in the causal estimates (the causal effect of body mass index on schizophrenia
risk), and the other containing outliers (the causal effect of low-density lipoprotein choles-
terol on Alzheimer’s disease risk). Through an extensive simulation study, we demonstrate
that robust regression applied to the inverse-variance weighted method with penalized
weights is a worthwhile additional sensitivity analysis for Mendelian randomization to pro-
vide robustness to variants with outlying causal estimates. The results from the applied
examples and simulation study highlight the importance of using methods that make differ-
ent assumptions to assess the robustness of findings from Mendelian randomization investi-
gations with multiple genetic variants.
Introduction
Mendelian randomization uses genetic variants as instrumental variables to estimate the causal
effect of a risk factor on an outcome using observational data [1, 2]. The genetic variants must
satisfy the following criteria (illustrated in Fig 1) to be a valid instrumental variable (IV):
• IV1: the variant is associated with the exposure X,
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• IV2: the variant is independent of all confounders U of the exposure-outcome association,
and
• IV3: the variant is independent of the outcome Y conditional on the exposure X and con-
founders U [3].
A recent development in Mendelian randomization is the availability of summarized data:
this consists of the associations (beta-coefficients and standard errors) of genetic variants with
the risk factor and with the outcome from regressing each variant in turn [4]. Summarized
data can be used to calculate an estimate of the causal effect of the risk factor on the outcome
for each genetic variant. The inverse-variance weighted (IVW) method [5] combines these
estimates to provide an overall estimate of the causal effect using summarized data from all the
genetic variants. If the genetic variants are uncorrelated, the IVW estimate is asymptotically
equal to the estimate from the two-stage least squares method commonly used with individ-
ual-level data [6].
The inclusion of a variant in a Mendelian randomization analysis that violates either the
IV2 or the IV3 assumption may lead to biased causal estimates [7]. Robust methods have
therefore been developed to estimate consistent causal effects under weaker assumptions when
there are multiple genetic variants. These methods include a median-based method [8] and
MR-Egger [9]. Genetic variants that violate the IV assumptions are likely to have heteroge-
neous causal estimates. We here consider heterogeneity in two settings: firstly, when there is
more variance between the variant-specific causal estimates than expected by chance, but the
burden of heterogeneity is shared across several genetic variants (over-dispersion); and sec-
ondly, when specific variants have outlying causal estimates, and they alone are responsible for
driving the observed heterogeneity.
Several robust methods have been proposed that try to identify and remove genetic variants
with heterogeneous causal estimates that are suspected to be invalid instruments. These
include the MR-PRESSO [10], global and individual tests for direct effects (GLIDE) [11], and
generalized summary Mendelian randomization (GSMR) [12] methods. Cochran’s Q-statistic
has been used in Mendelian randomization to downweight [8] or exclude genetic variants
with heterogeneous causal estimates [13]. The Q-statistic is based on the first order weights of
the IVW model which assumes that there is no measurement error (NOME) in the genetic
Fig 1. Causal directed acyclic graph illustrating the instrumental variable assumptions for the instrumental variable G, exposure X,
outcome Y, and the set of variables (U) that confound the association between X and Y.
https://doi.org/10.1371/journal.pone.0222362.g001
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associations with the risk factor [14]. If this assumption is invalid, then the type I error rate of
the Q-statistic will be inflated. Bowden et al. [14] have accounted for possible violations in the
NOME assumption by using adapted second order weights to calculate the Q-statistic.
We here propose three further ways of downweighting or excluding variants with hetero-
geneous causal estimates that could be considered as part of a sensitivity analysis in a Mende-
lian randomization study. The first two of these extensions can be used as modifications to
either the IVW or the MR-Egger method. These extensions have been influenced by the liter-
ature on robust statistics [15], and recent developments in robust methods for Mendelian
randomization.
First, we outline the parametric assumptions made throughout the paper and discuss the
estimation of the causal effect in a Mendelian randomization study. We then introduce three
robust approaches: robust regression (MM-estimation), penalized weights, and Lasso penaliza-
tion. We apply these approaches to published data on body mass index (BMI) and schizophre-
nia risk, and on low-density lipoprotein cholesterol (LDL-C) and Alzheimer’s disease (AD)
risk. Next, we perform a simulation study under realistic settings to compare bias and coverage
properties of the robust methods when some of the genetic variants are invalid IVs. Finally,
we discuss the results of the paper and its implications to applied Mendelian randomization
research. Software code for implementing all of the methods used in this paper, including
extracting the genetic association estimates for the applied examples, is provided in S1 Appen-
dix. The methods (excluding Lasso penalization) can also be applied using the R package Men-
delianRandomization [16].
Methods
Parametric assumptions
Throughout the paper, we assume linearity and no effect modification of the causal effect θ of
the risk factor on the outcome, and the associations of the genetic variants Gj (j = 1, . . ., J) with
the risk factor and with the outcome. These assumptions are not necessary to estimate a causal
effect, but they ensure that all valid IVs estimate the same causal parameter. Under these
assumptions, the association bYj between the variant Gj and the outcome can be decomposed
into an indirect effect via the risk factor and a direct (pleiotropic) effect αj (illustrated in Fig 2):
bYj ¼ aj þ ybXj : ð1Þ
We also assume that the outcome is a continuous variable. If the outcome is binary, then
the methods can be applied to the log odds ratios obtained from logistic regression of each
genetic variant on the outcome. The linearity assumption must now hold for the logit-trans-
formed probability of the outcome. Difficulties with interpreting the causal estimate of an
odds ratio with a binary outcome and a logistic-linear model have been widely discussed [17],
with evidence to suggest that the causal estimates tend to be unbiased under the null [18].
Estimating the causal effect
The causal effect θ can be estimated using the genetic associations with the risk factor (b^Xj)
and with the outcome (b^Yj). The ratio estimate of the causal effect for variant j is given by:
y^ j ¼
b^Yj
b^Xj
: ð2Þ
The J ratio estimates can be combined to provide an overall causal estimate by fitting weighted
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linear regression of the associations of the variants with the outcome on the associations of the
variants with the exposure, with the intercept set to zero and se ðb^YjÞ
  2
as weights:
b^Yj ¼ y b^Xj þ �j; �j � N ð0;c
2 se ðb^YjÞ
2
Þ : ð3Þ
The estimate obtained from Eq (3) is equivalent to the estimate from the IVW method [5].
Under a fixed-effects model, we set the residual standard error (ψ) to be equal to one by
dividing the standard error of the causal estimate by the estimated residual standard error.
To account for heterogeneity (overdispersion) in the causal estimates, the residual standard
error can be greater than one under a random-effects model. The causal estimate from the
fixed and multiplicative random-effects models will be the same, but the standard error of the
causal effect will be larger from the multiplicative random-effects model if there is heterogene-
ity between the causal estimates.
A genetic variant is pleiotropic if it has a direct effect on the outcome that is not via the risk
factor (αj 6¼ 0). The IVW method under a fixed or multiplicative random-effects model will
produce a consistent causal estimate when there is no pleiotropy (αj = 0 for all variants), or
when the average pleiotropic effect is zero (referred to as balanced pleiotropy) and the pleiotro-
pic effects are distributed independently of the associations of the genetic variants with the
risk factor (known as the InSIDE assumption—Instrument strength independent of the Direct
Effect) [9, 19]. If an intercept term in Eq (3) is estimated, then this is the MR-Egger method,
and the causal estimate will be consistent in the presence of directional pleiotropy (the average
pleiotropic effect differs from zero) if the InSIDE assumption is satisfied [9]:
b^Yj ¼ y0 þ y1 b^Xj þ �j; �j � N ð0;c
2
E se ðb^YjÞ
2
Þ : ð4Þ
If the genetic variants are all valid IVs, then the ratio estimates for each variant should be
similar. If the b^Yj estimates were plotted against the b^Xj estimates, a pleiotropic variant may
Fig 2. Decomposition of the association between the genetic variant Gj and the outcome Y into the indirect effect via the risk factor X and
direct (pleiotropic) effect αj.
https://doi.org/10.1371/journal.pone.0222362.g002
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appear as an outlier relative to the valid IVs as the direct effect of the pleiotropic variant will
result in the vertical displacement of b^Yj from the causal effect (Eq (1)). Robust methods that
downweight the contribution of variants with heterogeneous ratio estimates should reduce the
impact that variants with outlying or over-dispersed estimates have on the causal estimate. For
example, the simple median estimator is the median of the J ratio estimates θj (j = 1, . . ., J), and
will produce consistent causal estimates if at least 50% of the genetic variants are valid IVs [8].
Typically, applied Mendelian randomization analyses will use one variant from each gene
region. Under Mendel’s second law, these variants should be independently distributed due to
their physical separation. The methods discussed in this paper will therefore assume that the
variants are uncorrelated.
Robust regression (MM–estimation). The breakdown point is a measure of the robust-
ness of an estimator to contaminations (such as outliers) in the dataset [15]. Ordinary least
squares (OLS) has a breakdown point of 0% as all of the observations have equal weight and
just one outlying observation can heavily influence the estimator, resulting in an arbitrarily
large or small estimate. Robust regression methods, such as MM-estimation, have been pro-
posed where the breakdown point is greater than 0% [15].
In this paper, we use an MM-estimation approach proposed by Koller and Stahel [20] as it
retains the high asymptotic efficiency of the M-estimator (‘maximum likelihood type’), whilst
utilising the S-estimator (‘scale-type estimate’) to provide robustness against outliers and
leverage points. Under this method, a S-estimate is fitted to minimize the M-estimate of scale,
which has the desired high breakdown point but may lack efficiency. The estimates for the
scale and regression parameters obtained in this stage are then used to fit an M-estimator with
high efficiency, where the scale estimate is held constant to retain the high-breakdown point
[20].
Additional robustness in MM-estimation may be achieved by using Tukey’s bisquare objec-
tive function in the estimation procedure with its weighting function:
wðrjÞ ¼
1  
rj
c
� �2� �2
if jrjj < c
0 if jrjj � c
;
8
>
<
>
:
where rj are the standardized residuals, and w(rj) are used in the objective function of the itera-
tively reweighted least squares algorithm to obtain the MM-estimates. The recommended
values for the tuning parameter c maintain a high breakdown point in the S-estimation step
(c = 1.548) and provide efficiency in the M-estimation step (c = 4.685). In MM-estimation
with Tukey’s bisquare objective function, the weight of an observation decreases as rj tends
away from zero, and when |rj|� c the observation will have zero weight.
Throughout the paper, we will refer to this approach as robust regression. It is the default
implementation of robust regression for the lmrob command in the R package robustbase
[21]. Since the lmrob command allows the user to specify a vector of weights to be used in
conjunction with Tukey’s weighting function, robust regression can be used instead of ‘ordi-
nary regression’ (weighted least squares) for the IVW and MR-Egger methods.
Penalized weights. We assume that the NOME assumption is satisfied, and propose an
approach for downweighting genetic variants with heterogeneous ratio estimates in the IVW
model using Cochran’s Q statistic:
Q ¼
X
j
Qj ¼
X
j
se ðb^YjÞ
  2
ðb^Yj   y^b^XjÞ
2
; ð5Þ
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which has an approximate w2J  1 distribution under the null hypothesis that all J genetic variants
satisfy the IV assumptions, with the J components Qj (j = 1, . . ., J) having approximate w21 dis-
tributions [13]. Since penalized weights would normally be considered when pleiotropy is
suspected, the simple (unweighted) median estimate is used for the value of y^ in Eq (5) rather
than the IVW estimate.
To ensure that the weights ( se ðb^YjÞ
  2
) for the majority of the variants remain the same, we
use a penalization for the IVW method based on the one-sided upper tail probability (denoted
qj) of Qj on a w21 distribution by multiplying the weights by min(1, 100qj). A similar down-
weighting factor, min(1, 20qj), was used for the penalized–median estimator in the paper by
Bowden et al. [8]. Initially we used min(1, 20qj) but found that too many variants were being
penalized, resulting in over-precise estimates that had poor coverage of the true causal effect.
By multiplying the weights by min(1, 100qj), the outlying variants should be severely penalized,
without downweighting too many genetic variants that are valid IVs.
For the MR-Egger method, we consider the modified Q’ statistic [22]:
Q0 ¼
X
j
Q0j ¼
X
j
se ðb^YjÞ
  2
ðb^Yj   y^0   y^1b^XjÞ
2
; ð6Þ
where y^0 and y^1 are taken from the MR-Egger model. If the MR-Egger model is correct, the Q’
statistic in Eq (6) should follow an approximate w2J  2 distribution [23]. The penalized weights
described in this Section can also be applied to robust regression for the IVW and MR-Egger
methods, subsequently referred to as the robust and penalized approach (or robust regression
with penalized weights).
Lasso penalization. The application of Lasso regression in IV analyses has already been
considered in the literature [24–26]. The penalty term in Lasso regression shrinks the regres-
sion coefficients towards zero, and forces some coefficients to be zero [27]. The sparsity prop-
erty (shrinking some coefficients to zero) of Lasso regression has been used to identify and
remove invalid IVs. The IV methods that use Lasso regression have only been considered with
respect to individual level data.
We take the ‘post-lasso’ method proposed by Windmeijer et al. [25] for individual level
data and adapt this method to be used with summary level data. First, we consider the objec-
tive function for the MR-Egger model that is minimized when fitting the regression model of
Eq (4):
X
j
se ðb^YjÞ
  2
ðb^Yj   y0   y1b^XjÞ
2
:
To better model the pleiotropic effects αj in Eq (1), we propose replacing θ0 with a separate
intercept coefficient for each genetic variant y0j , and adding a Lasso-penalty term for the y0j
parameters:
X
j
se ðb^YjÞ
  2
ðb^Yj   y0j   y1b^XjÞ
2
þ l
X
j
jy0j j : ð7Þ
If y0j shrinks to zero in Eq (7), the genetic variant is treated as a valid IV. We take the genetic
variants with a zero intercept term y0j , and perform the IVW method using these variants
only to estimate the causal effect θ. The degree of shrinkage in Eq (7) is determined by
the value of the tuning parameter λ. If λ =1, then all of the genetic variants are assumed
to be valid instruments as y0j is forced to be zero for all J variants, and the IVW method is
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performed using the full set of genetic variants. If λ = 0, then all of the variants can be pleio-
tropic, and the parameters in Eq (7) are not identified.
To determine the value of λ, two rules were considered: 1) a heterogeneity stopping rule;
and 2) a cross-validation rule. The heterogeneity stopping rule is influenced by the method
used by Windmeijer et al. [25] and Cochran’s Q statistic. For the heterogeneity stopping rule,
we fit the Lasso penalization model (Eq (7)) over a range of values for λ, starting with a value
close to zero, and then increasing λ in small increments. We stop at λ = λn when the residual
standard error from the IVW model, based on the variants determined to be valid from λ =
λn+1, is greater than 1, and the increase in the residual standard error from λn to λn+1 is greater
than w2
1
ð0:95Þ=Jinc, where w21ð0:95Þ is the upper 95th percentile of a chi-squared distribution
on 1 degree of freedom, and Jinc is the number of genetic variants included in the IVW model
when λ = λn+1.
As an alternative to the heterogeneity stopping rule, we use the optL1 command in the R
package penalized [28]. optL1 compares the predictive ability of the Lasso regression model
for different values of λ through leave-one-out cross-validation. The optimal value of λ is then
determined by maximizing the cross-validated likelihood function.
Summary
In this Section, we have introduced three robust approaches that can be used in a Mendelian
randomization study as part of the sensitivity analysis. The approaches use summary level data
that either downweight or remove genetic variants that have heterogeneous causal ratio esti-
mates. In the next Section, we apply these approaches to published summary data to investi-
gate the causal effect of body mass index on schizophrenia risk, and the causal effect of low-
density lipoprotein cholesterol on Alzheimer’s disease risk.
Applied examples
To illustrate the performance of the proposed extensions, we considered two applied examples:
one where there was evidence of over-dispersion in the ratio estimates (the causal effect of
BMI on schizophrenia risk); and another that contained outliers (the causal effect of LDL-C
on AD risk). Using summary data (beta–coefficients and standard errors) from PhenoScanner
[29], we considered the IVW method with: 1) the full set of genetic variants; 2) robust regres-
sion; 3) penalized weights; and 4) robust regression and penalized weights. Lasso penalization
with the heterogeneity stopping and cross-validation rules, the simple median, the weighted
median, and the MR-Egger methods were also considered. Under the heterogeneity stopping
rule, the Lasso penalization model was applied to λ = 0.1, 0.2, . . ., 4.9, 5.0, 5.2, 5.4, . . ., 9.8, 10.0.
Multiplicative random-effects models were used in all analyses.
Causal effect of body mass index on schizophrenia risk
Although individuals with schizophrenia tend to be overweight [30], it is generally believed
that this is due to the effect of anti-psychotic medication on body composition (reverse causa-
tion) rather than any causal effect of BMI on schizophrenia risk [31]. For this Mendelian ran-
domization analysis, we used the 97 genetic variants reported by the Genetic Investigation of
Anthropometric Traits (GIANT) consortium that were associated with BMI in 339,224 Euro-
pean-descent individuals at a genome-wide level of significance (p-value < 5 × 10−8) [32]. Var-
iants were clumped at a correlation threshold of r2 > 0.1, and all 97 variants are separated by at
least 500 kilobases. The genetic associations with schizophrenia were obtained from the Psy-
chiatric Genomics Consortium (PGC) based on 35,476 cases and 46,839 controls mostly of
European descent [33]. The summarized data used in this paper were recently applied in a
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Mendelian randomization study investigating the causal effect of BMI on psychiatric disor-
ders, including schizophrenia risk [34].
Causal effect of low-density lipoprotein cholesterol on Alzheimer’s disease
risk
Epidemiological studies have provided evidence of an association between LDL-C and
increased risk of AD [35, 36]. However, there is also evidence to suggest that patients with AD
have altered lipid metabolism (reverse causation) [37]. In this Mendelian randomization analy-
sis, we used the 75 genetic variants previously demonstrated to be associated with LDL-C at
a genome-wide level of significance by the Global Lipids Genetics Consortium (GLGC) [38].
The point estimates for the genetic associations with LDL-C were taken from the linear regres-
sion in up to 188,578 participants from GLGC [39]. The majority of variants are separated by at
least 1 megabase. A second variant from a gene region was only selected if it was independently
associated with LDL-C and in low linkage disequilibrium with the lead variant (r2 < 0.05). A
recent Mendelian randomization study used summarized data from GLGC to investigate the
causal association between low LDL-C levels and AD risk using data on 380 variants. Our anal-
ysis is based on a smaller set of genetic variants compared to Benn et al. [40] as we excluded
variants that were associated with LDL-C and high-density lipoprotein and/or triglycerides.
The genetic associations with AD were obtained from the International Genomics of Alzhei-
mer’s Project (IGAP) based on 17,008 cases and 37,154 controls of European-descent [41].
Results
The estimated genetic associations with 95% confidence intervals for the two examples are dis-
played in Fig 3. The plots demonstrate the overdispersion in the ratio estimates for BMI and
Fig 3. Graph A) displays the estimated genetic associations and 95% confidence intervals with body mass index (BMI, standard deviation units) and with
schizophrenia (log odds ratios) for 97 genetic variants. Graph B) displays the estimated genetic associations and 95% confidence intervals with low-density
lipoprotein cholesterol (LDL-C, standard deviation units) and with Alzheimer’s disease (log odds ratios) for 75 genetic variants: the two outlying variants are
labelled with their rsID codes.
https://doi.org/10.1371/journal.pone.0222362.g003
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schizophrenia; and two outliers in the LDL-C and AD example. The outlying variants (rs6859
and rs7254892) for LDL-C and AD are located near to the APOE locus and are associated with
AD risk with odds ratios of 1.40 (95% CI: 1.35, 1.44) and 1.28 (95% CI: 1.15, 1.44) respectively
[41]. Studentized residuals from the IVW analysis for these variants are 16.5 and −0.95 (all
other variants had absolute Studentized residual less than 2), and Cook’s distances are 2.51
and 0.11 respectively (all other Cook’s distances were less than 0.06).
Estimates and 95% confidence intervals from the Mendelian randomization analyses are
provided in Table 1. All of the estimates for BMI and schizophrenia suggest a null causal effect
(as also observed in the Mendelian randomization study by Hartwig et al. [34]), although there
is wide variation in the standard errors. The use of penalized weights and robust regression in
the IVW method improved the precision of the estimates. There was little difference in the
point estimates or standard errors obtained from the IVW method with penalized weights,
and from the IVW method with robust regression and penalized weights. With exception of
the IVW and MR-Egger methods, the median estimates were the least precise.
Table 1. Estimates (standard errors) and 95% confidence intervals of the causal effect of body mass index on
schizophrenia risk (log odds ratio for schizophrenia per 1 standard deviation increase in body mass index) and
low-density lipoprotein cholesterol on Alzheimer’s disease risk (log odds ratio for Alzheimer’s per 1 standard
deviation increase in low-density lipoprotein cholesterol) from the IVW method with: 1) the full set of genetic var-
iants (IVW); 2) robust regression; 3) penalized weights; and 4) robust regression and penalized weights. Results
from Lasso penalization with the heterogeneity stopping rule and cross-validation, simple median, weighted median
and MR-Egger methods are also presented.
Estimate (SE) 95% CI
Applied example 1: Causal effect of BMI on schizophrenia risk
IVW -0.031 (0.100) -0.227, 0.165
Robust regression -0.024 (0.079) -0.180, 0.132
Penalized weights -0.056 (0.065) -0.184, 0.073
Robust regression with penalized weights -0.052 (0.066) -0.182, 0.078
Lasso penalization
Heterogeneity stopping rule -0.022 (0.055) -0.131, 0.086
Cross validation -0.036 (0.087) -0.207, 0.136
Median
Simple -0.073 (0.083) -0.237, 0.090
Weighted -0.075 (0.090) -0.252, 0.102
MR-Egger 0.336 (0.241) -0.136, 0.808
Applied example 2: Causal effect of LDL-C on AD risk
IVW 0.239 (0.102) 0.039, 0.439
Robust regression 0.048 (0.038) -0.027, 0.123
Penalized weights 0.040 (0.042) -0.043, 0.123
Robust regression with penalized weights 0.046 (0.032) -0.016, 0.108
Lasso penalization
Heterogeneity stopping rule 0.032 (0.044) -0.054, 0.118
Cross validation 0.088 (0.045) 0.000, 0.175
Median
Simple 0.108 (0.071) -0.031, 0.247
Weighted 0.046 (0.061) -0.073, 0.165
MR-Egger 0.391 (0.168) 0.061, 0.722
Abbreviations: SE, standard error; CI, confidence interval; BMI, body mass index; IVW, inverse-variance weighted;
LDL-C, low-density lipoprotein cholesterol; AD, Alzheimer’s disease.
https://doi.org/10.1371/journal.pone.0222362.t001
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The Lasso penalization estimates are displayed in Fig 4 where the causal estimates are
relatively similar across the different values of the tuning parameter. The value of the tuning
parameter λ was 1.9 under the heterogeneity stopping rule, with 64 genetic variants included
in the IVW method. The cross-validation method returned a much larger value of λ = 6.63,
with 95 of the 97 variants included in the IVW method.
The estimates from the IVW and MR-Egger methods suggested a positive causal effect of
LDL-C on AD risk. This effect was attenuated to the null for the other robust methods. Com-
pared to the robust methods that reported a null causal effect of LDL-C on AD risk, the simple
and weighted median estimates had larger standard errors. The estimates from the IVW and
MR-Egger methods from Benn et al. [40] indicated that lower LDL-C levels may be beneficial
Fig 4. Log odds ratio and 95% confidence intervals for schizophrenia per 1 standard deviation increase in body mass index for different
values of the tuning parameter (λ = 0.1, 0.2, . . ., 4.9, 5.0, 5.2, 5.4, . . ., 9.8, 10.0) included in the Lasso regression model. The number of
genetic variants included in the IVW models are also displayed. The dotted line at λ = 1.9 is the value of the tuning parameter chosen by the
heterogeneity stopping rule. The dashed line at λ = 6.63 is the value chosen by cross-validation.
https://doi.org/10.1371/journal.pone.0222362.g004
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in reducing AD risk, whereas their estimate from the weighted median method suggested a
null effect. Since the genetic variants in the APOE gene region tend to be highly pleiotropic
[10], it is likely that the positive effects obtained from the IVW models in our analysis and in
the paper by Benn et al. [40] are driven by these pleiotropic variants, rather than there being a
true causal effect of LDL-C on AD risk.
The λ values for the heterogeneity stopping rule (λ = 3.4 based on 72 genetic variants) and
cross-validation (λ = 4.00 based on 73 genetic variants) for Lasso penalization were similar
(Fig 5). However, the estimate based on 72 genetic variants was much closer to the null,
Fig 5. Log odds ratio and 95% confidence intervals for Alzheimer’s per 1 standard deviation increase in low-density lipoprotein
cholesterol for different values of the tuning parameter (λ = 0.1, 0.2, . . ., 4.9, 5.0, 5.2, 5.4, . . ., 9.8, 10.0) included in the Lasso regression
model. The number of genetic variants included in the IVW models are also displayed. The dotted line at λ = 3.4 is the value of the tuning
parameter chosen by the heterogeneity stopping rule. The dashed line at λ = 4.00 is the value chosen by cross-validation.
https://doi.org/10.1371/journal.pone.0222362.g005
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demonstrating the sensitivity of the IVW method to a single variant. None of the estimates in
Fig 5 include information on the rs6859 variant, and this outlying variant was only included
in the IVW model for Lasso penalization when λ = 19.8, whereas the other outlying variant
(rs57254892) was included when λ = 3.5.
The consistency of the results from the robust methods for the BMI and schizophrenia
example strengthened the evidence from the primary IVW analysis, providing similar point
estimates but with narrower confidence intervals. The LDL-C and AD example highlighted
the possibility that only using the IVW method may provide conclusions that are not represen-
tative of the majority of the data. Whilst in practice the outlying rs6859 variant could have
been identified and removed from the dataset prior to the analysis, the robust approaches
identified this outlying variant in an automated manner.
Simulation study
Approaches applied to the simulated data
We applied the approaches introduced in this paper to simulated datasets, including the IVW
method with: 1) all the J genetic variants (standard IVW method); 2) robust regression; 3)
penalized weights; and 4) robust regression and penalized weights. The Lasso penalization
method with the heterogeneity stopping rule was also considered. The bias and coverage prop-
erties of the estimates from these robust methods were compared to those from the simple
(unweighted) median, weighted median, and MR-Egger methods. Standard errors for the sim-
ple and weighted median estimates were obtained through bootstrapping [8]. Robust regres-
sion, penalized weights, and robust regression and penalized weights were also applied to the
MR-Egger model. The Lasso penalization method was applied to λ = 0.1, 0.2, . . ., 4.9, 5.0, 5.2,
5.4, . . ., 9.8, 10.0 under the heterogeneity stopping rule.
To allow for direct comparisons with the MR-Egger method, and to assess the performance
of the methods when the IV assumptions were violated, the simulations followed a similar
structure to the simulation study performed in the paper by Bowden et al. [8]. The data gener-
ating model used in the simulation study is outlined below.
Data generating model
The simulation study generated data in accordance to Fig 6 for participants indexed by i =
1, . . ., N, and genetic variants indexed with j = 1, . . ., J:
Ui ¼
XJ
j¼1
�jGij þ �Ui ;
Xi ¼
XJ
j¼1
bXjGij þ Ui þ �Xi ;
Yi ¼
XJ
j¼1
ajGij þ yXi þ Ui þ �Yi ;
Gij � Binomialð2; 0:3Þ independently for all j ¼ 1; . . . ; J ;
�Ui; �Xi; �Yi � N ð0; 1Þ independently ;
where αj represents the direct effect of the genetic variant Gj on the outcome, ϕj represents
the effect of the genetic variant on the confounder U of the risk factor X and outcome Y
association, bXj represents the genetic effect of Gj on X, and θ is the causal effect of X on Y. The
error terms �Ui, �Xi, and �Yi were drawn independently from standard normal distributions.
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The performance of the robust methods was investigated under a two-sample Mendelian
randomization setting with N = 10, 000 individuals and J = 15 genetic variants. Data were
generated for 2N participants, and the associations of the variants with the risk factor were
estimated in the first N participants, and associations with the outcome in the second N
participants. Only the summary level data (beta-coefficients and standard errors) were used
in the analyses. A one-sample setting was also considered where an additional N partici-
pants were simulated and all of the genetic associations were estimated from the same N
participants.
If a genetic variant is associated with a confounder of the risk factor–outcome association,
then this will affect the variant’s association with both the risk factor and the outcome, leading
to the violation of the InSIDE assumption. Using this observation, data were simulated to con-
sider the following four scenarios:
• Scenario 1—No pleiotropy, InSIDE automatically satisfied: αj and ϕj were set to zero for all j.
• Scenario 2—Balanced pleiotropy, InSIDE satisfied: αj� U[0.05, 0.15] for invalid variants,
with each αj having a 0.5 probability of being multiplied by -1. ϕj was set to zero for all j.
• Scenario 3—Directional pleiotropy, InSIDE satisfied: αj� U[0.05, 0.15] for invalid variants,
and ϕj was set to zero for all j.
• Scenario 4—Directional pleiotropy, InSIDE violated: ϕj� U[0.05, 0.10] for invalid variants,
and αj was set to zero for all j.
The genetic variants Gj were coded to correspond to a single nucleotide polymorphism
with minor allele frequency 0.3. If a genetic variant was a valid IV then αj and ϕj were set to
zero in all four scenarios. In Scenarios 2 to 4, the number of invalid IVs was set to 1, 3 and 6.
Fig 6. Causal directed acyclic graph used in the data generating model for the simulation study. U represents the set of variables that confound
the association between the risk factor X and outcome Y. The genetic effect of Gj on X is bXj , the direct (pleiotropic) effect of Gj on Y is αj, the effect
of Gj on U is ϕj, and the causal effect of X on Y is θ.
https://doi.org/10.1371/journal.pone.0222362.g006
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The causal effect of the risk factor on the outcome was either θ = 0 (null causal effect) or θ =
0.3 (positive causal effect). The effects of the genetic variants on the risk factor (bXj) were
drawn from a uniform distribution between 0.06 and 0.13. 10 000 simulated datasets were gen-
erated for each combination of parameters (24 different combinations in total).
Results
The mean proportion of variance in the risk factor explained by the genetic variants (R2 statis-
tic), mean F statistic, and mean I2 statistic are contained in Table A in the S2 Appendix for sce-
narios 1-4 for the null and positive causal effects by the number of invalid instruments. The
mean R2 values were greater than 3% for all of the scenarios, and the minimum mean F-statis-
tic was 20.8. The I2 statistic ranged from 39.1% to 80.9%. Since violations in the no measure-
ment error (NOME) assumption of the genetic associations with the risk factor can lead to
attenuation towards the null for the MR-Egger estimates, and this attenuation is approximately
equal to the I2 statistic, we expected the MR-Egger estimates for the positive causal effect to be
severely attenuated towards the null [42].
The number of robust regression models that did not report a standard error (maximum
of 2.6% across all of the scenarios considered) are given in Table B in the S2 Appendix. Apart
from the calculation of the mean standard error, the robust regression models that did not
report a standard error were included in the results, and the power calculations treated the
standard error as infinite.
When all of the genetic variants were valid IVs (Table 2), all of the methods produced unbi-
ased estimates of the null causal effect and the Type I error rates were close to the nominal
level of 5%. Apart from the simple median method, there was attenuation towards the null
with a positive causal effect for all methods, and as expected, this was particularly evident for
the MR-Egger method (also observed for Scenarios 2 and 3). Violation of the NOME assump-
tion can lead to inflation of the intercept term in the MR-Egger method [42], and this was
true for the simulation study where the power to detect the intercept term for Scenarios 1
and 2 was greater than 5% (Table C in the S2 Appendix). Only 7.5% of the MR-Egger models
Table 2. Mean estimate (mean standard error), standard deviation, coverage of the 95% confidence interval (%), and power at the 5% significance level (%) of the
estimates from the IVW model with: 1) the J genetic variants (IVW); 2) robust regression; 3) penalized weights; and 4) robust regression and penalized weights for
Scenario 1 with a null (θ = 0) or positive (θ = 0.3) causal effect. Results from Lasso penalization with the heterogeneity stopping rule, simple (unweighted) median,
weighted median and MR-Egger methods are also provided.
Null causal effect (θ = 0) Positive causal effect (θ = 0.3)
Estimate (SE) SD Cov. Pow. Estimate (SE) SD Cov. Pow.
Scenario 1. No pleiotropy, InSIDE automatically satisfied
IVW -0.001 (0.061) 0.058 95.7 4.3 0.287 (0.073) 0.069 95.5 98.2
Robust regression -0.001 (0.066) 0.060 95.1 4.9 0.287 (0.079) 0.072 94.7 94.8
Penalized weights -0.001 (0.060) 0.059 95.0 5.0 0.289 (0.072) 0.071 94.7 98.2
Robust regression with penalized weights -0.001 (0.064) 0.061 94.5 5.5 0.288 (0.077) 0.073 94.1 95.7
Lasso penalization -0.001 (0.060) 0.059 94.8 5.2 0.287 (0.072) 0.071 94.6 98.0
Median
Simple -0.002 (0.086) 0.074 97.9 2.1 0.301 (0.105) 0.090 98.0 86.9
Weighted -0.002 (0.080) 0.071 97.4 2.6 0.277 (0.097) 0.085 96.7 85.7
MR-Egger -0.001 (0.219) 0.207 96.1 3.9 0.143 (0.261) 0.251 91.0 7.5
Abbreviations: SE, standard error; SD, standard deviation; Cov., coverage; Pow., power; InSIDE, instrument strength independent of direct effect; IVW, inverse-
variance weighted.
https://doi.org/10.1371/journal.pone.0222362.t002
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detected a positive causal effect, and apart from the median estimators, all of the robust meth-
ods had approximately 95% power to detect the positive causal effect.
Although the mean estimates in Scenario 2 (Tables 3 and 4) were similar to those in Sce-
nario 1, there were clear differences in the precision of the estimates for the null and positive
causal effects, with most of the methods reporting larger mean standard errors under Sce-
nario 2. The mean standard error increased as the number of invalid instruments increased
for all methods. The IVW model with penalized weights had the most precise estimates,
but suffered from inflated Type I error rates and poor coverage. The simple and weighted
median estimators performed just as well, if not better, than the other robust methods for
Scenario 2.
Table 3. Mean estimate (mean standard error), standard deviation, coverage of the 95% confidence interval (%), and power at the 5% significance level (%) of the
estimates from the IVW model with: 1) the J genetic variants (IVW); 2) robust regression; 3) penalized weights; and 4) robust regression and penalized weights (R
and P) for Scenarios 2-4 with a null causal effect (θ = 0) by the number of invalid IVs. Results from Lasso penalization with the heterogeneity stopping rule, simple
median, weighted median and MR-Egger methods are also provided.
1 invalid IV 3 invalid IVs 6 invalid IVs
Est. (SE) SD Cov. Pow. Est. (SE) SD Cov. Pow. Est. (SE) SD Cov. Pow.
Scenario 2. Balanced pleiotropy, InSIDE satisfied
IVW -0.002 (0.089) 0.092 94.7 5.3 0.000 (0.133) 0.136 93.4 6.6 0.000 (0.180) 0.183 93.0 7.0
Robust -0.002 (0.069) 0.065 94.3 5.7 0.000 (0.096) 0.087 94.5 5.5 0.001 (0.196) 0.173 94.3 5.6
Penalized -0.002 (0.062) 0.064 94.2 5.8 0.000 (0.066) 0.077 91.1 8.9 0.001 (0.075) 0.116 81.5 18.5
R and P -0.002 (0.071) 0.065 94.6 5.4 0.001 (0.094) 0.078 94.7 5.2 0.001 (0.160) 0.119 91.5 7.3
Lasso -0.002 (0.063) 0.065 94.4 5.6 0.000 (0.071) 0.080 91.7 8.3 0.001 (0.088) 0.129 84.5 15.5
Median
Simple -0.002 (0.090) 0.080 97.4 2.6 0.001 (0.097) 0.094 96.5 3.5 0.002 (0.115) 0.132 92.7 7.3
Weighted -0.001 (0.082) 0.076 96.9 3.2 0.000 (0.089) 0.090 95.2 4.8 0.000 (0.101) 0.133 88.9 11.1
MR-Egger -0.004 (0.317) 0.335 92.7 7.3 -0.009 (0.477) 0.496 92.7 7.3 -0.006 (0.646) 0.661 93.0 7.0
Scenario 3. Directional pleiotropy, InSIDE satisfied
IVW 0.064 (0.089) 0.064 94.8 5.2 0.194 (0.126) 0.076 76.0 24.0 0.388 (0.154) 0.089 16.1 83.9
Robust 0.010 (0.069) 0.064 94.3 5.7 0.069 (0.113) 0.083 93.9 6.1 0.335 (0.227) 0.105 63.6 36.4
Penalized 0.007 (0.062) 0.063 94.2 5.8 0.033 (0.067) 0.078 89.2 10.8 0.148 (0.082) 0.137 57.3 42.7
R and P 0.005 (0.072) 0.065 94.8 5.2 0.025 (0.092) 0.079 93.2 6.7 0.115 (0.138) 0.147 78.6 20.9
Lasso 0.006 (0.063) 0.065 94.2 5.8 0.031 (0.071) 0.080 90.3 9.7 0.164 (0.096) 0.146 60.5 39.5
Median
Simple 0.021 (0.089) 0.077 97.3 2.7 0.074 (0.100) 0.086 92.9 7.2 0.224 (0.134) 0.124 64.3 35.7
Weighted 0.017 (0.082) 0.074 96.9 3.1 0.065 (0.090) 0.085 91.7 8.3 0.210 (0.110) 0.149 56.9 43.1
MR-Egger -0.003 (0.318) 0.334 92.9 7.2 -0.001 (0.450) 0.465 93.2 6.8 -0.004 (0.544) 0.562 92.4 7.6
Scenario 4. Directional pleiotropy, InSIDE violated
IVW 0.077 (0.070) 0.058 83.4 16.7 0.186 (0.075) 0.056 25.6 74.4 0.290 (0.071) 0.050 0.3 99.7
Robust 0.031 (0.085) 0.069 93.9 6.0 0.142 (0.127) 0.082 73.1 26.0 0.289 (0.079) 0.053 3.3 96.6
Penalized 0.021 (0.061) 0.070 89.2 10.8 0.083 (0.063) 0.091 64.1 35.9 0.231 (0.061) 0.092 12.2 87.8
R and P 0.018 (0.071) 0.070 92.7 7.3 0.075 (0.084) 0.095 76.2 23.7 0.230 (0.074) 0.101 19.0 80.8
Lasso 0.024 (0.062) 0.073 88.2 11.8 0.116 (0.066) 0.099 51.1 48.9 0.286 (0.066) 0.070 2.2 97.8
Median
Simple 0.020 (0.089) 0.077 97.3 2.7 0.071 (0.092) 0.083 89.9 10.1 0.192 (0.088) 0.091 40.0 60.0
Weighted 0.055 (0.082) 0.077 91.0 9.0 0.198 (0.081) 0.097 34.8 65.2 0.343 (0.069) 0.074 0.5 99.5
MR-Egger 0.305 (0.214) 0.219 66.8 33.2 0.539 (0.197) 0.183 21.3 78.7 0.644 (0.182) 0.165 5.1 94.9
Abbreviations: IV, instrumental variable; Est. estimate; SE, standard error; SD, standard deviation; Cov., coverage; Pow., power; InSIDE, instrument strength
independent of direct effect; IVW, inverse variance weighted method; R and P, robust and penalized.
https://doi.org/10.1371/journal.pone.0222362.t003
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In Scenario 3 (directional pleiotropy, InSIDE satisfied), the IVW method produced biased
causal estimates with inflated Type I error rates, and the degree of bias increased with the
number of invalid IVs. With one invalid instrument, estimates from the robust methods were
only slightly biased and Type I error rates were fairly well controlled. As the number of instru-
ments increased, bias in the estimates for the robust methods also increased, although the mag-
nitude of bias was smaller than the IVW method, and Type I error inflation was less severe.
Robust regression with penalized weights performed reasonably well when there was 1 or 3
invalid instruments. Although the median methods give unbiased estimates asymptotically
(that is, as the number of participants increases), when pleiotropic effects are directional there
is some bias with a finite sample.
Table 4. Mean estimate (mean standard error), standard deviation, coverage of the 95% confidence interval (%), and power at the 5% significance level (%) of the
estimates from the IVW model with: 1) the J genetic variants (IVW); 2) robust regression; 3) penalized weights; and 4) robust regression and penalized weights (R
and P) for Scenarios 2-4 with a positive causal effect (θ = 0.3) by the number of invalid IVs. Results from the Lasso penalization method with the heterogeneity stopping
rule, simple median, weighted median and MR-Egger methods are also provided.
1 invalid IV 3 invalid IVs 6 invalid IVs
Est. (SE) SD Cov. Pow. Est. (SE) SD Cov. Pow. Est. (SE) SD Cov. Pow.
Scenario 2. Balanced pleiotropy, InSIDE satisfied
IVW 0.286 (0.097) 0.100 94.0 80.9 0.288 (0.139) 0.140 93.5 54.5 0.285 (0.184) 0.184 93.3 34.3
Robust 0.287 (0.084) 0.079 93.9 91.0 0.288 (0.116) 0.107 93.6 71.1 0.286 (0.193) 0.178 93.8 34.5
Penalized 0.289 (0.074) 0.079 93.2 96.5 0.291 (0.080) 0.098 88.6 91.8 0.295 (0.090) 0.147 78.4 80.5
R and P 0.289 (0.083) 0.080 93.5 92.5 0.290 (0.100) 0.097 92.2 81.6 0.295 (0.145) 0.147 88.1 59.4
Lasso 0.287 (0.076) 0.080 93.2 95.4 0.288 (0.085) 0.102 89.4 88.0 0.288 (0.108) 0.167 80.5 69.9
Median
Simple 0.302 (0.109) 0.097 97.5 83.1 0.302 (0.118) 0.113 96.1 75.3 0.303 (0.136) 0.155 92.5 61.4
Weighted 0.276 (0.100) 0.091 96.1 81.9 0.277 (0.106) 0.108 94.0 75.6 0.277 (0.119) 0.152 88.2 63.2
MR-Egger 0.143 (0.349) 0.363 90.2 9.0 0.138 (0.495) 0.518 91.2 8.4 0.126 (0.657) 0.681 92.1 7.5
Scenario 3. Directional pleiotropy, InSIDE satisfied
IVW 0.353 (0.098) 0.075 96.1 97.8 0.482 (0.133) 0.087 81.5 99.3 0.673 (0.160) 0.101 28.3 100
Robust 0.306 (0.084) 0.077 95.1 94.8 0.383 (0.134) 0.099 93.9 86.2 0.631 (0.205) 0.112 60.8 90.8
Penalized 0.303 (0.074) 0.078 93.8 98.0 0.346 (0.081) 0.100 86.4 97.8 0.511 (0.098) 0.164 47.6 99.1
R and P 0.300 (0.083) 0.080 94.1 93.5 0.335 (0.102) 0.102 91.3 88.8 0.485 (0.142) 0.179 66.2 86.9
Lasso 0.301 (0.076) 0.079 94.0 97.4 0.340 (0.086) 0.104 88.2 96.5 0.513 (0.113) 0.168 53.8 98.5
Median
Simple 0.329 (0.110) 0.095 97.5 89.5 0.393 (0.125) 0.108 93.5 93.2 0.572 (0.158) 0.150 61.8 97.2
Weighted 0.300 (0.100) 0.090 97.2 88.1 0.356 (0.111) 0.104 94.5 93.0 0.516 (0.131) 0.161 63.6 97.4
MR-Egger 0.142 (0.345) 0.353 90.9 8.7 0.138 (0.468) 0.485 91.3 8.1 0.137 (0.555) 0.576 91.9 8.0
Scenario 4. Directional pleiotropy, InSIDE violated
IVW 0.367 (0.080) 0.071 88.8 99.8 0.478 (0.084) 0.067 42.2 100 0.582 (0.078) 0.062 2.3 100
Robust 0.329 (0.100) 0.082 94.3 90.2 0.447 (0.128) 0.085 73.7 90.2 0.581 (0.087) 0.066 8.2 99.7
Penalized 0.323 (0.072) 0.086 88.6 98.2 0.403 (0.072) 0.102 61.2 98.9 0.546 (0.068) 0.092 11.2 99.9
R and P 0.318 (0.085) 0.087 92.4 94.1 0.397 (0.095) 0.107 72.7 93.6 0.547 (0.077) 0.098 16.0 98.4
Lasso 0.323 (0.073) 0.089 87.9 97.6 0.430 (0.076) 0.105 52.7 99.3 0.579 (0.073) 0.079 4.4 100
Median
Simple 0.328 (0.108) 0.095 97.0 89.9 0.387 (0.111) 0.101 90.0 95.1 0.509 (0.101) 0.101 43.4 99.5
Weighted 0.344 (0.099) 0.095 94.0 94.4 0.496 (0.097) 0.108 47.2 99.7 0.625 (0.085) 0.087 3.4 100
MR-Egger 0.488 (0.254) 0.259 86.1 51.8 0.767 (0.233) 0.220 45.4 90.0 0.887 (0.214) 0.197 20.2 98.1
Abbreviations: IV, instrumental variable; Est. estimate; SE, standard error; SD, standard deviation; Cov., coverage; Pow., power; InSIDE, instrument strength
independent of direct effect; IVW, inverse variance weighted method; R and P, robust and penalized.
https://doi.org/10.1371/journal.pone.0222362.t004
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In Scenario 4 (directional pleiotropy, InSIDE violated), all of the robust methods produced
biased estimates. When there were only one invalid instrument, the magnitude of bias from
the robust methods was less severe than the IVW method, and this was particularly true for
robust regression with penalized weights. As the number of invalid IVs increased, the perfor-
mance of the robust methods worsened, and there was little advantage in applying the robust
methods compared to the median estimator in Scenario 4 when 6 of the 15 genetic variants
were invalid IVs. In this scenario, bias is greater for the weighted median than for the simple
median method as the invalid genetic variants are on average more strongly associated with
the risk factor than the valid ones. This is because invalid variants are associated with the
risk factor directly and via their effect on the confounder. In practical applications, invalid
genetic variants will not necessarily be more strongly associated with the risk factor than valid
ones, and so the simple median will not necessarily perform better than the weighted median
method.
While results were fairly similar for most of the methods, results from the MR-Egger
method were often quite different. This is because the other methods are fairly similar in
their assumptions (that most genetic variants are valid IVs) and their mode of operation
(variants with causal estimates that differ from the consensus are penalized or down-
weighted). This highlights the importance in an applied analysis of performing a range of
methods that make different assumptions, rather than multiple methods that make similar
assumptions [43].
Results from applying robust regression and penalized weights to the MR-Egger method
are provided in Table D in the S2 Appendix. Although we had hoped that the combination of
the MR-Egger method and approaches to reduce the influence of outlying variants would be
synergistic in improving robustness, findings were disappointing, and all of the models were
affected by the violation of the NOME assumption. A reason for this is the flexibility of the
method: in allowing the intercept to differ from zero and allowing outliers that deviate from
the regression model, the method permits the IV assumptions to be violated in quite a broad
way. In a substantial number of cases, the method identified the wrong variants as invalid,
finding an incorrect configuration of valid and invalid variants that appeared to fit the data
better.
Finally, results from the one-sample setting are provided in Tables E and F in the S2 Appen-
dix. Bias in the direction of the observational association was observed for all methods. As
with the two–sample setting, the median estimators and robust regression with penalized
weights produced the least biased estimates, and the IVW with penalized weights was the most
precise.
Increased number of genetic variants
Since many of the methods described in this paper are based on asymptotic theory, it was
anticipated that there would be an improvement in the performance of the methods when the
data were generated with a larger number of genetic variants. We therefore repeated the simu-
lation study for Scenarios 2–4 for 1 000 simulated datasets with the number of genetic variants
increased from 15 to 100, and the number of invalid IVs increased from 1, 3 and 6 to 5, 15 and
30. The bounds of the uniform distribution used to generate the genetic associations with the
risk factor (bXj) were multiplied by
ffiffiffiffiffi
15
100
q
to ensure the average R2 values were comparable
with the original simulation study. The IVW model with: 1) the full set of genetic variants; 2)
robust regression; 3) penalized weights; and 4) robust regression and penalized weights were
all applied to the dataset. The Lasso penalization method with the heterogeneity stopping rule
was also considered.
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Results. The mean R2 statistic, F-statistic, and I2 statistic are contained in Table G in the
S2 Appendix for Scenarios 2–4 for the null and positive causal effect by the number of invalid
IVs. The mean R2 values for the 100 genetic variants were slightly higher than the values
reported in the original simulation study (Table A in the S2 Appendix). For all of the scenarios
considered, there was a significant reduction in the mean F-statistic and I2 statistic, and we
therefore expected the estimates to be affected by weak instrument bias.
Results from the simulation study for the IVW model with: 1) the J genetic variants (IVW);
2) robust regression; 3) penalized weights; and 4) robust regression and penalized weights, and
the Lasso penalization method with the heterogeneity stopping rule are provided in Table 5.
The reduction in the strength of the IVs led to weak instrument bias, and there was severe
attenuation towards the null for the positive causal effect (Table 5). For the null causal effect,
there was little difference in the performance of the robust methods with the increased number
of genetic variants. In fact, the methods performed worst under Scenario 4 when 100 variants
were included in the data generating model rather than 15 (Table 5). Due to the attenuation of
the positive causal effect when the number of variants was increased to 100, it was difficult to
compare the results to the original simulations. Nevertheless, there was no evidence to suggest
that the performances of the robust methods improved when the number of genetic variants
was increased.
Discussion
In this paper, we have introduced three robust approaches for Mendelian randomization with
summary level data that downweight the influence of heterogeneous causal estimates. The
applied examples considered in this paper illustrate the importance of using a variety of meth-
ods in a Mendelian randomization analysis. The results from the robust methods support a
null causal effect of BMI on schizophrenia risk. While the IVW and MR-Egger methods pro-
duced positive estimates that were strongly influenced by pleiotropic variants in the APOE
gene region, the proposed methods were able to give null estimates that were unaffected by
these outlying variants.
We also performed a simulation study to compare the robust approaches to the IVW, simple
median, weighted median, and MR-Egger methods. The simulation study highlighted the sen-
sitivity of the IVW method to violations in the IV assumptions, and the requirement for robust
methods to be considered in the sensitivity analysis of a Mendelian randomization study. The
simulations also demonstrated the impact of violating the NOME assumption on the estimates
from the MR-Egger methods. Since it was not feasible to adjust for the violation of the NOME
assumption through the SIMEX method [42] in the simulation study for computational rea-
sons, it was difficult to compare the performance of the robust methods to MR-Egger.
Robust regression with penalized weights consistently produced the least biased estimates
in the simulation study. Although the power and bias of this approach was significantly better
than the standard IVW method when the IV assumptions were violated, it suffered from poor
coverage and increased Type I error rates, particularly when there was a high proportion of
invalid instruments. When there was only one invalid instrument, robust regression with
penalized weights produced more precise estimates than the median estimator. However, as
the number of invalid instruments increased there was little advantage of using robust regres-
sion with penalized weights compared to the median estimator.
Interpretation of heterogeneity among the causal ratio estimates
Throughout this paper, we have assumed that heterogeneity of the causal ratio estimates is
indicative of violations in the IV assumptions, particularly the presence of pleiotropic effects.
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Table 5. Results from the simulation study when 100 genetic variants were simulated for 1 000 datasets. Mean estimate (mean standard error), standard deviation, cov-
erage of the 95% confidence interval (%), and power at the 5% significance level (%) of the estimates from the IVW model with: 1) the J genetic variants (IVW); 2) robust
regression; 3) penalized weights; and 4) robust regression and penalized weights (R and P) for Scenarios 2-4 with a null causal effect (θ = 0) and positive causal effect (θ =
0.3) by the number of invalid instrumental variables. Results from the Lasso penalization method with the heterogeneity stopping rule are also presented.
5 invalid IV 15 invalid IVs 30 invalid IVs
Est. (SE) SD Cov. Pow. Est. (SE) SD Cov. Pow. Est. (SE) SD Cov. Pow.
Null causal effect (θ = 0)
Scenario 2. Balanced pleiotropy, InSIDE satisfied
IVW -0.003 (0.072) 0.071 95.0 5.0 -0.003 (0.103) 0.105 94.9 5.1 0.000 (0.138) 0.144 94.0 6.0
Robust -0.001 (0.054) 0.051 95.8 4.2 -0.001 (0.065) 0.066 93.7 6.3 0.005 (0.115) 0.114 95.7 4.3
Penalized -0.001 (0.051) 0.051 94.8 5.2 -0.001 (0.054) 0.063 91.3 8.7 0.001 (0.060) 0.081 86.3 13.7
R and P -0.001 (0.055) 0.052 95.8 4.2 -0.001 (0.064) 0.062 95.6 4.4 0.000 (0.087) 0.078 96.5 3.5
Lasso -0.001 (0.051) 0.052 94.2 5.8 -0.002 (0.055) 0.063 91.5 8.5 0.002 (0.062) 0.081 87.6 12.4
Scenario 3. Directional pleiotropy, InSIDE satisfied
IVW 0.096 (0.071) 0.058 77.3 22.7 0.287 (0.099) 0.070 9.0 91.0 0.572 (0.126) 0.088 0.0 100
Robust 0.014 (0.055) 0.053 94.8 5.2 0.070 (0.072) 0.064 87.0 13.0 0.355 (0.169) 0.103 41.3 58.7
Penalized 0.012 (0.051) 0.053 93.9 6.1 0.043 (0.054) 0.061 83.9 16.1 0.156 (0.062) 0.094 34.3 65.7
R and P 0.009 (0.055) 0.054 95.2 4.7 0.031 (0.064) 0.061 91.7 8.3 0.108 (0.087) 0.093 74.6 25.4
Lasso 0.013 (0.051) 0.054 93.2 6.8 0.044 (0.055) 0.062 83.4 16.6 0.165 (0.063) 0.095 32.6 67.4
Scenario 4. Directional pleiotropy, InSIDE violated
IVW 0.170 (0.052) 0.046 7.2 92.8 0.349 (0.049) 0.043 0.0 100 0.476 (0.043) 0.036 0.0 100
Robust 0.076 (0.079) 0.065 87.2 12.8 0.310 (0.089) 0.057 7.7 92.1 0.475 (0.048) 0.038 0.0 100
Penalized 0.053 (0.049) 0.064 72.9 27.1 0.187 (0.046) 0.082 13.5 86.5 0.401 (0.040) 0.062 0.0 100
R and P 0.047 (0.058) 0.064 84.5 15.5 0.184 (0.065) 0.087 26.7 73.3 0.409 (0.044) 0.062 0.0 100
Lasso 0.072 (0.048) 0.068 62.9 37.1 0.276 (0.043) 0.072 0.7 99.3 0.474 (0.035) 0.051 0.0 100
Positive causal effect (θ = 0.3)
Scenario 2. Balanced pleiotropy, InSIDE satisfied
IVW 0.227 (0.079) 0.076 17.8 82.2 0.229 (0.108) 0.113 45.5 54.5 0.228 (0.141) 0.136 64.2 35.8
Robust 0.227 (0.065) 0.062 6.1 93.9 0.233 (0.080) 0.082 18.6 81.4 0.230 (0.126) 0.119 54.3 45.7
Penalized 0.230 (0.061) 0.062 3.9 96.1 0.241 (0.064) 0.079 8.2 91.8 0.241 (0.071) 0.100 15.7 84.3
R and P 0.229 (0.064) 0.063 4.8 95.2 0.237 (0.072) 0.077 11.1 88.9 0.236 (0.088) 0.097 25.5 74.5
Lasso 0.227 (0.061) 0.064 4.8 95.2 0.232 (0.065) 0.079 9.2 90.8 0.230 (0.072) 0.095 17.8 82.2
Scenario 3. Directional pleiotropy, InSIDE satisfied
IVW 0.323 (0.079) 0.068 1.1 98.9 0.514 (0.107) 0.081 0 100 0.804 (0.133) 0.098 0.0 100
Robust 0.251 (0.066) 0.066 2.9 97.1 0.342 (0.093) 0.081 1.3 98.7 0.654 (0.162) 0.107 0.2 99.8
Penalized 0.251 (0.061) 0.066 2.1 97.9 0.308 (0.065) 0.080 0.8 99.2 0.490 (0.076) 0.121 0.0 100
R and P 0.246 (0.065) 0.067 4.1 95.9 0.291 (0.074) 0.080 3.2 96.8 0.442 (0.102) 0.123 1.6 98.3
Lasso 0.247 (0.061) 0.066 2.5 97.5 0.297 (0.065) 0.081 1.3 98.7 0.463 (0.074) 0.115 0.0 100
Scenario 4. Directional pleiotropy, InSIDE violated
IVW 0.411 (0.061) 0.060 0.0 100 0.609 (0.058) 0.054 0.0 100 0.747 (0.051) 0.045 0.0 100
Robust 0.327 (0.095) 0.076 4.5 95.5 0.575 (0.093) 0.065 0.6 99.4 0.746 (0.057) 0.047 0.0 100
Penalized 0.307 (0.058) 0.080 0.9 99.1 0.479 (0.053) 0.093 0.1 99.9 0.689 (0.046) 0.066 0.0 100
R and P 0.298 (0.072) 0.080 1.7 98.3 0.478 (0.073) 0.098 0.2 99.6 0.697 (0.051) 0.066 0.0 100
Lasso 0.314 (0.057) 0.08 0.3 99.7 0.544 (0.050) 0.081 0.0 100 0.742 (0.041) 0.061 0.0 100
Abbreviations: IV, instrumental variable; Est. estimate; SE, standard error; SD, standard deviation; Cov., coverage; Pow., power; InSIDE, instrument strength
independent of direct effect; IVW, inverse variance weighted; R and P, robust regression and penalized weights.
https://doi.org/10.1371/journal.pone.0222362.t005
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However, heterogeneity among the causal ratio estimates may arise for a number of reasons
[44]. For example, there may be multiple mechanisms of intervention on a complex risk factor,
each of which has an associated causal effect. For a two-sample Mendelian randomization
analysis, there may be heterogeneity among the causal ratio estimates due to substantial differ-
ences in the study populations used to estimate the genetic associations with the risk factor
and outcome. The robust approaches considered in this paper penalize genetic variants with
heterogeneous causal ratio estimates regardless of how this heterogeneity has materialised. As
such, these methods should only be employed if it is suspected that the IV assumptions have
been violated, and other possible reasons for heterogeneity among the causal ratio estimates
explored.
Issues with penalizing genetic variants
The simulation study has highlighted some of the disadvantages of excluding or downweight-
ing genetic variants from Mendelian randomization analyses. Excluding genetic variants with
heterogeneous causal estimates will generally reduce the standard error of the estimate. How-
ever, too much penalization can potentially result in artificial overconfidence in the precision
of the causal estimate, leading to poor coverage of the true causal effect and increased Type I
error rates, as seen for Lasso penalization. If the excluded genetic variants are truly invalid IVs
then removing them from the analysis will reduce bias and improve the precision of the causal
estimate. However, outlying or heterogeneous causal ratio estimates may be valid IVs, and so
removing them from the analysis would be inappropriate. On balance, it may be more appro-
priate to consider approaches that reduce the contribution that heterogeneous ratio estimates
have on the causal estimate, such as the median estimator or robust regression, rather than
excluding them from the analysis. If a large number of variants are identified as outliers, then
researchers should consider reporting that the Mendelian randomization analysis is inconclu-
sive, rather than reporting a causal estimate.
Implication for Mendelian randomization studies
The purpose of this paper was not to promote one robust method for Mendelian randomiza-
tion over another, but to emphasize the need for multiple sensitivity analyses that make
different sets of assumptions. Although we acknowledge that none of the proposed methods
performed significantly better than the median estimator, the extensions proposed in this
paper should provide additional confidence in the findings from a conventional Mendelian
randomization analysis, particularly when the causal estimates are consistent. Genetic variants
that are downweighted or excluded from the analysis by the robust methods should be exam-
ined for pleiotropy to determine whether they should be removed from the dataset. The meth-
ods proposed here are likely to be useful for Mendelian randomization analyses performed for
large numbers of risk factors in an automated manner, such as for -omics risk factors mea-
sured on a high-throughput platform. These methods can help a researcher rapidly triage
whether a positive causal estimate from the standard IVW method is evidenced just by a small
number of variants (as in the LDL-cholesterol and Alzheimer’s disease example), or by the
majority of variants.
The methods introduced in this paper, particularly robust regression with penalized
weights, may be more suited to certain scenarios than the median estimator. In the applied
example for LDL-C and AD risk, there were two variants that appeared to be clear outliers.
The median estimator and robust regression with penalized weights both suggested that there
was a null causal effect of LDL-C on AD risk, but the estimates from the median estimator
were less precise. This observation of robust regression producing more precise estimates was
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also observed in the simulation study when there was one invalid IV. Robust regression with
penalized weights may be a useful addition to sensitivity analyses in Mendelian randomization
when there are a small proportion of variants with heterogeneous causal estimates.
Limitations
We found that the Lasso penalization method may be more appropriate in an applied setting,
where the estimates can be reported over a range of values of the tuning parameter. The practi-
cality of applying Lasso penalization to the simulation study was more restrictive, and required
an automated approach to selecting the tuning parameter.
Whilst we appreciate the limitation of only considering methods with uncorrelated genetic
variants, we argue that robust methods should be used when the IV assumptions are in doubt,
and therefore using one genetic variant from each gene region is a sensible (although conserva-
tive) approach for robust methods in an applied Mendelian randomization analysis. This is
because including multiple variants from a single region may mean that region receives a dis-
proportionate weight in the analysis, and so the validity of the analysis would be overly depen-
dent on the validity of these variants. This could be problematic as correlated variants are
likely to all be valid or all be invalid, particularly if they are all in the same gene region. If
an analyst does want to include correlated variants in an analysis, this can be done by first
calculating the appropriate weighting matrix based on the inverse-variance weights and the
correlations between variants, and multiplying the genetic associations by the Cholesky
decomposition of this matrix, as described previously [45]. Software code to do this is provided
in S1 Appendix. However, we caution that no allowance is made that correlated variants are
likely to all be valid or all invalid simultaneously, as the methods treat all association estimates
as separate datapoints.
The violation of the NOME assumption limited the utility of the simulation study as the
estimates from MR-Egger could not be compared to the robust methods. Given that MR-Egger
is frequently used as part of a sensitivity analysis in Mendelian randomization studies, this
could be viewed as a weakness of the simulation study.
The main simulation study was also limited by the number of genetic variants considered
in the data generating model. Since GWASs are now being performed on large study popula-
tions, and estimates of genetic associations are publicly available from large consortia, only
considering 15 variants in the simulation study may have been conservative. We tried to rectify
this limitation by re-performing the simulation study with 100 genetic variants (but keeping
the overall R2 statistic similar) and found that there was significant attenuation towards the
null due to weak instrument bias. We had thought that the performances of some of the robust
methods would have improved by increasing the number of genetic variants as the methods
are based on asymptotic theory. However, we did not find any significant improvements in the
methods, and in some cases, the performance of the models worsened with the increased num-
ber of genetic variants.
Conclusion
This paper has highlighted the difficulty in robust causal inference when genetic variants in a
Mendelian randomization analysis violate the IV assumptions. The extensions proposed in
this paper are by no means perfect; even when a small proportion of the variants were invalid
IVs, all methods had inflated Type I error rates in at least one scenario. Nevertheless, the Type
I error rate for the proposed extensions was substantially better than the IVW method and
MR-Egger when the InSIDE assumption was violated.
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This paper has demonstrated the benefits of using multiple robust methods as part of a
sensitivity analysis. We suggest that the IVW method using robust regression with penalized
weights may be a worthwhile additional sensitivity analysis to be performed in a Mendelian
randomization analysis in addition to previously proposed methods.
Supporting information
S1 Appendix. Software code. R code for performing the approaches outlined in the paper,
and extracting genetic association estimates.
(PDF)
S2 Appendix. Supplementary tables from the simulation study. Additional results from the
simulation study.
(PDF)
Acknowledgments
We would like to thank Dr Jack Bowden (University of Bristol) for comments made on an ear-
lier version of this manuscript.
Author Contributions
Conceptualization: Stephen Burgess.
Data curation: Stephen Burgess.
Formal analysis: Jessica M. B. Rees.
Investigation: Angela M. Wood, Frank Dudbridge.
Methodology: Jessica M. B. Rees, Stephen Burgess.
Supervision: Stephen Burgess.
Writing – original draft: Jessica M. B. Rees, Stephen Burgess.
Writing – review & editing: Angela M. Wood, Frank Dudbridge.
References
1. Davey Smith G, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to under-
standing environmental determinants of disease? International Journal of Epidemiology. 2003; 32(1):1–
22.
2. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using
genes as instruments for making causal inferences in epidemiology. Statistics in Medicine. 2008; 27
(8):1133–1163. https://doi.org/10.1002/sim.3034 PMID: 17886233
3. Greenland S. An introduction to instrumental variables for epidemiologists. International Journal of Epi-
demiology. 2000; 29(4):722–729. https://doi.org/10.1093/ije/29.4.722 PMID: 10922351
4. Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG. Using published data in Mendelian
randomization: a blueprint for efficient identification of causal risk factors. European Journal of Epidemi-
ology. 2015; 30(7):543–552. https://doi.org/10.1007/s10654-015-0011-z PMID: 25773750
5. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic vari-
ants using summarized data. Genetic Epidemiology. 2013; 37(7):658–665. https://doi.org/10.1002/
gepi.21758 PMID: 24114802
6. Angrist JD, Imbens GW. Two-stage least squares estimation of average causal effects in models with
variable treatment intensity. Journal of the American Statistical Association. 1995; 90(430):431–442.
https://doi.org/10.1080/01621459.1995.10476535
Robust methods in Mendelian randomization via penalization of heterogeneous causal estimates
PLOS ONE | https://doi.org/10.1371/journal.pone.0222362 September 23, 2019 22 / 24
7. Burgess S, Thompson SG. Use of allele scores as instrumental variables for Mendelian randomization.
International Journal of Epidemiology. 2013; 42(4):1134–1144. https://doi.org/10.1093/ije/dyt093
PMID: 24062299
8. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomiza-
tion with Some Invalid Instruments Using a Weighted Median Estimator. Genetic Epidemiology. 2016;
40(4):304–314. https://doi.org/10.1002/gepi.21965 PMID: 27061298
9. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estima-
tion and bias detection through Egger regression. International Journal of Epidemiology. 2015; 44
(2):512–525. https://doi.org/10.1093/ije/dyv080 PMID: 26050253
10. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relation-
ships inferred from Mendelian randomization between complex traits and diseases. Nature Genetics.
2018; 50(5):693–698. https://doi.org/10.1038/s41588-018-0099-7 PMID: 29686387
11. Dai JY, Peters U, Wang X, Kocarnik J, Chang-Claude J, Slattery ML, et al. Diagnostics for Pleiotropy in
Mendelian Randomization Studies: Global and Individual Tests for Direct Effects. American Journal of
Epidemiology. 2018; 187(12):2672–2680. https://doi.org/10.1093/aje/kwy177 PMID: 30188971
12. Zhu Z, Zheng Z, Zhang F, Wu Y, Trzaskowski M, Maier R, et al. Causal associations between risk fac-
tors and common diseases inferred from GWAS summary data. Nature Communications. 2018; 9
(1):224. https://doi.org/10.1038/s41467-017-02317-2 PMID: 29335400
13. Del Greco M F, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in Mendelian randomisation
studies with summary data and a continuous outcome. Statistics in Medicine. 2015; 34(21):2926–2940.
https://doi.org/10.1002/sim.6522
14. Bowden J, Del Greco M F, Minelli C, Zhao Q, Lawlor DA, Sheehan NA, et al. Improving the accuracy of
two-sample summary-data Mendelian randomization: moving beyond the NOME assumption. Interna-
tional Journal of Epidemiology. 2018.
15. Huber P. Robust Statistics. Wiley; 2009.
16. Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian randomi-
zation analyses using summarized data. International Journal of Epidemiology. 2017. https://doi.org/10.
1093/ije/dyx034 PMID: 28398548
17. Burgess S, CCGC (CHD CRP Genetics Collaboration). Identifying the odds ratio estimated by a two-
stage instrumental variable analysis with a logistic regression model. Statistics in Medicine. 2013; 32
(27):4726–4747. https://doi.org/10.1002/sim.5871 PMID: 23733419
18. Vansteelandt S, Bowden J, Babanezhad M, Goetghebeur E. On instrumental variables estimation of
causal odds ratios. Statistical Science. 2011; 26(3):403–422. https://doi.org/10.1214/11-STS360
19. Kolesa´r M, Chetty R, Friedman J, Glaeser E, Imbens G. Identification and inference with many invalid
instruments. Journal of Business & Economic Statistics. 2015; 33(4):474–484. https://doi.org/10.1080/
07350015.2014.978175
20. Koller M, Stahel W. Sharpening wald-type inference in robust regression for small samples. Computa-
tional Statistics & Data Analysis. 2011; 55(8):2504–2515. https://doi.org/10.1016/j.csda.2011.02.014
21. Rousseeuw P, Croux C, Todorov V, Ruckstuhl A, Salibian-Barrera M, Verbeke T, et al. robustbase:
Basic Robust Statistics; 2015 URL http://cran.r-project.org/package=robustbase, R package version
0.92-5.
22. Bowden J, Hemani G, Davey Smith G. Invited Commentary: Detecting Individual and Global Horizon-
tal Pleiotropy in Mendelian Randomization—A Job for the Humble Heterogeneity Statistic? American
Journal of Epidemiology. 2018; 187(12):2681–2685. https://doi.org/10.1093/aje/kwy185 PMID:
30188969
23. Rucker G, Schwarzer G, Carpenter JR, Binder H, Schumacher M. Treatment effect estimates adjusted
for small-study effects via a limit meta-analysis. Biostatistics. 2011; 12(1):122–142. https://doi.org/10.
1093/biostatistics/kxq046 PMID: 20656692
24. Kang H, Zhang A, Cai T, Small D. Instrumental Variables Estimation With Some Invalid Instruments
and its Application to Mendelian Randomization. Journal of the American Statistical Association. 2016;
111(513):132–144. https://doi.org/10.1080/01621459.2014.994705
25. Windmeijer F, Farbmacher H, Davies N, Davey Smith G. On the Use of the Lasso for Instrumental Vari-
ables Estimation with Some Invalid Instruments. Journal of the American Statistical Association. 2018;
0(0):1–12. https://doi.org/10.1080/01621459.2018.1498346
26. Cheng X, Liao Z. Select the valid and relevant moments: An information-based LASSO for GMM with
many moments. Journal of Econometrics. 2015; 186(2):443–464. https://doi.org/10.1016/j.jeconom.
2015.02.019
27. Tibshirani R. Regression Shrinkage and Selection Via the Lasso. Journal of the Royal Statistical Soci-
ety, Series B (Methodological). 1996; 58:267–288. https://doi.org/10.1111/j.2517-6161.1996.tb02080.x
Robust methods in Mendelian randomization via penalization of heterogeneous causal estimates
PLOS ONE | https://doi.org/10.1371/journal.pone.0222362 September 23, 2019 23 / 24
28. Goeman J, Meijer R, Chaturvedi N, Lueder M. penalized: L1 (Lasso and Fused Lasso) and L2 (Ridge)
Penalized Estimation in GLMs and in the Cox Model; 2017 URL https://cran.r-project.org/web/
packages/penalized/penalized.pdf.
29. Staley JR, Blackshaw J, Kamat MA, Ellis S, Surendran P, Sun BB, et al. PhenoScanner: a database of
human genotype-phenotype associations. Bioinformatics. 2016; 32(20):3207–3209. https://doi.org/10.
1093/bioinformatics/btw373 PMID: 27318201
30. Coodin S. Body mass index in persons with schizophrenia. Canadian Journal of Psychiatry. 2001; 46
(6):549–555. https://doi.org/10.1177/070674370104600610 PMID: 11526812
31. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, et al. The distribution of body
mass index among individuals with and without schizophrenia. Journal of Clinical Psychiatry. 1999; 60
(4):215–220. https://doi.org/10.4088/jcp.v60n0402 PMID: 10221280
32. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. Genetic studies of body mass index
yield new insights for obesity biology. Nature. 2015; 518(7538):197–206. https://doi.org/10.1038/
nature14177 PMID: 25673413
33. Ripke S, Neale BM, Corvin A, Walters JT, Farh KH, Holmans PA, et al. Biological insights from 108
schizophrenia-associated genetic loci. Nature. 2014; 511(7510):421–427. https://doi.org/10.1038/
nature13595
34. Hartwig FP, Bowden J, Loret de Mola C, Tovo-Rodrigues L, Davey Smith G, Horta BL. Body mass
index and psychiatric disorders: a Mendelian randomization study. Scientific Reports. 2016; 6:32730.
https://doi.org/10.1038/srep32730 PMID: 27601421
35. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, et al. Serum total cholesterol,
apolipoprotein E epsilon 4 allele, and Alzheimer’s disease. Neuroepidemiology. 1998; 17(1):14–20.
https://doi.org/10.1159/000026149 PMID: 9549720
36. Solomon A, Kareholt I, Ngandu T, Winblad B, Nissinen A, Tuomilehto J, et al. Serum cholesterol
changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology. 2007; 68
(10):751–756. https://doi.org/10.1212/01.wnl.0000256368.57375.b7 PMID: 17339582
37. Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol level and statin use in Alzheimer disease: I.
Review of epidemiological and preclinical studies. JAMA Neurology. 2011; 68(10):1239–1244.
38. Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with
plasma triglycerides and risk for coronary artery disease. Nature Genetics. 2013; 45(11):1345–1352.
https://doi.org/10.1038/ng.2795 PMID: 24097064
39. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refine-
ment of loci associated with lipid levels. Nature Genetics. 2013; 45(11):1274–1283. https://doi.org/10.
1038/ng.2797 PMID: 24097068
40. Benn M, Nordestgaard BG, Frikke-Schmidt R, Tybjærg-Hansen A. Low LDL cholesterol, PCSK9 and
HMGCR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian rando-
misation study. British Medical Journal. 2017; 357. https://doi.org/10.1136/bmj.j1648 PMID: 28438747
41. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of
74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nature Genetics. 2013;
45(12):1452–1458. https://doi.org/10.1038/ng.2802 PMID: 24162737
42. Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan NA, Thompson JR. Assessing the suit-
ability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression:
the role of the I2 statistic. International Journal of Epidemiology. 2016; 45(6):1961–1974. https://doi.org/
10.1093/ije/dyw220 PMID: 27616674
43. Slob EA, Burgess S. A comparison of robust Mendelian randomization methods using summary data.
bioRxiv. 2019; p. 577940.
44. Hemani G, Bowden J, Davey Smith G. Evaluating the potential role of pleiotropy in Mendelian randomi-
zation studies. Human Molecular Genetics. 2018; 27(R2):R195–R208. https://doi.org/10.1093/hmg/
ddy163 PMID: 29771313
45. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger
method. European Journal of Epidemiology. 2017; 32(5):377–389. https://doi.org/10.1007/s10654-017-
0255-x PMID: 28527048
Robust methods in Mendelian randomization via penalization of heterogeneous causal estimates
PLOS ONE | https://doi.org/10.1371/journal.pone.0222362 September 23, 2019 24 / 24

Appendix C
Appendix to paper 1
Appendix to the published paper contained in Appendix B.
S1 Software code
We provide R code to implement the methods discussed in this paper. The associ-
ations of the genetic variants with the exposure are denoted betaXG with standard
errors sebetaXG. The associations of the genetic variants with the outcome are de-
noted betaYG with standard errors sebetaYG. We assume that the genetic variants
are uncorrelated.
Inverse-variance weighted estimate
The inverse-variance weighted (IVW) estimate can be calculated by weighted linear
regression:
betaIVW = summary(lm(betaYG~betaXG-1, weights=sebetaYG^-2))$coef[1]
sebetaIVW.fixed = summary(lm(betaYG~betaXG-1, weights=sebetaYG^-2))$coef[1,2]/
summary(lm(betaYG~betaXG-1, weights=sebetaYG^-2))$sigma
sebetaIVW.random = summary(lm(betaYG~betaXG-1, weights=sebetaYG^-2))$coef[1,2]/
min(summary(lm(betaYG~betaXG-1, weights=sebetaYG^-2))$sigma,1)
In the fixed-effect model, we divide the reported standard error by the estimated
residual standard error to force the residual standard error to be 1. In the multi-
plicative random-effects model, we divide by the estimated residual standard error
when the variability in the genetic associations is less than expected by chance (un-
derdispersion). When there is evidence of heterogeneity between the causal estimates
(overdispersion) the standard error is unaltered. The multiplicative random-effects
model will result in a larger standard error compared to the fixed-effect model if there
is heterogeneity between the causal estimates. The point estimate is unaffected by
the choice of a fixed- or multiplicative random-effects model.
Alternatively, the inverse-variance weighted estimate can be calculated by meta-
analysis, or via a simple formula:
# meta-analysis
library(meta)
betaIVW = metagen(betaYG/betaXG, abs(sebetaYG/betaXG))$TE.fixed
sebetaIVW.fixed = metagen(betaYG/betaXG, abs(sebetaYG/betaXG))$seTE.fixed
# simple formula
betaIVW = sum(betaYG*betaXG*sebetaYG^-2)/sum(betaXG^2*sebetaYG^-2)
sebetaIVW.fixed = 1/sqrt(sum(betaXG^2*sebetaYG^-2))
MR-Egger regression
The MR-Egger method is equivalent to the IVW method calculated using weighted
regression, except that that intercept term is estimated rather than being set to
zero. A test as to whether the intercept term is equal to zero is a test of directional
pleiotropy and the validity of the InSIDE assumption. The genetic associations with
the risk factor betaXG and outcome betaYG must be orientated with respect to the
risk increasing or decreasing allele of the risk factor. A random-effects model should
be used for inference as a fixed-effect model is not justifiable when the genetic variants
are not all valid instruments.
1
# coding of genetic variants
betaYG = betaYG*sign(betaXG); betaXG = abs(betaXG)
# causal estimate
betaEGGER = summary(lm(betaYG~betaXG, weights=sebetaYG^-2))$coef[2,1]
sebetaEGGER.random = summary(lm(betaYG~betaXG, weights=sebetaYG^-2))$coef[2,2]/
min(summary(lm(betaYG~betaXG, weights=sebetaYG^-2))$sigma, 1)
betaEGGER.lower = betaEGGER-qt(0.975,df=length(betaXG)-2)*sebetaEGGER.random
betaEGGER.upper = betaEGGER+qt(0.975,df=length(betaXG)-2)*sebetaEGGER.random
p.causal.random = 2*(1-pt(abs(betaEGGER/sebetaEGGER.random),df=length(betaXG)-2))
# test for directional pleiotropy
interEGGER = summary(lm(betaYG~betaXG, weights=sebetaYG^-2))$coef[1,1]
seinterEGGER.random = summary(lm(betaYG~betaXG, weights=sebetaYG^-2))$coef[1,2]/
min(summary(lm(betaYG~betaXG, weights=sebetaYG^-2))$sigma, 1)
p.dpleio.random = 2*(1-pt(abs(interEGGER/seinterEGGER.random),df=length(betaXG)-2))
In this code, we use a t-distribution with J − 2 degrees of freedom for inference.
If there is underdispersion, then the t-distribution may be overly conservative, as the
t-distribution assumes that the residual standard error is estimated (in case of under-
dispersion, the residual standard error is set to 1). Hence, if the residual standard
error is less than one, either a confidence interval using a residual standard error of 1
and a z-distribution, or else a confidence interval using the estimated residual standard
error and a t-distribution may be preferred (the wider of these two intervals should
be preferred – both of these will be narrower than the above confidence interval).
sigmaEGGER = summary(lm(betaYG~betaXG, weights=sebetaYG^-2))$sigma
betaEGGER.lower = ifelse(sigmaEGGER<1, min(betaEGGER-qnorm(0.975)*sebetaEGGER.random,
betaEGGER-qt(0.975,df=length(betaXG)-2)*sebetaEGGER.random*sigmaEGGER),
betaEGGER-qt(0.975,df=length(betaXG)-2)*sebetaEGGER.random)
betaEGGER.upper = ifelse(sigmaEGGER<1, max(betaEGGER+qnorm(0.975)*sebetaEGGER.random,
betaEGGER+qt(0.975,df=length(betaXG)-2)*sebetaEGGER.random*sigmaEGGER),
betaEGGER+qt(0.975,df=length(betaXG)-2)*sebetaEGGER.random)
Median-based method
The median-based method calculates the median (or weighted median) of the causal
estimates from each candidate instrument. This code calculates the simple median
and weighted median, employing bootstrapping to obtain a standard error that can
be used to provide a confidence interval.
weighted.median <- function(betaIV.in, weights.in) {
betaIV.order = betaIV.in[order(betaIV.in)]
weights.order = weights.in[order(betaIV.in)]
weights.sum = cumsum(weights.order)-0.5*weights.order
weights.sum = weights.sum/sum(weights.order)
below = max(which(weights.sum<0.5))
weighted.est = betaIV.order[below] + (betaIV.order[below+1]-betaIV.order[below])*
(0.5-weights.sum[below])/(weights.sum[below+1]-weights.sum[below])
return(weighted.est) }
#
weighted.median.boot = function(betaXG.in, betaYG.in, sebetaXG.in, sebetaYG.in, weights.in){
# the standard error is estimated based on 1000 bootstrap samples
med = NULL
for(i in 1:1000){
betaXG.boot = rnorm(length(betaXG.in), mean=betaXG.in, sd=sebetaXG.in)
betaYG.boot = rnorm(length(betaYG.in), mean=betaYG.in, sd=sebetaYG.in)
betaIV.boot = betaYG.boot/betaXG.boot
med[i] = weighted.median(betaIV.boot, weights.in)
}
return(sd(med)) }
#
2
betaIV = betaYG/betaXG
weights = rep(1, length(betaXG)) # unweighted median
betaSIMPLEMED = weighted.median(betaIV, weights)
sebetaSIMPLEMED = weighted.median.boot(betaXG, betaYG, sebetaXG, sebetaYG, weights)
lowerSIMPLEMED = betaSIMPLEMED-qnorm(0.975)*sebetaSIMPLEMED
upperSIMPLEMED = betaSIMPLEMED+qnorm(0.975)*sebetaSIMPLEMED
#
betaIV = betaYG/betaXG
weights = (sebetaYG/betaXG)^-2 # weighted median using inverse-variance weights
betaWEIGHTEDMED = weighted.median(betaIV, weights)
sebetaWEIGHTEDMED = weighted.median.boot(betaXG, betaYG, sebetaXG, sebetaYG, weights)
lowerWEIGHTEDMED = betaWEIGHTEDMED-qnorm(0.975)*sebetaWEIGHTEDMED
upperWEIGHTEDMED = betaWEIGHTEDMED+qnorm(0.975)*sebetaWEIGHTEDMED
Robust regression
The IVW and MR-Egger methods can be performed using robust regression (in partic-
ular, MM-estimation using Tukey’s bisquare objective function) rather than standard
linear regression:
library(robustbase)
betaIVW.robust = summary(lmrob(betaYG~betaXG-1, weights=sebetaYG^-2, k.max=500))$coef[1]
sebetaIVW.robust.fixed = summary(lmrob(betaYG~betaXG-1, weights=sebetaYG^-2, k.max=500))$coef[1,2]/
summary(lmrob(betaYG~betaXG-1, weights=sebetaYG^-2, k.max=500))$sigma
sebetaIVW.robust.random = summary(lmrob(betaYG~betaXG-1, weights=sebetaYG^-2, k.max=500))$coef[1,2]/
min(summary(lmrob(betaYG~betaXG-1, weights=sebetaYG^-2, k.max=500))$sigma,1)
betaEGGER.robust = summary(lmrob(betaYG~betaXG, weights=sebetaYG^-2, k.max=500))$coef[2]
sebetaEGGER.robust.random = summary(lmrob(betaYG~betaXG, weights=sebetaYG^-2, k.max=500))$coef[2,2]/
min(summary(lmrob(betaYG~betaXG, weights=sebetaYG^-2, k.max=500))$sigma,1)
The k.max option sets the maximum number of steps evaluated to find initial
parameter values in the S-step of the algorithm. The lmrob function sets the tuning
parameter to 1.548 to provide a high breakdown point in the S-estimation step, and
as 4.685 to provide efficiency in the M-estimation step.
Penalized weights
The IVW and MR-Egger methods can be performed using penalized weights:
betaIVW = sum(betaYG*betaXG*sebetaYG^-2)/sum(betaXG^2*sebetaYG^-2)
pweights = pchisq(betaXG^2/sebetaYG^2*(betaYG/betaXG-betaIVW)^2, df=1, lower.tail=FALSE)
pweightsE = pchisq(sebetaYG^-2*(betaYG - interEGGER - betaEGGER*betaXG)^2, df=1, lower.tail=FALSE)
rweights = sebetaYG^-2*pmin(1, pweights*100)
rweightsE = sebetaYG^-2*pmin(1, pweightsE*100)
betaIVW.penal = summary(lm(betaYG~betaXG-1, weights=rweights))$coef[1]
sebetaIVW.penal.fixed = summary(lm(betaYG~betaXG-1, weights=rweights))$coef[1,2]/
summary(lm(betaYG~betaXG-1, weights=rweights))$sigma
sebetaIVW.penal.random = summary(lm(betaYG~betaXG-1, weights=rweights))$coef[1,2]/
min(summary(lm(betaYG~betaXG-1, weights=rweights))$sigma,1)
betaEGGER.penal = summary(lm(betaYG~betaXG, weights=rweightsE))$coef[2]
sebetaEGGER.penal.random = summary(lm(betaYG~betaXG, weights=rweightsE))$coef[2,2]/
min(summary(lm(betaYG~betaXG, weights=rweightsE))$sigma,1)
Penalized weights can also be used in conjunction with robust regression.
3
Lasso penalization
Several packages are available for running Lasso penalization methods. We chose the
penalized package as this gave an option for some of the coefficients in the model to
be penalized (the pleiotropy intercept parameters), and others not to be penalized
(the causal effect parameter):
library(penalized)
# dividing the association estimates by sebetaYG is equivalent to weighting by
sebetaYG^-2
betaYGw = betaYG/sebetaYG
betaXGw = betaXG/sebetaYG
pleio = diag(rep(1, length(betaXG)))
# values of lambda for heterogeneity stopping rule
l1grid = c(seq(from=0.1, to=5, by=0.1), seq(from=5.2, to=10, by=0.2))
l1grid_rse = NULL; l1grid_length = NULL; l1grid_beta = NULL; l1grid_se = NULL
for (i in 1:length(l1grid)) {
l1grid_which = which(attributes(penalized(betaYGw, pleio, betaXGw,
lambda1=l1grid[i], trace=FALSE))$penalized==0)
l1grid_rse[i] = summary(lm(betaYG[l1grid_which]~betaXG[l1grid_which]-1,
weights=sebetaYG[l1grid_which]^-2))$sigma
l1grid_length[i] = length(l1grid_which)
l1grid_beta[i] = lm(betaYG[l1grid_which]~betaXG[l1grid_which]-1,
weights=sebetaYG[l1grid_which]^-2)$coef[1]
l1grid_se[i] = summary(lm(betaYG[l1grid_which]~betaXG[l1grid_which]-1,
weights=sebetaYG[l1grid_which]^-2))$coef[1,2]/
min(summary(lm(betaYG[l1grid_which]~betaXG[l1grid_which]-1,
weights=sebetaYG[l1grid_which]^-2))$sigma, 1)
}
# heterogeneity criterion for choosing lambda
l1which_hetero = c(which(l1grid_rse[1:(length(l1grid)-1)]>1
&diff(l1grid_rse)>qchisq(0.95, df=1)/
l1grid_length[2:length(l1grid)]), length(l1grid))[1]
l1hetero_beta = l1grid_beta[l1which_hetero]
l1hetero_se = l1grid_se[l1which_hetero]
# cross-validation criterion for choosing lambda
l1xval_lambda = optL1(betaYGw, pleio, betaXGw)$lambda
l1xval_which = which(attributes(penalized(betaYGw, pleio, betaXGw,
lambda1=l1xval_lambda))$penalized==0)
l1xval_beta = summary(lm(alpy[l1xval_which]~alpx[l1xval_which]-1,
weights=alpysd[l1xval_which]^-2))$coef[1]
l1xval_se = summary(lm(alpy[l1xval_which]~alpx[l1xval_which]-1,
weights=alpysd[l1xval_which]^-2))$coef[1,2]/
min(summary(lm(alpy[l1xval_which]~alpx[l1xval_which]-1,
weights=alpysd[l1xval_which]^-2))$sigma, 1)
We found that our choice of values of λ (0.1, 0.2, . . . , 4.9, 5.0, 5.2, 5.4, . . . , 9.8, 10.0)
worked well in both the simulations and the applied example. However, for different
sets of association estimates, a different choice of values may be preferred. Addi-
tionally, particularly with large numbers of variants, a more dense choice of values
may be preferred to ensure that at most one variant is added to the analysis at each
incremental step.
4
Regression diagnostics
Studentized residuals and Cook’s distance can be calculated for the IVW method as:
rstudent(lm(betaYG~betaXG-1, weights=sebetaYG^-2))
cooks.distance(lm(betaYG~betaXG-1, weights=sebetaYG^-2))
Correlated variants
The IVW method can be performed for correlated variants using the standard linear
regression command after weighting the data by the Cholesky decomposition of a
weighting matrix Omega that accounts for the inverse-variance weights and the cor-
relation between the genetic variants, where rho is the (signed) correlation matrix
whose (i, j)th element is the correlation between genetic variant i and genetic variant
j:
Omega = sebetaYG%o%sebetaYG*rho
c_betaXG = solve(t(chol(Omega)))%*%betaXG
c_betaYG = solve(t(chol(Omega)))%*%betaYG
beta_IVWcorrel = lm(c_betaYGc_betaXG1)$coef[1]
se_IVWcorrel.fixed = sqrt(1/(t(betaXG)%*%solve(Omega)%*%betaXG))
se_IVWcorrel.random = sqrt(1/(t(betaXG)%*%solve(Omega)%*%betaXG))*
max(summary(lm(c_betaYGc_betaXG1))$sigma,1)
The robust and penalized methods can be implemented for correlated variants
similarly by replacing the lm command with the appropriate function.
5
Genetic variants and genetic associations
We provide R code to obtain data for the applied examples from PhenoScanner, a
database of genetic association estimates. This code is included in the MendelianRandomization
package for R that is available through The Comprehensive R Archive Network
(CRAN) with kind permission of James Staley.
Body mass index and schizophrenia
In total, 97 genetic variants (listed below) were used in the analysis of body mass index
and schizophrenia. At the time of writing, PhenoScanner was not able to process
quadrallelic genetic variants, and so it only retrieved data on 95 of the variants. It is
hoped that this will be fixed in the near future.
library(MendelianRandomization)
bmi_snps = scan(what="character")
rs1558902 rs6567160 rs13021737 rs10938397 rs543874 rs2207139 rs11030104 rs3101336 rs7138803
rs10182181 rs3888190 rs1516725 rs12446632 rs2287019 rs16951275 rs3817334 rs2112347 rs12566985
rs3810291 rs7141420 rs13078960 rs10968576 rs17024393 rs657452 rs12429545 rs12286929 rs13107325
rs11165643 rs7903146 rs10132280 rs17405819 rs6091540 rs1016287 rs4256980 rs17094222 rs12401738
rs7599312 rs2365389 rs205262 rs2820292 rs12885454 rs9641123 rs12016871 rs16851483 rs1167827
rs758747 rs1928295 rs9925964 rs11126666 rs2650492 rs6804842 rs12940622 rs7164727 rs11847697
rs4740619 rs492400 rs13191362 rs3736485 rs17001654 rs11191560 rs2080454 rs7715256 rs2176040
rs1528435 rs2075650 rs1000940 rs2033529 rs11583200 rs7239883 rs2836754 rs9400239 rs10733682
rs11688816 rs11057405 rs9914578 rs977747 rs2121279 rs29941 rs11727676 rs3849570 rs9374842
rs6477694 rs4787491 rs1441264 rs7899106 rs2176598 rs2245368 rs17203016 rs17724992 rs7243357
rs16907751 rs1808579 rs13201877 rs2033732 rs9540493 rs1460676 rs6465468
bmi_obj = pheno_input(snps=bmi_snps,
exposure = "Body mass index", pmidE = "25673413", ancestryE = "European",
outcome = "Schizophrenia", pmidO = "25056061", ancestryO = "Mixed")
mr_ivw(bmi_obj) # IVW method
mr_egger(bmi_obj) # MR-Egger method
mr_median(bmi_obj) # Weighted median method
mr_ivw(bmi_obj, robust = TRUE) # Robust regression method
mr_ivw(bmi_obj, penalized = TRUE) # Penalized weights method
LDL-cholesterol and Alzheimer’s disease
In total, 75 genetic variants (listed below) were used in the analysis of LDL-cholesterol
and Alzheimer’s disease. Data for all these variants are available in PhenoScanner.
ldl_snps = scan(what="character")
rs10903129 rs4587594 rs6603981 rs646776 rs1010167 rs267733 rs2642438 rs903319 rs2587534
rs1367117 rs515135 rs6544713 rs4148218 rs2710642 rs17508045 rs2030746 rs16831243 rs1250229
rs11563251 rs9875338 rs7640978 rs17345563 rs7703051 rs4530754 rs6882076 rs2294261 rs1800562
rs2247056 rs868943 rs2297374 rs1564348 rs12670798 rs4722551 rs2073547 rs217386 rs4240624
rs10102164 rs2326077 rs2737252 rs2980885 rs2954022 rs7832643 rs3780181 rs1883025 rs8176720
rs579459 rs2255141 rs10832962 rs174532 rs1535 rs10790162 rs11220462 rs653178 rs6489818 rs1169288
rs4942486 rs8017377 rs9989419 rs2288002 rs2000999 rs314253 rs7225700 rs6511720 rs688 rs10401969
rs6859 rs7254892 rs492602 rs364585 rs2328223 rs7264396 rs6016381 rs6065311 rs1800961 rs5763662
ldl_obj = pheno_input(snps=ldl_snps,
exposure = "Low density lipoprotein", pmidE = "24097068", ancestryE = "European",
outcome = "Alzheimers disease", pmidO = "24162737", ancestryO = "European")
mr_ivw(ldl_obj) # IVW method (and so on)
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The genetic association estimates can also be obtained from the web-based version
of PhenoScanner at http://www.phenoscanner.medschl.cam.ac.uk/.
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S2 Supplementary tables from the simulation study
Mean values for the R2, F -statistic and I2 statistic
Table A contains the mean R2 (%), F-statistic and I2 (%) from the simulation study
for all scenarios considered.
Table A. Mean values of the R2 (%), F-statistic and I2 (%) for Scenarios 1-4 with a null (θ = 0) or positive
(θ = 0.3) causal effect by the number of invalid instrumental variables (IV).
No invalid IVs 1 invalid IV 3 invalid IVs 6 invalid IVs
R2 F I2 R2 F I2 R2 F I2 R2 F I2
Null causal effect: θ = 0
Scenario 1 3.0 20.8 39.6 - - - - - - - -
Scenario 2 - - - 3.0 20.8 39.6 3.0 20.8 39.3 3.0 20.8 39.5
Scenario 3 - - - 3.0 20.8 39.7 3.0 20.8 39.5 3.0 20.8 39.2
Scenario 4 - - - 3.4 23.6 56.5 4.2 29.3 70.7 5.4 37.7 77.5
Positive causal effect: θ = 0.3
Scenario 1 3.0 20.8 39.3 - - - - - - - -
Scenario 2 - - - 3.0 20.8 39.1 3.0 20.8 39.4 3.0 20.8 39.6
Scenario 3 - - - 3.0 20.8 39.9 3.0 20.8 39.7 3.0 20.8 39.6
Scenario 4 - - - 3.4 23.6 56.4 4.2 29.3 70.8 5.4 37.7 77.4
Number of robust regression analyses without a standard error
The number of robust regressions that did not report a standard error in the simu-
lations are presented in Table B. The proportion of simulations was less than 1.2%
across the different scenarios for the IVW model. Apart from the calculation of the
mean standard error, the simulations that did not report a standard error were in-
cluded in the results, and the power calculations treated the standard error as infinite.
Table B. Number of the 10 000 simulations that failed to report a standard error using robust regression
(without and with penalized weights) with the inverse-variance weighted (IVW) and MR-Egger methods, for
Scenarios 1-4 with a null (θ = 0) or positive (θ = 0.3) causal effect by the number of invalid instrumental
variables.
IVW MR-Egger
Robust Robust, penalized Robust Robust, penalized
No. invalid: 0 1 3 6 0 1 3 6 0 1 3 6 0 1 3 6
Null causal effect: θ = 0
Scenario 1 0 - - - 0 - - - 16 - - - 16 - - -
Scenario 2 - 1 2 5 - 3 9 120 - 24 72 78 - 45 98 258
Scenario 3 - 2 1 4 - 3 10 51 - 32 69 32 - 30 70 139
Scenario 4 - 3 84 11 - 5 6 22 - 144 100 5 - 124 76 9
Positive causal effect: θ = 0.3
Scenario 1 4 - - - 3 - - - 13 - - - 13 - - -
Scenario 2 - 0 0 1 - 1 3 54 - 20 55 47 - 24 71 211
Scenario 3 - 0 0 3 - 3 2 22 - 24 72 19 - 37 62 73
Scenario 4 - 2 30 4 - 0 9 9 - 151 91 10 - 122 81 15
Abbreviations: IVW, inverse-variance weighted; No., number.
1
MR-Egger intercept test
Table C contains information on the power (at the 5% significance level) of the inter-
cept test in the MR-Egger method for detecting directional pleiotropy and/or violation
of the InSIDE assumption for all scenarios.
Table C. Power (%) of the intercept test in the MR-Egger method for detecting directional pleiotropy
and/or violation of the InSIDE assumption for Scenarios 1-4 with a null (θ = 0) or positive (θ = 0.3) causal
effect by the number of invalid instrumental variables (IV).
Null causal effect Positive causal effect
No. invalid: 0 1 3 6 0 1 3 6
Scenario 1 3.7 - - - 8.7 - -
Scenario 2 - 7.2 7.5 7.0 - 9.4 8.5 7.8
Scenario 3 - 7.2 8.7 13.1 - 11.2 13.8 19.1
Scenario 4 - 22.8 49.9 55.9 - 8.6 26.2 32.0
2
Results from applying the robust methods to the MR-Egger method
Table D contains the results from the simulation study when the MR-Egger model
was applied to the simulated data with: 1) robust regression (R); 2) penalized weights
(P); and 3) robust regression and penalized weights (R and P).
Table D. Mean (standard error) estimates and power from the MR-Egger method with: robust regression
(R); penalized weights (P); and robust regression and penalized weights (R and P) for Scenarios 1-4 with a
null (θ = 0) or positive (θ = 0.3) causal effect by the number of invalid instrumental variables.
No invalid IVs 1 invalid IV 3 invalid IVs 6 invalid IVs
Mean Power, Mean Power, Mean Power, Mean Power,
(mean SE) % (mean SE) % (mean SE) % (mean SE) %
Null causal effect: θ = 0
Scenario 1. No pleiotropy, InSIDE satisfied
R 0.000 (0.231) 8.2 - - - - - -
P -0.001 (0.216) 4.3 - - - - - -
R and P 0.000 (0.230) 8.3 - - - - - -
Scenario 2. Balanced pleiotropy, InSIDE satisfied
R - - -0.006 (0.245) 9.7 -0.002 (0.375) 9.6 -0.007 (0.671) 10.8
P - - -0.006 (0.208) 9.9 -0.003 (0.231) 16.9 -0.009 (0.274) 31.5
R and P - - -0.007 (0.254) 9.2 -0.001 (0.333) 10.7 -0.008 (0.505) 20.3
Scenario 3. Directional pleiotropy, InSIDE satisfied
R - - -0.003 (0.246) 9.9 0.001 (0.376) 9.5 -0.004 (0.564) 13.8
P - - -0.004 (0.208) 10.1 0.001 (0.249) 18.7 -0.009 (0.343) 37.9
R and P - - -0.004 (0.256) 9.4 0.001 (0.309) 12.0 -0.005 (0.419) 32.4
Scenario 4. Directional pleiotropy, InSIDE violated
R - - 0.171 (0.291) 18.2 0.493 (0.234) 65.1 0.649 (0.158) 95.6
P - - 0.241 (0.196) 33.0 0.527 (0.178) 81.2 0.651 (0.159) 97.7
R and P - - 0.173 (0.272) 18.5 0.490 (0.215) 68.2 0.652 (0.148) 96.8
Positive causal effect: θ = 0.3
Scenario 1. No pleiotropy, InSIDE satisfied
R 0.144 (0.273) 13.1 - - - - - -
P 0.143 (0.258) 7.9 - - - - - -
R and P 0.144 (0.271) 13.3 - - - - - -
Scenario 2. Balanced pleiotropy, InSIDE satisfied
R - - 0.140 (0.295) 13.1 0.139 (0.430) 11.6 0.124 (0.665) 11.9
P - - 0.139 (0.255) 13.5 0.140 (0.282) 19.4 0.130 (0.331) 30.2
R and P - - 0.140 (0.297) 12.9 0.140 (0.363) 14.6 0.133 (0.508) 22.4
Scenario 3. Directional pleiotropy, InSIDE satisfied
R - - 0.141 (0.295) 13.2 0.135 (0.433) 11.8 0.136 (0.563) 14.7
P - - 0.140 (0.252) 13.2 0.137 (0.302) 19.9 0.137 (0.392) 30.7
R and P - - 0.140 (0.292) 13.3 0.135 (0.352) 15.9 0.138 (0.433) 31.0
Scenario 4. Directional pleiotropy, InSIDE violated
R - - 0.338 (0.340) 25.5 0.719 (0.274) 75.6 0.893 (0.190) 97.7
P - - 0.418 (0.233) 48.9 0.754 (0.210) 91.2 0.895 (0.188) 99.4
R and P - - 0.340 (0.319) 27.1 0.716 (0.249) 78.6 0.897 (0.179) 98.2
Abbreviations: IV, instrumental variable; SE, standard error; InSIDE, instrument strength independent of
direct effect; R, robust regression; P, penalized weights.
3
Results from the one-sample setting
Results from the simulation study when the data were generated from one sample are
contained in Table E (null causal effect θ = 0) and Table F (positive causal effect
θ = 0.3). Estimates from the IVW model with: 1) the J genetic variants (IVW); 2)
robust regression (R); 3) penalized weights (P); and 4) robust regression and penalized
weights (R and P), and the Lasso penalization (LP) method with the heterogeneity
stopping rule for Scenarios 1-4 are displayed in the Tables E and F.
Table E. Mean (standard error) and power (%) of the estimates from the IVW model with: 1) the J genetic
variants (IVW); 2) robust regression (R); 3) penalized weights (P); and 4) robust regression and penalized
weights (R and P) for Scenarios 1-4 with a null causal effect (θ = 0) by the number of invalid instrumental
variables for one-sample Mendelian randomization. Results from the Lasso penalization (LP) method with
the heterogeneity stopping rule are also provided.
No invalid IVs 1 invalid IV 3 invalid IVs 6 invalid IVs
Mean Pow., Mean Pow., Mean Pow., Mean Pow.,
(mean SE) % (mean SE) % (mean SE) % (mean SE) %
Null causal effect: θ = 0
Scenario 1. No pleiotropy, InSIDE satisfied
IVW 0.021 (0.061) 5.6 - - - - - -
R 0.021 (0.065) 6.8 - - - - - -
P 0.019 (0.060) 6.0 - - - - - -
R and P 0.020 (0.063) 7.2 - - - - - -
LP 0.021 (0.060) 6.2 - - - - - -
Scenario 2. Balanced pleiotropy, InSIDE satisfied
IVW - - 0.020 (0.088) 6.4 0.020 (0.132) 7.1 0.024 (0.180) 7.3
R - - 0.021 (0.068) 7.8 0.020 (0.096) 6.8 0.023 (0.195) 5.9
P - - 0.018 (0.062) 7.1 0.015 (0.066) 9.7 0.008 (0.075) 19.7
R and P - - 0.019 (0.070) 6.8 0.017 (0.092) 6.3 0.010 (0.156) 7.7
LP - - 0.020 (0.063) 7.1 0.020 (0.070) 9.2 0.019 (0.088) 16.9
Scenario 3. Directional pleiotropy, InSIDE satisfied
IVW - - 0.086 (0.088) 9.3 0.216 (0.123) 36.2 0.409 (0.150) 92.5
R - - 0.032 (0.067) 8.8 0.088 (0.109) 11.2 0.357 (0.222) 44.9
P - - 0.025 (0.062) 7.0 0.046 (0.067) 13.6 0.132 (0.081) 40.4
R and P - - 0.025 (0.070) 7.5 0.040 (0.088) 10.8 0.103 (0.125) 21.5
LP - - 0.027 (0.063) 7.2 0.049 (0.071) 12.6 0.173 (0.096) 42.8
Scenario 4. Directional pleiotropy, InSIDE violated
IVW - - 0.096 (0.068) 27.5 0.202 (0.072) 86.6 0.303 (0.067) 100.0
R - - 0.053 (0.081) 10.1 0.163 (0.119) 38.4 0.302 (0.072) 98.4
P - - 0.040 (0.061) 14.2 0.095 (0.062) 41.4 0.237 (0.061) 89.6
R and P - - 0.038 (0.069) 11.4 0.089 (0.079) 30.7 0.236 (0.071) 83.9
LP - - 0.048 (0.062) 17.2 0.138 (0.066) 58.8 0.300 (0.064) 99.1
Abbreviations: IV, instrumental variable; SE, standard error; Pow., power; InSIDE, instrument strength
independent of direct effect; IVW, inverse variance weighted; R, robust regression; P, penalized weights; LP,
lasso penalization.
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Table F. Mean (standard error) and power (%) of the estimates from the IVW model with: 1) the J genetic
variants (IVW); 2) robust regression (R); 3) penalized weights (P); and 4) robust regression and penalized
weights (R and P) for Scenarios 1-4 with a positive causal effect (θ = 0.3) by the number of invalid
instrumental variables for one-sample Mendelian randomization. Results from the Lasso penalization (LP)
method with the heterogeneity stopping rule are also provided.
No invalid IVs 1 invalid IV 3 invalid IVs 6 invalid IVs
Mean Pow., Mean Pow., Mean Pow., Mean Pow.,
(mean SE) % (mean SE) % (mean SE) % (mean SE) %
Positive causal effect: θ = 0.3
Scenario 1. No pleiotropy, InSIDE satisfied
IVW 0.321 (0.068) 99.7 - - - - - -
R 0.321 (0.073) 97.7 - - - - - -
P 0.321 (0.068) 99.7 - - - - - -
R and P 0.321 (0.072) 97.9 - - - - - -
LP 0.321 (0.068) 99.7 - - - - - -
Scenario 2. Balanced pleiotropy, InSIDE satisfied
IVW - - 0.322 (0.090) 91.2 0.322 (0.133) 66.2 0.323 (0.180) 43.9
R - - 0.322 (0.073) 97.2 0.321 (0.098) 86.1 0.323 (0.193) 43.6
P - - 0.320 (0.070) 99.1 0.316 (0.076) 96.4 0.308 (0.087) 85.4
R and P - - 0.321 (0.078) 96.3 0.317 (0.096) 88.4 0.310 (0.138) 67.3
LP - - 0.322 (0.071) 99.2 0.320 (0.079) 95.6 0.320 (0.099) 81.4
Scenario 3. Directional pleiotropy, InSIDE satisfied
IVW - - 0.386 (0.088) 99.7 0.517 (0.124) 100.0 0.710 (0.150) 100.0
R - - 0.332 (0.073) 97.9 0.390 (0.111) 93.3 0.655 (0.226) 86.8
P - - 0.330 (0.070) 99.7 0.362 (0.076) 99.5 0.465 (0.093) 99.5
R and P - - 0.328 (0.078) 96.0 0.351 (0.093) 92.6 0.434 (0.125) 89.1
LP - - 0.331 (0.071) 99.6 0.363 (0.079) 99.4 0.508 (0.108) 99.2
Scenario 4. Directional pleiotropy, InSIDE violated
IVW - - 0.396 (0.070) 100.0 0.502 (0.073) 100.0 0.601 (0.067) 100.0
R - - 0.352 (0.088) 95.5 0.463 (0.125) 89.7 0.601 (0.073) 99.7
P - - 0.349 (0.068) 99.7 0.424 (0.068) 99.7 0.561 (0.064) 99.9
R and P - - 0.343 (0.078) 97.0 0.414 (0.090) 95.7 0.562 (0.071) 98.8
LP - - 0.357 (0.068) 99.7 0.463 (0.070) 99.8 0.600 (0.066) 100.0
Abbreviations: IV, instrumental variable; SE, standard error; Pow., power; InSIDE, instrument strength
independent of direct effect; IVW, inverse variance weighted; R, robust regression; P, penalized weights; LP,
lasso penalization.
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Mean values for the R2, F -statistic and I2 statistic for 100 genetic
variants
Table G contains the mean R2 (%), F-statistic and I2 (%) when the simulation study
was re-performed for 100 genetic variants for Scenarios 2-4.
Table G. Mean values of the R2 (%), F-statistic and I2 (%) for Scenarios 2-4 with a null (θ = 0) or positive
(θ = 0.3) causal effect by the number of invalid instrumental variables (IV) when the simulation study was
re-perfomed for 100 genetic variants.
5 invalid IV 15 invalid IVs 30 invalid IVs
R2 F I2 R2 F I2 R2 F I2
Null causal effect: θ = 0
Scenario 2 4.0 4.2 3.0 4.0 4.2 3.3 4.0 4.2 2.9
Scenario 3 4.0 4.2 3.1 4.0 4.2 3.0 4.0 4.2 3.0
Scenario 4 5.2 5.4 32.9 7.3 7.8 58.3 10.3 11.4 69.5
Positive causal effect: θ = 0.3
Scenario 2 4.0 4.2 3.2 4.0 4.2 3.1 4.1 4.2 3.1
Scenario 3 4.0 4.2 3.3 4.1 4.2 3.1 4.0 4.2 2.9
Scenario 4 5.2 5.4 33.3 7.3 7.8 58.2 10.3 11.4 69.4
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Methods have been developed for Mendelian randomization that can obtain
consistent causal estimates while relaxing the instrumental variable assump-
tions. These includemultivariableMendelian randomization, inwhich a genetic
variant may be associated with multiple risk factors so long as any association
with the outcome is via themeasured risk factors (measured pleiotropy), and the
MR-Egger (Mendelian randomization-Egger) method, in which a genetic vari-
antmay be directly associatedwith the outcomenot via the risk factor of interest,
so long as the direct effects of the variants on the outcome are uncorrelated with
their associations with the risk factor (unmeasured pleiotropy). In this paper,
we extend the MR-Egger method to a multivariable setting to correct for both
measured and unmeasured pleiotropy. We show, through theoretical arguments
and a simulation study, that the multivariable MR-Egger method has advan-
tages over its univariable counterpart in terms of plausibility of the assumption
needed for consistent causal estimation and power to detect a causal effect when
this assumption is satisfied. Themethods are compared in an applied analysis to
investigate the causal effect of high-density lipoprotein cholesterol on coronary
heart disease risk. The multivariable MR-Egger method will be useful to anal-
yse high-dimensional data in situations where the risk factors are highly related
and it is difficult to find genetic variants specifically associated with the risk fac-
tor of interest (multivariable by design), and as a sensitivity analysis when the
genetic variants are known to have pleiotropic effects on measured risk factors.
KEYWORDS
invalid instruments, Mendelian randomization, MR-Egger, multivariable, pleiotropy
1 INTRODUCTION
Mendelian randomization (MR) uses genetic variants as instrumental variables to estimate the causal effect of a risk
factor on an outcome using observational data.1,2 Increases in the scale of genome-wide association studies have led
to large numbers of genetic variants that are associated with candidate risk factors being discovered.3 If the variants
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explain additional variability in the risk factor then using multiple variants in a MR analysis will increase power to detect
a causal effect.4,5 A pleiotropic genetic variant is associated with multiple risk factors; such a variant is not a valid instru-
mental variable and its inclusion in an (univariable) MR analysis may result in biased causal estimates and inappropriate
inferences.6 As more variants are used in an MR analysis, the chance of including a pleiotropic variant increases.
For some sets of risk factors, including lipid fractions, several risk factors have common genetic predictors. Although
such genetic variants are pleiotropic, they can be used to estimate causal effects in a multivariable MR framework.7 In
multivariable MR, the instrumental variable assumptions are extended to allow a genetic variant to be associated with
multiple risk factors, provided all associated risk factors are included in the analysis. Alternatively, when genetic variants
are suspected to violate the instrumental variable assumptions through unknown pleiotropic pathways, methods have
been developed to estimate consistent causal effects under weaker assumptions. These include the weighted median and
MR-Egger methods.8,9 The extension of MR-Egger to a multivariable setting has been implemented by Helgadottir et al
as part of a sensitivity analysis in their applied work investigating the effect of lipid fractions on coronary heart disease
(CHD) risk.10 However, there remains several methodological issues relating to the implementation of the method, and
the assumptions required.
In this paper, we expand univariableMR-Egger to themultivariable setting. In Section 2, we introduce the conventional
and MR-Egger methods in both univariable and multivariable contexts. We provide an example analysis using published
data on lipid fractions andCHD risk (Section 3), and compare results from the differentMRmethods in a simulation study
(Section 4). Finally (Section 5), we discuss the results of the paper and the implications for applied practice. Software code
for implementing all of the methods used in this paper is provided in the Web Appendix.
2 METHODS
Initially, we consider the causal effect of a risk factor X on an outcome Y using genetic variants Gj (j = 1, … , J)
that are assumed to be uncorrelated (not in linkage disequilibrium). Then, we expand to consider multiple risk factors
X1,X2, … ,XK. Increasingly, MR investigations are implemented using summarized data from consortia to leverage their
large sample sizes, thereby improving the precision of causal estimates.11 We therefore assume that summarized data are
available on the associations of each genetic variant with the risk factor (or with each risk factor for the multivariable
setting) and with the outcome: the beta-coefficients (𝛽Xj , 𝛽Yj) and their standard errors (se(𝛽Xj ), se(𝛽Yj)) from univariable
regression on each variantGj in turn. We additionally assume that the associations of genetic variants with the risk factor
and the outcome, and the causal effect of the risk factor on the outcome, are linear and homogeneous across the popu-
lation; these assumptions are discussed in detail elsewhere.12 To distinguish between the parameters from the different
methods considered, we use the following subscript notation: UI (“univariable inverse variance weighted (IVW)”); UE
(“univariable MR-Egger”); MI (“multivariable IVW”); and ME (“multivariable MR-Egger”).
2.1 Univariable Mendelian randomization
In a univariable MR analysis, each genetic variant must satisfy the following criteria to be a valid instrumental variable
(IV):
• IV1: The variant is associated with the risk factor X,
• IV2: The variant is independent of all confounders U of the risk factor-outcome association, and
• IV3: The variant is independent of the outcome Y conditional on the risk factor X and confounders U.13
These assumptions imply that the genetic variant should not have an effect on the outcome except via the risk factor.
Under linearity assumptions, the association between the genetic variant and the outcome can be decomposed into an
indirect effect via the risk factor and a direct effect:
𝛽Yj = 𝛼j + 𝜃𝛽Xj , (1)
where 𝜃 is the causal effect of the risk factor on the outcome. Genetic variant j is pleiotropic if 𝛼j ≠ 0, and 𝛼j is the direct
effect of the genetic variant on the outcome. Figure 1 contains a direct effect 𝛼j via an independent pathway, which violates
the IV3 assumption.
With a single genetic variant, G1 say, the causal estimate is 𝛽Y1∕𝛽X1 .14 This is a consistent estimate of the causal effect
𝜃 when 𝛼1 = 0. With multiple genetic variants, the inverse-variance weighted (IVW) estimate is the weighted average of
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FIGURE 1 Causal directed acyclic graph illustrating univariable Mendelian randomization assumptions with potential violation of IV3 by
a pleiotropic effect indicated by a dotted line. The genetic effect of Gj on X is 𝛽Xj , the direct (pleiotropic) effect of Gj on Y via an independent
pathway is 𝛼j (representing the potential violation of the IV3 assumption), and the causal effect of the risk factor X on the outcome Y is 𝜃. U
represents the set of variables that confound the association between X and Y
these causal estimates,15 using the inverse of their approximate variances se(𝛽Yj )2∕𝛽2Xj as weights:
?̂?UI =
∑
j 𝛽Yj𝛽Xjse(𝛽Yj )−2∑
j 𝛽
2
Xj
se(𝛽Yj )−2
. (2)
This estimate can also be obtained from individual-level data using the 2-stage least squares method.16 Alternatively,
the causal effect of the risk factor on the outcome can be estimated using a weighted linear regression of the genetic
association estimates,17 with the intercept set to zero:
𝛽Yj = 𝜃UI𝛽Xj + 𝜖UIj , weights = se(𝛽Yj)
−2. (3)
The above weighted regression model, where the residual standard error is set to one, is equivalent to performing a
fixed-effect meta-analysis of the variant-specific causal estimates.18 Under a multiplicative random effects model, the
residual standard error can be greater than one, allowing for heterogeneity in the causal estimates. The point estimate from
the fixed and random effect models will be the same, but the standard error of the causal effect from the multiplicative
random effects model will be larger if there is heterogeneity between the causal estimates. Throughout this paper, we
apply a multiplicative random effects model to all the analyses.
The MR-Egger estimate is obtained using the same regression model as Equation 2, but allowing the intercept to be
estimated9:
𝛽Yj = 𝜃0UE + 𝜃UE𝛽Xj + 𝜖UEj , weights = se(𝛽Yj)
−2. (4)
If the genetic variants are not pleiotropic, then the intercept term should tend to zero as the sample size increases, and
the MR-Egger estimate (?̂?UE) and the IVW estimate (?̂?UI) are both consistent estimates of the causal effect. Additionally,
if the genetic variants are pleiotropic but the direct effects 𝜶 (bold symbols represent vectors across the j genetic variants)
are independent of the associations of the variants with the risk factor 𝜷X (known as the InSIDE assumption—Instrument
Strength Independent of Direct Effect), then the MR-Egger estimate will be a consistent estimate of 𝜃.9,19
Under the InSIDE assumption, the intercept term ?̂?0UE can be interpreted as an estimate of the average direct effect of
the genetic variants.8 If the average direct effect is zero (referred to as “balanced pleiotropy”), and the InSIDE assumption
is satisfied, the intercept term should tend to zero as the sample size increases, and the MR-Egger estimate (?̂?UE) and the
IVW estimate (?̂?UI) are both consistent estimates of the causal effect. If the intercept term differs from zero, then either
the InSIDE assumption is violated or the average direct effect differs from zero (referred to as “directional pleiotropy”);
this is a test of the validity of the instrumental variable assumptions (the MR-Egger intercept test).
2.2 Multivariable Mendelian randomization
In a multivariable MR analysis, each genetic variant must satisfy the following criteria:
• IV1(M): The variant is associated with at least one of the risk factors Xk,
• IV2(M): The variant is independent of all confounders U of each of the risk factor-outcome associations, and
• IV3(M): The variant is independent of the outcome Y conditional on the risk factors Xk and confounders U.7
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FIGURE 2 Causal directed acyclic graph illustrating multivariable Mendelian randomization assumptions for a set of genetic variants Gj,
3 risk factors X1, X2, and X3, and outcome Y. The genetic effect of Gj on Xk is 𝛽Xkj , the direct (pleiotropic) effect of Gj on Y is 𝛼
′
j , and the causal
effect of the risk factor Xk on the outcome Y is 𝜃k. Uk represents the set of variables that confound the associations between Xk and Y
Now, the association of the genetic variants with the outcome can be decomposed into indirect effects via each of the
risk factors and a residual direct effect 𝛼′j . Assuming there are 3 risk factors and all relationships are linear:
𝛽Yj = 𝛼
′
j + 𝜃1𝛽X1j + 𝜃2𝛽X2j + 𝜃3𝛽X3j , (5)
where 𝜃k is the causal effect of the risk factor k on the outcome (Figure 2). We assume that the risk factors do not have
causal effects on each other; we later relax this assumption and allow for causal effects between the risk factors.
As in the univariable setting, causal estimates of the effect of each risk factor on the outcome can be obtained from
individual-level data using the 2-stage least squares method.7 The same estimates can also be obtained using multivari-
able weighted linear regression of the genetic association estimates, with the intercept set to zero (referred to as the
multivariable IVWmethod)20:
𝛽Yj = 𝜃1MI𝛽X1j + 𝜃2MI𝛽X2j + 𝜃3MI𝛽X3j + 𝜖MIj , weights = se(𝛽Yj )
−2. (6)
We propose the natural extension to multivariable MR-Egger using the same regression model but allowing the intercept
to be estimated:
𝛽Yj = 𝜃0ME + 𝜃1ME𝛽X1j + 𝜃2ME𝛽X2j + 𝜃3ME𝛽X3j + 𝜖MEj , weights = se(𝛽Yj)
−2. (7)
2.3 Assumptions for multivariable MR-Egger
We assume that the causal effect of risk factor 1 (𝜃1) is of interest and provide the assumptions necessary for theMR-Egger
estimate of 𝜃1 to be consistent. If all of the causal effects are to be interpreted, then these assumptions must apply for each
risk factor.
If the 𝜷X𝟏 parameters are independent of the 𝜷Xk parameters for all k = 2, 3, … ,K, then the InSIDE assumption for
multivariable MR-Egger is satisfied if the direct effects of the genetic variants 𝜶′ are independent of 𝜷X𝟏 . More formally,
we require:
𝜷X𝟏 ⟂𝜶
′, if 𝜷X𝟏 ⟂ 𝜷X𝟐 , … , 𝜷XK , (8)
for the estimate of 𝜃1 from multivariable MR-Egger to be consistent. If the InSIDE assumption is satisfied, then the
weighted covariance of 𝜷X𝟏 and 𝜶
′ (covw(𝜶′,𝜷X𝟏)) will tend to zero as the number of genetic variants J tends to infinity.
The estimate of 𝜃1 frommultivariableMR-Egger when the 𝜷X𝟏 parameters are independent of 𝜷Xk for all k = 2, 3, … ,K is
?̂?1ME =
covw(?̂?Y , ?̂?X𝟏)
varw(?̂?X𝟏 )
N→∞
−−→
covw(𝜷Y , 𝜷X𝟏 )
varw(𝜷X𝟏)
= 𝜃1 +
covw(𝜶′,𝜷X𝟏)
varw(𝜷X𝟏)
, (9)
which is equal to 𝜃1 if the InSIDE assumption is satisfied, where covw and varw represent the weighted covariance and
weighted variance using the inverse-variance weights se(𝛽Yj)−2:
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covw(𝜶′,𝜷X𝟏) =
∑
j (𝛼′j − 𝛼′w)(𝛽X1j − 𝛽X1w)se(𝛽Yj)
−2∑
j se(𝛽Yj)−2
varw(𝜷X𝟏) =
∑
j (𝛽X1j − 𝛽X1w)2se(𝛽Yj)−2∑
j se(𝛽Yj)−2
𝛼′w =
∑
j 𝛼
′
j se(𝛽Yj)
−2∑
j se(𝛽Yj)−2
𝛽X1w =
∑
j 𝛽X1jse(𝛽Yj)−2∑
j se(𝛽Yj)−2
.
(10)
If the 𝜷X𝟏 parameters are correlated with at least one of the sets of 𝜷Xk parameters (k = 2, 3, … ,K), then the InSIDE
assumption is required to hold for 𝜷X𝟏 and for all of the 𝜷Xk parameters that are correlated with 𝜷X𝟏 . More formally, we
require:
𝜷Xk ⟂ 𝜶
′, for all 𝜷Xk correlated with 𝜷X𝟏(including 𝜷X𝟏 itself). (11)
For example, if k = 2, and 𝜷X𝟏 is correlated with 𝜷X𝟐 , we require both of the weighted covariances of 𝜶
′ with 𝜷X𝟏 and
𝜷X𝟐 to be zero to produce a consistent estimate of 𝜃1. The estimate of 𝜃1 from multivariable MR-Egger with 2 risk factors
where 𝜷X𝟏 and 𝜷X𝟐 are correlated is
?̂?1ME =
covw(?̂?Y , ?̂?X𝟏)varw(?̂?X𝟐 ) − covw(?̂?Y , ?̂?X𝟐)covw(?̂?X𝟏 , ?̂?X𝟐)
varw(?̂?X𝟏)varw(?̂?X𝟐) − covw(?̂?X𝟏 , ?̂?X𝟐)2
N→∞
−−→
covw(𝜷Y , 𝜷X𝟏 )varw(𝜷X𝟐) − covw(𝜷Y ,𝜷X𝟐)covw(𝜷X𝟏 , 𝜷X𝟐 )
varw(𝜷X𝟏)varw(𝜷X𝟐 ) − covw(𝜷X𝟏 ,𝜷X𝟐)2
= 𝜃1 +
covw(𝜶′, 𝜷X𝟏)varw(𝜷X𝟐) − covw(𝜶
′, 𝜷X𝟐)covw(𝜷X𝟏 ,𝜷X𝟐)
varw(𝜷X𝟏 )varw(𝜷X𝟐) − covw(𝜷X𝟏 , 𝜷X𝟐 )2
,
(12)
which is equal to 𝜃1 if the InSIDE assumption holds with respect to 𝜷X𝟏 and 𝜷X𝟐 . As more risk factors with correlated sets
of association parameters with 𝜷X𝟏 are included in the multivariable MR-Egger model, additional terms will be added to
the bias term in Equation 12, and the InSIDE assumptionmust hold for these additional risk factors to obtain a consistent
estimate of 𝜃1.
The variance of the multivariable MR-Egger estimate ?̂?1ME will be heavily influenced by the denominator in the bias
term of Equation 12. As 𝜷X𝟏 and 𝜷X𝟐 become more highly correlated, the standard error of the causal estimate ?̂?1ME will
increase, and in some circumstances, the estimate frommultivariableMR-Eggerwill be less precise than the estimate from
univariable MR-Egger. The precision of the causal estimates from multivariable MR-Egger and univariable MR-Egger is
discussed further in the Web Appendix.
2.4 Advantages of multivariable MR-Egger and comparison with univariable MR-Egger
The bias for the causal estimate from univariable MR-Egger ?̂?UE depends on the weighted covariance between 𝜶 and
𝜷X𝟏 , where
𝛼j = 𝛼′j +
K∑
i=2
𝜃i𝛽Xij . (13)
The expression in Equation 13 follows from the multivariable framework outlined in Equation 5, where the direct
effect for univariable MR-Egger has been decomposed into the residual direct effect 𝛼′j of multivariable MR-Egger and the
indirect effects via each risk factor. The residual direct effect 𝛼′j will be altered with each additional risk factor included in
themultivariableMR-Eggermodel. If these additional risk factors are causally associated with the outcome (𝜃k ≠ 0), then
𝛼′j will consist of fewer components. It seems likely that the InSIDE assumptionwould be easier to satisfy formultivariable
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MR-Egger than its univariable counterpart as the direct effect for univariable MR-Egger consists of unmeasured and
measured pleiotropy.
If the 𝜷X𝟏 parameters are independent of the 𝜷Xk parameters for all k = 2, 3, … ,K, then the second term in Equation 13
(the measured direct effect) does not contribute to the value of covw (𝜶, 𝜷X𝟏). Under this scenario, bias for the univari-
able and multivariable MR-Egger estimates depends on the same covariance term covw(𝜶′,𝜷X𝟏). As a consequence, the
estimates of the causal effects from univariable MR-Egger ?̂?UE and multivariable MR-Egger ?̂?1ME will be asymptotically
the same. In this case, multivariable MR-Egger may improve precision of the causal estimate but will not affect the
asymptotic bias.
When the 𝜷X𝟏 parameters are correlated with at least one of the sets of 𝜷Xk parameters for k = 2, 3, … ,K, the second
term in Equation 13 now contributes to the value of covw (𝜶,𝜷X𝟏). The InSIDE assumption for univariable MR-Egger will
therefore be automatically violated as the weighted covariance between 𝜶 and 𝜷X𝟏 will not equal zero, resulting in biased
causal estimates of 𝜃1. If the InSIDE assumption holds for multivariable MR-Egger, and 𝜷Xk are included in the analysis
model, then ?̂?1ME will still be a consistent estimate of 𝜃1. Hence, in this case, multivariable MR-Egger should result in
reduced bias compared with univariable MR-Egger.
2.5 Orientation of the genetic variants
Genetic associations represent the average change in the risk factor or the outcome per additional copy of the reference
allele. There is no biological rationale why associations should be expressed with respect to either the major (wildtype) or
the minor (variant) allele. In the univariable andmultivariable IVWmethods, the estimate is not affected by the choice of
orientation, as the intercept is fixed at zero. However, in the univariable and multivariable MR-Egger methods, changing
the orientation of the variant affects the intercept term and the causal estimate as the orientation affects the definition
of the pleiotropy terms 𝛼j and 𝛼′j . Consequently, for each choice of orientation, there is a different version of the InSIDE
assumption.
To ensure that the MR-Egger analysis does not depend on the reported reference alleles, Bowden et al suggested the
genetic variants in univariableMR-Egger be orientated so the direction of association with the risk factor is either positive
for all variants or negative for all variants.9 However, this may not be possible for multivariable MR-Egger as the same
reference allele must be used for associations with each risk factor and with the outcome. We suggest that the variants
should be orientated with respect to their associations with the risk factor of primary interest, although we would recom-
mend a sensitivity analysis considering different orientations if multiple risk factors are of interest. If the genetic variants
are all valid instruments, then directional pleiotropy should not be detected with respect to any orientation.
3 EXAMPLE: CAUSAL EFFECT OF HDL-C ON CHD RISK
The effects of high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglyc-
erides on the risk of coronary heart disease (CHD) have been investigated by numerous MR studies.21 For HDL-C,
univariable MR suggested a causally protective role against CHD risk, whereas univariable MR-Egger provided no evi-
dence of a causal effect and the test for directional pleiotropy was statistically significant at the 5% level.8 A null causal
effect for HDL-C was also reported from a multivariable MR analysis that included LDL-C and triglycerides using the
multivariable IVW method,7 although a small but protective causal effect was estimated in a further multivariable MR
analysis using a wider range of 185 genetic variants.22
We investigate the causal effect of HDL-C on CHD risk further using the multivariable MR-Egger method. We con-
sider the 185 genetic variants having known association with at least one of HDL-C, LDL-C, and triglycerides at GWAS
significance in 188 578 participants reported by the Global Lipids Genetics Consortium.23 The point estimates for the asso-
ciations between these genetic variants and lipids were taken from Do et al.24 The CARDIoGRAMplusC4D consortium
consisting of 60 801 cases and 123 504 controlswas used to obtain the estimates of the association between the variants and
CHD risk.25 The IVW and MR-Egger methods were applied to the data under univariable and multivariable frameworks
as described in Section 2. For the univariable IVW andMR-Egger methods, the models were fitted using 2 sets of variants:
firstly using all 185 variants; and secondly using all variants associated with HDL-C at GWAS level of significance. The
genetic variants were orientated with respect to the risk increasing allele for HDL-C. These analyses differ from those
provided in Burgess et al and Do et al as they use summarized data from different versions of the CARDIoGRAMplusC4D
study22,24; here, we use associations from the 2015 data release.25
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TABLE 1 Log causal odds ratios (95% confidence intervals) for coronary heart disease per standard deviation increase in
HDL-C, with 2-sided P-values. Estimates of the intercept are given in univariable and multivariable MR-Egger
Causal Estimate MR-Egger Intercept Test
?̂?HDL-C (CI) se(?̂?HDL-C) P-value ?̂?0E se(?̂?0E) P-value
Univariable IVW
All variants −0.130 (−0.227, −0.033) 0.049 0.009 - - -
Reduced set of variantsa −0.114 (−0.211, −0.017) 0.049 0.022 - - -
Univariable MR-Egger
All variants −0.016 (−0.138, 0.106) 0.062 0.800 −0.007 0.002 0.004
Reduced set of variantsa 0.067 (−0.070, 0.204) 0.069 0.332 −0.012 0.004 0.001
Multivariable IVW −0.039 (−0.123, 0.045) 0.042 0.359 - - -
Multivariable MR-Egger 0.036 (−0.063, 0.134) 0.050 0.477 −0.005 0.002 0.008
Abbreviations: CI, confidence interval;HDL-C, high-density lipoprotein cholesterol; IVW, inverse-varianceweighted;MR,Mendelian randomization;
SE, standard error.
a95 variants associated with HDL-C at a genome-wide level of significance (P-value< 5 × 10−8).
TABLE 2 Causal log odds ratios (95% confidence intervals) for coronary heart disease per standard deviation increase in
HDL-C, LDL-C, and triglycerides from multivariable IVW and multivariable MR-Egger. Estimates from multivariable MR-Egger
are presented from 3 models where the reference allele is the risk increasing allele for HDL-C, LDL-C, or triglycerides. Estimates
of the intercept are given for multivariable MR-Egger
Causal Estimates MR-Egger Intercept
?̂?HDL-C ?̂?LDL-C ?̂?TG ?̂?0E
Multivariable IVW −0.039 (−0.123, 0.045) 0.375 (0.292, 0.457) 0.173 (0.063, 0.283) -
Multivariable MR-Egger
Orientation with respect toa:
HDL-C 0.036 (−0.063, 0.134) 0.378 (0.297, 0.458) 0.136 (0.024, 0.247) −0.005 (−0.009, −0.001)
LDL-C −0.034 (−0.118, 0.049) 0.420 (0.318, 0.522) 0.194 (0.081, 0.308) −0.003 (−0.007, 0.001)
TG −0.018 (−0.102, 0.066) 0.350 (0.267, 0.433) 0.083 (−0.045, 0.211) 0.005 (0.001, 0.009)
Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MR, Mendelian randomization; TG,
triglycerides.
aAlleles orientated for all genetic associations with respect to the risk increasing allele for HDL-C, LDL-C, or triglycerides.
The univariable IVW method suggested a significant protective effect of HDL-C for both sets of variants with a causal
odds ratio of 0.88 (95% CI: 0.80-0.97) for all variants (Table 1). This estimate attenuated to the null in the univariable
MR-Egger method (0.98, 95% CI: 0.87-1.11) with evidence of directional pleiotropy (P-value = 0.004). The causal odds
ratios frommultivariable IVW (0.96, 95%CI: 0.89-1.05) andmultivariableMR-Egger (1.04, 95%CI: 0.94-1.14) had opposite
directions of association, with both analyses indicating that HDL-C is not causally associated with CHD risk. The signifi-
cant result for directional pleiotropy in the multivariable MR-Egger method suggests that LDL-C and triglycerides do not
fully explain the direct effects of the genetic variants on the outcome, suggesting that there is still residual pleiotropy via
other unmeasured risk factors.
3.1 Varying the orientation of the genetic variants
As a sensitivity analysis, the multivariable MR-Egger method was reperformed with the genetic variants orientated with
respect to the risk increasing alleles for LDL-C and triglycerides.
The causal estimates for HDL-C, LDL-C, and triglycerides from multivariable MR-Egger when the variants were ori-
entated with respect to HDL-C, LDL-C or triglycerides are presented in Table 2. Estimates of the MR-Egger intercept are
also provided for the three models. To allow for comparisons between the multivariable methods, the causal estimates
from multivariable IVW are included in Table 2. The causal estimates in bold follow the recommendation outlined in
Section 2.5 that the genetic variants should be orientated with respect to the risk factor-increasing allele for the risk factor
of interest.
All of the causal odds ratios for HDL-C from the multivariable MR-Egger models indicated that HDL-C is not causally
associated with CHD risk. Significant adverse effects of LDL-C on CHD risk were reported from the multivariable IVW
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(1.45, 95% CI: 1.34-1.58) and multivariable MR-Egger (1.52, 95% CI: 1.37-1.69) methods. Orientating the variants with
respect to the risk increasing alleles for HDL-C and triglycerides had little impact on the causal estimates for LDL-C from
multivariable MR-Egger. The multivariable IVW method suggested a significant adverse effect of triglycerides on CHD
risk with a causal odds ratio of 1.19 (95% CI: 1.07, 1.33), this estimate was attenuated to the null in the multivariable
MR-Egger method (1.09, 95% CI: 0.96, 1.23). The causal odds ratios for triglycerides remained significant, however, when
the variants were orientated with respect to HDL-C and LDL-C in the multivariable MR-Egger models.
Since the orientation of the genetic variants affects the interpretation of the direct effect, and the definition of the InSIDE
assumption, the MR-Egger intercept will vary between different orientations. In this example, the MR-Egger intercept
differed from zerowhen the variantswere orientatedwith respect toHDL-C and triglycerides, yet therewas no evidence of
directional pleiotropy or the InSIDE assumption being violated when the variants were orientated with respect to LDL-C.
4 SIMULATION STUDY
To assess the merits of using multivariable MR-Egger over multivariable IVW and univariable MR-Egger in realistic set-
tings, we perform a simulation study. Univariable and multivariable MR-Egger will be compared with respect to the
consistency of the causal estimates and statistical power to detect the causal effect. The setup of the simulation study
corresponds to the applied example in Section 3 and will be considered under 2 broad scenarios: (1) 𝜷Xk are generated
independently for all k = 1, 2, … ,K; and (2) 𝜷Xk are correlated for all k = 1, 2, … ,K.
We simulated summarized level data for 185 genetic variants indexed by j = 1, 2, … , J for 3 risk factors (X1, X2, X3) and
an outcome Y from the following data-generating model:
⎛⎜⎜⎝
𝛽X1j
𝛽X2j
𝛽X3j
⎞⎟⎟⎠ ∼3
(( 0.08
0.03
−0.05
)
,
( 𝜎12 𝜌12𝜎1𝜎2 𝜌13𝜎1𝜎3
𝜌12𝜎1𝜎2 𝜎22 𝜌23𝜎2𝜎3
𝜌13𝜎1𝜎3 𝜌23𝜎2𝜎3 𝜎32
))
𝛽Yj = 𝛼′j + 𝜃1|𝛽X1j | + 𝜃2𝛽X2j + 𝜃3𝛽X3j + 𝜖j
𝜖j ∼ (0, 1)
𝛼′j ∼ (𝜇, 0.004).
(14)
The primary objective was to estimate 𝜃1, with the causal effects set to: 𝜃1 = 0 (null causal effect) or 𝜃1 = 0.3 (positive
causal effect); 𝜃2 = 0.1; and 𝜃3 = −0.3. The data were simulated to consider the following four scenarios:
1. No pleiotropy (𝛼′j = 0 for all j), InSIDE assumption automatically satisfied;
2. Balanced pleiotropy (𝜇 = 0), InSIDE assumption satisfied;
3. Directional pleiotropy (𝜇 = 0.01, 0.05 or 0.1), InSIDE assumption satisfied;
4. Directional pleiotropy (𝜇 = 0.01, 0.05 or 0.1), InSIDE assumption violated.
When the InSIDE assumption for multivariable MR-Egger was satisfied, 𝛼′j and 𝛽X1j were drawn from independent
distributions, and when it was violated, they were drawn from amultivariate normal distribution with cor(𝜶′,𝜷X𝟏) = 0.3.
The above 4 scenarios were applied to the simulated data when 𝜷Xk were generated independently for all k, with the
parameters in the covariance matrix set to: 𝜎21 = 0.03; 𝜎22 = 0.02; 𝜎
2
3 = 0.04; and 𝜌12 = 𝜌13 = 𝜌23 = 0. The 4 scenarios were
repeated when 𝜷Xk were correlated for all k (𝜌12 = 0.2, 𝜌13 = −0.3, 𝜌23 = 0.1). The mean F-statistics were greater than
200 and I2 statistics greater than 99% in each scenario; values are provided in Web Tables A1 and A2. In total, data were
simulated for 32 different choices of parameters.
To ensure the direction of association between Gj and X1 was the same for all j variants, the absolute value of the
genetic associations with X1 (|𝛽X1j |) were used to generate 𝛽Yj (Equation (14)). It was assumed that 𝛽Xkj (for all k) and 𝛽Yj
had the same reference allele and the genetic variants were uncorrelated. The multivariable IVW, univariable MR-Egger,
and multivariable MR-Egger methods were applied to the simulated datasets. The weights for the multivariable IVW and
multivariable MR-Egger are given by Equation 15, while Equation 16 contains the weights for univariable MR-Egger:
se(𝛽Yj )
−2 = (𝜖j2 + 𝜎𝛼′2)−1, (15)
se(𝛽Yj )
−2 = (𝜖j2 + 𝜎𝛼′2 + 𝜃22𝜎22 + 𝜃32𝜎32)−1. (16)
REES ET AL. 4713
4.1 Results
The results from the simulation study using 10 000 simulated datasets are presented in Table 3 (𝜷Xk generated indepen-
dently) and Table 4 (𝜷Xk correlated). For each scenario, the mean estimate, the mean standard error, and the statistical
power to detect a null or positive causal effect at a nominal 5% significance level are presented in Tables 3 and 4 for
the multivariable IVW, univariable MR-Egger, and multivariable MR-Egger methods. For univariable and multivariable
MR-Egger, the statistical power of the MR-Egger intercept test is also provided.
𝜷Xk generated independently∶ In scenarios 1 and 2 (no and balanced pleiotropy), estimates from all methods were
unbiased, and those from the multivariable IVW method were the most precise. In scenarios 3 and 4 (directional
pleiotropy), estimates from the multivariable IVW method were biased, with the magnitude of bias increasing as the
average value of𝜶′ increased from 0.01 to 0.1. In scenario 3 (InSIDE satisfied), estimates from the univariable andmul-
tivariable MR-Egger methods were unbiased, whereas in scenario 4 (InSIDE violated), they were biased. Although the
causal estimates for bothmultivariable IVWandmultivariableMR-Egger were biased under scenario 4, themagnitude
of bias was less for multivariable MR-Egger, with the exception of when 𝛼′j was generated from (0.01, 0.004). Preci-
sion and power to detect a causal effect were always better for the multivariable MR-Egger method than univariable
TABLE 3 Performance of multivariable IVW, univariable MR-Egger, and multivariable MR-Egger with respect to ?̂?1 for a null
(𝜃1 = 0) and positive (𝜃1 = 0.3) causal effect where 𝜷Xkare generated independently for all k. All tests were performed at the 5%
level of significance
Multivariable IVW Univariable MR-Egger Multivariable MR-Egger
Mean ?̂?1 Power, Mean ?̂?1 Power, % Mean ?̂?1 Power, %
(mean SE) % (mean SE) Intercept Causal (mean SE) Intercept Causal
Null causal effect: 𝜽1 = 0
1. No pleiotropy, InSIDE satisfied
0.000 (0.045) 3.8 −0.002 (0.158) 9.1 4.7 0.000 (0.084) 3.7 4.1
2. Balanced pleiotropy, InSIDE satisfied
𝛼′j ∼ (0,0.004) -0.001 (0.100) 4.7 −0.001 (0.187) 7.8 4.7 0.000 (0.165) 4.6 4.6
3. Directional pleiotropy, InSIDE satisfied
𝛼′j ∼ (0.01,0.004) 0.041 (0.100) 6.7 −0.003 (0.187) 12.2 4.3 −0.002 (0.165) 5.9 4.5
𝛼′j ∼ (0.05,0.004) 0.210 (0.100) 55.3 0.002 (0.187) 49.2 4.6 0.002 (0.166) 36.3 4.6
𝛼′j ∼ (0.1,0.004) 0.417 (0.102) 97.4 0.000 (0.187) 91.6 4.3 0.001 (0.165) 88.0 4.6
4. Directional pleiotropy, InSIDE violated
𝛼′j ∼ (0.01,0.004) 0.074 (0.100) 12.3 0.089 (0.187) 6.7 7.6 0.088 (0.165) 4.3 8.4
𝛼′j ∼ (0.05,0.004) 0.240 (0.100) 67.2 0.089 (0.187) 34.1 7.8 0.088 (0.165) 21.1 8.8
𝛼′j ∼ (0.1,0.004) 0.450 (0.101) 98.6 0.088 (0.187) 84.1 7.6 0.088 (0.165) 78.7 8.7
Positive causal effect: 𝜽1 = 0.3
1. No pleiotropy, InSIDE satisfied
0.300 (0.044) 98.9 0.300 (0.157) 9.3 50.1 0.300 (0.084) 4.3 87.3
2. Balanced pleiotropy, InSIDE satisfied
𝛼′j ∼ (0,0.004) 0.301 (0.100) 84.6 0.303 (0.187) 7.5 38.2 0.302 (0.166) 4.9 46.4
3. Directional pleiotropy, InSIDE satisfied
𝛼′j ∼ (0.01,0.004) 0.343 (0.100) 91.5 0.300 (0.187) 12.8 36.8 0.299 (0.165) 6.0 45.8
𝛼′j ∼ (0.05,0.004) 0.509 (0.100) 99.7 0.300 (0.188) 50.6 37.3 0.299 (0.166) 37.1 46.1
𝛼′j ∼ (0.1,0.004) 0.716 (0.102) 100.0 0.300 (0.187) 91.1 37.1 0.299 (0.166) 87.9 46.1
4. Directional pleiotropy, InSIDE violated
𝛼′j ∼ (0.01,0.004) 0.374 (0.099) 94.3 0.390 (0.187) 6.6 56.4 0.389 (0.165) 4.6 65.8
𝛼′j ∼ (0.05,0.004) 0.539 (0.100) 99.8 0.388 (0.187) 34.4 55.6 0.387 (0.165) 21.5 65.5
𝛼′j ∼ (0.1,0.004) 0.747 (0.101) 100.0 0.383 (0.187) 84.7 55.1 0.384 (0.165) 78.3 65.2
Abbreviations: InSIDE, Instrument Strength Independent of Direct Effect; IVW, inverse-variance weighted; MR, Mendelian randomization; SE,
standard error.
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TABLE 4 Performance of multivariable IVW, univariable MR-Egger, and multivariable MR-Egger with 𝜷Xkbeing correlated
for all k
Multivariable IVW Univariable MR-Egger Multivariable MR-Egger
Mean ?̂?1 Power, Mean ?̂?1 Power, % Mean ?̂?1 Power, %
(mean SE) % (mean SE) Intercept Causal (mean SE) Intercept Causal
Null causal effect: 𝜽1 = 0
1. No pleiotropy, InSIDE satisfied
0.000 (0.047) 4.0 0.099 (0.157) 4.3 10.1 0.000 (0.086) 4.4 4.6
2. Balanced pleiotropy, InSIDE satisfied
𝛼′j ∼ (0,0.004) −0.001 (0.104) 4.7 0.093 (0.187) 4.5 7.4 −0.003 (0.169) 4.6 4.4
3. Directional pleiotropy, InSIDE satisfied
𝛼′j ∼ (0.01,0.004) 0.043 (0.104) 7.0 0.099 (0.187) 5.8 8.0 0.001 (0.169) 5.9 4.8
𝛼′j ∼ (0.05,0.004) 0.213 (0.105) 52.7 0.095 (0.187) 33.3 7.6 0.000 (0.169) 37.2 4.5
𝛼′j ∼ (0.1,0.004) 0.426 (0.107) 96.3 0.096 (0.187) 84.5 7.6 −0.001 (0.169) 89.2 4.6
4. Directional pleiotropy, InSIDE violated
𝛼′j ∼ (0.01,0.004) 0.062 (0.104) 9.5 0.184 (0.187) 4.6 17.9 0.078 (0.169) 4.7 7.6
𝛼′j ∼ (0.05,0.004) 0.235 (0.104) 62.1 0.187 (0.187) 20.5 18.3 0.082 (0.169) 22.3 7.5
𝛼′j ∼ (0.1,0.004) 0.448 (0.106) 97.9 0.181 (0.187) 73.3 17.8 0.077 (0.169) 80.3 7.2
Positive causal effect: 𝜽1 = 0.3
1. No pleiotropy, InSIDE satisfied
0.300 (0.047) 98.7 0.395 (0.158) 4.4 70.8 0.299 (0.087) 3.9 86.2
2. Balanced pleiotropy, InSIDE satisfied
𝛼′j ∼ (0,0.004) 0.300 (0.104) 81.5 0.399 (0.187) 4.4 58.0 0.301 (0.169) 4.6 44.4
3. Directional pleiotropy, InSIDE satisfied
𝛼′j ∼ (0.01,0.004) 0.342 (0.104) 89.4 0.395 (0.187) 6.4 57.4 0.301 (0.169) 5.9 44.4
𝛼′j ∼ (0.05,0.004) 0.513 (0.105) 99.4 0.394 (0.187) 33.0 57.4 0.296 (0.169) 38.0 43.4
𝛼′j ∼ (0.1,0.004) 0.729 (0.107) 100.0 0.400 (0.187) 83.5 58.2 0.304 (0.169) 88.6 45.5
4. Directional pleiotropy, InSIDE violated
𝛼′j ∼ (0.01,0.004) 0.365 (0.104) 92.1 0.489 (0.187) 4.2 74.0 0.382 (0.169) 4.6 63.2
𝛼′j ∼ (0.05,0.004) 0.535 (0.104) 99.7 0.486 (0.187) 20.3 72.9 0.382 (0.169) 21.1 63.2
𝛼′j ∼ (0.1,0.004) 0.749 (0.106) 100.0 0.488 (0.187) 72.5 73.4 0.381 (0.169) 79.6 62.8
Abbreviations: InSIDE, Instrument Strength Independent of Direct Effect; IVW, inverse-variance weighted; MR, Mendelian randomization; SE,
standard error.
MR-Egger, although the univariable MR-Egger method detected directional pleiotropy more often. The average value
of 𝜶′ had no impact on the degree of bias for univariable or multivariable MR-Egger.
𝜷Xkcorrelated∶ Bias for the multivariable IVWmethod was present in scenarios 3 and 4 only, as in the independently
generated setting. In this setting, the InSIDE assumption for univariable MR-Egger was violated for all 4 scenarios,
resulting in biased point estimates of 𝜃1. However, the multivariable InSIDE assumption was satisfied for scenarios
1, 2, and 3, and so causal estimates from multivariable MR-Egger were unbiased. When the multivariable InSIDE
assumption was violated (scenario 4) the estimates from multivariable MR-Egger were biased, yet the magnitude of
bias was less compared with univariable MR-Egger as |cov(𝜶′,𝜷X𝟏)| < |cov(𝜶,𝜷X𝟏)|.
4.2 Causal relationships between the risk factors
The simulations performed in Section 4.1 assumed that the effect of each risk factor on the outcome is not mediated
through another risk factor. There may be circumstances where causal relationships between risk factors are biologically
plausible. Burgess et al illustrated that the multivariable IVWmethod estimates the direct causal effects (𝜃k) of each risk
factor on the outcome, irrespective of whether causal relationships between the risk factors exist.7
REES ET AL. 4715
FIGURE 3 Causal directed acyclic graph illustrating the causal relationships between the 2 risk factors X1 and X2, and outcome Y . The
causal effect of X1 on X2 is 𝛾 , and the direct causal effect of the risk factor Xk on the outcome Y is 𝜃k. The total causal effect of X1 on Y is
𝜃1 + 𝛾𝜃2, consisting of the direct effect (𝜃1) and the indirect effect via X2 (𝛾𝜃2). Uk represents the set of variables that confound the
associations between Xk and Y
In the applied example of the paper, there may also be deterministic dependencies between the risk factors. LDL-C
is rarely measured directly but is estimated from measurements of total cholesterol, triglycerides, and HDL-C via the
Friedewald equation as total cholesterol minus HDL-C minus 0.2 times triglycerides (assuming all measurements in
mg/dL).26 It has previously been shown that the coefficient for LDL-C is the same as the coefficient for non-HDL-C
(calculated as total cholesterol minus HDL-C) in a regression model including HDL-C and triglycerides (see Appendix 2
in the paper by Di Angelantonio et al).27 However, the coefficient for triglycerides will change, as the non-HDL-Cmeasure
containsmore triglycerides than the LDL-Cmeasure.Hence, in the case that there are deterministic relationships between
the risk factors, effect estimates may change as the choice of risk factors varies due to their interpretation as direct effects
conditional on other risk factors in the regression model.
We performed additional simulations to investigate the behaviour of the multivariable MR-Egger method when X2 is
causally dependent on X1, and the causal effect of X1 on X2 is 𝛾 (Figure 3). The total causal effect of X1 on Y is 𝜃1 + 𝛾𝜃2,
consisting of the direct effect (𝜃1) and the indirect effect via X2 (𝛾𝜃2). See the Web Appendix for more details on the data
generating model.
4.2.1 Results
The results from the additional simulations are provided in Web Table A3 and Web Table A4. In scenarios where there
was no bias in the original set of simulations, the multivariable IVW and multivariable MR-Egger methods consistently
estimated the direct effect of X1 on Y (𝜃1), while the univariable MR-Egger method consistently estimated the total causal
effect of X1 on Y (𝜃1 + 𝛾𝜃2). Compared to the results in Section 4.1, precision and power to detect a causal effect were
reduced for the multivariable IVW and multivariable MR-Egger methods. This reduction in power was anticipated since
the multivariable models condition on the mediator along a causal pathway, which is known to decrease power to detect
a causal effect.28
5 DISCUSSION
In this paper, we have extended univariable MR-Egger to the multivariable setting and outlined the assumptions required
to obtain consistent causal estimates in the presence of directional pleiotropy. Multivariable MR-Egger should be viewed
as a sensitivity analysis to provide robustness against both measured and unmeasured pleiotropy and to strengthen the
evidence from the original MR analysis. If the causal estimate from multivariable MR-Egger is substantially different
from the estimate obtained in the original analysis, then further investigation into the causal finding and the potential for
pleiotropy is required.
The simulation study has highlighted the benefits of using multivariable MR-Egger over its univariable counterpart.
This is particularly true when the associations of the genetic variants with the risk factor of interest are associated
with genetic associations with at least one of the risk factors (measured pleiotropy). Under this scenario, the InSIDE
assumption for univariable MR-Egger is likely to be violated, leading to biased causal estimates. Multivariable MR-Egger
will, however, produce consistent causal estimates if the InSIDE assumption for multivariable MR-Egger is satisfied.
Although the estimates from univariable and multivariable MR-Egger are asymptotically the same when genetic asso-
ciations with each risk factor are all independent, multivariable MR-Egger should also have greater power to detect a
causal effect when the InSIDE assumption is satisfied. Given these advantages, and the sensitivity of the multivariable
IVW method to directional pleiotropy, we believe that multivariable MR-Egger should be considered as an important
sensitivity analysis for a MR study.
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5.1 Multivariable by design, or multivariable as a sensitivity analysis?
There are 2 possible scenarios where multivariable MR-Egger may be used as a sensitivity analysis: either the primary
analysis is considered to be multivariable by design, or a multivariable framework is only considered as part of the sen-
sitivity analysis. The first case should be motivated by biological evidence where the set of risk factors are known to be
associated with common genetic variants, such as lipid fractions. Under this scenario, multivariable IVW should be used
as the primary analysis method with multivariable MR-Egger providing robustness against directional pleiotropy as a
sensitivity analysis.
In the second scenario, where there is a lack of biological evidence to suggest a multivariable framework, univariable
IVW would generally be considered as the primary analysis method and univariable MR-Egger as the main sensitivity
analysis. However, if the genetic variants are associated with other risk factors, multivariable MR-Egger could also be
used as a sensitivity analysis as its assumptions are more likely to be satisfied and it may have greater power to detect a
causal effect than univariable MR-Egger. An example of the use of multivariable MR as a sensitivity analysis is an MR
study on plasma urate concentrations and CHD risk.29 To account for measured and unmeasured pleiotropic associations
of the genetic variants, the authors performed the multivariable IVW and univariable MR-Egger methods as sensitivity
analyses. This investigation may have benefited from performing the multivariable MR-Egger method to simultaneously
account for both measured and unmeasured pleiotropic associations.
5.2 InSIDE assumption and orientation of genetic variants
The validity of multivariable MR-Egger and its ability to estimate consistent causal effects is dependent upon the InSIDE
assumption being satisfied. While it is not possible to determine whether the InSIDE assumption has been violated, we
believe it is more likely to hold for multivariable MR-Egger then univariable MR-Egger. When the 𝜷X1 parameters are
associated with at least one of the sets of 𝜷Xk parameters for k = 2, 3, … ,K, the InSIDE assumption for univariable
MR-Egger is automatically violated and causal estimates from the method will be inconsistent. The direct effects of the
genetic variants on the outcomewill consist of fewer components for multivariableMR-Egger compared to its univariable
counterpart, making it more plausible that the InSIDE assumption will hold for multivariable MR-Egger.
The recommendation of orientating the genetic variants in multivariable MR-Egger to the risk factor-increasing or risk
factor-decreasing allele for the risk factor of interest may be considered arbitrary. While we accept this limitation, we
would argue that it brings consistency to the results. This recommendation may result in the analysis being performed
up to K times to obtain the causal estimates for all K risk factors. The orientation of the genetic variants will also affect
the interpretation of the direct effect, thereby altering the InSIDE assumption. This may result in the MR-Egger intercept
estimate varying between different orientations. This was seen in the applied example where the intercept term was
non-significant when the alleles were orientated with respect to LDL-C, and significant when orientated with respect to
HDL-C and trigclyercides.
5.3 Linearity and homogeneity assumptions
Throughout this paper,wehave assumed linearity andhomogeneity (no effectmodification) of the causal effects of the risk
factors on the outcome, and of the associations between the genetic variants with the risk factors and with the outcome.
If the assumptions of linearity and homogeneity are violated then the methods discussed in this paper still provide a
valid test for the null hypothesis of whether the risk factor is causally associated with the outcome.12 The causal estimate,
however, would not have a literal interpretation if the assumptions were violated.30 Although linearity and homogeneity
are strong assumptions, the effect of genetic variants on the risk factor and outcome tend to be limited to a small range,
which may make the assumptions of linearity and homogeneity more reasonable in an MR analysis.
The multivariable models have assumed that the risk factors do not have causal effects on each other. The additional
simulation study has illustrated that the multivariable MR-Egger method estimates the direct causal effects of the risk
factors on the outcome, irrespective of whether the risk factors are causally related. There was, however, a reduction in
precision and power to detect the causal effect for multivariable MR-Egger when a causal relationship between the risk
factors was present. Conversely, univariable MR-Egger will produce consistent causal estimates of the total effect if the
InSIDE assumption for univariable MR-Egger is satisfied.
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5.4 Implication for future research
The paper by Helgadottir et al highlights the importance and need to develop sensitivity analyses for multivariable MR.10
This is particularly relevant given the recent advances in high-throughput phenotyping which has led to the introduction
of “-omics” data such asmetabolomics, genomics, and proteomics.31 Genome-wide analyses of high-dimensional “-omics”
data are becoming more popular,32,33 yet few MR analyses have been performed using these datasets.21 As summarized
data from large consortia become more accessible, the opportunities to use MR on high-dimensional datasets will only
increase. Methods such as multivariable MR-Egger will be valuable to investigate the causal effects of multiple related
phenotypes with shared genetic predictors.
Bowden et al have shown that uncertainty in the associations between the genetic variants and the risk factor in uni-
variable MR-Egger can lead to attenuation towards the null when a causal effect exists between the risk factor and the
outcome.34 This attenuation is approximately equal to the I2 statistic frommeta-analysis of the weighted associations with
the exposure 𝛽Xjse(𝛽Yj)−1, with standard errors se(𝛽Xj )se(𝛽Yj )−1.34 Since the mean I2 statistics for the simulation study in
this paper were close to 100%, there was no substantial bias in the causal estimates due to uncertainty in the genetic asso-
ciations for either the univariable or multivariable MR-Egger methods. However, it is unclear whether uncertainty in the
genetic associations with the risk factors would always lead to the attenuation of the causal estimates for themultivariable
MR-Egger method. Further research is required to investigate this.
Throughout the paper, we have assumed that the genetic variants are uncorrelated (not in linkage disequilibrium). This
assumption, and the requirement for further methodological development, is discussed in the Web Appendix.
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Web Appendix
A1 Sample software code
We provide sample code written in R to perform the analyses described in this pa-
per. The associations of the genetic variants with the risk factors are denoted bXk
with standard error bXk se, where k = 1, ..., K. The associations of the genetic
variants with the outcome are denoted bY with standard error bYse. The code for
the multivariable models will be based on three risk factors and can be easily adapted
to include the appropriate number of risk factors. It will be assumed that the causal
effect of risk factor 1 on the outcome is of primary interest and all the genetic variants
are uncorrelated.
Inverse-variance weighted estimate:
The inverse-variance weighted (IVW) estimate using summary statistics (equation 2)
can be calculated by:
thetaUI = sum(bY*bX1*bYse^-2)/sum(bX1^2*bYse^-2)
se_thetaUI = 1/sqrt(sum(bX1^2*bYse^-2))
The same IVW estimate using summary statistics can be obtained using weighted
linear regression (equation 3):
thetaUI = summary(lm(bY~bX1-1, weights=bYse^-2))$coef[1]
se_thetaUI.fixed = summary(lm(bY~bX1-1, weights=bYse^-2))$coef[1,2]/
summary(lm(bY~bX1-1, weights=bYse^-2))$sigma
se_thetaUI.random = summary(lm(bY~bX1-1, weights=bYse^-2))$coef[1,2]/
min(summary(lm(bY~bX1-1, weights=bYse^-2))$sigma,1)
In the fixed-effect model we divide the standard error of the causal estimate by
the estimated residual standard error to force the residual standard error to be 1.
For the multiplicative random-effect model the standard error is divided by the esti-
mated residual standard error when the variability in the genetic associations is less
than expected by chance (underdispersion). When there is evidence of heterogeneity
between the causal estimates (overdispersion) the standard error is unaltered. The
multiplicative random-effects model will result in a larger standard error compared
to the fixed-effect model if there is heterogeneity between the causal estimates. The
causal estimate obtained from the fixed- and multiplicative random-effects models will
be the same.
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Univariable MR-Egger:
The univariable MR-Egger method is the same as the IVW method using weighted
linear regression except the intercept term is estimated rather than being set to zero.
Testing whether the intercept term is equal to zero is equivalent to testing for direc-
tional pleiotropy and the validity of the InSIDE assumption. The genetic associations
with the risk factor bX1 and outcome bY must be orientated with respect to the risk
increasing or decreasing allele of the risk factor. Under the MR-Egger model, mul-
tiplicative random-effects should be used as the presence of pleiotropy will lead to
overdispersion. Since the residual standard error is estimated, we use the t-distribution
with J − 2 degrees of freedom for inference.
#Orientation of the genetic associations
bY<-ifelse(bX1>0, bY, bY*-1)
bX1<-abs(bX1)
#Causal estimate
thetaUE = summary(lm(bY~bX1, weights=bYse^-2))$coef[2]
se_thetaUE.random = summary(lm(bY~bX1, weights=bYse^-2))$coef[2,2]/
min(summary(lm(bY~bX1, weights=bYse^-2))$sigma,1)
lb_thetaUE = thetaUE - qt(0.975,df=length(bX1)-2)*se_thetaUE.random
ub_thetaUE = thetaUE + qt(0.975,df=length(bX1)-2)*se_thetaUE.random
p_thetaUE = 2*(1-pt(abs(thetaUE/se_thetaUE.random),df=length(bX1)-2))
#Test for directional pleiotropy
interUE = summary(lm(bY~bX1, weights=bYse^-2))$coef[1]
se_interUE.random = summary(lm(bY~bX1, weights=bYse^-2))$coef[1,2]/
min(summary(lm(bY~bX1, weights=bYse^-2))$sigma,1)
p_interUE = 2*(1-pt(abs(interUE/se_interUE.random),df=length(bX1)-2))
Multivariable IVW:
The multivariable IVW method expands the IVW method using weighted linear re-
gression by estimating the causal effects of the additional risk factors on the outcome.
We will include additional two risk factors and assume the causal estimate of interest is
the effect of risk factor 1 on the outcome. Either fixed- or multiplicative random-effects
can be used to estimate the standard error of the causal effect.
theta1MI = summary(lm(bY~bX1+bX2+bX3-1, weights=bYse^-2))$coef[1]
se_theta1MI.fixed = summary(lm(bY~bX1+bX2+bX3-1, weights=bYse^-2))$coef[1,2]/
summary(lm(bY~bX1+bX2+bX3-1, weights=bYse^-2))$sigma
se_theta1MI.random = summary(lm(bY~bX1+bX2+bX3-1, weights=bYse^-2))$coef[1,2]/
min(summary(lm(bY~bX1+bX2+bX3-1, weights=bYse^-2))$sigma,1)
Multivariable MR-Egger:
The multivariable MR-Egger method is equivalent to the multivariable IVW method
using weighted linear regression except the intercept is estimated rather than being
set to zero. Testing whether the intercept term is equal to zero is equivalent to testing
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for directional pleiotropy and the validity of the InSIDE assumption. As with uni-
variable MR-Egger, the standard errors should be calculated from the multiplicative
random-effects model. The genetic associations should be orientated with respect to
the risk increasing or decreasing allele of the risk factor of interest. In this sample
code we will assume the causal effect of risk factor 1 is of primary interest. Since the
residual standard error is estimated for the multivariable MR-Egger model we use the
t-distribution with J − (K + 1) degrees of freedom for inference.
#Orientation of the genetic associations with respect to X1
clist<-c("bX2","bX3","bY")
for (var in clist){
eval(parse(text=paste0(var,"<-ifelse(bX1>0,",var,",",var,"*-1)")))
}
bX1<-abs(bX1)
#Causal estimate for X1
theta1ME = summary(lm(bY~bX1+bX2+bX3, weights=bYse^-2))$coef[2]
se_theta1ME.random = summary(lm(bY~bX1+bX2+bX3, weights=bYse^-2))$coef[2,2]/
min(summary(lm(bY~bX1+bX2+bX3, weights=bYse^-2))$sigma,1)
lb_theta1ME = theta1ME - qt(0.975,df=length(bX1)-4)*se_theta1ME.random
ub_theta1ME = theta1ME + qt(0.975,df=length(bX1)-4)*se_theta1ME.random
p_theta1ME = 2*(1-pt(abs(theta1ME/se_theta1ME.random),df=length(bX1)-4))
#Test for directional pleiotropy
interME = summary(lm(bY~bX1+bX2+bX3, weights=bYse^-2))$coef[1]
se_interME.random = summary(lm(bY~bX1+bX2+bX3, weights=bYse^-2))$coef[1,2]/
min(summary(lm(bY~bX1+bX2+bX3, weights=bYse^-2))$sigma,1)
p_interME = 2*(1-pt(abs(interME/se_interME.random),df=length(bX1)-4))
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A2 Comparison between the precision of the causal
estimates from univariable and multivariable
MR-Egger
In this section, we compare the precision of the causal estimates from the univariable
(θˆ1UE) and multivariable (θˆ1ME) MR-Egger models. For the multivariable model, we
consider the genetic associations βXk with two risk factors (k = 2), where the variance
of the multivariable MR-Egger estimate θˆ1ME is given by:
var(θˆ1ME) =
φ2 var(βX2)
N(var(βX1) var(βX2)− cov(βX1 ,βX2)2)
∝ [var(βX1)(1− cor(βX1 ,βX2)2)]−1 (1)
Under a fixed-effect model, the variance of the univariable MR-Egger estimate is
proportional to the inverse of var(βX1).
1 The estimate from the multivariable MR-
Egger model θˆ1ME will be more precise than its univariable counterpart θˆ1UE if:
1
var(βX1)
>
1
var(βX1)(1− cor(βX1 ,βX2)2)
(2)
From the above inequality, θˆ1UE will always be more precise than θˆ1ME when βX1 and
βX2 are correlated. Under a multiplicative random-effects model (used throughout this
paper), the variance of the residual error is estimated under the univariable MR-Egger
model (φ2UE) and the multivariable MR-Egger model (φ
2
ME). For θˆ1ME to be more
precise than θˆ1UE, we require:
φ2UE
var(βX1)
>
φ2ME
var(βX1)(1− cor(βX1 ,βX2)2)
(3)
If βX2 explains additional independent variability in the genetic associations with the
outcome βY , and βX1 and βX2 are independent, then the estimate from multivariable
MR-Egger will be more precise than the estimate from univariable MR-Egger. If βX1
and βX2 are correlated, then the precision of θˆ1ME will depend upon the strength
of the correlation between βX1 and βX2 , and the amount of additional independent
variability βX2 explains in βY . As the correlation between βX1 and βX2 increases,
and βX2 explains no additional independent variability in βY , the precision of the
multivariable MR-Egger estimate θˆ1ME will decrease.
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A3 Summary statistics from the simulation study
The IVW and MR-Egger methods do not account for uncertainty in the genetic asso-
ciations with the risk factor, referred to by Bowden et al as NO Measurement Error
(NOME).1 If there is substantial uncertainty in these association estimates and in a
two-sample setting, the causal effect estimate from univariable MR-Egger may be bi-
ased towards the null. Bowden et al have shown that the relative attenuation in the
MR-Egger estimate is approximately equal to the I2 statistic from the meta-analysis
of the weighted associations with the exposure βˆXj se(βˆY j)
−1, with standard errors
se(βˆXj) se(βˆY j)
−1.1 The I2 statistic lies between 0 and 1, with smaller values corre-
sponding to more biased MR-Egger estimates. If the I2 statistic is close to 1, then
there should be little or no attenuation of the causal estimate from the univariable MR-
Egger method. Bowden et al recommend that methods to account for this uncertainty
be considered if the I2 statistic is less than 90%.1
The F-statistic is often reported in Mendelian randomization studies as a mea-
surement of the strength of the instrumental variables, with larger values represent-
ing stronger instruments. For a two-sample Mendelian randomization analysis with
summarized data, the F-statistic for each genetic variant j can be approximated by
Fj = βˆ
2
Xj
/ se(βˆXj)
2. We use this approximation below.
The data-generating model used in the simulation study did not provide the stan-
dard errors of the genetic associations with the three risk factors se(βˆXk), as they
were not required for the methods considered. To estimate the mean values of the
F-statistics and I2 statistics, we must make assumptions about the values of these
standard errors. We assume that the genetic associations with the risk factors are
provided on the standard deviation scale. If the associations were estimated from a
sample size of 10 000, this results in a standard error of 0.01. Assuming that the stan-
dard errors of the genetic associations with the three risk factors are 0.01 across the
185 genetic variants, we obtain the mean F-statistics and I2 statistics displayed in Ta-
ble A1 and Table A2. The I2 statistics (reported as a %) are close to 100% across the
different scenarios. These results are consistent with the simulation study where the
causal estimates from the univariable and multivariable MR-Egger methods showed no
attenuation towards the null.
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Table A1: Mean F-statistic and I2 statistic (reported as a %) for a null (θ1 = 0) and positive (θ1 = 0.3)
causal effect where βXk are generated independently for all k.
βˆX1j βˆX2j βˆX3j
F-statistic I2 statistic F-statistic I2 statistic F-statistic I2 statistic
Null causal effect: θ1 = 0
1. No pleiotropy, InSIDE satisfied
363.3 99.5 208.8 99.2 425.7 99.6
2. Balanced pleiotropy, InSIDE satisfied
α′j ∼ N (0,0.004) 364.3 99.5 209.1 99.2 425.6 99.6
3. Directional pleiotropy, InSIDE satisfied
α′j ∼ N (0.01,0.004) 364.4 99.5 208.9 99.2 425.6 99.6
α′j ∼ N (0.05,0.004) 363.5 99.5 209.6 99.2 424.9 99.6
α′j ∼ N (0.1,0.004) 364.0 99.5 209.2 99.2 425.5 99.6
4. Directional pleiotropy, InSIDE violated
α′j ∼ N (0.01,0.004) 364.1 99.5 208.8 99.2 425.4 99.6
α′j ∼ N (0.05,0.004) 364.4 99.5 208.7 99.2 425.4 99.6
α′j ∼ N (0.1,0.004) 363.8 99.5 209.1 99.2 425.1 99.6
Positive causal effect: θ1 = 0.3
1. No pleiotropy, InSIDE satisfied
363.9 99.5 209.2 99.2 424.7 99.6
2. Balanced pleiotropy, InSIDE satisfied
α′j ∼ N (0,0.004) 363.7 99.5 209.1 99.2 425.0 99.6
3. Directional pleiotropy, InSIDE satisfied
α′j ∼ N (0.01,0.004) 364.1 99.5 209.0 99.2 425.2 99.6
α′j ∼ N (0.05,0.004) 364.3 99.5 208.6 99.2 425.5 99.6
α′j ∼ N (0.1,0.004) 363.8 99.5 209.1 99.2 424.7 99.6
4. Directional pleiotropy, InSIDE violated
α′j ∼ N (0.01,0.004) 363.6 99.5 209.1 99.2 424.8 99.6
α′j ∼ N (0.05,0.004) 364.6 99.5 208.9 99.2 424.8 99.6
α′j ∼ N (0.1,0.004) 364.0 99.5 208.9 99.2 425.9 99.6
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Table A2: Mean F-statistic and I2 statistic (reported as a %) for a null (θ1 = 0) and positive (θ1 = 0.3)
causal effect with βXk being correlated for all k.
βˆX1j βˆX2j βˆX3j
F-statistic I2 statistic F-statistic I2 statistic F-statistic I2 statistic
Null causal effect: θ1 = 0
1. No pleiotropy, InSIDE satisfied
364.1 99.5 208.5 99.2 424.5 99.6
2. Balanced pleiotropy, InSIDE satisfied
α′j ∼ N (0,0.004) 363.8 99.5 209.4 99.2 424.4 99.6
3. Directional pleiotropy, InSIDE satisfied
α′j ∼ N (0.01,0.004) 363.5 99.5 208.8 99.2 424.6 99.6
α′j ∼ N (0.05,0.004) 364.3 99.5 209.0 99.2 425.1 99.6
α′j ∼ N (0.1,0.004) 364.3 99.5 208.9 99.2 424.7 99.6
4. Directional pleiotropy, InSIDE violated
α′j ∼ N (0.01,0.004) 364.0 99.5 208.9 99.2 425.0 99.6
α′j ∼ N (0.05,0.004) 364.0 99.5 209.4 99.2 425.2 99.6
α′j ∼ N (0.1,0.004) 364.3 99.5 209.1 99.2 425.2 99.6
Positive causal effect: θ1 = 0.3
1. No pleiotropy, InSIDE satisfied
364.0 99.5 208.9 99.2 425.2 99.6
2. Balanced pleiotropy, InSIDE satisfied
α′j ∼ N (0,0.004) 364.0 99.5 208.8 99.2 425.1 99.6
3. Directional pleiotropy, InSIDE satisfied
α′j ∼ N (0.01,0.004) 363.5 99.5 209.1 99.2 425.5 99.6
α′j ∼ N (0.05,0.004) 363.9 99.5 209.1 99.2 424.6 99.6
α′j ∼ N (0.1,0.004) 364.0 99.5 209.1 99.2 425.8 99.6
4. Directional pleiotropy, InSIDE violated
α′j ∼ N (0.01,0.004) 364.1 99.5 208.8 99.2 425.3 99.6
α′j ∼ N (0.05,0.004) 364.7 99.5 208.8 99.2 425.4 99.6
α′j ∼ N (0.1,0.004) 363.7 99.5 208.9 99.2 424.5 99.6
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A4 Details and results from the simulation study
investigating causal relationships between risk
factors
To investigate the behaviour of the multivariable MR-Egger method when causal rela-
tionships between risk factors exist, additional simulations were performed where X2
was causally dependent on X1. We assume that X2 is causally dependent on X1, and
the causal effect of X1 on X2 is γ. The total causal effect of X1 on Y is θ1 + γθ2;
consisting of the direct effect (θ1) and the indirect effect via X2 (γθ2). The simulations
outlined in Section 4 were repeated with the second line in the data generating model
replaced with:
βYj = α
′
j + θ1|βX1j |+ θ2(βX2j + γ|βX1j |) + θ3βX3j + j (4)
The causal effect of X1 on X2 (γ) was set to 0.5. All other parameters were taken as
in the original simulation study. |βX1j |, (βX2j + γ|βX1j |), and βX3j were the covariates
included in the multivariable IVW and multivariable MR-Egger models. Note that the
functional relationship between X1 and X2 induces a correlation structure between the
covariates |βX1j | and (βX2j + γ|βX1j |) included in the multivariable models, even when
βX1 and βX2 are generated independently. To account for the additional uncertainty in
βYj , the weights for univariable MR-Egger are given by equation 5, while the weights
for multivariable IVW and multivariable MR-Egger were the same as the original
simulation study (equation 15).
se(βYj)
−2 = (j2 + σα′2 + θ2
2σ2
2 + (θ2γ)
2σ1
2 + 2θ2γρ12σ1σ2 + θ3
2σ3
2)
−1
(5)
Results
The results from the simulations that included a causal relationship between X1 and
X2, using 10 000 simulated datasets, are presented in Web Table A3 (βXk generated
independently, with the functional relationship between X1 and X2 inducing a correla-
tion structure between |βX1j | and (βX2j +γ|βX1j |)) and Web Table A4 (βXk correlated).
βXk generated independently, with a correlation structure between the
covariates |βX1j | and (βX2j + γ|βX1j |): In scenarios where there was no bias in the
original set of simulations, the multivariable IVW and multivariable MR-Egger meth-
ods consistently estimated the direct effect of X1 on Y (θ1), whilst the univariable
MR-Egger method consistently estimated the total causal effect of X1 on Y (θ1 +γθ2).
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Bias for the multivariable IVW method was present in scenarios 3 and 4 only, as in
the original simulation study (Tables 3 and 4). Compared to the results in Table 3,
precision and power to detect a causal effect were reduced for the multivariable IVW
and multivariable MR-Egger methods. This reduction in power may be due to the
correlation structure between |βX1j | and (βX2j +γ|βX1j |), and the multivariable models
conditioning on a mediator. Univariable and multivariable MR-Egger methods pro-
duced biased estimates of the total and direct causal effects in scenario 4 (InSIDE
violated) only. Unlike the original simulation study, precision and power to detect a
causal effect were always better for the univariable MR-Egger method.
βXk correlated: The multivariable IVW and multivariable MR-Egger methods
estimated the direct effect of X1 on Y , as in the independently generated setting. As
with the original simulations (Tables 3 and 4), the InSIDE assumption for univariable
MR-Egger was violated for all four scenarios, resulting in biased point estimates. How-
ever, as with the original simulation study, the multivariable InSIDE assumption was
satisfied for scenarios 1,2 and 3, and so causal estimates from multivariable MR-Egger
were unbiased. There was a more noticeable reduction in the precision and power to
detect a causal effect for the multivariable IVW and multivariable MR-Egger methods
under the correlated setting.
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Table A3: Performance of multivariable IVW, univariable MR-Egger and multivariable MR-Egger
with respect to θˆ1 for a null (θ1 = 0) and positive (θ1 = 0.3) causal effect where βXk are generated
independently for all k (with a correlation structure between the covariates |βX1j | and (βX2j+γ|βX1j |)),
with a causal effect of X1 on X2 (γ = 0.5). All tests were performed at the 5% level of significance.
Multivariable IVW Univariable MR-Egger Multivariable MR-Egger
Mean θˆ1 Power, Mean θˆ1 Power, % Mean θˆ1 Power, %
(mean SE) % (mean SE) Intercept Causal (mean SE) Intercept Causal
Null causal effect: θ1 = 0
1. No pleiotropy, InSIDE satisfied
0.000 (0.057) 3.5 0.051 (0.158) 8.9 5.8 0.001 (0.090) 4.5 4.2
2. Balanced pleiotropy, InSIDE satisfied
α′j ∼ N (0,0.004) 0.001 (0.127) 4.4 0.049 (0.187) 7.6 5.6 0.001 (0.178) 4.6 4.2
3. Directional pleiotropy, InSIDE satisfied
α′j ∼ N (0.01,0.004) 0.041 (0.127) 6.0 0.049 (0.187) 12.3 5.4 0.000 (0.178) 5.8 4.8
α′j ∼ N (0.05,0.004) 0.195 (0.128) 34.4 0.048 (0.187) 50.1 5.3 -0.001 (0.178) 36.6 4.6
α′j ∼ N (0.1,0.004) 0.393 (0.130) 82.3 0.052 (0.187) 91.4 5.6 0.002 (0.178) 88.4 4.7
4. Directional pleiotropy, InSIDE violated
α′j ∼ N (0.01,0.004) 0.076 (0.127) 9.8 0.138 (0.187) 6.4 11.6 0.088 (0.178) 4.3 7.6
α′j ∼ N (0.05,0.004) 0.231 (0.127) 45.2 0.137 (0.187) 34.4 11.9 0.088 (0.178) 21.7 8.2
α′j ∼ N (0.1,0.004) 0.426 (0.129) 88.3 0.141 (0.187) 83.7 11.9 0.089 (0.178) 78.2 8.1
Positive causal effect: θ1 = 0.3
1. No pleiotropy, InSIDE satisfied
0.301 (0.057) 96.3 0.353 (0.158) 9.3 62.3 0.301 (0.090) 3.9 84.6
2. Balanced pleiotropy, InSIDE satisfied
α′j ∼ N (0,0.004) 0.298 (0.127) 65.4 0.350 (0.187) 7.4 47.8 0.298 (0.178) 4.4 41.2
3. Directional pleiotropy, InSIDE satisfied
α′j ∼ N (0.01,0.004) 0.338 (0.127) 75.5 0.352 (0.187) 11.8 48.3 0.300 (0.178) 6.1 41.1
α′j ∼ N (0.05,0.004) 0.494 (0.128) 95.2 0.348 (0.188) 49.2 46.9 0.298 (0.179) 36.8 40.3
α′j ∼ N (0.1,0.004) 0.689 (0.130) 99.6 0.347 (0.188) 91.5 47.1 0.296 (0.178) 88.2 39.6
4. Directional pleiotropy, InSIDE violated
α′j ∼ N (0.01,0.004) 0.375 (0.127) 82.6 0.440 (0.187) 6.6 65.7 0.390 (0.178) 4.7 60.1
α′j ∼ N (0.05,0.004) 0.530 (0.128) 97.0 0.438 (0.187) 34.7 65.5 0.386 (0.178) 21.7 59.9
α′j ∼ N (0.1,0.004) 0.728 (0.129) 99.7 0.441 (0.187) 83.6 65.8 0.390 (0.178) 78.5 60.1
Abbreviations: MR, Mendelian randomization; SE, standard error; IVW, inverse-variance weighted;
InSIDE, Instrument Strength Independent of Direct Effect.
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Table A4: Performance of multivariable IVW, univariable MR-Egger and multivariable MR-Egger
with βXk being correlated for all k, and a causal effect of X1 on X2
Multivariable IVW Univariable MR-Egger Multivariable MR-Egger
Mean θˆ1 Power, Mean θˆ1 Power, % Mean θˆ1 Power, %
(mean SE) % (mean SE) Intercept Causal (mean SE) Intercept Causal
Null causal effect: θ1 = 0
1. No pleiotropy, InSIDE satisfied
0.000 (0.062) 4.1 0.146 (0.158) 3.9 15.6 0.000 (0.097) 4.0 4.0
2. Balanced pleiotropy, InSIDE satisfied
α′j ∼ N (0,0.004) 0.000 (0.137) 4.5 0.146 (0.188) 4.1 11.9 0.000 (0.190) 4.6 4.7
3. Directional pleiotropy, InSIDE satisfied
α′j ∼ N (0.01,0.004) 0.041 (0.137) 5.7 0.151 (0.187) 5.4 12.8 0.003 (0.189) 5.7 4.4
α′j ∼ N (0.05,0.004) 0.209 (0.138) 34.2 0.148 (0.187) 32.8 12.6 0.000 (0.190) 36.9 4.7
α′j ∼ N (0.1,0.004) 0.422 (0.140) 82.2 0.151 (0.188) 83.0 12.9 0.004 (0.190) 89.0 4.8
4. Directional pleiotropy, InSIDE violated
α′j ∼ N (0.01,0.004) 0.053 (0.137) 6.2 0.235 (0.188) 4.3 25.7 0.069 (0.189) 4.9 6.4
α′j ∼ N (0.05,0.004) 0.218 (0.137) 37.2 0.235 (0.188) 20.3 26.4 0.067 (0.189) 21.8 6.7
α′j ∼ N (0.1,0.004) 0.429 (0.139) 84.3 0.238 (0.188) 71.3 26.7 0.071 (0.189) 79.2 6.6
Positive causal effect: θ1 = 0.3
1. No pleiotropy, InSIDE satisfied
0.299 (0.062) 94.7 0.446 (0.158) 4.1 79.7 0.300 (0.096) 4.0 81.3
2. Balanced pleiotropy, InSIDE satisfied
α′j ∼ N (0,0.004) 0.301 (0.137) 60.5 0.445 (0.187) 4.5 66.6 0.300 (0.189) 4.6 37.0
3. Directional pleiotropy, InSIDE satisfied
α′j ∼ N (0.01,0.004) 0.339 (0.137) 69.9 0.443 (0.188) 5.7 66.1 0.296 (0.190) 6.0 36.1
α′j ∼ N (0.05,0.004) 0.510 (0.138) 94.2 0.449 (0.188) 32.6 67.7 0.302 (0.190) 37.3 37.2
α′j ∼ N (0.1,0.004) 0.715 (0.140) 99.2 0.445 (0.187) 83.4 66.9 0.298 (0.189) 89.4 36.8
4. Directional pleiotropy, InSIDE violated
α′j ∼ N (0.01,0.004) 0.353 (0.137) 73.1 0.534 (0.188) 4.4 79.4 0.367 (0.189) 4.6 50.6
α′j ∼ N (0.05,0.004) 0.519 (0.138) 95.1 0.534 (0.188) 20.3 79.6 0.366 (0.190) 21.7 50.5
α′j ∼ N (0.1,0.004) 0.728 (0.139) 99.5 0.533 (0.188) 72.5 79.6 0.368 (0.189) 80.1 51.0
Abbreviations: MR, Mendelian randomization; SE, standard error; IVW, inverse-variance weighted;
InSIDE, Instrument Strength Independent of Direct Effect.
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A5 Correlated genetic variants
The methods discussed in this article have assumed that the genetic variants are un-
correlated (not in linkage disequilibrium). There may, however, be cases where using
multiple correlated variants from the same gene region will be more efficient than using
uncorrelated variants from different gene regions.2 If the genetic variants are in par-
tial linkage disequilibrium, and each variant explains independent variation in the risk
factor, then the inclusion of these variants will increase the power of the MR study.
The precision of a MR study will not increase, however, if the variants are perfectly
correlated.
If correlated variants are included in an MR study, using summarized level data, the
analysis should account for the correlation structure of the variants. If the correlation
of the variants is not taken into consideration, the causal estimate will be too precise
and this may lead to inappropriate inferences. To account for the correlation between
the genetic variants for the univariable and multivariable IVW methods, we can use
generalized weighted linear regression of the genetic associations, where the correlations
of the variants are included in the weighting matrix, with the intercept set to zero.2,3
If Ωst = se(βˆYs) se(βˆYt)ρst, where ρst is the correlation between variants s and t,
then the causal estimate from a weighted generalised linear regression for univariable
MR is:
θˆUIC = (βˆ
T
Xj
Ω−1βˆXj)
−1βˆTXjΩ
−1βˆYj (6)
with the standard error of the causal estimate:
θˆUIC =
√
(βˆTXjΩ
−1βˆXj)−1 (7)
Whilst the univariable MR-Egger estimates can be obtained by fitting the same general-
ized weighted linear regression model, but allowing the intercept term to be estimated,
the effect of using correlated genetic variants in the univariable MR-Egger method has
not been considered in detail. Further investigation into the impact correlated vari-
ants may have on the interpretation of the direct effect, and the InSIDE assumption,
must be considered at the univariable level first, and then expanded to multivariable
MR-Egger.
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Abstract
Background: Factorial Mendelian randomization is the use of genetic variants to answer
questions about interactions. Although the approach has been used in applied investiga-
tions, little methodological advice is available on how to design or perform a factorial
Mendelian randomization analysis. Previous analyses have employed a 2 2 approach,
using dichotomized genetic scores to divide the population into four subgroups as in a
factorial randomized trial.
Methods: We describe two distinct contexts for factorial Mendelian randomization: in-
vestigating interactions between risk factors, and investigating interactions between
pharmacological interventions on risk factors. We propose two-stage least squares meth-
ods using all available genetic variants and their interactions as instrumental variables,
and using continuous genetic scores as instrumental variables rather than dichotomized
scores. We illustrate our methods using data from UK Biobank to investigate the interac-
tion between body mass index and alcohol consumption on systolic blood pressure.
Results: Simulated and real data show that efficiency is maximized using the full set of
interactions between genetic variants as instruments. In the applied example, between
4- and 10-fold improvement in efficiency is demonstrated over the 22 approach.
Analyses using continuous genetic scores are more efficient than those using dichoto-
mized scores. Efficiency is improved by finding genetic variants that divide the popula-
tion at a natural break in the distribution of the risk factor, or else divide the population
into more equal-sized groups.
Conclusions: Previous factorial Mendelian randomization analyses may have been un-
derpowered. Efficiency can be improved by using all genetic variants and their interac-
tions as instrumental variables, rather than the 2 2 approach.
Key words: Mendelian randomization, instrumental variables, interaction, causal inference, factorial randomized trial
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Introduction
Mendelian randomization is the use of genetic variants as
proxies for interventions on risk factors to answer questions
of cause and effect using observational data.1,2 Formally,
Mendelian randomization can be viewed as instrumental var-
iable (IV) analysis using genetic variants as IVs.3,4 Factorial
Mendelian randomization is the use of genetic variants to an-
swer questions about interactions. It does this by proposing a
statistical model for the outcome as a function of the risk fac-
tors (or their genetic predictors) and a product term.
A statistical interaction is observed when the coefficient for
the product term in the model is non-zero. A statistical interac-
tion in the causal model for the outcome may represent a
causal interaction, meaning that the effect of one risk factor
on the outcome is dependent upon the value of the other risk
factor.5,6 This may arise due to a functional or biological inter-
action, in which there is a mechanistic connection between the
two risk factors in how they influence the outcome. However,
a statistical interaction may also arise due to non-linearity in
the effect of a risk factor, or due to effect modification, in
which the effect of one risk factor varies in strata of the other.
Hereafter, we take the word ‘interaction’ to mean a statistical
interaction in the causal model for the outcome, without im-
plying a functional interaction between the risk factors.
Factorial Mendelian randomization was proposed in
the seminal paper on Mendelian randomization by Davey
Smith and Ebrahim in 2003.1 The term is credited by the
authors to Sheila Bird (https://en.wikipedia.org/wiki/
Sheila_Bird). However, the idea was not readily taken up
in applied practice. The concept was raised again by Davey
Smith and Hemani in a 2014 review,7 who suggested that
genetic predictors of obesity and alcohol consumption
could be used to investigate the interaction between the
two risk factors on risk of liver disease. This question was
investigated for markers of liver function using data from
the Copenhagen General Population Study in 2018;8 no ev-
idence for an interaction was found.
In parallel to this, the term factorial Mendelian randomiza-
tion has been used for analyses employing genetic variants as
proxies for pharmacological interventions. Ference et al. per-
formed factorial Mendelian randomization to compare the ef-
fect of lowering low density lipoprotein (LDL) cholesterol
levels on the risk of coronary heart disease (CHD) with two
different LDL-cholesterol lowering agents (ezetimibe and
statin), and with a combination of both.9 Genetic variants as-
sociated with LDL-cholesterol were identified in the NPC1L1
gene (proxies for ezetimibe), and the HMGCR gene (proxies
for statins), and combined into separate gene scores. To mimic
a 2 2 factorial randomized trial, the two gene scores were
dichotomized to create a 2 2 contingency table. The gene
scores were dichotomized at their median values so that the
numbers of participants were balanced across the four groups.
Ference has conducted similar analyses for PCSK9 inhibitors
and statins,10 and for CETP inhibitors and statins.11 A similar
2 2 approach was used in each case, as well as in the analy-
sis of obesity and alcohol mentioned above.8
In this paper, we consider various aspects relating to the
conceptualization, design, analysis and interpretation of a
factorial Mendelian randomization investigation. First, we
demonstrate the analogy between factorial Mendelian ran-
domization and a factorial randomized trial, we make a con-
nection with multivariable Mendelian randomization, and
we describe two contexts in which factorial Mendelian ran-
domization may have utility: for investigating interactions be-
tween risk factors, and for investigating interactions between
pharmacological interventions on risk factors. We present
simulated data demonstrating that the 2 2 approach to
analysis, while being conceptually appealing, is inefficient for
detecting interactions. The same conclusion is reached in an
applied investigation considering interactions between body
mass index (BMI) and alcohol consumption on blood pres-
sure using data from UK Biobank. Finally, we discuss the
implications of our work for applied factorial Mendelian ran-
domization investigations.
Key Messages
• Factorial Mendelian randomization is an extension of the Mendelian randomization paradigm to answer questions
about interactions.
• There are two contexts in which factorial Mendelian randomization can be used: for investigating interactions be-
tween risk factors, and interactions between pharmacological interventions on risk factors.
• While most applications of factorial Mendelian randomization have dichotomized the population as in a 22 factorial
randomized trial, this approach is generally inefficient for detecting statistical interactions.
• In the first context, efficiency is maximized by including all genetic variants and their cross-terms as instrumental var-
iables for the two risk factors and their product term.
• In the second context, efficiency is maximized by using continuous genetic scores rather than dichotomized scores.
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Methods
Factorial randomized trials and Mendelian
randomization
A factorial randomized trial allows for the simultaneous
assessment of two or more treatments in a single study.12
In its simplest form, a 2 2 factorial trial investigates the
effect of two binary treatments A and B on a binary out-
come Y. Participants are randomly allocated to one of four
groups: to receive treatment A only; to receive treatment B
only; to receive both treatments A and B; or to receive nei-
ther treatment A nor B. The analogy between Mendelian
randomization and a randomized trial has been made
many times,13,14 and the analogy between factorial
Mendelian randomization and a factorial randomized trial
has also been made previously in the context of multivari-
able Mendelian randomization (Figure 1, adapted from15).
Multivariable Mendelian randomization was motivated
by the problem that some genetic variants are associated
with multiple risk factors, such that it is impossible to find
genetic variants that are specifically associated with a par-
ticular risk factor.15 For illustration, we assume there are
two risk factors (X1 and X2), and fit a model for the out-
come in terms of the risk factors:
EðYjX1;X2Þ ¼ h0 þ h1X1 þ h2X2: (1)
We assume that we have genetic variants G that satisfy
the multivariable IV assumptions for risk factors X1 and
X2.
15 Specifically:
i. Each variant is associated with at least one of the risk
factors.
ii. Each risk factor is associated with at least one of the
genetic variants.
iii. Variants are not confounded in their associations with
the outcome.
iv. Variants are not associated with the outcome condi-
tional on the risk factors and confounders.
If we have at least two genetic variants that are valid
multivariable IVs for X1 and X2, then causal effects h1 and
h2 can be estimated from the two-stage least squares
method by first regressing the risk factors on the genetic
variants, and then regressing the outcome on the fitted val-
ues of the risk factors from the first-stage regressions.16 If
summarized data on the genetic associations with the out-
come (b^Y) and the risk factors (b^X1; b^X2) are available,
then the same estimates can be obtained by weighted linear
regression of the beta-coefficients with the intercept set to
zero:
Eðb^Y jb^X1; b^X2Þ ¼ h1b^X1 þ h2b^X2; (2)
where weights are the reciprocals of variances of the gene–
outcome associations seðb^YÞ2.17
In the language of a factorial randomized trial, this is re-
ferred to as an analysis performed ‘at the margins’.18
Estimates represent the average direct effect of each of the
risk factors.19 If there is an interaction between the risk
factors, then these are marginal estimates—they are aver-
aged over the distribution of the other risk factor.
We can extend multivariable Mendelian randomization
by adding a term to the outcome model to estimate an in-
teraction between the risk factors:
EðYjX1;X2Þ ¼ h0 þ h1X1 þ h2X2 þ h12X12 (3)
where X12 is the product X1 X2, and h12 is the interac-
tion effect on an additive scale. In a factorial randomized
trial, this is referred to as an analysis performed ‘inside
the table’, as in a 2 2 setting, the interaction can be esti-
mated from the 2 2 contingency table.20 A factorial
Mendelian randomization analysis is primarily interested
in assessing the presence of, and estimating the interaction
effect h12.
For simplicity, we initially assume that the associations
of the genetic variants with the risk factors are homoge-
neous in the population and do not vary with time, also
that the model relating the risk factors to the outcome is
correctly specified, and the effects of the risk factors (and
their product) on the outcome are also homogeneous in the
population and do not vary with time. We return to the
question of how to interpret estimates in this and in more
realistic scenarios in the Discussion.
Figure 1. Comparison of a factorial randomized clinical trial and a factorial Mendelian randomization investigation with a 2 2 approach (adapted
from15).
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Two contexts: interactions between risk
factors and interactions between
interventions
Factorial Mendelian randomization study has been consid-
ered in two broad scenarios: (a) to estimate interaction
effects between risk factors by using genetic variants as
predictors of the risk factors; and (b) to identify interac-
tions between interventions by using genetic variants as
proxies for specific treatments. In the first case, the aim is
to identify an interaction in the effect of two distinct risk
factors on the outcome. In the second case, there may not
even be two distinct risk factors (as in the example of two
LDL-cholesterol lowering interventions discussed by
Ference et al.9) and the aim is to identify an interaction in
the associations of the genetic variants with the outcome.
In this case, an interaction is inferred between the interven-
tions for which the genetic variants are proxies. We con-
sider these two scenarios in turn.
Interactions between risk factors
The multivariable IV assumptions imply that there is no ef-
fect of the genetic variants on the outcome except poten-
tially indirectly via one or both of the risk factors. We
divide the genetic variants into three groups: G1 contains
variants that are associated with X1, G2 contains variants
that are associated with X2, and Gc contains shared var-
iants that are associated with X1 and X2 (Figure 2). We
can now perform two-stage least squares by first regressing
the risk factors X1, X2, and the product X12 on the genetic
variants, and then regressing the outcome on the fitted val-
ues of these risk factors. This analysis treats X12 as if it is a
separate risk factor unrelated to X1 and X2.
21 For the
second-stage regression model to be identified, at least
three IVs are required, as three parameters are estimated,
and all risk factors (X1, X2, X12) must be associated with
at least one IV.
If we assume that the risk factors X1 and X2 are linear
in the genetic variants:
E½X1jG ¼ a01 þ
P
a1jG1j þ
P
a1cjGcj and
E½X2jG ¼ a02 þ
P
a2jG2j þ
P
a2cjGcj;
(4)
then an interaction between the risk factors means that the
statistical model for the outcome includes cross-terms be-
tween the genetic variants (such as G11 G21).22 This
motivates the use of cross-terms between the genetic var-
iants as separate IVs.
If all the genetic variants and their cross-terms are used
as IVs, then under the homogeneity assumptions, the fitted
values of the risk factors and their product term can be
consistently estimated, and hence the regression model for
the outcome on these fitted values (as in the two-stage least
squares method) will be correctly specified. Thus the ho-
mogeneity assumptions lead to consistent estimates of the
parameters in equation (3).
Simulation study 1: interactions between
risk factors
To investigate the performance of methods for estimating
interactions between risk factors, we conduct a simulation
study. We assume there are 10 genetic variants that are as-
sociated with X1 and 10 genetic variants that are associ-
ated with X2, and vary the number of shared variants that
are associated with both X1 and X2 from 0 (20 distinct ge-
netic variants, each associated with one risk factor) to 10
(all 10 genetic variants associated with both risk factors).
Figure 2. Causal directed acyclic graph illustrating relationships between variables in a factorial Mendelian randomization framework for two risk fac-
tors (X1 and X2). There are three sets of genetic variants: G1 (affecting X1 only), G2 (affecting X2 only) and Gc (shared variants, affecting X1 and X2). X12
represents the product X1  X2. The main effects of the risk factors X1 and X2 on the outcome Y are h1 and h2, and the interaction effect of X1 and X2
on Y is h12. U1 and U2 are sets of confounders.
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All genetic variants are simulated as independent (i.e. not
in linkage disequilibrium). We compare four methods:
Method 1. Full set of interactions: we consider as IVs
all the genetic variants and all cross-terms—so when
there are 3 shared variants, there are 114 IVs in total:
7þ 7þ3¼ 17 linear terms, 3 quadratic terms (shared
variants only), 3 shared  shared variant cross-terms,
42 shared  non-shared variant cross-terms, and 49
non-shared  non-shared variant cross-terms.
Method 2. Reduced set of interactions: we consider as
IVs all the genetic variants and all cross-terms between
non-shared variants—so when there are 3 shared var-
iants, there are 17 linear terms and 49 cross-terms.
Method 3. Continuous gene scores: we construct weighted
gene scores for each risk factor using external weights,
and take the two gene scores and their product as IVs.
Method 4. Dichotomized gene scores: we dichotomize
both gene scores at their median, and take the two di-
chotomized gene scores and their product as IVs. This is
equivalent to a 22 analysis.
The data-generating model for the simulation study is pro-
vided in the Supplementary Material, available as
Supplementary data at IJE online. Data were generated
10 000 times for each set of parameters on 10 000 individ-
uals. Parameters were set such that the set of genetic var-
iants explains around 10% of the variance in each risk
factor. The effect of X1 on the outcome was h1 ¼ 0:3, the
effect of X2 on the outcome was h2 ¼ 0:2, and the interac-
tion effect of X12 on the outcome took values h12 ¼ 0:1,
0.3, and 0.5.
Simulation study 2: interactions between
interventions
We performed a further simulation study to investigate meth-
ods for detecting interactions between interventions. We as-
sume there are 3 independent genetic variants that are
proxies for intervention A, and the same for intervention B.
Fewer variants are considered here as typically variants for
such an analysis will come from a single gene region for each
intervention.9 We compare two approaches.
i. Continuous gene scores: we construct weighted gene
scores for changes in the risk factor corresponding to
each intervention using external weights, and take the
two gene scores and their product as IVs.
ii. Dichotomized gene scores: we dichotomize both gene
scores at their median, and take the two dichotomized
gene scores and their product as IVs. This is equivalent
to a 2  2 analysis.
In each case, we regressed the outcome on the IVs, and
estimated an interaction term between the gene scores that
act as proxies for the interventions. As before, the data-
generating model for the simulation study is provided in
the Supplementary Material, available as Supplementary
data at IJE online. Data were generated 10 000 times for
each set of parameters on 10 000 individuals. The interac-
tion effect took values 0.1, 0.3, and 0.5. We varied the mi-
nor allele frequencies of the genetic variants used as
proxies for interventions A and B, drawing from a uniform
distribution between 0.1 and 0.2 (uncommon), or between
0.4 and 0.5 (common), and the proportion of variance
explained by the genetic variants (3, 5 or 7%).
Applied example: the effects of BMI and alcohol
on systolic blood pressure
Increased systolic blood pressure (SBP) is associated with a
range of health conditions, including cardiovascular dis-
ease and diabetes.23,24 Whereas there have been numerous
studies highlighting the adverse effects of increased BMI on
SBP,25,26 and the adverse effects of increased alcohol con-
sumption,27 there has been little research on the combined
effect of BMI and alcohol consumption on SBP. We illus-
trate factorial Mendelian randomization by performing an
analysis using individual participant data from UK
Biobank to estimate the interaction effect of BMI and alco-
hol consumption on SBP. UK Biobank is a prospective,
population-based cohort consisting of 500 000 partici-
pants aged from 40 to 69 years at baseline living in the UK.
For the analysis, we considered 291 781 unrelated partici-
pants of European descent who passed data quality control
measures and had genetic data available.
We used the 77 genome-wide significant variants from
a meta-analysis by the Genetic Investigation of
ANthropometric Traits (GIANT) consortium in partici-
pants of European ancestry to act as IVs for BMI.28 For al-
cohol, we identified 10 genetic variants in the ADH1B
gene region that have been shown to be associated with al-
cohol consumption.29 We performed factorial Mendelian
randomization analyses using the full set of interactions,
continuous gene scores, and dichotomized gene scores. We
also performed analyses separately using the lead variant
from the ADH1B gene region (rs1229984) as the sole IV
for alcohol consumption, as was done in the analysis by
Carter et al.8
Results
Simulation study 1: interactions between risk
factors
Results from the simulation study for estimating interactions
between risk factors are displayed in Table 1 (no shared
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variants) and Table 2 (varying the number of shared var-
iants). All four approaches provided unbiased estimates of
the interaction effect in all scenarios, with coverage for the
95% confidence interval close to the nominal 95% level.
Power varied considerably between the methods. With no
shared variants, method 1 (full set of interactions) and
method 2 (reduced set of interactions) are equivalent and
gave the most efficient estimates throughout. Method 3
(continuous gene scores) was less efficient, and method 4 (di-
chotomized gene scores) was the least efficient. With shared
variants, method 1 was the most efficient throughout, and
its efficiency was not strongly affected by the risk factors
having genetic predictors in common. Between methods 2
and 3, method 2 was more efficient when most of the var-
iants were non-shared, whereas method 3 was more efficient
when most of the variants were shared. Again, method 4
was the least efficient in all scenarios. This suggests that the
22 approach may be underpowered in practice, and in-
stead approaches using all genetic variants and their cross-
terms should be considered.
We also varied the strength of the genetic variants due
to potential concerns about weak instruments.30 We con-
sidered scenarios in which the genetic variants explained
1% and 5% of variance in the risk factors. Although sub-
stantial weak instrument bias was observed for the main
effects, no bias was observed for the interaction term, even
when there were 100 IVs in the analysis and F-statistics
and conditional F-statistics31 for the product term were 1
Table 1. Simulation study results for interactions between
risk factors with no shared variants: median estimate, stan-
dard deviation (SD) of estimates, median standard error (SE),
empirical power (%) to reject null at 5% significance, and em-
pirical coverage (%) of 95% confidence interval
Median SD Median SE Power
(%)
Coverage
(%)
Methods 1 and 2—full set of interactions:a
h1 ¼ 0:3 0.3013 0.0917 0.0910 90.2 95.0
h2 ¼ 0:2 0.2022 0.0952 0.0945 57.1 94.9
h12 ¼ 0:1 0.1101 0.0721 0.0718 33.7 94.6
h1 ¼ 0:3 0.3043 0.0918 0.0910 91.0 95.0
h2 ¼ 0:2 0.2034 0.0947 0.0945 57.9 95.5
h12 ¼ 0:3 0.3080 0.0722 0.0718 98.8 95.2
h1 ¼ 0:3 0.3048 0.0911 0.0909 90.7 95.2
h2 ¼ 0:2 0.2050 0.0944 0.0945 58.4 95.2
h12 ¼ 0:5 0.5073 0.0715 0.0718 100.0 95.2
Method 3—continuous gene scores:
h1 ¼ 0:3 0.2993 0.1362 0.1333 61.4 95.4
h2 ¼ 0:2 0.1991 0.1415 0.1386 30.9 95.5
h12 ¼ 0:1 0.1010 0.1113 0.1091 15.4 95.5
h1 ¼ 0:3 0.2998 0.1359 0.1332 61.9 95.6
h2 ¼ 0:2 0.2019 0.1405 0.1387 31.5 95.8
h12 ¼ 0:3 0.3000 0.1106 0.1091 77.5 95.8
h1 ¼ 0:3 0.3004 0.1352 0.1331 61.5 95.4
h2 ¼ 0:2 0.2008 0.1409 0.1385 30.7 95.6
h12 ¼ 0:5 0.4995 0.1107 0.1092 98.7 95.6
Method 4—dichotomized gene scores:
h1 ¼ 0:3 0.2986 0.2155 0.2072 31.0 95.7
h2 ¼ 0:2 0.1989 0.2246 0.2168 15.0 96.2
h12 ¼ 0:1 0.1022 0.1786 0.1720 8.0 95.9
h1 ¼ 0:3 0.3039 0.2145 0.2074 32.1 95.8
h2 ¼ 0:2 0.2047 0.2236 0.2164 15.2 96.2
h12 ¼ 0:3 0.2972 0.1777 0.1722 41.8 96.0
h1 ¼ 0:3 0.3010 0.2148 0.2073 31.4 96.2
h2 ¼ 0:2 0.2002 0.2233 0.2163 15.3 96.1
h12 ¼ 0:5 0.5002 0.1776 0.1718 80.7 96.1
aAs there are no shared variants, methods 1 and 2 are equivalent.
Table 2. Simulation study results for interaction term be-
tween risk factors varying number of shared variants: median
estimate of h12 ¼ 0:3, standard deviation (SD) of estimates,
median standard error (SE), empirical power (%) to reject null
at 5% significance, and empirical coverage (%) of 95% confi-
dence interval
Shared
variants
Total
IVs
Median SD Median
SE
Power
(%)
Coverage
(%)
Method 1—full set of interactions:
0a 120 0.3080 0.0722 0.0718 98.8 95.2
1 119 0.3080 0.0723 0.0719 98.8 95.0
3 114 0.3090 0.0717 0.0716 98.9 95.3
5 105 0.3078 0.0716 0.0707 98.9 94.9
8 84 0.3073 0.0682 0.0687 99.3 95.2
10 65 0.3056 0.0670 0.0673 99.2 95.3
Method 2—reduced set of interactions:
1 100 0.3073 0.0804 0.0794 96.7 94.9
3 66 0.3088 0.1003 0.0997 86.1 95.2
5 40 0.3056 0.1340 0.1334 63.2 95.7
8 16 0.3054 0.2520 0.2471 23.9 97.1
10 10 0.3057 0.3883 0.3891 8.7 99.3
Method 3—continuous gene scores:
0 3 0.3000 0.1106 0.1091 77.5 95.8
1 3 0.3005 0.1111 0.1088 77.8 95.4
3 3 0.2998 0.1051 0.1048 81.0 95.6
5 3 0.3015 0.0997 0.0980 85.6 95.5
8 3 0.3003 0.0857 0.0858 93.0 95.8
10 3 0.2993 32.31 0.1711 42.7 99.2
Method 4—dichotomized gene scores:
0 3 0.2972 0.1777 0.1722 41.8 96.0
1 3 0.3028 0.1757 0.1724 42.2 96.3
3 3 0.3002 0.1818 0.1773 39.8 96.4
5 3 0.3005 0.1948 0.1884 36.6 96.6
8 3 0.3007 0.2474 0.2340 25.7 97.2
10 3 0.2896 133.5 1.3578 0.7 100.0
aWhen there are no shared variants, methods 1 and 2 are equivalent.
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(Supplementary Tables A1 and A2, available as
Supplementary data at IJE online). Similar findings were
observed in a one-sample setting when varying the direc-
tion of confounder effects on the risk factor and outcome
(results not shown). We also performed the simulation
study centering the values of the risk factors to reduce the
impact of collinearity. This changed the mean estimates of
the main effects h1 and h2 and improved precision for the
main effect estimates, but estimates and inferences for the
interaction term h12 were unchanged (Supplementary
Table A3, available as Supplementary data at IJE online).
These additional simulations suggest that factorial
Mendelian randomization should only be used when the
interaction is the main object of interest, and numerical
estimates for the main effects from this model should be
interpreted with caution.
Simulation study 2: interactions between
interventions
Results from the simulation study for estimating interac-
tions between the gene scores that act as proxies for the
interventions are displayed in Table 3. Whereas the numer-
ical values of estimates differed between the two
approaches, a consistent finding was that power to detect
an interaction was greater using continuous gene scores
than using dichotomized gene scores. Varying the propor-
tion of variance explained by the genetic variants had no
discernable effect on the power to detect an interaction.
This can be seen by comparing scenarios 1, 2 and 3, and
scenarios 5 and 6. However, varying the minor allele fre-
quency had a strong effect on power, with greater power
when the minor allele frequency was close to 0.5. This can
be seen by comparing scenarios 2, 4 and 5, and scenarios 3
and 6. This suggests that ensuring comparable size between
subgroups is an important factor for efficient detection of
interactions, and can be more important than ensuring that
the strongest variant is used in the analysis.
Applied example: the effects of BMI and alcohol
on systolic blood pressure
The lead variant (rs1229984) explained 0.24% of the vari-
ance in alcohol consumption, whereas the 10 variants
Table 3. Simulation study results for interaction between interventions: median estimate, standard deviation (SD) of estimates,
median standard error (SE), and empirical power (%) to reject null at 5% significance. The minor allele frequencies and propor-
tion of variance explained for variants that are proxies for interventions A and B are varied between scenarios
Continuous gene scores Dichotomized gene scores
Median SD Median SE Power Median SD Median SE Power
Scenario 1: (A) common variants, 3%; (B) common variants, 3%
h12¼0.1 0.0583 0.0420 0.0417 29.3 0.0368 0.0423 0.0421 13.5
h12¼0.3 0.0330 0.0080 0.0078 98.7 0.1102 0.0429 0.0423 73.5
h12¼0.5 0.0224 0.0034 0.0032 100.0 0.1846 0.0428 0.0427 98.9
Scenario 2: (A) common variants, 5%; (B) common variants, 5%
h12¼0.1 0.0484 0.0343 0.0343 29.1 0.0372 0.0420 0.0422 13.5
h12¼0.3 0.0304 0.0074 0.0072 98.8 0.1108 0.0424 0.0423 74.3
h12¼0.5 0.0212 0.0033 0.0030 100.0 0.1851 0.0439 0.0427 99.0
Scenario 3: (A) common variants, 3%; (B) common variants, 7%
h12¼0.1 0.0498 0.0350 0.0352 29.2 0.0371 0.0422 0.0422 14.1
h12¼0.3 0.0305 0.0075 0.0072 99.0 0.1106 0.0426 0.0423 74.2
h12¼0.5 0.0213 0.0033 0.0030 100.0 0.1844 0.0430 0.0427 99.1
Scenario 4: (A) uncommon variants, 5%; (B) uncommon variants, 5%
h12¼0.1 0.0824 0.1152 0.1150 10.9 0.0168 0.0435 0.0430 7.0
h12¼0.3 0.1082 0.0519 0.0500 58.8 0.0526 0.0434 0.0430 23.3
h12¼0.5 0.0996 0.0300 0.0278 94.6 0.0879 0.0436 0.0430 53.0
Scenario 5: (A) common variants, 5%; (B) uncommon variants, 5%
h12¼0.1 0.0669 0.0699 0.0685 16.7 0.0246 0.0434 0.0425 9.1
h12¼0.3 0.0618 0.0211 0.0204 85.5 0.0763 0.0433 0.0426 42.8
h12¼0.5 0.0489 0.0109 0.0097 99.9 0.1279 0.0434 0.0428 84.1
Scenario 6: (A) common variants, 3%; (B) uncommon variants, 7%
h12¼0.1 0.0748 0.0756 0.0742 17.8 0.0259 0.0432 0.0426 9.7
h12¼0.3 0.0649 0.0221 0.0215 85.4 0.0758 0.0430 0.0426 42.9
h12¼0.5 0.0510 0.0113 0.0101 99.9 0.1271 0.0435 0.0428 83.9
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explained 0.28% of the variance. Although the alcohol-
decreasing allele of the rs1229984 variant is dominant, its
frequency is only 2.5%. Dichotomizing participants based
on this variant led to unequal groups in the population,
whereas dichotomizing based on the 10 variant score led
to equal groups (Table 4). However, the difference in mean
alcohol levels between subgroups was reduced when using
the 10 variant score, as most of the difference is due to the
rs1229984 variant.
Estimates of the interaction between BMI and alcohol
consumption are displayed in Table 5. For the dichoto-
mized gene scores, efficiency is greater when the
rs1229984 variant is used, suggesting the importance of di-
chotomizing the risk factor at a natural break in its distri-
bution (if one exists) rather than ensuring that subgroups
are equal in size. However, efficiency is strikingly im-
proved using the full set of interactions, with the standard
error decreasing over 10-fold using the 10 variants, and by
a factor of 4 using the rs1229984 variant, compared with
the 2 2 analysis. All estimates are compatible with the
null, suggesting a lack of interaction in the effects of BMI
and alcohol on SBP. There was no evidence of weak instru-
ment bias, even though up to 857 IVs were used in the
analyses and F-statistics were generally low
(Supplementary Table A4, available as Supplementary data
at IJE online).
Discussion
In this paper, we have provided a brief review of factorial
Mendelian randomization, an approach that uses genetic
variants as IVs to detect interactions. We have described
two broad scenarios in which factorial Mendelian
randomization has been implemented: to explore interac-
tions between risk factors, and to explore interactions be-
tween interventions. Although most (perhaps even all)
factorial Mendelian randomization analyses have been
conducted using a 2 2 approach in which the sample is
divided into four subgroups, we have shown that this ap-
proach is generally inefficient, particularly for exploring
interactions between risk factors. This has been demon-
strated in simulation studies, and in an applied example in
which a 4- to 10-fold improvement in efficiency was
Table 4. Subgroups defined by genetic predictors of BMI and alcohol consumption: numbers (%) of participants and mean (stan-
dard deviation) of body mass index, alcohol consumption and systolic blood pressure in 2 2 subgroups when either 10 genetic
variants or the rs1229984 variant used as IVs for alcohol consumption
Mean (SD)
Participants (%) BMI (kg/m2) Alcohol (units/day) SBP (mmHg)
Overall 291, 781 (100.0) 27.1 (4.51) 2.54 (2.58) 140.0 (19.8)
10 variants for alcohol:
Low BMI, low alcohol 73, 003 (25.0) 26.6 (4.25) 2.50 (2.52) 140.6 (20.6)
High BMI, low alcohol 72, 889 (25.0) 27.5 (4.65) 2.47 (2.50) 141.2 (20.6)
Low BMI, high alcohol 72, 888 (25.0) 26.7 (4.30) 2.61 (2.68) 140.8 (20.7)
High BMI, high alcohol 73, 001 (25.0) 27.6 (4.71) 2.59 (2.59) 141.3 (20.6)
rs1229984 variant for alcohol:
Low BMI, low alcohol 6, 997 (2.4) 26.3 (4.10) 2.00 (2.04) 139.2 (20.2)
High BMI, low alcohol 6, 863 (2.4) 27.3 (4.50) 1.95 (1.99) 139.7 (20.2)
Low BMI, high alcohol 138, 894 (47.6) 26.7 (4.28) 2.59 (2.59) 140.8 (20.6)
High BMI, high alcohol 139, 027 (47.6) 27.6 (4.69) 2.56 (2.56) 141.3 (20.6)
Table 5. Factorial Mendelian randomization results for ap-
plied example: estimates of interaction between BMI and al-
cohol consumption on systolic blood pressure; estimates are
in mmHg units per 1 kg/m2 change in BMI and 1 unit/day
change in alcohol consumption
Total IVs Estimate Standard
error
P-value
10 variants for alcohol
Method 1: full set of
interactions
857 0.0023 0.0503 0.96
Method 2: continuous
gene scores
3 0.0655 0.3402 0.85
Method 3: binary gene
scores
3 0.1011 0.6411 0.87
rs1229984 variant for alcohol
Method 1: full set of
interactions
149 0.0170 0.1136 0.88
Method 2: continuous
gene scores
3 0.1917 0.3725 0.61
Method 3: binary gene
scores
3 0.1499 0.4174 0.72
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observed by an analysis using the full set of interactions be-
tween the genetic variants as IVs.
Choice of variants
Our findings suggest that factorial Mendelian randomiza-
tion analyses should be conducted using all available ge-
netic variants that are valid instruments, i.e. that satisfy the
multivariable IV assumptions. Analyses should not only in-
clude the genetic variants as main effects, but also all rele-
vant two-way cross-terms. A similar conclusion was made
in a different context by Bollen and Paxton.22 If investiga-
tors want to perform a 2 2 analysis, this should be done
to illustrate the method rather than being the main analysis
for testing the presence of an interaction. For a 2 2 analy-
sis, the primary consideration for choosing genetic variants
should be to divide the population at a natural break in the
distribution of the risk factor, in order to maximize the dif-
ference between the mean level of the risk factor in the two
halves of the population. If there is no natural break in the
distribution, then investigators should find a division that
splits the population as far as possible into equal groups.
This may entail selecting genetic variants that explain less
variance in the risk factor, but have minor allele frequency
closer to 50%. There can also be substantial benefit in in-
cluding multiple variants in a single gene region in an
analysis, even if these variants only explain a small addi-
tional proportion of variance in the risk factor.
Weak instrument bias and efficiency
Conventionally, it is discouraged to use large numbers of
genetic variants that are not strongly associated with the
risk factor in a Mendelian randomization analysis due to
weak instrument bias.32 Although we did not detect any
bias from weak instruments on interaction terms in our
simulations, we acknowledge that users of the method may
be reluctant to use hundreds of cross-terms as IVs. We
would therefore encourage the use of continuous gene
score methods as sensitivity analyses. Such analyses esti-
mate fewer parameters, so should be less susceptible to
bias. However, this advice is precautionary; no evidence of
weak instrument bias in interaction estimates was observed
in our simulations.
Summarized data
Whereas multivariable Mendelian randomization can be
performed using summarized data that are typically
reported from genome-wide association studies by large
consortia, this is not possible for factorial Mendelian ran-
domization. If summarized association estimates are
available on genetic associations with the product of the
two risk factors, as well as associations with the risk fac-
tors individually, then the interaction effect can in principle
be estimated by weighted linear regression of the beta-
coefficients as in multivariable Mendelian randomization.
However, if association estimates are only available for ge-
netic variants, then the regression model is not identified
asymptotically due to collinearity, and finite-sample esti-
mates will be biased.33 Association estimates for some
cross-terms of genetic variants are additionally required.
Hence, factorial Mendelian randomization can be per-
formed using summarized data, but only if bespoke sum-
marized data are available on associations of genetic
variants and their cross-terms with the risk factors and
their product.
Interpretation of the interaction effect
If genetic variants each satisfy the assumptions of an IV,
then an interaction between risk factors has a causal inter-
pretation. If the two risk factors are associated with the
outcome then an interaction will exist on at least one of
the additive or multiplicative scales.6 However, there is no
way of distinguishing a purely statistical interaction from a
mechanistic or biological interaction based on observa-
tional data. We therefore advise caution in the interpreta-
tion of interaction findings, as a statistical interaction can
arise due to non-linearity in the effect of a risk factor, or
because of the scale on which the outcome is measured (for
example, an interaction may occur on the original scale,
but not on a log-transformed scale). When considering an
interaction between interventions, researchers can investi-
gate whether there is an interaction between the interven-
tions on the risk factor(s) as well as on the outcome. This
may help reveal where any biological interaction may take
place.
Causal estimates from IV analysis have a clear interpre-
tation in two cases: under the monotonicity assumption,
and under the homogeneity assumption.34 In a randomized
controlled trial in which random allocation is taken as the
IV and the treatment is the risk factor, monotonicity means
that there are no individuals in the population (known as
‘defiers’) who would take the treatment only if they were
randomly allocated to the control group, and not if they
were allocated to the treatment group. Under monotonic-
ity, all individuals are either ‘always-takers’ (they would
always take the treatment whether assigned to or not),
‘never-takers’ (they would never take the treatment
whether assigned to or not), or ‘compliers’ (they would
take the treatment if and only if assigned to do so).35
Under the monotonicity assumption, the IV estimate repre-
sents the complier average causal effect—the average
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causal effect amongst compliers.36 However, these defini-
tions suppose that the IV and risk factor are binary. In
Mendelian randomization, these variables are typically
continuous, and so the straightforward interpretation of an
IV estimate as a single complier average causal effect is
lost—it instead represents a weighted average of complier
average causal effects.37 In contrast, the IV estimate under
the homogeneity assumption represents the average causal
effect. In its simplest form, the homogeneity assumption
states that causal effects are identical in all individuals in
the population. Weaker versions of this assumption have
been proposed.
If there is a non-zero interaction between the risk fac-
tors, then the homogeneity assumption in the multivariable
Mendelian randomization model is violated, and the IV es-
timate only has a clear interpretation under the monotonic-
ity assumption. However, the homogeneity assumption in
the factorial Mendelian randomization model may still
hold, if there is homogeneity in the effects of the two risk
factors and their product on the outcome. Hence under ho-
mogeneity, the interaction effect has an interpretation as
an average causal effect.
A further potential complication arises if genetic associ-
ations with the risk factor or outcome vary over time. As
genetic variants are assigned at conception for all individu-
als and tend to influence risk factor levels throughout the
life-course, Mendelian randomization estimates are natu-
rally interpreted as the impact of a life-long change in the
trajectory of a risk factor.38 Hence the natural interpreta-
tion of an interaction effect is that of a statistical interac-
tion in the relationship between the outcome and the risk
factors that relates to long-term changes in the risk factors.
If genetic associations vary over time, then the interpreta-
tion of the causal estimate from Mendelian randomization
is unclear. This is true for a conventional Mendelian ran-
domization analysis as well as for a factorial Mendelian
randomization analysis. One notable case to consider is if
the risk factors have mutual effects on each other, as in the
case of a feedback mechanism. In this situation, provided
that the associations of the genetic variants with the risk
factors remain linear (which would occur if all relation-
ships between variables are linear), then this would mean
that all genetic variants are associated with both risk fac-
tors. A factorial Mendelian randomization analysis would
still hold for the causal interaction between the risk factors,
as in the examples with shared genetic variants described
earlier in the paper. Hence feedback between the risk fac-
tors does not necessarily lead to a non-zero interaction esti-
mate. However, if the two variables of interest have a
complex longitudinal relationship, and in particular if
there are mutual dependencies that might vary over time,
then extra caution should be taken in interpreting results
from a Mendelian randomization investigation, especially
numerical estimates of causal effects. This advice is also
relevant if the effects of the risk factors on the outcome
may vary over time (for example if there is a critical period
when exposure to the risk factor influences the outcome).
If the associations between variables became non-linear,
then it may be worth considering using the control func-
tion approach, an extension to the two-stage least squares
method that makes stronger assumptions, but can result in
more efficient estimation.39
Comparison with previous work
Previous work investigating interactions using IVs has been
limited. A formal framework for defining interaction
effects in the context of clinical trials was proposed by
Blackwell,40 who used the language of principal stratifica-
tion (compliance classes and monotonicity) to define local
average interaction effects in a similar way to how local av-
erage causal effects (also called complier-averaged causal
effects) are defined for single risk factors.41 However, the
principal stratification framework presupposes that risk
factors are binary (or categorical) to assign compliance
classes, whereas risk factors in Mendelian randomization
are typically continuous. Additionally, the principal strati-
fication framework presupposes a single binary IV,
whereas Mendelian randomization investigations often use
multiple genetic variants. There is therefore little practical
advice in the literature on how to perform a factorial
Mendelian randomization analysis.
Limitations
There are several limitations to this work. We rely on the
assumption that all genetic variants included in our analy-
ses are valid IVs. The IV assumptions may be violated by
including genetic variants that are associated with the out-
come independently of the risk factors. This violation
would result in biased estimates, and could potentially lead
to incorrect inferences on the presence of an interaction ef-
fect. Our recommendations rely on simulated data.
Different choices for the parameters included in the simula-
tion studies may have resulted in different conclusions.
However, our findings were robust to different choices of
parameters considered in this paper, they correspond to
what we know about the theoretical properties of estima-
tors, and similar conclusions were observed from the ap-
plied analysis. We have only considered interactions on an
additive scale, although interactions could be considered
on a multiplicative scale by log-transforming the outcome.
Finally, we have not considered the impact of model mis-
specification on estimates. It would not be possible to
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perform simulation studies corresponding to all possible
ways that model misspecification could occur, meaning
that our recommendations cannot be proven to be optimal
in all settings. We believe that we have chosen parameters
and scenarios that are relevant to modern Mendelian ran-
domization analyses.
Conclusion
Overall, factorial Mendelian randomization is a promising
technique for assessing interactions using genetic variants
as IVs. Our findings suggest that current applications of
factorial Mendelian randomization based on a 22 analy-
sis could be improved by better selection of genetic var-
iants, and by better choice of analysis method.
Supplementary data
Supplementary data are available at IJE online.
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Appendix G
Appendix to paper 3
Appendix to the published paper contained in Appendix F.
Supplementary Material
In the Supplementary Material, we provide more detail on the two simulation studies and the
applied example presented in the paper.
Simulation study 1: interactions between risk factors
The two risk factors X1 and X2 were generated for i = 1, 2, . . . , 10 000 participants from the
following data-generating model:
X1i =
J1∑
j=1
α1jG1ji +
Jc∑
j=1
α1cjGcji + U1i + ǫ1i and
X2i =
J2∑
j=1
α2jG2ji +
Jc∑
j=1
α2cjGcji + U2i + ǫ2i ,
where G1 and G2 are the genetic variants associated with X1 and X2 respectively, and Gc
are the set of shared variants that are associated with both X1 and X2 (bold font represents
vectors). The genotypes (0, 1 or 2) were generated independently from binomial distributions
Bin(2,MAFj), where MAFj represents the minor allele frequency (MAF) of the j
th genetic
variant, and was drawn from a uniform distribution Unif(0.1, 0.5). α1 and α1c represent the
effects of the genetic variants G1 and Gc on X1, and α2 and α2c represent the effects of the
genetic variants G2 and Gc on X2. The genetic associations were calculated so that G1 and
Gc, and G2 and Gc, explained σ
2
1 = σ
2
2 = 10% of the variance in X1 and X2 respectively. To
ensure that each genetic variant explained the same amount of variation in the risk factor, we
rearranged:
var(G1j) = σ
2
1 = 2× α21jMAF1j(1−MAF1j) and
var(G2j) = σ
2
2 = 2× α22jMAF2j(1−MAF2j) ,
to calculate the genetic associations:
α1j =
√
σ21/(J1 + Jc)
2×MAF1j(1−MAF1j) ,
α1cj =
√
σ21/(J1 + Jc)
2×MAFcj(1−MAFcj) ,
α2j =
√
σ22/(J1 + Jc)
2×MAF2j(1−MAF2j) ,
α2cj =
√
σ22/(J1 + Jc)
2×MAFcj(1−MAFcj) .
U1 and U2 represent the set of confounding variables of the X1−Y and X2−Y associations.
To ensure the confounders explained 25% of the variation in the risk factors, U1 and U2 were
drawn independently from a normal distribution N (0, 0.25). To fix the variances of X1 and
X2 to one, the error terms ǫ1 and ǫ2 were generated independently from a normal distribution
A1
with mean zero, and variance:
σ2ǫ1 = 1− σ21 − 0.25 and σ2ǫ2 = 1− σ22 − 0.25 .
The outcome Y was generated from:
Yi = θ0 + θ1X1i + θ2X2i + θ12X12i + 0.5U1i + 0.5U2i + ǫY i ,
where θ1 and θ2 represent the main effects ofX1 and X2 on Y , and θ12 represents the interaction
effect of X1 and X2 on Y . X12 was generated by either: a) multiplying X1 and X2; or b)
multiplying the mean centred values of the risk factors (X1 − X¯1) and (X2 − X¯2), where
X¯1 and X¯2 are the mean values of X1 and X2. To ensure the risk factors and confounders
explained less than a third of the variance in the outcome, the error term ǫY was generated
from a standard normal distribution N (0, 1).
Two-stage least squares regression models were fitted to either: a) the directly generated
values of the risk factors (X1, X2, X12 = X1 ×X2); or b) the mean centred values of the risk
factors (X1 − X¯1, X2 − X¯2, X12 = (X1 − X¯1)× (X2 − X¯2)). When the risk factors were mean
centred, the model estimated the marginal effects θ1M and θ2M of X1 and X2 on Y , otherwise θ1
and θ2 were estimated. For example, when there were no shared variants Jc = 0, the marginal
effects were approximately:
θM1 = θ1 + 0.3θ12 + J2θ12
(√
0.1/J2
2× 0.3× 0.7 × 0.3× 2
)
,
θM2 = θ2 + 0.25θ12 + J1θ12
(√
0.1/J1
2× 0.3× 0.7 × 0.3× 2
)
. (A1)
The genetic variants were either treated as individual IVs or as a single instrument in
externally weighted gene scores GSX1 and GSX2 for X1 and X2. The external weights for the
gene scores were based on an independent set of 10 000 individuals, and were produced from
the same data generating model used for the main set of participants. The following four sets
of genetic variants were used as IVs in separate two-stage least squares regression models:
• Method 1 – full set of interactions: the J1, J2 and Jc genetic variants used to generate
X1 and X2, plus the unique interactions and quadratic terms of (G1+Gc)× (G2+Gc).
• Method 2 – reduced set of interactions: the J1, J2 and Jc genetic variants used to generate
X1 and X2, plus the interactions from the product G1 ×G2.
• Method 3 – continuous gene scores: the two weighted gene scores GSX1 and GSX2 , and
their product GSX1 ×GSX2 .
• Method 4 – dichotomized gene scores: the two dichotomized gene scores, and their
product.
Method 1 represents the oracle model as it includes all of the variables used in the data
generating model, whereas Methods 2 to 4 are misspecified and their performance should be
compared to Method 1. In Method 2, we have included a subset of the cross-terms between
the genetic variants to create a more realistic scenario where the full set of relevant IVs are
not included in the analysis. Method 3 considers the impact of including all of the genetic
variants into two separate weighted gene scores, and finally, Method 4 considers the impact of
dichotomizing the weighted gene scores.
A2
Data were generated 10 000 times with θ0 = 0.2, θ1 = 0.3, θ2 = 0.2, and θ12 = 0.1, 0.3 and
0.5. Each risk factor was associated with (J1 + Jc) = (J2 + Jc) = 10 genetic variants, and
the number of shared variants Jc was initially set to 0 to consider the scenario where none of
the genetic variants were associated with risk factors (Table 1). The data were re-generated
for σ21 = σ
2
2 = 5% and 1%, for Jc = 0 (Supplementary Table A1) and Jc = 5 (Supplementary
Table A2), and the analyses were re-performed on the directly generated values of the risk
factors. Estimates of the F-statistic and conditional F-statistic for X1, X2 and X12 were
recorded. The analyses were re-performed on the mean centred risk factors (Supplementary
Table A3), and the number of shared variants was set to Jc = 1, 3, 5, 8 and 10 (Table 2). The
following measurements were recorded for the estimates of θ1, θ2 and θ12: median estimate;
standard deviation of estimates; median standard error of estimates; empirical power at the
5% significance level; and empirical coverage of the 95% confidence interval. The conditional
F-statistic (also known as the Sanderson–Windmeijer F-statistic [1]) represents the strength of
the IVs for the risk factors in a joint model, and is the relevant measure of instrument strength
for a multivariable Mendelian randomization analysis [2].
A3
F-stat CF-stat Median SD Median SE Power Coverage
Variants explain 10% of the variance in risk factors:
Methods 1 & 2 a – full set of interactions
θ1 = 0.3 10.3 (0.6) 2.1 (0.3) 0.3043 0.0918 0.0910 91.0 95.0
θ2 = 0.2 10.3 (0.6) 2.1 (0.3) 0.2034 0.0947 0.0945 57.9 95.5
θ12 = 0.3 8.1 (0.6) 1.9 (0.2) 0.3080 0.0722 0.0718 98.8 95.2
Method 3 – continuous gene scores
θ1 = 0.3 364.2 (23.4) 104.5 (25.6) 0.2998 0.1359 0.1332 61.9 95.6
θ2 = 0.2 364.5 (23.2) 103.9 (25.3) 0.2019 0.1405 0.1387 31.5 95.8
θ12 = 0.3 273.7 (22.4) 97.8 (22.8) 0.3000 0.1106 0.1091 77.5 95.8
Method 4 - dichotomized gene scores
θ1 = 0.3 224.2 (17.7) 41.9 (13.4) 0.3039 0.2145 0.2074 32.1 95.8
θ2 = 0.2 224.4 (17.7) 41.7 (13.3) 0.2047 0.2236 0.2164 15.2 96.2
θ12 = 0.3 168.2 (16.3) 40.0 (12.4) 0.2972 0.1777 0.1722 41.8 96.0
Variants explain 5% of the variance in risk factors:
Methods 1 & 2 a – full set of interactions
θ1 = 0.3 5.4 (0.4) 1.5 (0.2) 0.3174 0.0931 0.0920 92.4 94.5
θ2 = 0.2 5.4 (0.4) 1.4 (0.2) 0.2166 0.0957 0.0959 62.0 94.8
θ12 = 0.3 3.9 (0.4) 1.2 (0.2) 0.3087 0.0889 0.0888 92.8 95.0
Method 3 – continuous gene scores
θ1 = 0.3 170.2 (15.5) 25.4 (11.7) 0.2988 0.2298 0.2121 29.9 96.9
θ2 = 0.2 170.1 (15.7) 25.2 (11.5) 0.1985 0.2421 0.2237 13.8 96.9
θ12 = 0.3 109.4 (13.3) 23.8 (10.4) 0.3020 0.2458 0.2276 26.7 96.9
Method 4 - dichotomized gene scores
θ1 = 0.3 107.3 (12.2) 10.7 (6.7) 0.2970 3.928 0.3367 12.6 98.9
θ2 = 0.2 106.9 (12.0) 10.6 (6.6) 0.1948 3.804 0.3551 5.4 98.7
θ12 = 0.3 68.8 (10.2) 10.2 (6.1) 0.3033 4.065 0.3654 10.8 98.8
Variants explain 1% of the variance in risk factors:
Methods 1 & 2 a – full set of interactions
θ1 = 0.3 1.8 (0.2) 1.4 (0.2) 0.3681 0.0910 0.0901 97.7 88.4
θ2 = 0.2 1.8 (0.2) 1.4 (0.2) 0.2670 0.0930 0.0930 81.4 88.6
θ12 = 0.3 1.4 (0.2) 1.0 (0.1) 0.3029 0.0971 0.0972 86.4 95.4
Method 3 – continuous gene scores
θ1 = 0.3 29.5 (6.4) 1.9 (2.9) 0.2854 29.26 0.8411 2.8 99.9
θ2 = 0.2 29.4 (6.4) 1.9 (2.8) 0.1883 31.58 0.9203 1.0 99.9
θ12 = 0.3 12.3 (4.1) 1.6 (2.1) 0.3185 52.32 1.537 0.7 100.0
Method 4 - dichotomized gene scores
θ1 = 0.3 19.1 (5.1) 1.6 (2.8) 0.2992 123.8 1.063 1.9 99.9
θ2 = 0.2 19.0 (5.0) 1.5 (2.4) 0.1930 217.5 1.163 0.6 100.0
θ12 = 0.3 8.1 (3.3) 1.2 (1.7) 0.3121 347.4 1.933 0.3 100.0
Supplementary Table A1: Simulation study results for interactions between risk factors varying
the amount of variance in the risk factors explained by the genetic variants, with no shared
variants and an interaction effect θ12 = 0.3: mean F-statistic (F-stat), mean conditional F-
statistic (CF-stat), median estimate, standard deviation (SD) of estimates, median standard
error (SE), empirical power (%) to reject null at 5% significance, and empirical coverage (%)
of 95% confidence interval.
aAs there are no shared variants, methods 1 and 2 are equivalent.
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F-stat CF-stat Median SD Median SE Power Coverage
Variants explain 10% of the variance in risk factors:
Method 1 – full set of interactions
θ1 = 0.3 11.6 (0.7) 2.5 (0.4) 0.2981 0.0933 0.0927 89.1 95.0
θ2 = 0.2 11.6 (0.7) 2.5 (0.4) 0.1988 0.0955 0.0960 55.0 95.5
θ12 = 0.3 13.4 (0.9) 2.2 (0.3) 0.3074 0.0707 0.0706 99.0 95.0
Method 2 – reduced set of interactions
θ1 = 0.3 28.8 (1.8) 2.6 (0.4) 0.2970 0.1664 0.1649 44.2 95.8
θ2 = 0.2 28.8 (1.8) 2.6 (0.4) 0.1966 0.1719 0.1715 21.0 95.9
θ12 = 0.3 32.6 (2.1) 2.3 (0.3) 0.3056 0.1337 0.1333 63.4 95.8
Method 3 – continuous gene scores
θ1 = 0.3 366.4 (23.2) 131.8 (30.9) 0.2993 0.1272 0.1244 67.0 95.4
θ2 = 0.2 366.3 (23.4) 131.0 (30.7) 0.1992 0.1314 0.1293 35.1 95.4
θ12 = 0.3 426.6 (29.1) 120.9 (26.9) 0.3008 0.1000 0.0978 84.8 95.4
Method 4 - dichotomized gene scores
θ1 = 0.3 233.5 (18.1) 35.8 (12.4) 0.2984 0.2399 0.2302 25.9 96.4
θ2 = 0.2 233.5 (18.2) 35.6 (12.3) 0.2005 0.2482 0.2396 13.0 96.4
θ12 = 0.3 284.1 (21.6) 33.8 (11.2) 0.3006 0.1950 0.1877 36.8 96.4
Variants explain 5% of the variance in risk factors:
Method 1 – full set of interactions
θ1 = 0.3 6.0 (0.5) 1.6 (0.2) 0.3052 0.0980 0.0983 87.7 95.2
θ2 = 0.2 6.0 (0.5) 1.5 (0.2) 0.2078 0.1018 0.1022 53.3 95.2
θ12 = 0.3 6.1 (0.5) 1.3 (0.2) 0.3097 0.0925 0.0919 91.3 95.3
Method 2 – reduced set of interactions
θ1 = 0.3 14.2 (1.2) 1.6 (0.3) 0.2982 0.1600 0.1588 48.4 96.3
θ2 = 0.2 14.2 (1.2) 1.6 (0.3) 0.1994 0.1665 0.1664 22.7 96.1
θ12 = 0.3 13.9 (1.3) 1.4 (0.2) 0.3087 0.1621 0.1615 49.0 96.1
Method 3 – continuous gene scores
θ1 = 0.3 171.8 (15.6) 32.9 (14.1) 0.3014 0.2078 0.1951 35.7 96.4
θ2 = 0.2 172.1 (15.4) 32.6 (13.9) 0.2041 0.2169 0.2043 16.9 96.5
θ12 = 0.3 171.7 (17.6) 30.0 (12.0) 0.2981 0.2147 0.2010 32.6 96.5
Method 4 - dichotomized gene scores
θ1 = 0.3 111.9 (12.5) 9.5 (6.4) 0.2933 0.8024 0.3732 10.2 99.1
θ2 = 0.2 112.2 (12.3) 9.4 (6.3) 0.1981 0.8127 0.3926 4.6 98.9
θ12 = 0.3 117.6 (13.5) 8.9 (5.7) 0.3066 0.8619 0.3967 9.6 99.1
Variants explain 1% of the variance in risk factors:
Method 1 – full set of interactions
θ1 = 0.3 2.0 (0.2) 1.4 (0.2) 0.3504 0.0975 0.0971 94.4 92.0
θ2 = 0.2 2.0 (0.2) 1.3 (0.2) 0.2478 0.1003 0.1002 69.6 92.2
θ12 = 0.3 1.6 (0.2) 1.0 (0.1) 0.3037 0.1051 0.1043 82.0 95.3
Method 2 – reduced set of interactions
θ1 = 0.3 3.5 (0.6) 1.4 (0.2) 0.3225 0.1398 0.1395 63.8 95.6
θ2 = 0.2 3.5 (0.5) 1.4 (0.2) 0.2243 0.1459 0.1457 34.3 95.7
θ12 = 0.3 2.6 (0.5) 1.1 (0.1) 0.3036 0.1771 0.1758 41.8 96.1
Method 3 – continuous gene scores
θ1 = 0.3 31.0 (6.6) 2.5 (3.7) 0.2912 47.33 0.7448 3.6 99.9
θ2 = 0.2 30.9 (6.5) 2.3 (3.4) 0.1939 41.15 0.8014 1.1 99.9
θ12 = 0.3 19.9 (5.4) 1.9 (2.4) 0.3030 72.69 1.315 0.6 99.9
Method 4 - dichotomized gene scores
θ1 = 0.3 20.9 (5.3) 1.6 (2.9) 0.2967 65.97 1.108 1.5 99.9
θ2 = 0.2 20.8 (5.2) 1.5 (2.5) 0.1959 54.84 1.208 0.4 100.0
θ12 = 0.3 14.1 (4.4) 1.2 (1.6) 0.3096 105.7 1.991 0.2 100.0
Supplementary Table A2: Simulation study results for interactions between risk factors varying
the amount of variance in the risk factors explained by the genetic variants, with 5 shared
variants and an interaction effect θ12 = 0.3: mean F-statistic (F-stat), mean conditional F-
statistic (CF-stat), median estimate, standard deviation (SD) of estimates, median standard
error (SE), empirical power (%) to reject null at 5% significance, and coverage (%) of 95%
confidence interval.
A5
Median SD Median SE Power (%) Coverage (%)
Methods 1 & 2 a – full set of interactions
θ1 = 0.3 0.4311 0.0327 0.0320 100.0 -
θ2 = 0.2 0.3370 0.0328 0.0320 100.0 -
θ12 = 0.1 0.1101 0.0721 0.0718 33.7 94.6
θ1 = 0.3 0.6679 0.0408 0.0320 100.0 -
θ2 = 0.2 0.5823 0.0413 0.0320 100.0 -
θ12 = 0.3 0.3080 0.0722 0.0718 98.8 95.2
θ1 = 0.3 0.9044 0.0527 0.0320 100.0 -
θ2 = 0.2 0.8290 0.0528 0.0320 100.0 -
θ12 = 0.5 0.5073 0.0715 0.0718 100.0 95.2
Method 3 – continuous gene scores
θ1 = 0.3 0.4178 0.0348 0.0343 100.0 -
θ2 = 0.2 0.3234 0.0349 0.0343 100.0 -
θ12 = 0.1 0.1010 0.1113 0.1091 15.4 95.5
θ1 = 0.3 0.6539 0.0424 0.0343 100.0 -
θ2 = 0.2 0.5691 0.0431 0.0343 100.0 -
θ12 = 0.3 0.3000 0.1106 0.1091 77.5 95.8
θ1 = 0.3 0.8906 0.0539 0.0343 100.0 -
θ2 = 0.2 0.8165 0.0543 0.0343 100.0 -
θ12 = 0.5 0.4995 0.1107 0.1092 98.7 95.6
Method 4 – dichotomized gene scores
θ1 = 0.3 0.4173 0.0438 0.0435 100.0 -
θ2 = 0.2 0.3236 0.0438 0.0434 100.0 -
θ12 = 0.1 0.1022 0.1786 0.1720 8.0 95.9
θ1 = 0.3 0.6538 0.0496 0.0435 100.0 -
θ2 = 0.2 0.5687 0.0506 0.0435 100.0 -
θ12 = 0.3 0.2972 0.1777 0.1722 41.8 96.0
θ1 = 0.3 0.8913 0.0597 0.0435 100.0 -
θ2 = 0.2 0.8165 0.0603 0.0435 100.0 -
θ12 = 0.5 0.5002 0.1776 0.1718 80.7 96.1
Supplementary Table A3: Simulation study results for interactions between risk factors with
no shared variants after centering the risk factors: median estimate, standard deviation (SD)
of estimates, median standard error (SE), empirical power (%) to reject null at 5% significance,
and empirical coverage (%) of 95% confidence interval. Note that centering changes the
estimands for the main effect terms, not only the estimates – hence coverage is only displayed
for the interaction term.
aAs there are no shared variants, methods 1 and 2 are equivalent.
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Simulation study 2: interactions between interventions
Using the same notation defined in the first simulation study, the risk factor X was generated
for i = 1, 2, . . . , 10 000 participants from the following data generating model:
Xi = 0.3 +
JA∑
j=1
αAjGAji +
JB∑
j=1
αBjGBji + αAB
JA×JB∑
j=1
GABji + Ui + ǫXi .
We assume that the two gene regions are distinct, and the genetic variants GA and GB are
not in linkage disequilibrium. The genotypes were generated independently from binomial
distributions Bin(2,MAFj), where MAFj represents the MAF for the j
th genetic variant.
MAFj was drawn from a uniform distribution U(MAFL,MAFU), where the value of MAFL
and MAFU were either taken as 0.4 and 0.5 (common variants), or 0.1 and 0.2 (uncommon
variants). We assumed that the interaction effect αAB was constant across the JA×JB product
terms for simplicity.
The approximate proportion of variance explained in X by GA (σ
2
A) and GB (σ
2
B) varied
between scenarios. As before, the genetic associationsαA andαB were calculated by rearranging
the formula for the variance of the genetic variants to ensure the amount of variance explained
by each variant was the same:
αAj =
√
σ2A/JA
2×MAFAj(1−MAFAj) and
αBj =
√
σ2B/JB
2×MAFBj(1−MAFBj) .
The confounders U were drawn from N (0, 0.25), and the error term ǫX was generated from
N (0, 0.65). The outcome Y was generated from:
Yi = θ0 + θ1Xi + Ui + ǫY i ,
where θ1 represents the causal effect of X on Y , and the error term ǫY was generated from a
standard normal distribution N (0, 1). The data was generated 10 000 times under the following
scenarios:
• Scenario 1: MAFA ∼ U(0.4, 0.5), MAFB ∼ U(0.4, 0.5), σ2A = 3% and σ2B = 3%
• Scenario 2: MAFA ∼ U(0.4, 0.5), MAFB ∼ U(0.4, 0.5), σ2A = 5% and σ2B = 5%
• Scenario 3: MAFA ∼ U(0.4, 0.5), MAFB ∼ U(0.4, 0.5), σ2A = 3% and σ2B = 7%
• Scenario 4: MAFA ∼ U(0.1, 0.2), MAFB ∼ U(0.1, 0.2), σ2A = 5% and σ2B = 5%
• Scenario 5: MAFA ∼ U(0.4, 0.5), MAFB ∼ U(0.1, 0.2), σ2A = 5% and σ2B = 5%
• Scenario 6: MAFA ∼ U(0.4, 0.5), MAFB ∼ U(0.1, 0.2), σ2A = 3% and σ2B = 7%
with JA = JB = 3, θ0 = 0.2, θ1 = 0.1, and αAB = 0.1, 0.3 and 0.5. The above scenarios were
selected to consider the impact of varying the MAF and the amount of variance in the risk
factor explained by the genetic variants had on the performance of the method.
For each scenario, optimal weighted gene scores GSA and GSB were generated for each
gene region, where the external weights were produced from an independent set of 10 000
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individuals from the same data-generating model used for the main set of participants. The
two gene scores were dichotomized at their median values to create two binary variables. The
outcome was then regressed against: a) the two continuous gene scores and their product; and
b) the dichotomized gene scores and their product. The following measurements were recorded
for the estimate of the interaction effect between the gene scores on the outcome: median
estimate; standard deviation of estimates; median standard error; and empirical power at the
5% significance level.
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Applied example: the effects of BMI and alcohol on systolic blood
pressure
UK Biobank is a prospective, population-based cohort consisting of approximately 500,000
participants aged between 40 and 69 years at baseline living in the UK. Extensive baseline
characteristics were collected at recruitment, including lifestyle factors, sociodemographic information,
and physical attributes. For the analysis, we considered 367,643 unrelated participants of
European descent who passed data quality control measures and had genetic data [3].
Body mass index (BMI, kg/m2) and systolic blood pressure (SBP, mmHg) were measured
at baseline when participants attended the assessment centre. Information on baseline alcohol
consumption was obtained from a touchscreen questionnaire which included questions on
alcohol drinking status, frequency of alcohol consumption, and beverage type. The responses to
the amount of alcohol drank and beverage type were used to create a continuous variable that
represented alcohol consumption in units per day. To adjust for blood pressure medication,
15 mmHg was added to SBP for individuals who reported to be on blood pressure lowering
medication [4]. Individuals were dropped from the analysis if they had missing data on BMI,
SBP, alcohol consumption, or relevant genetic variants. The final sample size was 291,781.
We used the 77 genome-wide significant variants from a meta-analysis by the Genetic
Investigation of ANthropometric Traits (GIANT) consortium in participants of European
ancestry to act as IVs for BMI [5]. For alcohol, we identified 10 genetic variants in the ADH1B
gene region that have been shown to be associated with alcohol consumption [6]. The genetic
variants used as IVs for BMI and alcohol consumption were cross-referenced to check for any
overlap. BMI was regressed separately against each of the 10 alcohol variants, and alcohol
consumption was regressed against each of the 77 BMI variants. All models were adjusted for
gender, age, and the first ten genomic principal components.
Internally-weighted gene scores were created for BMI based on the 77 genetic variants
(GSBMI), and for alcohol consumption based on the 10 genetic variants (GSAC), and these
gene scores were dichotomized at their median values to create two binary variables. A separate
binary variable was generated using the rs1229984 variant only, where participants were either
considered to have: a) a low alcohol consumption if they were homozygous or heterozygous for
the alcohol-decreasing allele; or b) a high alcohol consumption if they were homozygous for the
alcohol-increasing allele (as in the paper by Carter et al. [7]). Using these binary variables,
the following groups of participants were created:
• Low BMI, low alcohol consumption: GSBMI ≤ med(GSBMI) and GSAC ≤ med(GSAC)
or was homozygous or heterozygous for the alcohol decreasing allele for the rs1229984
variant,
• High BMI, low alcohol consumption: GSBMI > med(GSBMI) and GSAC ≤ med(GSAC)
or was homozygous or heterozygous for the alcohol decreasing allele for the rs1229984
variant,
• Low BMI, high alcohol consumption: GSBMI ≤ med(GSBMI) and GSAC > med(GSAC)
or was homozygous for the alcohol increasing allele for the rs1229984 variant, and
• High BMI, high alcohol consumption: GSBMI ≤ med(GSBMI) and GSAC > med(GSAC)
or was homozygous for the alcohol increasing allele for the rs1229984 variant.
The above criteria created four groups of participants based on the dichotomized gene scores
for BMI and alcohol consumption, and another four groups based on the dichotomized gene
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score for BMI and the rs1229984 variant. The numbers of participants, and the mean and
standard deviation of BMI, alcohol consumption, and SBP were recorded for each group.
Two-stage least squares regression models of SBP were fitted to BMI, alcohol consumption,
and the product of BMI and alcohol consumption. The following sets of IVs were considered:
• Method 1: the 77 variants for BMI and 10 variants for alcohol consumption, plus 770
cross-terms between the two sets of variants.
• Method 2: the continuous gene scores GSBMI and GSAC , plus their product GSBMI ×
GSAC .
• Method 3: the dichotomized gene scores of GSBMI and GSAC , plus their product.
The models were refitted excluding all of the variants for alcohol consumption apart from the
lead rs1229984 variant. All models were adjusted for gender, age, and the first ten genomic
principal components. For each model, the estimate and standard error of the interaction term
was recorded with its p-value. In total, six two-stage least squares regression models were fitted
to the dataset, and all of the models were adjusted for age, gender and the first 10 genomic
principal components. The F-statistic and the Sanderson–Windmeijer conditional F-statistic
were estimated for each set of IVs with respect to BMI, alcohol consumption, and the product
of BMI and alcohol consumption (Supplementary Table A4).
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Method 1 Method 2 Method 3
F-stat CF-stat F-stat CF-stat F-stat CF-stat
10 variants for alcohol:
BMI 6.8 1.3 1662.8 21.1 1054.1 7.0
Alcohol consumption 2.4 1.1 268.0 20.9 55.6 6.9
Product term 2.4 1.1 298.6 21.0 73.2 6.9
rs1229984 for alcohol:
BMI 32.8 1.3 1654.9 17.2 1066.8 13.5
Alcohol consumption 7.7 1.2 245.1 17.1 241.6 13.4
Product term 7.9 1.2 267.7 17.1 266.5 13.4
Supplementary Table A4: F-statistics (F-stat) and conditional F-statistics (CF-stat) for
applied example.
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Appendix H
Chapter 3 supplementary material
H.1 Non-convergent robust regression models
The number of robust regression models that did not converge in the simulation study
outlined in Section 3.5 are contained in Table H.1. Robust regression was applied to
the IVW and MR-Egger models, and was also considered in conjunction with penalized
weights.
Table H.1 Number of the 10 000 simulations that failed to report a standard error using
robust regression (without and with penalized weights) with the inverse-variance weighted
(IVW) and MR-Egger methods, for Scenarios 1-4 with a null (θ = 0) or positive (θ = 0.3)
causal effect by the number of invalid instrumental variables.
IVW MR-Egger
Robust Robust, penalized Robust Robust, penalized
No. invalid: 0 1 3 6 0 1 3 6 0 1 3 6 0 1 3 6
Null causal effect: θ = 0
Scenario 1 0 - - - 0 - - - 16 - - - 16 - - -
Scenario 2 - 1 2 5 - 3 9 120 - 24 72 78 - 45 98 258
Scenario 3 - 2 1 4 - 3 10 51 - 32 69 32 - 30 70 139
Scenario 4 - 3 84 11 - 5 6 22 - 144 100 5 - 124 76 9
Positive causal effect: θ = 0.3
Scenario 1 4 - - - 3 - - - 13 - - - 13 - - -
Scenario 2 - 0 0 1 - 1 3 54 - 20 55 47 - 24 71 211
Scenario 3 - 0 0 3 - 3 2 22 - 24 72 19 - 37 62 73
Scenario 4 - 2 30 4 - 0 9 9 - 151 91 10 - 122 81 15
Abbreviations: IVW, inverse-variance weighted; No., number.
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H.2 MR-Egger models
Table H.2 contains the results from the simulation study (Section 3.5) when the MR-
Egger model was applied to the simulated data with: 1) robust regression (Rr); 2)
penalized weights (PW); and 3) robust regression and penalized weights (Rr and PW).
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Table H.2 Mean (standard error) estimates and power from the MR-Egger method with:
robust regression (Rr); penalized weights (PW); and robust regression and penalized weights
(Rr and PW) for Scenarios 1-4 with a null (θ = 0) or positive (θ = 0.3) causal effect by the
number of invalid instrumental variables.
No invalid IVs 1 invalid IV 3 invalid IVs 6 invalid IVs
Mean Power, Mean Power, Mean Power, Mean Power,
(mean SE) % (mean SE) % (mean SE) % (mean SE) %
Null causal effect: θ = 0
Scenario 1. No pleiotropy, InSIDE satisfied
Rr 0.000 (0.231) 8.2 - - - - - -
PW -0.001 (0.216) 4.3 - - - - - -
Rr and PW 0.000 (0.230) 8.3 - - - - - -
Scenario 2. Balanced pleiotropy, InSIDE satisfied
Rr - - -0.006 (0.245) 9.7 -0.002 (0.375) 9.6 -0.007 (0.671) 10.8
PW - - -0.006 (0.208) 9.9 -0.003 (0.231) 16.9 -0.009 (0.274) 31.5
Rr and PW - - -0.007 (0.254) 9.2 -0.001 (0.333) 10.7 -0.008 (0.505) 20.3
Scenario 3. Directional pleiotropy, InSIDE satisfied
Rr - - -0.003 (0.246) 9.9 0.001 (0.376) 9.5 -0.004 (0.564) 13.8
PW - - -0.004 (0.208) 10.1 0.001 (0.249) 18.7 -0.009 (0.343) 37.9
Rr and PW - - -0.004 (0.256) 9.4 0.001 (0.309) 12.0 -0.005 (0.419) 32.4
Scenario 4. Directional pleiotropy, InSIDE violated
Rr - - 0.171 (0.291) 18.2 0.493 (0.234) 65.1 0.649 (0.158) 95.6
PW - - 0.241 (0.196) 33.0 0.527 (0.178) 81.2 0.651 (0.159) 97.7
Rr and PW - - 0.173 (0.272) 18.5 0.490 (0.215) 68.2 0.652 (0.148) 96.8
Positive causal effect: θ = 0.3
Scenario 1. No pleiotropy, InSIDE satisfied
Rr 0.144 (0.273) 13.1 - - - - - -
PW 0.143 (0.258) 7.9 - - - - - -
Rr and PW 0.144 (0.271) 13.3 - - - - - -
Scenario 2. Balanced pleiotropy, InSIDE satisfied
Rr - - 0.140 (0.295) 13.1 0.139 (0.430) 11.6 0.124 (0.665) 11.9
PW - - 0.139 (0.255) 13.5 0.140 (0.282) 19.4 0.130 (0.331) 30.2
Rr and PW - - 0.140 (0.297) 12.9 0.140 (0.363) 14.6 0.133 (0.508) 22.4
Scenario 3. Directional pleiotropy, InSIDE satisfied
Rr - - 0.141 (0.295) 13.2 0.135 (0.433) 11.8 0.136 (0.563) 14.7
PW - - 0.140 (0.252) 13.2 0.137 (0.302) 19.9 0.137 (0.392) 30.7
Rr and PW - - 0.140 (0.292) 13.3 0.135 (0.352) 15.9 0.138 (0.433) 31.0
Scenario 4. Directional pleiotropy, InSIDE violated
Rr - - 0.338 (0.340) 25.5 0.719 (0.274) 75.6 0.893 (0.190) 97.7
PW - - 0.418 (0.233) 48.9 0.754 (0.210) 91.2 0.895 (0.188) 99.4
Rr and PW - - 0.340 (0.319) 27.1 0.716 (0.249) 78.6 0.897 (0.179) 98.2
Abbreviations: IV, instrumental variable; SE, standard error; InSIDE, instrument strength independent of direct effect;
Rr, robust regression; PW, penalized weights.
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H.3 One-sample Mendelian randomization
Results from the simulation study (Section 3.5) when the data was generated from one
sample are contained in Table H.3 (null causal effect θ = 0) and Table H.4 (positive
causal effect θ = 0.3). Estimates from the IVW model with: 1) the J genetic variants
(IVW); 2) robust regression (Rr); 3) penalized weights (PW); 4) robust regression
and penalized weights (Rr and PW); and 5) the three sets of variants selected by the
least trimmed squared (LTS) estimator, and the Lasso selection (LS) method with the
heterogeneity stopping rule for Scenarios 1-4 are displayed in the Tables H.3 and H.4.
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Table H.3 Mean (standard error) and power (%) of the estimates from the IVW model
with: 1) the J genetic variants (IVW); 2) robust regression (Rr); 3) penalized weights (PW);
4) robust regression and penalized weights (Rr and PW); and 5) the three sets of variants
selected by the least trimmed squared (LTS) estimator for Scenarios 1-4 with a null causal
effect (θ = 0) by the number of invalid instrumental variables for one-sample Mendelian
randomization. Results from the Lasso selection (LS) method with the heterogeneity stopping
rule are also provided.
No invalid IVs 1 invalid IV 3 invalid IVs 6 invalid IVs
Mean Pow., Mean Pow., Mean Pow., Mean Pow.,
(mean SE) % (mean SE) % (mean SE) % (mean SE) %
Null causal effect: θ = 0
Scenario 1. No pleiotropy, InSIDE satisfied
IVW 0.021 (0.061) 5.6 - - - - - -
Rr 0.021 (0.065) 6.8 - - - - - -
PW 0.019 (0.060) 6.0 - - - - - -
Rr and PW 0.020 (0.063) 7.2 - - - - - -
LTSa
h 0.014 (0.078) 18.9 - - - - - -
wLTS,2 0.019 (0.061) 7.5 - - - - - -
Auto 0.021 (0.060) 5.9 - - - - - -
LS 0.021 (0.060) 6.2 - - - - - -
Scenario 2. Balanced pleiotropy, InSIDE satisfied
IVW - - 0.020 (0.088) 6.4 0.020 (0.132) 7.1 0.024 (0.180) 7.3
Rr - - 0.021 (0.068) 7.8 0.020 (0.096) 6.8 0.023 (0.195) 5.9
PW - - 0.018 (0.062) 7.1 0.015 (0.066) 9.7 0.008 (0.075) 19.7
Rr and PW - - 0.019 (0.070) 6.8 0.017 (0.092) 6.3 0.010 (0.156) 7.7
LTSa
h - - 0.014 (0.078) 18.5 0.013 (0.079) 17.8 0.012 (0.08) 15.6
wLTS,2 - - 0.019 (0.063) 7.4 0.019 (0.075) 9.0 0.022 (0.142) 15.2
Auto - - 0.020 (0.063) 6.9 0.020 (0.071) 9.3 0.019 (0.091) 17.8
LS - - 0.020 (0.063) 7.1 0.020 (0.070) 9.2 0.019 (0.088) 16.9
Scenario 3. Directional pleiotropy, InSIDE satisfied
IVW - - 0.086 (0.088) 9.3 0.216 (0.123) 36.2 0.409 (0.150) 92.5
Rr - - 0.032 (0.067) 8.8 0.088 (0.109) 11.2 0.357 (0.222) 44.9
PW - - 0.025 (0.062) 7.0 0.046 (0.067) 13.6 0.132 (0.081) 40.4
Rr and PW - - 0.025 (0.070) 7.5 0.040 (0.088) 10.8 0.103 (0.125) 21.5
LTSa
h - - 0.015 (0.078) 18.6 0.018 (0.079) 16.8 0.035 (0.08) 14.6
wLTS,2 - - 0.024 (0.063) 6.9 0.059 (0.076) 13.0 0.306 (0.129) 71.1
Auto - - 0.027 (0.063) 6.9 0.049 (0.072) 12.6 0.140 (0.095) 36.0
LS - - 0.027 (0.063) 7.2 0.049 (0.071) 12.6 0.173 (0.096) 42.8
Scenario 4. Directional pleiotropy, InSIDE violated
IVW - - 0.096 (0.068) 27.5 0.202 (0.072) 86.6 0.303 (0.067) 100.0
Rr - - 0.053 (0.081) 10.1 0.163 (0.119) 38.4 0.302 (0.072) 98.4
PW - - 0.040 (0.061) 14.2 0.095 (0.062) 41.4 0.237 (0.061) 89.6
Rr and PW - - 0.038 (0.069) 11.4 0.089 (0.079) 30.7 0.236 (0.071) 83.9
LTSa
h - - 0.021 (0.078) 20.1 0.039 (0.076) 24.6 0.169 (0.067) 53.1
wLTS,2 - - 0.038 (0.062) 13.7 0.113 (0.067) 47.9 0.282 (0.066) 95.8
Auto - - 0.049 (0.062) 17.4 0.132 (0.066) 58.9 0.285 (0.065) 95.6
LS - - 0.048 (0.062) 17.2 0.138 (0.066) 58.8 0.300 (0.064) 99.1
Abbreviations: IV, instrumental variable; SE, standard error; Pow., power; InSIDE, instrument strength independent
of direct effect; IVW, inverse variance weighted; Rr, robust regression; PW, penalized weights; LTS, least trimmed
squares; LS, Lasso selection; Auto, automated.
aThe following three sets of genetic variants were selected from the LTS estimator and included in the IVW model: 1)
the h=8 variants used to estimate the initial LTS estimate θˆLTS,h; 2) the variants with a weight of 1 in wLTS,2; and
3) the variants selected from the automated approach based on the heterogeneity stopping criteria.
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Table H.4 Mean (standard error) and power (%) of the estimates from the IVW model
with: 1) the J genetic variants (IVW); 2) robust regression (Rr); 3) penalized weights (PW);
4) robust regression and penalized weights (Rr and PW); and 5) the three sets of variants
selected by the least trimmed squared (LTS) estimator for Scenarios 1-4 with a positive causal
effect (θ = 0.3) by the number of invalid instrumental variables for one-sample Mendelian
randomization. Results from the Lasso selection (LS) method with the heterogeneity stopping
rule are also provided.
No invalid IVs 1 invalid IV 3 invalid IVs 6 invalid IVs
Mean Pow., Mean Pow., Mean Pow., Mean Pow.,
(mean SE) % (mean SE) % (mean SE) % (mean SE) %
Positive causal effect: θ = 0.3
Scenario 1. No pleiotropy, InSIDE satisfied
IVW 0.321 (0.068) 99.7 - - - - - -
Rr 0.321 (0.073) 97.7 - - - - - -
PW 0.321 (0.068) 99.7 - - - - - -
Rr and PW 0.321 (0.072) 97.9 - - - - - -
LTSa
h 0.312 (0.092) 84.8 - - - - - -
wLTS,2 0.319 (0.069) 99.0 - - - - - -
Auto 0.321 (0.068) 99.7 - - - - - -
LS 0.321 (0.068) 99.7 - - - - - -
Scenario 2. Balanced pleiotropy, InSIDE satisfied
IVW - - 0.322 (0.090) 91.2 0.322 (0.133) 66.2 0.323 (0.180) 43.9
Rr - - 0.322 (0.073) 97.2 0.321 (0.098) 86.1 0.323 (0.193) 43.6
PW - - 0.320 (0.070) 99.1 0.316 (0.076) 96.4 0.308 (0.087) 85.4
Rr and PW - - 0.321 (0.078) 96.3 0.317 (0.096) 88.4 0.310 (0.138) 67.3
LTSa
h - - 0.315 (0.092) 85.7 0.314 (0.093) 86.0 0.312 (0.093) 87.8
wLTS,2 - - 0.320 (0.071) 98.9 0.320 (0.081) 94.4 0.321 (0.142) 60.1
Auto - - 0.322 (0.071) 99.2 0.320 (0.079) 95.3 0.320 (0.103) 78.8
LS - - 0.322 (0.071) 99.2 0.320 (0.079) 95.6 0.320 (0.099) 81.4
Scenario 3. Directional pleiotropy, InSIDE satisfied
IVW - - 0.386 (0.088) 99.7 0.517 (0.124) 100.0 0.710 (0.150) 100.0
Rr - - 0.332 (0.073) 97.9 0.390 (0.111) 93.3 0.655 (0.226) 86.8
PW - - 0.330 (0.070) 99.7 0.362 (0.076) 99.5 0.465 (0.093) 99.5
Rr and PW - - 0.328 (0.078) 96.0 0.351 (0.093) 92.6 0.434 (0.125) 89.1
LTSa
h - - 0.316 (0.092) 86.2 0.320 (0.093) 86.9 0.336 (0.093) 91.1
wLTS,2 - - 0.324 (0.071) 99.1 0.361 (0.082) 99.1 0.602 (0.130) 99.3
Auto - - 0.331 (0.071) 99.6 0.365 (0.080) 99.4 0.499 (0.108) 98.2
LS - - 0.331 (0.071) 99.6 0.363 (0.079) 99.4 0.508 (0.108) 99.2
Scenario 4. Directional pleiotropy, InSIDE violated
IVW - - 0.396 (0.070) 100.0 0.502 (0.073) 100.0 0.601 (0.067) 100.0
Rr - - 0.352 (0.088) 95.5 0.463 (0.125) 89.7 0.601 (0.073) 99.7
PW - - 0.349 (0.068) 99.7 0.424 (0.068) 99.7 0.561 (0.064) 99.9
Rr and PW - - 0.343 (0.078) 97.0 0.414 (0.090) 95.7 0.562 (0.071) 98.8
LTSa
h - - 0.319 (0.092) 86.3 0.339 (0.090) 87.4 0.468 (0.079) 94.5
wLTS,2 - - 0.336 (0.070) 99.3 0.415 (0.071) 99.1 0.580 (0.067) 99.6
Auto - - 0.358 (0.068) 99.7 0.462 (0.070) 99.5 0.595 (0.066) 99.7
LS - - 0.357 (0.068) 99.7 0.463 (0.070) 99.8 0.600 (0.066) 100.0
Abbreviations: IV, instrumental variable; SE, standard error; Pow., power; InSIDE, instrument strength independent
of direct effect; IVW, inverse variance weighted; Rr, robust regression; PW, penalized weights; LTS, least trimmed
squares; LS, Lasso selection; Auto, automated.
aThe following three sets of genetic variants were selected from the LTS estimator and included in the IVW model: 1)
the h=8 variants used to estimate the initial LTS estimate θˆLTS,h; 2) the variants with a weight of 1 in wLTS,2; and
3) the variants selected from the automated approach based on the heterogeneity stopping criteria.
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I.1 One–sample Mendelian randomization study us-
ing data from UK Biobank
I.1.1 Histograms of the adiposity and body composition mea-
surements
Histograms of weight, height and BMI are contained in Figure I.1, and Figure I.2
contains histograms of the BIA measurements for FMI and FFMI. Figures I.1 and I.2
consist of the data used in the main analysis (n=360,409), and are presented for the
entire dataset, and by gender. Figure I.3 contains histograms of the DXA measurements
for FMI, FFMI and LMI, and these histograms are based on the 3,901 participants
with DXA measurements.
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Fig. I.1 Histograms of weight, height and body mass index (BMI) by gender of the 360,409
participants in UK Biobank included in the main analysis for the entire dataset and by
gender. The dotted red lines represent the mean values of the measurements.
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Fig. I.2 Histograms of the bioelectrical impedance analysis measurements of fat mass index
(FMI) and fat-free mass index (FFMI) by gender of the 360,409 participants in UK Biobank
included in the main analysis for the entire dataset and by gender. The dotted red lines
represent the mean values of the measurements.
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Fig. I.3 Histograms of the dual-energy X-ray (DXA) measurements fat mass index (FMI),
fat-free mass index (FFMI) and lean mass index (LMI) of the 3,901 participants with DXA
measurements by gender. The dotted red lines represent the mean values of the measurements.
	
	
	
	
0.000
0.005
0.010
0 100 200 300
fmi
de
ns
ity
0.000
0.005
0.010
0.015
0 100 200 300
fmi
de
ns
ity
sex
Female
Male
0.000
0.005
0.010
0.015
100 150 200 250
lmi
de
ns
ity
0.00
0.01
0.02
0.03
100 150 200 250
lmi
de
ns
ity
sex
Female
Male
0.000
0.005
0.010
0.015
150 200 250
ffmi
de
ns
ity
0.00
0.01
0.02
0.03
150 200 250
ffmi
de
ns
ity
sex
Female
Male
	FMI	(kg/m2)	 	 	 									 									FMI	(kg/m2)	
	
	LMI	(kg/m2)	 	 	 									 									LMI	(kg/m2)	
	
	FFMI	(kg/m2)	 	 	 											 	 	FFMI	(kg/m2)	
	
I.1 One–sample Mendelian randomization study 417
I.1.2 Information on the genetic variants considered for the
Mendelian randomization analysis
Table I.1 contains information on the genetic variants considered for the Mendelian
randomization analysis in adults using the UK Biobank dataset. The final two columns
in Table I.1 indicate whether the variant was included in the liberal or conservative
sets of genetic variants.
Table I.1 Information on the 77 genetic variants selected from the GIANT consortium [104]
and were considered for the Mendelian randomization analysis using the UK Biobank dataset.
The final two columns indicate whether the variant was included in the liberal or conservative
sets of genetic variants.
rs no. Chr. Gene Minor/ MAF Imputation Selection criteria
major allele quality Liberal Con.
rs11165643 1 PTBP2 C/T 0.4091 0.9981 Yes Yes
rs11583200 1 ELAVL4 C/T 0.3872 0.9939 No No
rs12401738 1 FUBP1 A/G 0.3793 0.9958 Yes No
rs12566985 1 FPGT- G/A 0.4376 0.9985 Yes Yes
TNNI3K
rs17024393 1 GNAT2 C/T 0.0260 0.9909 Yes Yes
rs2820292 1 NAV1 A/C 0.4339 1.0000 Yes No
rs3101336 1 NEGR1 T/C 0.3974 1.0000 No No
rs543874 1 SEC16B G/A 0.2058 1.0000 Yes No
rs657452 1 AGBL4 A/G 0.3913 0.9887 Yes Yes
rs1016287 2 LINC01122 T/C 0.2983 0.9979 Yes No
rs10182181 2 ADCY3 G/A 0.4867 0.9966 No No
rs11126666 2 KCNK3 A/G 0.2555 0.9970 Yes No
rs11688816 2 EHBP1 A/G 0.4593 0.9936 Yes Yes
rs13021737 2 TMEM18 A/G 0.1714 0.9999 No No
rs1528435 2 UBE2E3 C/T 0.3791 0.9978 Yes No
rs2121279 2 LRP1B T/C 0.1255 0.9918 No No
rs7599312 2 ERBB4 A/G 0.2677 0.9811 Yes Yes
rs13078960 3 CADM2 G/T 0.2009 0.9941 Yes Yes
rs1516725 3 ETV5 T/C 0.1371 0.9958 Yes No
rs16851483 3 RASA2 T/G 0.0660 0.9991 Yes No
rs2365389 3 FHIT T/C 0.4083 0.9948 Yes No
rs3849570 3 GBE1 A/C 0.3466 0.9998 Yes Yes
rs6804842 3 RARB A/G 0.4267 0.9930 Yes Yes
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rs10938397 4 GNPDA2 G/A 0.4344 1.0000 Yes No
rs11727676 4 HHIP C/T 0.0962 1.0000 Yes Yes
rs13107325 4 SLC39A8 T/C 0.0747 1.0000 No No
rs17001654 4 NUP54 G/C 0.1485 0.9760 Yes Yes
rs2112347 5 POC5 G/T 0.3598 1.0000 Yes No
rs13191362 6 PARK2 G/A 0.1246 0.9953 Yes No
rs2033529 6 TDRG1 G/A 0.2882 0.9922 Yes Yes
rs205262 6 C6orf106 G/A 0.2683 0.9986 Yes No
rs2207139 6 TFAP2B G/A 0.1696 0.9997 Yes Yes
rs9400239 6 FOXO3 T/C 0.2952 0.9957 No No
rs1167827 7 HIP1 A/G 0.4349 1.0000 Yes No
rs2245368 7 PMS2L11 C/T 0.1686 1.0000 Yes No
rs17405819 8 HNF4G C/T 0.2980 0.9999 Yes No
rs2033732 8 RALYL T/C 0.2551 1.0000 Yes Yes
rs10733682 9 LMX1B A/G 0.4733 0.9664 Yes Yes
rs10968576 9 LINGO2 G/A 0.3222 1.0000 Yes Yes
rs1928295 9 TLR4 C/T 0.4306 0.9999 Yes No
rs4740619 9 C9orf93 C/T 0.4490 0.9990 Yes No
rs6477694 9 EPB41L4B C/T 0.3531 0.9919 Yes Yes
rs11191560 10 NT5C2 C/T 0.0776 0.9998 Yes Yes
rs17094222 10 HIF1AN C/T 0.2131 0.9922 Yes Yes
rs7899106 10 GRID1 G/A 0.0501 0.9905 Yes Yes
rs7903146 10 TCF7L2 T/C 0.2906 1.0000 Yes Yes
rs11030104 11 BDNF G/A 0.2031 0.9990 No No
rs12286929 11 CADM1 A/G 0.4734 0.9969 Yes No
rs2176598 11 HSD17B12 T/C 0.2466 1.0000 Yes Yes
rs3817334 11 MTCH2 T/C 0.4079 1.0000 Yes Yes
rs4256980 11 TRIM66 C/G 0.3458 0.9963 Yes Yes
rs11057405 12 CLIP1 A/G 0.1051 1.0000 Yes Yes
rs7138803 12 BCDIN3D A/G 0.3688 1.0000 Yes Yes
rs12429545 13 OLFM4 A/G 0.1292 0.9820 Yes Yes
rs9581854 13 MTIF3 T/C 0.1796 0.9968 No No
rs10132280 14 STXBP6 A/C 0.3005 0.9891 Yes Yes
rs11847697 14 PRKD1 T/C 0.0437 1.0000 Yes Yes
rs12885454 14 PRKD1 A/C 0.3561 0.9984 Yes Yes
rs7141420 14 NRXN3 C/T 0.4835 0.9883 Yes No
rs16951275 15 MAP2K5 C/T 0.2257 0.9994 No No
rs3736485 15 SCG3 A/G 0.4609 0.9953 Yes Yes
rs12446632 16 GPRC5B A/G 0.1425 0.9998 Yes Yes
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rs1558902 16 FTO A/T 0.4031 0.9998 Yes Yes
rs2650492 16 SBK1 A/G 0.2971 0.9895 No No
rs3888190 16 ATP2A1 A/C 0.3997 0.9999 No No
rs758747 16 NLRC3 T/C 0.2780 0.9791 Yes No
rs9925964 16 KAT8 G/A 0.3587 0.9982 Yes Yes
rs1000940 17 RABEP1 G/A 0.3015 0.9987 Yes Yes
rs12940622 17 RPTOR A/G 0.4400 0.9990 Yes Yes
rs1808579 18 C18orf8 T/C 0.4832 0.9982 No No
rs6567160 18 MC4R C/T 0.2329 0.9988 Yes Yes
rs7243357 18 GRP G/T 0.1769 0.9919 Yes Yes
rs17724992 19 GDF15 G/A 0.2677 0.9917 No No
rs2075650 19 TOMM40 G/A 0.1458 1.0000 No No
rs2287019 19 QPCTL T/C 0.1824 0.9856 No No
rs29941 19 KCTD15 A/G 0.3262 1.0000 No No
rs3810291 19 ZC3H4 G/A 0.3247 1.0000 Yes Yes
Abbreviations: no., number; Chr., chromosome; MAF, minor allele frequency; Con., conservative.
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I.1.3 Genetic associations with the body composition mea-
surements and asthma
Tables I.2 to I.4 and Table I.7 contain estimates of the genetic associations for BMI,
FMI (BIA measurements), FFMI (BIA measurements) and asthma (ever diagnosis and
current) based on the 360,409 participants from UK Biobank used in the main analysis.
Tables I.5 to I.6 contain estimates of the genetic associations of the DXA measurements
for FMI and FFMI for the 3,901 participants with data on these measurements. The
genetic associations were adjusted for the first 10 PCs and gender, and the adiposity
associations were also adjusted for height.
Table I.2 Estimates (standard errors) and p-values of the genetic associations with body
mass index for the 60 genetic variants selected under the liberal criteria based on 360,409
participants from UK Biobank. The R2 value and F-statistic are provided from the model
when the body composition measurement was regressed against the genetic variant.
rs no. Chr. Gene Allelesa Estimate (se) P-value R2 F-stat
rs11165643 1 PTBP2 T/C 0.086 (0.011) 2.32×10−14 0.00017 60.0
rs12401738 1 FUBP1 A/G 0.091 (0.011) 1.72×10−15 0.00019 68.4
rs12566985 1 FPGT- G/A 0.090 (0.011) 6.70×10−16 0.00018 63.4
TNNI3K
rs17024393 1 GNAT2 C/T 0.331 (0.035) 2.01×10−21 0.00023 81.6
rs2820292 1 NAV1 C/A 0.091 (0.011) 3.55×10−16 0.00019 70.1
rs543874 1 SEC16B G/A 0.245 (0.014) 8.41×10−72 0.00089 322.0
rs657452 1 AGBL4 A/G 0.080 (0.011) 1.60×10−12 0.00013 48.6
rs1016287 2 LINC01122 T/C 0.088 (0.012) 3.44×10−13 0.00015 55.9
rs11126666 2 KCNK3 A/G 0.018 (0.013) 0.15529 0.00000 1.5
rs11688816 2 EHBP1 G/A 0.049 (0.011) 0.00001 0.00006 22.7
rs1528435 2 UBE2E3 T/C 0.075 (0.011) 4.28×10−11 0.00011 40.3
rs7599312 2 ERBB4 G/A 0.077 (0.013) 8.00×10−10 0.00012 43.3
rs13078960 3 CADM2 G/T 0.086 (0.014) 3.91×10−10 0.00010 34.8
rs1516725 3 ETV5 C/T 0.148 (0.016) 2.40×10−20 0.00022 79.8
rs16851483 3 RASA2 T/G 0.163 (0.022) 2.33×10−13 0.00017 61.2
rs2365389 3 FHIT C/T 0.082 (0.011) 3.89×10−13 0.00014 51.1
rs3849570 3 GBE1 A/C 0.048 (0.012) 0.00004 0.00005 18.7
rs6804842 3 RARB G/A 0.068 (0.011) 9.80×10−10 0.00008 29.7
rs10938397 4 GNPDA2 G/A 0.147 (0.011) 1.02×10−39 0.00051 184.0
rs11727676 4 HHIP T/C 0.018 (0.019) 0.34962 0.00001 2.5
rs17001654 4 NUP54 G/C 0.069 (0.016) 0.00001 0.00004 15.9
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rs2112347 5 POC5 T/G 0.132 (0.012) 1.37×10−30 0.00035 126.4
rs13191362 6 PARK2 A/G 0.083 (0.017) 7.37×10−7 0.00007 25.7
rs2033529 6 TDRG1 G/A 0.098 (0.012) 1.20×10−15 0.00017 62.4
rs205262 6 C6orf106 G/A 0.137 (0.012) 3.25×10−28 0.00028 100.3
rs2207139 6 TFAP2B G/A 0.186 (0.015) 9.31×10−37 0.00047 168.1
rs1167827 7 HIP1 G/A 0.102 (0.011) 7.06×10−20 0.00025 90.8
rs2245368 7 PMS2L11 C/T 0.122 (0.015) 1.08×10−16 0.00015 54.6
rs17405819 8 HNF4G T/C 0.102 (0.012) 3.58×10−17 0.00019 69.3
rs2033732 8 RALYL C/T 0.049 (0.013) 0.00011 0.00004 13.5
rs10733682 9 LMX1B A/G 0.063 (0.011) 1.71×10−8 0.00009 32.4
rs10968576 9 LINGO2 G/A 0.112 (0.012) 2.38×10−21 0.00029 106.1
rs1928295 9 TLR4 T/C 0.058 (0.011) 2.41×10−7 0.00008 29.5
rs4740619 9 C9orf93 T/C 0.085 (0.011) 2.26×10−14 0.00017 62.2
rs6477694 9 EPB41L4B C/T 0.062 (0.012) 9.54×10−8 0.00006 20.8
rs11191560 10 NT5C2 C/T 0.122 (0.021) 3.49×10−9 0.00009 31.3
rs17094222 10 HIF1AN C/T 0.066 (0.014) 8.77×10−7 0.00007 26.6
rs7899106 10 GRID1 G/A 0.141 (0.025) 3.05×10−8 0.00007 26.4
rs7903146 10 TCF7L2 C/T 0.075 (0.012) 5.45×10−10 0.00011 38.7
rs12286929 11 CADM1 G/A 0.062 (0.011) 1.97×10−8 0.00008 30.6
rs2176598 11 HSD17B12 T/C 0.091 (0.013) 1.58×10−12 0.00014 49.6
rs3817334 11 MTCH2 T/C 0.106 (0.011) 3.32×10−21 0.00031 112.8
rs4256980 11 TRIM66 G/C 0.074 (0.012) 1.52×10−10 0.00010 37.4
rs11057405 12 CLIP1 G/A 0.150 (0.018) 1.04×10−16 0.00014 49.3
rs7138803 12 BCDIN3D A/G 0.127 (0.011) 8.96×10−29 0.00031 112.8
rs12429545 13 OLFM4 A/G 0.137 (0.017) 1.61×10−16 0.00017 61.3
rs10132280 14 STXBP6 C/A 0.101 (0.012) 8.58×10−17 0.00021 74.3
rs11847697 14 PRKD1 T/C 0.108 (0.027) 0.00006 0.00004 13.4
rs12885454 14 PRKD1 C/A 0.079 (0.012) 8.88×10−12 0.00013 47.7
rs7141420 14 NRXN3 T/C 0.098 (0.011) 1.51×10−18 0.00020 72.8
rs3736485 15 SCG3 A/G 0.056 (0.011) 4.31×10−7 0.00006 22.8
rs12446632 16 GPRC5B G/A 0.138 (0.016) 2.58×10−18 0.00020 71.0
rs1558902 16 FTO A/T 0.353 (0.011) 9.29×10−217 0.00268 968.8
rs758747 16 NLRC3 T/C 0.052 (0.012) 0.00003 0.00005 18.1
rs9925964 16 KAT8 A/G 0.127 (0.012) 2.94×10−28 0.00036 128.6
rs1000940 17 RABEP1 G/A 0.070 (0.012) 4.76×10−9 0.00009 31.2
rs12940622 17 RPTOR G/A 0.096 (0.011) 4.33×10−18 0.00020 72.5
rs6567160 18 MC4R C/T 0.279 (0.013) 2.05×10−101 0.00105 380.6
rs7243357 18 GRP T/G 0.100 (0.015) 6.91×10−12 0.00011 38.4
422 Chapter 6 supplementary material
rs3810291 19 ZC3H4 A/G 0.128 (0.012) 2.43×10−27 0.00031 110.5
Abbreviations: no., number; Chr., chromosome; se, standard error; F-stat, F-statistic.
aAllele increasing/allele decreasing: genetic associations reported with respect to the trait increasing allele.
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Table I.3 Estimates (standard errors) and p-values of the genetic associations with the
bioelectrical impedance analysis (BIA) measurements for fat mass index for the 60 genetic
variants selected under the liberal criteria based on 360,409 participants from UK Biobank.
The R2 value and F-statistic are provided from the model when the body composition
measurement was regressed against the genetic variant.
rs no. Chr. Gene Allelesa Estimate (se) P-value R2 F-stat
rs11165643 1 PTBP2 T/C 0.061 (0.008) 7.37×10−15 0.00016 56.5
rs12401738 1 FUBP1 A/G 0.054 (0.008) 9.68×10−12 0.00015 54.4
rs12566985 1 FPGT G/A 0.053 (0.008) 7.00×10−12 0.00011 38
TNNI3K
rs17024393 1 GNAT2 C/T 0.221 (0.024) 1.29×10−19 0.00020 71.6
rs2820292 1 NAV1 C/A 0.058 (0.008) 1.15×10−13 0.00016 57.1
rs543874 1 SEC16B G/A 0.157 (0.010) 1.40×10−60 0.00065 235.2
rs657452 1 AGBL4 A/G 0.056 (0.008) 2.34×10−12 0.00011 38.4
rs1016287 2 LINC01122 T/C 0.059 (0.008) 2.96×10−12 0.00009 34.1
rs11126666 2 KCNK3 A/G 0.004 (0.009) 0.612284 0.00000 0.0
rs11688816 2 EHBP1 G/A 0.031 (0.008) 0.00007 0.00005 14.4
rs1528435 2 UBE2E3 T/C 0.054 (0.008) 8.88×10−12 0.00010 35.1
rs7599312 2 ERBB4 G/A 0.045 (0.009) 3.09×10−07 0.00006 22.6
rs13078960 3 CADM2 G/T 0.048 (0.010) 7.02×10−07 0.00006 21.1
rs1516725 3 ETV5 C/T 0.082 (0.011) 2.41×10−13 0.00010 36.4
rs16851483 3 RASA2 T/G 0.109 (0.016) 2.32×10−12 0.00015 52.8
rs2365389 3 FHIT C/T 0.049 (0.008) 3.39×10−10 0.00010 36.6
rs3849570 3 GBE1 A/C 0.036 (0.008) 8.38×10−06 0.00005 19.3
rs6804842 3 RARB G/A 0.038 (0.008) 1.10×10−06 0.00003 10.6
rs10938397 4 GNPDA2 G/A 0.100 (0.008) 7.39×10−38 0.00032 115.5
rs11727676 4 HHIP C/T 0.019 (0.013) 0.148552 0.00000 0.5
rs17001654 4 NUP54 G/C 0.040 (0.011) 0.00032 0.00002 6.9
rs2112347 5 POC5 T/G 0.090 (0.008) 4.16×10−29 0.00026 94.4
rs13191362 6 PARK2 A/G 0.045 (0.012) 0.00012 0.00003 9.3
rs2033529 6 TDRG1 G/A 0.060 (0.009) 1.52×10−12 0.00013 48.5
rs205262 6 C6orf106 G/A 0.090 (0.009) 3.12×10−25 0.00017 62.1
rs2207139 6 TFAP2B G/A 0.116 (0.010) 1.32×10−29 0.00032 117.1
rs1167827 7 HIP1 G/A 0.064 (0.008) 2.19×10−16 0.00013 45.6
rs2245368 7 PMS2L11 C/T 0.068 (0.010) 4.73×10−11 0.00011 38.7
rs17405819 8 HNF4G T/C 0.071 (0.008) 3.88×10−17 0.00016 56.6
rs2033732 8 RALYL C/T 0.025 (0.009) 0.00446 0.00001 4
rs10733682 9 LMX1B A/G 0.038 (0.008) 1.69×10−6 0.00005 17.4
rs10968576 9 LINGO2 G/A 0.069 (0.008) 3.59×10−17 0.00028 100.1
424 Chapter 6 supplementary material
rs1928295 9 TLR4 T/C 0.039 (0.008) 5.44×10−7 0.00006 20.6
rs4740619 9 C9orf93 T/C 0.068 (0.008) 2.95×10−18 0.00020 72.1
rs6477694 9 EPB41L4B C/T 0.038 (0.008) 3.33×10−6 0.00005 17.5
rs11191560 10 NT5C2 C/T 0.066 (0.014) 4.79×10−6 0.00003 10.2
rs17094222 10 HIF1AN C/T 0.048 (0.009) 4.21×10−7 0.00008 29.6
rs7899106 10 GRID1 G/A 0.079 (0.018) 7.86×10−6 0.00003 12.4
rs7903146 10 TCF7L2 C/T 0.050 (0.008) 2.93×10−9 0.00010 35.3
rs12286929 11 CADM1 G/A 0.037 (0.008) 2.00×10−6 0.00005 18.7
rs2176598 11 HSD17B12 T/C 0.058 (0.009) 7.00×10−11 0.00011 40.9
rs3817334 11 MTCH2 T/C 0.086 (0.008) 8.30×10−28 0.00036 129.5
rs4256980 11 TRIM66 G/C 0.053 (0.008) 7.52×10−11 0.00013 45.2
rs11057405 12 CLIP1 G/A 0.113 (0.013) 3.82×10−19 0.00014 48.8
rs7138803 12 BCDIN3D A/G 0.084 (0.008) 4.84×10−26 0.00025 89.1
rs12429545 13 OLFM4 A/G 0.088 (0.012) 3.28×10−14 0.00010 36.2
rs10132280 14 STXBP6 C/A 0.053 (0.008) 3.19×10−10 0.00012 42.8
rs11847697 14 PRKD1 T/C 0.071 (0.019) 0.00018 0.00003 11.5
rs12885454 14 PRKD1 C/A 0.050 (0.008) 5.11×10−10 0.00009 32.2
rs7141420 14 NRXN3 T/C 0.065 (0.008) 4.11×10−17 0.00013 46.7
rs3736485 15 SCG3 A/G 0.044 (0.008) 1.35×10−8 0.00006 23.3
rs12446632 16 GPRC5B G/A 0.069 (0.011) 4.85×10−10 0.00006 20.5
rs1558902 16 FTO A/T 0.217 (0.008) 7.79×10−168 0.00145 523.6
rs758747 16 NLRC3 T/C 0.032 (0.009) 0.00023 0.00004 12.8
rs9925964 16 KAT8 A/G 0.089 (0.008) 1.58×10−28 0.00037 135.1
rs1000940 17 RABEP1 G/A 0.048 (0.008) 1.22×10−8 0.00009 31.5
rs12940622 17 RPTOR G/A 0.063 (0.008) 6.52×10−16 0.00015 53.9
rs6567160 18 MC4R C/T 0.161 (0.009) 1.90×10−69 0.00062 225.3
rs7243357 18 GRP T/G 0.061 (0.010) 1.89×10−9 0.00007 25.2
rs3810291 19 ZC3H4 A/G 0.067 (0.008) 2.90×10−16 0.00016 58.8
Abbreviations: no., number; Chr., chromosome; se, standard error; F-stat, F-statistic.
aAllele increasing/allele decreasing: genetic associations reported with respect to the trait increasing allele.
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Table I.4 Estimates (standard errors) and p-values of the genetic associations with the
bioelectrical impedance analysis (BIA) measurements for fat-free mass index for the 60 genetic
variants selected under the liberal criteria based on 360,409 participants from UK Biobank.
The R2 value and F-statistic are provided from the model when the body composition
measurement was regressed against the genetic variant.
rs no. Chr. Gene Allelesa Estimate (se) P-value R2 F-stat
rs11165643 1 PTBP2 T/C 0.025 (0.004) 8.59×10−9 0.00004 13.4
rs12401738 1 FUBP1 A/G 0.037 (0.004) 4.11×10−17 0.00006 23.2
rs12566985 1 FPGT G/A 0.037 (0.004) 6.25×10−18 0.00010 35.1
TNNI3K
rs17024393 1 GNAT2 C/T 0.111 (0.013) 7.93×10−17 0.00006 22.1
rs2820292 1 NAV1 C/A 0.033 (0.004) 7.06×10−15 0.00006 22.6
rs543874 1 SEC16B G/A 0.088 (0.005) 2.24×10−64 0.00036 129.3
rs657452 1 AGBL4 A/G 0.025 (0.004) 1.39×10−8 0.00005 16.6
rs1016287 2 LINC01122 T/C 0.029 (0.005) 3.05×10−10 0.00008 30.1
rs11126666 2 KCNK3 A/G 0.013 (0.005) 0.00524 0.00001 4.0
rs11688816 2 EHBP1 G/A 0.018 (0.004) 0.00003 0.00003 11.5
rs1528435 2 UBE2E3 T/C 0.021 (0.004) 1.57×10−06 0.00003 11.1
rs7599312 2 ERBB4 G/A 0.032 (0.005) 1.46×10−11 0.00008 29.0
rs13078960 3 CADM2 G/T 0.039 (0.005) 2.51×10−13 0.00005 18.8
rs1516725 3 ETV5 C/T 0.066 (0.006) 2.17×10−27 0.00017 62.0
rs16851483 3 RASA2 T/G 0.054 (0.008) 1.74×10−10 0.00005 17.3
rs2365389 3 FHIT C/T 0.032 (0.004) 4.72×10−14 0.00006 21.3
rs3849570 3 GBE1 A/C 0.012 (0.004) 0.00787 0.00001 3.2
rs6804842 3 RARB G/A 0.030 (0.004) 1.25×10−12 0.00008 29.0
rs10938397 4 GNPDA2 G/A 0.047 (0.004) 2.43×10−28 0.00026 95.3
rs11727676 4 HHIP T/C 0.036 (0.007) 3.43×10−7 0.00004 15.0
rs17001654 4 NUP54 G/C 0.029 (0.006) 1.20×10−6 0.00004 13.0
rs2112347 5 POC5 T/G 0.042 (0.004) 5.29×10−22 0.00013 48.6
rs13191362 6 PARK2 A/G 0.038 (0.006) 2.50×10−9 0.00007 24.7
rs2033529 6 TDRG1 G/A 0.038 (0.005) 7.78×10−16 0.00006 22.3
rs205262 6 C6orf106 G/A 0.047 (0.005) 4.96×10−23 0.00015 53.0
rs2207139 6 TFAP2B G/A 0.070 (0.006) 6.43×10−36 0.00020 73.3
rs1167827 7 HIP1 G/A 0.038 (0.004) 6.59×10−19 0.00018 63.1
rs2245368 7 PMS2L11 C/T 0.055 (0.006) 2.69×10−22 0.00006 23.1
rs17405819 8 HNF4G T/C 0.031 (0.005) 2.14×10−11 0.00006 22.3
rs2033732 8 RALYL C/T 0.024 (0.005) 1.01×10−6 0.00004 15.2
rs10733682 9 LMX1B A/G 0.026 (0.004) 1.49×10−9 0.00006 21.0
rs10968576 9 LINGO2 G/A 0.042 (0.005) 3.76×10−21 0.00007 23.6
426 Chapter 6 supplementary material
rs1928295 9 TLR4 T/C 0.019 (0.004) 0.00002 0.00004 12.8
rs4740619 9 C9orf93 T/C 0.017 (0.004) 0.00004 0.00002 6.7
rs6477694 9 EPB41L4B C/T 0.024 (0.004) 4.09×10−8 0.00002 6.3
rs11191560 10 NT5C2 C/T 0.056 (0.008) 1.16×10−12 0.00009 33.0
rs17094222 10 HIF1AN C/T 0.019 (0.005) 0.00029 0.00001 3.4
rs7899106 10 GRID1 G/A 0.061 (0.010) 2.33×10−10 0.00006 19.9
rs7903146 10 TCF7L2 C/T 0.025 (0.005) 6.95×10−8 0.00003 9.4
rs12286929 11 CADM1 G/A 0.025 (0.004) 1.70×10−9 0.00005 16.6
rs2176598 11 HSD17B12 T/C 0.032 (0.005) 4.40×10−11 0.00004 15.6
rs3817334 11 MTCH2 T/C 0.020 (0.004) 1.77×10−6 0.00003 12.6
rs4256980 11 TRIM66 G/C 0.022 (0.004) 1.10×10−6 0.00001 3.3
rs11057405 12 CLIP1 G/A 0.037 (0.007) 6.87×10−8 0.00003 9.5
rs7138803 12 BCDIN3D A/G 0.043 (0.004) 5.76×10−23 0.00011 38.8
rs12429545 13 OLFM4 A/G 0.049 (0.006) 1.06×10−14 0.00010 34.6
rs10132280 14 STXBP6 C/A 0.048 (0.005) 6.98×10−25 0.00012 43.5
rs11847697 14 PRKD1 T/C 0.038 (0.010) 0.00028 0.00001 3.8
rs12885454 14 PRKD1 C/A 0.029 (0.004) 7.69×10−11 0.00006 22.0
rs7141420 14 NRXN3 T/C 0.032 (0.004) 1.87×10−14 0.00040 36.5
rs3736485 15 SCG3 A/G 0.012 (0.004) 0.00436 0.00001 4
rs12446632 16 GPRC5B G/A 0.069 (0.006) 1.37×10−30 0.00023 81.5
rs1558902 16 FTO A/T 0.137 (0.004) 2.06×10−222 0.00171 616.0
rs758747 16 NLRC3 T/C 0.020 (0.005) 0.00003 0.00002 7.6
rs9925964 16 KAT8 A/G 0.038 (0.004) 6.73×10−18 0.00006 20.3
rs1000940 17 RABEP1 G/A 0.023 (0.005) 8.71×10−7 0.00002 5.7
rs12940622 17 RPTOR G/A 0.034 (0.004) 1.87×10−15 0.00008 28.3
rs6567160 18 MC4R C/T 0.119 (0.005) 3.30×10−125 0.00059 214.3
rs7243357 18 GRP T/G 0.039 (0.006) 2.53×10−12 0.00005 18.6
rs3810291 19 ZC3H4 A/G 0.060 (0.004) 3.38×10−41 0.00020 71.9
Abbreviations: no., number; Chr., chromosome; se, standard error; F-stat, F-statistic.
aAllele increasing/allele decreasing: genetic associations reported with respect to the trait increasing allele.
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Table I.5 Estimates (standard errors) and p-values of the genetic associations with the
dual-energy X-ray (DXA) measurements for fat mass index for the 60 genetic variants selected
under the liberal criteria based on 3,901 participants from UK Biobank. The R2 value and F-
statistic are provided from the model when the body composition measurement was regressed
against the genetic variant.
rs no. Chr. Gene Allelesa Estimate (se) P-value R2 F-stat
rs11165643 1 PTBP2 C/T 0.038 (0.075) 0.61282 0.00008 0.3
rs12401738 1 FUBP1 A/G 0.106 (0.075) 0.15896 0.00084 3.3
rs12566985 1 FPGT A/G 0.028 (0.075) 0.71242 0.00005 0.2
TNNI3K
rs17024393 1 GNAT2 C/T 0.456 (0.246) 0.06379 0.00091 3.5
rs2820292 1 NAV1 C/A 0.039 (0.074) 0.59614 0.00022 0.9
rs543874 1 SEC16B G/A 0.064 (0.091) 0.48133 0.00004 0.2
rs657452 1 AGBL4 G/A 0.051 (0.075) 0.49583 0.00023 0.9
rs1016287 2 LINC01122 C/T 0.080 (0.080) 0.31698 0.00027 1.1
rs11126666 2 KCNK3 G/A 0.071 (0.084) 0.39654 0.00011 0.4
rs11688816 2 EHBP1 A/G 0.009 (0.074) 0.90260 0.00001 0.0
rs1528435 2 UBE2E3 T/C 0.036 (0.075) 0.62743 0.00000 0.0
rs7599312 2 ERBB4 G/A 0.077 (0.083) 0.35152 0.00045 1.7
rs13078960 3 CADM2 G/T 0.022 (0.092) 0.8148 0.00005 0.2
rs1516725 3 ETV5 T/C 0.048 (0.107) 0.65129 0.00025 1.0
rs16851483 3 RASA2 G/T 0.100 (0.149) 0.50337 0.00007 0.3
rs2365389 3 FHIT C/T 0.091 (0.075) 0.22437 0.00089 3.5
rs3849570 3 GBE1 C/A 0.061 (0.076) 0.42421 0.00004 0.2
rs6804842 3 RARB A/G 0.015 (0.074) 0.83936 0.00007 0.3
rs10938397 4 GNPDA2 A/G 0.003 (0.075) 0.96626 0.00006 0.2
rs11727676 4 HHIP T/C 0.010 (0.123) 0.93463 0.00006 0.2
rs17001654 4 NUP54 G/C 0.143 (0.103) 0.16758 0.00015 0.6
rs2112347 5 POC5 G/T 0.113 (0.076) 0.13553 0.00042 1.6
rs13191362 6 PARK2 G/A 0.041 (0.112) 0.71677 0.00011 0.4
rs2033529 6 TDRG1 G/A 0.000 (0.082) 0.99922 0.00005 0.2
rs205262 6 C6orf106 G/A 0.063 (0.083) 0.44482 0.00001 0.0
rs2207139 6 TFAP2B G/A 0.023 (0.099) 0.81892 0.00000 0.0
rs1167827 7 HIP1 G/A 0.098 (0.073) 0.18188 0.00026 1.0
rs2245368 7 PMS2L11 C/T 0.146 (0.101) 0.14578 0.00034 1.3
rs17405819 8 HNF4G T/C 0.093 (0.081) 0.25063 0.00023 0.9
rs2033732 8 RALYL C/T 0.177 (0.085) 0.03776 0.00088 3.4
rs10733682 9 LMX1B A/G 0.037 (0.074) 0.61441 0.00021 0.8
rs10968576 9 LINGO2 G/A 0.067 (0.08) 0.40286 0.00015 0.6
428 Chapter 6 supplementary material
rs1928295 9 TLR4 C/T 0.014 (0.073) 0.84496 0.00002 0.1
rs4740619 9 C9orf93 C/T 0.003 (0.074) 0.97016 0.00008 0.0
rs6477694 9 EPB41L4B C/T 0.086 (0.076) 0.25859 0.00042 1.6
rs11191560 10 NT5C2 T/C 0.020 (0.134) 0.87886 0.00003 0.1
rs17094222 10 HIF1AN C/T 0.115 (0.089) 0.20008 0.00027 1.0
rs7899106 10 GRID1 G/A 0.306 (0.171) 0.07277 0.00039 1.5
rs7903146 10 TCF7L2 C/T 0.014 (0.080) 0.85721 0.00010 0.4
rs12286929 11 CADM1 G/A 0.003 (0.074) 0.96457 0.00000 0.0
rs2176598 11 HSD17B12 T/C 0.114 (0.085) 0.17859 0.00060 2.3
rs3817334 11 MTCH2 T/C 0.041 (0.075) 0.58851 0.00007 0.3
rs4256980 11 TRIM66 G/C 0.069 (0.076) 0.36777 0.00023 0.9
rs11057405 12 CLIP1 G/A 0.161 (0.123) 0.19053 0.00017 0.7
rs7138803 12 BCDIN3D A/G 0.091 (0.075) 0.22791 0.00033 1.3
rs12429545 13 OLFM4 G/A 0.125 (0.109) 0.25182 0.00054 2.1
rs10132280 14 STXBP6 C/A 0.008 (0.079) 0.92308 0.00002 0.1
rs11847697 14 PRKD1 T/C 0.126 (0.175) 0.47347 0.00001 0.0
rs12885454 14 PRKD1 C/A 0.014 (0.076) 0.85200 0.00000 0.0
rs7141420 14 NRXN3 T/C 0.050 (0.074) 0.49775 0.00021 0.8
rs3736485 15 SCG3 A/G 0.038 (0.074) 0.61107 0.00000 0.0
rs12446632 16 GPRC5B G/A 0.147 (0.103) 0.15384 0.00060 2.3
rs1558902 16 FTO A/T 0.250 (0.074) 0.00080 0.00185 7.2
rs758747 16 NLRC3 T/C 0.124 (0.082) 0.13120 0.00064 2.5
rs9925964 16 KAT8 A/G 0.042 (0.077) 0.58680 0.00015 0.6
rs1000940 17 RABEP1 A/G 0.064 (0.078) 0.41699 0.00023 0.9
rs12940622 17 RPTOR G/A 0.157 (0.074) 0.03318 0.00141 5.5
rs6567160 18 MC4R C/T 0.095 (0.087) 0.27557 0.00010 0.4
rs7243357 18 GRP T/G 0.015 (0.097) 0.87527 0.00003 0.1
rs3810291 19 ZC3H4 A/G 0.137 (0.078) 0.07990 0.00048 1.9
Abbreviations: no., number; Chr., chromosome; se, standard error; F-stat, F-statistic.
aAllele increasing/allele decreasing: genetic associations reported with respect to the trait increasing allele.
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Table I.6 Estimates (standard errors) and p-values of the genetic associations with the
dual-energy X-ray (DXA) measurements for fat-free mass index for the 60 genetic variants
selected under the liberal criteria based on 3,901 participants from UK Biobank. The R2
value and F-statistic are provided from the model when the body composition measurement
was regressed against the genetic variant.
rs no. Chr. Gene Allelesa Beta (se) P-value R2 F-stat
rs11165643 1 PTBP2 T/C 0.002 (0.037) 0.94917 0.00000 0.0
rs12401738 1 FUBP1 A/G 0.025 (0.037) 0.50663 0.00002 0.1
rs12566985 1 FPGT A/G 0.010 (0.037) 0.79035 0.00018 0.7
TNNI3K
rs17024393 1 GNAT2 C/T 0.206 (0.121) 0.08918 0.00002 0.1
rs2820292 1 NAV1 C/A 0.019 (0.037) 0.59496 0.00007 0.3
rs543874 1 SEC16B G/A 0.028 (0.045) 0.53926 0.00020 0.8
rs657452 1 AGBL4 G/A 0.016 (0.037) 0.66958 0.00017 0.6
rs1016287 2 LINC01122 C/T 0.015 (0.039) 0.70911 0.00001 0.1
rs11126666 2 KCNK3 A/G 0.034 (0.041) 0.41609 0.00005 0.2
rs11688816 2 EHBP1 A/G 0.012 (0.037) 0.73284 0.00003 0.1
rs1528435 2 UBE2E3 T/C 0.007 (0.037) 0.84171 0.00044 1.7
rs7599312 2 ERBB4 G/A 0.073 (0.041) 0.07376 0.00020 0.8
rs13078960 3 CADM2 G/T 0.068 (0.045) 0.13379 0.00002 0.1
rs1516725 3 ETV5 C/T 0.063 (0.053) 0.23308 0.00082 3.2
rs16851483 3 RASA2 T/G 0.056 (0.073) 0.44795 0.00006 0.2
rs2365389 3 FHIT C/T 0.091 (0.037) 0.01361 0.00016 0.6
rs3849570 3 GBE1 A/C 0.005 (0.037) 0.89144 0.00010 0.4
rs6804842 3 RARB G/A 0.031 (0.037) 0.39096 0.00018 0.7
rs10938397 4 GNPDA2 A/G 0.044 (0.037) 0.23556 0.00027 1.1
rs11727676 4 HHIP T/C 0.008 (0.061) 0.89510 0.00015 0.6
rs17001654 4 NUP54 G/C 0.041 (0.051) 0.42731 0.00073 2.9
rs2112347 5 POC5 G/T 0.034 (0.037) 0.36312 0.00023 0.9
rs13191362 6 PARK2 A/G 0.053 (0.055) 0.34157 0.00081 3.2
rs2033529 6 TDRG1 A/G 0.013 (0.040) 0.74232 0.00029 1.1
rs205262 6 C6orf106 G/A 0.072 (0.041) 0.07896 0.00104 4.0
rs2207139 6 TFAP2B G/A 0.045 (0.049) 0.35575 0.00063 2.5
rs1167827 7 HIP1 G/A 0.056 (0.036) 0.12278 0.00039 1.5
rs2245368 7 PMS2L11 C/T 0.056 (0.050) 0.26189 0.00016 0.6
rs17405819 8 HNF4G T/C 0.050 (0.040) 0.21098 0.00021 0.8
rs2033732 8 RALYL C/T 0.071 (0.042) 0.09143 0.00066 2.6
rs10733682 9 LMX1B A/G 0.016 (0.036) 0.65733 0.00016 0.6
rs10968576 9 LINGO2 A/G 0.016 (0.039) 0.69000 0.00009 0.3
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rs1928295 9 TLR4 T/C 0.022 (0.036) 0.55169 0.00021 0.8
rs4740619 9 C9orf93 T/C 0.048 (0.037) 0.18915 0.00026 1.0
rs6477694 9 EPB41L4B C/T 0.077 (0.037) 0.03904 0.00010 0.4
rs11191560 10 NT5C2 C/T 0.029 (0.066) 0.65739 0.00009 0.3
rs17094222 10 HIF1AN C/T 0.043 (0.044) 0.32529 0.00032 1.3
rs7899106 10 GRID1 G/A 0.024 (0.084) 0.77334 0.00000 0.0
rs7903146 10 TCF7L2 C/T 0.002 (0.039) 0.96940 0.00026 1.0
rs12286929 11 CADM1 A/G 0.009 (0.037) 0.81406 0.00000 0.0
rs2176598 11 HSD17B12 T/C 0.019 (0.042) 0.64603 0.00001 0.1
rs3817334 11 MTCH2 C/T 0.027 (0.037) 0.46186 0.00001 0.0
rs4256980 11 TRIM66 G/C 0.013 (0.038) 0.72791 0.00003 0.1
rs11057405 12 CLIP1 A/G 0.039 (0.061) 0.52044 0.00000 0.0
rs7138803 12 BCDIN3D A/G 0.038 (0.037) 0.29981 0.00002 0.1
rs12429545 13 OLFM4 G/A 0.011 (0.054) 0.83867 0.00002 0.1
rs10132280 14 STXBP6 C/A 0.022 (0.039) 0.57731 0.00036 1.4
rs11847697 14 PRKD1 T/C 0.032 (0.086) 0.71241 0.00014 0.5
rs12885454 14 PRKD1 C/A 0.007 (0.038) 0.86129 0.00001 0.0
rs7141420 14 NRXN3 C/T 0.011 (0.036) 0.76915 0.00013 0.5
rs3736485 15 SCG3 G/A 0.001 (0.037) 0.97750 0.00016 0.6
rs12446632 16 GPRC5B G/A 0.108 (0.051) 0.03419 0.00041 1.6
rs1558902 16 FTO A/T 0.033 (0.037) 0.36684 0.00112 4.4
rs758747 16 NLRC3 T/C 0.045 (0.041) 0.26420 0.00009 0.4
rs9925964 16 KAT8 A/G 0.066 (0.038) 0.08290 0.00021 0.8
rs1000940 17 RABEP1 G/A 0.025 (0.039) 0.51302 0.00013 0.5
rs12940622 17 RPTOR G/A 0.090 (0.036) 0.01351 0.00011 0.4
rs6567160 18 MC4R C/T 0.108 (0.043) 0.01221 0.00116 4.5
rs7243357 18 GRP T/G 0.005 (0.048) 0.92267 0.00004 0.2
rs3810291 19 ZC3H4 A/G 0.150 (0.038) 0.00009 0.00231 9.0
Abbreviations: no., number; Chr., chromosome; se, standard error; F-stat, F-statistic.
aAllele increasing/allele decreasing: genetic associations reported with respect to the trait increasing allele.
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Table I.7 Estimates (standard errors) and p-values of the genetic associations with asthma
(ever diagnosis and current asthma) for the 60 genetic variants selected under the liberal
criteria based on 360,409 participants from UK Biobank.
Ever Current
rs no. Chr. Gene Allelea Beta (se) P-value Beta (se) P-value
rs11165643 1 PTBP2 T/C 0.016 (0.007) 0.0316 0.019 (0.009) 0.0404
rs12401738 1 FUBP1 A/G 0.008 (0.008) 0.3156 0.005 (0.009) 0.5985
rs12566985 1 FPGT G/A 0.022 (0.007) 0.0029 0.018 (0.009) 0.0457
TNNI3K
rs17024393 1 GNAT2 C/T 0.050 (0.023) 0.0308 0.050 (0.028) 0.0731
rs2820292 1 NAV1 C/A 0.001 (0.007) 0.8434 0.001 (0.009) 0.9297
rs543874 1 SEC16B G/A 0.008 (0.009) 0.3737 0.006 (0.011) 0.5636
rs657452 1 AGBL4 G/A 0.005 (0.008) 0.5479 0.003 (0.009) 0.7191
rs1016287 2 LINC01122 T/C 0.007 (0.008) 0.4174 0.015 (0.010) 0.1349
rs11126666 2 KCNK3 G/A 0.013 (0.008) 0.1144 0.012 (0.010) 0.2559
rs11688816 2 EHBP1 G/A 0.004 (0.007) 0.5533 -0.001 (0.009) 0.9088
rs1528435 2 UBE2E3 T/C 0.011 (0.008) 0.1596 0.013 (0.009) 0.1442
rs7599312 2 ERBB4 A/G 0.018 (0.008) 0.0316 0.023 (0.010) 0.0264
rs13078960 3 CADM2 T/G 0.015 (0.009) 0.1077 0.021 (0.011) 0.0607
rs1516725 3 ETV5 C/T 0.001 (0.011) 0.8998 -0.012 (0.013) 0.3404
rs16851483 3 RASA2 G/T 0.016 (0.015) 0.2855 0.027 (0.018) 0.1390
rs2365389 3 FHIT C/T 0.003 (0.008) 0.6543 0.008 (0.009) 0.4056
rs3849570 3 GBE1 C/A 0.001 (0.008) 0.8646 -0.007 (0.009) 0.4453
rs6804842 3 RARB G/A 0.003 (0.007) 0.6894 0.006 (0.009) 0.5265
rs10938397 4 GNPDA2 G/A 0.017 (0.007) 0.0236 0.019 (0.009) 0.0313
rs11727676 4 HHIP C/T 0.012 (0.012) 0.3320 0.026 (0.015) 0.0877
rs17001654 4 NUP54 G/C 0.016 (0.010) 0.1353 0.020 (0.013) 0.1214
rs2112347 5 POC5 T/G 0.005 (0.008) 0.5115 0.012 (0.009) 0.2042
rs13191362 6 PARK2 A/G 0.021 (0.011) 0.0585 0.021 (0.014) 0.1195
rs2033529 6 TDRG1 A/G 0.004 (0.008) 0.6072 0.004 (0.010) 0.6645
rs205262 6 C6orf106 A/G 0.012 (0.008) 0.1332 0.017 (0.010) 0.1026
rs2207139 6 TFAP2B G/A 0.014 (0.010) 0.1520 0.018 (0.012) 0.1281
rs1167827 7 HIP1 G/A 0.011 (0.007) 0.1264 0.020 (0.009) 0.0294
rs2245368 7 PMS2L11 T/C 0.005 (0.010) 0.6085 0.000 (0.012) 0.9999
rs17405819 8 HNF4G T/C 0.004 (0.008) 0.6523 -0.009 (0.010) 0.3695
rs2033732 8 RALYL C/T 0.011 (0.008) 0.1944 0.013 (0.010) 0.2245
rs10733682 9 LMX1B A/G 0.006 (0.007) 0.4500 0.005 (0.009) 0.6189
rs10968576 9 LINGO2 A/G 0.000 (0.008) 0.9579 0.003 (0.010) 0.7835
rs1928295 9 TLR4 T/C 0.012 (0.007) 0.1083 0.013 (0.009) 0.1566
rs4740619 9 C9orf93 T/C 0.015 (0.007) 0.0365 0.014 (0.009) 0.1096
rs6477694 9 EPB41L4B C/T 0.011 (0.008) 0.1560 0.010 (0.009) 0.3075
rs11191560 10 NT5C2 C/T 0.018 (0.014) 0.1951 0.030 (0.017) 0.0710
rs17094222 10 HIF1AN C/T 0.004 (0.009) 0.6817 0.009 (0.011) 0.4307
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rs7899106 10 GRID1 G/A 0.035 (0.017) 0.0357 0.036 (0.020) 0.0764
rs7903146 10 TCF7L2 C/T 0.005 (0.008) 0.5245 0.003 (0.010) 0.7342
rs12286929 11 CADM1 G/A 0.001 (0.007) 0.8617 0.011 (0.009) 0.2265
rs2176598 11 HSD17B12 T/C 0.001 (0.009) 0.9038 0.005 (0.010) 0.6121
rs3817334 11 MTCH2 T/C 0.000 (0.007) 0.9514 0.003 (0.009) 0.7513
rs4256980 11 TRIM66 C/G 0.000 (0.008) 0.9985 -0.001 (0.009) 0.9328
rs11057405 12 CLIP1 G/A 0.020 (0.012) 0.0904 0.010 (0.015) 0.4750
rs7138803 12 BCDIN3D G/A 0.002 (0.008) 0.7583 0.003 (0.009) 0.7842
rs12429545 13 OLFM4 A/G 0.003 (0.011) 0.7918 0.000 (0.013) 0.9705
rs10132280 14 STXBP6 C/A 0.009 (0.008) 0.2422 0.007 (0.010) 0.4546
rs11847697 14 PRKD1 T/C 0.017 (0.018) 0.3347 0.008 (0.022) 0.7218
rs12885454 14 PRKD1 A/C 0.003 (0.008) 0.6737 0.007 (0.009) 0.4310
rs7141420 14 NRXN3 T/C 0.015 (0.007) 0.0478 0.014 (0.009) 0.1271
rs3736485 15 SCG3 A/G 0.015 (0.007) 0.0396 0.020 (0.009) 0.0231
rs12446632 16 GPRC5B G/A 0.000 (0.011) 0.9775 0.012 (0.013) 0.3642
rs1558902 16 FTO A/T 0.016 (0.007) 0.0340 0.028 (0.009) 0.0024
rs758747 16 NLRC3 C/T 0.018 (0.008) 0.0312 0.013 (0.010) 0.1979
rs9925964 16 KAT8 A/G 0.006 (0.008) 0.4129 0.006 (0.009) 0.4909
rs1000940 17 RABEP1 G/A 0.003 (0.008) 0.6763 0.001 (0.010) 0.9357
rs12940622 17 RPTOR G/A 0.005 (0.007) 0.4673 0.008 (0.009) 0.3582
rs6567160 18 MC4R C/T 0.005 (0.009) 0.5723 0.005 (0.011) 0.6676
rs7243357 18 GRP G/T 0.021 (0.010) 0.0269 0.019 (0.012) 0.1120
rs3810291 19 ZC3H4 A/G 0.023 (0.008) 0.0035 0.030 (0.010) 0.0016
Abbreviations: no., number; Chr., chromosome; se, standard error.
aAllele increasing/allele decreasing: genetic associations reported with respect to the trait increasing allele under the
primary definition.
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I.2 Two-sample Mendelian randomization study
I.2.1 Genetic associations with asthma from the GABRIEL
consortium
Table I.8 contains the genetic associations with asthma for the 42 liberal variants
extracted from the GABRIEL consortium. The rs number and r2 value (measure of
linkage disequilibrium) of the proxy variant are given when relevant. The final column
in Table I.8 indicates whether the variant was included in the conservative set.
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Table I.8 Estimates (standard errors) and p-values of the genetic associations with asthma
extracted from the GABRIEL consortium. The rs number and r2 value (measure of linkage
disequilibrium) of the proxy variant are given when relevant. The final column indicates
whether the variant was included in the conservative set.
rs no. Proxy no. Chr. Gene r2 Minor/ MAF Effect Estimate (se) P-value Con
major allele
rs11165643 1 PTBP2 C/T 0.491 C -0.003 (0.020) 0.880 Yes
rs12401738 rs4130548 1 FUBP1 1.000 C/T 0.422 C -0.014 (0.021) 0.502 No
rs12566985 rs6604872 1 FPGT- 1.000 T/C 0.394 C 0.001 (0.021) 0.951 Yes
TNNI3K
rs2820292 rs1032524 1 NAV1 0.894 T/C 0.399 T 0.018 (0.020) 0.357 No
rs657452 1 AGBL4 G/A 0.432 A 0.007 (0.021) 0.751 Yes
rs11126666 2 KCNK3 A/G 0.447 A -0.014 (0.022) 0.530 No
rs11688816 2 EHBP1 G/A 0.417 A 0.012 (0.020) 0.545 Yes
rs7599312 2 ERBB4 A/G 0.327 A 0.030 (0.023) 0.191 Yes
rs1516725 rs6809651 3 ETV5 1.000 A/G 0.172 G 0.021 (0.030) 0.473 No
rs16851483 rs3821709 3 RASA2 1.000 C/T 0.117 T 0.002 (0.040) 0.965 No
rs3849570 rs7620240 3 GBE1 0.991 T/G 0.270 G -0.037 (0.021) 0.074 Yes
rs6804842 3 RARB G/A 0.487 A -0.007 (0.020) 0.717 Yes
rs10938397 rs12641981 4 GNPDA2 0.992 T/C 0.359 C -0.010 (0.020) 0.608 No
rs17001654 rs17001561 4 NUP54 0.952 A/G 0.229 G -0.070 (0.027) 0.010 Yes
rs2033529 6 TDRG1 G/A 0.241 G 0.002 (0.022) 0.941 Yes
rs205262 6 C6orf106 G/A 0.224 G -0.005 (0.022) 0.811 No
rs2207139 rs943005 6 TFAP2B 1.000 T/C 0.101 C -0.011 (0.026) 0.683 Yes
rs1167827 7 HIP1 G/A 0.458 A -0.043 (0.020) 0.033 No
rs10733682 9 LMX1B G/A 0.403 A 0.007 (0.020) 0.708 Yes
rs10968576 9 LINGO2 G/A 0.263 A -0.015 (0.021) 0.489 Yes
rs1928295 9 TLR4 T/C 0.417 C -0.003 (0.020) 0.894 No
rs4740619 9 C9orf93 T/C 0.488 C 0.030 (0.020) 0.134 No
rs6477694 9 EPB41L4B T/C 0.486 C 0.002 (0.021) 0.937 Yes
rs17094222 rs17113301 10 HIF1AN 0.903 A/C 0.277 A 0.065 (0.024) 0.007 Yes
rs7899106 rs11201714 10 GRID1 1.000 A/C 0.073 C -0.012 (0.047) 0.793 Yes
rs7903146 10 TCF7L2 T/C 0.137 C -0.010 (0.022) 0.663 Yes
rs12286929 rs12421648 11 CADM1 0.821 G/A 0.429 G 0.033 (0.020) 0.099 No
rs3817334 rs7124681 11 MTCH2 0.992 A/C 0.456 C -0.023 (0.020) 0.266 Yes
rs4256980 rs2316901 11 TRIM66 0.996 A/G 0.407 A 0.015 (0.021) 0.479 Yes
rs11057405 12 CLIP1 A/G 0.154 A -0.005 (0.034) 0.883 Yes
rs7138803 12 BCDIN3D A/G 0.469 A 0.047 (0.020) 0.021 Yes
rs12429545 13 OLFM4 A/G 0.162 A -0.046 (0.030) 0.129 Yes
rs10132280 rs8015400 14 STXBP6 0.890 C/A 0.289 C 0.003 (0.021) 0.904 Yes
rs12885454 rs1307813 14 PRKD1 0.996 C/A 0.285 C -0.004 (0.021) 0.851 Yes
rs7141420 14 NRXN3 T/C 0.467 C -0.026 (0.020) 0.196 No
rs12446632 16 GPRC5B A/G 0.192 A -0.036 (0.029) 0.211 Yes
rs758747 16 NLRC3 T/C 0.220 C 0.000 (0.022) 0.989 No
rs9925964 rs889548 16 KAT8 1.000 T/C 0.292 C -0.022 (0.021) 0.294 Yes
rs1000940 17 RABEP1 G/A 0.189 G -0.012 (0.022) 0.566 Yes
rs12940622 17 RPTOR A/G 0.500 A 0.003 (0.020) 0.885 Yes
rs6567160 rs571312 18 MC4R 1.000 A/C 0.297 A -0.007 (0.023) 0.759 Yes
rs7243357 rs9961404 18 GRP 0.872 T/C 0.113 T -0.036 (0.027) 0.190 Yes
Abbreviations: no., number; Chr., chromosome; MAF, minor allele frequency; se, standard error; Con., conservative.
I.2.2 Genetic associations with BMI from UK Biobank
Table I.9 contains the estimates of the genetic associations with the 19 proxy variants used from the GABRIEL consortium for BMI, FMI (BIA
and DXA) and FFMI (BIA and DXA) based on the 360,409 participants from UK Biobank. The genetic associations were adjusted for the first
10 PCs, gender, and height.
Table I.9 Estimates (standard errors) and p-values of the genetic associations with body mass index, fat mass index (BIA and DXA) and fat-free mass
index (BIA and DXA) for the 19 proxy genetic variants used in the two-sample Mendelian randomization analysis based on the 360,409 participants from
UK Biobank.
BMI FMI (BIA) FFMI (BIA) FMI (DXA) FFMI (DXA)
rs no. Proxy no. Chr. Allelesa Estimate (se) P-value Estimate (se) P-value Estimate (se) P-value Estimate (se) P-value Estimate (se) P-value
rs2820292 rs1032524 1 C/T 0.090 (0.011) 4.26×10−16 0.056 (0.008) 3.50×10−13 0.034 (0.004) 1.26×10−16 0.052 (0.073) 0.480 0.019 (0.036) 0.600
rs12401738 rs4130548 1 C/T 0.090 (0.011) 2.48×10−15 0.054 (0.008) 1.33×10−11 0.036 (0.004) 5.60×10−17 0.111 (0.075) 0.137 0.027 (0.037) 0.469
rs12566985 rs6604872 1 C/T -0.090 (0.011) 6.78×10−16 -0.053 (0.008) 7.33×10−12 -0.037 (0.004) 5.81×10−18 0.028 (0.075) 0.712 0.010 (0.037) 0.791
rs16851483 rs3821709 3 C/T 0.162 (0.022) 2.88×10−13 0.109 (0.016) 2.41×10−12 0.054 (0.008) 2.67×10−10 -0.096 (0.148) 0.517 0.054 (0.073) 0.458
rs1516725 rs6809651 3 A/G -0.148 (0.016) 2.76×10−20 -0.082 (0.011) 2.97×10−13 -0.067 (0.006) 1.89×10−27 0.044 (0.107) 0.679 -0.065 (0.053) 0.222
rs3849570 rs7620240 3 T/G 0.047 (0.012) 4.65×10−5 0.036 (0.008) 9.86×10−6 0.011 (0.004) 0.010 -0.061 (0.076) 0.417 0.004 (0.037) 0.916
rs10938397 rs12641981 4 T/C 0.147 (0.011) 1.42×10−39 0.100 (0.008) 1.41×10−37 0.047 (0.004) 1.83×10−28 -0.006 (0.075) 0.935 -0.044 (0.037) 0.234
rs17001654 rs17001561 4 A/G 0.071 (0.015) 4.19×10−6 0.041 (0.011) 0.001 0.030 (0.006) 3.18×10−7 0.103 (0.102) 0.310 0.018 (0.050) 0.716
rs2207139 rs943005 6 T/C 0.187 (0.015) 5.19×10−37 0.117 (0.010) 7.02×10−30 0.07 (0.006) 5.06×10−36 0.019 (0.098) 0.847 0.044 (0.049) 0.369
rs7899106 rs11201714 10 A/C 0.141 (0.025) 2.71×10−8 0.080 (0.018) 7.23×10−6 0.062 (0.01) 2.02×10−10 0.306 (0.171) 0.073 0.024 (0.084) 0.778
rs17094222 rs17113301 10 A/C 0.067 (0.013) 4.64×10−7 0.049 (0.009) 1.91×10−7 0.019 (0.005) 0.002 0.118 (0.088) 0.183 0.026 (0.044) 0.547
rs12286929 rs12421648 11 A/G 0.062 (0.011) 3.15×10−8 0.037 (0.008) 1.85×10−6 0.025 (0.004) 7.36×10−9 0.024 (0.074) 0.749 -0.008 (0.037) 0.832
rs4256980 rs2316901 11 A/G -0.074 (0.012) 1.79×10−10 -0.053 (0.008) 9.23×10−11 -0.022 (0.004) 1.16×10−6 -0.076 (0.076) 0.322 -0.010 (0.038) 0.788
rs3817334 rs7124681 11 A/C 0.108 (0.011) 5.88×10−22 0.087 (0.008) 2.01×10−28 0.021 (0.004) 5.33×10−7 0.037 (0.075) 0.619 -0.029 (0.037) 0.427
rs12885454 rs1307813 14 A/C 0.079 (0.012) 7.74×10−12 0.050 (0.008) 4.43×10−10 0.029 (0.004) 7.18×10−11 0.014 (0.076) 0.854 0.004 (0.038) 0.918
rs10132280 rs8015400 14 A/C 0.105 (0.012) 6.01×10−19 0.057 (0.008) 3.53×10−12 0.048 (0.005) 3.98×10−26 0.055 (0.078) 0.478 0.038 (0.038) 0.322
rs9925964 rs889548 16 T/C -0.127 (0.012) 2.78×10−28 -0.089 (0.008) 1.50×10−28 -0.038 (0.004) 6.40×10−18 -0.042 (0.077) 0.590 -0.067 (0.038) 0.081
rs6567160 rs571312 18 A/C 0.277 (0.013) 2.10×10−100 0.160 (0.009) 4.95E-69 0.117 (0.005) 2.70×10−123 0.082 (0.087) 0.346 0.108 (0.043) 0.012
rs7243357 rs9961404 18 T/C -0.099 (0.015) 2.51×10−11 -0.059 (0.010) 1.30×10−8 -0.04 (0.006) 1.29×10−12 0.072 (0.099) 0.468 -0.005 (0.049) 0.919
Abbreviations: BMI, body mass index; FMI, fat mass index; FFMI, fat-free mass index; BIA, bioelectrical impedance analysis; DXA, dual X-ray emission absorptiometry; no., number; Chr.,
chromosome; se, standard error.
aEffect allele/non-effect allele.

